assays_assay_id,assays_variant_id,assays_assay_tissue,assays_src_assay_id,assays_src_id,assays_relationship_type,assays_tid,assays_tissue_id,assays_description,assays_confidence_score,assays_chembl_id,assays_assay_organism,assays_assay_subcellular_fraction,assays_assay_type,assays_assay_tax_id,assays_assay_test_type,assays_assay_cell_type,assays_curated_by,assays_cell_id,assays_bao_format
7524,,Kidney,,1,N,50597,2113.0,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,CHEMBL618647,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7525,,Kidney,,1,N,50597,2113.0,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,1,CHEMBL618648,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7526,,Kidney,,1,N,50597,2113.0,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,1,CHEMBL618649,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7527,,Liver,,1,N,50597,2107.0,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,CHEMBL618650,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7528,,Liver,,1,N,50597,2107.0,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,1,CHEMBL618651,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7529,,Liver,,1,N,50597,2107.0,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,1,CHEMBL876497,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7530,,Lung,,1,N,50597,2048.0,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,CHEMBL618652,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7531,,Lung,,1,N,50597,2048.0,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,1,CHEMBL618653,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7532,,Lung,,1,N,50597,2048.0,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,1,CHEMBL618654,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7533,,,,1,N,50597,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,1,CHEMBL618655,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7534,,,,1,N,50597,,Compound was tested for solubility in water,1,CHEMBL618656,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7535,,,,1,U,22229,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),0,CHEMBL618657,,,P,,,,Intermediate,,BAO_0000100
7536,,,,1,N,50597,,Solubility was determined,1,CHEMBL618658,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7537,,,,1,N,50597,,solubility in water (ug/mL) at 37 degree C.,1,CHEMBL618659,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7538,,,,1,N,50597,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,1,CHEMBL618660,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7539,,,,1,N,50597,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,1,CHEMBL618661,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7540,,,,1,N,50597,,Half life in rats,1,CHEMBL873807,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7541,,,,1,N,50597,,Half life in Dawley rat,1,CHEMBL618662,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7542,,,,1,N,50597,,Half life period after 3 mg/kg iv administration,1,CHEMBL618663,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7543,,,,1,N,50597,,Half life period after 3 mg/kg iv administration in rat,1,CHEMBL618664,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7544,,,,1,N,50597,,Half life period after 3 mg/kg iv administration in the rat,1,CHEMBL618665,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7545,,,,1,N,50597,,Half life period in female Sprague-Dawley rats,1,CHEMBL876498,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7546,,,,1,N,50597,,Half life period in rat,1,CHEMBL618666,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7547,,,,1,N,50597,,Half-life in rats was determined,1,CHEMBL620440,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7548,,,,1,N,50597,,Half-life in rats with metabolic oxidation,1,CHEMBL620441,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7549,,,,1,N,50597,,Half-life in rats,1,CHEMBL620442,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7550,,,,1,N,50597,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,CHEMBL620443,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7551,,,,1,N,50597,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,CHEMBL620444,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7552,,,,1,N,50597,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,CHEMBL620445,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7553,,,,1,N,50597,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,CHEMBL620446,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7554,,Plasma,,1,N,50597,1969.0,Biological half-life measured in plasma of rat,1,CHEMBL620447,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7555,,Plasma,,1,N,50597,1969.0,Biological half-life measured in plasma of rat; 22-25,1,CHEMBL621129,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7556,,Plasma,,1,N,50597,1969.0,Biological half-life measured in plasma of rat; 9-16,1,CHEMBL621130,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7557,,,,1,N,50597,,Compound was evaluated for its half life when administered intravenously in rat,1,CHEMBL873808,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7558,,,,1,N,50597,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,1,CHEMBL876598,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7559,,,,1,N,50597,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,1,CHEMBL621131,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7560,,,,1,N,50597,,Half life (T1/2) after oral administration in rat,1,CHEMBL621132,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7561,,,,1,N,50597,,Half life of compound after iv administration of 20 mg/kg dose in rat,1,CHEMBL621133,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7562,,,,1,N,50597,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,CHEMBL621312,Rattus norvegicus,,A,10116.0,In vivo,,Expert,,BAO_0000218
7563,,,,1,N,50597,,Half life of compound was determined in rat,1,CHEMBL621313,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7564,,Blood,,1,N,50597,178.0,Half life of compound was determined in rat blood,1,CHEMBL621314,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7565,,,,1,N,50597,,Half life at 1 mg/kg was determined in rat,1,CHEMBL621315,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7566,,,,1,N,50597,,Half life at 10 mg/kg was determined in rat,1,CHEMBL621316,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7567,,,,1,N,50597,,Half life in rats,1,CHEMBL621317,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7568,,,,1,N,50597,,Half life in rats in hours,1,CHEMBL621318,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7569,,,,1,N,50597,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,CHEMBL621319,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7570,,,,1,N,50597,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,1,CHEMBL621377,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7571,,,,1,N,50597,,Half life was determined,1,CHEMBL621378,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7572,,,,1,N,50597,,Half life after i.v. administration,1,CHEMBL876599,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7573,,,,1,N,50597,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,1,CHEMBL621379,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7574,,Plasma,,1,N,50597,1969.0,Half life in rat plasma,1,CHEMBL621380,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7575,,Plasma,,1,N,50597,1969.0,Half life in rat plasma; Not detected,1,CHEMBL621381,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7576,,,,1,N,50597,,Half life in rats,1,CHEMBL618515,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7577,,,,1,N,50597,,Half life period of compound was determined after peroral administration,1,CHEMBL618516,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7578,,,,1,N,50597,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,1,CHEMBL618517,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7579,,,,1,N,50597,,Half life period in rat,1,CHEMBL618518,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7580,,,,1,N,50597,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,CHEMBL618519,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7581,,,,1,N,50597,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,CHEMBL618698,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7582,,,,1,N,50597,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,1,CHEMBL618862,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7583,,,,1,N,50597,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,CHEMBL618863,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7584,,,,1,N,50597,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,1,CHEMBL618864,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7585,,,,1,N,50597,,Half life time in rat the dose of 2 mg/kg,1,CHEMBL618865,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7586,,,,1,N,50597,,Half-life 24 hr after 10 mg/kg iv administration in rats,1,CHEMBL618866,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7587,,,,1,N,50597,,Half-life 24 hr after 2 mg/kg iv administration in rats,1,CHEMBL618867,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7588,,,,1,N,50597,,Half-life consistent with the observed metabolic steady state in rats,1,CHEMBL875828,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7589,,,,1,N,50597,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,CHEMBL618868,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7590,,,,1,N,50597,,Half-life for oxidative metabolic stability was determined using male human,1,CHEMBL618869,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7591,,,,1,N,50597,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",1,CHEMBL618870,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7592,,Plasma,,1,N,50597,1969.0,Half-life in rat plasma,1,CHEMBL618871,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7593,,Plasma,,1,N,50597,1969.0,Half-life in rat plasma was determined,1,CHEMBL618872,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7594,,,,1,N,50597,,Half-life in rats was determined,1,CHEMBL873816,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7595,,,,1,U,22224,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,0,CHEMBL618873,,,A,,,,Autocuration,,BAO_0000218
7596,,,,1,U,22224,,Area under curve after oral dose of 0.1 mg//kg,0,CHEMBL621602,,,A,,,,Autocuration,,BAO_0000019
7597,,,,1,U,22224,,Area under curve after oral dose of 0.3 mg/kg,0,CHEMBL621603,,,A,,,,Autocuration,,BAO_0000218
7598,,,,1,U,22224,,Area under curve after oral dose of 1 mg/kg,0,CHEMBL621604,,,A,,,,Autocuration,,BAO_0000218
7599,,,,1,U,22224,,Area under curve after oral dose of 10 mg/kg,0,CHEMBL621605,,,A,,,,Autocuration,,BAO_0000218
7600,,,,1,U,22224,,Area under curve after oral dose of 23.4 mg/kg,0,CHEMBL621606,,,A,,,,Autocuration,,BAO_0000218
7601,,,,1,U,22224,,Area under curve after oral dose of 3 mg/kg,0,CHEMBL621607,,,A,,,,Autocuration,,BAO_0000218
7602,,,,1,U,22224,,Area under curve after oral dose of 3.87 mg/kg,0,CHEMBL621608,,,A,,,,Autocuration,,BAO_0000218
7603,,,,1,U,22224,,Area under curve was determined,0,CHEMBL621609,,,A,,,,Autocuration,,BAO_0000019
7604,,,,1,U,22224,,Area under curve at a dose of 10 mg/kg,0,CHEMBL621610,,,A,,,,Autocuration,,BAO_0000218
7605,,,,1,N,50597,,Area under curve was determined; ND=No data,1,CHEMBL621611,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7606,,,,1,N,50597,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,CHEMBL621612,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7607,,,,1,N,50597,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,CHEMBL622308,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7608,,,,1,N,50597,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,CHEMBL622309,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7609,,,,1,N,50597,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,1,CHEMBL622310,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7610,,,,1,N,50597,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,CHEMBL622311,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7611,,,,1,N,50597,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,1,CHEMBL622312,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7612,,,,1,N,50597,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,CHEMBL622931,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7613,,,,1,N,50597,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,1,CHEMBL622932,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7614,,Plasma,,1,N,50597,1969.0,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,CHEMBL622736,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7615,,Plasma,,1,N,50597,1969.0,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,CHEMBL622737,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7616,,Plasma,,1,N,50597,1969.0,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,CHEMBL622738,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7617,,Plasma,,1,N,50597,1969.0,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,1,CHEMBL622739,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7618,,Plasma,,1,N,50597,1969.0,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,CHEMBL622740,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7619,,Plasma,,1,N,50597,1969.0,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,1,CHEMBL622741,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7620,,Plasma,,1,N,50597,1969.0,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,CHEMBL622742,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7621,,Plasma,,1,N,50597,1969.0,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,1,CHEMBL622743,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7622,,Plasma,,1,N,50594,1969.0,AUC in mice,1,CHEMBL622744,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7623,,,,1,U,22224,,Area under curve was measured from the graph obtained from concentration Vs time,0,CHEMBL624134,,,A,,,,Autocuration,,BAO_0000019
7624,,,,1,U,22224,,Area under curve value of compound per hour after oral administration,0,CHEMBL624135,,,A,,,,Autocuration,,BAO_0000019
7625,,,,1,N,50597,,Area under curve was determined after oral administration in rats,1,CHEMBL624136,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7626,,,,1,N,50597,,Area under curve was determined after oral administration in rats; No data,1,CHEMBL624137,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7627,,,,1,N,50597,,Area under curve was determined after oral administration in rats;No data,1,CHEMBL624320,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7628,,,,1,N,50588,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,CHEMBL624321,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7629,,,,1,N,50597,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,1,CHEMBL624322,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7630,,,,1,N,50597,,Area under curve was determined for the compound after iv dose of 5.06 in rats,1,CHEMBL624323,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7631,,,,1,N,50597,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,1,CHEMBL624324,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7632,,,,1,N,50597,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,1,CHEMBL624325,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7633,,,,1,N,50597,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,1,CHEMBL624326,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7634,,,,1,N,50597,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,1,CHEMBL624327,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7635,,,,1,N,50597,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,1,CHEMBL624328,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7636,,,,1,N,50588,,Area under curve was determined in Dogs after peroral administration,1,CHEMBL627848,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7637,,,,1,N,50597,,Area under curve was determined in Rats after peroral administration,1,CHEMBL627849,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7638,,,,1,N,50597,,Area under curve was determined in carotid blood of rat when administered intradermally,1,CHEMBL627850,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7639,,,,1,N,50597,,Area under curve was determined in portal blood of rat when administered intradermally,1,CHEMBL627851,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7640,,,,1,N,50594,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,CHEMBL627852,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7641,,,,1,N,50594,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,CHEMBL627853,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7642,,,,1,N,50594,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,CHEMBL627854,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7643,,,,1,N,50594,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,CHEMBL627855,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7644,,,,1,N,50594,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),1,CHEMBL627856,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7645,,,,1,N,50594,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,CHEMBL875339,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7646,,,,1,N,50594,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),1,CHEMBL627857,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7647,,Spleen,,1,N,50597,2106.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,1,CHEMBL627858,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7648,,Blood,,1,N,50597,178.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,1,CHEMBL627859,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7649,,Brain,,1,N,50597,955.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,1,CHEMBL627860,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7650,,Heart,,1,N,50597,948.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,1,CHEMBL627019,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7651,,Liver,,1,N,50597,2107.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,1,CHEMBL627020,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7652,,Lung,,1,N,50597,2048.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,1,CHEMBL627021,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7653,,Muscle tissue,,1,N,50597,2385.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,1,CHEMBL627022,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7654,,,,1,N,50597,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,1,CHEMBL627023,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7655,,Spleen,,1,N,50597,2106.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,1,CHEMBL627024,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7656,,Thyroid gland,,1,N,50597,2046.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,1,CHEMBL627025,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7657,,Kidney,,1,N,50597,2113.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,1,CHEMBL627026,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7658,,Blood,,1,N,50597,178.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,1,CHEMBL627027,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7659,,Brain,,1,N,50597,955.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,1,CHEMBL627028,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7660,,Heart,,1,N,50597,948.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,1,CHEMBL627029,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7661,,Kidney,,1,N,50597,2113.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,1,CHEMBL627030,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7662,,Liver,,1,N,50597,2107.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,1,CHEMBL627031,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7663,,Lung,,1,N,50597,2048.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,1,CHEMBL627032,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7664,,Muscle tissue,,1,N,50597,2385.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,1,CHEMBL627033,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7665,,,,1,N,50597,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,1,CHEMBL627034,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7666,,Spleen,,1,N,50597,2106.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,1,CHEMBL627035,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7667,,Thyroid gland,,1,N,50597,2046.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,1,CHEMBL627036,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7668,,Blood,,1,N,50597,178.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,1,CHEMBL875340,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7669,,Heart,,1,N,50597,948.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,1,CHEMBL627037,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7670,,Kidney,,1,N,50597,2113.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,1,CHEMBL627038,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7671,,Liver,,1,N,50597,2107.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,1,CHEMBL627039,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7672,,Muscle tissue,,1,N,50597,2385.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,1,CHEMBL627040,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7673,,Spleen,,1,N,50597,2106.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,1,CHEMBL624663,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7674,,Thyroid gland,,1,N,50597,2046.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,1,CHEMBL625963,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7675,,Brain,,1,N,50597,955.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,1,CHEMBL876799,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7676,,Lung,,1,N,50597,2048.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,1,CHEMBL626133,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7677,,,,1,N,50597,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,1,CHEMBL626134,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7678,,,,1,N,50597,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,CHEMBL626135,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7679,,,,1,N,50597,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,CHEMBL626136,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7680,,,,1,N,50597,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,1,CHEMBL626137,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7681,,,,1,N,50597,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,CHEMBL626138,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7682,,,,1,N,50597,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,CHEMBL626139,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7683,,,,1,N,50597,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,CHEMBL626140,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7684,,,,1,N,50597,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,CHEMBL626141,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7685,,,,1,N,50597,,C24h in rat p.o. at 20 mg/kg concentration,1,CHEMBL626142,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7686,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,CHEMBL627930,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7687,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,1,CHEMBL627931,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7688,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,1,CHEMBL627932,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7689,,Spleen,,1,N,50597,2106.0,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,CHEMBL627933,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7690,,Spleen,,1,N,50597,2106.0,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,1,CHEMBL627934,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7691,,Spleen,,1,N,50597,2106.0,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,1,CHEMBL627935,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7692,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,CHEMBL627936,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7693,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,1,CHEMBL627937,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7694,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,CHEMBL627938,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7695,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,1,CHEMBL627939,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7696,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,1,CHEMBL627940,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7697,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,CHEMBL627941,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7698,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,CHEMBL876800,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7699,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,1,CHEMBL627942,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7700,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,CHEMBL627943,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7701,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,1,CHEMBL627944,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7702,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,1,CHEMBL627945,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7703,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,1,CHEMBL628584,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7704,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA at 15 min,1,CHEMBL628585,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7705,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,1,CHEMBL628586,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7706,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA at 30 min,1,CHEMBL628587,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7707,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,1,CHEMBL628588,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7708,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,1,CHEMBL628589,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7709,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,1,CHEMBL625304,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7710,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,1,CHEMBL625305,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7711,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,1,CHEMBL625306,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7712,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,1,CHEMBL625307,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7713,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,1,CHEMBL625308,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7714,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,1,CHEMBL627740,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7715,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,1,CHEMBL627741,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7716,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,CHEMBL627742,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7717,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,1,CHEMBL627743,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7718,,Blood,,1,N,50597,178.0,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,1,CHEMBL627744,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7719,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,1,CHEMBL627745,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7720,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,CHEMBL627746,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7721,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,CHEMBL627747,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7722,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,1,CHEMBL876810,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7723,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,1,CHEMBL627748,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7724,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,CHEMBL627749,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7725,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,CHEMBL627750,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7726,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,1,CHEMBL618728,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7727,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,CHEMBL618729,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7728,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA at 15 min,1,CHEMBL618730,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7729,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,1,CHEMBL618731,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7730,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA at 30 min,1,CHEMBL618732,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7731,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,1,CHEMBL618733,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7732,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,1,CHEMBL618734,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7733,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,1,CHEMBL618735,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7734,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,1,CHEMBL876602,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7735,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,1,CHEMBL618736,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7736,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,1,CHEMBL618737,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7737,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,1,CHEMBL618738,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7738,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,1,CHEMBL618739,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7739,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,1,CHEMBL618740,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7740,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,CHEMBL618741,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7741,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,1,CHEMBL618742,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7742,,Bone,,1,N,50597,10000001.0,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,1,CHEMBL618743,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7743,,Plasma,,1,N,50597,1969.0,Half-life from rat plasma at a single oral dose of 25 mg/kg,1,CHEMBL618744,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7744,,,,1,N,50597,,Half-life in male rat,1,CHEMBL618745,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7745,,,,1,N,50597,,Half-life in rat after peroral administration at 10 mg/kg concentration,1,CHEMBL620479,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7746,,,,1,N,50597,,Half-life in rat after peroral administration at 5 mg/kg concentration,1,CHEMBL620480,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7747,,,,1,N,50597,,Half-life in rat at a dose of 3 mg/kg,1,CHEMBL620481,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7748,,,,1,N,50597,,Half-life was evaluated in rats,1,CHEMBL620482,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7749,,,,1,N,50597,,Half-life was measured in rat,1,CHEMBL876603,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7750,,,,1,N,50597,,Half-life period for the compound was determined in rats at 50 mg/kg dose,1,CHEMBL620483,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7751,,,,1,N,50597,,Half-life period in rats after intravenous administration at 5 mg/kg,1,CHEMBL620484,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7752,,,,1,N,50597,,Half-life period in rat at 10 mg/kg,1,CHEMBL620485,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7753,,,,1,N,50597,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",1,CHEMBL620486,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7754,,,,1,N,50597,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",1,CHEMBL620487,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7755,,,,1,N,50597,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",1,CHEMBL620488,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7756,,,,1,N,50597,,Half-life time in rat the dose of 2 mg/kg,1,CHEMBL620489,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7757,,,,1,N,50597,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,1,CHEMBL620490,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7758,,,,1,N,50597,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,1,CHEMBL620491,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7759,,Plasma,,1,N,50597,1969.0,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,CHEMBL876604,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7760,,,,1,N,50597,,Oral half life was determined,1,CHEMBL620492,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7761,,,,1,N,50597,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",1,CHEMBL620493,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7762,,,,1,N,50597,,Pharmacokinetic property (t1/2) in rat,1,CHEMBL620494,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7763,,Plasma,,1,N,50597,1969.0,Plasma elimination half-life was determined,1,CHEMBL620495,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7764,,Plasma,,1,N,50597,1969.0,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,CHEMBL620496,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7765,,Plasma,,1,N,50597,1969.0,Plasma half life was observed after intravenous administration in rat,1,CHEMBL620497,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7766,,Plasma,,1,N,50597,1969.0,Plasma half-life was determined,1,CHEMBL620498,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7767,,Plasma,,1,N,50597,1969.0,Plasma half-life following oral administration in Fisher rats,1,CHEMBL620499,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7768,,Plasma,,1,N,50597,1969.0,Plasma half-life in rat,1,CHEMBL620500,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7769,,Plasma,,1,N,50597,1969.0,Plasmatic Half-life after intravenous administration to rat,1,CHEMBL873809,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7770,,,,1,N,50597,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,CHEMBL620501,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7771,,,,1,N,50597,,Terminal half life after intravenous administration (1 mg/kg) in rat,1,CHEMBL620502,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7772,,,,1,N,50597,,Terminal half life in Rat at a oral dose of 5 mg/kg,1,CHEMBL620503,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7773,,,,1,N,50597,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,CHEMBL620504,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7774,,,,1,N,50597,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,1,CHEMBL876605,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7775,,,,1,N,50597,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,1,CHEMBL620505,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7776,,Plasma,,1,N,50597,1969.0,plasma half life was observed after intravenous administration in rat,1,CHEMBL873811,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7777,,,,1,N,50597,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,CHEMBL624016,Rattus norvegicus,,A,10116.0,In vivo,,Expert,,BAO_0000218
7778,,,,1,N,50597,,Half life of compound determined in rat,1,CHEMBL624017,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7779,,,,1,N,50597,,Mean residence time determined in rat,1,CHEMBL624018,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7780,,,,1,N,50597,,Plasma half life determined in rat,1,CHEMBL624019,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7781,,Brain,,1,N,50597,955.0,Compound was evaluated for Tmax in brain after intravenous administration in male rats,1,CHEMBL624020,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7782,,,,1,N,50597,,Compound was evaluated for pharmacokinetic parameter maximum time period,1,CHEMBL624201,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7783,,,,1,N,50597,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,CHEMBL872528,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7784,,,,1,N,50597,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,CHEMBL624202,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7785,,,,1,N,50597,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,CHEMBL624203,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7786,,,,1,N,50597,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,CHEMBL624350,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7787,,,,1,N,50597,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,CHEMBL621320,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7788,,,,1,N,50597,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,CHEMBL621321,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7789,,,,1,N,50597,,Maximum time (Tmax) required to reach Cmax in rats,1,CHEMBL621322,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7790,,,,1,N,50597,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,CHEMBL621323,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7791,,,,1,N,50597,,Maximum time of clearance of compound in rats after peroral administration,1,CHEMBL621324,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7792,,,,1,N,50597,,Maximum time at the dose of 2 mg/kg in rat,1,CHEMBL621325,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7793,,Plasma,,1,N,50597,1969.0,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,1,CHEMBL875837,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7794,,Plasma,,1,N,50597,1969.0,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,1,CHEMBL621326,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7795,,,,1,N,50597,,Tmax in Guinea pig (PO dose),1,CHEMBL621327,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7796,,,,1,N,50597,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",1,CHEMBL621328,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7797,,,,1,N,50597,,Pharmacokinetic parameter (Tmax) in rat,1,CHEMBL621329,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7798,,,,1,N,50597,,Pharmacokinetic parameter (Tmax) was estimated,1,CHEMBL621330,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7799,,,,1,N,50597,,Pharmacokinetic property (Tmax) in rat,1,CHEMBL621331,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7800,,,,1,N,50597,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,CHEMBL621332,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7801,,,,1,N,50597,,T max in Rat at a oral dose of 5 mg/kg,1,CHEMBL621333,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7802,,,,1,N,50597,,T max was determined at 10 mg/kg po dose in rats,1,CHEMBL621334,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7803,,,,1,N,50594,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),1,CHEMBL621335,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7804,,,,1,N,50588,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,1,CHEMBL621336,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7805,,,,1,N,50597,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,1,CHEMBL621337,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7806,,,,1,N,50588,,Area under curve was measured after i.v. administration into Beagle dog.,1,CHEMBL621338,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7807,,,,1,N,50588,,Area under curve was measured after iv administration into Beagle dog,1,CHEMBL875838,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7808,,,,1,N,50588,,Area under curve was measured after po administration into Beagle dog,1,CHEMBL621339,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7809,,,,1,N,50588,,Area under curve was measured after po administration into Beagle dog.,1,CHEMBL621340,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7810,,,,1,U,22224,,Area under curve was measured at peroral dose of 3 mg/kg,0,CHEMBL621341,,,A,,,,Autocuration,,BAO_0000218
7811,,,,1,U,22224,,Area under curve was measured by using concentration Vs time,0,CHEMBL621342,,,A,,,,Autocuration,,BAO_0000019
7812,,,,1,U,22224,,Area under curve was measured by using concentration Vs time; not tested,0,CHEMBL621343,,,A,,,,Autocuration,,BAO_0000019
7813,,,,1,N,50594,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),1,CHEMBL621344,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7814,,,,1,N,50594,,Area under curve(AUC) was measured in mice after oral administration.,1,CHEMBL621345,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7815,,,,1,U,22224,,Area under curve(AUC) value of the compound,0,CHEMBL621346,,,A,,,,Autocuration,,BAO_0000019
7816,,,,1,U,22224,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,0,CHEMBL621347,,,A,,,,Autocuration,,BAO_0000218
7817,,,,1,N,50588,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,1,CHEMBL621348,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7818,,Blood,,1,U,22224,178.0,Area under curve(carotid artery) was determined by the availability in blood,0,CHEMBL621349,,,A,,,,Autocuration,,BAO_0000019
7819,,Blood,,1,U,22224,178.0,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,0,CHEMBL621350,,,A,,,,Autocuration,,BAO_0000019
7820,,Blood,,1,U,22224,178.0,Area under curve(carotid artery) was determined by the availability in blood; No data,0,CHEMBL875839,,,A,,,,Autocuration,,BAO_0000019
7821,,Blood,,1,U,22224,178.0,Area under curve(portal vein) was determined by the availability in blood,0,CHEMBL620211,,,A,,,,Autocuration,,BAO_0000019
7822,,Blood,,1,U,22224,178.0,Area under curve(portal vein) was determined by the availability in blood; ND means no data,0,CHEMBL620212,,,A,,,,Autocuration,,BAO_0000019
7823,,Blood,,1,U,22224,178.0,Area under curve(portal vein) was determined by the availability in blood; No data,0,CHEMBL620213,,,A,,,,Autocuration,,BAO_0000019
7824,,Plasma,,1,N,50797,1969.0,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,CHEMBL620214,Macaca mulatta,,A,9544.0,,,Intermediate,,BAO_0000218
7825,,Plasma,,1,N,50797,1969.0,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,CHEMBL620215,Macaca mulatta,,A,9544.0,,,Intermediate,,BAO_0000218
7826,,Plasma,,1,N,50797,1969.0,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,1,CHEMBL620216,Macaca mulatta,,A,9544.0,,,Intermediate,,BAO_0000218
7827,,Plasma,,1,N,50588,1969.0,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",1,CHEMBL620888,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7828,,Plasma,,1,N,50588,1969.0,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",1,CHEMBL620889,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7829,,Plasma,,1,U,22224,1969.0,Area under plasma concentration vs time curve observed in rats for 0-3 h,0,CHEMBL620890,,,A,,,,Autocuration,,BAO_0000019
7830,,Plasma,,1,N,50597,1969.0,Area under plasma time curve determined in male rat,1,CHEMBL620891,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7831,,,,1,U,22224,,Area under the MAP curve measured over 5 min.,0,CHEMBL620892,,,A,,,,Autocuration,,BAO_0000019
7832,,,,1,N,50594,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,1,CHEMBL621079,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7833,,,,1,N,50594,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,1,CHEMBL621080,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
7834,,,,1,N,50588,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,1,CHEMBL621081,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7835,,,,1,N,100712,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,1,CHEMBL621082,Cricetinae,,A,10026.0,,,Intermediate,,BAO_0000218
7836,,,,1,N,50597,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,1,CHEMBL621083,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7837,,,,1,N,50588,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,1,CHEMBL621084,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7838,,,,1,N,50588,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,1,CHEMBL621085,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7839,,,,1,N,50588,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,1,CHEMBL621086,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7840,,,,1,N,50588,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,CHEMBL621087,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7841,,,,1,N,50588,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),1,CHEMBL622607,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7842,,,,1,N,50588,,Serum AUC in marmosets (IV dose),1,CHEMBL622608,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7843,,,,1,U,22224,,Area under the curve after intravenous administration at a dose of 10 umol/kg,0,CHEMBL624481,,,A,,,,Autocuration,,BAO_0000019
7844,,,,1,U,22224,,Area under the curve after intravenous administration at a dose of 2 umol/kg,0,CHEMBL624482,,,A,,,,Autocuration,,BAO_0000019
7845,,,,1,U,22224,,Area under the curve after intravenous administration at a dose of 4 umol/kg,0,CHEMBL624483,,,A,,,,Autocuration,,BAO_0000019
7846,,,,1,U,22224,,Area under the curve after intravenous administration at a dose of 40 umol/kg,0,CHEMBL624484,,,A,,,,Autocuration,,BAO_0000019
7847,,,,1,U,22224,,Area under the curve after intravenous administration at a dose of 5 umol/kg,0,CHEMBL624485,,,A,,,,Autocuration,,BAO_0000019
7848,,,,1,N,50597,,Area under the curve for fumarate salt was evaluated in F344 Rats.,1,CHEMBL624486,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7849,,,,1,U,22224,,Area under the curve for the compound was calculated.,0,CHEMBL624487,,,A,,,,Autocuration,,BAO_0000019
7850,,,,1,U,22224,,Area under the curve in concentration/ time,0,CHEMBL624488,,,A,,,,Autocuration,,BAO_0000019
7851,,,,1,N,50597,,Area under the curve administered intraintestinal in rats.,1,CHEMBL624489,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7852,,,,1,N,50597,,Area under the curve administered intravenously in rats.,1,CHEMBL625184,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7853,,,,1,U,22224,,Area under the curve during intravenous administration,0,CHEMBL625185,,,A,,,,Autocuration,,BAO_0000019
7854,,,,1,U,22224,,Area under the curve during intravenous administration; Not determined,0,CHEMBL875954,,,A,,,,Autocuration,,BAO_0000019
7855,,,,1,U,22224,,Area under the curve during systemic administration,0,CHEMBL625186,,,A,,,,Autocuration,,BAO_0000019
7856,,,,1,U,22224,,Area under the curve during systemic administration; Not determined,0,CHEMBL625187,,,A,,,,Autocuration,,BAO_0000019
7857,,,,1,U,22224,,Area under the curve was calculated for the compound.,0,CHEMBL625188,,,A,,,,Autocuration,,BAO_0000019
7858,,,,1,N,50588,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,1,CHEMBL625189,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7859,,,,1,N,50588,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,1,CHEMBL625190,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
7860,,,,1,N,50597,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,1,CHEMBL621733,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7861,,,,1,N,50597,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,1,CHEMBL621734,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7862,,,,1,N,50597,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,1,CHEMBL621735,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7863,,Plasma,,1,N,50597,1969.0,Clearance of the drug was measured in the plasma of rat; No data,1,CHEMBL621736,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7864,,Plasma,,1,N,50597,1969.0,The pharmacokinetic parameter plasma clearance in vivo in rats,1,CHEMBL621737,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7865,,,,1,N,50597,,Plasma clearance at the dose of 2 mg/kg in rat,1,CHEMBL621738,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7866,,,,1,N,50597,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,CHEMBL622806,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7867,,,,1,N,50597,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,CHEMBL623519,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7868,,,,1,N,50597,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,CHEMBL623520,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7869,,,,1,N,50597,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,CHEMBL623521,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7870,,,,1,N,50597,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,CHEMBL623522,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7871,,,,1,N,50597,,Clearance rate in rat,1,CHEMBL623523,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7872,,,,1,N,50597,,Clearance rate in rat,1,CHEMBL623690,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7873,,,,1,N,50597,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,CHEMBL623691,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7874,,,,1,N,50597,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,CHEMBL623692,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7875,,,,1,N,50597,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,CHEMBL623693,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7876,,,,1,N,50597,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,CHEMBL623694,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7877,,,,1,N,50597,,Clearance of compound after iv administration of 20 mg/kg dose in rat,1,CHEMBL623695,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7878,,,,1,N,50597,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,1,CHEMBL623696,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7879,,,,1,N,50597,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,1,CHEMBL623697,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7880,,Plasma,,1,U,22224,1969.0,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,0,CHEMBL623698,Macaca mulatta,,A,9544.0,In vivo,,Intermediate,,BAO_0000218
7881,,Plasma,,1,U,22224,1969.0,Compound was tested for its plasma clearance rate in Sprague Dawley rats,0,CHEMBL623699,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7882,,,,1,N,50597,,Mean (%CV) PK parameters for CL(mL/min/kg).,1,CHEMBL623700,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7883,,,,1,N,50597,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,1,CHEMBL623701,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7884,,Plasma,,1,N,50597,1969.0,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,1,CHEMBL623702,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7885,,,,1,N,50597,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,1,CHEMBL623703,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7886,,,,1,N,50597,,Plasma clearance in rat was determined,1,CHEMBL623704,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7887,,,,1,N,50597,,Plasma clearance in rat after administration of 2 mg/kg iv,1,CHEMBL623705,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7888,,,,1,N,50597,,Plasma clearance in rat after administration of 2 mg/kg iv,1,CHEMBL623706,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7889,,,,1,N,50597,,Plasma clearance was determined,1,CHEMBL623707,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7890,,,,1,N,50597,,Plasma clearance in rat,1,CHEMBL623708,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7891,,,,1,N,50597,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,1,CHEMBL623709,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7892,,,,1,N,50597,,Plasma clearance in rat by iv administration,1,CHEMBL623710,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7893,,,,1,N,50597,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,1,CHEMBL623711,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7894,,,,1,N,50597,,Plasma clearance in rat p.o.,1,CHEMBL623712,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7895,,,,1,N,50597,,Plasma clearance in rats,1,CHEMBL623713,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7896,,,,1,N,50597,,Plasma clearance was determined; ND denotes no data,1,CHEMBL623714,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7897,,,,1,N,50597,,Plasma clearance was determined; ND denotes not determined,1,CHEMBL623715,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7898,,,,1,N,50597,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,CHEMBL623716,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7899,,,,1,N,50597,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,CHEMBL622980,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7900,,,,1,N,50597,,Plasma administration to rats,1,CHEMBL622981,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7901,,,,1,N,50597,,Plasma clearance of the compound in female Sprague-Dawley rats,1,CHEMBL622982,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7902,,,,1,N,50597,,Plasma clearance was observed after intravenous administration in rat,1,CHEMBL622983,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7903,,,,1,N,50597,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,1,CHEMBL622984,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7904,,,,1,N,50597,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,1,CHEMBL622985,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7905,,Plasma,,1,N,50597,1969.0,plasma clearance was observed after intravenous administration in rat,1,CHEMBL623631,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7906,,,,1,N,50597,,In vivo CL/F determined,1,CHEMBL623632,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7907,,Plasma,,1,N,50597,1969.0,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,1,CHEMBL623633,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7908,,Plasma,,1,N,50597,1969.0,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,1,CHEMBL623634,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7909,,,,1,N,50597,,Compound was tested for the lower blood clearance in rat,1,CHEMBL623635,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7910,,,,1,N,50597,,Evaluated for the low clearance in rat (in vivo),1,CHEMBL621195,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7911,,,,1,N,50597,,Pharmacokinetic property (CLb)of the compound was determined in rat,1,CHEMBL621196,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7912,,,,1,N,50597,,Rapid clearance after intravenous administration in rat was determined,1,CHEMBL875287,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7913,,,,1,N,50597,,Clearance measured in rat,1,CHEMBL621197,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7914,,Plasma,,1,N,50597,1969.0,Compound was evaluated for plasma clearance in rat,1,CHEMBL621198,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7915,,Plasma,,1,N,50597,1969.0,Low plasma clearance was calculated in rat,1,CHEMBL621199,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7916,,,,1,N,50597,,Pharmacokinetic property (Clp) in rat,1,CHEMBL621200,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7917,,,,1,N,50597,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,1,CHEMBL621201,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7918,,,,1,N,50597,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,1,CHEMBL621202,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7919,,,,1,N,50597,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,1,CHEMBL621203,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7920,,,,1,N,50597,,Plasma clearance after IV dosing at 1 mg/kg in rat,1,CHEMBL621204,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7921,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,1,CHEMBL621205,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7922,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,1,CHEMBL621206,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7923,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,CHEMBL621207,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7924,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,1,CHEMBL621208,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7925,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,1,CHEMBL621209,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7926,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,1,CHEMBL876484,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7927,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,CHEMBL621210,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7928,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,1,CHEMBL621211,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7929,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,CHEMBL621212,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7930,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA at 15 min,1,CHEMBL621213,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7931,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,1,CHEMBL621214,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7932,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA at 30 min,1,CHEMBL621215,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7933,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,1,CHEMBL621216,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7934,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,1,CHEMBL621217,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7935,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,1,CHEMBL621218,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7936,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,1,CHEMBL621219,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7937,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,1,CHEMBL621220,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7938,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,1,CHEMBL621221,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7939,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,1,CHEMBL621222,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7940,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,1,CHEMBL621223,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7941,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,1,CHEMBL876485,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7942,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,CHEMBL621224,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7943,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,1,CHEMBL621225,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7944,,Heart,,1,N,50597,948.0,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,1,CHEMBL621226,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7945,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,1,CHEMBL621227,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7946,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,CHEMBL621228,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7947,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,CHEMBL621229,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7948,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,1,CHEMBL621230,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7949,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,CHEMBL621231,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7950,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,CHEMBL621232,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7951,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,CHEMBL621233,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7952,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,1,CHEMBL621234,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7953,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,CHEMBL621235,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7954,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,CHEMBL621236,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7955,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,1,CHEMBL621237,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7956,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,1,CHEMBL876486,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7957,,Intestine,,1,N,50597,160.0,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,1,CHEMBL622436,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7958,,Intestine,,1,N,50597,160.0,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,1,CHEMBL622437,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7959,,Intestine,,1,N,50597,160.0,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,1,CHEMBL622438,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7960,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,1,CHEMBL622439,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7961,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,1,CHEMBL622440,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7962,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,1,CHEMBL622441,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7963,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,CHEMBL622442,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7964,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,1,CHEMBL622443,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7965,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,CHEMBL622444,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7966,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,1,CHEMBL622445,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7967,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,CHEMBL622446,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7968,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,CHEMBL622447,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7969,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,1,CHEMBL622448,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7970,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,CHEMBL622449,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7971,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,1,CHEMBL622450,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7972,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,1,CHEMBL622451,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7973,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA at 15 min,1,CHEMBL622452,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7974,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,1,CHEMBL622453,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7975,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA at 30 min,1,CHEMBL622454,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7976,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,1,CHEMBL622455,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7977,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,1,CHEMBL876024,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7978,,,,1,N,50597,,T max was determined at 3 mg/kg po dose in rats,1,CHEMBL622456,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7979,,,,1,N,50597,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL622457,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7980,,,,1,N,50597,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL622458,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7981,,,,1,N,50597,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,1,CHEMBL622459,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7982,,,,1,N,50597,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,1,CHEMBL873343,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7983,,,,1,N,50597,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,1,CHEMBL622460,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7984,,Plasma,,1,N,50597,1969.0,Time for maximum plasma concentration determined in rat,1,CHEMBL622461,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7985,,Plasma,,1,N,50597,1969.0,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,CHEMBL622462,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7986,,,,1,N,50597,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,1,CHEMBL622463,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7987,,,,1,N,50597,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,1,CHEMBL622464,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7988,,,,1,N,50597,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,1,CHEMBL622465,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7989,,,,1,N,50597,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,1,CHEMBL622466,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7990,,,,1,N,50597,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,1,CHEMBL622467,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7991,,Plasma,,1,N,50597,1969.0,Time of maximum plasma concentration in rat,1,CHEMBL622468,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7992,,Plasma,,1,N,50597,1969.0,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,CHEMBL876025,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7993,,Plasma,,1,N,50597,1969.0,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,CHEMBL622469,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7994,,Plasma,,1,N,50597,1969.0,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,CHEMBL622470,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7995,,,,1,N,50597,,Time required to reach maximum concentration (Cmax) after oral administration in rat,1,CHEMBL622471,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7996,,Plasma,,1,N,50597,1969.0,Time required to reach maximum concentration in rat plasma,1,CHEMBL622472,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
7997,,Plasma,,1,N,50597,1969.0,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,CHEMBL622473,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7998,,Plasma,,1,N,50597,1969.0,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,CHEMBL624282,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
7999,,Plasma,,1,N,50597,1969.0,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,CHEMBL624283,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8000,,Plasma,,1,N,50597,1969.0,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,CHEMBL624284,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8001,,Plasma,,1,N,50597,1969.0,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,CHEMBL624285,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8002,,,,1,N,50597,,Time to reach Cmax after oral administration to rats,1,CHEMBL624286,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8003,,,,1,N,50597,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,1,CHEMBL624287,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8004,,,,1,N,50597,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,1,CHEMBL624288,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8005,,Plasma,,1,N,50597,1969.0,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,1,CHEMBL624289,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8006,,Plasma,,1,N,50597,1969.0,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,1,CHEMBL873344,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8007,,,,1,N,50597,,Tmax after peroral administration (10 mg/kg) was determined in rat,1,CHEMBL619623,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8008,,,,1,N,50597,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,1,CHEMBL621399,Rattus norvegicus,,A,10116.0,In vivo,,Expert,,BAO_0000218
8009,,,,1,N,50597,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,1,CHEMBL621400,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8010,,,,1,N,50597,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",1,CHEMBL621401,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8011,,,,1,N,50597,,Tmax was determined,1,CHEMBL621402,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8012,,,,1,N,50597,,Tmax was determined,1,CHEMBL621403,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8013,,,,1,N,50597,,Tmax after oral administration in rat,1,CHEMBL621121,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8014,,,,1,N,50597,,Tmax after peroral administration in rats at 2.4 uM/kg,1,CHEMBL872525,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8015,,,,1,N,50597,,Tmax in male rat,1,CHEMBL621122,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8016,,,,1,N,50597,,Tmax in rat at 10 mg/kg,1,CHEMBL621123,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8017,,,,1,N,50597,,Tmax in rat by po administration at a dose of 40 mg/kg,1,CHEMBL621124,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8018,,,,1,N,50597,,Tmax in rats,1,CHEMBL621125,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8019,,,,1,N,50597,,Tmax was measured in rats after peroral administration at 5 mg/kg,1,CHEMBL621126,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8020,,,,1,N,50597,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,1,CHEMBL621127,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8021,,,,1,N,50597,,Tmax value after administration of 20 mg/Kg oral dose in rat,1,CHEMBL621128,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8022,,,,1,N,50597,,Tmax value at a dose of 10 mg/kg in male SD rats,1,CHEMBL618263,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8023,,,,1,N,50597,,Tmax value at a dose of 100 mg/kg in male SD rats,1,CHEMBL618264,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8024,,,,1,N,50597,,Tmax value at a dose of 50 mg/kg in male SD rats,1,CHEMBL618265,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8025,,Plasma,,1,N,50597,1969.0,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,CHEMBL618266,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8026,,,,1,N,50597,,time required to reach maximum concentration (Cmax) after oral administration in rat,1,CHEMBL618267,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8027,,Urine,,1,N,50597,1088.0,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),1,CHEMBL618450,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8028,,Urine,,1,N,50597,1088.0,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),1,CHEMBL618451,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8029,,,,1,N,50597,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,CHEMBL618452,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8030,,Urine,,1,N,50597,1088.0,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,1,CHEMBL618453,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8031,,Urine,,1,N,50597,1088.0,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,1,CHEMBL618454,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8032,,Urine,,1,N,50597,1088.0,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,1,CHEMBL618455,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8033,,,,1,N,50597,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,1,CHEMBL618456,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8034,,,,1,N,50597,,Compound distribution in rat tissues was determined,1,CHEMBL618457,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8035,,,,1,N,50597,,Volume of distribution was evaluated in rat,1,CHEMBL618458,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8036,,,,1,N,50597,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,1,CHEMBL618459,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8037,,,,1,N,50597,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,1,CHEMBL876733,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8038,,,,1,N,50588,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,1,CHEMBL618460,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
8039,,,,1,N,50597,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,1,CHEMBL618461,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8040,,,,1,U,22224,,Area under the curve was determined after oral administration (300 uM/Kg),0,CHEMBL618462,,,A,,,,Autocuration,,BAO_0000019
8041,,,,1,N,50597,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,1,CHEMBL618463,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8042,,,,1,N,50597,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,1,CHEMBL618464,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8043,,,,1,N,50597,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,1,CHEMBL618465,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8044,,,,1,N,50597,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,1,CHEMBL618466,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8045,,,,1,N,50597,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,1,CHEMBL618467,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8046,,,,1,N,50597,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,1,CHEMBL618468,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8047,,Plasma,,1,N,50588,1969.0,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,1,CHEMBL618469,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
8048,,Plasma,,1,N,50588,1969.0,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,1,CHEMBL618470,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
8049,,,,1,U,22224,,Plasma drug AUC in rat (PO dose),0,CHEMBL618471,,,A,,,,Autocuration,,BAO_0000218
8050,,,,1,N,50594,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,1,CHEMBL618472,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8051,,,,1,U,22224,,Area under was determined at a dose of 30 mg/kg,0,CHEMBL618473,,,A,,,,Autocuration,,BAO_0000218
8052,,,,1,N,50506,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,1,CHEMBL621699,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
8053,,,,1,N,50597,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,1,CHEMBL621700,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8054,,,,1,N,50597,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,1,CHEMBL621701,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8055,,,,1,N,50506,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,1,CHEMBL621702,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
8056,,,,1,N,50588,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,1,CHEMBL621703,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
8057,,,,1,N,50588,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,1,CHEMBL621704,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
8058,,,,1,N,50597,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",1,CHEMBL624259,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8059,,,,1,N,50597,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",1,CHEMBL624260,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8060,,,,1,N,50597,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",1,CHEMBL624430,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8061,,,,1,N,50597,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",1,CHEMBL624431,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8062,,,,1,N,50597,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",1,CHEMBL624432,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8063,,,,1,N,50597,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",1,CHEMBL624433,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8064,,,,1,N,50597,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",1,CHEMBL624434,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8065,,,,1,N,50597,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",1,CHEMBL624435,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8066,,,,1,N,50594,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,1,CHEMBL618570,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8067,,,,1,N,50594,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,CHEMBL618571,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8068,,,,1,N,50594,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,1,CHEMBL618572,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8069,,,,1,N,50594,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,CHEMBL618573,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8070,,,,1,N,50594,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,1,CHEMBL619267,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8071,,,,1,N,50594,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,CHEMBL619431,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8072,,,,1,N,50594,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,1,CHEMBL619432,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8073,,,,1,N,50594,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,CHEMBL619433,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8074,,Plasma,,1,U,22224,1969.0,AUC in mice after oral dose (50 mg/kg),0,CHEMBL619434,,,A,,,,Autocuration,,BAO_0000218
8075,,Serum,,1,N,50594,1977.0,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,1,CHEMBL619435,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8076,,Plasma,,1,U,22224,1969.0,AUC (0-4 hr) ug/ml/h,0,CHEMBL619436,,,A,,,,Autocuration,,BAO_0000019
8077,,,,1,N,50597,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,1,CHEMBL619437,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8078,,,,1,U,22224,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,0,CHEMBL619438,,,A,,,,Autocuration,,BAO_0000218
8079,,,,1,N,50594,,Compound was evaluated for Area under curve in mice,1,CHEMBL619439,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8080,,,,1,N,50597,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,CHEMBL619440,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8081,,,,1,U,22224,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,0,CHEMBL619441,,,F,,,,Autocuration,,BAO_0000218
8082,,,,1,N,50597,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,CHEMBL619442,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8083,,,,1,U,22224,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,0,CHEMBL875156,,,A,,,,Autocuration,,BAO_0000019
8084,,,,1,U,22224,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,0,CHEMBL619443,,,A,,,,Autocuration,,BAO_0000019
8085,,,,1,U,22224,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,0,CHEMBL619444,,,A,,,,Autocuration,,BAO_0000019
8086,,,,1,U,22224,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,0,CHEMBL623464,,,A,,,,Autocuration,,BAO_0000019
8087,,,,1,N,50594,,Compound was evaluated for area under curve when administered through oral route in mouse,1,CHEMBL623465,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8088,,,,1,N,50597,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,1,CHEMBL623466,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8089,,,,1,N,50597,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,1,CHEMBL623467,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8090,,,,1,N,50597,,Plasma clearance in rat,1,CHEMBL623468,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8091,,,,1,N,50597,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,CHEMBL622660,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8092,,,,1,N,50597,,Plasma clearance rate in Sprague-Dawley rats,1,CHEMBL622661,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8093,,,,1,N,50597,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,1,CHEMBL622662,Rattus norvegicus,,F,10116.0,In vivo,,Intermediate,,BAO_0000218
8094,,,,1,N,50597,,Pharmacokinetic property (total body clearance) in rat,1,CHEMBL622663,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8095,,,,1,N,50597,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,1,CHEMBL622664,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8096,,,,1,N,50597,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,CHEMBL622665,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8097,,,,1,N,50597,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,CHEMBL622666,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8098,,,,1,N,50597,,Cl in rat i.v. at 2 mg/kg concentration,1,CHEMBL621615,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8099,,,,1,N,50597,,Clearance of compound after intravenous administration in rats at 24 uM/kg,1,CHEMBL621616,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8100,,,,1,N,50597,,Clearance was determined,1,CHEMBL621617,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8101,,,,1,N,50597,,Clearance by intravenous administration of 3.4 mg/kg in rat,1,CHEMBL621618,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8102,,,,1,N,50597,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,CHEMBL621619,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8103,,,,1,N,50597,,Clearance rate after i.v. administration in rats,1,CHEMBL621620,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8104,,,,1,N,50597,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,CHEMBL621786,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8105,,,,1,N,50597,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,CHEMBL621787,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8106,,,,1,N,50597,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,1,CHEMBL621788,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8107,,,,1,N,50597,,Clearance (Cl) after oral administration in rat,1,CHEMBL621789,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8108,,,,1,N,50597,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,1,CHEMBL621790,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8109,,Plasma,,1,N,50597,1969.0,Compound was tested for plasma clearance in rat,1,CHEMBL621791,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8110,,,,1,N,50597,,In vitro microsome metabolism clearance in rat was determined,1,CHEMBL621792,Rattus norvegicus,Microsomes,A,10116.0,In vitro,,Intermediate,,BAO_0000218
8111,,,,1,N,50597,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,1,CHEMBL621793,Rattus norvegicus,Microsomes,A,10116.0,In vitro,,Intermediate,,BAO_0000218
8112,,,,1,N,50597,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,CHEMBL621794,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8113,,Plasma,,1,N,50597,1969.0,In vivo plasma clearance was determined,1,CHEMBL621795,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8114,,,,1,N,50597,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,1,CHEMBL621796,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8115,,Liver,,1,N,50597,2107.0,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,1,CHEMBL621797,Rattus norvegicus,,A,10116.0,In vivo,Hepatocyte,Intermediate,401.0,BAO_0000218
8116,,,,1,N,50597,,Pharmacokinetic property (Plasma clearance) was measured in rat,1,CHEMBL621798,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8117,,,,1,N,50597,,Pharmacokinetic property (clearance) in rat i.v.,1,CHEMBL621799,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8118,,,,1,N,50597,,"Plasma Clearance was evaluated in rats, iv",1,CHEMBL621800,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8119,,,,1,N,50597,,Plasma clearance (in vivo) in rats was determined,1,CHEMBL621801,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8120,,,,1,N,50597,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,1,CHEMBL621802,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8121,,,,1,N,50597,,Plasma clearance was determined,1,CHEMBL618596,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8122,,,,1,N,50597,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,1,CHEMBL618597,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8123,,,,1,N,50597,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,1,CHEMBL618598,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8124,,,,1,N,50597,,Plasma clearance in rats,1,CHEMBL618599,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8125,,,,1,N,50597,,Plasma clearance rate determined in rat,1,CHEMBL618600,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8126,,,,1,N,50597,,Plasma clearance was determined in rat,1,CHEMBL618601,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8127,,,,1,N,50597,,Plasma clearance was determined,1,CHEMBL618602,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8128,,,,1,N,50597,,Plasma clearance value in rat,1,CHEMBL618603,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8129,,Liver,,1,N,50597,2107.0,Clearance rate constant using isolated perfused rat liver (IPRL) assay,1,CHEMBL618604,Rattus norvegicus,,A,10116.0,Ex vivo,,Intermediate,,BAO_0000218
8130,,,,1,N,50597,,Clearance in rat,1,CHEMBL618605,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8131,,,,1,N,50597,,Total body clearance in rat i.v. at 2 mg/kg concentration,1,CHEMBL618606,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8132,,,,1,N,50597,,Clearance of compound in rats after intravenous administration,1,CHEMBL618607,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8133,,,,1,N,50597,,Clearance after iv administration to rats,1,CHEMBL618608,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8134,,,,1,N,50597,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,CHEMBL618609,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8135,,,,1,N,50597,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,CHEMBL618610,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8136,,,,1,N,50597,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,1,CHEMBL618611,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8137,,,,1,N,50597,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,CHEMBL618612,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8138,,,,1,N,50597,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,CHEMBL618613,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8139,,,,1,N,50597,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,CHEMBL621076,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8140,,,,1,N,50597,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,CHEMBL621077,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8141,,,,1,N,50597,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",1,CHEMBL621078,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8142,,,,1,N,50597,,Clearance in rat,1,CHEMBL621251,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8143,,,,1,N,50597,,Clearance in rat after oral administration at 10 mg/kg,1,CHEMBL621252,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8144,,,,1,N,50597,,Clearance in rat.,1,CHEMBL621253,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8145,,,,1,N,50597,,Clearance rate following an oral dose of 20 mg/kg in rats,1,CHEMBL621254,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8146,,,,1,N,50597,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,1,CHEMBL621255,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8147,,Plasma,,1,N,50597,1969.0,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,1,CHEMBL621256,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8148,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,1,CHEMBL621257,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8149,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,1,CHEMBL621258,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8150,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,1,CHEMBL621259,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8151,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,1,CHEMBL621260,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8152,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,1,CHEMBL876494,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8153,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,1,CHEMBL621261,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8154,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,1,CHEMBL621262,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8155,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,CHEMBL621263,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8156,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,1,CHEMBL621264,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8157,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,1,CHEMBL621265,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8158,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,1,CHEMBL621266,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8159,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,1,CHEMBL621267,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8160,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,1,CHEMBL621268,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8161,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,1,CHEMBL621269,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8162,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,1,CHEMBL621270,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8163,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,1,CHEMBL621271,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8164,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,1,CHEMBL621272,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8165,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,1,CHEMBL621273,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8166,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,1,CHEMBL621274,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8167,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,1,CHEMBL876495,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8168,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,1,CHEMBL621275,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8169,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,1,CHEMBL621276,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8170,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,1,CHEMBL621277,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8171,,Intestine,,1,N,50597,160.0,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,1,CHEMBL621278,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8172,,Intestine,,1,N,50597,160.0,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,1,CHEMBL621279,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8173,,Intestine,,1,N,50597,160.0,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),1,CHEMBL621280,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8174,,Spleen,,1,N,50597,2106.0,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,1,CHEMBL621281,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8175,,Spleen,,1,N,50597,2106.0,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,1,CHEMBL621282,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8176,,Spleen,,1,N,50597,2106.0,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,CHEMBL621283,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8177,,Spleen,,1,N,50597,2106.0,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,1,CHEMBL621284,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8178,,Spleen,,1,N,50597,2106.0,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,1,CHEMBL621285,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8179,,Spleen,,1,N,50597,2106.0,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,1,CHEMBL621286,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8180,,Spleen,,1,N,50597,2106.0,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,1,CHEMBL623220,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8181,,Spleen,,1,N,50597,2106.0,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,1,CHEMBL623221,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8182,,Spleen,,1,N,50597,2106.0,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,1,CHEMBL876029,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8183,,Stomach,,1,N,50597,945.0,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,1,CHEMBL623222,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8184,,Stomach,,1,N,50597,945.0,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,1,CHEMBL623223,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8185,,Stomach,,1,N,50597,945.0,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,1,CHEMBL621445,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8186,,Blood,,1,N,50597,178.0,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621446,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8187,,Blood,,1,N,50597,178.0,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621447,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8188,,Blood,,1,N,50597,178.0,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619681,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8189,,Blood,,1,N,50597,178.0,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619682,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8190,,Blood,,1,N,50597,178.0,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619683,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8191,,Brain,,1,N,50597,955.0,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619684,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8192,,Brain,,1,N,50597,955.0,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619685,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8193,,Brain,,1,N,50597,955.0,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619686,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8194,,Brain,,1,N,50597,955.0,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619687,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8195,,Brain,,1,N,50597,955.0,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619688,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8196,,Heart,,1,N,50597,948.0,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619689,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8197,,Heart,,1,N,50597,948.0,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619690,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8198,,Heart,,1,N,50597,948.0,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619691,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8199,,,,1,N,50597,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,CHEMBL619692,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8200,,,,1,N,50597,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,1,CHEMBL619693,Rattus norvegicus,,A,10116.0,,,Expert,,BAO_0000218
8201,,,,1,N,50597,,Vc value after IV dose at a dose of 5 mg/kg in rats.,1,CHEMBL619694,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8202,,,,1,N,50597,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,1,CHEMBL619695,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8203,,,,1,N,50597,,Compound was evaluated for pharmacokinetic parameter volume of distribution,1,CHEMBL619696,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8204,,,,1,N,50597,,Compound was evaluated for volume of distribution in rat,1,CHEMBL619697,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8205,,,,1,N,50597,,Steady state volume distribution was determined; steady state(ss),1,CHEMBL619698,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8206,,,,1,N,50597,,Steady state volume of distribution after iv administration to rats,1,CHEMBL619699,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8207,,,,1,N,50597,,Steady state volume of distribution dosing at 3 mg/kg iv,1,CHEMBL619700,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8208,,,,1,N,50597,,The compound was evaluated for volume of distribution in rat,1,CHEMBL619701,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8209,,,,1,N,50597,,The compound was tested for volume of distribution in rat,1,CHEMBL619702,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8210,,,,1,N,50597,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,1,CHEMBL620335,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8211,,,,1,N,50597,,Volume distribution (VD) after oral administration in rat,1,CHEMBL620336,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8212,,,,1,N,50597,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,CHEMBL620337,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8213,,,,1,N,50597,,Volume distribution in rat,1,CHEMBL620520,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8214,,,,1,N,50597,,Volume distribution in rat,1,CHEMBL620521,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8215,,,,1,N,50597,,Volume distribution in rat after peroral administration at 10 mg/kg,1,CHEMBL875825,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8216,,,,1,N,50597,,Volume distribution in rat after peroral administration at 5 mg/kg,1,CHEMBL620522,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8217,,,,1,N,50597,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,CHEMBL620523,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8218,,,,1,N,50597,,Volume of distribution in rat.,1,CHEMBL620524,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8219,,,,1,N,50597,,Volume of distribution in rat,1,CHEMBL620525,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8220,,,,1,N,50597,,Volume of distribution in rat,1,CHEMBL620526,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8221,,,,1,N,50597,,Volume of distribution in rat by iv administration,1,CHEMBL620527,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8222,,,,1,N,50597,,Volume of distribution in rats,1,CHEMBL620528,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8223,,,,1,N,50597,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,CHEMBL620529,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8224,,,,1,N,50597,,Volume distribution at the dose of 2 mg/kg in rat,1,CHEMBL620530,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8225,,,,1,N,50597,,Steady state volume of distribution was determined,1,CHEMBL620531,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8226,,,,1,U,22224,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,0,CHEMBL620532,Macaca mulatta,,A,9544.0,In vivo,,Intermediate,,BAO_0000218
8227,,,,1,U,22224,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,0,CHEMBL620533,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8228,,,,1,U,22224,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,0,CHEMBL620534,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8229,,,,1,N,50597,,Mean (%CV) PK parameters for Vdss(mL/kg).,1,CHEMBL620535,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8230,,,,1,N,50597,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,1,CHEMBL875826,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8231,,,,1,N,50597,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,1,CHEMBL620536,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8232,,,,1,N,50597,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,CHEMBL620537,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8233,,,,1,N,50597,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,1,CHEMBL618526,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8234,,,,1,N,50597,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,1,CHEMBL618527,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8235,,,,1,N,50597,,Pharmacokinetic property (Vdss) in rat,1,CHEMBL618528,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8236,,,,1,N,50597,,Pharmacokinetic property (vdss) was measured in rat,1,CHEMBL618529,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8237,,,,1,N,50597,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,1,CHEMBL618530,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8238,,,,1,N,50597,,Volume of distribution in rat,1,CHEMBL618531,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8239,,,,1,N,50597,,The pharmacokinetic parameter volume of distribution in vivo in rats,1,CHEMBL618532,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8240,,,,1,N,50597,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,1,CHEMBL618533,Rattus norvegicus,,F,10116.0,In vivo,,Intermediate,,BAO_0000218
8241,,,,1,N,50597,,Vdss in rat i.v. at 2 mg/kg concentration,1,CHEMBL618534,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8242,,,,1,N,50597,,Volume distribution after intravenous administration (1 mg/kg) in rat,1,CHEMBL618535,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8243,,,,1,N,50597,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,CHEMBL618536,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8244,,,,1,N,50597,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,CHEMBL618537,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8245,,,,1,N,50597,,Volume distribution at a dose of 10 uM/kg in rat was determined,1,CHEMBL618538,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8246,,,,1,N,50597,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,CHEMBL618539,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8247,,,,1,N,50597,,Volume distribution was calculated in rat,1,CHEMBL618540,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8248,,,,1,N,50597,,Volume distribution was determined,1,CHEMBL618541,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8249,,,,1,N,50597,,Volume of distribution after intravenous administration was evaluated in rat,1,CHEMBL618542,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8250,,,,1,N,50597,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,CHEMBL622544,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8251,,,,1,N,50597,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",1,CHEMBL622545,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8252,,,,1,N,50597,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,CHEMBL622546,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8253,,,,1,N,50597,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",1,CHEMBL622547,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8254,,,,1,N,50597,,Volume of distribution in steady state was determined in rat,1,CHEMBL622548,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8255,,,,1,N,50597,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,1,CHEMBL622549,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8256,,,,1,N,50597,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,CHEMBL622550,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8257,,,,1,N,50594,,Compound was evaluated for area under curve when administered through oral route to mouse,1,CHEMBL622551,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8258,,,,1,N,50597,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,CHEMBL622552,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8259,,,,1,N,50597,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,CHEMBL622553,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8260,,,,1,U,22224,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,0,CHEMBL622554,,,F,,In vivo,,Autocuration,,BAO_0000218
8261,,,,1,N,50588,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,1,CHEMBL622555,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
8262,,,,1,N,50594,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,1,CHEMBL622556,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8263,,,,1,N,50594,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,1,CHEMBL622557,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8264,,Blood,,1,N,50594,178.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,1,CHEMBL622558,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8265,,Blood,,1,N,50594,178.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,1,CHEMBL622559,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8266,,,,1,N,50588,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,1,CHEMBL622560,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
8267,,,,1,N,50597,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,CHEMBL622561,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8268,,,,1,N,50597,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,1,CHEMBL622562,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8269,,,,1,N,50597,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,CHEMBL622563,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8270,,,,1,U,22224,,Concentration of compound in Central nervous system,0,CHEMBL622564,,,A,,,,Autocuration,,BAO_0000019
8271,,,,1,U,22224,,Concentration of compound in Central nervous system; Not detectable,0,CHEMBL622565,,,A,,,,Autocuration,,BAO_0000019
8272,,,,1,N,50594,,"Concentration of diester in the blood, following oral administration in mice",1,CHEMBL622566,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8273,,,,1,N,50594,,"Concentration of monoester in the blood, following oral administration in mice",1,CHEMBL624515,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8274,,,,1,N,50594,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,1,CHEMBL624516,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8275,,,,1,U,22224,,Evaluated for Pharmacokinetic property: Area under the curve,0,CHEMBL624517,,,A,,,,Autocuration,,BAO_0000019
8276,,,,1,N,50594,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,1,CHEMBL624518,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8277,,,,1,N,100710,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,1,CHEMBL624519,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8278,,,,1,N,100710,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,1,CHEMBL624520,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8279,,,,1,N,100710,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,1,CHEMBL624521,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8280,,,,1,N,100710,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,1,CHEMBL624522,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8281,,,,1,N,100710,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,1,CHEMBL624523,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8282,,,,1,N,100710,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,CHEMBL624409,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8283,,,,1,N,100710,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",1,CHEMBL624410,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8284,,,,1,N,100710,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,CHEMBL624411,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8285,,,,1,N,100710,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",1,CHEMBL623531,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8286,,,,1,N,100710,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",1,CHEMBL623532,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8287,,,,1,N,100710,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",1,CHEMBL623533,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8288,,,,1,N,100710,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,CHEMBL623534,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
8289,,,,1,N,50594,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,1,CHEMBL623535,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8290,,,,1,N,50594,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,1,CHEMBL623536,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8291,,,,1,N,50594,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,1,CHEMBL623537,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8292,,,,1,N,50594,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,1,CHEMBL623538,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8293,,,,1,N,50594,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,1,CHEMBL623539,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8294,,,,1,N,50594,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,1,CHEMBL623540,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8295,,,,1,N,50594,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",1,CHEMBL623541,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8296,,,,1,N,50594,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",1,CHEMBL623542,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8297,,,,1,N,50594,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",1,CHEMBL623543,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8298,,,,1,N,50594,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",1,CHEMBL623544,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8299,,,,1,N,50594,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",1,CHEMBL623545,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8300,,,,1,N,50594,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",1,CHEMBL623546,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8301,,Plasma,,1,N,50597,1969.0,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,CHEMBL623547,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8302,,,,1,N,50597,,High i.v. clearance in Dawley rats,1,CHEMBL623548,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8303,,Liver,,1,N,50597,2107.0,In vitro clearance in rat liver microsomes,1,CHEMBL623549,Rattus norvegicus,Microsomes,A,10116.0,In vitro,,Intermediate,,BAO_0000218
8304,,Liver,,1,N,50597,2107.0,Intrinsic clearance in rat liver microsomes was determined,1,CHEMBL623550,Rattus norvegicus,Microsomes,A,10116.0,In vitro,,Intermediate,,BAO_0000218
8305,,Liver,,1,N,50597,2107.0,Intrinsic clearance in rat hepatocytes was determined,1,CHEMBL875276,Rattus norvegicus,,A,10116.0,In vitro,Hepatocyte,Intermediate,401.0,BAO_0000218
8306,,,,1,N,50597,,Plasma Clearance was determined,1,CHEMBL621872,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8307,,,,1,N,50597,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,1,CHEMBL621873,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8308,,,,1,N,50597,,Plasma clearance in rat.,1,CHEMBL621874,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8309,,,,1,N,50597,,Plasma clearance in rats,1,CHEMBL621875,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8310,,,,1,N,50597,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,1,CHEMBL621876,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8311,,,,1,N,50597,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,1,CHEMBL621877,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8312,,,,1,N,50597,,Plasma clearance was measured in rat,1,CHEMBL621878,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8313,,,,1,N,50597,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,CHEMBL621879,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8314,,Plasma,,1,N,50597,1969.0,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",1,CHEMBL621880,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8315,,,,1,N,50597,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,1,CHEMBL621881,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8316,,,,1,N,50597,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,CHEMBL621882,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8317,,,,1,N,50597,,Total clearance at 1 mg/kg was determined in rat,1,CHEMBL875283,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8318,,,,1,N,50597,,Total clearance at 10 mg/kg was determined in rat,1,CHEMBL621883,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8319,,,,1,N,50597,,Clearance in rat,1,CHEMBL621884,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8320,,,,1,N,50597,,Plasma clearance rate determined in rats,1,CHEMBL621885,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8321,,,,1,N,50597,,Clearance of compound in rat was evaluated,1,CHEMBL621886,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8322,,Plasma,,1,N,50597,1969.0,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1,CHEMBL621887,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8323,,,,1,N,50597,,Pharmacokinetic property (blood clearance) in rat,1,CHEMBL621888,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8324,,,,1,N,50597,,Plasma clearance in rat,1,CHEMBL621889,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8325,,,,1,N,50597,,Plasma clearance in rats,1,CHEMBL621890,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8326,,Liver,,1,N,50597,2107.0,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,1,CHEMBL621891,Rattus norvegicus,Microsomes,A,10116.0,In vitro,,Intermediate,,BAO_0000218
8327,,,,1,N,50597,,Clearance in Dawley rat,1,CHEMBL621892,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8328,,,,1,N,50597,,Clearance rat,1,CHEMBL621893,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8329,,,,1,N,50597,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),1,CHEMBL621894,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8330,,,,1,N,50597,,Clearance rat; Not determined,1,CHEMBL621895,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8331,,,,1,N,50597,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,1,CHEMBL875284,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8332,,,,1,N,50597,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,CHEMBL618699,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8333,,,,1,N,50597,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,CHEMBL618700,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8334,,,,1,N,50597,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,CHEMBL618701,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8335,,Plasma,,1,N,50597,1969.0,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,CHEMBL876600,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8336,,,,1,N,50597,,Clearance of compound in rat after 1 mg/kg i.v. administration,1,CHEMBL618702,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8337,,,,1,N,50597,,Compound was evaluated for Hepatic clearance in rat,1,CHEMBL618703,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8338,,,,1,N,50597,,In vivo clearance after 5 mg/kg dose,1,CHEMBL618704,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8339,,Plasma,,1,N,50597,1969.0,Compound was tested for plasma clearance in rats,1,CHEMBL618705,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8340,,,,1,N,50597,,Hepatic clearance after intravenous administration was evaluated in rat,1,CHEMBL618706,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8341,,,,1,N,50597,,Lower clearance in rat (i.v.) at 0.5 mpk,1,CHEMBL618707,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8342,,Plasma,,1,N,50597,1969.0,Pharmacokinetic parameter expressed as plasma clearance in rat,1,CHEMBL618708,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8343,,,,1,N,50597,,Pharmacokinetic property (Clp) in rat,1,CHEMBL618709,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8344,,,,1,N,50597,,Plasma clearance in Sprague-Dawley rats,1,CHEMBL618710,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8345,,,,1,N,50597,,Plasma clearance (Clp) in rat,1,CHEMBL618711,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8346,,,,1,N,50597,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,1,CHEMBL618712,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8347,,,,1,N,50597,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,1,CHEMBL618713,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8348,,,,1,N,50597,,Plasma clearance after intravenous administration of 1 mg/kg in rat,1,CHEMBL618714,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8349,,,,1,N,50597,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,CHEMBL618715,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8350,,,,1,N,50597,,Plasma clearance in rat was determined,1,CHEMBL618716,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8351,,,,1,N,50597,,Plasma clearance measured in rat,1,CHEMBL876601,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8352,,,,1,N,50597,,Plasma clearance was calculated in rat,1,CHEMBL618717,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8353,,,,1,N,50597,,Plasma clearance in rat,1,CHEMBL618718,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8354,,,,1,N,50597,,Plasma clearance in rat,1,CHEMBL618719,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8355,,,,1,N,50597,,Plasma clearance in rat,1,CHEMBL618720,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8356,,,,1,N,50597,,Plasma clearance in rat,1,CHEMBL618721,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8357,,,,1,N,50597,,Plasma clearance in rats,1,CHEMBL621477,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8358,,,,1,N,50597,,Plasma clearance in rat,1,CHEMBL621478,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8359,,,,1,N,50597,,Plasma clearance was evaluated in rat,1,CHEMBL621479,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8360,,,,1,N,50597,,Plasma clearance was evaluated in rat; Not tested,1,CHEMBL621480,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8361,,,,1,N,50597,,Plasma clearance rate was determined for the compound in rat,1,CHEMBL621481,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8362,,,,1,N,50597,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",1,CHEMBL621482,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8363,,,,1,N,50597,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,CHEMBL621483,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8364,,,,1,N,50597,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",1,CHEMBL621484,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8365,,Heart,,1,N,50597,948.0,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621485,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8366,,Heart,,1,N,50597,948.0,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621486,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8367,,Intestine,,1,N,50597,160.0,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621487,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8368,,Intestine,,1,N,50597,160.0,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621488,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8369,,Intestine,,1,N,50597,160.0,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621489,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8370,,Intestine,,1,N,50597,160.0,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621490,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8371,,Intestine,,1,N,50597,160.0,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621491,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8372,,Kidney,,1,N,50597,2113.0,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621492,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8373,,Kidney,,1,N,50597,2113.0,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,1,CHEMBL621493,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8374,,Kidney,,1,N,50597,2113.0,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621494,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8375,,Kidney,,1,N,50597,2113.0,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621495,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8376,,Kidney,,1,N,50597,2113.0,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621496,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8377,,Liver,,1,N,50597,2107.0,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621497,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8378,,Liver,,1,N,50597,2107.0,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621498,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8379,,Liver,,1,N,50597,2107.0,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL621499,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8380,,Liver,,1,N,50597,2107.0,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,1,CHEMBL618634,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8381,,Liver,,1,N,50597,2107.0,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL618635,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8382,,Lung,,1,N,50597,2048.0,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL618636,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8383,,Lung,,1,N,50597,2048.0,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619737,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8384,,Lung,,1,N,50597,2048.0,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL619738,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8385,,Lung,,1,N,50597,2048.0,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL624329,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8386,,Lung,,1,N,50597,2048.0,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL624330,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8387,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL624331,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8388,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL624332,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8389,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL624333,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8390,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL624334,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8391,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL624335,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8392,,Spleen,,1,N,50597,2106.0,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL620016,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8393,,Spleen,,1,N,50597,2106.0,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL620169,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8394,,Spleen,,1,N,50597,2106.0,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL620170,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8395,,Spleen,,1,N,50597,2106.0,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,1,CHEMBL620171,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8396,,Spleen,,1,N,50597,2106.0,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL620172,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8397,,Stomach,,1,N,50597,945.0,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL620173,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8398,,Stomach,,1,N,50597,945.0,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,1,CHEMBL620174,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8399,,Stomach,,1,N,50597,945.0,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL620175,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8400,,Stomach,,1,N,50597,945.0,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL620176,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8401,,Stomach,,1,N,50597,945.0,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,CHEMBL620177,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8402,,Cerebellum,,1,N,50597,2037.0,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620178,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8403,,Cerebellum,,1,N,50597,2037.0,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620179,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8404,,,,1,N,50597,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620180,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8405,,,,1,N,50597,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,1,CHEMBL620181,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8406,,,,1,N,50597,,Volume of distribution of compound in rats after intravenous administration,1,CHEMBL620182,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8407,,,,1,N,50597,,Volume of distribution in rat,1,CHEMBL620183,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8408,,,,1,N,50597,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,1,CHEMBL620184,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8409,,,,1,N,50597,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,CHEMBL620185,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8410,,,,1,N,50597,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,CHEMBL620186,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8411,,,,1,N,50597,,Volume of distribution was determined in Dawley rat,1,CHEMBL620187,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8412,,,,1,N,50597,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,CHEMBL620188,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8413,,,,1,N,50597,,Volume of distribution was reported in Sprague-Dawley rat,1,CHEMBL620189,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8414,,,,1,N,50597,,Volumes of distribution in rat after peroral administration,1,CHEMBL620190,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8415,,,,1,N,50597,,Volumes of distribution in rat after po administration,1,CHEMBL620191,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8416,,,,1,N,50597,,Volumes of distribution in rat after po administration; Not determined,1,CHEMBL620192,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8417,,,,1,N,50597,,Pharmacokinetic property (Volume) in rat i.v.,1,CHEMBL620193,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8418,,,,1,N,50597,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,1,CHEMBL620194,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8419,,,,1,N,50597,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",1,CHEMBL876730,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8420,,,,1,N,50597,,Volume distribution in rat after oral administration at 10 mg/kg,1,CHEMBL620195,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8421,,,,1,N,50597,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,CHEMBL620196,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8422,,,,1,N,50597,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,CHEMBL620197,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8423,,,,1,N,50597,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,1,CHEMBL620198,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8424,,,,1,N,50597,,Volume of distribution in rats,1,CHEMBL620199,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8425,,,,1,N,50597,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,1,CHEMBL620200,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8426,,,,1,N,50597,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,1,CHEMBL620201,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8427,,,,1,N,50597,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,CHEMBL620202,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8428,,,,1,N,50597,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,CHEMBL620203,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8429,,,,1,N,50597,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,1,CHEMBL620204,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8430,,,,1,N,50597,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,CHEMBL620205,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8431,,,,1,N,50597,,Pharmacokinetic parameter (Vss) in rat,1,CHEMBL624664,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8432,,,,1,N,50597,,Pharmacokinetic property (Volume) in rat i.v.,1,CHEMBL624665,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8433,,,,1,N,50597,,Pharmacokinetic property (Vss) in rat,1,CHEMBL624666,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8434,,,,1,N,50597,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,CHEMBL624667,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8435,,,,1,N,50597,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,1,CHEMBL624668,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8436,,,,1,N,50597,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,CHEMBL624669,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8437,,,,1,N,50597,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,CHEMBL624670,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8438,,,,1,N,50597,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,CHEMBL624671,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8439,,,,1,N,50597,,Steady state volume distribution in rat,1,CHEMBL624672,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8440,,Plasma,,1,N,50597,1969.0,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",1,CHEMBL624673,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8441,,,,1,N,50597,,Steady state volume of distribution determined in rat,1,CHEMBL624674,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8442,,,,1,N,50597,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,CHEMBL624675,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8443,,,,1,N,50597,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,1,CHEMBL621728,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8444,,,,1,N,50597,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,1,CHEMBL621729,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8445,,,,1,N,50597,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,1,CHEMBL621730,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8446,,,,1,N,50597,,Volume distribution in rat after administration of 2 mg/kg iv,1,CHEMBL621731,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8447,,,,1,N,50597,,Volume distribution in rat after administration of 2 mg/kg iv,1,CHEMBL621732,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8448,,,,1,N,50597,,Volume in steady state distribution value was determined,1,CHEMBL621908,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8449,,,,1,N,50597,,Volume in steady state distribution value was determined; ND denotes no data,1,CHEMBL875347,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8450,,,,1,N,50597,,Volume in steady state distribution value was determined; ND denotes not determined,1,CHEMBL621909,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8451,,,,1,N,50597,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,CHEMBL621910,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8452,,,,1,N,50597,,Volume of distribution at steady state was evaluated in rats,1,CHEMBL621911,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8453,,,,1,N,50597,,Volume of distribution at steady state was observed after intravenous administration in rat,1,CHEMBL621912,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8454,,,,1,N,50597,,Volume of distribution in steady state was determined in rat,1,CHEMBL621913,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8455,,,,1,N,50597,,Volume of distribution in steady state was determined in rat,1,CHEMBL621914,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8456,,,,1,N,50597,,Volume of distribution after i.v. administration,1,CHEMBL621915,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8457,,,,1,N,50597,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,CHEMBL621916,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8458,,Liver,,1,N,50594,2107.0,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,CHEMBL621917,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8459,,Liver,,1,N,50594,2107.0,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,CHEMBL621918,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8460,,Spleen,,1,N,50594,2106.0,Biodistribution of compound (oxidized form) in spleen tissue,1,CHEMBL621919,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8461,,Spleen,,1,N,50594,2106.0,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,CHEMBL621920,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8462,,Spleen,,1,N,50594,2106.0,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,CHEMBL621921,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8463,,Spleen,,1,N,50594,2106.0,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,CHEMBL622401,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8464,,Spleen,,1,N,50594,2106.0,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,CHEMBL875348,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8465,,Spleen,,1,N,50594,2106.0,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,CHEMBL622402,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8466,,Blood,,1,N,50594,178.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,1,CHEMBL622403,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8467,,Blood,,1,N,50594,178.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,CHEMBL622404,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8468,,Brain,,1,N,50594,955.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,1,CHEMBL622405,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8469,,Brain,,1,N,50594,955.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,CHEMBL622406,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8470,,Brain,,1,N,50594,955.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,CHEMBL622407,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8471,,Heart,,1,N,50594,948.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,1,CHEMBL622408,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8472,,Heart,,1,N,50594,948.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,CHEMBL622409,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8473,,Heart,,1,N,50594,948.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,CHEMBL622410,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8474,,Kidney,,1,N,50594,2113.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,1,CHEMBL622411,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8475,,Kidney,,1,N,50594,2113.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,CHEMBL627864,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8476,,Kidney,,1,N,50594,2113.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,CHEMBL627865,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8477,,Liver,,1,N,50594,2107.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,1,CHEMBL627866,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8478,,Liver,,1,N,50594,2107.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,CHEMBL627751,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8479,,Spleen,,1,N,50594,2106.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,1,CHEMBL627752,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8480,,Spleen,,1,N,50594,2106.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,CHEMBL627753,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8481,,Spleen,,1,N,50594,2106.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,CHEMBL627754,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8482,,,,1,N,50594,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,1,CHEMBL627755,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8483,,Brain,,1,N,50594,955.0,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),1,CHEMBL627756,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8484,,Brain,,1,N,50594,955.0,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL627757,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8485,,Brain,,1,N,50594,955.0,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL627758,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8486,,Brain,,1,N,50594,955.0,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL627759,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8487,,Brain,,1,N,50594,955.0,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL627760,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8488,,Brain,,1,N,50594,955.0,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL627761,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8489,,Heart,,1,N,50594,948.0,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),1,CHEMBL876811,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8490,,Heart,,1,N,50594,948.0,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL627762,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8491,,Heart,,1,N,50594,948.0,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL627763,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8492,,Heart,,1,N,50594,948.0,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL627764,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8493,,Heart,,1,N,50594,948.0,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL627765,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8494,,Heart,,1,N,50594,948.0,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL627766,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8495,,Kidney,,1,N,50594,2113.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),1,CHEMBL627767,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8496,,Kidney,,1,N,50594,2113.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL627768,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8497,,Kidney,,1,N,50594,2113.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL628422,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8498,,Kidney,,1,N,50594,2113.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL628423,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8499,,,,1,N,50597,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,1,CHEMBL628424,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8500,,,,1,N,50597,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,1,CHEMBL628425,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8501,,,,1,N,50597,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,1,CHEMBL628426,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8502,,,,1,N,50597,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,CHEMBL628427,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8503,,,,1,N,50597,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,CHEMBL626938,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8504,,,,1,N,50597,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,CHEMBL626939,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8505,,,,1,N,50597,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,CHEMBL626940,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8506,,,,1,N,50597,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,CHEMBL626941,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8507,,,,1,N,50597,,Plasma clearance was reported in Sprague-Dawley rat,1,CHEMBL626942,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8508,,,,1,N,50597,,Plasma clearance after intravenous administration (1 mg/kg) in rat,1,CHEMBL876812,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8509,,,,1,N,50597,,Plasma clearance of compound in rats was evaluated,1,CHEMBL626943,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8510,,,,1,N,50597,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,1,CHEMBL626944,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8511,,,,1,N,50597,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,1,CHEMBL626945,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8512,,,,1,N,50597,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,CHEMBL626946,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8513,,,,1,N,50597,,Plasma clearance rate in Sprague-Dawley rats,1,CHEMBL626856,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8514,,,,1,N,50597,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),1,CHEMBL626857,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8515,,Plasma,,1,N,50597,1969.0,The compound was evaluated for plasma clearance in rat,1,CHEMBL626858,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8516,,Plasma,,1,N,50597,1969.0,Total plasma clearance in rat,1,CHEMBL627018,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8517,,Blood,,1,N,50597,178.0,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,1,CHEMBL625331,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8518,,Blood,,1,N,50597,178.0,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,1,CHEMBL625332,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8519,,,,1,N,50597,,C max was determined at 10 mg/kg po dose in rats,1,CHEMBL877590,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8520,,,,1,N,50597,,C max was determined at 3 mg/kg po dose in rats,1,CHEMBL625333,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8521,,,,1,N,50597,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,1,CHEMBL625334,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8522,,,,1,N,50597,,Cmax after single intravenous bolus of 1 mg/kg in rats,1,CHEMBL625335,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8523,,,,1,N,50597,,Cmax of compound at 5 mg/kg after po administration was determined in rat,1,CHEMBL625336,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8524,,,,1,N,50597,,Cmax 24 hr after 10 mg/kg oral administration in rats,1,CHEMBL625337,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8525,,,,1,N,50597,,Cmax 24 hr after 2 mg/kg oral administration in rats,1,CHEMBL625338,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8526,,Plasma,,1,N,50597,1969.0,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,1,CHEMBL625339,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8527,,,,1,N,50597,,Cmax in rat after administration of 2 mg/kg iv,1,CHEMBL625340,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8528,,,,1,N,50597,,Cmax in rat after administration of 2 mg/kg iv,1,CHEMBL625341,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8529,,,,1,N,50597,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,1,CHEMBL622687,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8530,,Plasma,,1,N,50597,1969.0,Cmax wa determined in rat plasma at 30 mg/kg after po administration,1,CHEMBL622688,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8531,,Blood,,1,N,50597,178.0,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,1,CHEMBL622689,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8532,,Blood,,1,N,50597,178.0,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,1,CHEMBL620295,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8533,,,,1,N,50597,,Cmax after 10 mg/kg oral administration in rat,1,CHEMBL620296,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8534,,,,1,N,50597,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,1,CHEMBL620297,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8535,,,,1,N,50597,,Cmax after IV dosing at 1 mg/kg in rat; no data,1,CHEMBL620298,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8536,,,,1,N,50597,,Cmax after oral administration at 20 mpk in rats,1,CHEMBL620299,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8537,,,,1,N,50597,,Cmax after oral administration at 20 mpk in rats; Not performed.,1,CHEMBL620300,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8538,,,,1,N,50597,,Cmax after oral administration at 20 mpk in rats d; Not performed.,1,CHEMBL620301,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8539,,,,1,N,50597,,Cmax after oral administration in rat,1,CHEMBL620302,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8540,,,,1,N,50597,,Cmax after oral administration at a dose of 2 mg/kg in rat,1,CHEMBL620303,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8541,,,,1,N,50597,,Cmax after oral administration at a dose of 4 mg/kg in rat,1,CHEMBL620304,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8542,,,,1,N,50597,,Cmax in rats after 20 mg/kg oral dose,1,CHEMBL620305,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8543,,,,1,N,50597,,Cmax after peroral administration in rats at 2.4 uM/kg,1,CHEMBL620306,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8544,,,,1,N,50597,,Cmax at the dose of 2 mg/Kg administered perorally in rats,1,CHEMBL620307,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8545,,,,1,N,50597,,Cmax at the dose of 5 mg/Kg administered perorally in rats,1,CHEMBL620308,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8546,,,,1,N,50597,,Cmax by administering at 20 mg/kg p.o. in rats,1,CHEMBL620309,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8547,,,,1,N,50597,,Cmax in male rat,1,CHEMBL620310,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8548,,,,1,N,50597,,Cmax in rat,1,CHEMBL620311,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8549,,,,1,N,50597,,Cmax in rat,1,CHEMBL620312,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8550,,,,1,N,50597,,Cmax in rat,1,CHEMBL620313,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8551,,,,1,N,50597,,Cmax in rat at 10 mg/kg,1,CHEMBL620314,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8552,,,,1,N,50597,,Cmax in rat at the dose of 1 mg/kg i.v.,1,CHEMBL620315,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8553,,,,1,N,50597,,Cmax in rat by po administration at a dose of 40 mg/kg,1,CHEMBL620316,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8554,,,,1,N,50597,,Cmax in rat p.o. at 20 mg/kg concentration,1,CHEMBL620317,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8555,,,,1,N,50597,,Cmax in rats,1,CHEMBL620318,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8556,,,,1,N,50597,,Cmax in rats,1,CHEMBL620319,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8557,,,,1,N,50597,,Cmax was evaluated after 20 uM/kg of peroral administration,1,CHEMBL620320,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8558,,,,1,N,50597,,Cmax was measured in rats after peroral administration at 3 mg/kg,1,CHEMBL620321,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8559,,,,1,N,50597,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,1,CHEMBL620322,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8560,,,,1,N,50597,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620323,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8561,,Frontal cortex,,1,N,50597,1870.0,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620324,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8562,,Frontal cortex,,1,N,50597,1870.0,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620325,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8563,,Hippocampus,,1,N,50597,10000000.0,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620326,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8564,,Hippocampus,,1,N,50597,10000000.0,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620327,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8565,,,,1,N,50597,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620328,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8566,,,,1,N,50597,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620329,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8567,,Midbrain,,1,N,50597,1891.0,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620330,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8568,,Midbrain,,1,N,50597,1891.0,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,CHEMBL875286,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8569,,,,1,N,50597,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620331,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8570,,,,1,N,50597,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620332,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8571,,Striatum,,1,N,50597,2435.0,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620333,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8572,,Striatum,,1,N,50597,2435.0,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,CHEMBL620334,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8573,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL621015,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8574,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,CHEMBL621016,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8575,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL621191,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8576,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL621192,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8577,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,CHEMBL621193,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8578,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,CHEMBL621194,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8579,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,CHEMBL624204,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8580,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,CHEMBL624205,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8581,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,CHEMBL624206,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8582,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,CHEMBL624207,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8583,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,CHEMBL624208,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8584,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,CHEMBL624209,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8585,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,CHEMBL624210,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8586,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,CHEMBL624211,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8587,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,CHEMBL624212,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8588,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,CHEMBL624213,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8589,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL876611,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8590,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL624214,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8591,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL624215,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8592,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL624216,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8593,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL624217,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8594,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL624218,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8595,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL624219,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8596,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL624220,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8597,,Blood,,1,N,50597,178.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL624221,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8598,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL624222,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8599,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,CHEMBL624223,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8600,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL624224,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8601,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL624225,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8602,,,,1,N,50597,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,1,CHEMBL622420,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8603,,,,1,N,50597,,Volume of steady state distribution after i.v. administration in rats,1,CHEMBL622421,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8604,,,,1,N,50597,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,1,CHEMBL622422,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8605,,,,1,N,50597,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,CHEMBL622423,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8606,,,,1,N,50597,,Vss was determined,1,CHEMBL622424,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8607,,,,1,N,50597,,Vss in rat,1,CHEMBL622425,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8608,,,,1,N,50597,,Vss was evaluated after 10 uM/kg of intra arterial administration,1,CHEMBL876612,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8609,,,,1,N,50597,,volume of distribution at steady state was observed after intravenous administration in rat,1,CHEMBL622426,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8610,,,,1,N,50597,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,CHEMBL622427,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8611,,,,1,N,50597,,Pharmacokinetic (PK) parameter Vz in rat,1,CHEMBL622428,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8612,,,,1,N,50597,,Volume distribution in rats,1,CHEMBL622429,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8613,,,,1,N,50597,,Volume of distribution in rat; No data,1,CHEMBL622430,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8614,,,,1,N,50597,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,CHEMBL622431,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8615,,Ileum,,1,N,50597,2116.0,% absorption predicted from in vitro rat ileum transport studies,1,CHEMBL622432,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8616,,,,1,N,50597,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,CHEMBL622433,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8617,,,,1,N,50597,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,CHEMBL622434,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8618,,,,1,N,50597,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,1,CHEMBL622435,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8619,,,,1,N,50597,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),1,CHEMBL618748,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8620,,,,1,N,50597,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,CHEMBL618749,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8621,,,,1,N,50597,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,CHEMBL618750,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8622,,,,1,N,50597,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,CHEMBL618751,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8623,,,,1,N,50597,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,CHEMBL618752,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8624,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL618753,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8625,,Plasma,,1,N,50597,1969.0,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,1,CHEMBL618754,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8626,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL618755,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8627,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL618756,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8628,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL618757,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8629,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL618758,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8630,,,,1,N,50597,,Oral bioavailability in rat (dose 30 mg/kg),1,CHEMBL621088,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8631,,,,1,N,50597,,Pharmacokinetic property (cLogP) in rat,1,CHEMBL621089,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8632,,Blood,,1,N,50597,178.0,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,1,CHEMBL621090,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
8633,,Blood,,1,N,50597,178.0,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,1,CHEMBL621091,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
8634,,,,1,N,50597,,Clearance in rat.,1,CHEMBL876731,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8635,,,,1,N,50597,,Compound was evaluated for its clearance when administered intravenously in rat,1,CHEMBL621092,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8636,,,,1,N,50597,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,CHEMBL621093,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8637,,,,1,N,50597,,Blood: Brain distribution ratio is determined in rat,1,CHEMBL621094,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8638,,,,1,N,50597,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,1,CHEMBL621095,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8639,,,,1,N,50597,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,1,CHEMBL621096,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8640,,Kidney,,1,N,50597,2113.0,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL621097,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8641,,,,1,N,50597,,Percent dose excreted in 0-48 hours administered ip to male rat,1,CHEMBL621098,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
8642,,Cerebellum,,1,N,50597,2037.0,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL621099,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8643,,Cerebellum,,1,N,50597,2037.0,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL621100,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8644,,Cerebellum,,1,N,50597,2037.0,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL621101,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8645,,Cerebellum,,1,N,50597,2037.0,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL621102,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8646,,Cerebellum,,1,N,50597,2037.0,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL876732,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8647,,,,1,N,50597,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL621103,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8648,,,,1,N,50597,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL621104,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8649,,,,1,N,50597,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL621105,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8650,,,,1,N,50597,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL621106,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8651,,,,1,N,50597,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL621107,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8652,,,,1,N,50597,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL621108,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8653,,,,1,N,50597,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL621109,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8654,,Kidney,,1,N,50594,2113.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL621110,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8655,,Kidney,,1,N,50594,2113.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL621111,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8656,,Liver,,1,N,50594,2107.0,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),1,CHEMBL622541,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8657,,Liver,,1,N,50594,2107.0,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL622542,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8658,,Liver,,1,N,50594,2107.0,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL622543,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8659,,Liver,,1,N,50594,2107.0,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL624412,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8660,,Liver,,1,N,50594,2107.0,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL624413,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8661,,Liver,,1,N,50594,2107.0,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL624414,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8662,,Lung,,1,N,50594,2048.0,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),1,CHEMBL624415,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8663,,Lung,,1,N,50594,2048.0,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL624416,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8664,,Lung,,1,N,50594,2048.0,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL624417,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8665,,Lung,,1,N,50594,2048.0,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL624418,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8666,,Lung,,1,N,50594,2048.0,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL624419,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8667,,Lung,,1,N,50594,2048.0,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL624420,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8668,,Muscle tissue,,1,N,50594,2385.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),1,CHEMBL624421,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8669,,Muscle tissue,,1,N,50594,2385.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL624422,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8670,,Muscle tissue,,1,N,50594,2385.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL624423,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8671,,Muscle tissue,,1,N,50594,2385.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL625123,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8672,,Muscle tissue,,1,N,50594,2385.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL625124,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8673,,Muscle tissue,,1,N,50594,2385.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL625125,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8674,,Zone of skin,,1,N,50594,14.0,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),1,CHEMBL625126,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8675,,Zone of skin,,1,N,50594,14.0,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL626947,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8676,,Zone of skin,,1,N,50594,14.0,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL626948,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8677,,Zone of skin,,1,N,50594,14.0,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL626949,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8678,,Zone of skin,,1,N,50594,14.0,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL626950,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8679,,Zone of skin,,1,N,50594,14.0,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL626951,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8680,,Spleen,,1,N,50594,2106.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),1,CHEMBL626952,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8681,,Spleen,,1,N,50594,2106.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL626953,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8682,,Spleen,,1,N,50594,2106.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL626954,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8683,,Spleen,,1,N,50594,2106.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL626955,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8684,,Spleen,,1,N,50594,2106.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL626956,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8685,,Spleen,,1,N,50594,2106.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL626957,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8686,,Blood,,1,N,50594,178.0,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),1,CHEMBL626958,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8687,,Blood,,1,N,50594,178.0,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL626959,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8688,,Blood,,1,N,50594,178.0,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL626960,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8689,,Blood,,1,N,50594,178.0,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL626961,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8690,,Blood,,1,N,50594,178.0,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),1,CHEMBL627589,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8691,,Blood,,1,N,50594,178.0,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),1,CHEMBL627590,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8692,,,,1,N,50594,,Time taken for EC90 was determined when tested in mouse,1,CHEMBL627591,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8693,,,,1,N,50594,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,1,CHEMBL627592,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8694,,,,1,N,50594,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),1,CHEMBL627593,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8695,,,,1,N,50594,,Half life in mice,1,CHEMBL627594,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8696,,,,1,N,50594,,Half life period in mouse after 10 mg/Kg dose,1,CHEMBL876813,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8697,,,,1,N,50594,,Half life period in mouse after 10 mg/kg dose,1,CHEMBL627595,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8698,,,,1,N,50594,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,CHEMBL627596,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8699,,,,1,N,50597,,Cmax value at 5 mg/kg po was determined in rat,1,CHEMBL627597,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8700,,,,1,N,50597,,Cmax value evaluated in rat,1,CHEMBL627598,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8701,,Brain,,1,N,50597,955.0,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,1,CHEMBL627599,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8702,,,,1,N,50597,,Cmax value after administration of 20 mg/Kg oral dose in rat,1,CHEMBL627600,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8703,,,,1,N,50597,,Cmax value at 1 mg/kg po in rat,1,CHEMBL627601,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8704,,,,1,N,50597,,Cmax value at 5 mg/kg po in rat,1,CHEMBL627776,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8705,,,,1,N,50597,,Cmax value at a dose of 10 mg/kg in male SD rats,1,CHEMBL627777,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8706,,,,1,N,50597,,Cmax value at a dose of 100 mg/kg in male SD rats,1,CHEMBL627778,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8707,,,,1,N,50597,,Cmax value at a dose of 50 mg/kg in male SD rats,1,CHEMBL627779,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8708,,,,1,N,50597,,Cmax value in rats at 10 mg/kg,1,CHEMBL876814,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8709,,,,1,N,50597,,Cmax value was evaluated in rats at a dose of 20 mg/kg,1,CHEMBL627780,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8710,,,,1,N,50597,,Cmax value was determined after peroral administration of 20 mg/kg in rat,1,CHEMBL627781,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8711,,,,1,N,50597,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,CHEMBL627782,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8712,,Plasma,,1,N,50597,1969.0,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,1,CHEMBL627783,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8713,,Plasma,,1,N,50597,1969.0,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,1,CHEMBL627784,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8714,,,,1,N,50597,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,1,CHEMBL627785,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8715,,,,1,N,50597,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,1,CHEMBL627786,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8716,,Plasma,,1,N,50597,1969.0,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,1,CHEMBL627787,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8717,,Plasma,,1,N,50597,1969.0,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,1,CHEMBL627788,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8718,,Plasma,,1,N,50597,1969.0,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,1,CHEMBL626579,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8719,,Plasma,,1,N,50597,1969.0,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,1,CHEMBL626580,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8720,,,,1,N,50597,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,1,CHEMBL876815,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8721,,Plasma,,1,N,50597,1969.0,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,1,CHEMBL626581,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8722,,Plasma,,1,N,50597,1969.0,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,1,CHEMBL626582,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8723,,,,1,N,50597,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,1,CHEMBL626583,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8724,,,,1,N,50597,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,CHEMBL626205,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8725,,,,1,N,50597,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,CHEMBL626206,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8726,,,,1,N,50597,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,CHEMBL626207,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8727,,,,1,N,50597,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,CHEMBL623882,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8728,,,,1,N,50597,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,1,CHEMBL623883,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8729,,,,1,N,50597,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,1,CHEMBL623884,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8730,,Plasma,,1,N,50597,1969.0,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,CHEMBL623885,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8731,,Plasma,,1,N,50597,1969.0,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,1,CHEMBL623886,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8732,,,,1,N,50597,,Maximal concentration in rat was determined,1,CHEMBL623887,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8733,,,,1,N,50597,,Maximal concentration after i.v. administration,1,CHEMBL623888,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8734,,Plasma,,1,N,50597,1969.0,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,1,CHEMBL623889,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8735,,Plasma,,1,N,50597,1969.0,Maximal plasma concentration in rat after oral administration at 50 mg/kg,1,CHEMBL623890,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8736,,Plasma,,1,N,50597,1969.0,Cmax in rat plasma after oral dose (50 mg/Kg),1,CHEMBL623891,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8737,,Plasma,,1,N,50597,1969.0,Maximal plasma concentration was determined.,1,CHEMBL623892,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8738,,Plasma,,1,N,50597,1969.0,Maximal plasma drug concentration was determined,1,CHEMBL623893,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8739,,,,1,N,50597,,Maximal concentration in rats after peroral administration,1,CHEMBL877616,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8740,,,,1,N,50597,,Maximum concentration in rat after 2 mg/kg peroral administration,1,CHEMBL623894,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8741,,Plasma,,1,N,50597,1969.0,Maximum concentration in rat plasma after 5 mg/kg oral gavage,1,CHEMBL623895,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8742,,,,1,N,50597,,Maximum concentration of compound in rat was evaluated.,1,CHEMBL623896,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8743,,,,1,N,50597,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,1,CHEMBL623897,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8744,,,,1,N,50597,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,1,CHEMBL623898,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8745,,,,1,N,50597,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,1,CHEMBL623899,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8746,,,,1,N,50597,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,1,CHEMBL623900,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8747,,,,1,N,50597,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,1,CHEMBL623901,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8748,,,,1,N,50597,,Maximum concentration was evaluated in rats,1,CHEMBL623902,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8749,,Cerebrospinal fluid,,1,N,50597,1359.0,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,1,CHEMBL623903,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8750,,Plasma,,1,N,50597,1969.0,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,1,CHEMBL623904,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8751,,Plasma,,1,N,50597,1969.0,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,CHEMBL877617,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8752,,,,1,N,50597,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,1,CHEMBL623905,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8753,,,,1,N,50597,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,1,CHEMBL623906,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8754,,Plasma,,1,N,50597,1969.0,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,CHEMBL623907,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8755,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,CHEMBL623908,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8756,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,1,CHEMBL623909,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8757,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,CHEMBL623910,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8758,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,CHEMBL623911,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8759,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,CHEMBL623912,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8760,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,CHEMBL624616,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8761,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,CHEMBL624617,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8762,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,CHEMBL624618,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8763,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,CHEMBL624619,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8764,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,CHEMBL624794,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8765,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,CHEMBL624795,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8766,,,,1,N,50597,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,CHEMBL623921,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8767,,,,1,N,50597,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL623922,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8768,,,,1,N,50597,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL623923,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8769,,,,1,N,50597,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL623924,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8770,,,,1,N,50597,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL623925,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8771,,,,1,N,50597,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL623926,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8772,,,,1,N,50597,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL623927,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8773,,,,1,N,50597,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL623928,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8774,,,,1,N,50597,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL623929,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8775,,,,1,N,50597,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL623930,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8776,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL623931,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8777,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,CHEMBL622165,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8778,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL621249,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8779,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL621250,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8780,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,CHEMBL621448,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8781,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,CHEMBL621449,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8782,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,CHEMBL621450,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8783,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,CHEMBL621451,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8784,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,CHEMBL621452,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8785,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,CHEMBL621453,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8786,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,CHEMBL621454,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8787,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,CHEMBL621455,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8788,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,CHEMBL621456,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8789,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,CHEMBL625145,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8790,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,CHEMBL875847,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8791,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,CHEMBL625146,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8792,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL625147,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8793,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL625148,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8794,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL625149,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8795,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL625150,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8796,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL625151,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8797,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL625152,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8798,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL625153,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8799,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL625154,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8800,,Brain,,1,N,50597,955.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL625155,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8801,,,,1,N,50597,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL625156,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8802,,,,1,N,50597,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624354,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8803,,Hippocampus,,1,N,50597,10000000.0,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624355,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8804,,Hippocampus,,1,N,50597,10000000.0,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624356,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8805,,Hippocampus,,1,N,50597,10000000.0,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624357,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8806,,Hippocampus,,1,N,50597,10000000.0,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624358,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8807,,Striatum,,1,N,50597,2435.0,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624359,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8808,,Striatum,,1,N,50597,2435.0,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624360,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8809,,Striatum,,1,N,50597,2435.0,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL624361,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8810,,Striatum,,1,N,50597,2435.0,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624362,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8811,,Striatum,,1,N,50597,2435.0,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624363,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8812,,Blood,,1,N,50597,178.0,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624364,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8813,,Blood,,1,N,50597,178.0,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624365,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8814,,Blood,,1,N,50597,178.0,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624366,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8815,,Blood,,1,N,50597,178.0,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624367,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8816,,Brain,,1,N,50597,955.0,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624368,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8817,,Brain,,1,N,50597,955.0,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL624369,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8818,,Brain,,1,N,50597,955.0,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL624370,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8819,,Brain,,1,N,50597,955.0,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL625069,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8820,,Brain,,1,N,50597,955.0,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL625070,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8821,,Heart,,1,N,50597,948.0,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL626051,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8822,,Heart,,1,N,50597,948.0,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL626052,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8823,,Heart,,1,N,50597,948.0,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL626053,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8824,,Heart,,1,N,50597,948.0,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL626054,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8825,,Heart,,1,N,50597,948.0,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL626055,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8826,,Kidney,,1,N,50597,2113.0,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL626056,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8827,,Kidney,,1,N,50597,2113.0,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL626057,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8828,,Kidney,,1,N,50597,2113.0,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL625193,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8829,,Kidney,,1,N,50597,2113.0,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL625194,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8830,,Liver,,1,N,50597,2107.0,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL625195,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8831,,Liver,,1,N,50597,2107.0,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL625196,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8832,,Liver,,1,N,50597,2107.0,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL625197,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8833,,Liver,,1,N,50597,2107.0,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL625198,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8834,,Liver,,1,N,50597,2107.0,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL627929,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8835,,Lung,,1,N,50597,2048.0,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL627074,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8836,,Lung,,1,N,50597,2048.0,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL627075,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8837,,Lung,,1,N,50597,2048.0,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL627076,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8838,,Lung,,1,N,50597,2048.0,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL627077,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8839,,Lung,,1,N,50597,2048.0,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL627078,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8840,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL627079,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8841,,,,1,N,50594,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,1,CHEMBL873824,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8842,,Plasma,,1,N,50594,1969.0,Half life in mouse plasma was determined at dose 25 mg/kg,1,CHEMBL627080,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8843,,,,1,N,50594,,Half life was determined,1,CHEMBL627081,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8844,,,,1,N,50594,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,CHEMBL627082,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8845,,,,1,N,50594,,Half-life in male mice after 1 mg/kg intravenous dose,1,CHEMBL627083,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8847,,Plasma,,1,N,50594,1969.0,Half life in mice plasma,1,CHEMBL627085,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8848,,,,1,N,50594,,Half life in mouse,1,CHEMBL627086,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8849,,Plasma,,1,N,50594,1969.0,Half life in mouse plasma at dose 25 mg/kg,1,CHEMBL627087,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8850,,,,1,N,50594,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,1,CHEMBL627088,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8851,,,,1,N,50594,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,1,CHEMBL627089,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8852,,,,1,N,50594,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,1,CHEMBL627090,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8853,,,,1,N,50594,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,CHEMBL627091,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8854,,,,1,N,50594,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",1,CHEMBL627092,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8855,,,,1,N,50594,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",1,CHEMBL876785,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8856,,,,1,N,50594,,Half-life by iv administration in mouse,1,CHEMBL627093,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8857,,,,1,N,50594,,Half-life by oral administration in mouse,1,CHEMBL627094,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8858,,,,1,N,50594,,Half-life in mice,1,CHEMBL627095,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8859,,Brain,,1,N,50594,955.0,Half-life using mouse brain homogenate,1,CHEMBL627096,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8860,,,,1,N,50594,,Half-life was measured in mice,1,CHEMBL627097,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8861,,,,1,N,50594,,Half-life was measured in mouse after an iv dose of 1 mg/kg,1,CHEMBL627098,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8862,,Blood,,1,N,50594,178.0,Half-life period was determined in mouse blood,1,CHEMBL627099,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8863,,Brain,,1,N,50594,955.0,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",1,CHEMBL627100,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8864,,Plasma,,1,N,50594,1969.0,Plasma half life in mouse,1,CHEMBL627101,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8865,,,,1,N,50594,,Stability of the peptide in the presence of mouse serum,1,CHEMBL627102,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8866,,,,1,N,50594,,Terminal half life of compound was determined in mouse,1,CHEMBL627103,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8867,,,,1,N,50594,,Terminal half life was evaluated in mice after intravenous administration,1,CHEMBL627104,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8868,,,,1,N,50594,,Terminal half life was evaluated in mice after oral administration,1,CHEMBL627105,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8869,,,,1,N,50594,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,1,CHEMBL876786,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8870,,,,1,N,50594,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,1,CHEMBL873825,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8871,,,,1,N,50594,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,1,CHEMBL627106,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8872,,,,1,N,50594,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,1,CHEMBL626336,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8873,,,,1,N,50594,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",1,CHEMBL877462,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8874,,,,1,N,50594,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",1,CHEMBL626337,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8875,,,,1,N,50594,,Half life after intraperitoneal administration of 100 mg/kg in mice,1,CHEMBL626338,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
8876,,,,1,N,50594,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,1,CHEMBL626339,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8877,,,,1,N,50594,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,CHEMBL626340,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8878,,,,1,N,50594,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,1,CHEMBL625377,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8879,,,,1,N,50594,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,1,CHEMBL625378,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8880,,,,1,N,50594,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,1,CHEMBL625379,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
8881,,,,1,U,22224,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),0,CHEMBL625380,Sus scrofa,Microsomes,A,9823.0,,,Autocuration,,BAO_0000251
8882,,,,1,U,22224,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),0,CHEMBL625381,Sus scrofa,Microsomes,A,9823.0,,,Autocuration,,BAO_0000251
8883,,,,1,U,22224,,Stability to porcine renal DHP-I,0,CHEMBL625382,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000019
8884,,,,1,U,22224,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,0,CHEMBL873828,Sus scrofa,,A,9823.0,In vivo,,Autocuration,,BAO_0000218
8885,,,,1,U,22224,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,0,CHEMBL625383,Sus scrofa,,A,9823.0,In vivo,,Autocuration,,BAO_0000218
8886,,,,1,U,22224,,Half-life of the parent prodrug in porcine esterase solution,0,CHEMBL625384,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000019
8887,,,,1,U,22224,,"First order rate constant, k was determined in in pig liver Esterase",0,CHEMBL625385,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000019
8888,,Liver,,1,U,22224,2107.0,Half life of the in pig liver Esterase,0,CHEMBL625386,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000221
8889,,Liver,,1,U,22224,2107.0,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,0,CHEMBL623571,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000221
8890,,Liver,,1,U,22224,2107.0,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,0,CHEMBL623572,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000221
8891,,Liver,,1,U,22224,2107.0,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,0,CHEMBL623573,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000221
8892,,Liver,,1,U,22224,2107.0,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,0,CHEMBL623574,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000221
8893,,Liver,,1,U,22224,2107.0,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,0,CHEMBL623575,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000221
8894,,Liver,,1,U,22224,2107.0,Half-life in the presence of pig liver esterase(PLE) was evaluated.,0,CHEMBL623749,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000221
8895,,Liver,,1,U,22224,2107.0,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,0,CHEMBL623750,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000221
8896,,Liver,,1,U,22224,2107.0,Half-life in vitro in pig liver,0,CHEMBL623751,Sus scrofa,,A,9823.0,In vitro,,Autocuration,,BAO_0000221
8897,,Liver,,1,U,22224,2107.0,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,0,CHEMBL623752,Sus scrofa,,A,9823.0,,,Autocuration,,BAO_0000221
8898,,Plasma,,1,N,50597,1969.0,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1,CHEMBL623753,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8899,,Plasma,,1,N,50597,1969.0,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,CHEMBL623754,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8900,,Plasma,,1,N,50597,1969.0,Maximum concentration in rat plasma was determined,1,CHEMBL623755,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8901,,,,1,N,50597,,Maximum concentration in rats,1,CHEMBL623756,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8902,,,,1,N,50597,,Maximum concentration in rats at 1-2 hours,1,CHEMBL623757,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8903,,,,1,N,50597,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,1,CHEMBL623758,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8904,,Brain,,1,N,50597,955.0,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,1,CHEMBL623759,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8905,,,,1,N,50597,,Maximum concentration at the dose of 2 mg/kg in rat,1,CHEMBL623760,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8906,,,,1,N,50597,,Maximum concentration was evaluated in rats,1,CHEMBL623761,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8907,,Plasma,,1,N,50597,1969.0,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,1,CHEMBL623762,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8908,,Plasma,,1,N,50597,1969.0,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,1,CHEMBL877594,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8909,,Plasma,,1,N,50597,1969.0,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,1,CHEMBL623763,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8910,,Plasma,,1,N,50597,1969.0,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,1,CHEMBL623764,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8911,,Plasma,,1,N,50597,1969.0,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,1,CHEMBL623765,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8912,,Blood,,1,N,50597,178.0,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,1,CHEMBL623766,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8913,,Blood,,1,N,50597,178.0,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,1,CHEMBL623767,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8914,,Blood,,1,N,50597,178.0,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,1,CHEMBL623768,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8915,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,1,CHEMBL623769,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8916,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,1,CHEMBL623770,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8917,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,1,CHEMBL623771,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8918,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,1,CHEMBL623772,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8919,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,1,CHEMBL623773,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8920,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,1,CHEMBL623774,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8921,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,1,CHEMBL623775,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8922,,,,1,N,50597,,Cmax in rat (PO dose),1,CHEMBL623776,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8923,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL622191,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8924,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL622192,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8925,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration determined in rat,1,CHEMBL622193,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8926,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,CHEMBL622194,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8927,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,CHEMBL622195,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8928,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration in rat,1,CHEMBL622196,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8929,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,CHEMBL622197,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8930,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,1,CHEMBL622198,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8931,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,1,CHEMBL622199,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8932,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration of compound was measured in rat,1,CHEMBL622200,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8933,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration after 20 mg/kg oral administration in rat,1,CHEMBL622201,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8934,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration after oral administration to rats,1,CHEMBL623990,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8935,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,CHEMBL623991,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8936,,Plasma,,1,N,50597,1969.0,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",1,CHEMBL623992,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8937,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,CHEMBL623993,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8938,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,1,CHEMBL623994,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8939,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,1,CHEMBL623995,Rattus norvegicus,,F,10116.0,In vivo,,Intermediate,,BAO_0000218
8940,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,1,CHEMBL623996,Rattus norvegicus,,F,10116.0,In vivo,,Intermediate,,BAO_0000218
8941,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,1,CHEMBL623997,Rattus norvegicus,,F,10116.0,In vivo,,Intermediate,,BAO_0000218
8942,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration dosed orally in rats,1,CHEMBL623998,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8943,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration dosed orally in rats after 6 hours,1,CHEMBL623999,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8944,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,1,CHEMBL624000,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8945,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,CHEMBL624001,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8946,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration in rat after po administration,1,CHEMBL624002,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8947,,Plasma,,1,N,50597,1969.0,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",1,CHEMBL624003,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8948,,Plasma,,1,N,50597,1969.0,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",1,CHEMBL624004,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8949,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL624005,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8950,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,CHEMBL624006,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8951,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL624007,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8952,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL624008,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8953,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,CHEMBL624009,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8954,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,CHEMBL874387,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8955,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,CHEMBL624010,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8956,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,CHEMBL624011,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8957,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,CHEMBL624012,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8958,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,CHEMBL624013,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8959,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,CHEMBL624736,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8960,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,CHEMBL624737,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8961,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL624738,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8962,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL624739,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8963,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL624740,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8964,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL624896,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8965,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL624897,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8966,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL624108,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8967,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL624109,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8968,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL624110,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8969,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL624111,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8970,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,CHEMBL624112,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8971,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,CHEMBL624113,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8972,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,CHEMBL619709,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8973,,Heart,,1,N,50597,948.0,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,CHEMBL619710,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8974,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL619711,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8975,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,CHEMBL619712,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8976,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL619713,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8977,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL619714,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8978,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,CHEMBL619715,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8979,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,CHEMBL619716,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8980,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,CHEMBL619717,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8981,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,CHEMBL619718,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8982,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,CHEMBL619719,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8983,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,CHEMBL875329,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8984,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,CHEMBL619720,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8985,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,CHEMBL619721,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8986,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,CHEMBL619722,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8987,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,CHEMBL619723,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8988,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,CHEMBL619724,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8989,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,CHEMBL619725,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8990,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL619726,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8991,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL619727,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8992,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL619728,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8993,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL619729,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
8994,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL619730,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8995,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL619731,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8996,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL619732,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8997,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL619733,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8998,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL619734,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
8999,,Zone of skin,,1,N,50597,14.0,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL619735,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9000,,Zone of skin,,1,N,50597,14.0,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL875330,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9001,,Zone of skin,,1,N,50597,14.0,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL628465,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9002,,Zone of skin,,1,N,50597,14.0,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL628466,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9003,,Zone of skin,,1,N,50597,14.0,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL628467,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9004,,Spleen,,1,N,50597,2106.0,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL628468,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9005,,Spleen,,1,N,50597,2106.0,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL628469,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9006,,Spleen,,1,N,50597,2106.0,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL628470,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9007,,Spleen,,1,N,50597,2106.0,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL628471,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9008,,Spleen,,1,N,50597,2106.0,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL628472,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9009,,Thyroid gland,,1,N,50597,2046.0,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL625191,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9010,,Thyroid gland,,1,N,50597,2046.0,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL625192,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9011,,Thyroid gland,,1,N,50597,2046.0,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,CHEMBL875337,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9012,,Thyroid gland,,1,N,50597,2046.0,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL626341,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9013,,Thyroid gland,,1,N,50597,2046.0,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL626342,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9014,,Liver,,1,N,50597,2107.0,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,CHEMBL621943,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9015,,,,1,N,50597,,Half life in rats,1,CHEMBL621944,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9016,,,,1,N,50597,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,1,CHEMBL621945,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9017,,,,1,N,50597,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),1,CHEMBL621946,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9018,,,,1,N,50597,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,CHEMBL621947,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9019,,,,1,N,50597,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),1,CHEMBL621948,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9020,,,,1,N,50597,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,CHEMBL621949,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9021,,,,1,N,50597,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),1,CHEMBL621950,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9022,,,,1,N,50597,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,1,CHEMBL621951,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9023,,Blood,,1,N,50597,178.0,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,1,CHEMBL621952,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9024,,Liver,,1,N,50597,2107.0,Stability (%) in rat liver microsomes,1,CHEMBL621953,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9025,,,,1,N,50597,,Area under curve was calculated after intravenous administration,1,CHEMBL621954,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9026,,,,1,N,50597,,Area under the curve was calculated after iv administration in rat,1,CHEMBL621955,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9027,,,,1,N,50597,,Area under the curve was calculated in rat after peroral administration,1,CHEMBL621956,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9028,,,,1,N,50597,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,CHEMBL621957,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9029,,,,1,N,50597,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,1,CHEMBL621958,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9030,,,,1,N,50597,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,1,CHEMBL621959,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9031,,,,1,N,50597,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,1,CHEMBL621960,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9032,,,,1,N,50597,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,1,CHEMBL621961,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9033,,,,1,N,50597,,p value of the compound,1,CHEMBL621962,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9034,,,,1,N,50597,,p value of the compound,1,CHEMBL876787,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
9035,,,,1,N,50597,,p value of the compound,1,CHEMBL621963,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9036,,Stomach,,1,N,50597,945.0,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,CHEMBL622637,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9037,,Stomach,,1,N,50597,945.0,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,CHEMBL622638,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9038,,Stomach,,1,N,50597,945.0,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,CHEMBL626561,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9039,,,,1,U,22224,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),0,CHEMBL626562,Oryctolagus cuniculus,,F,9986.0,,,Autocuration,,BAO_0000019
9040,,,,1,U,22224,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),0,CHEMBL626563,Oryctolagus cuniculus,,A,9986.0,,,Autocuration,,BAO_0000218
9041,,,,1,U,22224,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),0,CHEMBL626564,Oryctolagus cuniculus,,A,9986.0,,,Autocuration,,BAO_0000218
9042,,,,1,U,22224,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,0,CHEMBL626565,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9043,,,,1,U,22224,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,0,CHEMBL626566,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9044,,,,1,U,22224,,Clearance rate in rabbits,0,CHEMBL626567,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9045,,,,1,U,22224,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,0,CHEMBL626568,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9046,,,,1,U,22224,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,0,CHEMBL626569,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9047,,,,1,U,22224,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,0,CHEMBL626570,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9048,,,,1,U,22224,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,0,CHEMBL626571,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9049,,,,1,U,22224,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,0,CHEMBL626572,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9050,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,0,CHEMBL626573,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9051,,Liver,,1,U,22224,2107.0,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,0,CHEMBL626574,Oryctolagus cuniculus,Microsomes,A,9986.0,,,Autocuration,,BAO_0000251
9052,,Liver,,1,U,22224,2107.0,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,0,CHEMBL626575,Oryctolagus cuniculus,Microsomes,A,9986.0,,,Autocuration,,BAO_0000251
9053,,,,1,U,22224,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,0,CHEMBL626576,Oryctolagus cuniculus,,A,9986.0,,,Autocuration,,BAO_0000218
9054,,,,1,U,22224,,Dose at which bioavailability of perorally administered compound was tested in rabbit,0,CHEMBL626577,Oryctolagus cuniculus,,A,9986.0,,,Autocuration,,BAO_0000218
9055,,,,1,U,22224,,The compound was tested for its bioavailability in rabbit (by oral dosage).,0,CHEMBL626578,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9056,,,,1,U,22224,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,0,CHEMBL625263,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9057,,,,1,U,22224,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,0,CHEMBL625264,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9058,,,,1,U,22224,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,0,CHEMBL625265,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9059,,,,1,U,22224,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),0,CHEMBL625266,Oryctolagus cuniculus,Microsomes,A,9986.0,,,Autocuration,,BAO_0000251
9060,,,,1,U,22224,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),0,CHEMBL876796,Oryctolagus cuniculus,Microsomes,A,9986.0,,,Autocuration,,BAO_0000251
9061,,,,1,U,22224,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,0,CHEMBL625267,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9062,,Plasma,,1,U,22224,1969.0,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,0,CHEMBL625268,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9063,,Plasma,,1,U,22224,1969.0,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,0,CHEMBL625269,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9064,,Plasma,,1,U,22224,1969.0,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,0,CHEMBL624689,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9065,,,,1,U,22224,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,0,CHEMBL624690,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9066,,Urine,,1,U,22224,1088.0,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),0,CHEMBL624691,Oryctolagus cuniculus,,A,9986.0,,,Autocuration,,BAO_0000218
9067,,Urine,,1,U,22224,1088.0,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),0,CHEMBL624692,Oryctolagus cuniculus,,A,9986.0,,,Autocuration,,BAO_0000218
9068,,,,1,U,22224,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,0,CHEMBL624693,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9069,,,,1,U,22224,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,0,CHEMBL624694,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9070,,,,1,U,22224,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,0,CHEMBL877596,Oryctolagus cuniculus,,A,9986.0,In vitro,,Autocuration,,BAO_0000221
9071,,,,1,U,22224,,Time within which only 10% of the drug was degraded,0,CHEMBL624695,Oryctolagus cuniculus,,A,9986.0,,,Autocuration,,BAO_0000019
9072,,Liver,,1,U,22224,2107.0,Half life period in rabbit liver homogenate,0,CHEMBL624696,Oryctolagus cuniculus,,A,9986.0,,,Autocuration,,BAO_0000221
9073,,,,1,U,22224,,Half life value in rabbits,0,CHEMBL624697,Oryctolagus cuniculus,,A,9986.0,,,Autocuration,,BAO_0000019
9074,,Blood,,1,U,22224,178.0,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,0,CHEMBL624698,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9075,,Blood,,1,U,22224,178.0,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,0,CHEMBL624699,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9076,,,,1,U,22224,,Half-life period in rabbits following intravenous administration at 2 mg/kg,0,CHEMBL624700,Oryctolagus cuniculus,,A,9986.0,In vivo,,Autocuration,,BAO_0000218
9077,,Plasma,,1,N,50597,1969.0,AUC 0-8 hr value in rats at 10 mg/kg,1,CHEMBL622903,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9078,,Plasma,,1,N,50597,1969.0,AUC after administration at 2000 mg/kg/day in rats,1,CHEMBL622904,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9079,,Plasma,,1,N,50597,1969.0,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,1,CHEMBL622905,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9080,,Plasma,,1,N,50597,1969.0,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,CHEMBL622906,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9081,,Plasma,,1,N,50597,1969.0,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,CHEMBL622907,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9082,,Plasma,,1,N,50597,1969.0,AUC in rat after oral administration at 10.5 mg/kg dose,1,CHEMBL622908,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9083,,Plasma,,1,N,50597,1969.0,AUC in rat after oral administration at 11.2 mg/kg dose,1,CHEMBL622909,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9084,,Plasma,,1,N,50597,1969.0,AUC in rat after oral administration at 9.7 mg/kg dose,1,CHEMBL622910,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9085,,Brain,,1,N,50597,955.0,AUC in rat brain after oral administration at 10 mg/kg,1,CHEMBL622911,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9086,,Plasma,,1,N,50597,1969.0,AUC in rat p.o.,1,CHEMBL622912,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9087,,Plasma,,1,N,50597,1969.0,AUC in rat p.o. at 20 mg/kg concentration,1,CHEMBL622913,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9088,,Plasma,,1,N,50597,1969.0,AUC in rat plasma after oral administration at 10 mg/kg,1,CHEMBL622914,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9089,,Plasma,,1,N,50597,1969.0,AUC in rats,1,CHEMBL622915,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9090,,Plasma,,1,N,50597,1969.0,AUC value after IV dose at a dose of 5 mg/kg in rats.,1,CHEMBL622916,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9091,,Plasma,,1,N,50597,1969.0,AUC value after oral dose at a dose of 10 mg/kg in rats.,1,CHEMBL622917,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9092,,Plasma,,1,N,50597,1969.0,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,CHEMBL622918,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9093,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,1,CHEMBL622919,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9094,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration was evaluated in rat,1,CHEMBL622920,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9095,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,CHEMBL622921,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9096,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1,CHEMBL622922,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9097,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,CHEMBL622923,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9098,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,CHEMBL877604,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9099,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,1,CHEMBL622924,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9100,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,1,CHEMBL622925,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9101,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,1,CHEMBL622926,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9102,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,1,CHEMBL623625,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9103,,Plasma,,1,N,50597,1969.0,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,1,CHEMBL623626,Rattus norvegicus,,A,10116.0,In vivo,,Expert,,BAO_0000218
9104,,Plasma,,1,N,50597,1969.0,Maximum plasma drug concentration was determined,1,CHEMBL623627,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9105,,,,1,N,50597,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,1,CHEMBL623628,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9106,,Plasma,,1,N,50597,1969.0,Mean peak plasma concentration was observed after intravenous administration in rat,1,CHEMBL623629,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9107,,Plasma,,1,N,50597,1969.0,Mean peak plasma concentration was observed after oral administration in rat,1,CHEMBL623630,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9108,,,,1,N,50597,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,1,CHEMBL623804,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9109,,,,1,N,50597,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,1,CHEMBL623805,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9110,,Plasma,,1,N,50597,1969.0,Peak oral plasma concentration was determined in rats by oral administration,1,CHEMBL623806,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9111,,Plasma,,1,N,50597,1969.0,Peak plasma concentration (Cmax) was determined,1,CHEMBL623807,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9112,,Plasma,,1,N,50597,1969.0,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,1,CHEMBL623808,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9113,,Plasma,,1,N,50597,1969.0,Peak plasma concentration (Cmax) in rats,1,CHEMBL623809,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9114,,Plasma,,1,N,50597,1969.0,Peak plasma concentration at 1 mg/kg peroral administration,1,CHEMBL623810,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9115,,Plasma,,1,N,50597,1969.0,Peak plasma concentration in rat,1,CHEMBL623811,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9116,,Plasma,,1,N,50597,1969.0,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",1,CHEMBL623812,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9117,,,,1,N,50597,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,1,CHEMBL877605,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9118,,,,1,N,50597,,Pharmacokinetic property (Cmax) in rat,1,CHEMBL623813,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9119,,,,1,N,50597,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,CHEMBL623814,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9120,,,,1,N,50597,,Cmax in rat after 3mg/kg oral dose,1,CHEMBL623815,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9121,,,,1,N,50597,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,1,CHEMBL623816,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9122,,,,1,N,50597,,Cmax in rats after 20 mg/kg oral dose,1,CHEMBL623145,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9123,,Plasma,,1,N,50597,1969.0,Cmax in rat plasma after 30mg/kg oral dose,1,CHEMBL623146,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9124,,Plasma,,1,N,50597,1969.0,Plasma concentration after oral administration of 100 mg/kg to rats,1,CHEMBL623147,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9125,,Brain,,1,N,50597,955.0,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,CHEMBL623042,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9126,,,,1,N,50597,,Tested for the Cmax in rat at 10 mg/kg per orally,1,CHEMBL623043,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9127,,,,1,N,50597,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL623044,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9128,,,,1,N,50597,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL623045,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9129,,,,1,N,50597,,Bioavailability as oral Cmax in rats at 30 mins,1,CHEMBL623046,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9130,,,,1,N,50597,,Bioavailability as oral Cmax in rats at 6hr,1,CHEMBL623226,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9131,,,,1,N,50597,,The maximum concentration of compound was measured at the dose of 100 umol/kg,1,CHEMBL623227,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9132,,,,1,N,50597,,The maximum concentration of compound was measured at the dose of 300 umol/kg,1,CHEMBL623228,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9133,,,,1,N,50597,,The maximum concentration of compound was measured at the dose of 30 umol/kg,1,CHEMBL623229,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9134,,Plasma,,1,N,50597,1969.0,The maximum plasma levels for the compounds were determined by LC-MS.,1,CHEMBL623230,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9135,,Plasma,,1,N,50597,1969.0,mean peak plasma concentration was observed after intravenous administration in rat,1,CHEMBL623231,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9136,,Plasma,,1,N,50597,1969.0,mean peak plasma concentration was observed after oral administration in rat,1,CHEMBL623232,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9137,,,,1,N,50597,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,1,CHEMBL623233,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9138,,,,1,N,50597,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,1,CHEMBL623234,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9139,,,,1,N,50597,,Concentration in plasma (portal) following oral dose in rats at 1 hr,1,CHEMBL623235,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9140,,,,1,N,50597,,Concentration in plasma (portal) following oral dose in rats at 2 hr,1,CHEMBL623236,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9141,,,,1,N,50597,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,1,CHEMBL623237,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9142,,,,1,N,50597,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,1,CHEMBL623238,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9143,,,,1,N,50597,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,1,CHEMBL623239,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9144,,Plasma,,1,U,22224,1969.0,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,0,CHEMBL623240,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9145,,Hypothalamus,,1,N,50597,1898.0,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",1,CHEMBL623241,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9146,,Hypothalamus,,1,N,50597,1898.0,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",1,CHEMBL623242,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9147,,,,1,N,50597,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",1,CHEMBL874394,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9148,,,,1,N,50597,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",1,CHEMBL623243,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9149,,,,1,N,50597,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL623244,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9150,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL623245,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9151,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL623246,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9152,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL623247,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9153,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL623248,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9154,,Kidney,,1,N,50597,2113.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL623249,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9155,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL625072,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9156,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,CHEMBL625073,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9157,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL625074,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9158,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL625075,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9159,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,1,CHEMBL625076,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9160,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,CHEMBL625077,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9161,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,CHEMBL625078,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9162,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,CHEMBL874395,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9163,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,CHEMBL625079,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9164,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,CHEMBL625080,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9165,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,CHEMBL625081,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9166,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,CHEMBL625082,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9167,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,CHEMBL625083,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9168,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,CHEMBL625084,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9169,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,CHEMBL625085,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9170,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,CHEMBL625086,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9171,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL625087,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9172,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL625088,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9173,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL622205,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9174,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL622206,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9175,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL622207,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9176,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL622366,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9177,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL622367,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9178,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL875331,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9179,,Liver,,1,N,50597,2107.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL622368,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9180,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL622369,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9181,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,CHEMBL622370,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9182,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL622371,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9183,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL622372,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9184,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,CHEMBL622373,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9185,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,CHEMBL622374,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9186,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,CHEMBL622375,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9187,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,CHEMBL622376,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9188,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,CHEMBL622377,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9189,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,CHEMBL622378,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9190,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,CHEMBL622379,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9191,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,CHEMBL622380,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9192,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,CHEMBL622381,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9193,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,CHEMBL622382,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9194,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL622383,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9195,,Stomach,,1,N,50597,945.0,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,CHEMBL875332,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9196,,Stomach,,1,N,50597,945.0,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,CHEMBL622384,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9197,,Stomach,,1,N,50597,945.0,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,CHEMBL622385,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9198,,Stomach,,1,N,50597,945.0,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,CHEMBL622386,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9199,,,,1,N,50597,,The compound was tested for the plasma binding in rat,1,CHEMBL622387,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9200,,,,1,N,50597,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",1,CHEMBL622388,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9201,,,,1,N,50597,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",1,CHEMBL622389,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9202,,,,1,N,50597,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",1,CHEMBL622390,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9203,,,,1,N,50597,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),1,CHEMBL622391,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9204,,,,1,N,50597,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),1,CHEMBL622392,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9205,,,,1,N,50597,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),1,CHEMBL622393,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9206,,,,1,N,50597,,Plasma level at 2 hr after administration of the compound,1,CHEMBL622394,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9207,,,,1,N,50597,,plasma level at 2 hr after administration of the compound,1,CHEMBL622395,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9208,,Serum,,1,N,50597,1977.0,Stability in rat serum measured as % recovery at 1 min,1,CHEMBL622396,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9209,,Serum,,1,N,50597,1977.0,Stability in rat serum measured as % recovery at 10 min,1,CHEMBL624894,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9210,,Serum,,1,N,50597,1977.0,Stability in rat serum measured as % recovery at 10 mins,1,CHEMBL624895,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9211,,Serum,,1,N,50597,1977.0,Stability in rat serum measured as % recovery at 2 hr,1,CHEMBL624058,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9212,,Serum,,1,N,50597,1977.0,Stability in rat serum measured as % recovery at 3 min,1,CHEMBL624059,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9213,,Serum,,1,N,50597,1977.0,Stability in rat serum measured as % recovery at 3 mins,1,CHEMBL624060,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9214,,Serum,,1,N,50597,1977.0,Stability in rat serum measured as % recovery at 5 min,1,CHEMBL624061,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9215,,Serum,,1,N,50597,1977.0,Stability in rat serum measured as % recovery at 5 mins,1,CHEMBL624062,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9216,,,,1,N,50597,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,CHEMBL624063,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9217,,,,1,N,50597,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,CHEMBL624064,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9218,,Plasma,,1,N,50597,1969.0,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,1,CHEMBL624065,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9219,,Plasma,,1,N,50597,1969.0,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,1,CHEMBL624066,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9220,,,,1,N,50597,,Half life tested in mature male rat at a dose of 30 mg/kg,1,CHEMBL877490,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9221,,,,1,N,50597,,Half life after intravenous administration of 1 mg/kg in rat,1,CHEMBL874442,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9222,,,,1,N,50597,,Half life period after administration (30 mg/kg) in rat,1,CHEMBL626890,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9223,,,,1,N,50597,,Half life period in rat after 5 mg/Kg dose,1,CHEMBL626891,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9224,,,,1,N,50597,,Half life period in rat after 5 mg/kg dose,1,CHEMBL626892,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9225,,,,1,N,50597,,Half life period was determined,1,CHEMBL626893,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9226,,,,1,N,50597,,Half life period was evaluated in rat,1,CHEMBL626894,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9227,,,,1,N,50597,,Half life period was evaluated in rat; 0.5-1.0,1,CHEMBL626895,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9228,,,,1,N,50597,,Half life period was evaluated in rat; 5.9-7.5,1,CHEMBL626896,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9229,,Plasma,,1,N,50597,1969.0,Half-life in rat plasma,1,CHEMBL626897,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9230,,,,1,N,50597,,Half-life time in rat was determined,1,CHEMBL626898,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9231,,,,1,N,50597,,Terminal half-life after iv administration to rats,1,CHEMBL626899,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9232,,,,1,N,50597,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,1,CHEMBL626900,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9233,,,,1,N,50597,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,1,CHEMBL626901,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9234,,,,1,N,50597,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),1,CHEMBL626902,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9235,,,,1,N,50597,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),1,CHEMBL626903,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9236,,,,1,N,50597,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,1,CHEMBL874443,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9237,,,,1,N,50597,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,1,CHEMBL626904,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9238,,,,1,N,50597,,Half life in rats,1,CHEMBL626905,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9239,,Plasma,,1,N,50597,1969.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,CHEMBL873830,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9240,,,,1,N,50597,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,1,CHEMBL626906,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9241,,Plasma,,1,N,50597,1969.0,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,CHEMBL631076,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9242,,Plasma,,1,N,50597,1969.0,Biological half-life was measured in plasma of rats,1,CHEMBL631077,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9243,,,,1,N,50597,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,CHEMBL631078,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9244,,,,1,N,50597,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,1,CHEMBL631079,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9245,,,,1,N,50597,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,1,CHEMBL631080,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9246,,,,1,N,50597,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,1,CHEMBL631081,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9247,,,,1,N,50597,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,1,CHEMBL631239,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9248,,Plasma,,1,N,50597,1969.0,Compound was evaluated for plasma half life in rat,1,CHEMBL631240,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9249,,Plasma,,1,N,50597,1969.0,AUC value at a dose of 5 mg/kg (p.o.) in rats,1,CHEMBL631241,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9250,,Plasma,,1,N,50597,1969.0,AUC value after administration of 20 mg/Kg oral dose in rat,1,CHEMBL631242,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9251,,Plasma,,1,N,50597,1969.0,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,1,CHEMBL631243,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9252,,Plasma,,1,N,50597,1969.0,AUC0-96 after administration at 50 mg/kg,1,CHEMBL874444,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9253,,Plasma,,1,N,50597,1969.0,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,1,CHEMBL631244,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9254,,,,1,N,50597,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",1,CHEMBL631245,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9255,,,,1,N,50597,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,1,CHEMBL627162,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9256,,,,1,N,50597,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,1,CHEMBL627163,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9257,,,,1,N,50597,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,1,CHEMBL627164,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9258,,Kidney,,1,N,50597,2113.0,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,1,CHEMBL627165,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9259,,,,1,N,50597,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,1,CHEMBL627166,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9260,,,,1,N,50597,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,1,CHEMBL627167,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9261,,,,1,N,50597,,Area under curve (AUC) at a dose of 30 mg/kg in rats,1,CHEMBL627822,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9262,,,,1,N,50597,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,CHEMBL627823,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9263,,,,1,N,50597,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,1,CHEMBL627824,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9264,,,,1,N,50597,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,CHEMBL627825,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9265,,,,1,N,50597,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,1,CHEMBL627826,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9266,,,,1,N,50597,,Area under curve (Pharmacokinetic property) was determined,1,CHEMBL627827,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9267,,,,1,N,50597,,Area under curve (Pharmacokinetic property) of the compound; Not determined,1,CHEMBL627828,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9268,,,,1,N,50597,,Area under curve after intravenous administration (1 mg/kg) in rat,1,CHEMBL627829,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9269,,,,1,N,50597,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,1,CHEMBL627830,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9270,,,,1,N,50597,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,1,CHEMBL627831,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9271,,,,1,N,50597,,Area under curve in male SD rats was observed after oral administration in rat,1,CHEMBL627832,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9272,,,,1,N,50597,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,1,CHEMBL627833,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9273,,,,1,N,50597,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,1,CHEMBL627834,Rattus norvegicus,,A,10116.0,,,Expert,,BAO_0000218
9274,,,,1,N,50597,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,1,CHEMBL628004,Rattus norvegicus,,A,10116.0,,,Expert,,BAO_0000218
9275,,,,1,N,50597,,Area under curve at 5 mg/kg po was determined in rat,1,CHEMBL628005,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9276,,,,1,N,50597,,Area under curve in Rat at a oral dose of 5 mg/kg,1,CHEMBL628006,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9277,,,,1,N,50597,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,CHEMBL628007,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9278,,,,1,N,50597,,Area under curve was determined,1,CHEMBL625676,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9279,,,,1,N,50597,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,1,CHEMBL631309,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9280,,,,1,N,50597,,Area under curve after intravenous administration at 3 mg/kg,1,CHEMBL631310,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9281,,,,1,N,50597,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,1,CHEMBL631311,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9282,,,,1,N,50597,,Area under curve at 4 hr in rat,1,CHEMBL631312,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9283,,,,1,N,50597,,Area under curve at a dose of 30 mg/kg,1,CHEMBL631313,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9284,,,,1,N,50597,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,1,CHEMBL631314,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9285,,,,1,N,50597,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,1,CHEMBL631315,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9286,,,,1,N,50597,,Area under curve for a 2-mpk po dose in SD rats,1,CHEMBL631316,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9287,,,,1,N,50597,,Area under curve in SD rats,1,CHEMBL631317,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9288,,,,1,N,50597,,Area under curve in rat after oral administration at 13 mg/kg dose,1,CHEMBL874471,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9289,,,,1,N,50597,,Area under curve in rat by po administration at 0-24 hr,1,CHEMBL631318,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9290,,Plasma,,1,N,50597,1969.0,Area under curve in rat plasma,1,CHEMBL631319,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9291,,,,1,N,50597,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,1,CHEMBL631320,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9292,,,,1,N,50597,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,1,CHEMBL631321,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9293,,,,1,N,50597,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,1,CHEMBL631322,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9294,,,,1,N,50597,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,1,CHEMBL631323,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9295,,,,1,N,50597,,Area under curve value in rat at a dose of 5 mg/kg,1,CHEMBL631324,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9296,,,,1,N,50597,,Area under curve was determined after oral administration in rats,1,CHEMBL631325,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9297,,,,1,N,50597,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,CHEMBL631326,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9298,,,,1,N,50597,,Area under curve was determined after peroral administration in rat,1,CHEMBL631327,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9299,,,,1,N,50597,,Area under curve was determined at a dose 30 mpk administered orally.,1,CHEMBL631328,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9300,,,,1,N,50597,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,1,CHEMBL631329,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9301,,,,1,N,50597,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,1,CHEMBL627217,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9302,,,,1,N,50597,,Area under curve was determined in male rat,1,CHEMBL626352,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9303,,,,1,N,50597,,Area under curve was determined in rat after PO administration,1,CHEMBL626353,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9304,,,,1,N,50597,,Area under curve was determined in rat after a 3 mg/kg of oral dose,1,CHEMBL626354,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9305,,,,1,N,50597,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,1,CHEMBL626355,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9306,,,,1,N,50597,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,1,CHEMBL626356,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9307,,,,1,N,50597,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,1,CHEMBL626357,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9308,,,,1,N,50597,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL626358,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9309,,,,1,N,50597,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL626359,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9310,,Plasma,,1,N,50597,1969.0,Peak plasma concentration in rat at a dose of 3 mg/kg,1,CHEMBL626360,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9311,,,,1,N,50597,,Plasma concentration at 2 hr in rats was evaluated.,1,CHEMBL626361,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9312,,,,1,N,50597,,Plasma concentration at 2 hr in rats was evaluated; Not available,1,CHEMBL626362,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9313,,,,1,N,50597,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL626363,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9314,,,,1,N,50597,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,CHEMBL626970,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9315,,,,1,N,50597,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,CHEMBL626971,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9316,,Plasma,,1,N,50597,1969.0,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,CHEMBL626972,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9317,,Plasma,,1,N,50597,1969.0,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,CHEMBL626973,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9318,,Plasma,,1,N,50597,1969.0,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,CHEMBL626974,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9319,,Plasma,,1,N,50597,1969.0,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,CHEMBL874592,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9320,,,,1,N,50597,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,1,CHEMBL626975,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9321,,,,1,N,50597,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,1,CHEMBL626976,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9322,,,,1,N,50597,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,1,CHEMBL626977,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9323,,,,1,N,50597,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,1,CHEMBL626978,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9324,,,,1,N,50597,,PK study was carried to determine the relative absorption ranking in rat.,1,CHEMBL626979,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9325,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,1,CHEMBL626980,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9326,,Blood,,1,N,50597,178.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",1,CHEMBL626981,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9327,,Blood,,1,N,50597,178.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",1,CHEMBL626982,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9328,,Blood,,1,N,50597,178.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",1,CHEMBL626983,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9329,,Blood,,1,N,50597,178.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",1,CHEMBL622522,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9330,,Blood,,1,N,50597,178.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",1,CHEMBL622523,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9331,,Blood,,1,N,50597,178.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",1,CHEMBL622524,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9332,,Brain,,1,N,50597,955.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",1,CHEMBL622525,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9333,,Brain,,1,N,50597,955.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",1,CHEMBL622526,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9334,,Brain,,1,N,50597,955.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",1,CHEMBL619849,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9335,,Brain,,1,N,50597,955.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",1,CHEMBL619850,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9336,,Brain,,1,N,50597,955.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",1,CHEMBL623864,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9337,,Brain,,1,N,50597,955.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",1,CHEMBL623865,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9338,,Heart,,1,N,50597,948.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",1,CHEMBL623866,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9339,,Heart,,1,N,50597,948.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",1,CHEMBL623867,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9340,,Heart,,1,N,50597,948.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",1,CHEMBL877615,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9341,,Heart,,1,N,50597,948.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",1,CHEMBL623868,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9342,,Heart,,1,N,50597,948.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",1,CHEMBL623869,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9343,,Heart,,1,N,50597,948.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",1,CHEMBL623870,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9344,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL623871,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9345,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL623872,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9346,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL622129,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9347,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL622130,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9348,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL622131,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9349,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL622132,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9350,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL622133,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9351,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL622134,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9352,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,CHEMBL622135,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9353,,Lung,,1,N,50597,2048.0,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,CHEMBL622136,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9354,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL622137,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9355,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,CHEMBL622138,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9356,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL623017,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9357,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL623018,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9358,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,CHEMBL623019,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9359,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,CHEMBL623020,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9360,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,1,CHEMBL623021,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9361,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,CHEMBL623022,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9362,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,CHEMBL623023,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9363,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,CHEMBL623024,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9364,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,CHEMBL623025,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9365,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,CHEMBL620545,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9366,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,CHEMBL620546,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9367,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,CHEMBL620547,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9368,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,CHEMBL620548,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9369,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,CHEMBL620549,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9370,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL620550,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9371,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL620551,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9372,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL620552,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9373,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL620553,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9374,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL620554,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9375,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL875845,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9376,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL620555,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9377,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL620556,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9378,,Muscle tissue,,1,N,50597,2385.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL620557,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9379,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL620558,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9380,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,CHEMBL620559,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9381,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL622939,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9382,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL622940,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9383,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,CHEMBL622941,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9384,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,CHEMBL622942,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9385,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,CHEMBL622943,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9386,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,CHEMBL622944,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9387,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,CHEMBL622945,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9388,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,CHEMBL622946,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9389,,,,1,N,50597,,Compound was evaluated for terminal half life in rat,1,CHEMBL622947,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9390,,Plasma,,1,N,50597,1969.0,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,1,CHEMBL622948,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9391,,Plasma,,1,N,50597,1969.0,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,1,CHEMBL622949,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9392,,,,1,N,50597,,Compound was tested for its half life in rat,1,CHEMBL622950,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9393,,Plasma,,1,U,22224,1969.0,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,0,CHEMBL622951,Macaca mulatta,,A,9544.0,In vivo,,Intermediate,,BAO_0000218
9394,,Plasma,,1,U,22224,1969.0,Compound was tested for its plasma half life in Sprague Dawley rats,0,CHEMBL622952,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000366
9395,,Plasma,,1,U,22224,1969.0,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,0,CHEMBL622953,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000366
9396,,Plasma,,1,N,50597,1969.0,Compound was tested for plasma half-life period in rat,1,CHEMBL873818,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9397,,,,1,N,50597,,Elimination half life after i.v. administration of compound in rats,1,CHEMBL622954,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9398,,,,1,N,50597,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,1,CHEMBL622955,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9399,,,,1,N,50597,,Elimination half-life after IV dosing at 1 mg/kg in rat,1,CHEMBL875229,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9400,,,,1,N,50597,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,1,CHEMBL622956,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9401,,,,1,N,50597,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,1,CHEMBL622957,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9402,,Brain,,1,N,50597,955.0,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,CHEMBL622958,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9403,,Plasma,,1,N,50597,1969.0,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,CHEMBL622959,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9404,,Brain,,1,N,50597,955.0,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,CHEMBL622960,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9405,,Plasma,,1,N,50597,1969.0,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,CHEMBL622961,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9406,,,,1,N,50597,,Evaluated for the half life in rat (in vivo),1,CHEMBL622962,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9407,,,,1,N,50597,,Hafl life in rat,1,CHEMBL622963,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9408,,,,1,N,50597,,Hafl life rat,1,CHEMBL622964,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9409,,,,1,N,50597,,Hafl life rat,1,CHEMBL622965,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9410,,,,1,N,50597,,Hafl life rat; Not determined,1,CHEMBL622966,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9411,,,,1,N,50597,,Hafl life rat; Not determined,1,CHEMBL622967,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9412,,Kidney,,1,N,50597,2113.0,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL622968,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9413,,Liver,,1,N,50597,2107.0,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL622969,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9414,,Lung,,1,N,50597,2048.0,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL875327,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9415,,,,1,N,50597,,Half life in rat after 1 mg/kg i.v. administration,1,CHEMBL628638,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9416,,,,1,N,50597,,Half life in rat after 2 mg/kg peroral administration,1,CHEMBL628639,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9417,,,,1,N,50597,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL625840,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9418,,,,1,N,50597,,Half life of 10 mg/kg oral dose determined in rats,1,CHEMBL625841,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9419,,,,1,N,50597,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,CHEMBL625842,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9420,,,,1,N,50597,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL625843,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9421,,,,1,N,50597,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL625844,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9422,,,,1,N,50597,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL873822,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9423,,,,1,N,50597,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,CHEMBL625845,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9424,,,,1,N,50597,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,CHEMBL627059,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9425,,,,1,N,50597,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL627060,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9426,,,,1,N,50597,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,CHEMBL627061,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9427,,,,1,N,50597,,Half life of compound at 5 mg/kg after po administration was determined in rat,1,CHEMBL627709,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9428,,,,1,N,50597,,Half life of compound determined after intravenous administration to rat,1,CHEMBL627710,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9429,,,,1,N,50597,,Half life of compound was determined in rat,1,CHEMBL627711,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9430,,Plasma,,1,N,50597,1969.0,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1,CHEMBL627712,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9431,,,,1,N,50597,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL627713,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9432,,,,1,N,50597,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL627714,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9433,,,,1,U,22224,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,0,CHEMBL627889,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
9434,,,,1,U,22224,,Half life determined in rat by intravenous administration,0,CHEMBL627890,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9435,,,,1,N,50597,,Half life determined in rats after iv administration,1,CHEMBL627891,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9436,,Plasma,,1,N,50597,1969.0,Half life in rat plasma after administration of 2 mg/kg iv,1,CHEMBL627892,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9437,,Plasma,,1,N,50597,1969.0,Half life in rat plasma after administration of 2 mg/kg iv,1,CHEMBL627893,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9438,,Plasma,,1,N,50597,1969.0,Half life in rat plasma was determined,1,CHEMBL627894,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9439,,Plasma,,1,N,50597,1969.0,Half life in rat plasma was determined; NA means not applicable,1,CHEMBL627895,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9440,,,,1,N,50597,,Half life in rat was tested,1,CHEMBL627896,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9441,,Plasma,,1,N,50597,1969.0,Half life measured in rat plasma,1,CHEMBL627897,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9442,,,,1,N,50597,,Half life recorded in rats,1,CHEMBL627898,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9443,,,,1,N,50597,,Half life was calculated,1,CHEMBL627899,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9444,,,,1,N,50597,,Half life was calculated in rat,1,CHEMBL873823,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9445,,,,1,N,50597,,Half life was determined,1,CHEMBL627900,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9446,,,,1,N,50597,,Half life after 10 mg/kg oral administration in rat,1,CHEMBL627901,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9447,,,,1,N,50597,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,1,CHEMBL627902,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9448,,,,1,N,50597,,Half life after administering orally a dose of 30 mg/kg,1,CHEMBL627903,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9449,,,,1,N,50597,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,1,CHEMBL627904,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9450,,,,1,N,50597,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,1,CHEMBL627905,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9451,,,,1,N,50597,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,1,CHEMBL627906,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9452,,,,1,N,50597,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,1,CHEMBL627907,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9453,,,,1,N,50597,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,1,CHEMBL876783,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9454,,,,1,N,50597,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,1,CHEMBL627908,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9455,,,,1,N,50597,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,CHEMBL627909,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9456,,,,1,N,50597,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,1,CHEMBL627910,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9457,,,,1,N,50597,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),1,CHEMBL627911,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9458,,,,1,N,50597,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),1,CHEMBL627912,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9459,,,,1,N,50597,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),1,CHEMBL627913,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9460,,,,1,N,50597,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),1,CHEMBL627914,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9461,,,,1,N,50597,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,1,CHEMBL627915,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9462,,,,1,N,50597,,Area under the curve was evaluated after 20 uM/kg of peroral administration,1,CHEMBL627916,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9463,,,,1,N,50597,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,1,CHEMBL627917,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9464,,,,1,N,50597,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,1,CHEMBL627918,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9465,,,,1,N,50597,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,1,CHEMBL627919,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9466,,,,1,N,50597,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,1,CHEMBL627920,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9467,,,,1,N,50597,,Area under the curve was evaluated at an oral dose of 30 mg/kg,1,CHEMBL627921,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9468,,,,1,N,50597,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL627922,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9469,,,,1,N,50597,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL876784,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9470,,,,1,N,50597,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL627923,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9471,,,,1,N,50597,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL626208,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9472,,,,1,N,50597,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL626209,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9473,,,,1,N,50597,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL626210,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9474,,Plasma,,1,N,50597,1969.0,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,CHEMBL627994,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9475,,,,1,N,50597,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,1,CHEMBL627995,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9476,,,,1,N,50597,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,1,CHEMBL627996,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9477,,,,1,N,50597,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,1,CHEMBL627997,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9478,,,,1,N,50597,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,1,CHEMBL627998,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9479,,,,1,N,50597,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,1,CHEMBL628640,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9480,,,,1,N,50597,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,1,CHEMBL628641,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9481,,,,1,N,50597,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,1,CHEMBL628642,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9482,,,,1,N,50597,,Compound was evaluated for area under the curve expressed as (h*ug/ml),1,CHEMBL628643,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9483,,,,1,N,50597,,Compound was tested for area under curve in rat,1,CHEMBL628644,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9484,,,,1,N,50597,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,1,CHEMBL628645,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9485,,,,1,N,50597,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,CHEMBL628646,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9486,,,,1,N,50597,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),1,CHEMBL628647,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9487,,,,1,N,50597,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,CHEMBL628648,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9488,,,,1,N,50597,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,CHEMBL625358,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9489,,,,1,N,50597,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,CHEMBL625359,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9490,,,,1,N,50597,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,CHEMBL625360,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9491,,,,1,N,50597,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),1,CHEMBL625361,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9492,,,,1,N,50597,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),1,CHEMBL625362,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9493,,,,1,N,50597,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),1,CHEMBL625363,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9494,,,,1,N,50597,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,CHEMBL625364,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9495,,,,1,N,50597,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,CHEMBL625365,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9496,,,,1,N,50597,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,CHEMBL625366,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9497,,,,1,N,50597,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,CHEMBL625367,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9498,,Kidney,,1,N,50597,2113.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",1,CHEMBL625368,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9499,,Kidney,,1,N,50597,2113.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",1,CHEMBL625369,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9500,,Kidney,,1,N,50597,2113.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",1,CHEMBL625370,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9501,,Kidney,,1,N,50597,2113.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",1,CHEMBL625371,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9502,,Kidney,,1,N,50597,2113.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",1,CHEMBL625372,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9503,,Kidney,,1,N,50597,2113.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",1,CHEMBL625373,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9504,,Liver,,1,N,50597,2107.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",1,CHEMBL625374,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9505,,Liver,,1,N,50597,2107.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",1,CHEMBL877593,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9506,,Liver,,1,N,50597,2107.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",1,CHEMBL625375,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9507,,Liver,,1,N,50597,2107.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",1,CHEMBL625376,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9508,,Liver,,1,N,50597,2107.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",1,CHEMBL621973,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9509,,Liver,,1,N,50597,2107.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",1,CHEMBL621974,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9510,,Lung,,1,N,50597,2048.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",1,CHEMBL621975,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9511,,Lung,,1,N,50597,2048.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",1,CHEMBL622166,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9512,,Lung,,1,N,50597,2048.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",1,CHEMBL622167,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9513,,Lung,,1,N,50597,2048.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",1,CHEMBL622168,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9514,,Lung,,1,N,50597,2048.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",1,CHEMBL622169,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9515,,Lung,,1,N,50597,2048.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",1,CHEMBL622170,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9516,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",1,CHEMBL622171,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9517,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",1,CHEMBL622172,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9518,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",1,CHEMBL622173,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9519,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",1,CHEMBL622174,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9520,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",1,CHEMBL622175,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9521,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",1,CHEMBL622176,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9522,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",1,CHEMBL622177,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9523,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",1,CHEMBL622178,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9524,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",1,CHEMBL622179,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9525,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",1,CHEMBL622180,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9526,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,CHEMBL622181,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9527,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,CHEMBL622182,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9528,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,CHEMBL622183,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9529,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,CHEMBL622184,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9530,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,CHEMBL622185,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9531,,,,1,N,50597,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,CHEMBL622186,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9532,,,,1,N,50597,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL622187,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9533,,,,1,N,50597,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL625002,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9534,,,,1,N,50597,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL622090,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9535,,,,1,N,50597,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL622091,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9536,,,,1,N,50597,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL622092,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9537,,,,1,N,50597,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL622093,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9538,,,,1,N,50597,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL622094,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9539,,,,1,N,50597,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL622095,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9540,,,,1,N,50597,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL622264,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9541,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL622265,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9542,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,CHEMBL622266,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9543,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL622267,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9544,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL622268,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9545,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,CHEMBL622269,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9546,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,CHEMBL625071,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9547,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,CHEMBL621621,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9548,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,CHEMBL621622,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9549,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,CHEMBL621623,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9550,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,CHEMBL621624,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9551,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,CHEMBL621625,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9552,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,CHEMBL621626,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9553,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,CHEMBL621627,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9554,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,CHEMBL621628,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9555,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,CHEMBL875328,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9556,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,CHEMBL621629,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9557,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL621630,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9558,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL621631,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9559,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL621632,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9560,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL621633,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9561,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL621634,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9562,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL621635,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9563,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL621636,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9564,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL621637,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9565,,Spleen,,1,N,50597,2106.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL621638,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9566,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL618883,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9567,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,CHEMBL618884,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9568,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL628627,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9569,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL628628,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9570,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,CHEMBL628629,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9571,,,,1,N,50597,,Half life after administering orally a dose of 3 mg/kg,1,CHEMBL628630,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9572,,,,1,N,50597,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,1,CHEMBL628631,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9573,,,,1,N,50597,,Half life after administering intravenously a dose of 1 mg/kg,1,CHEMBL628632,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9574,,,,1,N,50597,,Half life after oral dosing in rats,1,CHEMBL628633,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9575,,,,1,N,50597,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,1,CHEMBL628634,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9576,,,,1,N,50597,,Half life by intravenous administration of 3.4 mg/kg in rat,1,CHEMBL627789,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9577,,,,1,N,50597,,Half life in rat,1,CHEMBL627790,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9578,,,,1,N,50597,,Half life in rat,1,CHEMBL627791,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9579,,,,1,N,50597,,Half life in rat,1,CHEMBL627792,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9580,,,,1,N,50597,,Half life in rat after intravenous administration of the compound,1,CHEMBL627793,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9581,,Plasma,,1,N,50597,1969.0,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,1,CHEMBL627794,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9582,,,,1,N,50597,,Half life in rat after po administration of the compound,1,CHEMBL627795,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9583,,,,1,N,50597,,Half life in rat after po administration of the compound; ND means Not determined,1,CHEMBL627796,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9584,,Plasma,,1,N,50597,1969.0,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,1,CHEMBL875335,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9585,,Plasma,,1,N,50597,1969.0,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,1,CHEMBL627797,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9586,,,,1,N,50597,,Half life in rat i.v.,1,CHEMBL627798,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9587,,,,1,N,50597,,Half life in rat i.v. at 2 mg/kg concentration,1,CHEMBL627799,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9588,,,,1,N,50597,,Half life in rats,1,CHEMBL627800,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9589,,,,1,N,50597,,Half life in rats after intravenous administration,1,CHEMBL627801,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9590,,,,1,N,50597,,Half life in rats at the dose of 1.0 mpk by i.v. administration,1,CHEMBL627802,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9591,,,,1,N,50597,,Half life in rat,1,CHEMBL627803,Rattus norvegicus,,A,10116.0,,,Expert,,BAO_0000218
9592,,,,1,N,50597,,Half life was evaluated after intravenous administration to rats,1,CHEMBL873820,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9593,,,,1,N,50597,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),1,CHEMBL627804,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9594,,,,1,N,50597,,Half life was evaluated in rat,1,CHEMBL627805,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9595,,,,1,N,50597,,Half life was evaluated in rat,1,CHEMBL627806,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9596,,,,1,N,50597,,Half life was evaluated in rat; Not tested,1,CHEMBL627107,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9597,,,,1,N,50597,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,1,CHEMBL627108,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9598,,,,1,N,50597,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,1,CHEMBL627109,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9599,,Blood,,1,N,50597,178.0,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,1,CHEMBL627110,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9600,,,,1,U,22224,,Half life was measured in monkey at dose of 10 mg/kg by po administration,0,CHEMBL627111,Primates,,A,9443.0,In vivo,,Intermediate,,BAO_0000218
9601,,,,1,U,22224,,Half life was measured in monkey at dose of 10 mg/kg by po administration,0,CHEMBL627112,Primates,,A,9443.0,In vivo,,Intermediate,,BAO_0000218
9602,,,,1,U,22224,,Half life was measured in rat at dose of 30 mg/kg by iv administration,0,CHEMBL627113,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9603,,,,1,U,22224,,Half life was measured in rat at dose of 30 mg/kg by po administration,0,CHEMBL627114,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9604,,,,1,N,50597,,Half life (t1/2) was determined,1,CHEMBL627115,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9605,,,,1,N,50597,,Half life period at a dose of 10 uM/kg in rat was determined,1,CHEMBL627116,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9606,,,,1,N,50597,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,1,CHEMBL627117,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9607,,,,1,N,50597,,Half life period was determined,1,CHEMBL627118,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9608,,,,1,N,50597,,Half life period after intravenous administration at 20 mpk in rats,1,CHEMBL627119,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9609,,,,1,N,50597,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,1,CHEMBL627120,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9610,,,,1,N,50597,,Half life period after intravenous administration in rat,1,CHEMBL626922,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9611,,,,1,N,50597,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,CHEMBL626923,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9612,,,,1,N,50597,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,CHEMBL626924,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9613,,Plasma,,1,N,50597,1969.0,Half life period in 80% rat plasma at 37 degree Centigrade,1,CHEMBL626925,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9614,,,,1,N,50597,,Half life period in SD rats,1,CHEMBL626926,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9615,,Plasma,,1,N,50597,1969.0,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),1,CHEMBL626927,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9616,,Plasma,,1,N,50597,1969.0,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),1,CHEMBL626928,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9617,,Plasma,,1,N,50597,1969.0,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,CHEMBL626929,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9618,,Plasma,,1,N,50597,1969.0,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,CHEMBL626930,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9619,,,,1,N,50597,,Half life period in rat,1,CHEMBL626931,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9620,,,,1,N,50597,,Half life period in rat,1,CHEMBL626932,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9621,,,,1,N,50597,,Half life period in rat,1,CHEMBL626933,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9622,,,,1,N,50597,,Half life period in rat after oral administration at 10.5 mg/kg dose,1,CHEMBL873826,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9623,,,,1,N,50597,,Half life period in rat after oral administration at 11.2 mg/kg dose,1,CHEMBL626934,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9624,,,,1,N,50597,,Half life period in rat after oral administration at 13 mg/kg dose,1,CHEMBL626935,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9625,,,,1,N,50597,,Half life period in rat after oral administration at 9.7 mg/kg dose,1,CHEMBL626936,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9626,,,,1,N,50597,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,CHEMBL626937,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9627,,,,1,N,50597,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,CHEMBL625906,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9628,,,,1,N,50597,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,CHEMBL625907,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9629,,,,1,N,50597,,PK study was carried to determine AUC (area under curve) value in rat,1,CHEMBL625908,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9630,,,,1,N,50597,,Pharmacokinetic parameter AUC after intravenous administration to rats,1,CHEMBL625909,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9631,,,,1,N,50597,,Pharmacokinetic parameter AUC after oral administration to rats,1,CHEMBL625910,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9632,,,,1,N,50597,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,1,CHEMBL625911,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9633,,,,1,N,50597,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,1,CHEMBL625912,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9634,,,,1,N,50597,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,1,CHEMBL626538,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9635,,,,1,N,50597,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,1,CHEMBL876794,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9636,,,,1,N,50597,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,1,CHEMBL626539,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9637,,,,1,N,50597,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,1,CHEMBL626540,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9638,,,,1,N,50597,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,1,CHEMBL626541,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9639,,,,1,N,50597,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,1,CHEMBL626542,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9640,,,,1,N,50597,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,1,CHEMBL626543,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9641,,,,1,N,50597,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,1,CHEMBL626544,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9642,,,,1,N,50597,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,1,CHEMBL626545,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9643,,,,1,N,50597,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,1,CHEMBL626546,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9644,,,,1,N,50597,,Pharmacokinetic parameter area under curve was reported,1,CHEMBL626547,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9645,,,,1,N,50597,,Pharmacokinetic property (AUC) in rat,1,CHEMBL626548,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9646,,,,1,N,50597,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,1,CHEMBL626549,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9647,,,,1,N,50597,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,1,CHEMBL626550,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9648,,,,1,N,50597,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,1,CHEMBL626551,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9649,,,,1,N,50597,,Pharmacokinetic property was determined,1,CHEMBL623777,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9650,,,,1,N,50597,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,1,CHEMBL623778,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9651,,,,1,N,50597,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,1,CHEMBL623779,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9652,,Plasma,,1,N,50597,1969.0,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,CHEMBL623780,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9653,,Plasma,,1,N,50597,1969.0,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,1,CHEMBL622015,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9654,,Plasma,,1,N,50597,1969.0,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,1,CHEMBL622016,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9655,,,,1,N,50597,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",1,CHEMBL622017,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9656,,,,1,N,50597,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",1,CHEMBL622018,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9657,,,,1,N,50597,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",1,CHEMBL622019,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9658,,,,1,N,50597,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",1,CHEMBL622020,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9659,,,,1,N,50597,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,1,CHEMBL622021,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9660,,,,1,N,50597,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,1,CHEMBL622022,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9661,,,,1,N,50597,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,1,CHEMBL622023,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9662,,,,1,N,50597,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,1,CHEMBL622024,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9663,,,,1,N,50597,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),1,CHEMBL622693,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9664,,,,1,N,50597,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),1,CHEMBL622694,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9665,,,,1,N,50597,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,CHEMBL622695,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9666,,,,1,N,50597,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,CHEMBL622696,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9667,,,,1,N,50597,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",1,CHEMBL622697,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9668,,,,1,N,50597,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",1,CHEMBL622874,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9669,,,,1,N,50597,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",1,CHEMBL622875,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9670,,,,1,N,50597,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,1,CHEMBL622876,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9671,,,,1,N,50597,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,CHEMBL622877,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9672,,,,1,N,50597,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,CHEMBL622878,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9673,,Plasma,,1,N,50597,1969.0,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,1,CHEMBL622879,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9674,,,,1,N,50597,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,1,CHEMBL877602,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9675,,,,1,N,50597,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL622880,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9676,,,,1,N,50597,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL622881,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9677,,,,1,N,50597,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL622882,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9678,,,,1,N,50597,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL622883,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9679,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",1,CHEMBL622884,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9680,,Thyroid gland,,1,N,50597,2046.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",1,CHEMBL622885,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9681,,,,1,N,50597,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,CHEMBL622886,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9682,,,,1,N,50597,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,CHEMBL622887,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9683,,Urine,,1,N,50597,1088.0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,CHEMBL622888,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9684,,Blood,,1,N,50597,178.0,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622889,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9685,,Blood,,1,N,50597,178.0,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622890,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9686,,Blood,,1,N,50597,178.0,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622891,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9687,,Blood,,1,N,50597,178.0,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL877603,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9688,,Brain,,1,N,50597,955.0,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622892,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9689,,Brain,,1,N,50597,955.0,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622893,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9690,,Brain,,1,N,50597,955.0,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622894,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9691,,Brain,,1,N,50597,955.0,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622895,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9692,,Brain,,1,N,50597,955.0,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,1,CHEMBL622896,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9693,,Heart,,1,N,50597,948.0,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622897,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9694,,Heart,,1,N,50597,948.0,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622898,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9695,,Heart,,1,N,50597,948.0,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622899,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9696,,Kidney,,1,N,50597,2113.0,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622900,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9697,,Kidney,,1,N,50597,2113.0,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL624114,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9698,,Kidney,,1,N,50597,2113.0,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL624115,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9699,,Kidney,,1,N,50597,2113.0,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL624116,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9700,,Liver,,1,N,50597,2107.0,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL624117,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9701,,Liver,,1,N,50597,2107.0,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL624118,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9702,,Liver,,1,N,50597,2107.0,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL624119,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9703,,Liver,,1,N,50597,2107.0,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL624120,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9704,,Lung,,1,N,50597,2048.0,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL624121,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9705,,Lung,,1,N,50597,2048.0,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL624122,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9706,,Lung,,1,N,50597,2048.0,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL624123,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9707,,Lung,,1,N,50597,2048.0,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL624124,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9708,,Muscle tissue,,1,N,50597,2385.0,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL624125,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9709,,Muscle tissue,,1,N,50597,2385.0,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL624126,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9710,,Muscle tissue,,1,N,50597,2385.0,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL624127,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9711,,Muscle tissue,,1,N,50597,2385.0,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL624128,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9712,,Zone of skin,,1,N,50597,14.0,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL624129,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9713,,Zone of skin,,1,N,50597,14.0,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL624130,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9714,,Zone of skin,,1,N,50597,14.0,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622340,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9715,,Zone of skin,,1,N,50597,14.0,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622341,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9716,,Intestine,,1,N,50597,160.0,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622342,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9717,,Intestine,,1,N,50597,160.0,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622343,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9718,,Intestine,,1,N,50597,160.0,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622344,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9719,,Intestine,,1,N,50597,160.0,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622345,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9720,,Spleen,,1,N,50597,2106.0,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622346,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9721,,Spleen,,1,N,50597,2106.0,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622347,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9722,,Spleen,,1,N,50597,2106.0,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622348,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9723,,Spleen,,1,N,50597,2106.0,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622349,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9724,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,CHEMBL622350,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9725,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,CHEMBL622351,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9726,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,CHEMBL622352,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9727,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,CHEMBL622353,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9728,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,CHEMBL622354,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9729,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,CHEMBL622355,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9730,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,CHEMBL622356,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9731,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,CHEMBL622357,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9732,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,CHEMBL622358,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9733,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,CHEMBL622359,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9734,,,,1,N,50597,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,CHEMBL874393,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9735,,,,1,N,50597,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL622872,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9736,,,,1,N,50597,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL622873,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9737,,,,1,N,50597,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL623047,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9738,,,,1,N,50597,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL623048,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9739,,,,1,N,50597,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL623049,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9740,,,,1,N,50597,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL623050,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9741,,,,1,N,50597,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL623051,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9742,,,,1,N,50597,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL623052,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9743,,,,1,N,50597,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL626343,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9744,,,,1,N,50597,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,CHEMBL626344,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9745,,,,1,N,50597,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,CHEMBL626345,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9746,,,,1,N,50597,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,CHEMBL626346,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9747,,,,1,N,50597,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,CHEMBL626347,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9748,,,,1,N,50597,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,CHEMBL626348,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9749,,,,1,N,50597,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,CHEMBL626349,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9750,,,,1,N,50597,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,CHEMBL626350,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
9751,,,,1,N,50597,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,CHEMBL626351,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9752,,,,1,N,50597,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,CHEMBL627650,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9753,,,,1,N,50597,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,CHEMBL627651,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
9754,,,,1,N,50597,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,CHEMBL627652,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9755,,,,1,N,50597,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,CHEMBL627653,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9756,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,1,CHEMBL627654,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9757,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,1,CHEMBL627835,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9758,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,1,CHEMBL627836,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9759,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,1,CHEMBL627837,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9760,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,1,CHEMBL627838,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9761,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,1,CHEMBL875338,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9762,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,1,CHEMBL627839,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9763,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,1,CHEMBL627840,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9764,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,1,CHEMBL627841,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9765,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,1,CHEMBL627842,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9766,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,1,CHEMBL627843,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9767,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,1,CHEMBL627844,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9768,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,1,CHEMBL627845,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9769,,,,1,N,50597,,Half life period in rat by iv administration at a dose of 3 mg/kg,1,CHEMBL627846,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9770,,Plasma,,1,N,50597,1969.0,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),1,CHEMBL627847,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9771,,Plasma,,1,N,50597,1969.0,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),1,CHEMBL873821,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9772,,Plasma,,1,N,50597,1969.0,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,CHEMBL626079,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9773,,Plasma,,1,N,50597,1969.0,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,CHEMBL626080,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9774,,Plasma,,1,N,50597,1969.0,Half life period was evaluated in rat plasma,1,CHEMBL626081,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9775,,Plasma,,1,N,50597,1969.0,Half life period was evaluated in rat plasma; Not tested,1,CHEMBL875344,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9776,,,,1,N,50597,,Half life period was evaluated in rats,1,CHEMBL626082,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9777,,,,1,N,50597,,"Half life period was evaluated in rats, iv",1,CHEMBL626250,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9778,,,,1,N,50597,,Half life period after intravenous administration at 5 mg/kg in rat,1,CHEMBL626251,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9779,,,,1,N,50597,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,CHEMBL626252,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9780,,,,1,N,50597,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,1,CHEMBL626253,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9781,,Plasma,,1,N,50597,1969.0,Half life stability of compound was evaluated in rat plasma,1,CHEMBL626254,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9782,,,,1,N,50597,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,1,CHEMBL626255,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9783,,,,1,N,50597,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,CHEMBL626256,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9784,,,,1,N,50597,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,CHEMBL626257,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9785,,,,1,N,50597,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,1,CHEMBL626258,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9786,,,,1,N,50597,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,1,CHEMBL626259,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9787,,,,1,N,50597,,Half in rat i.v.,1,CHEMBL626260,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9788,,,,1,N,50597,,Half period in rat after intravenous administration,1,CHEMBL875345,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9789,,,,1,N,50597,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,1,CHEMBL626261,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9790,,Liver,,1,N,50597,2107.0,Half-life measured in in vitro Cathepsin B assay in rat liver,1,CHEMBL626262,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
9791,,,,1,N,50597,,Half-life of compound was determined in rats,1,CHEMBL626263,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9792,,,,1,N,50597,,Half-life at 10 mg/kg in rat upon intravenous administration,1,CHEMBL625270,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9793,,,,1,N,50597,,Half-life determined in rat,1,CHEMBL625271,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9794,,,,1,N,50597,,Half-life determined in rat,1,CHEMBL625272,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9795,,Brain,,1,N,50597,955.0,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,1,CHEMBL625273,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9796,,Plasma,,1,N,50597,1969.0,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",1,CHEMBL625274,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9797,,,,1,N,50597,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,CHEMBL625275,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9798,,Plasma,,1,N,50597,1969.0,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,1,CHEMBL625276,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9799,,Plasma,,1,N,50597,1969.0,Half-life in rat plasma,1,CHEMBL625277,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9800,,Plasma,,1,N,50597,1969.0,Half-life in rat plasma was determined,1,CHEMBL625278,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9801,,Plasma,,1,N,50597,1969.0,Half-life in rat plasma; Not tested,1,CHEMBL625279,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9802,,Serum,,1,N,50597,1977.0,Half-life in rat serum,1,CHEMBL625280,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9803,,Serum,,1,N,50597,1977.0,Half-life in rat serum; na is not available,1,CHEMBL876797,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9804,,,,1,N,50597,,Half-life was calculated in rat,1,CHEMBL625281,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9805,,Plasma,,1,N,50597,1969.0,Half-life was calculated in rat plasma,1,CHEMBL873827,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9806,,,,1,N,50597,,Half-life was determined,1,CHEMBL625282,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9807,,,,1,N,50597,,Half-life was determined,1,CHEMBL625283,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9808,,,,1,N,50597,,Half-life after administration of 20 mg/Kg oral dose in rat,1,CHEMBL625284,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9809,,,,1,N,50597,,Half-life after administration of 3.2 mg/kg intravenously in male rat,1,CHEMBL625285,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9810,,,,1,N,50597,,Half-life after intravenous administration in female rat,1,CHEMBL625286,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9811,,,,1,N,50597,,Half-life after intravenous administration in male rat,1,CHEMBL625287,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9812,,,,1,N,50597,,Half-life after intravenous dose in rat,1,CHEMBL625288,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9813,,Liver,,1,N,50597,2107.0,Half-life in a rat liver homogenate preparation,1,CHEMBL625289,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9814,,Plasma,,1,N,50597,1969.0,Half-life in plasma of rat,1,CHEMBL625290,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9815,,Plasma,,1,N,50597,1969.0,Half-life in plasma of rat at dose of 3-10 mgkg,1,CHEMBL876798,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9816,,,,1,N,50597,,Half-life in rat,1,CHEMBL625291,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9817,,,,1,N,50597,,Half-life in rat,1,CHEMBL625292,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9818,,,,1,N,50597,,Half-life in rat,1,CHEMBL625293,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9819,,,,1,N,50597,,Half-life in rat,1,CHEMBL622832,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9820,,,,1,N,50597,,Half-life in rat,1,CHEMBL622833,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9821,,,,1,N,50597,,Half-life in rat,1,CHEMBL622834,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9822,,,,1,N,50597,,Half-life in rat after oral administration at 10 mg/kg,1,CHEMBL622835,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9823,,,,1,N,50597,,Half-life in rat after po administration at a dose of 10 mg/kg,1,CHEMBL622836,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9824,,,,1,N,50597,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,CHEMBL622837,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9825,,,,1,N,50597,,Half-life in rat at 3 mg/kg dose administered intravenously,1,CHEMBL622838,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9826,,Brain,,1,N,50597,955.0,Half-life in rat brain homogenate,1,CHEMBL622839,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9827,,Plasma,,1,N,50597,1969.0,Half-life in rat plasma,1,CHEMBL622840,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9828,,,,1,N,50597,,Half-life in rats,1,CHEMBL622841,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9829,,,,1,N,50597,,Half-life in Dawley rats,1,CHEMBL622842,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9830,,Plasma,,1,N,50597,1969.0,Half-life in vitro in rat plasma,1,CHEMBL622843,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
9831,,Plasma,,1,N,50597,1969.0,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,1,CHEMBL622844,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
9832,,,,1,N,50597,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",1,CHEMBL622845,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9833,,,,1,N,50597,,The area under the curve of compound was measured at the dose of 100 umol/kg,1,CHEMBL622846,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9834,,,,1,N,50597,,The area under the curve of compound was measured at the dose of 300 umol/kg,1,CHEMBL622847,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9835,,,,1,N,50597,,The area under the curve of compound was measured at the dose of 30 umol/kg,1,CHEMBL622848,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9836,,,,1,N,50597,,Bioavailability as oral AUC in rats,1,CHEMBL622849,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9837,,Plasma,,1,N,50597,1969.0,The plasma concentration versus time curve (AUC) was determined,1,CHEMBL622850,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9838,,,,1,N,50597,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL876807,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9839,,,,1,N,50597,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL622851,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9840,,,,1,N,50597,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL622852,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9841,,,,1,N,50597,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,1,CHEMBL622853,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9842,,,,1,N,50597,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,1,CHEMBL622854,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9843,,,,1,N,50597,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,CHEMBL622855,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9844,,Plasma,,1,N,50597,1969.0,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",1,CHEMBL622856,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9845,,Plasma,,1,N,50597,1969.0,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",1,CHEMBL622857,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9846,,Plasma,,1,N,50597,1969.0,AUC in rat after po administration at a dose of 10 mg/kg,1,CHEMBL622858,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9847,,Plasma,,1,N,50597,1969.0,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,1,CHEMBL622859,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9848,,,,1,N,50597,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,1,CHEMBL622860,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9849,,,,1,N,50597,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,1,CHEMBL622861,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9850,,,,1,N,50597,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,1,CHEMBL622862,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9851,,,,1,N,50597,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,1,CHEMBL622863,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9852,,,,1,N,50597,,Area under curve value 6 hr after po administration in rat,1,CHEMBL623817,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9853,,,,1,N,50597,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,CHEMBL623818,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9854,,,,1,N,50597,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",1,CHEMBL623819,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9855,,,,1,N,50597,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,CHEMBL623820,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9856,,,,1,N,50597,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,1,CHEMBL623821,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9857,,Plasma,,1,N,50597,1969.0,AUC normalized for dose (AUCN) in rat,1,CHEMBL623822,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9858,,,,1,N,50597,,Area under curve in rat after p.o. administration,1,CHEMBL623823,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9859,,,,1,N,50597,,Area under curve in rat after p.o. administration,1,CHEMBL623824,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9860,,,,1,N,50597,,Area under curve in rat after p.o. administration; Not determined,1,CHEMBL623825,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9861,,,,1,N,50597,,Area under curve in rat after peroral administration,1,CHEMBL622070,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9862,,,,1,N,50597,,Area under curve (carotid artery) value of the compound,1,CHEMBL622071,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9863,,,,1,N,50597,,Bioavailability expressed as the area under curve of rat carotid artery,1,CHEMBL622072,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9864,,,,1,N,50597,,Area under curve in male SD rats was observed after intravenous administration in rat,1,CHEMBL622073,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9865,,,,1,N,50597,,Area under curve of the compound was determined,1,CHEMBL622074,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9866,,,,1,N,50597,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,1,CHEMBL622075,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9867,,Plasma,,1,N,50597,1969.0,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,1,CHEMBL622076,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9868,,Plasma,,1,N,50597,1969.0,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,1,CHEMBL622077,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9869,,,,1,N,50597,,Area under curve (portal vein) value of the compound,1,CHEMBL622078,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9870,,,,1,N,50597,,Bioavailability expressed as the area under curve of rat portal vein,1,CHEMBL622079,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9871,,Plasma,,1,N,50597,1969.0,Area Under plasma concentration time curve in rat upon peroral administration,1,CHEMBL622080,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9872,,,,1,N,50597,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,1,CHEMBL877612,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9873,,,,1,N,50597,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,1,CHEMBL622081,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9874,,,,1,N,50597,,Compound was evaluated for oral bioavailability in rats,1,CHEMBL622082,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9875,,,,1,N,50597,,Compound was evaluated for oral bioavailability in rats after iv administration,1,CHEMBL622083,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9876,,,,1,N,50597,,Compound was evaluated for oral bioavailability in rats; 30-80,1,CHEMBL622084,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9877,,,,1,N,50597,,Compound was evaluated for oral bioavailability in rats; 50-60,1,CHEMBL622085,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9878,,,,1,N,50597,,Compound was evaluated for oral bioavailability in rats; no data,1,CHEMBL622086,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9879,,,,1,N,50597,,Compound was evaluated for oral bioavailability in rats; peptide,1,CHEMBL622087,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9880,,Blood,,1,N,50597,178.0,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",1,CHEMBL622088,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9881,,Blood,,1,N,50597,178.0,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",1,CHEMBL622089,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9882,,Blood,,1,N,50597,178.0,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",1,CHEMBL623685,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9883,,Blood,,1,N,50597,178.0,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",1,CHEMBL623686,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9884,,Stomach,,1,N,50597,945.0,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL623687,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9885,,Stomach,,1,N,50597,945.0,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL623688,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9886,,Stomach,,1,N,50597,945.0,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL623689,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9887,,Stomach,,1,N,50597,945.0,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622485,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9888,,Thyroid gland,,1,N,50597,2046.0,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622486,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9889,,Thyroid gland,,1,N,50597,2046.0,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL877613,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9890,,Thyroid gland,,1,N,50597,2046.0,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622487,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9891,,Thyroid gland,,1,N,50597,2046.0,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622488,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9892,,Heart,,1,N,50597,948.0,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,CHEMBL622489,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9893,,Urine,,1,N,50597,1088.0,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,CHEMBL622490,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9894,,Urine,,1,N,50597,1088.0,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,CHEMBL622491,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9895,,Liver,,1,N,50597,2107.0,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,1,CHEMBL622492,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9896,,Urine,,1,N,50597,1088.0,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,CHEMBL622493,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9897,,Urine,,1,N,50597,1088.0,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,CHEMBL622494,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9898,,Muscle tissue,,1,N,50597,2385.0,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,CHEMBL622495,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9899,,,,1,N,50597,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,1,CHEMBL622496,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9900,,Urine,,1,N,50597,1088.0,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,CHEMBL622497,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9901,,,,1,N,50597,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,1,CHEMBL622498,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9902,,Urine,,1,N,50597,1088.0,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,1,CHEMBL624918,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9903,,Urine,,1,N,50597,1088.0,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,1,CHEMBL624919,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9904,,Blood,,1,N,50597,178.0,Biodistribution of compound in rat blood after 5 min of administration,1,CHEMBL624920,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9905,,Blood,,1,N,50597,178.0,Biodistribution of compound in rat blood after 5 min of administration.,1,CHEMBL624921,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9906,,Brain,,1,N,50597,955.0,Biodistribution of compound in rat brain after 5 min of administration,1,CHEMBL624922,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9907,,Heart,,1,N,50597,948.0,Biodistribution of compound in rat heart after 5 min of administration,1,CHEMBL624923,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9908,,Heart,,1,N,50597,948.0,Biodistribution of compound in rat heart after 5 min of administration.,1,CHEMBL624924,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9909,,Kidney,,1,N,50597,2113.0,Biodistribution of compound in rat kidney after 5 min of administration,1,CHEMBL624925,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9910,,Kidney,,1,N,50597,2113.0,Biodistribution of compound in rat kidney after 5 min of administration.,1,CHEMBL624926,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9911,,Liver,,1,N,50597,2107.0,Biodistribution of compound in rat liver after 5 min of administration,1,CHEMBL624927,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9912,,Liver,,1,N,50597,2107.0,Biodistribution of compound in rat liver after 5 min of administration.,1,CHEMBL874402,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9913,,Lung,,1,N,50597,2048.0,Biodistribution of compound in rat lung after 5 min of administration,1,CHEMBL624928,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9914,,Lung,,1,N,50597,2048.0,Biodistribution of compound in rat lung after 5 min of administration.,1,CHEMBL624929,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9915,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of compound in rat muscle after 5 min of administration,1,CHEMBL624930,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9916,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of compound in rat muscle after 5 min of administration.,1,CHEMBL624931,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9917,,Heart,,1,N,50597,948.0,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,CHEMBL624932,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9918,,Heart,,1,N,50597,948.0,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,CHEMBL624933,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9919,,Liver,,1,N,50597,2107.0,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,CHEMBL624934,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9920,,Liver,,1,N,50597,2107.0,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,CHEMBL624935,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9921,,,,1,N,50597,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,CHEMBL624936,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9922,,,,1,N,50597,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,CHEMBL624937,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9923,,Spleen,,1,N,50597,2106.0,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,CHEMBL624938,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9924,,Spleen,,1,N,50597,2106.0,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,CHEMBL624939,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9925,,,,1,N,50597,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,CHEMBL624940,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9926,,,,1,N,50597,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,CHEMBL874403,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9927,,,,1,N,50597,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,1,CHEMBL624941,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9928,,Urine,,1,N,50597,1088.0,Dose required to lower urine osmolality to 300 mOsm/kg in rat,1,CHEMBL624942,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9929,,Urine,,1,N,50597,1088.0,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,1,CHEMBL624943,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9930,,,,1,N,50597,,% Bioavailability after 1 day of the drug administration in rats,1,CHEMBL624944,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9931,,,,1,N,50597,,% Bioavailability after 4 day of the drug administration in rats,1,CHEMBL624945,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9932,,,,1,N,50597,,Absolute bioavailability was evaluated in rat,1,CHEMBL624946,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9933,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,1,CHEMBL624947,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9934,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,1,CHEMBL624948,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9935,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,1,CHEMBL624949,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9936,,Kidney,,1,N,50597,2113.0,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,1,CHEMBL622025,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9937,,Kidney,,1,N,50597,2113.0,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,1,CHEMBL622026,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9938,,Kidney,,1,N,50597,2113.0,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,1,CHEMBL622027,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9939,,Kidney,,1,N,50597,2113.0,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,1,CHEMBL622028,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9940,,Liver,,1,N,50597,2107.0,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,1,CHEMBL622029,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9941,,Liver,,1,N,50597,2107.0,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,1,CHEMBL622208,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9942,,Liver,,1,N,50597,2107.0,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,1,CHEMBL622209,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9943,,Liver,,1,N,50597,2107.0,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,1,CHEMBL622210,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9944,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,1,CHEMBL622211,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9945,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,1,CHEMBL622212,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9946,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,1,CHEMBL622213,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9947,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,1,CHEMBL874404,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9948,,Muscle tissue,,1,N,50597,2385.0,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,1,CHEMBL620452,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9949,,Muscle tissue,,1,N,50597,2385.0,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,1,CHEMBL620453,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9950,,Muscle tissue,,1,N,50597,2385.0,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,1,CHEMBL620454,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9951,,Muscle tissue,,1,N,50597,2385.0,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,1,CHEMBL624067,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9952,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,1,CHEMBL624068,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9953,,Female gonad,,1,N,50597,992.0,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,1,CHEMBL624069,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9954,,Female gonad,,1,N,50597,992.0,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,1,CHEMBL624070,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9955,,Female gonad,,1,N,50597,992.0,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,1,CHEMBL624071,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9956,,Uterus,,1,N,50597,995.0,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,1,CHEMBL624072,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9957,,Uterus,,1,N,50597,995.0,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,1,CHEMBL624073,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9958,,Uterus,,1,N,50597,995.0,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,1,CHEMBL624788,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9959,,Uterus,,1,N,50597,995.0,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,1,CHEMBL624789,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9960,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,1,CHEMBL624790,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9961,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,1,CHEMBL624791,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9962,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,1,CHEMBL624792,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9963,,,,1,N,50597,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,1,CHEMBL624793,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9964,,Muscle tissue,,1,N,50597,2385.0,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,1,CHEMBL877491,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9965,,Muscle tissue,,1,N,50597,2385.0,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,1,CHEMBL624957,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9966,,Muscle tissue,,1,N,50597,2385.0,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,1,CHEMBL624958,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9967,,Muscle tissue,,1,N,50597,2385.0,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,1,CHEMBL624959,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9968,,,,1,N,50597,,Dissociation constant was determined,1,CHEMBL624960,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9969,,,,1,N,50597,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",1,CHEMBL624961,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9970,,,,1,N,50597,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL624962,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9971,,,,1,N,50597,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL624963,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9972,,,,1,N,50597,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,1,CHEMBL624964,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9973,,,,1,N,50597,,LogP value was evaluated in the in situ rat gut perfusion assay,1,CHEMBL624965,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9974,,,,1,N,50597,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,CHEMBL624966,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9975,,,,1,N,50597,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,1,CHEMBL624967,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9976,,,,1,N,50597,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,1,CHEMBL624968,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9977,,,,1,N,50597,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,1,CHEMBL624969,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9978,,,,1,N,50597,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,1,CHEMBL624970,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000218
9979,,,,1,N,50597,,Half-life was evaluated after 10 uM/kg of intra arterial administration,1,CHEMBL624971,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9980,,,,1,N,50597,,Half-life was evaluated after 20 uM/kg of peroral administration,1,CHEMBL624972,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9981,,,,1,N,50597,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,CHEMBL624973,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9982,,Plasma,,1,N,50597,1969.0,Half-life was evaluated in plasma of rat,1,CHEMBL624974,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9983,,,,1,N,50597,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,1,CHEMBL624975,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9984,,,,1,N,50597,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,1,CHEMBL877492,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9985,,,,1,N,50597,,Half-life was measured in rat after an iv dose of 1 mg/kg,1,CHEMBL624976,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9986,,,,1,N,50597,,Half-life period of compound in rats after peroral administration,1,CHEMBL624977,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9987,,Plasma,,1,N,50597,1969.0,Half-life period of compound was measured in rat plasma.,1,CHEMBL626848,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9988,,Plasma,,1,N,50597,1969.0,Half-life period of compound was measured in rat plasma; ND is not determined,1,CHEMBL626849,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9989,,Plasma,,1,N,50597,1969.0,Half-life period of compound was measured in rat plasma; not determined,1,CHEMBL626850,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9990,,,,1,N,50597,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,CHEMBL626851,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9991,,,,1,N,50597,,Half-life period in rat by iv administration,1,CHEMBL626852,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9992,,,,1,N,50597,,Half-life period in rats following intravenous administration at 2 mg/kg,1,CHEMBL626853,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9993,,,,1,N,50597,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,CHEMBL626854,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9994,,,,1,N,50597,,Half-life period was determined for the compound in rat,1,CHEMBL627486,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
9995,,,,1,N,50597,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",1,CHEMBL627487,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9996,,,,1,N,50597,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",1,CHEMBL627488,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9997,,,,1,N,50597,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,1,CHEMBL627489,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9998,,,,1,N,50597,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,CHEMBL627490,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
9999,,,,1,N,50597,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),1,CHEMBL873829,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10000,,,,1,N,50597,,Half-life was determined in rat at a dose of 1 mpk i.v.,1,CHEMBL627655,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10001,,,,1,N,50597,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,CHEMBL625994,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10002,,,,1,N,50597,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,CHEMBL625995,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10003,,,,1,N,50597,,Half-life in rat,1,CHEMBL625996,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10004,,Plasma,,1,N,50597,1969.0,In vitro half life in rat plasma,1,CHEMBL625850,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
10005,,Plasma,,1,N,50597,1969.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",1,CHEMBL625851,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
10006,,,,1,N,50597,,In vitro half life in rat,1,CHEMBL625852,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
10007,,,,1,N,50597,,In vivo half life period after intravenous administration in rat,1,CHEMBL625853,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10008,,,,1,N,50597,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,CHEMBL625854,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10009,,,,1,N,50597,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,CHEMBL874450,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10010,,,,1,N,50597,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,CHEMBL625855,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10011,,,,1,N,50597,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,CHEMBL625856,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10012,,,,1,N,50597,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,CHEMBL625857,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10013,,,,1,N,50597,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,CHEMBL873831,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10014,,,,1,N,50597,,Longer half-life in rat (i.v.) at 0.5 mpk,1,CHEMBL625858,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10015,,,,1,N,50597,,Longer half-life in rat (p.o.) at 2.0 mpk,1,CHEMBL625859,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10016,,,,1,N,50597,,Pharmacokinetic property (half life) in rat,1,CHEMBL625860,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10017,,,,1,N,50597,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,1,CHEMBL625861,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10018,,,,1,N,50597,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,1,CHEMBL625862,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10019,,,,1,N,50597,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,1,CHEMBL625863,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10020,,,,1,N,50597,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,1,CHEMBL625864,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10021,,,,1,N,50597,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,1,CHEMBL625865,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10022,,,,1,N,50597,,Pharmacokinetic half time was determined intravenously in rats.,1,CHEMBL625866,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10023,,Plasma,,1,N,50597,1969.0,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,1,CHEMBL625867,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10024,,Plasma,,1,N,50597,1969.0,Plasma half life of hydrolysis of the compound,1,CHEMBL625868,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10025,,Plasma,,1,N,50597,1969.0,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,1,CHEMBL625869,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10026,,Plasma,,1,N,50597,1969.0,Plasma half life period was calculated in rat,1,CHEMBL874451,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10027,,Plasma,,1,N,50597,1969.0,Plasma half-life in Sprague-Dawley rats,1,CHEMBL625870,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10028,,Plasma,,1,N,50597,1969.0,Plasma half-life in Sprague-Dawley rats; Not determined,1,CHEMBL625871,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10029,,Plasma,,1,N,50597,1969.0,Plasma half-life in rats,1,CHEMBL625872,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10030,,Plasma,,1,N,50597,1969.0,Plasma half-life in rats; <MQL,1,CHEMBL625873,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10031,,Plasma,,1,N,50597,1969.0,Plasma half-life period (0-8 h) was determined,1,CHEMBL625874,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10032,,Plasma,,1,N,50597,1969.0,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,1,CHEMBL625875,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10033,,Plasma,,1,N,50597,1969.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,CHEMBL625876,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10034,,Plasma,,1,N,50597,1969.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,CHEMBL631258,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10035,,Plasma,,1,N,50597,1969.0,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,1,CHEMBL631259,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10036,,Plasma,,1,N,50597,1969.0,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,1,CHEMBL631260,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10037,,Blood,,1,N,50597,178.0,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",1,CHEMBL631261,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10038,,Blood,,1,N,50597,178.0,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",1,CHEMBL631262,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10039,,Blood,,1,N,50597,178.0,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",1,CHEMBL631263,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10040,,,,1,N,50597,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",1,CHEMBL631264,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10041,,,,1,N,50597,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",1,CHEMBL631265,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10042,,,,1,N,50597,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",1,CHEMBL631266,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10043,,,,1,N,50597,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",1,CHEMBL631267,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10044,,,,1,N,50597,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",1,CHEMBL631268,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10045,,,,1,N,50597,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",1,CHEMBL631269,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10046,,,,1,N,50597,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",1,CHEMBL631270,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10047,,Heart,,1,N,50597,948.0,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,CHEMBL631271,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10048,,Heart,,1,N,50597,948.0,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",1,CHEMBL631272,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10049,,Heart,,1,N,50597,948.0,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",1,CHEMBL631273,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10050,,Heart,,1,N,50597,948.0,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",1,CHEMBL631274,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10051,,Heart,,1,N,50597,948.0,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",1,CHEMBL631275,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10052,,Heart,,1,N,50597,948.0,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",1,CHEMBL626984,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10053,,Heart,,1,N,50597,948.0,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",1,CHEMBL626985,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10054,,Liver,,1,N,50597,2107.0,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,CHEMBL626986,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10055,,Liver,,1,N,50597,2107.0,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",1,CHEMBL626987,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10056,,Liver,,1,N,50597,2107.0,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",1,CHEMBL626988,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10057,,Liver,,1,N,50597,2107.0,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",1,CHEMBL626989,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10058,,Liver,,1,N,50597,2107.0,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",1,CHEMBL626990,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10059,,Liver,,1,N,50597,2107.0,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",1,CHEMBL626991,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10060,,Liver,,1,N,50597,2107.0,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",1,CHEMBL626992,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10061,,Lung,,1,N,50597,2048.0,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",1,CHEMBL626993,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10062,,Lung,,1,N,50597,2048.0,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",1,CHEMBL874593,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10063,,Lung,,1,N,50597,2048.0,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",1,CHEMBL626994,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10064,,Lung,,1,N,50597,2048.0,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",1,CHEMBL626995,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10065,,Lung,,1,N,50597,2048.0,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",1,CHEMBL626190,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10066,,Lung,,1,N,50597,2048.0,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",1,CHEMBL626191,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10067,,Lung,,1,N,50597,2048.0,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",1,CHEMBL626364,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10068,,Thyroid gland,,1,N,50597,2046.0,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",1,CHEMBL626365,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10069,,Thyroid gland,,1,N,50597,2046.0,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",1,CHEMBL626366,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10070,,Thyroid gland,,1,N,50597,2046.0,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",1,CHEMBL626367,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10071,,Thyroid gland,,1,N,50597,2046.0,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",1,CHEMBL626368,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10072,,Thyroid gland,,1,N,50597,2046.0,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",1,CHEMBL626369,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10073,,Thyroid gland,,1,N,50597,2046.0,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",1,CHEMBL626370,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10074,,,,1,N,50597,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",1,CHEMBL626371,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10075,,,,1,N,50597,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",1,CHEMBL626372,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10076,,,,1,N,50597,,Bioavailability after a dose of 10 mg/kg p.o.,1,CHEMBL626373,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10077,,,,1,N,50597,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,1,CHEMBL626374,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10078,,,,1,N,50597,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,1,CHEMBL626375,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10079,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),1,CHEMBL626376,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10080,,,,1,N,50597,,Bioavailability in rat po was determined,1,CHEMBL626377,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10081,,,,1,N,50597,,Bioavailability of compound at 10 mg/kg in rat after oral administration,1,CHEMBL626378,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10082,,,,1,N,50597,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,1,CHEMBL626379,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10083,,,,1,N,50597,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,CHEMBL626380,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10084,,,,1,N,50597,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,CHEMBL626381,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10085,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL626382,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10086,,,,1,N,50597,,Bioavailability in rat (Sprague-Dawley) (female),1,CHEMBL626383,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10087,,,,1,N,50597,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,CHEMBL874652,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10088,,,,1,N,50597,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),1,CHEMBL626384,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10089,,,,1,N,50597,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,1,CHEMBL626385,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10090,,,,1,N,50597,,Bioavailability in rat at an oral dose of 2 mg/kg,1,CHEMBL626386,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10091,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL626387,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10092,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL626388,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10093,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL626389,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10094,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL626390,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10095,,,,1,N,50597,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,1,CHEMBL626391,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10096,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL626392,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10097,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL626393,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10098,,,,1,N,50597,,Bioavailability was determined in rat,1,CHEMBL623026,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10099,,,,1,N,50597,,Bioavailability,1,CHEMBL623027,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10100,,,,1,N,50597,,Bioavailability,1,CHEMBL623028,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10101,,,,1,N,50597,,Bioavailability in rat after 1 day dosing,1,CHEMBL623029,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10102,,,,1,N,50597,,Bioavailability in rat after 4 day dosing,1,CHEMBL623030,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10103,,,,1,N,50597,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,1,CHEMBL623031,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10104,,,,1,N,50597,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,1,CHEMBL623032,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10105,,,,1,N,50597,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,1,CHEMBL623033,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10106,,,,1,N,50597,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,1,CHEMBL623034,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10107,,,,1,N,50597,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,1,CHEMBL623035,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10108,,,,1,N,50597,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,CHEMBL623036,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10109,,,,1,N,50597,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,CHEMBL623037,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10110,,,,1,N,50597,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,1,CHEMBL623038,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10111,,Plasma,,1,N,50597,1969.0,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,1,CHEMBL874385,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10112,,,,1,N,50597,,Bioavailability in rat (Fisher) (fasted),1,CHEMBL623039,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10113,,,,1,U,22224,,Bioavailability in monkey after po administration of 10 mg/kg dose,0,CHEMBL623040,Primates,,A,9443.0,In vivo,,Intermediate,,BAO_0000218
10114,,,,1,U,22224,,Oral bioavailability in monkey (dose 10 mg/kg),0,CHEMBL623041,Primates,,A,9443.0,In vivo,,Intermediate,,BAO_0000218
10115,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL623741,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10116,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL623742,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10117,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL623743,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10118,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL623744,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10119,,,,1,N,50597,,Bioavailability in rat (dose 2.0 mg/kg p.o.),1,CHEMBL623745,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10120,,,,1,N,50597,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),1,CHEMBL623746,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10121,,,,1,N,50597,,Oral bioavailability in rat (dose 5 mg/kg p.o.),1,CHEMBL623747,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10122,,,,1,U,22224,,Bioavailability in rat after po administration of 30 mg/kg dose,0,CHEMBL623748,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10123,,,,1,U,22224,,Bioavailability in rat after po administration of 30 mg/kg dose,0,CHEMBL623916,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10124,,,,1,N,50597,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,CHEMBL623917,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10125,,,,1,N,50597,,Bioavailability in rat (dose 2 mg/kg i.v.),1,CHEMBL623918,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10126,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL874386,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10127,,Plasma,,1,N,50597,1969.0,Bioavailability in rat; Only traces detected in rat plasma,1,CHEMBL623919,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10128,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL623920,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10129,,,,1,N,50597,,Bioavailability upon oral administration of compound,1,CHEMBL623148,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10130,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),1,CHEMBL623149,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10131,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL623150,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10132,,,,1,N,50597,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",1,CHEMBL623151,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10133,,,,1,N,50597,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",1,CHEMBL623152,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10134,,,,1,N,50597,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,1,CHEMBL623153,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000218
10135,,,,1,N,50597,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,1,CHEMBL623154,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000218
10136,,,,1,N,50597,,In vitro and metabolic stability was determined,1,CHEMBL623155,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10137,,,,1,N,50597,,In vitro metabolic stability in rat hepatocytes,1,CHEMBL623156,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10138,,,,1,N,50597,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,1,CHEMBL623157,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10139,,Liver,,1,N,50597,2107.0,Metabolic rate for compound was observed in rat hepatocytes,1,CHEMBL623158,Rattus norvegicus,,A,10116.0,In vitro,Hepatocyte,Intermediate,401.0,BAO_0000218
10140,,,,1,N,50597,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,1,CHEMBL623159,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10141,,,,1,N,50597,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),1,CHEMBL874390,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10142,,,,1,N,50597,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),1,CHEMBL623160,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10143,,,,1,N,50597,,Metabolism of compound in rat S9 microsomes; Trace,1,CHEMBL623161,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10144,,,,1,N,50597,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,1,CHEMBL623162,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10145,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,1,CHEMBL623163,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10146,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,1,CHEMBL623164,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10147,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,1,CHEMBL623165,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10148,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,1,CHEMBL623166,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10149,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,1,CHEMBL624983,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10150,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,1,CHEMBL624984,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10151,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,1,CHEMBL624985,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10152,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,1,CHEMBL622970,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10153,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,1,CHEMBL622971,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10154,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,1,CHEMBL622972,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10155,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,1,CHEMBL622973,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10156,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,1,CHEMBL622974,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10157,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,1,CHEMBL622975,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10158,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,1,CHEMBL622976,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10159,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,1,CHEMBL622977,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10160,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,CHEMBL624351,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10161,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,1,CHEMBL624352,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10162,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,CHEMBL624353,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10163,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,1,CHEMBL622397,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10164,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,1,CHEMBL622398,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10165,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,1,CHEMBL622399,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10166,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,CHEMBL622400,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10167,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,CHEMBL628428,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10168,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,1,CHEMBL628590,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10169,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,CHEMBL628591,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10170,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,1,CHEMBL628592,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10171,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,CHEMBL628593,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10172,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,1,CHEMBL875333,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10173,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,CHEMBL628594,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10174,,Plasma,,1,N,50597,1969.0,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,1,CHEMBL628595,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10175,,Plasma,,1,N,50597,1969.0,Stability in rat plasma was determined,1,CHEMBL628596,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10176,,Plasma,,1,N,50597,1969.0,Stability in rat plasma was determined; ND= no data,1,CHEMBL628597,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10177,,Plasma,,1,N,50597,1969.0,Tested for plasma half life period in rat (0-8 hr),1,CHEMBL628598,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10178,,Plasma,,1,N,50597,1969.0,Tested for plasma half life period in rat (0-8 hr); Not determined,1,CHEMBL628599,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10179,,,,1,N,50597,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,1,CHEMBL628600,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10180,,,,1,N,50597,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,1,CHEMBL628601,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10181,,,,1,N,50597,,Tested for the half life in rat,1,CHEMBL628602,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10182,,,,1,N,50597,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,1,CHEMBL628603,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
10183,,,,1,N,50597,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,1,CHEMBL628604,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
10184,,,,1,N,50597,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,1,CHEMBL628605,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
10185,,,,1,N,50597,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,1,CHEMBL628606,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
10186,,,,1,N,50597,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,1,CHEMBL628607,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
10187,,,,1,N,50597,,The biological half life the compound was measured at the dose of 100 umol/kg,1,CHEMBL628608,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10188,,,,1,N,50597,,The biological half life the compound was measured at the dose of 30 umol/kg,1,CHEMBL628609,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10189,,Plasma,,1,N,50597,1969.0,The compound was evaluated for plasma half life period in rat,1,CHEMBL628610,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10190,,,,1,N,50597,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL873819,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10191,,,,1,N,50597,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL628611,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10192,,,,1,N,50597,,The pharmacokinetic parameter half-life period in vivo in rats,1,CHEMBL628612,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10193,,,,1,N,50597,,"The pharmacokinetic property, Half-life was determined",1,CHEMBL628613,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10194,,,,1,N,50597,,"The pharmacokinetic property, Half-life in rat in vivo",1,CHEMBL628614,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10195,,,,1,N,50597,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",1,CHEMBL628615,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10196,,,,1,N,50597,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",1,CHEMBL628616,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10197,,Plasma,,1,N,50597,1969.0,The plasma half life period in rats,1,CHEMBL627924,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10198,,Liver,,1,N,50597,2107.0,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,1,CHEMBL627925,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10199,,,,1,N,50597,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,CHEMBL627926,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10200,,,,1,N,50597,,t1/2 (apparent elimination)of the compound was determined,1,CHEMBL627927,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10201,,,,1,N,50597,,t1/2 value in rat,1,CHEMBL627928,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10202,,,,1,N,50597,,Half life in rat,1,CHEMBL627539,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10203,,Plasma,,1,N,50597,1969.0,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,CHEMBL876790,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10204,,,,1,N,50597,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,1,CHEMBL858186,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10205,,,,1,N,50597,,Half-life period in fasted rats,1,CHEMBL627540,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10206,,,,1,N,50597,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,1,CHEMBL627541,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10207,,,,1,N,50597,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,1,CHEMBL627715,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10208,,,,1,N,50597,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,CHEMBL627716,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10209,,,,1,N,50597,,Maximum time required to achieve Cmax was determined in rat,1,CHEMBL627717,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10210,,,,1,N,50597,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,CHEMBL627718,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10211,,,,1,N,50597,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,CHEMBL627719,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10212,,,,1,N,50597,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,1,CHEMBL627720,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10213,,,,1,N,50597,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,1,CHEMBL627721,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10214,,,,1,N,50597,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,1,CHEMBL627722,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10215,,,,1,N,50597,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL627723,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10216,,,,1,N,50597,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL626058,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10217,,,,1,N,50597,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL626059,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10218,,,,1,N,50597,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL626060,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10219,,Plasma,,1,N,50597,1969.0,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,1,CHEMBL626061,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10220,,,,1,N,50597,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL876791,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10221,,,,1,N,50597,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,CHEMBL626062,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10222,,,,1,N,50597,,Tmax at the dose of 2 mg/Kg administered perorally in rats,1,CHEMBL626063,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10223,,,,1,N,50597,,Tmax at the dose of 5 mg/Kg administered perorally in rats,1,CHEMBL626064,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10224,,Plasma,,1,N,50597,1969.0,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,1,CHEMBL626065,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10225,,Plasma,,1,N,50597,1969.0,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,1,CHEMBL626066,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10226,,,,1,N,50597,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,1,CHEMBL626067,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10227,,,,1,N,50597,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,1,CHEMBL626068,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
10228,,,,1,N,50597,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,1,CHEMBL626069,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
10229,,,,1,N,50597,,Percent total excretion of 3-methoxyacetaminophen glucuronide,1,CHEMBL626070,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
10230,,,,1,N,50597,,Percent total excretion of N-methoxyacetaminophen glucuronide,1,CHEMBL626071,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
10231,,,,1,N,50597,,Percent total excretion of N-methoxyacetaminophen sulfate,1,CHEMBL626072,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
10232,,,,1,N,50597,,Percent total excretion of acetaminophen,1,CHEMBL626073,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
10233,,Thyroid gland,,1,N,50597,2046.0,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",1,CHEMBL626741,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10234,,,,1,N,50597,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",1,CHEMBL626742,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10235,,,,1,N,50597,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,1,CHEMBL626743,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10236,,,,1,N,50597,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,1,CHEMBL876792,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10237,,,,1,N,50597,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,CHEMBL626744,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10238,,,,1,N,50597,,Compound was tested for antidiuretic activity in rats,1,CHEMBL626745,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10239,,Plasma,,1,N,50597,1969.0,AUC in rat after 3mg/kg oral dose,1,CHEMBL626746,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10240,,,,1,N,50597,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,1,CHEMBL626747,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10241,,,,1,N,50597,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,1,CHEMBL626748,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10242,,,,1,N,50597,,Bioavailability administered orally at a dose of 10 mg/kg to rats,1,CHEMBL626749,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10243,,,,1,N,50597,,Oral Bioavailability was determined,1,CHEMBL626750,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10244,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL626751,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10245,,,,1,N,50597,,Oral bioavailability in rat; Not performed.,1,CHEMBL626913,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10246,,,,1,N,50597,,Bioavailability,1,CHEMBL626914,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10247,,,,1,N,50597,,Bioavailability was determined; ND denotes no data,1,CHEMBL626915,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10248,,,,1,N,50597,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,1,CHEMBL626916,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10249,,,,1,N,50597,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,1,CHEMBL626917,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10250,,,,1,N,50597,,Binding towards rat plasma protein at 10 uM,1,CHEMBL626918,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10251,,,,1,N,50597,,Binding towards rat plasma protein at 100 uM,1,CHEMBL626919,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10252,,,,1,N,50597,,Bioavailability in rat (dose 20 mg/kg p.o.),1,CHEMBL626920,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10253,,,,1,N,50597,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,CHEMBL621976,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10254,,,,1,N,50597,,Bioavailability in rat after 5 mg/kg oral gavage,1,CHEMBL877599,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10255,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL621977,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10256,,,,1,N,50597,,Bioavailability in rat (dose 1 mg/kg i.v.),1,CHEMBL621978,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10257,,,,1,N,50597,,Bioavailability in rat (dose 3 mg/kg p.o.),1,CHEMBL621979,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10258,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL621980,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10259,,,,1,N,50597,,Bioavailability of the compound in rats after administration of 30 mg/kg,1,CHEMBL621981,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10260,,,,1,N,50597,,Bioavailability after administration of 10 mg/kg in rats,1,CHEMBL621982,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10261,,,,1,N,50597,,Bioavailability after administration of 2 mg/kg in rats,1,CHEMBL882953,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10262,,,,1,N,50597,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,1,CHEMBL621983,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10263,,,,1,N,50597,,Bioavailability in dogs was determined; high,1,CHEMBL621984,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10264,,,,1,N,50597,,Bioavailability in monkey after intravenous administration at 1 mpk,1,CHEMBL621985,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10265,,,,1,N,50597,,Bioavailability in monkey after peroral administration at 10 mpk,1,CHEMBL621986,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10266,,,,1,N,50597,,Bioavailability in rat after intravenous administration at 1 mpk,1,CHEMBL621987,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10267,,,,1,N,50597,,Bioavailability in rat after intravenous administration at 2 mpk,1,CHEMBL877600,Rattus norvegicus,,F,10116.0,In vivo,,Intermediate,,BAO_0000218
10268,,,,1,N,50597,,Bioavailability in rat after peroral administration at 30 mpk,1,CHEMBL621988,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10269,,,,1,N,50597,,Bioavailability in rat after peroral administration at at 100 mpk,1,CHEMBL621989,Rattus norvegicus,,F,10116.0,In vivo,,Intermediate,,BAO_0000218
10270,,,,1,N,50597,,Bioavailability in rats was evaluated,1,CHEMBL621990,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10271,,,,1,N,50597,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,1,CHEMBL621991,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10272,,,,1,N,50597,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,1,CHEMBL621992,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10273,,,,1,N,50597,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,1,CHEMBL621993,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10274,,,,1,N,50597,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,1,CHEMBL621994,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10275,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL621995,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10276,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL621996,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10277,,,,1,N,50597,,Oral bioavailability in rat (dose 10 mg/kg),1,CHEMBL621997,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10278,,,,1,N,50597,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,CHEMBL621998,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10279,,,,1,N,50597,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,1,CHEMBL621999,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10280,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622000,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10281,,,,1,N,50597,,Bioavailability was measured in rat after oral administration; 2-4,1,CHEMBL622001,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10282,,,,1,N,50597,,Bioavailability was measured in rat after oral administration; 3-7,1,CHEMBL622002,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10283,,,,1,N,50597,,Bioavailability in rat (intraduodenal administration),1,CHEMBL622003,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10284,,,,1,N,50597,,Bioavailability in rat (intraduodenal administration),1,CHEMBL877601,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10285,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL624871,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10286,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622004,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10287,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),1,CHEMBL882954,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10288,,,,1,N,50597,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,1,CHEMBL622005,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10289,,,,1,N,50597,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,1,CHEMBL622006,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10290,,,,1,N,50597,,Bioavailability was measured in rat,1,CHEMBL622007,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10291,,,,1,N,50597,,Bioavailability was reported,1,CHEMBL622008,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10292,,,,1,N,50597,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,CHEMBL622009,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10293,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,CHEMBL622010,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10294,,,,1,N,50597,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,CHEMBL622011,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10295,,,,1,N,50597,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),1,CHEMBL622012,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10296,,,,1,N,50597,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),1,CHEMBL622013,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10297,,,,1,N,50597,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,CHEMBL622014,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10298,,,,1,N,50597,,Bioavailability was determined at 3 mg/kg po dose in rats,1,CHEMBL624749,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10299,,,,1,N,50597,,Oral bioavailability in rat (dose 2 mg/kg),1,CHEMBL624750,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10300,,,,1,N,50597,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",1,CHEMBL624751,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10301,,,,1,N,50597,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,CHEMBL624752,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10302,,,,1,N,50597,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,CHEMBL624753,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10303,,,,1,N,50597,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,1,CHEMBL624754,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10304,,,,1,N,50597,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,CHEMBL624755,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10305,,,,1,N,50597,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,CHEMBL624756,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10306,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL624757,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10307,,,,1,N,50597,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,CHEMBL624758,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10308,,,,1,N,50597,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,CHEMBL622270,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10309,,,,1,N,50597,,Bioavailability in rat (Sprague-Dawley),1,CHEMBL622271,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10310,,,,1,N,50597,,Bioavailability in rat at the dose of 2 mg/kg,1,CHEMBL622272,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10311,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622273,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10312,,,,1,N,50597,,Bioavailability in rat (cannulated) (dose 2 mg/kg),1,CHEMBL622274,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10313,,,,1,N,50597,,Bioavailability value of compound in rats was determined after peroral administration,1,CHEMBL622275,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10314,,,,1,N,50597,,Oral bioavailability in rat (dose 20 mg/kg),1,CHEMBL622276,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10315,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622277,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10316,,,,1,N,50597,,Oral bioavailability in rat (dose 5 mg/kg),1,CHEMBL622278,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10317,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622279,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10318,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622280,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10319,,,,1,N,50597,,Compound was evaluated for oral bioavailability in rats; 15-27 %,1,CHEMBL624083,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10320,,,,1,N,50597,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,1,CHEMBL624084,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10321,,,,1,N,50597,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),1,CHEMBL624085,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10322,,,,1,N,50597,,Compound was tested for bioavailability in rats,1,CHEMBL624086,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10323,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL624087,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10324,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL624088,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10325,,,,1,U,22224,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,0,CHEMBL624089,Macaca mulatta,,A,9544.0,In vivo,,Intermediate,,BAO_0000218
10326,,,,1,U,22224,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),0,CHEMBL624090,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10327,,,,1,N,50597,,Evaluated for the bioavailability in rat (in vivo),1,CHEMBL624091,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10328,,,,1,N,50597,,F value of compound in rats was determined after peroral administration,1,CHEMBL624092,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10329,,,,1,N,50597,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,CHEMBL624093,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10330,,,,1,N,50597,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,CHEMBL624094,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10331,,,,1,N,50597,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,CHEMBL624095,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10332,,,,1,N,50597,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,CHEMBL624096,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10333,,,,1,N,50597,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",1,CHEMBL624097,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10334,,,,1,N,50597,,Maximum fall in carotid flow in rat,1,CHEMBL624098,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10335,,,,1,N,50597,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,1,CHEMBL874392,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10336,,,,1,N,50597,,Oral bioavailability in rat (dose 5 mg/kg),1,CHEMBL624099,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10337,,,,1,N,50597,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,CHEMBL624100,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10338,,,,1,N,50597,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,CHEMBL624101,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10339,,,,1,N,50597,,Oral bioavailability in rat (male Wistar),1,CHEMBL624102,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10340,,,,1,N,50597,,Oral bioavailability after administration (30 mg/kg) in rat; good,1,CHEMBL624103,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10341,,,,1,N,50597,,Oral bioavailability at the dose of 2 mg/kg in rat,1,CHEMBL624104,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10342,,,,1,N,50597,,Oral bioavailability determined in rats,1,CHEMBL624105,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10343,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),1,CHEMBL624106,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10344,,,,1,N,50597,,Oral bioavailability in rat (dose single 10 mg/kg),1,CHEMBL624107,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10345,,,,1,N,50597,,Oral bioavailability in rat (dose single 10 mg/kg),1,CHEMBL623943,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10346,,,,1,N,50597,,Oral bioavailability in rat (dose 5 mg/kg,1,CHEMBL623944,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10347,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,1,CHEMBL623945,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10348,,,,1,N,50597,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,1,CHEMBL623946,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10349,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,1,CHEMBL623947,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10350,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,1,CHEMBL623948,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10351,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,1,CHEMBL623949,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10352,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,1,CHEMBL623950,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10353,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,1,CHEMBL874398,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10354,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,1,CHEMBL623951,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10355,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,1,CHEMBL623952,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10356,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,1,CHEMBL623953,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10357,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,1,CHEMBL623954,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10358,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,1,CHEMBL623955,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10359,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,1,CHEMBL623956,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10360,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,1,CHEMBL627807,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10361,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,1,CHEMBL627808,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10362,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,1,CHEMBL627809,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10363,,,,1,N,50597,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,1,CHEMBL627810,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10364,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",1,CHEMBL627811,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10365,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",1,CHEMBL627812,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10366,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",1,CHEMBL627813,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10367,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",1,CHEMBL627814,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10368,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",1,CHEMBL875336,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10369,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",1,CHEMBL627815,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10370,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",1,CHEMBL627816,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10371,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",1,CHEMBL627817,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10372,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",1,CHEMBL627818,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10373,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",1,CHEMBL627819,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10374,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",1,CHEMBL627820,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10375,,,,1,N,50597,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",1,CHEMBL627821,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10376,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,CHEMBL628464,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10377,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,1,CHEMBL626239,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10378,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,1,CHEMBL626240,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10379,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,1,CHEMBL626241,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10380,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,1,CHEMBL626242,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10381,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,1,CHEMBL626243,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10382,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,CHEMBL626244,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10383,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,1,CHEMBL626907,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10384,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,CHEMBL626908,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10385,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,CHEMBL626909,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10386,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,CHEMBL626910,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10387,,,,1,N,50597,,Percent total excretion of acetaminophen cysteine conjugate,1,CHEMBL875342,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
10388,,,,1,N,50597,,Percent total excretion of acetaminophen glucuronide,1,CHEMBL626911,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
10389,,,,1,N,50597,,Percent total excretion of acetaminophen sulfate,1,CHEMBL626912,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
10390,,,,1,N,50597,,Percent total excretion of acetaminophen-mercapturic acid,1,CHEMBL627065,Rattus norvegicus,,F,10116.0,,,Intermediate,,BAO_0000218
10391,,Urine,,1,N,50597,1088.0,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,1,CHEMBL627066,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10392,,,,1,N,50597,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,CHEMBL627067,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10393,,Muscle tissue,,1,U,22224,2385.0,Biodistribution of compound in rat muscle after 5 min of administration,0,CHEMBL627068,ratrat,,A,8656.0,In vivo,,Autocuration,,BAO_0000218
10394,,Muscle tissue,,1,U,22224,2385.0,Biodistribution of compound in rat muscle after 5 min of administration.,0,CHEMBL627069,ratrat,,A,8656.0,In vivo,,Autocuration,,BAO_0000218
10395,,,,1,U,22224,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),0,CHEMBL627070,Ovis aries,,A,9940.0,In vivo,,Autocuration,,BAO_0000218
10396,,,,1,U,22224,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),0,CHEMBL627071,Ovis aries,,A,9940.0,In vivo,,Autocuration,,BAO_0000218
10397,,,,1,U,22224,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),0,CHEMBL627072,Ovis aries,,A,9940.0,In vivo,,Autocuration,,BAO_0000218
10398,,,,1,U,22224,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),0,CHEMBL627073,Ovis aries,,A,9940.0,In vivo,,Autocuration,,BAO_0000218
10399,,,,1,U,22224,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),0,CHEMBL625387,Ovis aries,,A,9940.0,In vivo,,Autocuration,,BAO_0000218
10400,,,,1,U,22224,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),0,CHEMBL625388,Ovis aries,,A,9940.0,In vivo,,Autocuration,,BAO_0000218
10401,,Plasma,,1,U,22224,1969.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),0,CHEMBL625389,Ovis aries,,A,9940.0,In vivo,,Autocuration,,BAO_0000218
10402,,Plasma,,1,U,22224,1969.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),0,CHEMBL875343,Ovis aries,,A,9940.0,In vivo,,Autocuration,,BAO_0000218
10403,,,,1,N,50497,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),1,CHEMBL876795,Serpentes,,A,8570.0,,,Intermediate,,BAO_0000218
10404,,,,1,N,50497,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,1,CHEMBL626552,Serpentes,,A,8570.0,,,Intermediate,,BAO_0000218
10405,,,,1,N,50497,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,1,CHEMBL626553,Serpentes,,A,8570.0,,,Intermediate,,BAO_0000218
10406,,Plasma,,1,U,22224,1969.0,The human biological plasma half life of the compound,0,CHEMBL626554,Homo sapiens,,A,9606.0,,,Autocuration,,BAO_0000366
10407,,Urine,,1,N,50597,1088.0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,CHEMBL626555,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10408,,,,1,N,50597,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,1,CHEMBL626556,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10409,,,,1,N,50597,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,1,CHEMBL626557,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10410,,,,1,N,50597,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,1,CHEMBL626558,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10411,,,,1,N,50597,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,1,CHEMBL626559,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10412,,,,1,N,50597,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,1,CHEMBL626560,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10413,,,,1,N,50597,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,1,CHEMBL876803,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10414,,,,1,N,50597,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,1,CHEMBL627964,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10415,,,,1,N,50597,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,1,CHEMBL627965,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10416,,,,1,N,50597,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,1,CHEMBL627966,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10417,,,,1,N,50597,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,1,CHEMBL627967,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10418,,,,1,N,50597,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,1,CHEMBL627968,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10419,,,,1,N,50597,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,1,CHEMBL627969,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10420,,,,1,N,50597,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,1,CHEMBL627970,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10421,,Blood,,1,N,50597,178.0,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,1,CHEMBL627971,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10422,,Blood,,1,N,50597,178.0,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,1,CHEMBL627972,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10423,,,,1,D,180,,Dissociation constant against binding to human cyclophilin A,9,CHEMBL856029,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
10424,,,,1,H,11591,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,8,CHEMBL627973,Bos taurus,,B,9913.0,,,Expert,,BAO_0000019
10425,,,,1,U,22224,,-Log C was determined by performing the electroshock minimum test,0,CHEMBL627974,,,A,,,,Autocuration,,BAO_0000019
10426,,,,1,U,22224,,-Log C was determined by performing the foot shock test,0,CHEMBL627975,,,A,,,,Autocuration,,BAO_0000019
10427,,,,1,U,22224,,-Log C was determined by performing the incl screen test,0,CHEMBL627976,,,A,,,,Autocuration,,BAO_0000019
10428,,,,1,U,22224,,-Log C was determined by performing the maximum electroshock test,0,CHEMBL627977,,,A,,,,Autocuration,,BAO_0000019
10429,,,,1,U,22224,,-Log C was determined by performing the pentylenetetrazole test,0,CHEMBL627978,,,A,,,,Autocuration,,BAO_0000019
10430,,,,1,U,22224,,Tested for experimental arotinoid inhibitory dose,0,CHEMBL627979,,,A,,,,Autocuration,,BAO_0000019
10431,,,,1,U,22224,,Negative log transformed activity,0,CHEMBL876804,,,A,,,,Autocuration,,BAO_0000019
10432,,,,1,U,22224,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",0,CHEMBL627980,,,A,,,,Autocuration,,BAO_0000019
10433,,,,1,N,50512,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,1,CHEMBL627981,Cavia porcellus,,A,10141.0,,,Intermediate,,BAO_0000218
10434,,,,1,N,50512,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,1,CHEMBL627982,Cavia porcellus,,A,10141.0,,,Intermediate,,BAO_0000218
10435,,,,1,N,50512,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,1,CHEMBL627983,Cavia porcellus,,A,10141.0,,,Intermediate,,BAO_0000218
10436,,Ileum,,1,N,50512,2116.0,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,1,CHEMBL627984,Cavia porcellus,,A,10141.0,,,Intermediate,,BAO_0000218
10437,,,,1,U,22229,,Solubility in water was determined; values expressed as -log,0,CHEMBL627985,,,P,,,,Autocuration,,BAO_0000100
10438,,,,1,U,22224,,Ratio of Kcat to that of Km was determined,0,CHEMBL627986,,,A,,,,Autocuration,,BAO_0000019
10439,,,,1,U,22224,,Observed first order rate constant,0,CHEMBL627987,,,A,,,,Autocuration,,BAO_0000019
10440,,,,1,U,22224,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,0,CHEMBL627988,,,A,,,,Autocuration,,BAO_0000019
10441,,,,1,N,50597,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,1,CHEMBL627989,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10442,,,,1,N,50597,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,1,CHEMBL627990,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10443,,,,1,N,50597,,Oral Bioavailability after administration of 10 mg/kg in male rat,1,CHEMBL876805,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10444,,,,1,N,50597,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),1,CHEMBL627991,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10445,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL627992,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10446,,,,1,N,50597,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,CHEMBL627993,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10447,,,,1,N,50597,,Oral bioavailability at 1 mg/kg was determined in rat,1,CHEMBL622817,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10448,,,,1,N,50597,,Oral bioavailability at 10 mg/kg was determined in rat,1,CHEMBL622818,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10449,,,,1,N,50597,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",1,CHEMBL622819,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10450,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL872267,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10451,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622820,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10452,,,,1,N,50597,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,1,CHEMBL622821,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10453,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622822,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10454,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622823,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10455,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622824,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10456,,,,1,N,50597,,Oral bioavailability in rat at a dose of 3 mg/kg,1,CHEMBL622825,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10457,,,,1,N,50597,,Oral bioavailability in rat after oral administration at 10 mg/kg,1,CHEMBL622901,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10458,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622902,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10459,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL621844,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10460,,,,1,N,50597,,Oral bioavailability in Dawley rats,1,CHEMBL621845,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10461,,,,1,N,50597,,Oral bioavailability,1,CHEMBL621846,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10462,,,,1,N,50597,,Oral bioavailability in rat (dose 30 mg/kg),1,CHEMBL621847,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10463,,,,1,N,50597,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,CHEMBL877609,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10464,,,,1,N,50597,,Bioavailability in rat (dose 3 mg/kg i.v.),1,CHEMBL621848,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10465,,,,1,N,50597,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,CHEMBL621849,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10466,,,,1,N,50597,,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,CHEMBL622030,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10467,,,,1,N,50597,,Percent oral bioavailability determined in rats,1,CHEMBL622031,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10468,,,,1,N,50597,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,CHEMBL622032,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10469,,,,1,N,50597,,The compound was evaluated for bioavailability in rats; 32-51,1,CHEMBL622033,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10470,,,,1,N,50597,,Bioavailability in rat (dose 20 mg/kg p.o.),1,CHEMBL622034,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10471,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622035,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10472,,,,1,N,50597,,Bioavailability percent in rat at the dose of 2 mg/kg,1,CHEMBL882966,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10473,,,,1,N,50597,,Bioavailability was evaluated after 20 uM/kg of peroral administration,1,CHEMBL622036,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10474,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622037,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10475,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622038,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10476,,,,1,N,50597,,Bioavailability in rats,1,CHEMBL622039,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10477,,Blood,,1,N,50597,178.0,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,1,CHEMBL622040,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10478,,Blood,,1,N,50597,178.0,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,1,CHEMBL622041,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10479,,Blood,,1,N,50597,178.0,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,1,CHEMBL622042,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10480,,Blood,,1,N,50597,178.0,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,1,CHEMBL622043,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10481,,Blood,,1,N,50597,178.0,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,1,CHEMBL622044,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10482,,Bone,,1,N,50597,10000001.0,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,1,CHEMBL622045,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10483,,Bone,,1,N,50597,10000001.0,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,1,CHEMBL622046,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10484,,Bone,,1,N,50597,10000001.0,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,1,CHEMBL622047,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10485,,Bone,,1,N,50597,10000001.0,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,1,CHEMBL877610,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10486,,Brain,,1,N,50597,955.0,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,1,CHEMBL622048,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10487,,Brain,,1,N,50597,955.0,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,1,CHEMBL622049,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10488,,Brain,,1,N,50597,955.0,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,1,CHEMBL622050,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10489,,Brain,,1,N,50597,955.0,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,1,CHEMBL622051,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10490,,,,1,N,50597,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,1,CHEMBL622052,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10491,,,,1,N,50597,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,1,CHEMBL622053,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10492,,,,1,N,50597,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,1,CHEMBL622054,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10493,,,,1,N,50597,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,1,CHEMBL622055,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10494,,,,1,N,50597,,Oral bioavailability in rats was determined; High,1,CHEMBL622056,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10495,,,,1,N,50597,,Oral bioavailability in the rat was determined,1,CHEMBL622057,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10496,,,,1,N,50597,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,1,CHEMBL628008,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10497,,,,1,N,50597,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),1,CHEMBL622058,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10498,,,,1,N,50597,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL622059,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10499,,,,1,N,50597,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL622060,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10500,,,,1,N,50597,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL622061,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10501,,,,1,N,50597,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,CHEMBL622062,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10502,,,,1,N,50597,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,1,CHEMBL622063,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10503,,,,1,N,50597,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,1,CHEMBL877611,Rattus norvegicus,,A,10116.0,In vivo,,Expert,,BAO_0000218
10504,,,,1,N,50597,,Oral bioavailability of compound in Sprague Dawley rats,1,CHEMBL622064,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10505,,,,1,N,50597,,Oral bioavailability of compound in rat,1,CHEMBL622065,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10506,,,,1,N,50597,,Oral bioavailability in rat (dose 2 mg/kg),1,CHEMBL622066,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10507,,,,1,N,50597,,Oral bioavailability of compound in rat was determined,1,CHEMBL622067,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10508,,,,1,N,50597,,Oral bioavailability of compound in rats,1,CHEMBL622068,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10509,,,,1,N,50597,,Oral bioavailability of compound was determined in rats,1,CHEMBL622069,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10510,,,,1,N,50597,,Oral bioavailability at a dose of 30 mg/kg in rats,1,CHEMBL624796,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10511,,,,1,N,50597,,Oral bioavailability in rat (dose 10 mg/kg),1,CHEMBL624797,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10512,,,,1,N,50597,,Oral bioavailability in rat (dose 10 mg/kg),1,CHEMBL623053,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10513,,,,1,N,50597,,Oral bioavailability evaluated in rat,1,CHEMBL623054,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10514,,,,1,N,50597,,Oral bioavailability in fasted rat,1,CHEMBL623055,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10515,,,,1,N,50597,,Oral bioavailability in fed rat,1,CHEMBL623056,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10516,,,,1,N,50597,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),1,CHEMBL623057,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10517,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623058,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10518,,,,1,N,50597,,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,CHEMBL623059,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10519,,,,1,N,50597,,Oral bioavailability in rat after administration of 10 mg/kg po,1,CHEMBL623060,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10520,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623061,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10521,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623062,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10522,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623063,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10523,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623064,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10524,,,,1,N,50597,,Oral bioavailability in ratrs,1,CHEMBL623065,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10525,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623066,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10526,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623067,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10527,,,,1,N,50597,,Oral bioavailability in rats was determined; High,1,CHEMBL623068,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10528,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623069,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10529,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623070,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10530,,,,1,N,50597,,Oral bioavailability was calculated in rat,1,CHEMBL623071,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10531,,,,1,N,50597,,Oral bioavailability,1,CHEMBL623072,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10532,,,,1,N,50597,,Oral bioavailability,1,CHEMBL623073,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10533,,,,1,N,50597,,Oral bioavailability,1,CHEMBL623074,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10534,,,,1,N,50597,,Oral bioavailability,1,CHEMBL623075,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10535,,,,1,N,50597,,Oral bioavailability after i.v. administration,1,CHEMBL623076,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10536,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,CHEMBL623077,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10537,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley),1,CHEMBL623078,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10538,,,,1,N,50597,,Oral bioavailability in Sprague-Dawley rats,1,CHEMBL623079,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10539,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,CHEMBL623080,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10540,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,CHEMBL623081,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10541,,,,1,N,50597,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,1,CHEMBL623082,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10542,,,,1,N,50597,,Oral bioavailability in fasted rat,1,CHEMBL874400,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10543,,,,1,N,50597,,Oral bioavailability in fed rat,1,CHEMBL623083,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10544,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623084,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10545,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623085,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10546,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623086,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10547,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623087,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10548,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623088,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10549,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623089,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10550,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623090,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10551,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623091,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10552,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623092,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10553,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623093,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10554,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL874401,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10555,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623094,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10556,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL623095,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10557,,,,1,N,50597,,Oral bioavailability in rat after peroral administration at 10 mg/kg,1,CHEMBL623096,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10558,,,,1,N,50597,,Oral bioavailability in rat after peroral administration at 5 mg/kg,1,CHEMBL624913,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10559,,,,1,N,50597,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),1,CHEMBL624914,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10560,,,,1,N,50597,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,1,CHEMBL624915,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10561,,,,1,N,50597,,Oral bioavailability in rat; Not measured,1,CHEMBL624916,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10562,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL624917,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10563,,,,1,N,50597,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,1,CHEMBL625157,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10564,,Liver,,1,N,50597,2107.0,In vitro metabolic potential in rat liver microsomes,1,CHEMBL625158,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10565,,,,1,N,50597,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",1,CHEMBL625159,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10566,,,,1,N,50597,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",1,CHEMBL625160,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10567,,,,1,N,50597,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,1,CHEMBL625161,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10568,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL625162,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10569,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL625163,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10570,,,,1,N,50597,,Oral bioavailability in rats at 10 mg/kg,1,CHEMBL625164,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10571,,,,1,N,50597,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,CHEMBL625165,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10572,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL625166,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10573,,,,1,N,50597,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,1,CHEMBL625167,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10574,,,,1,N,50597,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,1,CHEMBL625168,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10575,,,,1,N,50597,,Plasma clearance of the compound,1,CHEMBL625169,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10576,,,,1,N,50597,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,1,CHEMBL626264,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10577,,,,1,N,50597,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,1,CHEMBL626265,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10578,,Plasma,,1,N,50597,1969.0,The compound was tested for plasma clearance in rat,1,CHEMBL626266,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10579,,Plasma,,1,N,50597,1969.0,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,1,CHEMBL626267,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10580,,,,1,N,50597,,Plasma concentration upon oral administration of 1 mg/Kg in rats,1,CHEMBL626268,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10581,,,,1,N,50597,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,1,CHEMBL626269,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10582,,,,1,N,50597,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,1,CHEMBL626270,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10583,,,,1,N,50597,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,1,CHEMBL626271,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10584,,,,1,N,50597,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",1,CHEMBL626272,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10585,,,,1,N,50597,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,CHEMBL626273,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10586,,,,1,N,50597,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,CHEMBL875346,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10587,,,,1,N,50597,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",1,CHEMBL626274,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10588,,,,1,N,50597,,Compound was tested for protein binding in rat plasma,1,CHEMBL626275,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10589,,,,1,N,50597,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,1,CHEMBL624646,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10590,,,,1,N,50597,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,1,CHEMBL624647,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10591,,Liver,,1,N,50597,2107.0,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,1,CHEMBL624648,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10592,,,,1,N,50597,,Area under curve ratio was determined (po/iv) in rat,1,CHEMBL624649,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10593,,,,1,N,50597,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,1,CHEMBL624650,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10594,,,,1,N,50597,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,1,CHEMBL624651,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10595,,,,1,N,50597,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,1,CHEMBL624652,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10596,,,,1,N,50597,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,1,CHEMBL624653,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10597,,,,1,N,50597,,Ratio of AUCbrain to AUCplasma,1,CHEMBL624654,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10598,,,,1,N,50597,,Ratio of brain to plasma,1,CHEMBL624655,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10599,,,,1,N,50597,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,1,CHEMBL624656,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10600,,,,1,N,50597,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,CHEMBL624657,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10601,,,,1,N,50597,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,CHEMBL624658,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10602,,,,1,N,50597,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,1,CHEMBL624659,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10603,,,,1,N,50597,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,1,CHEMBL624660,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10604,,,,1,N,50597,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,1,CHEMBL624661,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10605,,,,1,N,50597,,Steady state brain :blood ratio was determined,1,CHEMBL624662,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10606,,,,1,N,50597,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,CHEMBL625199,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10607,,,,1,N,50597,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,CHEMBL625200,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10608,,,,1,N,50597,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,CHEMBL625201,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10609,,,,1,N,50597,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,CHEMBL625202,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10610,,,,1,N,50597,,Percentage recovery after 3h incubation with rat hapatocytes was determined,1,CHEMBL625203,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10611,,,,1,N,50597,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,1,CHEMBL625204,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10612,,,,1,N,50597,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,1,CHEMBL625205,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10613,,,,1,N,50597,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,1,CHEMBL625206,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10614,,,,1,U,22224,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",0,CHEMBL625207,,,A,,,,Autocuration,,BAO_0000019
10615,,,,1,U,22224,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,0,CHEMBL625208,,,A,,,,Autocuration,,BAO_0000019
10616,,,,1,N,50587,,In vivo absorption in Caco-2 cell line monolayers was determined,1,CHEMBL625209,Homo sapiens,,A,9606.0,,Caco-2,Intermediate,495.0,BAO_0000218
10617,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625210,,,P,,,,Autocuration,,BAO_0000100
10618,,,,1,N,50597,,Area under curve was determine after peroral administration at 10 mpk in Rat,1,CHEMBL625211,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10619,,,,1,N,50797,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,1,CHEMBL625212,Macaca mulatta,,A,9544.0,,,Intermediate,,BAO_0000218
10620,,,,1,N,50597,,Area under curve was determine after peroral administration at 160 mpk in Rat,1,CHEMBL625213,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10621,,,,1,N,50597,,Area under curve was determine after peroral administration at 20 mpk in Rat,1,CHEMBL625214,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10622,,,,1,N,50597,,Area under curve was determine after peroral administration at 50 mpk in Rat,1,CHEMBL874542,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10623,,,,1,U,22229,,Calculated partition coefficient (clogP) (AlogP),0,CHEMBL625215,,,P,,,,Autocuration,,BAO_0000100
10624,,,,1,U,22224,,Activated partial thromboplastin time measured,0,CHEMBL625216,,,A,,,,Autocuration,,BAO_0000019
10625,,,,1,U,22224,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),0,CHEMBL625217,,,P,,,,Autocuration,,BAO_0000100
10626,,,,1,U,22224,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),0,CHEMBL625218,,,P,,,,Autocuration,,BAO_0000100
10627,,Plasma,,1,N,50588,1969.0,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,1,CHEMBL622864,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10628,,Plasma,,1,N,50597,1969.0,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,1,CHEMBL622865,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10629,,Plasma,,1,N,50597,1969.0,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,1,CHEMBL622866,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10630,,Plasma,,1,N,50588,1969.0,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,1,CHEMBL622867,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10631,,Plasma,,1,N,50512,1969.0,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,1,CHEMBL876808,Cavia porcellus,,A,10141.0,,,Intermediate,,BAO_0000218
10632,,Brain,,1,U,22224,955.0,AUC in brain,0,CHEMBL627725,,,A,,,,Autocuration,,BAO_0000019
10633,,Serum,,1,U,22224,1977.0,AUC in serum,0,CHEMBL627726,,,A,,,,Autocuration,,BAO_0000019
10634,,Plasma,,1,U,22224,1969.0,AUC was determined,0,CHEMBL627727,,,A,,,,Autocuration,,BAO_0000019
10635,,Plasma,,1,U,22224,1969.0,AUC of the compound.,0,CHEMBL627728,,,A,,,,Autocuration,,BAO_0000019
10636,,Plasma,,1,U,22224,1969.0,AUC value (0-4 hr),0,CHEMBL627729,,,A,,,,Autocuration,,BAO_0000019
10637,,Plasma,,1,U,22224,1969.0,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",0,CHEMBL627730,,,A,,,,Autocuration,,BAO_0000019
10638,,Plasma,,1,U,22224,1969.0,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,0,CHEMBL627731,,,A,,,,Autocuration,,BAO_0000019
10639,,Plasma,,1,U,22224,1969.0,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",0,CHEMBL627732,,,A,,,,Autocuration,,BAO_0000019
10640,,Plasma,,1,U,22224,1969.0,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",0,CHEMBL627733,,,A,,,,Autocuration,,BAO_0000019
10641,,Plasma,,1,N,50597,1969.0,AUC(area under curve) was determined after intravenous administration in rats,1,CHEMBL627734,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10642,,Plasma,,1,N,50597,1969.0,AUC(area under curve) was determined after oral administration in rats,1,CHEMBL627735,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10643,,Plasma,,1,N,50512,1969.0,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,1,CHEMBL627736,Cavia porcellus,,A,10141.0,,,Intermediate,,BAO_0000218
10644,,Plasma,,1,N,50597,1969.0,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,1,CHEMBL876809,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10645,,,,1,U,22224,,Area Under Curve after oral dosing of 100 uM/Kg,0,CHEMBL627737,,,A,,,,Autocuration,,BAO_0000019
10646,,,,1,U,22224,,Area Under Curve after oral dosing of 30 uM/Kg,0,CHEMBL627738,,,A,,,,Autocuration,,BAO_0000019
10647,,,,1,U,22224,,Area Under Curve was measured by ploting the graph between concentration verses time,0,CHEMBL627739,,,A,,,,Autocuration,,BAO_0000019
10648,,,,1,N,50588,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,1,CHEMBL626143,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10649,,,,1,U,22224,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,0,CHEMBL626144,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
10650,,,,1,N,50592,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,1,CHEMBL626145,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
10651,,,,1,N,50597,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,1,CHEMBL626146,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10652,,Blood,,1,N,50597,178.0,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,1,CHEMBL626147,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10653,,,,1,U,22224,,Area under curve (AUC) was determined,0,CHEMBL626148,,,A,,,,Autocuration,,BAO_0000019
10654,,,,1,U,22224,,Area under curve (AUC) following ip administration at 1 mg/kg,0,CHEMBL626149,,,A,,,,Autocuration,,BAO_0000218
10655,,,,1,U,22224,,Area under curve (AUC) was determined; ND is Not determined,0,CHEMBL626150,,,A,,,,Autocuration,,BAO_0000019
10656,,,,1,N,50588,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,1,CHEMBL626151,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10657,,,,1,N,50588,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,1,CHEMBL626152,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10658,,,,1,N,50588,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,1,CHEMBL626153,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10659,,,,1,U,22224,,Area under curve (AUR) was determined,0,CHEMBL626154,,,A,,,,Autocuration,,BAO_0000019
10660,,,,1,U,22224,,Area under curve at 1 uM/dg administered intravenously,0,CHEMBL626155,,,A,,,,Autocuration,,BAO_0000019
10661,,,,1,U,22224,,Area under curve at 10 uM/dg administered perorally,0,CHEMBL626156,,,A,,,,Autocuration,,BAO_0000019
10662,,,,1,U,22224,,Area under curve at 2 uM/dg administered intravenously,0,CHEMBL626157,,,A,,,,Autocuration,,BAO_0000019
10663,,,,1,U,22224,,Area under curve at 20 uM/dg administered perorally,0,CHEMBL626158,,,A,,,,Autocuration,,BAO_0000019
10664,,,,1,N,50588,,Area under curve at a peroral dose of 3 mg/kg in dog,1,CHEMBL626159,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10665,,,,1,N,50597,,Area under curve at a peroral dose of 3 mg/kg in rat,1,CHEMBL626160,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10666,,,,1,N,50588,,Area under curve at an iv dose of 1 mg/kg in dog,1,CHEMBL626161,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10667,,,,1,N,50597,,Area under curve at an iv dose of 1 mg/kg in rat,1,CHEMBL626162,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10668,,,,1,U,22224,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,0,CHEMBL626163,,,A,,,,Autocuration,,BAO_0000019
10669,,,,1,U,22224,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,0,CHEMBL626164,,,A,,,,Autocuration,,BAO_0000019
10670,,,,1,N,50594,,Area under curve measured as conc vs time after intravenous administration to mice.,1,CHEMBL626165,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
10671,,,,1,N,50594,,Area under curve measured as conc vs time after peroral administration to mice.,1,CHEMBL626166,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
10672,,,,1,N,50588,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,CHEMBL626167,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10673,,,,1,N,50588,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,1,CHEMBL626168,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10674,,,,1,N,50588,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,1,CHEMBL877463,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10675,,,,1,N,50588,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,1,CHEMBL626169,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10676,,Heart,,1,N,50597,948.0,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,1,CHEMBL626170,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10677,,Heart,,1,N,50597,948.0,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,1,CHEMBL626171,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10678,,Heart,,1,N,50597,948.0,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,1,CHEMBL626172,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10679,,Heart,,1,N,50597,948.0,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,1,CHEMBL626173,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10680,,Kidney,,1,N,50597,2113.0,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,1,CHEMBL626174,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10681,,Kidney,,1,N,50597,2113.0,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,1,CHEMBL626175,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10682,,Kidney,,1,N,50597,2113.0,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,1,CHEMBL626176,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10683,,Kidney,,1,N,50597,2113.0,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,1,CHEMBL626177,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10684,,Kidney,,1,N,50597,2113.0,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,1,CHEMBL622499,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10685,,Liver,,1,N,50597,2107.0,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,1,CHEMBL622500,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10686,,Liver,,1,N,50597,2107.0,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,1,CHEMBL622501,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10687,,Liver,,1,N,50597,2107.0,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,1,CHEMBL622502,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10688,,Liver,,1,N,50597,2107.0,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,1,CHEMBL622503,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10689,,Liver,,1,N,50597,2107.0,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,1,CHEMBL877614,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10690,,Lung,,1,N,50597,2048.0,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,1,CHEMBL624839,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10691,,Lung,,1,N,50597,2048.0,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,1,CHEMBL624840,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10692,,Lung,,1,N,50597,2048.0,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,1,CHEMBL624841,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10693,,Lung,,1,N,50597,2048.0,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,1,CHEMBL624842,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10694,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,1,CHEMBL624843,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10695,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,1,CHEMBL624844,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10696,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,1,CHEMBL624845,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10697,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,1,CHEMBL621904,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10698,,Blood,,1,N,50597,178.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,1,CHEMBL621905,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10699,,Blood,,1,N,50597,178.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,1,CHEMBL874382,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10700,,Blood,,1,N,50597,178.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,1,CHEMBL621906,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10701,,Brain,,1,N,50597,955.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,1,CHEMBL621907,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10702,,Brain,,1,N,50597,955.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,1,CHEMBL622096,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10703,,Brain,,1,N,50597,955.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,1,CHEMBL622097,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10704,,Heart,,1,N,50597,948.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,1,CHEMBL622098,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10705,,Heart,,1,N,50597,948.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,1,CHEMBL622099,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10706,,Heart,,1,N,50597,948.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,1,CHEMBL622100,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10707,,Kidney,,1,N,50597,2113.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,1,CHEMBL622101,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10708,,Kidney,,1,N,50597,2113.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,1,CHEMBL622102,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10709,,Kidney,,1,N,50597,2113.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,1,CHEMBL622103,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10710,,Liver,,1,N,50597,2107.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,1,CHEMBL622104,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10711,,Liver,,1,N,50597,2107.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,1,CHEMBL622105,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10712,,Liver,,1,N,50597,2107.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,1,CHEMBL622106,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10713,,Lung,,1,N,50597,2048.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,1,CHEMBL622107,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10714,,Lung,,1,N,50597,2048.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,1,CHEMBL622108,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10715,,Lung,,1,N,50597,2048.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,1,CHEMBL622109,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10716,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,1,CHEMBL622110,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10717,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,1,CHEMBL622111,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10718,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,1,CHEMBL874383,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10719,,Zone of skin,,1,N,50597,14.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,1,CHEMBL622112,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10720,,Zone of skin,,1,N,50597,14.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,1,CHEMBL622113,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10721,,Zone of skin,,1,N,50597,14.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,1,CHEMBL622114,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10722,,Spleen,,1,N,50597,2106.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,1,CHEMBL622115,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10723,,Spleen,,1,N,50597,2106.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,1,CHEMBL622116,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10724,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622117,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10725,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622118,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10726,,,,1,N,50597,,Oral bioavailability in rats at 6 mg/kg,1,CHEMBL622119,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10727,,,,1,N,50597,,Oral bioavailability in rat (dose 6 mg/kg),1,CHEMBL622120,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10728,,,,1,N,50597,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,1,CHEMBL622121,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10729,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622122,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10730,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622123,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10731,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL622124,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10732,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL622125,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10733,,,,1,N,50597,,Oral bioavailability,1,CHEMBL622126,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10734,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,CHEMBL620455,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10735,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL620456,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10736,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL620457,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10737,,,,1,N,50597,,Oral bioavailability was evaluated; Not tested,1,CHEMBL620458,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10738,,,,1,N,50597,,Oral bioavailability,1,CHEMBL620459,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10739,,,,1,N,50597,,Oral bioavailability in rat by oral dosing,1,CHEMBL620460,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10740,,,,1,N,50597,,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,CHEMBL620461,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10741,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley),1,CHEMBL620462,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10742,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,CHEMBL620463,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10743,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,CHEMBL620464,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10744,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,CHEMBL620465,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10745,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),1,CHEMBL620466,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10746,,,,1,N,50597,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,1,CHEMBL620467,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10747,,,,1,N,50597,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,1,CHEMBL620468,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10748,,,,1,N,50597,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,1,CHEMBL620469,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10749,,,,1,N,50597,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,1,CHEMBL620470,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10750,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL620471,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10751,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL620472,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10752,,,,1,N,50597,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,1,CHEMBL620473,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10753,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL620474,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10754,,,,1,N,50597,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),1,CHEMBL620475,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10755,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL620476,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10756,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL620477,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10757,,,,1,N,50597,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,1,CHEMBL620478,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10758,,,,1,N,50597,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,1,CHEMBL618768,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10759,,,,1,N,50597,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,1,CHEMBL618769,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10760,,,,1,N,50597,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,1,CHEMBL618770,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10761,,,,1,N,50597,,Oral bioavailability (dose 20 mg/kg p.o.),1,CHEMBL618771,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10762,,,,1,N,50597,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,1,CHEMBL618772,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10763,,,,1,N,50597,,Oral bioavailability in rat at 10 mg/kg of the compound,1,CHEMBL618773,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10764,,,,1,N,50597,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,CHEMBL875842,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10765,,,,1,N,50597,,Bioavailability in rat (dose 3 mg/kg i.v.),1,CHEMBL618774,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10766,,,,1,N,50597,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,CHEMBL618775,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10767,,,,1,N,50597,,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,CHEMBL618776,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10768,,,,1,N,50597,,Percent bioavailability (F) in rats after iv administration,1,CHEMBL618777,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10769,,,,1,N,50597,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,1,CHEMBL618778,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10770,,,,1,N,50597,,Bioavailability in rat (dose 5 uM/kg p.o.),1,CHEMBL618779,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10771,,,,1,N,50597,,Oral bioavailability,1,CHEMBL618780,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10772,,,,1,N,50597,,Bioavailability in rat (dose 2 mg/kg p.o.),1,CHEMBL618781,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10773,,,,1,N,50597,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,1,CHEMBL618782,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10774,,,,1,N,50597,,Oral bioavailability in rat (dose 20 mg/kg),1,CHEMBL618783,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10775,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL618784,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10776,,,,1,N,50597,,Percent oral bioavailability evaluated in rat,1,CHEMBL618785,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10777,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL618786,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10778,,,,1,N,50597,,Percent oral bioavailability in rat; Not determined,1,CHEMBL618787,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10779,,,,1,N,50597,,Oral bioavailability in rat,1,CHEMBL618788,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10780,,,,1,N,50597,,Bioavailability in rat,1,CHEMBL618789,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10781,,,,1,N,50597,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),1,CHEMBL618790,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10782,,,,1,N,50597,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),1,CHEMBL618791,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10783,,,,1,N,50597,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,1,CHEMBL875843,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10784,,,,1,N,50597,,Oral bioavailability in rat (dose 20 mg/kg p.o.),1,CHEMBL618792,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10785,,,,1,N,50597,,Cmax at a dose of 30 mg/kg in rat,1,CHEMBL623395,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10786,,,,1,U,22224,,Cmax in monkeys at a dose of 1 mg/kg,0,CHEMBL623396,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
10787,,,,1,N,50597,,Cmax in rat,1,CHEMBL623397,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10788,,,,1,N,50597,,Cmax in rats at a dose of 1 mg/kg,1,CHEMBL623398,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10789,,,,1,N,50594,,Cmax was measured in mice after an oral dose of 50 mg/kg.,1,CHEMBL623399,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10790,,,,1,U,22224,,"Cmax value at a dose of 12.7 uM/kg, po",0,CHEMBL623400,,,A,,In vivo,,Autocuration,,BAO_0000218
10791,,,,1,U,22224,,"Cmax value at a dose of 6.3 uM/kg, iv",0,CHEMBL623401,,,A,,In vivo,,Autocuration,,BAO_0000218
10792,,,,1,U,22224,,"Cmax value at a dose of 7.1 uM/kg, iv",0,CHEMBL623402,,,A,,In vivo,,Autocuration,,BAO_0000218
10793,,,,1,U,22224,,Cmax value of compound was determined after 1 hr,0,CHEMBL623403,,,A,,In vivo,,Autocuration,,BAO_0000218
10794,,,,1,U,22224,,Cmax value of the compound,0,CHEMBL623404,,,A,,In vivo,,Autocuration,,BAO_0000218
10795,,,,1,N,50597,,Cmax value administered intraintestinal in rats.,1,CHEMBL625997,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10796,,,,1,N,50597,,Cmax value administered perorally was determined in rat; Not determined,1,CHEMBL625998,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10797,,,,1,U,22224,,Cmax value at the dose of 2.3 mg/kg,0,CHEMBL625999,,,A,,In vivo,,Autocuration,,BAO_0000218
10798,,,,1,U,22224,,Cmax value at the dose of 5 mg/kg,0,CHEMBL626000,,,A,,In vivo,,Autocuration,,BAO_0000218
10799,,,,1,U,22224,,Cmax value in the period of 8 hr after dosing. ,0,CHEMBL626001,,,A,,In vivo,,Autocuration,,BAO_0000218
10800,,,,1,U,22224,,Cmax value at a oral dose of 20 mg/kg; Not tested,0,CHEMBL626002,,,A,,In vivo,,Autocuration,,BAO_0000218
10801,,,,1,U,22224,,Cmax value at a oral dose of 20 mg/kg,0,CHEMBL626003,,,A,,In vivo,,Autocuration,,BAO_0000218
10802,,,,1,N,50597,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,CHEMBL626004,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10803,,,,1,N,50512,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,1,CHEMBL626005,Cavia porcellus,,A,10141.0,In vivo,,Intermediate,,BAO_0000218
10804,,,,1,N,50597,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,1,CHEMBL626006,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10805,,Plasma,,1,N,50597,1969.0,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,1,CHEMBL626007,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10806,,Plasma,,1,N,50594,1969.0,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1,CHEMBL626008,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10807,,Liver,,1,N,50588,2107.0,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,1,CHEMBL626009,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10808,,,,1,N,50588,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,1,CHEMBL626010,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10809,,Blood,,1,N,50594,178.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,1,CHEMBL626011,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10810,,Blood,,1,N,50594,178.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,1,CHEMBL626012,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10811,,Blood,,1,N,50594,178.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,1,CHEMBL626013,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10812,,Blood,,1,N,50594,178.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,1,CHEMBL626014,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10813,,Blood,,1,N,50594,178.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,1,CHEMBL877496,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10814,,,,1,N,50588,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,1,CHEMBL626015,Canis lupus familiaris,,F,9615.0,In vivo,,Intermediate,,BAO_0000218
10815,,,,1,N,50588,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,1,CHEMBL626016,Canis lupus familiaris,,F,9615.0,In vivo,,Intermediate,,BAO_0000218
10816,,,,1,N,50588,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,1,CHEMBL626017,Canis lupus familiaris,,F,9615.0,In vivo,,Intermediate,,BAO_0000218
10817,,Plasma,,1,N,50588,1969.0,Bioavailability as maximal plasma concentration in dogs,1,CHEMBL626018,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10818,,Plasma,,1,N,50588,1969.0,Bioavailability as maximal plasma concentration in dogs,1,CHEMBL626692,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10819,,Plasma,,1,N,50597,1969.0,Bioavailability as maximal plasma concentration in rats,1,CHEMBL626693,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10820,,Plasma,,1,U,22224,1969.0,Bioavailability as maximal plasma concentration in rats,0,CHEMBL626694,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
10821,,Blood,,1,N,50588,178.0,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,CHEMBL626695,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10822,,Blood,,1,N,50588,178.0,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,CHEMBL626696,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10823,,Blood,,1,N,50588,178.0,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,CHEMBL626697,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10824,,Blood,,1,N,50588,178.0,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,1,CHEMBL626859,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10825,,Blood,,1,N,50588,178.0,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,CHEMBL626860,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10826,,Blood,,1,N,50588,178.0,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,CHEMBL626861,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10827,,,,1,N,50597,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,CHEMBL626296,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10828,,,,1,U,22224,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,0,CHEMBL626297,,,A,,In vivo,,Autocuration,,BAO_0000218
10829,,Plasma,,1,U,22224,1969.0,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,0,CHEMBL626298,,,A,,In vivo,,Autocuration,,BAO_0000218
10830,,Plasma,,1,N,50597,1969.0,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",1,CHEMBL626299,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10831,,Plasma,,1,N,50597,1969.0,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,1,CHEMBL626300,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10832,,Plasma,,1,N,50597,1969.0,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,1,CHEMBL626301,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10833,,Plasma,,1,N,50597,1969.0,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,1,CHEMBL626962,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10834,,Plasma,,1,N,50597,1969.0,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,1,CHEMBL626963,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10835,,Plasma,,1,N,50597,1969.0,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,1,CHEMBL626964,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10836,,Plasma,,1,N,100710,1969.0,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,1,CHEMBL626965,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
10837,,Plasma,,1,N,50594,1969.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,CHEMBL626966,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10838,,Plasma,,1,N,50594,1969.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,CHEMBL626967,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10839,,Plasma,,1,N,100710,1969.0,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,1,CHEMBL626968,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
10840,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,1,CHEMBL626969,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10841,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,1,CHEMBL627126,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10842,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,1,CHEMBL631276,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10843,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,1,CHEMBL631277,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10844,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,1,CHEMBL631278,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10845,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,1,CHEMBL874457,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10846,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,1,CHEMBL631279,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10847,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,1,CHEMBL631280,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10848,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,1,CHEMBL631281,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10849,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,1,CHEMBL631968,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10850,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,1,CHEMBL631969,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10851,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,1,CHEMBL631970,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10852,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,1,CHEMBL631971,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10853,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,1,CHEMBL631972,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10854,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,1,CHEMBL630435,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10855,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,1,CHEMBL630436,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10856,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,1,CHEMBL630437,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10857,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,1,CHEMBL630438,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10858,,Heart,,1,N,50597,948.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,1,CHEMBL630439,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10859,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,1,CHEMBL630440,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10860,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,1,CHEMBL630441,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10861,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,1,CHEMBL630442,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10862,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,1,CHEMBL625234,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10863,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,1,CHEMBL625235,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10864,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,1,CHEMBL625236,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10865,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,1,CHEMBL625237,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10866,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,1,CHEMBL626125,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10867,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,1,CHEMBL626126,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10868,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,1,CHEMBL626127,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10869,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,1,CHEMBL626128,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10870,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,1,CHEMBL626129,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10871,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,1,CHEMBL626130,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10872,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,1,CHEMBL626131,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10873,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,1,CHEMBL626132,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10874,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,1,CHEMBL626752,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10875,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,1,CHEMBL626753,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10876,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,1,CHEMBL626754,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10877,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,1,CHEMBL626755,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10878,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,1,CHEMBL626756,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10879,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,1,CHEMBL626757,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10880,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,1,CHEMBL626758,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10881,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,1,CHEMBL626759,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10882,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,1,CHEMBL626760,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10883,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,CHEMBL626394,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10884,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,1,CHEMBL626395,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10885,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,CHEMBL626396,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10886,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,CHEMBL626397,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10887,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,CHEMBL626398,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10888,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,CHEMBL626399,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10889,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,1,CHEMBL874653,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10890,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,CHEMBL626400,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10891,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,CHEMBL626401,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10892,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,CHEMBL626402,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10893,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL626403,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10894,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,CHEMBL626404,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10895,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,1,CHEMBL626405,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10896,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,CHEMBL625529,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10897,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,CHEMBL625530,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10898,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,CHEMBL625531,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10899,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL625532,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10900,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,CHEMBL625533,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10901,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,1,CHEMBL875474,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10902,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,CHEMBL625534,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10903,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,CHEMBL625535,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10904,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),1,CHEMBL625536,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10905,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL625537,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10906,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,CHEMBL625538,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10907,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,1,CHEMBL625539,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10908,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,CHEMBL625540,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10909,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,CHEMBL625541,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10910,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,CHEMBL625542,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10911,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL625543,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10912,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,CHEMBL625544,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
10913,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,1,CHEMBL625545,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10914,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,CHEMBL625546,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10915,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,1,CHEMBL625547,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10916,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,CHEMBL625548,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10917,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,CHEMBL625549,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10918,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,CHEMBL625550,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10919,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,CHEMBL625551,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10920,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,CHEMBL875475,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10921,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,CHEMBL625552,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10922,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,CHEMBL625553,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10923,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,CHEMBL625554,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10924,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,CHEMBL625555,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10925,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,CHEMBL625556,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10926,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,1,CHEMBL624986,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10927,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,CHEMBL624987,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10928,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,CHEMBL624988,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
10929,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,1,CHEMBL624989,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10930,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,1,CHEMBL624990,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10931,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,1,CHEMBL874391,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10932,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,1,CHEMBL624991,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10933,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,1,CHEMBL624992,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10934,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,1,CHEMBL624993,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10935,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,1,CHEMBL624994,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10936,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,1,CHEMBL624995,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10937,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,1,CHEMBL624996,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10938,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,1,CHEMBL624997,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10939,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,1,CHEMBL624998,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10940,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,1,CHEMBL624999,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10941,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,1,CHEMBL882955,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10942,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,1,CHEMBL625000,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10943,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,1,CHEMBL625001,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10944,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,1,CHEMBL625089,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10945,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,1,CHEMBL625090,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10946,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,1,CHEMBL625091,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10947,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,1,CHEMBL625092,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10948,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,1,CHEMBL625093,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10949,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,1,CHEMBL625094,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10950,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,1,CHEMBL625095,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10951,,,,1,N,50588,,Compound was evaluated for its bioavailability in the dogs,1,CHEMBL625096,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10952,,,,1,N,50597,,Compound was evaluated for its bioavailability in the rats,1,CHEMBL625097,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10953,,,,1,U,22224,,Compound was evaluated for oral bioavailability,0,CHEMBL882956,,,A,,In vivo,,Autocuration,,BAO_0000218
10954,,,,1,N,50597,,Compound was evaluated for percentage of Oral bioavailability in rats,1,CHEMBL625098,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10955,,,,1,U,22224,,Bioavailability in guinea pig,0,CHEMBL625099,Cavia porcellus,,A,10141.0,In vivo,,Autocuration,,BAO_0000218
10956,,,,1,N,50597,,Compound was evaluated for the oral bioavailability in rat,1,CHEMBL625100,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10957,,,,1,N,50588,,Compound was evaluated for the oral bioavailability in dog,1,CHEMBL625101,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10958,,,,1,N,50597,,Compound was evaluated for the oral bioavailability in rat,1,CHEMBL874396,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10959,,,,1,U,22224,,Bioavailability in dog (dosed i.v.),0,CHEMBL625102,Canis lupus familiaris,,F,9615.0,In vivo,,Autocuration,,BAO_0000218
10960,,,,1,N,50588,,Compound was tested for in vivo bioavailability in dog,1,CHEMBL625103,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
10961,,,,1,N,100712,,Compound was tested for in vivo bioavailability in hamsters,1,CHEMBL625104,Cricetinae,,A,10026.0,In vivo,,Intermediate,,BAO_0000218
10962,,,,1,U,22224,,Compound was tested for in vivo bioavailability in monkey,0,CHEMBL625105,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
10963,,,,1,N,50597,,Compound was tested for in vivo bioavailability in rat,1,CHEMBL625106,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10964,,,,1,U,22224,,Oral bioavailability in mouse,0,CHEMBL625107,Mus musculus,,A,10090.0,In vivo,,Autocuration,,BAO_0000218
10965,,,,1,N,50594,,Compound was tested for percent of oral bioavailability in mice; 56-74,1,CHEMBL625108,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10966,,,,1,U,22224,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),0,CHEMBL625109,Mus musculus,,A,10090.0,In vivo,,Autocuration,,BAO_0000218
10967,,,,1,U,22224,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),0,CHEMBL625110,Macaca fascicularis,,A,9541.0,In vivo,,Autocuration,,BAO_0000218
10968,,,,1,U,22224,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),0,CHEMBL625111,Macaca fascicularis,,A,9541.0,In vivo,,Autocuration,,BAO_0000218
10969,,,,1,N,50594,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),1,CHEMBL625112,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10970,,,,1,N,50594,,Oral bioavailability in nude mice,1,CHEMBL875334,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10971,,,,1,U,22224,,Bioavailability in monkey (i.d. dosing),0,CHEMBL628617,Primates,,A,9443.0,In vivo,,Autocuration,,BAO_0000218
10972,,,,1,U,22224,,Bioavailability in rat,0,CHEMBL628618,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
10973,,,,1,U,22224,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,0,CHEMBL628619,,,A,,In vivo,,Autocuration,,BAO_0000218
10974,,,,1,U,22224,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,0,CHEMBL628620,,,A,,In vivo,,Autocuration,,BAO_0000218
10975,,,,1,N,100710,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,CHEMBL628621,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
10976,,,,1,N,100710,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,CHEMBL628622,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
10977,,,,1,N,100710,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,CHEMBL628623,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
10978,,Plasma,,1,N,100710,1969.0,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,1,CHEMBL628624,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
10979,,Plasma,,1,N,50594,1969.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,CHEMBL628625,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10980,,Plasma,,1,N,100710,1969.0,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,1,CHEMBL628626,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
10981,,Plasma,,1,N,50594,1969.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,CHEMBL627041,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10982,,Plasma,,1,N,50594,1969.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,CHEMBL627042,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10983,,Plasma,,1,N,50594,1969.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,CHEMBL627043,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10984,,Plasma,,1,U,22224,1969.0,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,0,CHEMBL627044,,,A,,In vivo,,Autocuration,,BAO_0000218
10985,,Plasma,,1,N,50594,1969.0,Cmax in mouse plasma,1,CHEMBL627045,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10986,,Plasma,,1,U,22224,1969.0,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,0,CHEMBL627046,,,A,,In vivo,,Autocuration,,BAO_0000218
10987,,Plasma,,1,N,50597,1969.0,Maximal plasma concentration in rat,1,CHEMBL627047,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10988,,Plasma,,1,N,50597,1969.0,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,1,CHEMBL627048,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10989,,,,1,N,50597,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,1,CHEMBL627049,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10990,,,,1,N,50597,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,1,CHEMBL627050,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10991,,,,1,N,50597,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,1,CHEMBL627051,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10992,,,,1,N,50597,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,1,CHEMBL627052,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10993,,,,1,N,50597,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,1,CHEMBL627053,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10994,,,,1,N,50597,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,1,CHEMBL627054,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
10995,,,,1,N,50594,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,CHEMBL627055,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10996,,,,1,N,50594,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,CHEMBL627056,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10997,,,,1,N,50594,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,CHEMBL627057,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10998,,,,1,N,50594,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,CHEMBL627058,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
10999,,,,1,N,50594,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,CHEMBL626211,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11000,,,,1,U,22224,,Maximum Concentration of the compound.,0,CHEMBL626212,,,A,,In vivo,,Autocuration,,BAO_0000218
11001,,,,1,N,50588,,Maximum Concentration was measured after iv administration into Beagle dog,1,CHEMBL626213,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11002,,,,1,N,50588,,Maximum Concentration was measured after iv administration into Beagle dog.,1,CHEMBL626214,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11003,,,,1,N,50588,,Maximum Concentration was measured after po administration into Beagle dog,1,CHEMBL626215,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11004,,,,1,N,50588,,Maximum Concentration was measured after po administration into Beagle dog.,1,CHEMBL626216,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11005,,Blood,,1,U,22224,178.0,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,0,CHEMBL626217,,,A,,In vivo,,Autocuration,,BAO_0000218
11006,,Blood,,1,U,22224,178.0,Maximum blood level reached after an iv dose of 12.2 uM/kg,0,CHEMBL626218,,,A,,In vivo,,Autocuration,,BAO_0000218
11007,,Blood,,1,U,22224,178.0,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,0,CHEMBL626219,,,A,,In vivo,,Autocuration,,BAO_0000218
11008,,Blood,,1,U,22224,178.0,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,0,CHEMBL626220,,,A,,In vivo,,Autocuration,,BAO_0000218
11009,,Blood,,1,U,22224,178.0,Maximum blood level reached after an oral dose of 5.0 mg/kg,0,CHEMBL626221,,,A,,In vivo,,Autocuration,,BAO_0000218
11010,,Blood,,1,U,22224,178.0,Maximum blood level reached at dose of 10.6 uM/kg orally,0,CHEMBL626222,,,A,,In vivo,,Autocuration,,BAO_0000218
11011,,,,1,N,50512,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,1,CHEMBL626223,Cavia porcellus,,A,10141.0,In vivo,,Intermediate,,BAO_0000218
11012,,,,1,N,50512,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,1,CHEMBL626224,Cavia porcellus,,A,10141.0,In vivo,,Intermediate,,BAO_0000218
11013,,Brain,,1,N,50597,955.0,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,1,CHEMBL626225,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11014,,Brain,,1,N,50597,955.0,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,1,CHEMBL626226,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11015,,Brain,,1,N,50597,955.0,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,1,CHEMBL626227,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11016,,Brain,,1,N,50597,955.0,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,1,CHEMBL626228,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11017,,,,1,N,50597,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,CHEMBL626229,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11018,,,,1,N,50597,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,1,CHEMBL626921,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11019,,,,1,N,50597,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,1,CHEMBL876793,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11020,,,,1,N,50597,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,1,CHEMBL625309,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11021,,,,1,N,50278,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,CHEMBL625310,Bacillus subtilis,,A,1423.0,In vivo,,Intermediate,,BAO_0000218
11022,,,,1,U,22224,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,0,CHEMBL625311,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11023,,,,1,N,50597,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,1,CHEMBL625312,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11024,,,,1,U,22224,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,0,CHEMBL625313,,,A,,In vivo,,Autocuration,,BAO_0000218
11025,,,,1,N,50594,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,1,CHEMBL625314,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11026,,,,1,N,50597,,Maximum concentration in male rats after iv administration of 20 mg/kg,1,CHEMBL625315,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11027,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,1,CHEMBL625316,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11028,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,1,CHEMBL625317,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11029,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,1,CHEMBL625318,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11030,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,1,CHEMBL625319,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11031,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,1,CHEMBL625320,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11032,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,1,CHEMBL625321,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11033,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,1,CHEMBL625322,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11034,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,1,CHEMBL876801,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11035,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,1,CHEMBL625323,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11036,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,1,CHEMBL625324,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11037,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,1,CHEMBL625325,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11038,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,1,CHEMBL625326,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11039,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,1,CHEMBL625327,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11040,,Liver,,1,N,50597,2107.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,1,CHEMBL625328,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11041,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,1,CHEMBL625329,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11042,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,1,CHEMBL625330,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11043,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,1,CHEMBL627774,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11044,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,1,CHEMBL627775,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11045,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,1,CHEMBL627949,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11046,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,1,CHEMBL627950,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11047,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,1,CHEMBL627951,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11048,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,1,CHEMBL627952,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11049,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,1,CHEMBL627953,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11050,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,1,CHEMBL627954,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11051,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,1,CHEMBL627955,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11052,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,1,CHEMBL627956,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11053,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,1,CHEMBL876802,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11054,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,1,CHEMBL627957,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11055,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,1,CHEMBL627958,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11056,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,1,CHEMBL627959,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11057,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,1,CHEMBL627960,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11058,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,1,CHEMBL627961,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11059,,Lung,,1,N,50597,2048.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,1,CHEMBL627962,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11060,,,,1,N,50597,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,CHEMBL627963,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11061,,,,1,N,50597,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,CHEMBL624759,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11062,,,,1,N,50597,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,CHEMBL624760,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11063,,,,1,N,50597,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,CHEMBL624761,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11064,,,,1,N,50597,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,CHEMBL877607,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11065,,Liver,,1,N,50597,2107.0,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,CHEMBL624762,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11066,,Liver,,1,N,50597,2107.0,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,CHEMBL624763,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11067,,Liver,,1,N,50597,2107.0,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,CHEMBL624764,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11068,,Liver,,1,N,50597,2107.0,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,CHEMBL624765,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11069,,Liver,,1,N,50597,2107.0,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,CHEMBL624766,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11070,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,CHEMBL624767,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11071,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,1,CHEMBL624768,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11072,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,CHEMBL624769,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11073,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,CHEMBL624770,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11074,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,CHEMBL624771,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11075,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,CHEMBL624772,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11076,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,1,CHEMBL624773,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11077,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,CHEMBL624774,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11078,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,CHEMBL624775,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11079,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,CHEMBL624776,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11080,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL624777,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11081,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,CHEMBL624778,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11082,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,1,CHEMBL624779,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11083,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,CHEMBL624780,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11084,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL624781,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11085,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,CHEMBL877608,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11086,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,CHEMBL624782,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11087,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,CHEMBL624783,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11088,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,1,CHEMBL624784,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11089,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,CHEMBL624785,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11090,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,CHEMBL624786,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11091,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL624787,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11092,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,CHEMBL628676,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11093,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,1,CHEMBL621842,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11094,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,CHEMBL621843,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11095,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,CHEMBL623873,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11096,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,CHEMBL623874,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11097,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL623875,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11098,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,CHEMBL623876,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11099,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,1,CHEMBL623877,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11100,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,CHEMBL623878,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11101,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,1,CHEMBL623879,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11102,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,CHEMBL623880,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11103,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,CHEMBL623881,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11104,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,CHEMBL623957,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11105,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,CHEMBL623958,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11106,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,CHEMBL623959,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11107,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,CHEMBL623960,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11108,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,CHEMBL623961,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11109,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,CHEMBL623962,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11110,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,CHEMBL624676,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11111,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,CHEMBL624677,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11112,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,1,CHEMBL624678,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11113,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,CHEMBL624679,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11114,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,CHEMBL624680,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11115,,,,1,U,22224,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,0,CHEMBL624849,,,A,,In vivo,,Autocuration,,BAO_0000218
11116,,,,1,U,22224,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,0,CHEMBL624850,,,A,,In vivo,,Autocuration,,BAO_0000218
11117,,,,1,U,22224,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,0,CHEMBL874399,,,A,,In vivo,,Autocuration,,BAO_0000218
11118,,,,1,U,22224,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,0,CHEMBL624851,,,A,,In vivo,,Autocuration,,BAO_0000218
11119,,,,1,U,22224,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,0,CHEMBL624852,,,A,,In vivo,,Autocuration,,BAO_0000218
11120,,,,1,U,22224,,Oral bioavailability in rat (dose 10 mg/kg),0,CHEMBL624853,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11121,,,,1,U,22224,,Oral bioavailability in rat (Sprague-Dawley),0,CHEMBL624854,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11122,,,,1,U,22224,,Oral bioavailability in rat,0,CHEMBL624855,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11123,,,,1,U,22224,,Oral bioavailability in rats was determined in vivo,0,CHEMBL624856,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11124,,,,1,U,22224,,Oral bioavailability in dog,0,CHEMBL882957,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
11125,,,,1,U,22224,,Oral bioavailability of compound in monkey,0,CHEMBL624857,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11126,,,,1,N,50597,,Oral bioavailability of compound in rat,1,CHEMBL622202,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11127,,,,1,U,22224,,Bioavailability in rat of PMEA prodrug,0,CHEMBL622203,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11128,,,,1,N,50597,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,1,CHEMBL625522,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11129,,,,1,U,22224,,Serum conc at 3 hours following 25 mg/kg dose,0,CHEMBL622868,Macaca mulatta,,A,9544.0,In vivo,,Autocuration,,BAO_0000218
11130,,Urine,,1,U,22224,1088.0,Urine conc 0-5 hours following 25 mg/kg dose,0,CHEMBL622869,Macaca mulatta,,A,9544.0,In vivo,,Autocuration,,BAO_0000218
11131,,Urine,,1,U,22224,1088.0,Urine conc 0-24 hours following 25 mg/kg dose,0,CHEMBL622870,Macaca mulatta,,A,9544.0,In vivo,,Autocuration,,BAO_0000218
11132,,,,1,U,22224,,Oral bioavailability in African green monkeys; 20-25,0,CHEMBL622871,Chlorocebus aethiops,,A,9534.0,In vivo,,Autocuration,,BAO_0000218
11133,,,,1,N,100710,,Oral bioavailability in cynomolgus monkey.,1,CHEMBL620560,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
11134,,,,1,U,22224,,Oral bioavailability in dog,0,CHEMBL620561,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
11135,,,,1,N,50588,,Oral bioavailability in dog at 10 mg/kg oral dose,1,CHEMBL620562,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11136,,,,1,N,100712,,Oral bioavailability in hamster at 10 mg/kg oral dose,1,CHEMBL620563,Cricetinae,,A,10026.0,In vivo,,Intermediate,,BAO_0000218
11137,,,,1,N,50597,,Oral bioavailability in rat at 10 mg/kg oral dose,1,CHEMBL620564,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11138,,,,1,U,22224,,Oral bioavailability in rat,0,CHEMBL872265,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11139,,,,1,U,22224,,Oral bioavailability in rat,0,CHEMBL620565,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11140,,,,1,U,22224,,Oral bioavailability,0,CHEMBL620566,Eutheria,,A,9347.0,In vivo,,Autocuration,,BAO_0000218
11141,,,,1,U,22224,,Oral bioavailability was determined; range 49-102%,0,CHEMBL620567,,,A,,In vivo,,Autocuration,,BAO_0000218
11142,,,,1,N,50588,,Oral bioavailability was determined in dogs,1,CHEMBL620568,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11143,,,,1,U,22224,,Oral bioavailability in rat,0,CHEMBL620569,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11144,,,,1,U,22224,,Oral bioavailability,0,CHEMBL620570,Eutheria,,A,9347.0,In vivo,,Autocuration,,BAO_0000218
11145,,,,1,U,22224,,Oral bioavailability was determined; Not orally available,0,CHEMBL620571,,,A,,In vivo,,Autocuration,,BAO_0000218
11146,,,,1,N,50594,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),1,CHEMBL620572,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11147,,,,1,U,22224,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),0,CHEMBL620573,Mus musculus,,A,10090.0,In vivo,,Autocuration,,BAO_0000218
11148,,,,1,U,22224,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,0,CHEMBL620574,Mus musculus,,A,10090.0,In vivo,,Autocuration,,BAO_0000218
11149,,,,1,U,22224,,Oral bioavailability in Rhesus monkey,0,CHEMBL620575,Macaca mulatta,,A,9544.0,In vivo,,Autocuration,,BAO_0000218
11150,,,,1,U,22224,,Oral bioavailability in dog (female mongrel),0,CHEMBL620576,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
11151,,,,1,U,22224,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,0,CHEMBL875846,,,A,,In vivo,,Autocuration,,BAO_0000218
11152,,,,1,U,22224,,Oral bioavailability in dog,0,CHEMBL620577,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
11153,,,,1,U,22224,,Percentage Bioavailability was evaluated.,0,CHEMBL620578,,,A,,In vivo,,Autocuration,,BAO_0000218
11154,,,,1,U,22224,,Bioavailability in rat administered i.d.,0,CHEMBL620579,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11155,,,,1,U,22224,,Bioavailability,0,CHEMBL621248,Eutheria,,A,9347.0,In vivo,,Autocuration,,BAO_0000218
11156,,,,1,U,22224,,Bioavailability in dog (male Beagle) i.v. administration,0,CHEMBL625390,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
11157,,,,1,U,22224,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",0,CHEMBL625391,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11158,,,,1,U,22224,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),0,CHEMBL872266,Primates,,A,9443.0,In vivo,,Autocuration,,BAO_0000218
11159,,,,1,U,22224,,Oral bioavailability in rat (Sprague-Dawley) (male),0,CHEMBL625392,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11160,,,,1,N,50597,,The oral bioavailability was measured on rats after oral administration,1,CHEMBL625393,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11161,,,,1,N,50597,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,CHEMBL625394,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11162,,,,1,N,50797,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,CHEMBL625395,Macaca mulatta,,A,9544.0,In vivo,,Intermediate,,BAO_0000218
11163,,,,1,U,22224,,Bioavailability in rat (dose 10 mg/kg i.d.),0,CHEMBL625396,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11164,,,,1,U,22224,,Bioavailability in dog (male Beagle) i.v. administration,0,CHEMBL625397,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
11165,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL625398,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11166,,Blood,,1,N,50594,178.0,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL625399,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11167,,Cerebellum,,1,N,50594,2037.0,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL626074,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11168,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL626075,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11169,,Plasma,,1,N,50597,1969.0,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,CHEMBL626076,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11170,,Plasma,,1,N,50797,1969.0,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,CHEMBL626077,Macaca mulatta,,A,9544.0,In vivo,,Intermediate,,BAO_0000218
11171,,Blood,,1,N,50597,178.0,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),1,CHEMBL626078,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11172,,Blood,,1,U,22224,178.0,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),0,CHEMBL625846,,,A,,In vivo,,Autocuration,,BAO_0000218
11173,,Blood,,1,U,22224,178.0,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),0,CHEMBL625847,,,A,,In vivo,,Autocuration,,BAO_0000218
11174,,,,1,N,50597,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,1,CHEMBL625848,Rattus norvegicus,,A,10116.0,In vivo,,Expert,,BAO_0000218
11175,,Plasma,,1,N,50597,1969.0,Maximum concentration of compound in plasma administered orally to rats,1,CHEMBL625849,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11176,,Plasma,,1,N,50588,1969.0,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",1,CHEMBL626023,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11177,,Plasma,,1,N,50588,1969.0,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",1,CHEMBL626024,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11178,,Plasma,,1,N,50588,1969.0,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",1,CHEMBL626025,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11179,,,,1,U,22224,,Maximum concentration after 10 mg/kg by oral administration,0,CHEMBL626026,,,A,,In vivo,,Autocuration,,BAO_0000218
11180,,,,1,U,22224,,Maximum concentration at a dose of 1.5 mg/kg,0,CHEMBL626027,,,A,,In vivo,,Autocuration,,BAO_0000218
11181,,,,1,U,22224,,Maximum concentration at a dose of 2.0 mg/kg,0,CHEMBL626028,,,A,,In vivo,,Autocuration,,BAO_0000218
11182,,Plasma,,1,N,50588,1969.0,Maximum concentration in dog plasma,1,CHEMBL626029,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11183,,Plasma,,1,U,22224,1969.0,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,0,CHEMBL626030,,,A,,In vivo,,Autocuration,,BAO_0000218
11184,,Plasma,,1,U,22224,1969.0,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,0,CHEMBL626031,,,A,,In vivo,,Autocuration,,BAO_0000218
11185,,Plasma,,1,U,22224,1969.0,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,0,CHEMBL626032,,,A,,In vivo,,Autocuration,,BAO_0000218
11186,,Plasma,,1,U,22224,1969.0,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,0,CHEMBL626033,,,A,,In vivo,,Autocuration,,BAO_0000218
11187,,Plasma,,1,U,22224,1969.0,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,0,CHEMBL626034,,,A,,In vivo,,Autocuration,,BAO_0000218
11188,,Plasma,,1,N,50588,1969.0,Maximum concentration in plasma after oral administration in dog (25 mg/kg),1,CHEMBL626035,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11189,,Plasma,,1,U,22224,1969.0,Maximum concentration in plasma at Tmax,0,CHEMBL626036,,,A,,In vivo,,Autocuration,,BAO_0000218
11190,,Plasma,,1,N,50588,1969.0,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,1,CHEMBL626037,Canis lupus familiaris,,A,9615.0,In vivo,,Expert,,BAO_0000218
11191,,Plasma,,1,N,100712,1969.0,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,1,CHEMBL626038,Cricetinae,,A,10026.0,In vivo,,Intermediate,,BAO_0000218
11192,,Plasma,,1,N,50597,1969.0,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,1,CHEMBL626039,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11193,,Plasma,,1,N,50597,1969.0,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,1,CHEMBL626040,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11194,,Plasma,,1,N,50592,1969.0,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,1,CHEMBL626041,Oryctolagus cuniculus,,A,9986.0,In vivo,,Intermediate,,BAO_0000218
11195,,,,1,U,22224,,Maximum concentration was calculated,0,CHEMBL626042,,,A,,In vivo,,Autocuration,,BAO_0000218
11196,,,,1,U,22224,,Maximum concentration was calculated.,0,CHEMBL626043,,,A,,In vivo,,Autocuration,,BAO_0000218
11197,,,,1,U,22224,,Maximum concentration at a peroral dose of 10 mg/kg,0,CHEMBL626044,,,A,,In vivo,,Autocuration,,BAO_0000218
11198,,,,1,U,22224,,Maximum concentration of the drug at 10 uM/dg administered perorally,0,CHEMBL626045,,,A,,In vivo,,Autocuration,,BAO_0000218
11199,,,,1,U,22224,,Maximum concentration of the drug at 2 uM/dg administered intravenously,0,CHEMBL626046,,,A,,In vivo,,Autocuration,,BAO_0000218
11200,,Plasma,,1,N,50588,1969.0,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",1,CHEMBL626047,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11201,,Plasma,,1,N,100712,1969.0,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",1,CHEMBL626048,Cricetinae,,A,10026.0,In vivo,,Intermediate,,BAO_0000218
11202,,Plasma,,1,N,50597,1969.0,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",1,CHEMBL626049,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11203,,Plasma,,1,N,50597,1969.0,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,1,CHEMBL626050,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11204,,Plasma,,1,N,50588,1969.0,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,1,CHEMBL874541,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11205,,Plasma,,1,N,100712,1969.0,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,1,CHEMBL622826,Cricetinae,,A,10026.0,In vivo,,Intermediate,,BAO_0000218
11206,,Plasma,,1,N,100712,1969.0,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,1,CHEMBL622827,Cricetinae,,A,10026.0,In vivo,,Intermediate,,BAO_0000218
11207,,Plasma,,1,N,50597,1969.0,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,1,CHEMBL622828,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11208,,Plasma,,1,N,50597,1969.0,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,1,CHEMBL622829,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11209,,,,1,N,50597,,Maximum concentration reached following intravenous administration in male rat,1,CHEMBL876806,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11210,,,,1,N,50588,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,1,CHEMBL622830,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11211,,,,1,N,50597,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,1,CHEMBL622831,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11212,,,,1,N,50588,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,1,CHEMBL626794,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11213,,,,1,N,50597,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,1,CHEMBL626795,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11214,,,,1,N,50597,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,1,CHEMBL626796,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11215,,,,1,N,50597,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,1,CHEMBL626797,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11216,,,,1,N,50597,,Maximum drug concentration is determined after oral dosing in rats.,1,CHEMBL626798,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11217,,,,1,N,50588,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,1,CHEMBL626799,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11218,,,,1,N,50588,,Maximum observed concentration in oral (5 mg/kg) fed dogs,1,CHEMBL626800,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11219,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration,0,CHEMBL626801,,,A,,In vivo,,Autocuration,,BAO_0000218
11220,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,1,CHEMBL876816,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11221,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,1,CHEMBL626802,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11222,,Plasma,,1,N,50588,1969.0,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,1,CHEMBL626803,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11223,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration following oral administration of 30 umol/kg,0,CHEMBL626804,,,A,,In vivo,,Autocuration,,BAO_0000218
11224,,Plasma,,1,N,50597,1969.0,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,1,CHEMBL626805,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11225,,Plasma,,1,N,50597,1969.0,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,CHEMBL626309,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11226,,Plasma,,1,N,50597,1969.0,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,CHEMBL626310,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11227,,Plasma,,1,N,50597,1969.0,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,CHEMBL626311,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11228,,Plasma,,1,N,50597,1969.0,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,CHEMBL626312,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11229,,Uterus,,1,N,50597,995.0,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,CHEMBL626313,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11230,,Uterus,,1,N,50597,995.0,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,CHEMBL626314,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11231,,Uterus,,1,N,50597,995.0,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,CHEMBL626315,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11232,,Uterus,,1,N,50597,995.0,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,CHEMBL626316,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11233,,Uterus,,1,N,50597,995.0,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,CHEMBL626317,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11234,,,,1,N,50597,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),1,CHEMBL626318,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11235,,,,1,N,50597,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),1,CHEMBL626319,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11236,,,,1,N,50597,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),1,CHEMBL626320,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11237,,,,1,N,50597,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),1,CHEMBL875053,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11238,,,,1,N,50597,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),1,CHEMBL626321,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11239,,,,1,N,50597,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),1,CHEMBL626322,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11240,,,,1,N,50597,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),1,CHEMBL626323,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11241,,,,1,N,50597,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),1,CHEMBL626324,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11242,,,,1,N,50597,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),1,CHEMBL626325,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11243,,,,1,N,50597,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),1,CHEMBL626326,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11244,,,,1,N,50597,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),1,CHEMBL626327,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11245,,,,1,N,50597,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),1,CHEMBL626328,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11246,,Blood,,1,N,50597,178.0,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",1,CHEMBL626329,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11247,,Blood,,1,N,50597,178.0,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",1,CHEMBL626330,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11248,,Blood,,1,N,50597,178.0,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",1,CHEMBL626331,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11249,,Blood,,1,N,50597,178.0,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",1,CHEMBL626332,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11250,,Blood,,1,N,50597,178.0,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",1,CHEMBL626333,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11251,,Blood,,1,N,50597,178.0,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",1,CHEMBL626334,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11252,,Blood,,1,N,50597,178.0,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",1,CHEMBL626335,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11253,,Blood,,1,N,50597,178.0,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",1,CHEMBL624798,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11254,,Brain,,1,N,50597,955.0,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",1,CHEMBL624799,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11255,,Brain,,1,N,50597,955.0,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",1,CHEMBL624800,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11256,,Brain,,1,N,50597,955.0,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",1,CHEMBL624801,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11257,,Brain,,1,N,50597,955.0,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",1,CHEMBL624802,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11258,,Brain,,1,N,50597,955.0,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",1,CHEMBL624803,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11259,,Brain,,1,N,50597,955.0,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",1,CHEMBL624804,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11260,,Brain,,1,N,50597,955.0,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",1,CHEMBL624805,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11261,,Brain,,1,N,50597,955.0,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",1,CHEMBL624806,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11262,,,,1,N,50597,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",1,CHEMBL624807,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11263,,,,1,N,50597,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",1,CHEMBL624808,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11264,,,,1,N,50597,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",1,CHEMBL624809,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11265,,,,1,N,50597,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",1,CHEMBL624810,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11266,,,,1,N,50597,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",1,CHEMBL877618,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11267,,,,1,N,50597,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",1,CHEMBL624811,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11268,,,,1,N,50597,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",1,CHEMBL624812,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11269,,,,1,N,50597,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",1,CHEMBL624813,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11270,,,,1,N,50597,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",1,CHEMBL624814,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11271,,,,1,N,50597,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",1,CHEMBL624815,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11272,,,,1,N,50597,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",1,CHEMBL624816,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11273,,,,1,N,50597,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",1,CHEMBL624817,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11274,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,CHEMBL624818,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11275,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,1,CHEMBL624819,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11276,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,CHEMBL624820,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11277,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,CHEMBL624821,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11278,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,CHEMBL624822,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11279,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,CHEMBL624823,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11280,,,,1,N,50212,,Observed diffusion coefficient in organic solvent for Escherichia coli,1,CHEMBL624824,Escherichia coli,,A,562.0,,,Intermediate,,BAO_0000218
11281,,Blood,,1,N,50597,178.0,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,CHEMBL624825,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11282,,Blood,,1,N,50597,178.0,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,CHEMBL624826,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11283,,Cardiac atrium,,1,N,50597,2081.0,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,CHEMBL876817,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11284,,Cardiac atrium,,1,N,50597,2081.0,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,CHEMBL624827,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11285,,,,1,N,50597,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,CHEMBL624828,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11286,,,,1,N,50597,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,CHEMBL624829,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11287,,Liver,,1,N,50597,2107.0,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,CHEMBL624830,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11288,,Liver,,1,N,50597,2107.0,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,CHEMBL624831,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11289,,Cardiac atrium,,1,N,50597,2081.0,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,CHEMBL624832,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11290,,Cardiac atrium,,1,N,50597,2081.0,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,CHEMBL624833,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11291,,,,1,N,50597,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,CHEMBL624834,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11292,,,,1,N,50597,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,CHEMBL624835,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11293,,Spleen,,1,N,50597,2106.0,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,CHEMBL624836,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11294,,Spleen,,1,N,50597,2106.0,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,CHEMBL624837,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11295,,Blood,,1,N,50597,178.0,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,1,CHEMBL624838,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11296,,Blood,,1,N,50597,178.0,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,1,CHEMBL622188,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11297,,Heart,,1,N,50597,948.0,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,1,CHEMBL622189,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11298,,Heart,,1,N,50597,948.0,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,1,CHEMBL622190,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11299,,Heart,,1,N,50597,948.0,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,1,CHEMBL625170,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11300,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,1,CHEMBL625171,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11301,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,1,CHEMBL625172,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11302,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,1,CHEMBL625173,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11303,,Liver,,1,N,50597,2107.0,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,1,CHEMBL625174,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11304,,Liver,,1,N,50597,2107.0,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,1,CHEMBL625175,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11305,,Liver,,1,N,50597,2107.0,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,1,CHEMBL625176,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11306,,Lung,,1,N,50597,2048.0,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,1,CHEMBL625177,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11307,,Lung,,1,N,50597,2048.0,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,1,CHEMBL625178,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11308,,Lung,,1,N,50597,2048.0,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,1,CHEMBL625179,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11309,,Lung,,1,N,50597,2048.0,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,1,CHEMBL625180,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11310,,,,1,U,22224,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",0,CHEMBL625181,,,A,,,,Autocuration,,BAO_0000218
11311,,Urine,,1,N,50594,1088.0,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,1,CHEMBL625182,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11312,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,CHEMBL625183,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11313,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,1,CHEMBL875848,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11314,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,CHEMBL622260,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11315,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,1,CHEMBL622261,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11316,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,CHEMBL622262,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11317,,Kidney,,1,N,50597,2113.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,CHEMBL622263,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11318,,Kidney,,1,N,50597,2113.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,CHEMBL622418,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11319,,Liver,,1,N,50597,2107.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,1,CHEMBL622419,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11320,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL623388,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11321,,Liver,,1,N,50594,2107.0,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL623389,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11322,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL623390,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11323,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL623391,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11324,,Blood,,1,N,50594,178.0,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL623392,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11325,,Cerebellum,,1,N,50594,2037.0,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL623393,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11326,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL623394,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11327,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL618885,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11328,,Liver,,1,N,50594,2107.0,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL618886,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11329,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL618887,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11330,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL619535,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11331,,Blood,,1,N,50594,178.0,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL619536,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11332,,Cerebellum,,1,N,50594,2037.0,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL619537,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11333,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL619705,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11334,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL619706,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11335,,Liver,,1,N,50594,2107.0,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL619707,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11336,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL619708,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11337,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL625219,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11338,,Blood,,1,N,50594,178.0,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL625220,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11339,,Cerebellum,,1,N,50594,2037.0,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL625221,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11340,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL625222,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11341,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL625223,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11342,,Liver,,1,N,50594,2107.0,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL625224,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11343,,,,1,N,50594,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,CHEMBL625225,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11344,,Blood,,1,N,50597,178.0,Biodistribution in Rat blood after 24 hours of iv administration,1,CHEMBL625226,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11345,,Blood,,1,N,50597,178.0,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,1,CHEMBL625227,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11346,,Blood,,1,N,50597,178.0,Biodistribution in Rat blood after 30 minutes of iv administration,1,CHEMBL625228,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11347,,Blood,,1,N,50597,178.0,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,1,CHEMBL875354,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11348,,Blood,,1,N,50597,178.0,Biodistribution in Rat blood after 5 minutes of iv administration,1,CHEMBL625229,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11349,,Blood,,1,N,50597,178.0,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,1,CHEMBL625230,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11350,,Heart,,1,N,50597,948.0,Biodistribution in Rat heart after 24 hours of iv administration,1,CHEMBL625231,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11351,,Heart,,1,N,50597,948.0,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,1,CHEMBL625900,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11352,,Heart,,1,N,50597,948.0,Biodistribution in Rat heart after 30 minutes of iv administration,1,CHEMBL625901,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11353,,Heart,,1,N,50597,948.0,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,1,CHEMBL625902,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11354,,Heart,,1,N,50597,948.0,Biodistribution in Rat heart after 5 minutes of iv administration,1,CHEMBL625903,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11355,,Heart,,1,N,50597,948.0,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,1,CHEMBL625904,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11356,,Liver,,1,N,50597,2107.0,Biodistribution in Rat liver after 24 hours of iv administration,1,CHEMBL625905,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11357,,Liver,,1,N,50597,2107.0,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,1,CHEMBL627861,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11358,,Liver,,1,N,50597,2107.0,Biodistribution in Rat liver after 30 minutes of iv administration,1,CHEMBL627862,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11359,,Liver,,1,N,50597,2107.0,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,1,CHEMBL627863,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11360,,Liver,,1,N,50597,2107.0,Biodistribution in Rat liver after 30 minutes of iv administration,1,CHEMBL627769,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11361,,Plasma,,1,N,50588,1969.0,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,1,CHEMBL627770,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11362,,,,1,N,100710,,Cmax in cynomolgus monkey (PO dose),1,CHEMBL627771,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
11363,,,,1,N,50597,,Cmax in rat (PO dose),1,CHEMBL627772,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11364,,,,1,N,50597,,Cmax in rat (PO dose),1,CHEMBL627773,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11365,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,1,CHEMBL621922,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11366,,Plasma,,1,N,50597,1969.0,Cmax in rat plasma after oral dose (10 mg/kg),1,CHEMBL621923,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11367,,Plasma,,1,U,22224,1969.0,Cmax in plasma after oral dose (10 mg/kg),0,CHEMBL621924,,,A,,In vivo,,Autocuration,,BAO_0000218
11368,,Plasma,,1,N,50588,1969.0,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,1,CHEMBL621925,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11369,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,0,CHEMBL621926,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11370,,Plasma,,1,N,50592,1969.0,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,1,CHEMBL621927,Oryctolagus cuniculus,,A,9986.0,In vivo,,Intermediate,,BAO_0000218
11371,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,1,CHEMBL621928,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11372,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,1,CHEMBL621929,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11373,,Plasma,,1,N,50594,1969.0,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,1,CHEMBL621930,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11374,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration after oral dosing in rat,1,CHEMBL621931,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11375,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,0,CHEMBL621932,,,A,,In vivo,,Autocuration,,BAO_0000218
11376,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,0,CHEMBL621933,,,A,,In vivo,,Autocuration,,BAO_0000218
11377,,Plasma,,1,N,50588,1969.0,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,1,CHEMBL621934,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11378,,Plasma,,1,N,50588,1969.0,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,1,CHEMBL621935,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11379,,Plasma,,1,N,50597,1969.0,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,1,CHEMBL621936,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11380,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration was determined,0,CHEMBL621937,,,A,,In vivo,,Autocuration,,BAO_0000218
11381,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,0,CHEMBL621938,,,A,,In vivo,,Autocuration,,BAO_0000218
11382,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,0,CHEMBL621939,,,A,,In vivo,,Autocuration,,BAO_0000218
11383,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,0,CHEMBL621940,,,A,,In vivo,,Autocuration,,BAO_0000218
11384,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,0,CHEMBL621941,,,A,,In vivo,,Autocuration,,BAO_0000218
11385,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,0,CHEMBL621942,,,A,,In vivo,,Autocuration,,BAO_0000218
11386,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,0,CHEMBL626178,,,A,,In vivo,,Autocuration,,BAO_0000218
11387,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,0,CHEMBL626179,,,A,,In vivo,,Autocuration,,BAO_0000218
11388,,Plasma,,1,U,22224,1969.0,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,0,CHEMBL626180,,,A,,In vivo,,Autocuration,,BAO_0000218
11389,,Plasma,,1,N,50597,1969.0,Plasma Cmax in rat (PO dose),1,CHEMBL626181,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11390,,,,1,N,50597,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,1,CHEMBL626182,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11391,,,,1,N,50597,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,1,CHEMBL626183,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11392,,,,1,N,50597,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,1,CHEMBL626184,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11393,,,,1,N,50597,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,1,CHEMBL626185,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11394,,Plasma,,1,N,50588,1969.0,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,1,CHEMBL626186,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11395,,Plasma,,1,N,50588,1969.0,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,1,CHEMBL877589,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11396,,,,1,U,22224,,Maximum concentration of the drug at 1 uM/dg administered intravenously,0,CHEMBL626187,,,A,,In vivo,,Autocuration,,BAO_0000218
11397,,,,1,U,22224,,Maximum concentration of the drug at 20 uM/dg administered perorally,0,CHEMBL626188,,,A,,In vivo,,Autocuration,,BAO_0000218
11398,,,,1,U,22224,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,0,CHEMBL626189,,,A,,In vivo,,Autocuration,,BAO_0000218
11399,,Blood,,1,U,22224,178.0,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,0,CHEMBL626855,,,A,,In vivo,,Autocuration,,BAO_0000218
11400,,Blood,,1,U,22224,178.0,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,0,CHEMBL623781,,,A,,In vivo,,Autocuration,,BAO_0000218
11401,,Blood,,1,U,22224,178.0,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,0,CHEMBL623782,,,A,,In vivo,,Autocuration,,BAO_0000218
11402,,Plasma,,1,N,50597,1969.0,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,1,CHEMBL623783,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11403,,Plasma,,1,N,50588,1969.0,Cmax in dog plasma after 1mg/kg oral dose,1,CHEMBL623784,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11404,,Plasma,,1,N,50588,1969.0,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,1,CHEMBL623785,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11405,,Plasma,,1,N,50597,1969.0,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,1,CHEMBL623786,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11406,,,,1,N,50597,,Oral maximum concentration in rat,1,CHEMBL623787,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11407,,,,1,N,50597,,Oral maximum concentration in rat,1,CHEMBL623788,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11408,,Plasma,,1,N,50594,1969.0,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,1,CHEMBL623789,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11409,,Blood,,1,N,50594,178.0,Peak concentration in blood after intravenous administration to mice,1,CHEMBL623790,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11410,,Blood,,1,N,50594,178.0,Peak concentration in blood after peroral administration to mice,1,CHEMBL623791,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11411,,Plasma,,1,N,50597,1969.0,Peak concentration in rat plasma was determined,1,CHEMBL623792,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11412,,Plasma,,1,U,22224,1969.0,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,0,CHEMBL623793,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11413,,Plasma,,1,N,50594,1969.0,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,1,CHEMBL623794,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11414,,Plasma,,1,N,50597,1969.0,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,1,CHEMBL623795,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11415,,,,1,N,50597,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",1,CHEMBL623796,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11416,,,,1,N,50597,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",1,CHEMBL623797,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11417,,,,1,N,50597,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",1,CHEMBL623798,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11418,,,,1,N,50597,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",1,CHEMBL623799,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11419,,Intestine,,1,N,50597,160.0,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",1,CHEMBL624490,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11420,,Intestine,,1,N,50597,160.0,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",1,CHEMBL624491,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11421,,Intestine,,1,N,50597,160.0,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",1,CHEMBL624492,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11422,,Intestine,,1,N,50597,160.0,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",1,CHEMBL624493,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11423,,Intestine,,1,N,50597,160.0,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",1,CHEMBL877595,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11424,,Intestine,,1,N,50597,160.0,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",1,CHEMBL624494,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11425,,Intestine,,1,N,50597,160.0,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",1,CHEMBL624495,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11426,,Intestine,,1,N,50597,160.0,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",1,CHEMBL624681,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11427,,,,1,N,50597,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",1,CHEMBL624682,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11428,,,,1,N,50597,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",1,CHEMBL624683,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11429,,,,1,N,50597,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",1,CHEMBL624684,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11430,,,,1,N,50597,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",1,CHEMBL624685,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11431,,,,1,N,50597,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",1,CHEMBL624686,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11432,,,,1,N,50597,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",1,CHEMBL624687,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11433,,,,1,N,50597,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",1,CHEMBL624688,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11434,,,,1,N,50597,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",1,CHEMBL627161,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11435,,,,1,N,50597,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",1,CHEMBL622127,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11436,,,,1,N,50597,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",1,CHEMBL622128,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11437,,,,1,N,50597,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",1,CHEMBL874384,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11438,,,,1,N,50597,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",1,CHEMBL624898,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11439,,,,1,N,50597,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",1,CHEMBL624899,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11440,,,,1,N,50597,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",1,CHEMBL624900,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11441,,,,1,N,50597,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",1,CHEMBL624901,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11442,,,,1,N,50597,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",1,CHEMBL624902,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11443,,,,1,N,50597,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",1,CHEMBL624903,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11444,,,,1,N,50597,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",1,CHEMBL624904,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11445,,,,1,N,50597,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",1,CHEMBL624905,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11446,,,,1,N,50597,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",1,CHEMBL624906,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11447,,,,1,N,50597,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",1,CHEMBL624907,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11448,,,,1,N,50597,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",1,CHEMBL624908,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11449,,,,1,N,50597,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",1,CHEMBL624909,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11450,,,,1,N,50597,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",1,CHEMBL624910,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11451,,Muscle tissue,,1,N,50597,2385.0,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",1,CHEMBL624911,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11452,,Muscle tissue,,1,N,50597,2385.0,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",1,CHEMBL874388,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11453,,Muscle tissue,,1,N,50597,2385.0,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",1,CHEMBL624912,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11454,,Muscle tissue,,1,N,50597,2385.0,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",1,CHEMBL622930,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11455,,Muscle tissue,,1,N,50597,2385.0,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",1,CHEMBL623121,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11456,,Muscle tissue,,1,N,50597,2385.0,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",1,CHEMBL623122,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11457,,Muscle tissue,,1,N,50597,2385.0,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",1,CHEMBL623123,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11458,,Muscle tissue,,1,N,50597,2385.0,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",1,CHEMBL623124,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11459,,,,1,N,50597,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",1,CHEMBL623125,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11460,,,,1,N,50597,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",1,CHEMBL623126,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11461,,,,1,N,50597,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",1,CHEMBL623127,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11462,,,,1,N,50597,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",1,CHEMBL623128,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11463,,,,1,N,50597,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",1,CHEMBL623129,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11464,,,,1,N,50597,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",1,CHEMBL623130,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11465,,,,1,N,50597,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",1,CHEMBL623131,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11466,,,,1,N,50597,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",1,CHEMBL623132,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11467,,Liver,,1,N,50597,2107.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,CHEMBL623133,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11468,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,CHEMBL623134,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11469,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,CHEMBL874389,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11470,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,1,CHEMBL623135,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11471,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,CHEMBL623136,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11472,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,1,CHEMBL623137,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11473,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,CHEMBL623138,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11474,,Kidney,,1,N,50597,2113.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,CHEMBL623139,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11475,,Kidney,,1,N,50597,2113.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,CHEMBL623140,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11476,,Liver,,1,N,50597,2107.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,1,CHEMBL623141,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11477,,Liver,,1,N,50597,2107.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,CHEMBL623142,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11478,,,,1,N,50597,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,CHEMBL623143,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11479,,Urine,,1,N,50594,1088.0,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,1,CHEMBL623144,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11480,,Urine,,1,N,50597,1088.0,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,1,CHEMBL623405,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11481,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,CHEMBL624074,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11482,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,1,CHEMBL624075,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11483,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,CHEMBL624076,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11484,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,1,CHEMBL624077,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11485,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,CHEMBL624078,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11486,,Kidney,,1,N,50597,2113.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,CHEMBL624079,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11487,,Kidney,,1,N,50597,2113.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,CHEMBL624261,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11488,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,1,CHEMBL624262,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11489,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,CHEMBL624263,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11490,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,CHEMBL624264,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11491,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,CHEMBL624265,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11492,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,1,CHEMBL624266,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11493,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,CHEMBL624267,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11494,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,1,CHEMBL624268,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11495,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,CHEMBL875227,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11496,,Kidney,,1,N,50597,2113.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,CHEMBL624269,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11497,,Kidney,,1,N,50597,2113.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,CHEMBL624270,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11498,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,1,CHEMBL624271,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11499,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,CHEMBL624272,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11500,,,,1,N,50597,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,CHEMBL624273,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11501,,Urine,,1,N,50597,1088.0,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,1,CHEMBL624274,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11502,,Urine,,1,N,50597,1088.0,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,1,CHEMBL624275,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11503,,Urine,,1,N,50597,1088.0,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,1,CHEMBL624276,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11504,,Urine,,1,N,50597,1088.0,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,1,CHEMBL624277,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11505,,,,1,U,22224,,% dose converted to 2-amino-5-chlorophenyl sulfate,0,CHEMBL624278,,,A,,,,Autocuration,,BAO_0000019
11506,,,,1,U,22224,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),0,CHEMBL624279,,,A,,,,Autocuration,,BAO_0000019
11507,,Feces,,1,N,50597,1988.0,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1,CHEMBL624280,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11508,,Feces,,1,N,50597,1988.0,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1,CHEMBL624281,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11509,,Feces,,1,N,50597,1988.0,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1,CHEMBL622933,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11510,,Feces,,1,N,50597,1988.0,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1,CHEMBL622934,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11511,,Liver,,1,N,50597,2107.0,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,1,CHEMBL622935,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11512,,Liver,,1,N,50597,2107.0,Biodistribution in Rat liver after 5 minutes of iv administration,1,CHEMBL622936,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11513,,Liver,,1,N,50597,2107.0,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,1,CHEMBL875228,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11514,,Lung,,1,N,50597,2048.0,Biodistribution in Rat lung after 24 hours of iv administration,1,CHEMBL622937,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11515,,Lung,,1,N,50597,2048.0,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,1,CHEMBL622938,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11516,,Lung,,1,N,50597,2048.0,Biodistribution in Rat lung after 30 minutes of iv administration,1,CHEMBL619736,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11517,,Lung,,1,N,50597,2048.0,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,1,CHEMBL625117,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11518,,Lung,,1,N,50597,2048.0,Biodistribution in Rat lung after 5 minutes of iv administration,1,CHEMBL625118,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11519,,Lung,,1,N,50597,2048.0,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,1,CHEMBL625119,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11520,,Cerebellum,,1,N,50597,2037.0,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",1,CHEMBL625120,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11521,,,,1,N,50597,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",1,CHEMBL625121,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11522,,Thalamus,,1,N,50597,10000006.0,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",1,CHEMBL625122,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11523,,Blood,,1,N,50597,178.0,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL622204,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11524,,Blood,,1,N,50597,178.0,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL877503,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11525,,Blood,,1,N,50597,178.0,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL627127,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11526,,Hippocampus,,1,U,22224,10000000.0,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,0,CHEMBL627128,,,A,,In vivo,,Autocuration,,BAO_0000218
11527,,Hippocampus,,1,U,22224,10000000.0,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,0,CHEMBL627129,,,A,,In vivo,,Autocuration,,BAO_0000218
11528,,Hippocampus,,1,U,22224,10000000.0,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,0,CHEMBL627130,,,A,,In vivo,,Autocuration,,BAO_0000218
11529,,Brain,,1,N,50597,955.0,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL627131,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11530,,Brain,,1,N,50597,955.0,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL627132,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11531,,Brain,,1,N,50597,955.0,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL627133,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11532,,Cerebellum,,1,N,50597,2037.0,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL627134,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11533,,Cerebellum,,1,N,50597,2037.0,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL627135,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11534,,Cerebellum,,1,N,50597,2037.0,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL627136,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11535,,,,1,N,50597,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL628435,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11536,,,,1,N,50597,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL628436,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11537,,,,1,N,50597,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL628437,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11538,,Heart,,1,N,50597,948.0,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL628438,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11539,,Heart,,1,N,50597,948.0,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL628439,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11540,,Heart,,1,N,50597,948.0,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL628440,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11541,,Hippocampus,,1,N,50597,10000000.0,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL628441,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11542,,Hippocampus,,1,N,50597,10000000.0,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL628442,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11543,,Hippocampus,,1,N,50597,10000000.0,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL628443,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11544,,Kidney,,1,N,50597,2113.0,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL628444,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11545,,Kidney,,1,N,50597,2113.0,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL628445,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11546,,Kidney,,1,N,50597,2113.0,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL877504,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11547,,Liver,,1,N,50597,2107.0,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL628446,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11548,,Liver,,1,N,50597,2107.0,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL626874,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11549,,Liver,,1,N,50597,2107.0,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL626875,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11550,,Lung,,1,N,50597,2048.0,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL626876,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11551,,Lung,,1,N,50597,2048.0,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL626877,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11552,,Lung,,1,N,50597,2048.0,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL626878,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11553,,Muscle tissue,,1,N,50597,2385.0,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL626879,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11554,,Plasma,,1,U,22224,1969.0,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,0,CHEMBL626880,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11555,,Plasma,,1,N,50594,1969.0,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,1,CHEMBL626881,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11556,,Plasma,,1,N,50597,1969.0,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,1,CHEMBL626882,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11557,,Plasma,,1,N,50588,1969.0,Peak plasma concentration was measured in dogs,1,CHEMBL626883,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11558,,,,1,N,50597,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,CHEMBL626884,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11559,,,,1,N,50597,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,1,CHEMBL626885,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11560,,,,1,N,50597,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,1,CHEMBL626886,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11561,,,,1,N,50597,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,1,CHEMBL626887,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11562,,,,1,N,50597,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,CHEMBL626888,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11563,,,,1,N,50588,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,1,CHEMBL626889,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11564,,,,1,U,22224,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,0,CHEMBL626761,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11565,,,,1,N,50588,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,1,CHEMBL626762,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11566,,,,1,N,50588,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,1,CHEMBL626763,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11567,,,,1,N,50597,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,1,CHEMBL626764,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11568,,,,1,N,50597,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,1,CHEMBL626765,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11569,,,,1,N,50588,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,1,CHEMBL626766,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11570,,,,1,N,50597,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,1,CHEMBL626767,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11571,,,,1,N,50597,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,1,CHEMBL626768,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11572,,,,1,N,50588,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,1,CHEMBL626769,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11573,,,,1,N,50588,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,1,CHEMBL874463,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11574,,,,1,U,22224,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,0,CHEMBL626770,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11575,,,,1,U,22224,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,0,CHEMBL626771,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11576,,,,1,N,50597,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,1,CHEMBL626772,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11577,,,,1,N,100710,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,1,CHEMBL626773,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
11578,,,,1,N,50594,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,1,CHEMBL626774,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11579,,,,1,N,50588,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,1,CHEMBL626775,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11580,,,,1,N,50588,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,1,CHEMBL626776,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11581,,,,1,N,50597,,Maximum concentration (Cmax) in rat when administered orally,1,CHEMBL626777,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11582,,Plasma,,1,U,22224,1969.0,Maximal concentration in monkey plasma after 25 mg/kg oral dose,0,CHEMBL626778,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11583,,,,1,U,22224,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",0,CHEMBL626779,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11584,,,,1,U,22224,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",0,CHEMBL626780,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11585,,Plasma,,1,U,22224,1969.0,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,0,CHEMBL626781,,,A,,In vivo,,Autocuration,,BAO_0000218
11586,,,,1,N,50597,,Pharmacokinetic profile Cmax was evaluated in rats,1,CHEMBL632164,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11587,,,,1,N,50588,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),1,CHEMBL632165,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11588,,,,1,N,50594,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),1,CHEMBL632166,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11589,,,,1,N,50588,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),1,CHEMBL632167,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11590,,,,1,N,50594,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),1,CHEMBL632168,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11591,,Plasma,,1,U,22224,1969.0,Cmax in rat plasma,0,CHEMBL632169,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
11592,,Plasma,,1,N,50588,1969.0,Cmax in dog plasma after 30mg/kg oral dose,1,CHEMBL632170,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11593,,Plasma,,1,N,50597,1969.0,Cmax in rat plasma after 30mg/kg oral dose,1,CHEMBL632171,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11594,,Plasma,,1,N,50597,1969.0,Plasma level in rats at 30 mg/kg,1,CHEMBL632172,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11595,,Plasma,,1,N,50594,1969.0,Tested for maximum plasma concentration in mice,1,CHEMBL632173,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11596,,,,1,N,50597,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL632174,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11597,,,,1,N,50597,,The Cmax values in female wistar rats.,1,CHEMBL632175,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11598,,Plasma,,1,N,50588,1969.0,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,1,CHEMBL632176,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11599,,Plasma,,1,N,50597,1969.0,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,1,CHEMBL632177,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11600,,Plasma,,1,N,50597,1969.0,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,1,CHEMBL632178,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11601,,,,1,N,50597,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,1,CHEMBL632179,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11602,,Blood,,1,N,50597,178.0,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,1,CHEMBL632180,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11603,,Blood,,1,N,50597,178.0,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,1,CHEMBL632181,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11604,,Blood,,1,N,50597,178.0,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,1,CHEMBL632182,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11605,,Blood,,1,U,22224,178.0,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,0,CHEMBL632183,Mus musculus,,A,10090.0,In vivo,,Autocuration,,BAO_0000218
11606,,,,1,N,50588,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,1,CHEMBL632184,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11607,,,,1,N,50597,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,1,CHEMBL874470,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11608,,,,1,N,50597,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",1,CHEMBL631302,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11609,,,,1,N,50597,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",1,CHEMBL631303,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11610,,,,1,N,50597,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",1,CHEMBL631304,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11611,,,,1,N,50597,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",1,CHEMBL631305,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11612,,,,1,N,50597,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",1,CHEMBL631306,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11613,,,,1,N,50597,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",1,CHEMBL631307,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11614,,,,1,N,50597,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",1,CHEMBL631308,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11615,,,,1,N,50597,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",1,CHEMBL625557,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11616,,Spleen,,1,N,50597,2106.0,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",1,CHEMBL625558,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11617,,Spleen,,1,N,50597,2106.0,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",1,CHEMBL625559,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11618,,Spleen,,1,N,50597,2106.0,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",1,CHEMBL625560,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11619,,Spleen,,1,N,50597,2106.0,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",1,CHEMBL625561,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11620,,Spleen,,1,N,50597,2106.0,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",1,CHEMBL625562,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11621,,Spleen,,1,N,50597,2106.0,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",1,CHEMBL875320,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11622,,Spleen,,1,N,50597,2106.0,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",1,CHEMBL625563,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11623,,Spleen,,1,N,50597,2106.0,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",1,CHEMBL625564,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11624,,Uterus,,1,N,50597,995.0,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",1,CHEMBL625565,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11625,,Uterus,,1,N,50597,995.0,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",1,CHEMBL625566,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11626,,Uterus,,1,N,50597,995.0,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",1,CHEMBL625567,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11627,,Uterus,,1,N,50597,995.0,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",1,CHEMBL625568,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11628,,Uterus,,1,N,50597,995.0,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",1,CHEMBL628217,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11629,,Uterus,,1,N,50597,995.0,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",1,CHEMBL628218,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11630,,Uterus,,1,N,50597,995.0,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",1,CHEMBL628219,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11631,,Uterus,,1,N,50597,995.0,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",1,CHEMBL628220,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11632,,,,1,U,22224,,Distribution in the blood after 120 min of intravenous administration,0,CHEMBL628221,,,A,,,,Autocuration,,BAO_0000019
11633,,,,1,U,22224,,Distribution in the blood after 15 min of intravenous administration,0,CHEMBL628222,,,A,,,,Autocuration,,BAO_0000019
11634,,,,1,U,22224,,Distribution in the blood after 30 min of intravenous administration,0,CHEMBL628223,,,A,,,,Autocuration,,BAO_0000019
11635,,,,1,U,22224,,Distribution in the blood after 5 min of intravenous administration,0,CHEMBL628224,,,A,,,,Autocuration,,BAO_0000019
11636,,,,1,U,22224,,Distribution in the blood after 60 min of intravenous administration,0,CHEMBL628225,,,A,,,,Autocuration,,BAO_0000019
11637,,,,1,U,22224,,Distribution in the blood after 90 min of intravenous administration,0,CHEMBL628226,,,A,,,,Autocuration,,BAO_0000019
11638,,,,1,U,22224,,Distribution in the bone after 120 min of intravenous administration,0,CHEMBL628227,,,A,,,,Autocuration,,BAO_0000019
11639,,,,1,U,22224,,Distribution in the bone after 15 min of intravenous administration,0,CHEMBL875481,,,A,,,,Autocuration,,BAO_0000019
11640,,,,1,U,22224,,Distribution in the bone after 30 min of intravenous administration,0,CHEMBL628228,,,A,,,,Autocuration,,BAO_0000019
11641,,,,1,U,22224,,Distribution in the bone after 5 min of intravenous administration,0,CHEMBL628229,,,A,,,,Autocuration,,BAO_0000019
11642,,,,1,U,22224,,Distribution in the bone after 60 min of intravenous administration,0,CHEMBL628230,,,A,,,,Autocuration,,BAO_0000019
11643,,,,1,U,22224,,Distribution in the bone after 90 min of intravenous administration,0,CHEMBL628231,,,A,,,,Autocuration,,BAO_0000019
11644,,,,1,U,22224,,Distribution in the heart after 120 min of intravenous administration,0,CHEMBL628232,,,A,,,,Autocuration,,BAO_0000019
11645,,,,1,U,22224,,Distribution in the heart after 15 min of intravenous administration,0,CHEMBL628233,,,A,,,,Autocuration,,BAO_0000019
11646,,,,1,U,22224,,Distribution in the heart after 30 min of intravenous administration,0,CHEMBL628234,,,A,,,,Autocuration,,BAO_0000019
11647,,,,1,U,22224,,Distribution in the heart after 5 min of intravenous administration,0,CHEMBL628235,,,A,,,,Autocuration,,BAO_0000019
11648,,,,1,U,22224,,Distribution in the heart after 60 min of intravenous administration,0,CHEMBL628236,,,A,,,,Autocuration,,BAO_0000019
11649,,,,1,U,22224,,Distribution in the heart after 90 min of intravenous administration,0,CHEMBL628237,,,A,,,,Autocuration,,BAO_0000019
11650,,,,1,U,22224,,Distribution in the kidneys after 120 min of intravenous administration,0,CHEMBL628238,,,A,,,,Autocuration,,BAO_0000019
11651,,,,1,U,22224,,Distribution in the kidneys after 15 min of intravenous administration,0,CHEMBL628239,,,A,,,,Autocuration,,BAO_0000019
11652,,,,1,U,22224,,Distribution in the kidneys after 30 min of intravenous administration,0,CHEMBL628240,,,A,,,,Autocuration,,BAO_0000019
11653,,,,1,U,22224,,Distribution in the kidneys after 5 min of intravenous administration,0,CHEMBL628241,,,A,,,,Autocuration,,BAO_0000019
11654,,,,1,U,22224,,Distribution in the kidneys after 60 min of intravenous administration,0,CHEMBL628242,,,A,,,,Autocuration,,BAO_0000019
11655,,,,1,U,22224,,Distribution in the kidneys after 90 min of intravenous administration,0,CHEMBL875482,,,A,,,,Autocuration,,BAO_0000019
11656,,,,1,U,22224,,Distribution in the liver after 120 min of intravenous administration,0,CHEMBL628243,,,A,,,,Autocuration,,BAO_0000019
11657,,,,1,U,22224,,Distribution in the liver after 15 min of intravenous administration,0,CHEMBL628244,,,A,,,,Autocuration,,BAO_0000019
11658,,,,1,U,22224,,Distribution in the liver after 30 min of intravenous administration,0,CHEMBL628245,,,A,,,,Autocuration,,BAO_0000019
11659,,,,1,U,22224,,Distribution in the liver after 5 min of intravenous administration,0,CHEMBL628246,,,A,,,,Autocuration,,BAO_0000019
11660,,,,1,U,22224,,Distribution in the liver after 60 min of intravenous administration,0,CHEMBL628247,,,A,,,,Autocuration,,BAO_0000019
11661,,,,1,U,22224,,Distribution in the liver after 90 min of intravenous administration,0,CHEMBL628248,,,A,,,,Autocuration,,BAO_0000019
11662,,,,1,U,22224,,Distribution in the lung after 120 min of intravenous administration,0,CHEMBL628249,,,A,,,,Autocuration,,BAO_0000019
11663,,,,1,N,50594,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",1,CHEMBL625452,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11664,,,,1,N,50594,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",1,CHEMBL625453,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11665,,,,1,N,50594,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",1,CHEMBL625454,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11666,,,,1,N,50594,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",1,CHEMBL623844,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11667,,,,1,N,50597,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,1,CHEMBL623845,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11668,,,,1,N,50597,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,1,CHEMBL623846,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11669,,,,1,U,22224,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,0,CHEMBL623847,,,A,,,,Autocuration,,BAO_0000218
11670,,,,1,N,100710,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,CHEMBL623848,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
11671,,,,1,N,100710,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,1,CHEMBL623849,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
11672,,,,1,N,100710,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,CHEMBL623850,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
11673,,,,1,N,100710,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,1,CHEMBL623851,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
11674,,,,1,U,22224,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,0,CHEMBL623852,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
11675,,,,1,N,50506,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,1,CHEMBL624551,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
11676,,,,1,N,50506,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",1,CHEMBL624552,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
11677,,,,1,U,22224,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,0,CHEMBL624553,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
11678,,,,1,U,22224,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,0,CHEMBL624554,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
11679,,,,1,N,50597,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,1,CHEMBL624555,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11680,,,,1,N,50597,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,CHEMBL624741,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11681,,,,1,N,50588,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",1,CHEMBL624742,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11682,,,,1,N,100712,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",1,CHEMBL624743,Cricetinae,,A,10026.0,,,Intermediate,,BAO_0000218
11683,,,,1,N,50597,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",1,CHEMBL877606,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11684,,,,1,U,22224,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,0,CHEMBL624744,,,A,,,,Autocuration,,BAO_0000218
11685,,Blood,,1,U,22224,178.0,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,0,CHEMBL624745,,,A,,,,Autocuration,,BAO_0000218
11686,,Blood,,1,U,22224,178.0,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,0,CHEMBL624746,,,A,,,,Autocuration,,BAO_0000218
11687,,Blood,,1,U,22224,178.0,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,0,CHEMBL624747,,,A,,,,Autocuration,,BAO_0000218
11688,,,,1,U,22224,,Oral absorption expressed as Area under curve was determined,0,CHEMBL624748,,,A,,,,Autocuration,,BAO_0000019
11689,,,,1,N,50588,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,1,CHEMBL622504,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11690,,,,1,N,50588,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",1,CHEMBL622505,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11691,,,,1,N,100712,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",1,CHEMBL622506,Cricetinae,,A,10026.0,,,Intermediate,,BAO_0000218
11692,,,,1,N,100712,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",1,CHEMBL622507,Cricetinae,,A,10026.0,,,Intermediate,,BAO_0000218
11693,,,,1,N,50597,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",1,CHEMBL622508,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11694,,,,1,U,22224,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,0,CHEMBL622509,,,A,,,,Autocuration,,BAO_0000019
11695,,,,1,N,50597,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,CHEMBL622510,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11696,,,,1,N,50597,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),1,CHEMBL622511,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11697,,,,1,N,100710,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,1,CHEMBL622512,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
11698,,,,1,N,100710,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,1,CHEMBL622513,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
11699,,,,1,N,100710,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,1,CHEMBL622514,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
11700,,,,1,N,50588,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,1,CHEMBL622515,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11701,,,,1,N,50588,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,1,CHEMBL622516,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11702,,,,1,N,50597,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,1,CHEMBL622517,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11703,,,,1,N,50597,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,1,CHEMBL622518,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11704,,,,1,N,50597,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,1,CHEMBL622519,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11705,,Muscle tissue,,1,N,50597,2385.0,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL622520,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11706,,Muscle tissue,,1,N,50597,2385.0,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL622521,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11707,,Zone of skin,,1,N,50594,14.0,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL625113,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11708,,Zone of skin,,1,N,50597,14.0,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL625114,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11709,,Zone of skin,,1,N,50597,14.0,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL874397,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11710,,Spleen,,1,N,50597,2106.0,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL625115,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11711,,Spleen,,1,N,50597,2106.0,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL625116,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11712,,Spleen,,1,N,50597,2106.0,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL623932,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11713,,Striatum,,1,N,50597,2435.0,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL623933,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11714,,Striatum,,1,N,50597,2435.0,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL623934,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11715,,Striatum,,1,N,50597,2435.0,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL623935,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11716,,Thyroid gland,,1,N,50597,2046.0,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,CHEMBL623936,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11717,,Thyroid gland,,1,N,50597,2046.0,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,CHEMBL623937,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11718,,Thyroid gland,,1,N,50597,2046.0,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,CHEMBL623938,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11719,,,,1,N,50594,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,CHEMBL623939,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11720,,,,1,N,50594,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,CHEMBL623940,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11721,,,,1,N,50594,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,CHEMBL623941,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11722,,,,1,N,50594,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,CHEMBL627216,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11723,,,,1,N,50594,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,CHEMBL623942,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11724,,Brain,,1,N,50594,955.0,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,CHEMBL618793,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11725,,Brain,,1,N,50594,955.0,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,CHEMBL618794,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11726,,Brain,,1,N,50594,955.0,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,CHEMBL618795,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11727,,,,1,N,50594,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,CHEMBL618796,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11728,,,,1,N,50594,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,CHEMBL618797,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11729,,Kidney,,1,N,50594,2113.0,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,1,CHEMBL618798,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11730,,Kidney,,1,N,50594,2113.0,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,CHEMBL618799,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11731,,Kidney,,1,N,50594,2113.0,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,CHEMBL618800,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11732,,Kidney,,1,N,50594,2113.0,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,CHEMBL618801,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11733,,Kidney,,1,N,50594,2113.0,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,CHEMBL618802,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11734,,Kidney,,1,N,50594,2113.0,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,CHEMBL618803,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11735,,Liver,,1,N,50594,2107.0,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,1,CHEMBL618804,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11736,,Liver,,1,N,50594,2107.0,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,CHEMBL618805,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11737,,Liver,,1,N,50594,2107.0,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,CHEMBL618806,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11738,,Liver,,1,N,50594,2107.0,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,CHEMBL618807,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11739,,Liver,,1,N,50594,2107.0,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,CHEMBL618808,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11740,,Liver,,1,N,50594,2107.0,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,CHEMBL618809,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11741,,Muscle tissue,,1,N,50594,2385.0,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,CHEMBL618810,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11742,,Muscle tissue,,1,N,50594,2385.0,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,CHEMBL618811,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11743,,Muscle tissue,,1,N,50594,2385.0,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,CHEMBL875844,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11744,,Muscle tissue,,1,N,50594,2385.0,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,CHEMBL618812,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11745,,Muscle tissue,,1,N,50594,2385.0,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,CHEMBL618813,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11746,,,,1,N,50594,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,CHEMBL618814,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11747,,,,1,N,50594,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,CHEMBL618815,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11748,,,,1,N,50594,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,CHEMBL618816,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11749,,,,1,N,50594,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,CHEMBL618817,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11750,,,,1,N,50594,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,CHEMBL620544,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11751,,,,1,N,50597,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,1,CHEMBL626230,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11752,,,,1,N,50597,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,1,CHEMBL626231,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11753,,,,1,N,50597,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,1,CHEMBL626232,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11754,,Plasma,,1,N,50588,1969.0,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,1,CHEMBL626233,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11755,,Plasma,,1,N,50597,1969.0,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,1,CHEMBL626234,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11756,,Plasma,,1,N,50597,1969.0,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,1,CHEMBL875341,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11757,,Plasma,,1,N,50587,1969.0,The maximum plasma concentration (100 mg/kg) administered orally in human,1,CHEMBL626235,Homo sapiens,,A,9606.0,In vivo,,Intermediate,,BAO_0000218
11758,,Plasma,,1,U,22224,1969.0,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,0,CHEMBL626236,Callithrix,,A,9481.0,In vivo,,Autocuration,,BAO_0000218
11759,,Plasma,,1,U,22224,1969.0,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,0,CHEMBL626237,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11760,,Plasma,,1,N,50588,1969.0,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,1,CHEMBL626238,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11761,,Plasma,,1,N,50587,1969.0,The maximum plasma concentration (200 mg/kg) administered orally in human,1,CHEMBL622412,Homo sapiens,,A,9606.0,In vivo,,Intermediate,,BAO_0000218
11762,,Plasma,,1,N,50597,1969.0,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,1,CHEMBL623114,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11763,,Plasma,,1,U,22224,1969.0,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,0,CHEMBL623115,Callithrix,,A,9481.0,In vivo,,Autocuration,,BAO_0000218
11764,,Plasma,,1,U,22224,1969.0,The maximum plasma concentration (25 mg/kg) administered orally in monkey,0,CHEMBL623116,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11765,,Plasma,,1,U,22224,1969.0,The maximum plasma concentration (30 mg/kg) administered orally in dog,0,CHEMBL623117,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
11766,,Plasma,,1,N,50587,1969.0,The maximum plasma concentration (400 mg/kg) administered orally in human,1,CHEMBL623118,Homo sapiens,,A,9606.0,In vivo,,Intermediate,,BAO_0000218
11767,,Plasma,,1,N,50597,1969.0,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,1,CHEMBL623119,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11768,,Plasma,,1,N,50597,1969.0,The maximum plasma concentration (50 mg/kg) administered orally in rat,1,CHEMBL623120,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11769,,Plasma,,1,N,50587,1969.0,The maximum plasma concentration (800 mg/kg) administered orally in human,1,CHEMBL623286,Homo sapiens,,A,9606.0,In vivo,,Intermediate,,BAO_0000218
11770,,Plasma,,1,N,50597,1969.0,The maximum plasma concentration was measured on rats,1,CHEMBL623287,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11771,,Plasma,,1,N,50597,1969.0,The maximum plasma concentration was measured on rats after oral administration,1,CHEMBL623288,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11772,,Plasma,,1,N,50597,1969.0,Plasma drug Cmax in rat (PO dose),1,CHEMBL623289,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11773,,,,1,U,22224,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,0,CHEMBL623290,,,A,,In vivo,,Autocuration,,BAO_0000218
11774,,Plasma,,1,N,50588,1969.0,maximum Plasma concentration in Dog was determined after Peroral administration,1,CHEMBL623291,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11775,,Plasma,,1,N,50597,1969.0,maximum Plasma concentration in Rats was determined after Peroral administration,1,CHEMBL623292,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11776,,Plasma,,1,N,50588,1969.0,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,1,CHEMBL623293,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
11777,,Plasma,,1,U,22224,1969.0,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,0,CHEMBL623294,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
11778,,Plasma,,1,N,50597,1969.0,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,1,CHEMBL623295,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11779,,,,1,N,50594,,maximum concentration was measured when administered through oral route in mice,1,CHEMBL623296,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
11780,,,,1,N,50594,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,1,CHEMBL875349,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11781,,,,1,U,22224,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,0,CHEMBL623297,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000019
11782,,,,1,U,22224,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,0,CHEMBL623298,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000019
11783,,,,1,U,22224,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,0,CHEMBL623299,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000019
11784,,,,1,N,50597,,Pharmacokinetic parameter was evaluated in rats,1,CHEMBL623300,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11785,,,,1,N,50594,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,1,CHEMBL623301,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11786,,,,1,N,50594,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,1,CHEMBL623302,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11787,,,,1,N,50594,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,1,CHEMBL623303,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11788,,,,1,N,50594,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,1,CHEMBL623304,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11789,,,,1,N,50594,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,1,CHEMBL623305,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11790,,Plasma,,1,N,50597,1969.0,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,1,CHEMBL623306,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11791,,Plasma,,1,N,50597,1969.0,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,1,CHEMBL623307,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11792,,Plasma,,1,N,50597,1969.0,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,1,CHEMBL623308,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11793,,Plasma,,1,N,50594,1969.0,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,1,CHEMBL623309,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11794,,,,1,N,50594,,Plasma Concentration after 120 min of oral administration to mice,1,CHEMBL623310,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11795,,,,1,N,50594,,Plasma Concentration after 30 min of oral administration to mice,1,CHEMBL623311,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11796,,,,1,N,100710,,Plasma Concentration after 60 min of oral administration to mice,1,CHEMBL623312,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
11797,,,,1,N,50594,,Plasma Concentration after 60 min of oral administration to mice; Not determined,1,CHEMBL875350,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11798,,,,1,N,50594,,Plasma Concentration after 90 min of oral administration to mice,1,CHEMBL628635,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11799,,,,1,N,50597,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,1,CHEMBL628636,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11800,,,,1,N,50597,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,1,CHEMBL628637,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11801,,,,1,N,50597,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,1,CHEMBL628058,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11802,,,,1,N,50597,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,1,CHEMBL628059,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11803,,,,1,N,50597,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,1,CHEMBL628060,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11804,,,,1,U,22224,,Distribution in the lung after 15 min of intravenous administration,0,CHEMBL628061,,,A,,,,Autocuration,,BAO_0000019
11805,,,,1,U,22224,,Distribution in the lung after 30 min of intravenous administration,0,CHEMBL628062,,,A,,,,Autocuration,,BAO_0000019
11806,,,,1,U,22224,,Distribution in the lung after 5 min of intravenous administration,0,CHEMBL628063,,,A,,,,Autocuration,,BAO_0000019
11807,,,,1,U,22224,,Distribution in the lung after 60 min of intravenous administration,0,CHEMBL628064,,,A,,,,Autocuration,,BAO_0000019
11808,,,,1,U,22224,,Distribution in the lung after 90 min of intravenous administration,0,CHEMBL628065,,,A,,,,Autocuration,,BAO_0000019
11809,,Muscle tissue,,1,U,22224,2385.0,Distribution in the muscle after 120 min of intravenous administration,0,CHEMBL628066,,,A,,,,Autocuration,,BAO_0000019
11810,,Muscle tissue,,1,U,22224,2385.0,Distribution in the muscle after 15 min of intravenous administration,0,CHEMBL628067,,,A,,,,Autocuration,,BAO_0000019
11811,,Muscle tissue,,1,N,50594,2385.0,Distribution in the muscle after 30 min of intravenous administration,1,CHEMBL874646,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11812,,Muscle tissue,,1,U,22224,2385.0,Distribution in the muscle after 5 min of intravenous administration,0,CHEMBL628068,,,A,,,,Autocuration,,BAO_0000019
11813,,Muscle tissue,,1,U,22224,2385.0,Distribution in the muscle after 60 min of intravenous administration,0,CHEMBL628069,,,A,,,,Autocuration,,BAO_0000019
11814,,Muscle tissue,,1,U,22224,2385.0,Distribution in the muscle after 90 min of intravenous administration,0,CHEMBL628070,,,A,,,,Autocuration,,BAO_0000019
11815,,Spleen,,1,U,22224,2106.0,Distribution in the spleen after 120 min of intravenous administration,0,CHEMBL628071,,,A,,,,Autocuration,,BAO_0000019
11816,,Spleen,,1,U,22224,2106.0,Distribution in the spleen after 15 min of intravenous administration,0,CHEMBL628072,,,A,,,,Autocuration,,BAO_0000019
11817,,Spleen,,1,U,22224,2106.0,Distribution in the spleen after 30 min of intravenous administration,0,CHEMBL628073,,,A,,,,Autocuration,,BAO_0000019
11818,,Spleen,,1,U,22224,2106.0,Distribution in the spleen after 5 min of intravenous administration,0,CHEMBL628074,,,A,,,,Autocuration,,BAO_0000019
11819,,Spleen,,1,U,22224,2106.0,Distribution in the spleen after 60 min of intravenous administration,0,CHEMBL628075,,,A,,,,Autocuration,,BAO_0000019
11820,,Spleen,,1,U,22224,2106.0,Distribution in the spleen after 90 min of intravenous administration,0,CHEMBL628076,,,A,,,,Autocuration,,BAO_0000019
11821,,Adrenal cortex,,1,N,50597,1235.0,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,1,CHEMBL628077,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11822,,Blood,,1,N,50597,178.0,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,1,CHEMBL628078,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11823,,Liver,,1,N,50597,2107.0,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,1,CHEMBL628079,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11824,,Female gonad,,1,N,50597,992.0,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,1,CHEMBL628080,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11825,,Thyroid gland,,1,N,50597,2046.0,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,1,CHEMBL628081,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11826,,Adrenal cortex,,1,N,50597,1235.0,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,1,CHEMBL628082,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11827,,Blood,,1,N,50597,178.0,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,1,CHEMBL874647,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11828,,Liver,,1,N,50597,2107.0,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,1,CHEMBL626406,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11829,,Female gonad,,1,N,50597,992.0,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,1,CHEMBL626407,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11830,,Thyroid gland,,1,N,50597,2046.0,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,1,CHEMBL626408,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11831,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",1,CHEMBL626409,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11832,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",1,CHEMBL626410,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11833,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",1,CHEMBL626411,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11834,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",1,CHEMBL626412,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11835,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",1,CHEMBL626413,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11836,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",1,CHEMBL626414,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11837,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",1,CHEMBL626415,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11838,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",1,CHEMBL626416,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11839,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",1,CHEMBL627062,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11840,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",1,CHEMBL627063,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11841,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",1,CHEMBL627064,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11842,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",1,CHEMBL627227,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11843,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",1,CHEMBL627228,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11844,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",1,CHEMBL627229,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11845,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",1,CHEMBL625792,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11846,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",1,CHEMBL625793,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11847,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",1,CHEMBL625794,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11848,,Blood,,1,N,50597,178.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",1,CHEMBL625795,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11849,,,,1,N,50594,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,1,CHEMBL625796,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11850,,,,1,N,50588,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,1,CHEMBL625797,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11851,,,,1,N,50588,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,1,CHEMBL625798,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
11852,,,,1,U,22224,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,0,CHEMBL875613,,,A,,,,Autocuration,,BAO_0000218
11853,,,,1,U,22224,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,0,CHEMBL625799,,,A,,,,Autocuration,,BAO_0000218
11854,,,,1,U,22224,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,0,CHEMBL625800,,,A,,,,Autocuration,,BAO_0000218
11855,,,,1,U,22224,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,0,CHEMBL625801,,,A,,,,Autocuration,,BAO_0000218
11856,,,,1,U,22224,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,0,CHEMBL625802,,,A,,,,Autocuration,,BAO_0000218
11857,,,,1,U,22224,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,0,CHEMBL625803,,,A,,,,Autocuration,,BAO_0000218
11858,,,,1,U,22224,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,0,CHEMBL625804,,,A,,,,Autocuration,,BAO_0000019
11859,,,,1,U,22224,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,0,CHEMBL622530,,,A,,,,Autocuration,,BAO_0000218
11860,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,1,CHEMBL622531,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11861,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,CHEMBL622532,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11862,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,CHEMBL623176,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11863,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),1,CHEMBL623177,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11864,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,CHEMBL623178,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11865,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,1,CHEMBL623179,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11866,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),1,CHEMBL623180,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11867,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,CHEMBL623181,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11868,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,CHEMBL624131,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11869,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),1,CHEMBL624132,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11870,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),1,CHEMBL624133,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11871,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,1,CHEMBL624846,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11872,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),1,CHEMBL624847,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11873,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,CHEMBL624848,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11874,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,CHEMBL625012,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11875,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,CHEMBL625013,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11876,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,1,CHEMBL625014,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11877,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),1,CHEMBL625015,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11878,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),1,CHEMBL625016,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11879,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,1,CHEMBL625017,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11880,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,CHEMBL625018,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11881,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),1,CHEMBL625019,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11882,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),1,CHEMBL625020,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11883,,,,1,N,50594,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,1,CHEMBL625021,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11884,,,,1,N,50597,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,CHEMBL625022,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11885,,,,1,N,50594,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,1,CHEMBL625023,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11886,,,,1,N,100710,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,1,CHEMBL625024,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
11887,,,,1,N,100710,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,1,CHEMBL627626,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
11888,,Brain,,1,U,22224,955.0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,0,CHEMBL627627,,,A,,,,Autocuration,,BAO_0000218
11889,,Serum,,1,U,22224,1977.0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,0,CHEMBL627628,,,A,,,,Autocuration,,BAO_0000218
11890,,Brain,,1,U,22224,955.0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,0,CHEMBL627629,,,A,,,,Autocuration,,BAO_0000218
11891,,Serum,,1,U,22224,1977.0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,0,CHEMBL627630,,,A,,,,Autocuration,,BAO_0000218
11892,,,,1,U,22224,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),0,CHEMBL627631,,,A,,,,Autocuration,,BAO_0000019
11893,,,,1,U,22224,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),0,CHEMBL629515,,,A,,,,Autocuration,,BAO_0000218
11894,,Spleen,,1,N,50594,2106.0,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,CHEMBL629516,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11895,,Spleen,,1,N,50594,2106.0,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,CHEMBL629517,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11896,,Spleen,,1,N,50594,2106.0,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,CHEMBL629518,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11897,,,,1,N,50594,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,CHEMBL877499,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11898,,,,1,N,50594,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,CHEMBL629519,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11899,,,,1,N,50594,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,CHEMBL629520,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11900,,,,1,N,50594,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,CHEMBL629521,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11901,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),1,CHEMBL629522,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11902,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),1,CHEMBL629523,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11903,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),1,CHEMBL629524,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11904,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),1,CHEMBL629525,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11905,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),1,CHEMBL629526,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11906,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),1,CHEMBL629527,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11907,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),1,CHEMBL629528,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11908,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),1,CHEMBL629529,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11909,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),1,CHEMBL629530,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11910,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),1,CHEMBL629531,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11911,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),1,CHEMBL628656,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11912,,,,1,N,50594,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),1,CHEMBL628657,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
11913,,,,1,N,50597,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL628658,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11914,,,,1,N,50597,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,CHEMBL628659,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11915,,,,1,N,50597,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,CHEMBL877500,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11916,,,,1,N,50597,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,CHEMBL628660,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11917,,,,1,N,50597,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,CHEMBL628661,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11918,,,,1,N,50597,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL628662,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11919,,,,1,N,50597,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,CHEMBL628663,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11920,,,,1,N,50597,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,CHEMBL628664,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11921,,Blood,,1,N,50597,178.0,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,CHEMBL628665,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11922,,Blood,,1,N,50597,178.0,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,CHEMBL628666,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11923,,Blood,,1,N,50597,178.0,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,CHEMBL628667,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11924,,Blood,,1,N,50597,178.0,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,CHEMBL628668,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11925,,Blood,,1,N,50597,178.0,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL628669,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11926,,Blood,,1,N,50597,178.0,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,CHEMBL628670,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11927,,Blood,,1,N,50597,178.0,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,CHEMBL628671,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11928,,Bone,,1,N,50597,10000001.0,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,CHEMBL628672,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11929,,Bone,,1,N,50597,10000001.0,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,CHEMBL630300,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11930,,Bone,,1,N,50597,10000001.0,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,CHEMBL629787,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11931,,Bone,,1,N,50597,10000001.0,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL629788,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11932,,Brain,,1,N,50597,955.0,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,CHEMBL629789,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11933,,Brain,,1,N,50597,955.0,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,CHEMBL629790,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11934,,Brain,,1,N,50597,955.0,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,CHEMBL629791,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11935,,Brain,,1,N,50597,955.0,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,CHEMBL629792,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11936,,Brain,,1,N,50597,955.0,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL629793,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11937,,Brain,,1,N,50597,955.0,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,CHEMBL629794,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11938,,,,1,N,50597,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,1,CHEMBL874459,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11939,,,,1,N,50597,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,1,CHEMBL629795,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11940,,,,1,N,50597,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,1,CHEMBL629796,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11941,,,,1,N,50597,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,1,CHEMBL629797,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11942,,,,1,N,50597,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,1,CHEMBL629798,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11943,,Adrenal gland,,1,N,50597,2369.0,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL629799,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11944,,Adrenal gland,,1,N,50597,2369.0,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL629800,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11945,,Adrenal gland,,1,N,50597,2369.0,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL629801,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11946,,Adrenal gland,,1,N,50597,2369.0,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,1,CHEMBL629802,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11947,,Adrenal gland,,1,N,50597,2369.0,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL629803,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11948,,Blood,,1,N,50597,178.0,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL629804,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11949,,Blood,,1,N,50597,178.0,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL629805,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11950,,Blood,,1,N,50597,178.0,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,CHEMBL629806,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11951,,Blood,,1,N,50597,178.0,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL629807,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11952,,Blood,,1,N,50597,178.0,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL629808,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11953,,Brain,,1,N,50597,955.0,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL629809,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11954,,Brain,,1,N,50597,955.0,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL629810,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11955,,Brain,,1,N,50597,955.0,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,CHEMBL629811,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11956,,Brain,,1,N,50597,955.0,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL629812,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11957,,Brain,,1,N,50597,955.0,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,1,CHEMBL629813,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11958,,Brain,,1,N,50597,955.0,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL874460,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11959,,,,1,N,50597,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL629814,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11960,,,,1,N,50597,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL629815,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11961,,,,1,N,50597,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL629816,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11962,,,,1,N,50597,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL629817,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11963,,Kidney,,1,N,50597,2113.0,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL626643,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11964,,Kidney,,1,N,50597,2113.0,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL626644,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11965,,Kidney,,1,N,50597,2113.0,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL626806,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11966,,Kidney,,1,N,50597,2113.0,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL626807,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11967,,Liver,,1,N,50597,2107.0,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL627261,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11968,,Liver,,1,N,50597,2107.0,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL627262,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11969,,Liver,,1,N,50597,2107.0,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL627263,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11970,,Liver,,1,N,50597,2107.0,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL627264,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11971,,Lung,,1,N,50597,2048.0,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL627265,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11972,,Lung,,1,N,50597,2048.0,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL627266,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11973,,Lung,,1,N,50597,2048.0,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL627267,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11974,,Lung,,1,N,50597,2048.0,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL627268,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11975,,Muscle tissue,,1,N,50597,2385.0,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL627269,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11976,,Muscle tissue,,1,N,50597,2385.0,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL627270,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
11977,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",1,CHEMBL627271,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11978,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",1,CHEMBL627946,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11979,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",1,CHEMBL875472,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11980,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",1,CHEMBL627947,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11981,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",1,CHEMBL627948,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11982,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",1,CHEMBL628113,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11983,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",1,CHEMBL628114,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11984,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",1,CHEMBL628115,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11985,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",1,CHEMBL628116,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11986,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",1,CHEMBL628117,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11987,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",1,CHEMBL628118,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11988,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",1,CHEMBL628119,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11989,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",1,CHEMBL628120,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11990,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",1,CHEMBL628121,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11991,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",1,CHEMBL628122,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11992,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",1,CHEMBL627297,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11993,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",1,CHEMBL627298,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11994,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",1,CHEMBL627299,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11995,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",1,CHEMBL627300,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11996,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",1,CHEMBL627301,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11997,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",1,CHEMBL627302,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11998,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",1,CHEMBL627303,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
11999,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",1,CHEMBL627304,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12000,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",1,CHEMBL627305,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12001,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",1,CHEMBL627306,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12002,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",1,CHEMBL623982,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12003,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",1,CHEMBL623983,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12004,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",1,CHEMBL623984,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12005,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",1,CHEMBL623985,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12006,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",1,CHEMBL623986,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12007,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",1,CHEMBL623987,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12008,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",1,CHEMBL623988,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12009,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",1,CHEMBL623989,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12010,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",1,CHEMBL622215,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12011,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",1,CHEMBL622216,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12012,,,,1,N,50597,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",1,CHEMBL877481,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12013,,,,1,U,22224,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),0,CHEMBL622217,,,A,,,,Autocuration,,BAO_0000218
12014,,,,1,N,50594,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),1,CHEMBL622218,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12015,,,,1,N,50597,,Pharmacokinetic profile AUC was evaluated in rats,1,CHEMBL622219,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12016,,,,1,U,22224,,Pharmacokinetic property (Area under curve),0,CHEMBL622220,,,A,,,,Autocuration,,BAO_0000019
12017,,,,1,N,50588,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",1,CHEMBL622221,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12018,,,,1,N,50594,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",1,CHEMBL622222,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12019,,,,1,N,50588,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",1,CHEMBL622223,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12020,,,,1,N,50594,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",1,CHEMBL622224,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12021,,,,1,U,22224,,Plasma concentration (AUC) was determined,0,CHEMBL622225,,,A,,,,Autocuration,,BAO_0000019
12022,,,,1,U,22224,,Plasma concentration (AUC) was determined; Not detectable,0,CHEMBL622226,,,A,,,,Autocuration,,BAO_0000019
12023,,,,1,N,50512,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),1,CHEMBL624154,Cavia porcellus,,A,10141.0,,,Intermediate,,BAO_0000218
12024,,,,1,N,50597,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,1,CHEMBL624155,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12025,,,,1,N,50597,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,1,CHEMBL624156,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12026,,,,1,N,50597,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,1,CHEMBL624157,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12027,,,,1,N,50597,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,1,CHEMBL624158,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12028,,,,1,N,50597,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,1,CHEMBL624159,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12029,,,,1,N,50597,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,1,CHEMBL624160,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12030,,,,1,N,50597,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,1,CHEMBL624161,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12031,,,,1,N,50597,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,1,CHEMBL624162,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12032,,,,1,N,50588,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,1,CHEMBL624163,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12033,,,,1,N,50597,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL624164,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12034,,,,1,N,50597,,The AUC(0-infinity) values in female wistar rats.,1,CHEMBL624165,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12035,,,,1,N,50597,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL624166,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12036,,,,1,N,50597,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",1,CHEMBL624167,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12037,,,,1,N,50597,,The AUC(0-t)values in female wistar rats.,1,CHEMBL624168,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12038,,,,1,N,50597,,The Area under the concentration time curve of compound was measured on rats,1,CHEMBL624169,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12039,,,,1,N,50587,,The area under curve (100 mg/kg) administered orally in humans,1,CHEMBL624170,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12040,,,,1,U,22224,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,0,CHEMBL624171,Callithrix,,A,9481.0,,,Autocuration,,BAO_0000218
12041,,,,1,U,22224,,The area under curve (12.5 mg/kg) administered intravenously in monkey,0,CHEMBL624172,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
12042,,,,1,N,50588,,The area under curve (15 mg/kg) administered intravenously in dog,1,CHEMBL624173,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12043,,,,1,N,50587,,The area under curve (200 mg/kg) administered orally in humans,1,CHEMBL877488,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12044,,,,1,N,50597,,The area under curve (25 mg/kg) administered intravenously in rat,1,CHEMBL624174,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12045,,,,1,U,22224,,The area under curve (25 mg/kg) administered orally in marmoset,0,CHEMBL624175,Callithrix,,A,9481.0,,,Autocuration,,BAO_0000218
12046,,,,1,U,22224,,The area under curve (25 mg/kg) administered orally in monkey,0,CHEMBL624176,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
12047,,,,1,N,50588,,The area under curve (30 mg/kg) administered orally in dog,1,CHEMBL624177,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12048,,,,1,N,50587,,The area under curve (400 mg/kg) administered orally in humans,1,CHEMBL624178,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12049,,,,1,N,50597,,The area under curve (50 mg/kg) administered orally in fasted rat,1,CHEMBL624179,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12050,,,,1,N,50597,,The area under curve (50 mg/kg) administered orally in rat,1,CHEMBL627689,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12051,,,,1,N,50587,,The area under curve (800 mg/kg) administered orally in humans,1,CHEMBL627690,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12052,,,,1,U,22224,,The compound was evaluated for area under the curve,0,CHEMBL627691,,,A,,,,Autocuration,,BAO_0000019
12053,,,,1,U,22224,,The compound was evaluated for area under the curve in marmosets,0,CHEMBL627692,Callithrix,,A,9481.0,,,Autocuration,,BAO_0000019
12054,,,,1,U,22224,,The compound was evaluated for area under the curve in marmosets,0,CHEMBL627693,Callithrix,,A,9481.0,,,Autocuration,,BAO_0000019
12055,,,,1,N,50597,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,CHEMBL627694,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12056,,,,1,N,50597,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,1,CHEMBL627695,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12057,,,,1,U,22224,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),0,CHEMBL627696,,,A,,,,Autocuration,,BAO_0000218
12058,,,,1,N,50597,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,CHEMBL627697,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12059,,,,1,N,50597,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,CHEMBL627698,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12060,,,,1,N,50597,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,1,CHEMBL627699,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12061,,,,1,N,50597,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,1,CHEMBL627700,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12062,,,,1,N,50597,,Total drug exposure is determined after oral dosing in rats.,1,CHEMBL627701,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12063,,,,1,U,22224,,Total drug exposure (5 mg/kg) when administered intravenously,0,CHEMBL627702,,,A,,,,Autocuration,,BAO_0000218
12064,,,,1,U,22224,,Total drug exposure (5 mg/kg) when administered orally,0,CHEMBL627703,,,A,,,,Autocuration,,BAO_0000218
12065,,,,1,U,22224,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,0,CHEMBL626873,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
12066,,,,1,N,50597,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,1,CHEMBL629583,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12067,,,,1,N,50588,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,1,CHEMBL629584,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12068,,,,1,N,50588,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,1,CHEMBL629585,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12069,,Brain,,1,N,50597,955.0,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,CHEMBL629586,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12070,,Brain,,1,N,50597,955.0,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL629587,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12071,,,,1,N,50597,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,CHEMBL629588,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12072,,,,1,N,50597,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,CHEMBL629589,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12073,,,,1,N,50597,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,CHEMBL629590,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12074,,,,1,N,50597,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,CHEMBL629591,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12075,,,,1,N,50597,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL629592,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12076,,,,1,N,50597,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,CHEMBL629593,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12077,,,,1,N,50597,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,CHEMBL629594,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12078,,Heart,,1,N,50597,948.0,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,CHEMBL629595,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12079,,Heart,,1,N,50597,948.0,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,CHEMBL630290,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12080,,Heart,,1,N,50597,948.0,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,CHEMBL627137,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12081,,Heart,,1,N,50597,948.0,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,CHEMBL627138,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12082,,Heart,,1,N,50597,948.0,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL627139,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12083,,Heart,,1,N,50597,948.0,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,CHEMBL627140,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12084,,Heart,,1,N,50597,948.0,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,CHEMBL627141,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12085,,Kidney,,1,N,50597,2113.0,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,CHEMBL627142,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12086,,Kidney,,1,N,50597,2113.0,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,CHEMBL627143,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12087,,Kidney,,1,N,50597,2113.0,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,CHEMBL874449,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12088,,Kidney,,1,N,50597,2113.0,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,CHEMBL627144,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12089,,Kidney,,1,N,50597,2113.0,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL627145,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12090,,Kidney,,1,N,50597,2113.0,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,CHEMBL627146,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12091,,Kidney,,1,N,50597,2113.0,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,CHEMBL627147,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12092,,Liver,,1,N,50597,2107.0,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,CHEMBL627148,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12093,,Lung,,1,N,50597,2048.0,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,CHEMBL627149,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12094,,Lung,,1,N,50597,2048.0,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,CHEMBL632160,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12095,,Lung,,1,N,50597,2048.0,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,CHEMBL632161,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12096,,Lung,,1,N,50597,2048.0,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,CHEMBL632162,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12097,,Lung,,1,N,50597,2048.0,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL632163,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12098,,Lung,,1,N,50597,2048.0,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,CHEMBL874469,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12099,,Lung,,1,N,50597,2048.0,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,CHEMBL627182,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12100,,Muscle tissue,,1,N,50597,2385.0,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,CHEMBL627183,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12101,,Muscle tissue,,1,N,50597,2385.0,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,CHEMBL627184,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12102,,Muscle tissue,,1,N,50597,2385.0,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,CHEMBL627185,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12103,,Muscle tissue,,1,N,50597,2385.0,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,CHEMBL627186,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12104,,Muscle tissue,,1,N,50597,2385.0,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL627187,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12105,,Muscle tissue,,1,N,50597,2385.0,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,CHEMBL627188,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12106,,Muscle tissue,,1,N,50597,2385.0,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,CHEMBL627189,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12107,,,,1,N,50597,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL627190,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12108,,Liver,,1,N,50597,2107.0,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,CHEMBL627191,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12109,,Liver,,1,N,50597,2107.0,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,CHEMBL627192,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12110,,Liver,,1,N,50597,2107.0,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,CHEMBL627193,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12111,,Muscle tissue,,1,N,50597,2385.0,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,CHEMBL874590,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12112,,Muscle tissue,,1,N,50597,2385.0,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL627194,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12113,,Muscle tissue,,1,N,50597,2385.0,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL627195,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12114,,Female gonad,,1,N,50597,992.0,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL627196,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12115,,Female gonad,,1,N,50597,992.0,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL627197,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12116,,Female gonad,,1,N,50597,992.0,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL627198,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12117,,Female gonad,,1,N,50597,992.0,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,1,CHEMBL627199,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12118,,Female gonad,,1,N,50597,992.0,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL627200,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12119,,Plasma,,1,N,50597,1969.0,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL627201,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12120,,Plasma,,1,N,50597,1969.0,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL627202,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12121,,Plasma,,1,N,50597,1969.0,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL627203,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12122,,Plasma,,1,N,50597,1969.0,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL627204,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12123,,Spleen,,1,N,50597,2106.0,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL627205,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12124,,Spleen,,1,N,50597,2106.0,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL627206,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12125,,Spleen,,1,N,50597,2106.0,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL627207,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12126,,Spleen,,1,N,50597,2106.0,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL627208,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12127,,Thyroid gland,,1,N,50597,2046.0,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL627209,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12128,,Thyroid gland,,1,N,50597,2046.0,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL627210,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12129,,Thyroid gland,,1,N,50597,2046.0,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL627211,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12130,,Thyroid gland,,1,N,50597,2046.0,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL627212,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12131,,Uterus,,1,N,50597,995.0,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,CHEMBL627213,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12132,,Uterus,,1,N,50597,995.0,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,CHEMBL626599,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12133,,Uterus,,1,N,50597,995.0,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,CHEMBL626600,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12134,,Uterus,,1,N,50597,995.0,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,CHEMBL626601,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12135,,,,1,U,22224,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,0,CHEMBL627484,,,A,,,,Autocuration,,BAO_0000019
12136,,Plasma,,1,N,100710,1969.0,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),1,CHEMBL627485,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
12137,,Plasma,,1,N,100710,1969.0,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,1,CHEMBL628147,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
12138,,Plasma,,1,N,100710,1969.0,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,1,CHEMBL628148,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
12139,,Plasma,,1,N,50588,1969.0,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),1,CHEMBL628149,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12140,,Plasma,,1,N,50588,1969.0,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,1,CHEMBL628150,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12141,,Plasma,,1,N,50588,1969.0,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,1,CHEMBL628318,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12142,,Plasma,,1,N,50588,1969.0,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,1,CHEMBL628319,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12143,,,,1,N,50588,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",1,CHEMBL875609,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12144,,,,1,U,22224,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,0,CHEMBL628320,,,A,,,,Autocuration,,BAO_0000019
12145,,,,1,U,22224,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,0,CHEMBL628321,,,A,,,,Autocuration,,BAO_0000019
12146,,,,1,U,22224,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,0,CHEMBL628322,,,A,,,,Autocuration,,BAO_0000019
12147,,,,1,U,22224,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,0,CHEMBL628323,,,A,,,,Autocuration,,BAO_0000019
12148,,,,1,U,22224,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,0,CHEMBL628324,,,A,,,,Autocuration,,BAO_0000019
12149,,,,1,U,22224,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,0,CHEMBL628325,,,A,,,,Autocuration,,BAO_0000019
12150,,,,1,U,22224,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,0,CHEMBL628326,,,A,,,,Autocuration,,BAO_0000019
12151,,Adrenal medulla,,1,N,50588,1236.0,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",1,CHEMBL628327,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12152,,Adrenal medulla,,1,N,50588,1236.0,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",1,CHEMBL628328,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12153,,Blood,,1,N,50588,178.0,"Concentration of compound in blood of dog 1, after administering intravenously",1,CHEMBL628329,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12154,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",1,CHEMBL628330,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12155,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",1,CHEMBL628331,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12156,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",1,CHEMBL628332,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12157,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",1,CHEMBL628333,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12158,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",1,CHEMBL628334,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12159,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",1,CHEMBL628335,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12160,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",1,CHEMBL628336,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12161,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",1,CHEMBL628337,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12162,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",1,CHEMBL628338,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12163,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",1,CHEMBL875610,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12164,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",1,CHEMBL628339,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12165,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",1,CHEMBL628340,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12166,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",1,CHEMBL628341,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12167,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",1,CHEMBL622214,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12168,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",1,CHEMBL623167,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12169,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",1,CHEMBL623168,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12170,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",1,CHEMBL623169,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12171,,Liver,,1,N,50597,2107.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",1,CHEMBL623170,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12172,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",1,CHEMBL627224,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12173,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",1,CHEMBL875634,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12174,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",1,CHEMBL627225,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12175,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",1,CHEMBL627226,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12176,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",1,CHEMBL626083,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12177,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",1,CHEMBL626084,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12178,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",1,CHEMBL626085,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12179,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",1,CHEMBL626086,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12180,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",1,CHEMBL626087,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12181,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",1,CHEMBL626088,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12182,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",1,CHEMBL626089,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12183,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",1,CHEMBL626090,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12184,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",1,CHEMBL626091,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12185,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",1,CHEMBL626092,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12186,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",1,CHEMBL626093,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12187,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",1,CHEMBL626094,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12188,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",1,CHEMBL626095,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12189,,Lung,,1,N,50597,2048.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",1,CHEMBL626096,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12190,,,,1,U,22224,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,0,CHEMBL626097,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
12191,,,,1,N,50597,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,1,CHEMBL626098,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12192,,Plasma,,1,U,22224,1969.0,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,0,CHEMBL626099,,,A,,,,Autocuration,,BAO_0000218
12193,,Plasma,,1,U,22224,1969.0,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,0,CHEMBL626100,,,A,,,,Autocuration,,BAO_0000218
12194,,Plasma,,1,N,50588,1969.0,AUC 0-inf in dog,1,CHEMBL626101,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12195,,Plasma,,1,N,50512,1969.0,AUC 0-inf in guinea pig,1,CHEMBL626102,Cavia porcellus,,A,10141.0,,,Intermediate,,BAO_0000218
12196,,Plasma,,1,N,50588,1969.0,AUC 0-t in dog,1,CHEMBL626103,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12197,,Plasma,,1,N,50512,1969.0,AUC 0-t in guinea pig,1,CHEMBL628391,Cavia porcellus,,A,10141.0,,,Intermediate,,BAO_0000218
12198,,,,1,N,50597,,The compound was tested for brain to plasma partition in rat,1,CHEMBL628392,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12199,,,,1,N,50597,,The compound was tested for brain to plasma partition in rat.,1,CHEMBL628393,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12200,,Blood,,1,U,22224,178.0,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,0,CHEMBL628394,,,A,,,,Autocuration,,BAO_0000019
12201,,,,1,N,50588,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,1,CHEMBL628395,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12202,,,,1,U,22224,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,0,CHEMBL628396,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
12203,,,,1,N,50592,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,1,CHEMBL628397,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12204,,,,1,N,50597,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,1,CHEMBL628398,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12205,,,,1,N,50797,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,1,CHEMBL628399,Macaca mulatta,,A,9544.0,,,Intermediate,,BAO_0000218
12206,,,,1,N,50588,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,1,CHEMBL628400,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12207,,,,1,N,50597,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,1,CHEMBL874907,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12208,,,,1,U,22224,,Area under curve of the compound was determined,0,CHEMBL628401,,,A,,,,Autocuration,,BAO_0000019
12209,,Plasma,,1,U,22224,1969.0,AUC in monkeys at a dose of 1 mg/kg,0,CHEMBL628402,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
12210,,Plasma,,1,N,50597,1969.0,AUC in rats at a dose of 1 mg/kg,1,CHEMBL628403,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12211,,,,1,U,22224,,Compound was evaluated for the overall absorbance loss at pH of 2,0,CHEMBL628404,,,A,,,,Autocuration,,BAO_0000019
12212,,,,1,U,22224,,Compound was evaluated for the overall absorbance loss at pH of 4,0,CHEMBL628405,,,A,,,,Autocuration,,BAO_0000019
12213,,,,1,U,22224,,Compound was evaluated for the overall absorbance loss at pH of 7,0,CHEMBL628406,,,A,,,,Autocuration,,BAO_0000019
12214,,,,1,N,50597,,Compound was evaluated for its absorption in the rats,1,CHEMBL628407,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12215,,Urine,,1,N,50597,1088.0,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1,CHEMBL628408,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12216,,Urine,,1,N,50597,1088.0,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,1,CHEMBL629171,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12217,,Urine,,1,N,50597,1088.0,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1,CHEMBL629172,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12218,,Urine,,1,N,50597,1088.0,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,1,CHEMBL629173,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12219,,,,1,N,50597,,In vitro percent permeability into rat ileum,1,CHEMBL629174,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12220,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 10-17,1,CHEMBL629175,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12221,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 10-18,1,CHEMBL629176,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12222,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 10-19,1,CHEMBL629177,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12223,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 12-15,1,CHEMBL629178,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12224,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 13-19,1,CHEMBL631869,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12225,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 14-17,1,CHEMBL631870,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12226,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 15-18,1,CHEMBL631871,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12227,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 2-5,1,CHEMBL631872,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12228,,Ileum,,1,U,22224,2116.0,In vitro percent permeability into rat ileum; Range is 23-42,0,CHEMBL875775,,,A,,,,Autocuration,,BAO_0000221
12229,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 28-36,1,CHEMBL631873,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12230,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 29-35,1,CHEMBL631874,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12231,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 46-66,1,CHEMBL631875,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12232,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 50-68,1,CHEMBL631876,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12233,,,,1,N,50597,,In vitro percent permeability into rat ileum; Range is 78-81,1,CHEMBL631877,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12234,,,,1,N,50597,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,1,CHEMBL631878,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12235,,,,1,N,50597,,In vitro percent permeability into rat ileum; nd indicates not detected,1,CHEMBL631879,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12236,,,,1,N,50597,,In vitro percent permeability into rat ileum; nt indicates not detected,1,CHEMBL631880,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12237,,,,1,N,50597,,In vitro percent permeability into rat ileum; nt indicates not tested,1,CHEMBL631881,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12238,,,,1,N,50597,,Compound was tested for oral absorption in bile-duct cannulated rats,1,CHEMBL631882,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12239,,,,1,N,50597,,Compound was tested for oral absorption in bile-duct cannulated rats.,1,CHEMBL630749,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12240,,,,1,N,50587,,Oral absorption using Caco-2 cell monolayers.,1,CHEMBL630750,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12241,,,,1,N,50587,,Percent of the drug absorbed after administration to humans was determined,1,CHEMBL630253,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12242,,Plasma,,1,N,50597,1969.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1,CHEMBL630254,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12243,,Plasma,,1,N,50597,1969.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1,CHEMBL630255,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12244,,Plasma,,1,N,50597,1969.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1,CHEMBL630256,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12245,,Liver,,1,N,50597,2107.0,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,CHEMBL875781,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12246,,Liver,,1,N,50597,2107.0,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,CHEMBL630257,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12247,,Liver,,1,N,50597,2107.0,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,CHEMBL630258,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12248,,,,1,N,50597,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",1,CHEMBL630259,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12249,,Striatum,,1,N,50597,2435.0,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",1,CHEMBL630260,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12250,,Striatum,,1,N,50597,2435.0,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",1,CHEMBL630261,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12251,,,,1,N,50597,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,1,CHEMBL630262,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12252,,,,1,N,50597,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,1,CHEMBL630263,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12253,,,,1,N,50597,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,1,CHEMBL630264,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12254,,,,1,N,50597,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,1,CHEMBL630265,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12255,,,,1,N,50597,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,1,CHEMBL630266,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12256,,Kidney,,1,N,50597,2113.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,1,CHEMBL630267,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12257,,Kidney,,1,N,50597,2113.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,1,CHEMBL630268,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12258,,,,1,N,50597,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,1,CHEMBL630269,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12259,,,,1,N,50597,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,1,CHEMBL630270,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12260,,Lung,,1,N,50597,2048.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,1,CHEMBL630141,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12261,,Lung,,1,N,50597,2048.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,1,CHEMBL630142,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12262,,Muscle tissue,,1,N,50597,2385.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,1,CHEMBL630143,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12263,,Muscle tissue,,1,N,50597,2385.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,1,CHEMBL630144,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12264,,Prostate gland,,1,N,50597,2367.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,1,CHEMBL630145,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12265,,Prostate gland,,1,N,50597,2367.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,1,CHEMBL630146,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12266,,,,1,N,50597,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,1,CHEMBL630147,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12267,,,,1,N,50597,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,1,CHEMBL630148,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12268,,,,1,N,50597,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,1,CHEMBL630149,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12269,,Spleen,,1,N,50597,2106.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,1,CHEMBL630150,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12270,,Spleen,,1,N,50597,2106.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,1,CHEMBL630151,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12271,,Thyroid gland,,1,N,50597,2046.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,1,CHEMBL632031,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12272,,Thyroid gland,,1,N,50597,2046.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,1,CHEMBL632032,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12273,,,,1,N,50597,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,1,CHEMBL632033,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12274,,,,1,N,50597,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,1,CHEMBL632034,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12275,,Muscle tissue,,1,N,50597,2385.0,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,1,CHEMBL632035,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12276,,,,1,N,50597,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,1,CHEMBL632036,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12277,,Thyroid gland,,1,N,50597,2046.0,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,1,CHEMBL632037,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12278,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,1,CHEMBL632038,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12279,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,1,CHEMBL632039,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12280,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,1,CHEMBL632040,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12281,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,1,CHEMBL632041,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12282,,Blood,,1,N,50588,178.0,"Concentration of compound in blood of dog 2, after administering intravenously",1,CHEMBL632042,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12283,,,,1,N,50588,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",1,CHEMBL632043,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12284,,,,1,N,50588,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",1,CHEMBL632044,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12285,,Liver,,1,N,50588,2107.0,"Concentration of compound in liver of dog 1, after administering intravenously",1,CHEMBL632045,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12286,,Liver,,1,N,50588,2107.0,"Concentration of compound in liver of dog 2, after administering intravenously",1,CHEMBL632046,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12287,,Lung,,1,N,50588,2048.0,"Concentration of compound in lung of dog 1, after administering intravenously",1,CHEMBL632047,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12288,,Lung,,1,N,50588,2048.0,"Concentration of compound in lung of dog 2, after administering intravenously",1,CHEMBL632048,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12289,,Muscle tissue,,1,N,50588,2385.0,"Concentration of compound in muscle of dog 1, after administering intravenously",1,CHEMBL632049,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12290,,Muscle tissue,,1,N,50588,2385.0,"Concentration of compound in muscle of dog 2, after administering intravenously",1,CHEMBL876418,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12291,,Spleen,,1,N,50588,2106.0,"Concentration of compound in spleen of dog 1,after administering intravenously",1,CHEMBL632050,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12292,,Spleen,,1,N,50588,2106.0,"Concentration of compound in spleen of dog 2, after administering intravenously",1,CHEMBL632051,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12293,,,,1,U,22224,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,0,CHEMBL632052,,,F,,,,Autocuration,,BAO_0000218
12294,,,,1,U,22224,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,0,CHEMBL632053,,,F,,,,Autocuration,,BAO_0000218
12295,,,,1,U,22224,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,0,CHEMBL632054,,,A,,,,Autocuration,,BAO_0000218
12296,,,,1,U,22224,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,0,CHEMBL632055,,,F,,,,Autocuration,,BAO_0000218
12297,,,,1,U,22224,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,0,CHEMBL631181,,,F,,,,Autocuration,,BAO_0000218
12298,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,0,CHEMBL631182,,,A,,,,Autocuration,,BAO_0000218
12299,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,0,CHEMBL631183,,,A,,,,Autocuration,,BAO_0000218
12300,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,0,CHEMBL631184,,,A,,,,Autocuration,,BAO_0000218
12301,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,0,CHEMBL629774,,,A,,,,Autocuration,,BAO_0000218
12302,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,0,CHEMBL629775,,,A,,,,Autocuration,,BAO_0000218
12303,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,0,CHEMBL876549,,,A,,,,Autocuration,,BAO_0000218
12304,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,0,CHEMBL628172,,,A,,,,Autocuration,,BAO_0000218
12305,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,0,CHEMBL628173,,,A,,,,Autocuration,,BAO_0000218
12306,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,0,CHEMBL628174,,,A,,,,Autocuration,,BAO_0000218
12307,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,0,CHEMBL628175,,,A,,,,Autocuration,,BAO_0000218
12308,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,0,CHEMBL628176,,,A,,,,Autocuration,,BAO_0000218
12309,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,0,CHEMBL628177,,,A,,,,Autocuration,,BAO_0000218
12310,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,0,CHEMBL628178,,,A,,,,Autocuration,,BAO_0000218
12311,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,0,CHEMBL628179,,,A,,,,Autocuration,,BAO_0000218
12312,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,0,CHEMBL628180,,,A,,,,Autocuration,,BAO_0000218
12313,,,,1,U,22224,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,0,CHEMBL628181,,,A,,,,Autocuration,,BAO_0000218
12314,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,0,CHEMBL628182,,,A,,,,Autocuration,,BAO_0000218
12315,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,0,CHEMBL628183,,,A,,,,Autocuration,,BAO_0000218
12316,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,0,CHEMBL628184,,,A,,,,Autocuration,,BAO_0000218
12317,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,0,CHEMBL628185,,,A,,,,Autocuration,,BAO_0000218
12318,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,0,CHEMBL875617,,,A,,,,Autocuration,,BAO_0000218
12319,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,0,CHEMBL628186,,,A,,,,Autocuration,,BAO_0000218
12320,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,0,CHEMBL628187,,,A,,,,Autocuration,,BAO_0000218
12321,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,0,CHEMBL628188,,,A,,,,Autocuration,,BAO_0000218
12322,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,0,CHEMBL628189,,,A,,,,Autocuration,,BAO_0000218
12323,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,0,CHEMBL628190,,,A,,,,Autocuration,,BAO_0000218
12324,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,0,CHEMBL628191,,,A,,,,Autocuration,,BAO_0000218
12325,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,0,CHEMBL626513,,,A,,,,Autocuration,,BAO_0000218
12326,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",1,CHEMBL626514,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12327,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",1,CHEMBL626515,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12328,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",1,CHEMBL626516,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12329,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",1,CHEMBL626517,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12330,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",1,CHEMBL626518,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12331,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",1,CHEMBL626519,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12332,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",1,CHEMBL626520,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12333,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",1,CHEMBL626521,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12334,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",1,CHEMBL626522,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12335,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",1,CHEMBL626523,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12336,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",1,CHEMBL626524,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12337,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",1,CHEMBL626688,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12338,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",1,CHEMBL626689,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12339,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",1,CHEMBL626690,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12340,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",1,CHEMBL626691,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12341,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",1,CHEMBL627319,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12342,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",1,CHEMBL624052,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12343,,Thyroid gland,,1,N,50597,2046.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",1,CHEMBL624053,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12344,,,,1,N,50597,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,CHEMBL624054,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12345,,,,1,N,50597,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,CHEMBL624055,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12346,,,,1,N,50597,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,CHEMBL624056,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12347,,Uterus,,1,N,50597,995.0,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,CHEMBL624057,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12348,,Uterus,,1,N,50597,995.0,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,CHEMBL622281,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12349,,Uterus,,1,N,50597,995.0,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,CHEMBL622282,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12350,,Uterus,,1,N,50597,995.0,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,CHEMBL622283,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12351,,Uterus,,1,N,50597,995.0,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,CHEMBL622284,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12352,,Uterus,,1,N,50597,995.0,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,CHEMBL622285,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12353,,Uterus,,1,N,50597,995.0,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,CHEMBL622286,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12354,,,,1,U,22224,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,0,CHEMBL622287,,,P,,,,Autocuration,,BAO_0000100
12355,,,,1,N,50594,,Partition coefficient (logD7.4),1,CHEMBL622288,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12356,,,,1,N,50594,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",1,CHEMBL622289,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12357,,Brain,,1,N,50594,955.0,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",1,CHEMBL622290,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12358,,,,1,N,50594,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,1,CHEMBL622291,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12359,,Brain,,1,N,50594,955.0,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,1,CHEMBL622292,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12360,,,,1,N,50594,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",1,CHEMBL622293,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12361,,Brain,,1,N,50594,955.0,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",1,CHEMBL622294,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12362,,,,1,N,50594,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,1,CHEMBL622295,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12363,,Brain,,1,N,50597,955.0,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,1,CHEMBL622296,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12364,,Plasma,,1,N,50597,1969.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,1,CHEMBL874409,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12365,,Plasma,,1,N,50597,1969.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1,CHEMBL622297,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12366,,Plasma,,1,N,50597,1969.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1,CHEMBL622298,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12367,,Plasma,,1,N,50597,1969.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1,CHEMBL622299,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12368,,Plasma,,1,N,50597,1969.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1,CHEMBL622300,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12369,,Plasma,,1,N,50597,1969.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1,CHEMBL622301,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12370,,Plasma,,1,N,50597,1969.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1,CHEMBL622302,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12371,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1,CHEMBL622303,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12372,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1,CHEMBL622304,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12373,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,1,CHEMBL622305,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12374,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1,CHEMBL622306,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12375,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,1,CHEMBL626864,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12376,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1,CHEMBL626865,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12377,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,1,CHEMBL626866,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12378,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1,CHEMBL626867,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12379,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1,CHEMBL626868,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12380,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,1,CHEMBL626869,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12381,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1,CHEMBL626870,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12382,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,1,CHEMBL626871,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12383,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1,CHEMBL626872,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12384,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1,CHEMBL632185,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12385,,Plasma,,1,N,50597,1969.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,1,CHEMBL632186,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12386,,,,1,U,22224,,Amount of acetic acid produced by the compound,0,CHEMBL629310,,,A,,,,Autocuration,,BAO_0000019
12387,,,,1,U,22224,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,0,CHEMBL629311,,,A,,,,Autocuration,,BAO_0000019
12388,,,,1,N,50597,,Log of (Cbrain/Cblood) in rats,1,CHEMBL629312,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12389,,,,1,U,22224,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),0,CHEMBL629313,,,A,,,,Autocuration,,BAO_0000221
12390,,,,1,U,22224,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),0,CHEMBL629314,,,A,,,,Autocuration,,BAO_0000221
12391,,,,1,U,22224,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),0,CHEMBL629315,,,A,,,,Autocuration,,BAO_0000221
12392,,,,1,U,22224,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),0,CHEMBL629316,,,B,,,,Autocuration,,BAO_0000219
12393,,,,1,U,22224,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),0,CHEMBL629317,,,A,,,,Autocuration,,BAO_0000221
12394,,,,1,U,22224,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),0,CHEMBL629318,,,A,,,,Autocuration,,BAO_0000019
12395,,,,1,U,22224,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),0,CHEMBL877497,,,A,,,,Autocuration,,BAO_0000019
12396,,,,1,U,22224,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),0,CHEMBL629319,,,A,,,,Autocuration,,BAO_0000019
12397,,,,1,U,22224,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),0,CHEMBL629320,,,A,,,,Autocuration,,BAO_0000019
12398,,,,1,U,22224,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),0,CHEMBL629496,,,A,,,,Autocuration,,BAO_0000019
12399,,,,1,U,22224,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),0,CHEMBL629497,,,A,,,,Autocuration,,BAO_0000019
12400,,,,1,U,22224,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),0,CHEMBL629498,,,A,,,,Autocuration,,BAO_0000019
12401,,,,1,U,22224,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),0,CHEMBL629499,,,A,,,,Autocuration,,BAO_0000019
12402,,,,1,U,22224,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),0,CHEMBL629500,,,A,,,,Autocuration,,BAO_0000019
12403,,,,1,U,22224,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),0,CHEMBL629501,,,A,,,,Autocuration,,BAO_0000019
12404,,,,1,U,22224,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),0,CHEMBL629502,,,A,,,,Autocuration,,BAO_0000019
12405,,,,1,U,22224,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,0,CHEMBL629503,,,F,,In vivo,,Autocuration,,BAO_0000218
12406,,,,1,N,50588,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,1,CHEMBL629504,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12407,,,,1,U,22224,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,0,CHEMBL629505,,,A,,,,Autocuration,,BAO_0000019
12408,,,,1,U,22224,,Compound was evaluated for total body clearance,0,CHEMBL629506,,,A,,,,Autocuration,,BAO_0000019
12409,,,,1,U,22224,,Compound was evaluated for volume of distribution at steady state,0,CHEMBL629507,,,A,,,,Autocuration,,BAO_0000019
12410,,,,1,U,22224,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,0,CHEMBL877498,,,A,,,,Autocuration,,BAO_0000019
12411,,,,1,U,22224,,Percentage of the diamine which is monoprotonated at pH 7.4,0,CHEMBL629508,,,A,,,,Autocuration,,BAO_0000019
12412,,,,1,U,22224,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,0,CHEMBL629509,,,A,,,,Autocuration,,BAO_0000019
12413,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,1,CHEMBL629510,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12414,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,CHEMBL629511,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12415,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,CHEMBL629512,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12416,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,CHEMBL629513,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12417,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,1,CHEMBL629514,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12418,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,CHEMBL628447,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12419,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,1,CHEMBL628448,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12420,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,1,CHEMBL628449,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12421,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,1,CHEMBL631119,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12422,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,1,CHEMBL631120,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12423,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,1,CHEMBL631121,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12424,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,1,CHEMBL874458,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12425,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,CHEMBL631122,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12426,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,CHEMBL631123,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12427,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,CHEMBL631124,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12428,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,CHEMBL631125,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12429,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,CHEMBL631290,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12430,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,CHEMBL631291,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12431,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,CHEMBL631292,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12432,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,CHEMBL631293,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12433,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,CHEMBL631294,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12434,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,CHEMBL631295,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12435,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,1,CHEMBL631296,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12436,,Blood,,1,N,50597,178.0,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,CHEMBL631297,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12437,,,,1,U,22224,,Maximum biodistribution (Bmax) was determined.,0,CHEMBL631298,,,A,,,,Autocuration,,BAO_0000218
12438,,,,1,N,50594,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,1,CHEMBL631299,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12439,,,,1,N,50594,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,1,CHEMBL631300,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12440,,,,1,N,50594,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,1,CHEMBL631301,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12441,,,,1,N,50594,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,1,CHEMBL630291,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12442,,,,1,U,22224,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,0,CHEMBL630292,,,A,,,,Autocuration,,BAO_0000218
12443,,,,1,U,22224,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,0,CHEMBL630293,,,A,,,,Autocuration,,BAO_0000218
12444,,,,1,U,22224,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,0,CHEMBL630294,,,A,,,,Autocuration,,BAO_0000218
12445,,,,1,U,22224,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,0,CHEMBL630295,,,A,,,,Autocuration,,BAO_0000218
12446,,,,1,U,22224,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,0,CHEMBL630296,,,A,,,,Autocuration,,BAO_0000218
12447,,,,1,U,22224,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,0,CHEMBL626782,,,A,,,,Autocuration,,BAO_0000218
12448,,,,1,U,22224,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,0,CHEMBL626783,,,A,,,,Autocuration,,BAO_0000218
12449,,,,1,U,22224,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,0,CHEMBL626784,,,A,,,,Autocuration,,BAO_0000218
12450,,,,1,U,22224,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,0,CHEMBL626785,,,A,,,,Autocuration,,BAO_0000218
12451,,,,1,U,22224,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,0,CHEMBL626786,,,A,,,,Autocuration,,BAO_0000218
12452,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,0,CHEMBL626787,,,A,,,,Autocuration,,BAO_0000218
12453,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,0,CHEMBL626788,,,A,,,,Autocuration,,BAO_0000218
12454,,,,1,U,22224,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,0,CHEMBL625927,,,A,,,,Autocuration,,BAO_0000218
12455,,Blood,,1,N,50597,178.0,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL625928,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12456,,Blood,,1,N,50597,178.0,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,CHEMBL625929,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12457,,Blood,,1,N,50597,178.0,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,1,CHEMBL625930,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12458,,Blood,,1,N,50597,178.0,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",1,CHEMBL625931,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12459,,Blood,,1,N,50597,178.0,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,1,CHEMBL627230,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12460,,Blood,,1,N,50597,178.0,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627231,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12461,,Blood,,1,N,50597,178.0,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,CHEMBL627232,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12462,,Blood,,1,N,50597,178.0,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,1,CHEMBL627233,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12463,,Blood,,1,N,50597,178.0,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL875470,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12464,,Blood,,1,N,50597,178.0,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627234,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12465,,Blood,,1,N,50597,178.0,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627235,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12466,,Blood,,1,N,50597,178.0,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627236,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12467,,Blood,,1,N,50597,178.0,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627237,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12468,,Blood,,1,N,50597,178.0,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627238,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12469,,Blood,,1,N,50597,178.0,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627239,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12470,,Blood,,1,N,50597,178.0,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627240,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12471,,Blood,,1,N,50597,178.0,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627241,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12472,,Blood,,1,N,50597,178.0,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627242,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12473,,Blood,,1,N,50597,178.0,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,1,CHEMBL627243,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12474,,Blood,,1,N,50597,178.0,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,CHEMBL627244,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12475,,Blood,,1,N,50597,178.0,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627245,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12476,,Blood,,1,N,50597,178.0,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627246,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12477,,Blood,,1,N,50597,178.0,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627247,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12478,,Blood,,1,N,50597,178.0,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627248,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12479,,Blood,,1,N,50597,178.0,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627249,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12480,,Blood,,1,N,50597,178.0,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL625569,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12481,,Blood,,1,N,50597,178.0,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL625570,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12482,,Blood,,1,N,50597,178.0,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL625571,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12483,,Blood,,1,N,50597,178.0,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,CHEMBL625572,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12484,,Blood,,1,N,50597,178.0,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,CHEMBL625573,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12485,,Blood,,1,N,50597,178.0,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,1,CHEMBL625574,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12486,,Blood,,1,N,50597,178.0,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,CHEMBL626245,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12487,,Blood,,1,N,50597,178.0,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL626246,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12488,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,0,CHEMBL626247,,,A,,,,Autocuration,,BAO_0000218
12489,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,0,CHEMBL626248,,,A,,,,Autocuration,,BAO_0000218
12490,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,0,CHEMBL626249,,,A,,,,Autocuration,,BAO_0000218
12491,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,0,CHEMBL626420,,,A,,,,Autocuration,,BAO_0000218
12492,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,0,CHEMBL626421,,,A,,,,Autocuration,,BAO_0000218
12493,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,0,CHEMBL626422,,,A,,,,Autocuration,,BAO_0000218
12494,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,0,CHEMBL626423,,,A,,,,Autocuration,,BAO_0000218
12495,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,0,CHEMBL626424,,,A,,,,Autocuration,,BAO_0000218
12496,,,,1,N,50588,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,1,CHEMBL626425,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12497,,,,1,N,50597,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,1,CHEMBL875476,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12498,,,,1,N,100710,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,1,CHEMBL626426,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
12499,,,,1,U,22224,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,0,CHEMBL626427,,,P,,,,Autocuration,,BAO_0000100
12500,,,,1,U,22224,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,0,CHEMBL626428,,,P,,,,Autocuration,,BAO_0000100
12501,,,,1,U,22224,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,0,CHEMBL626429,,,A,,,,Autocuration,,BAO_0000019
12502,,Urine,,1,U,22224,1088.0,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,0,CHEMBL625025,,,A,,,,Autocuration,,BAO_0000019
12503,,Blood,,1,N,50597,178.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,CHEMBL625026,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12504,,Blood,,1,N,50597,178.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,CHEMBL625027,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12505,,Blood,,1,N,50597,178.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,CHEMBL874410,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12506,,Blood,,1,N,50597,178.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,CHEMBL625028,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12507,,Blood,,1,N,50597,178.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,CHEMBL625029,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12508,,Blood,,1,N,50597,178.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,CHEMBL625030,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12509,,Blood,,1,N,50597,178.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,CHEMBL625031,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12510,,Blood,,1,N,50597,178.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,CHEMBL625032,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12511,,Blood,,1,N,50597,178.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,CHEMBL625033,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12512,,Blood,,1,N,50597,178.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,CHEMBL625034,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12513,,Heart,,1,N,50597,948.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,CHEMBL624872,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12514,,Heart,,1,N,50597,948.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,CHEMBL624873,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12515,,Heart,,1,N,50597,948.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,CHEMBL624874,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12516,,Heart,,1,N,50597,948.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,CHEMBL624875,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12517,,Heart,,1,N,50597,948.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,CHEMBL624876,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12518,,Heart,,1,N,50597,948.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,CHEMBL624877,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12519,,Heart,,1,N,50597,948.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,CHEMBL624878,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12520,,Heart,,1,N,50597,948.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,CHEMBL624879,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12521,,Heart,,1,N,50597,948.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,CHEMBL624880,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12522,,Heart,,1,N,50597,948.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,1,CHEMBL624881,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12523,,Heart,,1,N,50597,948.0,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",1,CHEMBL624882,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12524,,Kidney,,1,N,50597,2113.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,CHEMBL624883,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12525,,Kidney,,1,N,50597,2113.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,CHEMBL624884,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12526,,Kidney,,1,N,50597,2113.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,CHEMBL624885,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12527,,Kidney,,1,N,50597,2113.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,CHEMBL624886,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12528,,Kidney,,1,N,50597,2113.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,CHEMBL624887,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12529,,Kidney,,1,N,50597,2113.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,CHEMBL624888,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12530,,Kidney,,1,N,50597,2113.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,CHEMBL624889,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12531,,Kidney,,1,N,50597,2113.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,CHEMBL624890,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12532,,Kidney,,1,N,50597,2113.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,CHEMBL621964,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12533,,Kidney,,1,N,50597,2113.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,CHEMBL621965,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12534,,Liver,,1,N,50597,2107.0,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,CHEMBL621966,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12535,,Liver,,1,N,50597,2107.0,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,CHEMBL621967,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12536,,Liver,,1,N,50597,2107.0,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,CHEMBL622164,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12537,,,,1,U,22224,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),0,CHEMBL623097,,,A,,,,Autocuration,,BAO_0000019
12538,,,,1,U,22224,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),0,CHEMBL623098,,,A,,,,Autocuration,,BAO_0000019
12539,,,,1,U,22224,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,0,CHEMBL623099,,,A,,,,Autocuration,,BAO_0000019
12540,,,,1,U,22224,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,0,CHEMBL623100,,,A,,,,Autocuration,,BAO_0000019
12541,,,,1,N,50597,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",1,CHEMBL628673,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12542,,,,1,N,50597,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",1,CHEMBL628674,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12543,,,,1,N,50597,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",1,CHEMBL628675,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12544,,,,1,N,50597,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",1,CHEMBL627644,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12545,,,,1,N,50597,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",1,CHEMBL627645,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12546,,,,1,N,50597,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",1,CHEMBL627646,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12547,,,,1,N,50597,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",1,CHEMBL627647,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12548,,,,1,N,50597,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",1,CHEMBL627648,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12549,,,,1,N,50597,,Free level in rat plasma,1,CHEMBL627649,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12550,,,,1,U,22224,,Level reaching in blood plasma of rat or human was determined,0,CHEMBL628313,,,A,,,,Autocuration,,BAO_0000019
12551,,,,1,N,50597,,Log (Cbrain/Cblood) in rats,1,CHEMBL628314,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12552,,,,1,U,22224,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,0,CHEMBL628315,,,A,,,,Autocuration,,BAO_0000019
12553,,,,1,U,22224,,Mean percentage of compound transport through membrane; expressed as membrane transport,0,CHEMBL628316,,,A,,,,Autocuration,,BAO_0000019
12554,,,,1,U,22224,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,0,CHEMBL628317,,,A,,,,Autocuration,,BAO_0000218
12555,,,,1,U,22224,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,0,CHEMBL628473,,,A,,,,Autocuration,,BAO_0000019
12556,,,,1,U,22224,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",0,CHEMBL628474,,,A,,,,Autocuration,,BAO_0000019
12557,,,,1,U,22224,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,0,CHEMBL628475,,,A,,,,Autocuration,,BAO_0000019
12558,,,,1,U,22224,,Net water uptake by a carrier mediated transport (%cm) mechanism,0,CHEMBL628476,,,A,,,,Autocuration,,BAO_0000019
12559,,,,1,U,22224,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,0,CHEMBL628477,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
12560,,,,1,N,50506,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,1,CHEMBL628478,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
12561,,,,1,N,50506,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",1,CHEMBL628479,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
12562,,,,1,U,22224,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,0,CHEMBL628480,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
12563,,,,1,U,22224,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",0,CHEMBL628481,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
12564,,,,1,N,50597,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,1,CHEMBL628482,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12565,,,,1,N,50597,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,CHEMBL628483,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12566,,Plasma,,1,N,50597,1969.0,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1,CHEMBL628484,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12567,,Plasma,,1,N,50597,1969.0,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,CHEMBL628485,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12568,,Plasma,,1,N,100710,1969.0,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",1,CHEMBL628486,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
12569,,Plasma,,1,N,50587,1969.0,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",1,CHEMBL628487,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12570,,Plasma,,1,N,50597,1969.0,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1,CHEMBL628488,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12571,,Plasma,,1,N,50597,1969.0,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,CHEMBL628489,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12572,,Plasma,,1,N,50597,1969.0,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,CHEMBL628490,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12573,,,,1,N,100710,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,CHEMBL628491,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
12574,,,,1,N,100710,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,CHEMBL877507,Macaca fascicularis,,A,9541.0,,,Intermediate,,BAO_0000218
12575,,,,1,U,22224,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,0,CHEMBL628492,,,A,,,,Autocuration,,BAO_0000218
12576,,,,1,U,22224,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),0,CHEMBL628493,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000019
12577,,,,1,U,22224,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),0,CHEMBL628494,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000019
12578,,,,1,U,22224,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),0,CHEMBL628495,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000019
12579,,,,1,N,50587,,Permeability in Caco-2 assay at 10E-6,1,CHEMBL628496,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12580,,Brain,,1,U,22224,955.0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,0,CHEMBL628497,,,A,,,,Autocuration,,BAO_0000218
12581,,Brain,,1,U,22224,955.0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,0,CHEMBL628498,,,A,,,,Autocuration,,BAO_0000218
12582,,,,1,U,22224,,Plasma protein binding was determined,0,CHEMBL628499,,,A,,,,Autocuration,,BAO_0000019
12583,,,,1,U,22224,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,0,CHEMBL627656,,,A,,,,Autocuration,,BAO_0000218
12584,,,,1,U,22224,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,0,CHEMBL627657,,,A,,,,Autocuration,,BAO_0000218
12585,,,,1,U,22224,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,0,CHEMBL626808,,,A,,,,Autocuration,,BAO_0000218
12586,,,,1,U,22224,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,0,CHEMBL626809,,,A,,,,Autocuration,,BAO_0000218
12587,,,,1,U,22224,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,0,CHEMBL626810,,,A,,,,Autocuration,,BAO_0000218
12588,,,,1,U,22224,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,0,CHEMBL626811,,,A,,,,Autocuration,,BAO_0000218
12589,,,,1,U,22224,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,0,CHEMBL874465,,,A,,,,Autocuration,,BAO_0000218
12590,,,,1,U,22224,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,0,CHEMBL626812,,,A,,,,Autocuration,,BAO_0000218
12591,,,,1,U,22224,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,0,CHEMBL626813,,,A,,,,Autocuration,,BAO_0000218
12592,,,,1,U,22224,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,0,CHEMBL626814,,,A,,,,Autocuration,,BAO_0000218
12593,,,,1,U,22224,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,0,CHEMBL626815,,,A,,,,Autocuration,,BAO_0000019
12594,,,,1,U,22224,,Partition coefficient (logP),0,CHEMBL628566,,,A,,,,Autocuration,,BAO_0000019
12595,,,,1,U,22229,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),0,CHEMBL628567,,,P,,,,Autocuration,,BAO_0000100
12596,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL628568,,,P,,,,Autocuration,,BAO_0000100
12597,,,,1,N,50588,,C max in dog,1,CHEMBL628569,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12598,,,,1,N,50512,,C max in guinea pig,1,CHEMBL628570,Cavia porcellus,,A,10141.0,In vivo,,Intermediate,,BAO_0000218
12599,,,,1,U,22224,,C max value was evaluated,0,CHEMBL628571,,,A,,In vivo,,Autocuration,,BAO_0000218
12600,,,,1,U,22224,,Cmax value after oral dose of 0.1 mg//kg,0,CHEMBL628572,,,A,,In vivo,,Autocuration,,BAO_0000218
12601,,,,1,U,22224,,Cmax value after oral dose of 0.3 mg/kg,0,CHEMBL628573,,,A,,In vivo,,Autocuration,,BAO_0000218
12602,,,,1,U,22224,,Cmax value after oral dose of 1 mg/kg,0,CHEMBL628574,,,A,,In vivo,,Autocuration,,BAO_0000218
12603,,,,1,U,22224,,Cmax value after oral dose of 10 mg/kg,0,CHEMBL628575,,,A,,In vivo,,Autocuration,,BAO_0000218
12604,,,,1,U,22224,,Cmax value after oral dose of 23.4 mg/kg,0,CHEMBL628576,,,A,,In vivo,,Autocuration,,BAO_0000218
12605,,,,1,U,22224,,Cmax value after oral dose of 3 mg/kg,0,CHEMBL628577,,,A,,In vivo,,Autocuration,,BAO_0000218
12606,,,,1,U,22224,,Cmax value after oral dose of 3.87 mg/kg,0,CHEMBL628578,,,A,,In vivo,,Autocuration,,BAO_0000218
12607,,,,1,N,50588,,Cmax value in female Beagle dogs,1,CHEMBL874466,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12608,,,,1,N,50597,,Cmax value in male rats,1,CHEMBL628579,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12609,,Plasma,,1,N,50597,1969.0,Cmax value in rat plasma when administered 20 mg/kg perorally,1,CHEMBL628580,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12610,,Plasma,,1,N,50588,1969.0,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,CHEMBL628581,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12611,,Plasma,,1,N,50588,1969.0,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,CHEMBL628582,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12612,,,,1,N,50588,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,1,CHEMBL628583,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12613,,,,1,U,22224,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,0,CHEMBL625782,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
12614,,,,1,N,50592,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,1,CHEMBL625783,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12615,,,,1,N,50597,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,1,CHEMBL625784,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12616,,Plasma,,1,N,50797,1969.0,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,1,CHEMBL625785,Macaca mulatta,,A,9544.0,,,Intermediate,,BAO_0000218
12617,,,,1,N,50597,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,1,CHEMBL625786,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12618,,,,1,U,22224,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,0,CHEMBL874467,,,A,,,,Autocuration,,BAO_0000019
12619,,,,1,N,50588,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",1,CHEMBL625787,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12620,,,,1,N,50677,,cytotoxicity against HIV protease enzyme.,1,CHEMBL625964,Human immunodeficiency virus,,A,12721.0,,,Intermediate,,BAO_0000218
12621,,,,1,N,50594,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,1,CHEMBL625965,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12622,,,,1,N,50594,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,1,CHEMBL625966,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12623,,Plasma,,1,N,50588,1969.0,The plasma clearance in dog.,1,CHEMBL625967,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12624,,Plasma,,1,N,50597,1969.0,The plasma clearance in rat.,1,CHEMBL625968,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12625,,Plasma,,1,N,50597,1969.0,Clearance from plasma in male Sprague-Dawley rats,1,CHEMBL625969,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12626,,Plasma,,1,N,100710,1969.0,Clearance from plasma in male cynomolgus monkeys,1,CHEMBL625970,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
12627,,Plasma,,1,N,50588,1969.0,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",1,CHEMBL625971,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12628,,Plasma,,1,N,50588,1969.0,Clearance of compound in dog plasma,1,CHEMBL625972,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12629,,Plasma,,1,N,50587,1969.0,Clearance of compound in human plasma,1,CHEMBL625973,Homo sapiens,,A,9606.0,In vivo,,Intermediate,,BAO_0000218
12630,,,,1,N,50588,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,1,CHEMBL625974,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12631,,,,1,N,50588,,Clearance of compound when administered intravenously as an individual dose to a single dog.,1,CHEMBL625975,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12632,,Plasma,,1,N,50588,1969.0,"Clearance (10 mg/kg, intravenously) in dog plasma",1,CHEMBL625976,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12633,,,,1,N,50588,,Clearance value in dog,1,CHEMBL625977,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12634,,,,1,N,50512,,Clearance value in guinea pig,1,CHEMBL625978,Cavia porcellus,,A,10141.0,In vivo,,Intermediate,,BAO_0000218
12635,,,,1,N,50597,,Clearance values in rats after iv administration.,1,CHEMBL874468,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12636,,Plasma,,1,U,22224,1969.0,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,0,CHEMBL625421,,,A,,In vivo,,Autocuration,,BAO_0000218
12637,,,,1,N,50592,,In vivo clearance (5 mg/kg) was determined in rabbits,1,CHEMBL625422,Oryctolagus cuniculus,,A,9986.0,In vivo,,Intermediate,,BAO_0000218
12638,,,,1,N,50597,,Plasma Clearance rate was determined for the compound in rats,1,CHEMBL625423,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12639,,,,1,U,22224,,Plasma Clearance rate was determined for the compound in squirrel monkeys,0,CHEMBL625424,Saimiri,,A,9520.0,In vivo,,Autocuration,,BAO_0000218
12640,,,,1,N,50597,,Plasma clearance in rat,1,CHEMBL625425,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12641,,,,1,U,22224,,Plasma clearance of the compound,0,CHEMBL625426,,,A,,In vivo,,Autocuration,,BAO_0000218
12642,,,,1,N,50512,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,1,CHEMBL625427,Cavia porcellus,,A,10141.0,In vivo,,Intermediate,,BAO_0000218
12643,,,,1,N,50512,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,1,CHEMBL625428,Cavia porcellus,,A,10141.0,In vivo,,Intermediate,,BAO_0000218
12644,,,,1,U,22224,,Plasma clearance was determined,0,CHEMBL625429,,,A,,In vivo,,Autocuration,,BAO_0000218
12645,,,,1,N,50588,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,1,CHEMBL625430,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12646,,,,1,N,50597,,Plasma clearance rate was determined for the compound in rats,1,CHEMBL625431,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12647,,,,1,U,22224,,Plasma clearance rate was determined for the compound in squirrel monkeys,0,CHEMBL627307,Saimiri,,A,9520.0,In vivo,,Autocuration,,BAO_0000218
12648,,,,1,U,22224,,Slow clearance (CL) was determined,0,CHEMBL627308,,,A,,In vivo,,Autocuration,,BAO_0000218
12649,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,0,CHEMBL627309,,,A,,,,Autocuration,,BAO_0000218
12650,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,0,CHEMBL627310,,,A,,,,Autocuration,,BAO_0000218
12651,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,0,CHEMBL627311,,,A,,,,Autocuration,,BAO_0000218
12652,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,0,CHEMBL627312,,,A,,,,Autocuration,,BAO_0000218
12653,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,0,CHEMBL627313,,,A,,,,Autocuration,,BAO_0000218
12654,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,0,CHEMBL627314,,,A,,,,Autocuration,,BAO_0000218
12655,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,0,CHEMBL627315,,,A,,,,Autocuration,,BAO_0000218
12656,,,,1,U,22224,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,0,CHEMBL627316,,,A,,,,Autocuration,,BAO_0000218
12657,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,0,CHEMBL627317,,,A,,,,Autocuration,,BAO_0000218
12658,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,0,CHEMBL627318,,,A,,,,Autocuration,,BAO_0000218
12659,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,0,CHEMBL627999,,,A,,,,Autocuration,,BAO_0000218
12660,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,0,CHEMBL628000,,,A,,,,Autocuration,,BAO_0000218
12661,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,0,CHEMBL628001,,,A,,,,Autocuration,,BAO_0000218
12662,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,0,CHEMBL628002,,,A,,,,Autocuration,,BAO_0000218
12663,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,0,CHEMBL625610,,,A,,,,Autocuration,,BAO_0000218
12664,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,0,CHEMBL625611,,,A,,,,Autocuration,,BAO_0000218
12665,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,0,CHEMBL625612,,,A,,,,Autocuration,,BAO_0000218
12666,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,0,CHEMBL625613,,,A,,,,Autocuration,,BAO_0000218
12667,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,0,CHEMBL875479,,,A,,,,Autocuration,,BAO_0000218
12668,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,0,CHEMBL625614,,,A,,,,Autocuration,,BAO_0000218
12669,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,0,CHEMBL625615,,,A,,,,Autocuration,,BAO_0000218
12670,,,,1,U,22224,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,0,CHEMBL626302,,,A,,,,Autocuration,,BAO_0000218
12671,,Blood,,1,N,50597,178.0,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL626303,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12672,,Blood,,1,N,50597,178.0,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,CHEMBL627420,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12673,,,,1,N,50597,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,1,CHEMBL627421,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12674,,,,1,N,50597,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,1,CHEMBL625695,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12675,,,,1,N,50597,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,1,CHEMBL625696,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12676,,Brain,,1,N,50594,955.0,Distribution of compound in mice brain was measured after 1 hr,1,CHEMBL875606,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12677,,Brain,,1,N,50594,955.0,Distribution of compound in mice brain was measured after 24 hr r,1,CHEMBL625697,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12678,,Brain,,1,N,50594,955.0,Distribution of compound in mice brain was measured after 2 hr,1,CHEMBL625698,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12679,,Brain,,1,N,50594,955.0,Distribution of compound in mice brain was measured after 3 hr,1,CHEMBL625699,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12680,,Brain,,1,N,50594,955.0,Distribution of compound in mice brain was measured after 6 hr,1,CHEMBL625700,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12681,,,,1,N,50594,,Distribution of compound in mice liver was measured after 1 hr,1,CHEMBL625701,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12682,,,,1,N,50594,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,1,CHEMBL625702,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12683,,,,1,N,50594,,Distribution of compound in mice liver was measured after 2 hr,1,CHEMBL625703,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12684,,,,1,N,50594,,Distribution of compound in mice liver was measured after 3 hr,1,CHEMBL625704,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12685,,,,1,N,50594,,Distribution of compound in mice liver was measured after 6 hr,1,CHEMBL625705,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12686,,Adrenal medulla,,1,N,50588,1236.0,Distribution in dog adrenal medulla 30 min after administration.,1,CHEMBL625706,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12687,,Adrenal medulla,,1,N,50588,1236.0,Distribution in dog adrenal medulla 72 hours after administration.,1,CHEMBL625707,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12688,,,,1,N,50588,,Distribution in female dog Ovary 24 hours after administration.,1,CHEMBL625708,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12689,,,,1,N,50588,,Distribution in female dog Ovary 72 hours after administration.,1,CHEMBL625709,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12690,,,,1,N,50588,,Distribution in female dog adipose 24 hours after administration.,1,CHEMBL624180,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12691,,,,1,N,50588,,Distribution in female dog adipose 72 hours after administration.,1,CHEMBL624181,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12692,,Adrenal cortex,,1,N,50588,1235.0,Distribution in female dog adrenal cortex 72 hours after administration.,1,CHEMBL624182,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12693,,Adrenal cortex,,1,N,50588,1235.0,Distribution in female dog adrenal cortex 72 hours after administration.,1,CHEMBL624183,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12694,,Liver,,1,N,50597,2107.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,CHEMBL624184,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12695,,Liver,,1,N,50597,2107.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,CHEMBL877489,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12696,,Liver,,1,N,50597,2107.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,CHEMBL624185,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12697,,Liver,,1,N,50597,2107.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,CHEMBL624186,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12698,,Liver,,1,N,50597,2107.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,CHEMBL624187,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12699,,Liver,,1,N,50597,2107.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,CHEMBL624188,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12700,,Lung,,1,N,50597,2048.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,CHEMBL624189,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12701,,Lung,,1,N,50597,2048.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,CHEMBL624190,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12702,,Lung,,1,N,50597,2048.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,CHEMBL624191,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12703,,Lung,,1,N,50597,2048.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,CHEMBL624192,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12704,,Lung,,1,N,50597,2048.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,CHEMBL624193,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12705,,Lung,,1,N,50597,2048.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,CHEMBL624194,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12706,,Lung,,1,N,50597,2048.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,CHEMBL624891,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12707,,Lung,,1,N,50597,2048.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,CHEMBL624892,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12708,,Lung,,1,N,50597,2048.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,CHEMBL624893,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12709,,Lung,,1,N,50597,2048.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,CHEMBL627632,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12710,,,,1,N,50597,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,CHEMBL627633,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12711,,,,1,N,50597,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,CHEMBL627634,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12712,,,,1,N,50597,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,CHEMBL627635,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12713,,,,1,N,50597,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,CHEMBL627636,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12714,,,,1,N,50597,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,CHEMBL626816,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12715,,,,1,N,50597,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,CHEMBL626817,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12716,,,,1,N,50597,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,CHEMBL626818,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12717,,,,1,N,50597,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,CHEMBL626819,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12718,,,,1,N,50597,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,CHEMBL626820,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12719,,,,1,N,50597,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,CHEMBL626821,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12720,,Thyroid gland,,1,N,50597,2046.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,CHEMBL626822,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12721,,Thyroid gland,,1,N,50597,2046.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,CHEMBL626823,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12722,,Thyroid gland,,1,N,50597,2046.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,CHEMBL626824,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12723,,Thyroid gland,,1,N,50597,2046.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,CHEMBL626825,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12724,,Thyroid gland,,1,N,50597,2046.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,CHEMBL626826,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12725,,Thyroid gland,,1,N,50597,2046.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,CHEMBL626827,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12726,,Thyroid gland,,1,N,50597,2046.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,CHEMBL626828,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12727,,Thyroid gland,,1,N,50597,2046.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,CHEMBL626829,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12728,,Thyroid gland,,1,N,50597,2046.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,CHEMBL626830,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12729,,,,1,N,50597,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,CHEMBL627150,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12730,,,,1,N,50597,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,CHEMBL627151,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12731,,,,1,N,50597,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,CHEMBL627152,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12732,,,,1,N,50597,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,CHEMBL627153,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12733,,,,1,U,22224,,Rate of acetate production by the compound was determined,0,CHEMBL627154,,,A,,,,Autocuration,,BAO_0000019
12734,,,,1,U,22224,,Rate of acetate production by the compound was determined; Not determined,0,CHEMBL627155,,,A,,,,Autocuration,,BAO_0000019
12735,,,,1,U,22224,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,0,CHEMBL627156,,,A,,,,Autocuration,,BAO_0000019
12736,,,,1,U,22224,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,0,CHEMBL627157,,,A,,,,Autocuration,,BAO_0000019
12737,,,,1,N,50592,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,1,CHEMBL627158,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12738,,Plasma,,1,N,50592,1969.0,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,1,CHEMBL627159,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12739,,,,1,N,50594,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,1,CHEMBL627160,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12740,,,,1,N,50597,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,1,CHEMBL628540,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12741,,Plasma,,1,N,50597,1969.0,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,1,CHEMBL628541,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12742,,Plasma,,1,N,50597,1969.0,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,1,CHEMBL628542,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12743,,,,1,U,22229,,Solubility after at a pH 1.2,0,CHEMBL628543,,,P,,,,Autocuration,,BAO_0000100
12744,,,,1,U,22229,,Solubility after at pH 1.2,0,CHEMBL628544,,,P,,,,Autocuration,,BAO_0000100
12745,,,,1,U,22229,,Solubility after injection of water,0,CHEMBL628545,,,P,,,,Autocuration,,BAO_0000100
12746,,,,1,U,22224,,Statistical significance of IC 50 values; Expressed as R value,0,CHEMBL628546,,,A,,,,Autocuration,,BAO_0000019
12747,,,,1,U,22224,,Systemic availability with respect to methyldopa was determined,0,CHEMBL874455,,,A,,,,Autocuration,,BAO_0000019
12748,,,,1,N,50597,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,1,CHEMBL628547,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12749,,Plasma,,1,N,50597,1969.0,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,1,CHEMBL628548,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12750,,Feces,,1,N,50592,1988.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",1,CHEMBL628549,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12751,,Feces,,1,N,50592,1988.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",1,CHEMBL628550,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12752,,Feces,,1,N,50592,1988.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",1,CHEMBL628551,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12753,,Urine,,1,N,50592,1088.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",1,CHEMBL628552,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12754,,Urine,,1,N,50592,1088.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",1,CHEMBL628553,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12755,,Urine,,1,N,50592,1088.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",1,CHEMBL628554,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12756,,Urine,,1,N,50592,1088.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",1,CHEMBL628555,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12757,,Urine,,1,N,50592,1088.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",1,CHEMBL628556,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12758,,Kidney,,1,N,50592,2113.0,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",1,CHEMBL628557,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12759,,Feces,,1,N,50592,1988.0,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",1,CHEMBL628558,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12760,,Feces,,1,N,50592,1988.0,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",1,CHEMBL628559,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12761,,Feces,,1,N,50592,1988.0,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",1,CHEMBL628560,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12762,,Urine,,1,N,50592,1088.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",1,CHEMBL874456,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12763,,Feces,,1,N,50592,1988.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",1,CHEMBL628561,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12764,,Feces,,1,N,50592,1988.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",1,CHEMBL628562,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12765,,Urine,,1,N,50592,1088.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",1,CHEMBL628563,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12766,,Urine,,1,N,50592,1088.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",1,CHEMBL628564,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12767,,Urine,,1,N,50592,1088.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",1,CHEMBL628565,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12768,,Urine,,1,N,50592,1088.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",1,CHEMBL631248,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12769,,Urine,,1,N,50592,1088.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",1,CHEMBL631249,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12770,,Kidney,,1,N,50592,2113.0,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",1,CHEMBL627214,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12771,,Feces,,1,N,50592,1988.0,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",1,CHEMBL874591,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12772,,Feces,,1,N,50592,1988.0,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",1,CHEMBL627215,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12773,,Feces,,1,N,50592,1988.0,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,1,CHEMBL625471,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12774,,,,1,N,50592,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,1,CHEMBL625472,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12775,,,,1,N,50592,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,1,CHEMBL625473,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12776,,,,1,N,50588,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,1,CHEMBL625474,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12777,,,,1,N,50588,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,1,CHEMBL625475,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12778,,,,1,N,50597,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,1,CHEMBL625476,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12779,,,,1,N,50597,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,1,CHEMBL625477,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12780,,,,1,N,50597,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,1,CHEMBL625478,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12781,,esophageal tunica muscularis mucosae,,1,N,50597,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,1,CHEMBL625479,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
12782,,esophageal tunica muscularis mucosae,,1,N,50597,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,1,CHEMBL625480,Rattus norvegicus,,A,10116.0,In vitro,,Intermediate,,BAO_0000218
12783,,Plasma,,1,N,50597,1969.0,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,1,CHEMBL625481,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12784,,,,1,N,50597,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,1,CHEMBL625482,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12785,,,,1,N,50597,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,1,CHEMBL625483,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12786,,,,1,N,50597,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,1,CHEMBL625484,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12787,,,,1,N,50597,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,1,CHEMBL625485,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12788,,Plasma,,1,N,50588,1969.0,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,1,CHEMBL625486,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12789,,Plasma,,1,N,50597,1969.0,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,1,CHEMBL625487,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12790,,Plasma,,1,N,50597,1969.0,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,1,CHEMBL625488,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12791,,Plasma,,1,N,50597,1969.0,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,1,CHEMBL625489,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12792,,Plasma,,1,N,50597,1969.0,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,1,CHEMBL625490,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12793,,Plasma,,1,N,50588,1969.0,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,1,CHEMBL625491,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12794,,Plasma,,1,N,50597,1969.0,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,1,CHEMBL625492,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12795,,Plasma,,1,N,50587,1969.0,plasma clearance in human,1,CHEMBL625493,Homo sapiens,,A,9606.0,In vivo,,Intermediate,,BAO_0000218
12796,,,,1,N,50597,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,1,CHEMBL625494,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12797,,,,1,N,50597,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,1,CHEMBL625495,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12798,,,,1,N,50597,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,1,CHEMBL625496,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12799,,,,1,U,22229,,1-Octanol/water partition coefficient measured at 7.4,0,CHEMBL625497,,,P,,,,Autocuration,,BAO_0000100
12800,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625498,,,P,,,,Autocuration,,BAO_0000100
12801,,,,1,U,22224,,Partition coefficient (logP),0,CHEMBL625499,,,A,,,,Autocuration,,BAO_0000019
12802,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625500,,,P,,,,Autocuration,,BAO_0000100
12803,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625501,,,P,,,,Autocuration,,BAO_0000100
12804,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625502,,,P,,,,Autocuration,,BAO_0000100
12805,,,,1,U,22229,,Calculated partition coefficient (clogP) (relative to BAY K 8644),0,CHEMBL625503,,,P,,,,Autocuration,,BAO_0000100
12806,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625504,,,P,,,,Autocuration,,BAO_0000100
12807,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625505,,,P,,,,Autocuration,,BAO_0000100
12808,,,,1,U,22229,,Calculated partition coefficient of the compound,0,CHEMBL625506,,,P,,,,Autocuration,,BAO_0000100
12809,,,,1,U,22224,,Partition coefficient (logP),0,CHEMBL625507,,,A,,,,Autocuration,,BAO_0000019
12810,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625508,,,P,,,,Autocuration,,BAO_0000100
12811,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625509,,,P,,,,Autocuration,,BAO_0000100
12812,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625510,,,P,,,,Autocuration,,BAO_0000100
12813,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL883125,,,P,,,,Autocuration,,BAO_0000100
12814,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625511,,,P,,,,Autocuration,,BAO_0000100
12815,,,,1,U,22224,,Partition coefficient of the compound,0,CHEMBL874650,,,A,,,,Autocuration,,BAO_0000019
12816,,,,1,U,22224,,Partition coefficient of the compound,0,CHEMBL625512,,,A,,,,Autocuration,,BAO_0000019
12817,,,,1,U,22224,,Partition coefficient of compound was determined,0,CHEMBL625513,,,A,,,,Autocuration,,BAO_0000019
12818,,,,1,U,22224,,Partition coefficient was determined,0,CHEMBL625514,,,A,,,,Autocuration,,BAO_0000019
12819,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625515,,,P,,,,Autocuration,,BAO_0000100
12820,,,,1,U,22229,,partition coefficient of compound was determined,0,CHEMBL625516,,,P,,,,Autocuration,,BAO_0000100
12821,,,,1,N,50588,,The total body administered intravenously in dog,1,CHEMBL625517,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12822,,,,1,N,50597,,The total body administered intravenously in rats,1,CHEMBL625518,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12823,,,,1,N,50594,,Time taken for the administration to female NIH mice weighing 25-30 g.,1,CHEMBL625519,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
12824,,,,1,U,22224,,Time taken for the administration,0,CHEMBL625520,,,A,,,,Autocuration,,BAO_0000019
12825,,,,1,N,50588,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,1,CHEMBL874651,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
12826,,,,1,U,22224,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,0,CHEMBL625521,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
12827,,,,1,N,50592,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,1,CHEMBL623171,Oryctolagus cuniculus,,A,9986.0,In vivo,,Intermediate,,BAO_0000218
12828,,,,1,N,50597,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,1,CHEMBL623853,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
12829,,,,1,U,22224,,Plasma clearance for the compound was determined.,0,CHEMBL623854,,,A,,,,Autocuration,,BAO_0000019
12830,,,,1,U,22224,,CLog P value of the compound,0,CHEMBL874405,,,P,,,,Autocuration,,BAO_0000100
12831,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL623855,,,P,,,,Autocuration,,BAO_0000100
12832,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL623856,,,P,,,,Autocuration,,BAO_0000100
12833,,,,1,U,22224,,ClogP value of the compound; nd ='no data',0,CHEMBL623857,,,P,,,,Autocuration,,BAO_0000100
12834,,,,1,U,22224,,ClogP value of the compound; nd ='not determined',0,CHEMBL623858,,,P,,,,Autocuration,,BAO_0000100
12835,,,,1,U,22224,,CLog P was determined,0,CHEMBL623859,,,P,,,,Autocuration,,BAO_0000100
12836,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL839829,,,P,,,,Autocuration,,BAO_0000100
12837,,,,1,U,22224,,CLogP was calculated,0,CHEMBL623860,,,A,,,,Autocuration,,BAO_0000019
12838,,,,1,U,22224,,CLogP value was determined,0,CHEMBL623861,,,A,,,,Autocuration,,BAO_0000019
12839,,,,1,U,22224,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,0,CHEMBL623862,,,A,,,,Autocuration,,BAO_0000019
12840,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL874406,,,P,,,,Autocuration,,BAO_0000100
12841,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL623863,,,P,,,,Autocuration,,BAO_0000100
12842,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624021,,,P,,,,Autocuration,,BAO_0000100
12843,,Adrenal medulla,,1,N,50588,1236.0,Distribution in female dog adrenal medulla 24 hours after administration.,1,CHEMBL624022,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12844,,Adrenal medulla,,1,N,50588,1236.0,Distribution in female dog adrenal medulla 72 hours after administration.,1,CHEMBL624023,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12845,,,,1,N,50588,,Distribution in female dog bile 24 hours after administration.,1,CHEMBL624024,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12846,,,,1,N,50588,,Distribution in female dog bile 72 hr after administration.,1,CHEMBL624025,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12847,,,,1,N,50588,,Distribution in female dog blood 24 hours after administration.,1,CHEMBL624026,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12848,,,,1,N,50588,,Distribution in female dog blood 72 hours after administration.,1,CHEMBL624027,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12849,,,,1,N,50588,,Distribution in female dog heart 24 hours after administration.,1,CHEMBL624028,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12850,,,,1,N,50588,,Distribution in female dog heart 72 hours after administration.,1,CHEMBL624029,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12851,,,,1,N,50588,,Distribution in female dog kidney 24 hours after administration.,1,CHEMBL624030,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12852,,,,1,N,50588,,Distribution in female dog kidney 72 hours after administration.,1,CHEMBL624031,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12853,,Intestine,,1,N,50588,160.0,Distribution in female dog large intestine 24 hours after administration.,1,CHEMBL624032,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12854,,Intestine,,1,N,50588,160.0,Distribution in female dog large intestine 72 hours after administration.,1,CHEMBL874407,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12855,,,,1,N,50588,,Distribution in female dog liver 24 hours after administration.,1,CHEMBL624033,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12856,,,,1,N,50588,,Distribution in female dog liver 72 hours after administration.,1,CHEMBL624034,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12857,,,,1,N,50588,,Distribution in female dog lung 24 hours after administration.,1,CHEMBL624035,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12858,,,,1,N,50588,,Distribution in female dog lung 72 hours after administration.,1,CHEMBL624036,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12859,,Muscle tissue,,1,N,50588,2385.0,Distribution in female dog muscle 24 hours after administration.,1,CHEMBL624037,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12860,,Muscle tissue,,1,N,50588,2385.0,Distribution in female dog muscle 72 hours after administration.,1,CHEMBL624038,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12861,,,,1,N,50588,,Distribution in female dog pancreas 24 hours after administration.,1,CHEMBL624039,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12862,,,,1,N,50588,,Distribution in female dog pancreas 72 hours after administration.,1,CHEMBL624040,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12863,,Intestine,,1,N,50588,160.0,Distribution in female dog small intestine 24 hours after administration.,1,CHEMBL624041,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12864,,Intestine,,1,N,50588,160.0,Distribution in female dog small intestine 72 hours after administration.,1,CHEMBL624042,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12865,,Spleen,,1,N,50588,2106.0,Distribution in female dog spleen 24 hours after administration.,1,CHEMBL624043,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12866,,Spleen,,1,N,50588,2106.0,Distribution in female dog spleen 72 hours after administration.,1,CHEMBL624044,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12867,,Stomach,,1,N,50588,945.0,Distribution in female dog stomach 24 hours after administration.,1,CHEMBL624045,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12868,,Stomach,,1,N,50588,945.0,Distribution in female dog stomach 72 hours after administration.,1,CHEMBL624046,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12869,,Thyroid gland,,1,N,50588,2046.0,Distribution in female dog thyroid 24 hours after administration.,1,CHEMBL624047,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12870,,Thyroid gland,,1,N,50588,2046.0,Distribution in female dog thyroid 72 hours after administration.,1,CHEMBL624048,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12871,,Urine,,1,N,50588,1088.0,Distribution in female dog urine 24 hours after administration.,1,CHEMBL874408,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12872,,Urine,,1,N,50588,1088.0,Distribution in female dog urine 72 hr after administration.,1,CHEMBL624049,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12873,,Plasma,,1,U,22224,1969.0,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,0,CHEMBL624050,,,A,,,,Autocuration,,BAO_0000218
12874,,,,1,U,22224,,Plasma concentration at 7 hr after intravenous dosing,0,CHEMBL624051,,,A,,,,Autocuration,,BAO_0000019
12875,,,,1,N,50597,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,1,CHEMBL623278,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12876,,,,1,N,50597,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,1,CHEMBL623279,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12877,,,,1,N,50597,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,1,CHEMBL623280,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12878,,,,1,N,50597,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,1,CHEMBL623963,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12879,,,,1,N,50597,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,1,CHEMBL623964,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12880,,,,1,N,50597,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,1,CHEMBL623965,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12881,,,,1,N,50597,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,1,CHEMBL623966,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12882,,,,1,N,50597,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,1,CHEMBL874415,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12883,,,,1,N,50597,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,1,CHEMBL623967,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12884,,,,1,N,50597,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,1,CHEMBL623968,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12885,,,,1,N,50597,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,1,CHEMBL623969,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12886,,,,1,N,50597,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,1,CHEMBL628409,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12887,,,,1,N,50597,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,1,CHEMBL628410,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12888,,,,1,N,50597,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,1,CHEMBL628411,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12889,,,,1,N,50597,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,1,CHEMBL628412,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12890,,,,1,U,22224,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,0,CHEMBL628413,,,A,,,,Autocuration,,BAO_0000019
12891,,Plasma,,1,U,22224,1969.0,The concentration in plasmat; Not determined,0,CHEMBL628414,,,A,,,,Autocuration,,BAO_0000019
12892,,,,1,N,50597,,Tissue level at 10 mg/kg/po in wistar rats in blood,1,CHEMBL628415,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12893,,,,1,N,50597,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,1,CHEMBL628416,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12894,,,,1,N,50597,,Tissue level at 10 mg/kg/po in wistar rats in heart,1,CHEMBL628417,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12895,,Liver,,1,N,50597,2107.0,Tissue level at 10 mg/kg/po in wistar rats in liver,1,CHEMBL874908,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12896,,,,1,N,50597,,Tissue level at 10 mg/kg/po in wistar rats in plasma,1,CHEMBL628418,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12897,,Muscle tissue,,1,N,50597,2385.0,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,1,CHEMBL628419,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12898,,,,1,N,50597,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,1,CHEMBL628420,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12899,,,,1,U,22224,,Water solubility at 37 degree C.,0,CHEMBL628421,,,A,,,,Autocuration,,BAO_0000019
12900,,,,1,U,22229,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,0,CHEMBL626726,,,P,,,,Autocuration,,BAO_0000100
12901,,,,1,U,22229,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,0,CHEMBL626727,,,P,,,,Autocuration,,BAO_0000100
12902,,Blood,,1,N,50597,178.0,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,CHEMBL626728,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12903,,Blood,,1,N,50597,178.0,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,CHEMBL626729,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12904,,Blood,,1,N,50597,178.0,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,CHEMBL626730,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12905,,Blood,,1,N,50597,178.0,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,CHEMBL626731,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12906,,Blood,,1,N,50597,178.0,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,CHEMBL626732,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12907,,Heart,,1,N,50597,948.0,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,CHEMBL626733,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12908,,Heart,,1,N,50597,948.0,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,CHEMBL626734,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12909,,Heart,,1,N,50597,948.0,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,CHEMBL626735,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12910,,Heart,,1,N,50597,948.0,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,CHEMBL874909,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12911,,Heart,,1,N,50597,948.0,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,CHEMBL626736,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12912,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,CHEMBL626737,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12913,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,CHEMBL630999,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12914,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,CHEMBL631000,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12915,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,CHEMBL631001,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12916,,Kidney,,1,N,50597,2113.0,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,CHEMBL631002,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12917,,Liver,,1,N,50597,2107.0,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,CHEMBL631003,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12918,,Liver,,1,N,50597,2107.0,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,CHEMBL631004,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12919,,Liver,,1,N,50597,2107.0,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,CHEMBL631005,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12920,,Liver,,1,N,50597,2107.0,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,CHEMBL631006,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12921,,Liver,,1,N,50597,2107.0,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,CHEMBL631007,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12922,,Lung,,1,N,50597,2048.0,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,CHEMBL631008,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12923,,Lung,,1,N,50597,2048.0,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,CHEMBL631009,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12924,,Lung,,1,N,50597,2048.0,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,CHEMBL631010,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12925,,Lung,,1,N,50597,2048.0,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,CHEMBL631011,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12926,,Lung,,1,N,50597,2048.0,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,CHEMBL631012,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12927,,Thyroid gland,,1,N,50597,2046.0,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,CHEMBL630271,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12928,,Thyroid gland,,1,N,50597,2046.0,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,CHEMBL630272,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12929,,Thyroid gland,,1,N,50597,2046.0,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,CHEMBL630273,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12930,,Thyroid gland,,1,N,50597,2046.0,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,CHEMBL630274,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12931,,Thyroid gland,,1,N,50597,2046.0,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,CHEMBL630275,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12932,,,,1,N,50597,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,1,CHEMBL875782,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12933,,,,1,N,50597,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,1,CHEMBL630276,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12934,,,,1,N,50597,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,1,CHEMBL630277,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12935,,,,1,N,50597,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,1,CHEMBL630278,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12936,,,,1,N,50597,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,1,CHEMBL630279,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12937,,,,1,U,22224,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,0,CHEMBL630280,,,A,,,,Autocuration,,BAO_0000019
12938,,,,1,U,22224,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,0,CHEMBL630281,,,A,,,,Autocuration,,BAO_0000019
12939,,,,1,N,50592,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,1,CHEMBL630282,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12940,,,,1,N,50592,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,1,CHEMBL630283,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12941,,,,1,U,22224,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),0,CHEMBL630284,,,A,,,,Autocuration,,BAO_0000019
12942,,,,1,U,22224,,Alkylating activity was determined,0,CHEMBL630285,,,A,,,,Autocuration,,BAO_0000019
12943,,,,1,U,22224,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),0,CHEMBL630286,,Microsomes,A,,,,Autocuration,,BAO_0000251
12944,,,,1,N,50592,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",1,CHEMBL630069,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12945,,,,1,N,50592,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",1,CHEMBL630070,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12946,,,,1,N,50592,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",1,CHEMBL630071,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12947,,,,1,N,50592,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",1,CHEMBL630072,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12948,,,,1,N,50592,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",1,CHEMBL875110,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12949,,,,1,N,50597,,Compound was tested for antidiuretic activity in rats,1,CHEMBL630073,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12950,,,,1,U,22224,,Compound was tested for inactivation kinetic values,0,CHEMBL630074,,,A,,,,Autocuration,,BAO_0000019
12951,,,,1,U,22224,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,0,CHEMBL630075,,,A,,In vivo,,Autocuration,,BAO_0000218
12952,,,,1,U,22224,,Dissociation rate calculated from the first-order equation using the t1/2 value,0,CHEMBL630076,,,A,,,,Autocuration,,BAO_0000019
12953,,,,1,U,22229,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,0,CHEMBL630077,,,P,,,,Autocuration,,BAO_0000100
12954,,,,1,U,22229,,Aqueous solubility was measured,0,CHEMBL630078,,,P,,,,Autocuration,,BAO_0000100
12955,,,,1,U,22229,,Aqueous solubility was measured at a pH 4,0,CHEMBL630079,,,P,,,,Autocuration,,BAO_0000100
12956,,,,1,U,22229,,Aqueous solubility (pH 7),0,CHEMBL630080,,,P,,,,Autocuration,,BAO_0000100
12957,,,,1,U,22229,,Aqueous solubility was measured at a pH 9,0,CHEMBL630081,,,P,,,,Autocuration,,BAO_0000100
12958,,,,1,U,22224,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",0,CHEMBL630082,,,A,,,,Autocuration,,BAO_0000019
12959,,,,1,U,22224,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",0,CHEMBL630083,,,A,,,,Autocuration,,BAO_0000019
12960,,,,1,U,22224,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",0,CHEMBL630084,,,A,,,,Autocuration,,BAO_0000019
12961,,,,1,U,22229,,Aqueous solubility of the compound,0,CHEMBL629198,,,P,,,,Autocuration,,BAO_0000100
12962,,,,1,U,22229,,Aqueous solubility at 37 degree Celsius at pH 7.38,0,CHEMBL629199,,,P,,,,Autocuration,,BAO_0000100
12963,,,,1,U,22229,,Aqueous solubility in pH 7.4 phosphate buffer,0,CHEMBL629200,,,P,,,,Autocuration,,BAO_0000100
12964,,,,1,N,50588,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,1,CHEMBL629201,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12965,,,,1,N,50588,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,1,CHEMBL629202,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
12966,,,,1,N,50587,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,1,CHEMBL875111,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12967,,,,1,N,50587,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,1,CHEMBL629203,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12968,,,,1,N,50587,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,1,CHEMBL629204,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12969,,,,1,N,50587,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,1,CHEMBL629205,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12970,,,,1,N,50587,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,1,CHEMBL629206,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
12971,,,,1,U,22224,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,0,CHEMBL631185,,,A,,,,Autocuration,,BAO_0000019
12972,,,,1,N,50597,,Compound was evaluated for the average bile flow rat in rats,1,CHEMBL631186,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
12973,,,,1,N,50592,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",1,CHEMBL631187,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12974,,,,1,N,50592,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",1,CHEMBL631188,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
12975,,,,1,U,22224,,Average half life period was determined,0,CHEMBL876419,,,A,,,,Autocuration,,BAO_0000019
12976,,,,1,U,22224,,Average half life period was determined,0,CHEMBL631189,,,A,,,,Autocuration,,BAO_0000019
12977,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,1,CHEMBL631190,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
12978,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,1,CHEMBL631191,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
12979,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,1,CHEMBL631192,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
12980,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,1,CHEMBL632400,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
12981,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,1,CHEMBL630564,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
12982,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,1,CHEMBL630565,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
12983,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,1,CHEMBL630566,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
12984,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,1,CHEMBL631229,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
12985,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,1,CHEMBL631230,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
12986,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL876428,,,P,,,,Autocuration,,BAO_0000100
12987,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL631231,,,P,,,,Autocuration,,BAO_0000100
12988,,,,1,U,22229,,Calculated partition coefficient (clogP) (MacLogP),0,CHEMBL631232,,,P,,,,Autocuration,,BAO_0000100
12989,,,,1,U,22224,,Hydrophilicity was determined,0,CHEMBL631233,,,A,,,,Autocuration,,BAO_0000019
12990,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL631234,,,P,,,,Autocuration,,BAO_0000100
12991,,,,1,U,22224,,Increased absorption was determined,0,CHEMBL883126,,,A,,,,Autocuration,,BAO_0000019
12992,,,,1,U,22224,,Lipophilicity value was evaluated,0,CHEMBL631235,,,P,,,,Autocuration,,BAO_0000100
12993,,,,1,U,22224,,Log P value of the compound.,0,CHEMBL631236,,,P,,,,Autocuration,,BAO_0000100
12994,,,,1,U,22224,,Partition coefficient of compound was determined,0,CHEMBL631237,,,A,,,,Autocuration,,BAO_0000019
12995,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL631238,,,P,,,,Autocuration,,BAO_0000100
12996,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL876429,,,P,,,,Autocuration,,BAO_0000100
12997,,,,1,U,22224,,Partition coefficient was measured by medchem software; Not calculated,0,CHEMBL631414,,,A,,,,Autocuration,,BAO_0000019
12998,,,,1,U,22224,,Partition coefficient was measured by octanol-water using standard shake-flask method,0,CHEMBL631415,,,P,,,,Autocuration,,BAO_0000100
12999,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL631416,,,P,,,,Autocuration,,BAO_0000100
13000,,,,1,U,22224,,Partition coefficient (logP),0,CHEMBL631417,,,A,,,,Autocuration,,BAO_0000019
13001,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL631418,,,P,,,,Autocuration,,BAO_0000100
13002,,,,1,U,22229,,The Octanol/Water partition coefficient CLogP,0,CHEMBL631419,,,P,,,,Autocuration,,BAO_0000100
13003,,,,1,U,22224,,The pharmacokinetic parameter C Log p was reported,0,CHEMBL631420,,,A,,,,Autocuration,,BAO_0000019
13004,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL631421,,,P,,,,Autocuration,,BAO_0000100
13005,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL631422,,,P,,,,Autocuration,,BAO_0000100
13006,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL631423,,,P,,,,Autocuration,,BAO_0000100
13007,,Plasma,,1,N,50597,1969.0,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,CHEMBL876430,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13008,,Plasma,,1,N,50597,1969.0,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,1,CHEMBL631424,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13009,,Plasma,,1,N,50588,1969.0,Compound was administered intravenously in dog to evaluate plasma clearance values,1,CHEMBL631425,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13010,,Plasma,,1,U,22224,1969.0,Compound was administered intravenously in monkey to evaluate plasma clearance values,0,CHEMBL631426,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
13011,,Plasma,,1,N,50594,1969.0,Compound was administered intravenously in mouse to evaluate plasma clearance values,1,CHEMBL631427,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13012,,Plasma,,1,N,50588,1969.0,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,1,CHEMBL631428,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13013,,Liver,,1,N,50797,2107.0,Intrinsic clearance in Rhesus liver microsome,1,CHEMBL631429,Macaca mulatta,Microsomes,A,9544.0,In vitro,,Intermediate,,BAO_0000218
13014,,Liver,,1,N,50588,2107.0,Intrinsic clearance in dog liver microsome,1,CHEMBL631430,Canis lupus familiaris,Microsomes,A,9615.0,In vitro,,Intermediate,,BAO_0000218
13015,,Liver,,1,N,50597,2107.0,Intrinsic clearance in rat liver microsome,1,CHEMBL631431,Rattus norvegicus,Microsomes,A,10116.0,In vitro,,Intermediate,,BAO_0000218
13016,,Plasma,,1,N,50797,1969.0,Low plasma clearance was calculated in rhesus monkey,1,CHEMBL631432,Macaca mulatta,,A,9544.0,In vivo,,Intermediate,,BAO_0000218
13017,,,,1,N,50588,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,CHEMBL631433,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13018,,,,1,U,22224,,Plasma clearance after intravenous dose of 0.3 mg/kg,0,CHEMBL631434,,,A,,In vivo,,Autocuration,,BAO_0000218
13019,,,,1,U,22224,,Plasma clearance after intravenous dose of 1 mg/kg,0,CHEMBL631435,,,A,,In vivo,,Autocuration,,BAO_0000218
13020,,,,1,U,22224,,Plasma clearance after intravenous dose of 3 mg/kg,0,CHEMBL631436,,,A,,In vivo,,Autocuration,,BAO_0000218
13021,,,,1,U,22224,,Plasma clearance after intravenous dose of 3.87 mg/kg,0,CHEMBL631437,,,A,,In vivo,,Autocuration,,BAO_0000218
13022,,,,1,N,50597,,Plasma clearance after peroral administration at 10 mpk in Rat,1,CHEMBL631438,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13023,,,,1,N,50797,,Plasma clearance after peroral administration at 10 mpk in Rhesus,1,CHEMBL876431,Macaca mulatta,,A,9544.0,In vivo,,Intermediate,,BAO_0000218
13024,,,,1,N,50588,,Plasma clearance after peroral administration at 10 mpk in dog,1,CHEMBL631439,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13025,,,,1,N,50597,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,1,CHEMBL631440,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13026,,,,1,U,22224,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),0,CHEMBL631441,,,A,,,,Autocuration,,BAO_0000019
13027,,,,1,U,22224,,Critical Micellar concentration was determined,0,CHEMBL631442,,,A,,,,Autocuration,,BAO_0000019
13028,,,,1,U,22224,,Critical Micellar concentration of the compound. was determined,0,CHEMBL626525,,,A,,,,Autocuration,,BAO_0000019
13029,,,,1,U,22224,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,0,CHEMBL627168,,,A,,,,Autocuration,,BAO_0000019
13030,,,,1,U,22224,,Critical micellar concentration was measured in water by the dye solubilization method,0,CHEMBL875618,,,A,,,,Autocuration,,BAO_0000019
13031,,,,1,U,22224,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,0,CHEMBL626612,,,B,,,,Autocuration,,BAO_0000019
13032,,,,1,U,22224,,CMR value (relative to BAY K 8644),0,CHEMBL626613,,,A,,,,Autocuration,,BAO_0000019
13033,,,,1,U,22224,,Carbamoylating activity was determined,0,CHEMBL626614,,,A,,,,Autocuration,,BAO_0000019
13034,,,,1,U,22224,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,0,CHEMBL626615,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13035,,,,1,U,22224,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,0,CHEMBL626616,,,A,,,,Autocuration,,BAO_0000019
13036,,,,1,U,22224,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,0,CHEMBL626617,,,A,,,,Autocuration,,BAO_0000019
13037,,Plasma,,1,N,50588,1969.0,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,1,CHEMBL626618,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13038,,Plasma,,1,N,50597,1969.0,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,1,CHEMBL626619,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13039,,,,1,N,50588,,"Clearance rate at 0.46 mg/kg, iv, in dogs",1,CHEMBL626620,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13040,,,,1,N,50597,,"Clearance rate at 5.5 mg/kg, iv, in rat",1,CHEMBL626621,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13041,,,,1,N,100710,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,1,CHEMBL626622,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
13042,,,,1,N,100710,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,1,CHEMBL626623,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
13043,,,,1,N,50588,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,1,CHEMBL626624,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13044,,,,1,N,50597,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,1,CHEMBL626625,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13045,,Liver,,1,N,50597,2107.0,Clearance rate constant using isolated perfused rat liver (IPRL) assay,1,CHEMBL626626,Rattus norvegicus,,A,10116.0,Ex vivo,,Intermediate,,BAO_0000218
13046,,,,1,U,22224,,Tested for the total clearance of the compound,0,CHEMBL626627,,,A,,In vivo,,Autocuration,,BAO_0000218
13047,,,,1,N,50588,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,1,CHEMBL626628,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13048,,,,1,U,22224,,Total body clearance was determined,0,CHEMBL626629,,,A,,In vivo,,Autocuration,,BAO_0000218
13049,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,CHEMBL626630,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13050,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,CHEMBL626631,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13051,,,,1,U,22229,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,0,CHEMBL626632,,,P,,,,Autocuration,,BAO_0000100
13052,,,,1,U,22229,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,0,CHEMBL626633,,,P,,,,Autocuration,,BAO_0000100
13053,,,,1,U,22229,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,0,CHEMBL626634,,,P,,,,Autocuration,,BAO_0000100
13054,,,,1,U,22229,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,0,CHEMBL626635,,,P,,,,Autocuration,,BAO_0000100
13055,,,,1,U,22229,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,0,CHEMBL626636,,,P,,,,Autocuration,,BAO_0000100
13056,,,,1,U,22229,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,0,CHEMBL626637,,,P,,,,Autocuration,,BAO_0000100
13057,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),1,CHEMBL626638,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13058,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,1,CHEMBL626639,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13059,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,1,CHEMBL626640,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13060,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,1,CHEMBL626641,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13061,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,1,CHEMBL627272,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13062,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,1,CHEMBL627273,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13063,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),1,CHEMBL627441,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13064,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),1,CHEMBL628355,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13065,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),1,CHEMBL628356,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13066,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),1,CHEMBL628357,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13067,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),1,CHEMBL628358,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13068,,,,1,N,50339,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),1,CHEMBL622307,Pneumocystis carinii,,A,4754.0,,,Intermediate,,BAO_0000218
13069,,,,1,U,22224,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,0,CHEMBL622527,,,A,,,,Autocuration,,BAO_0000019
13070,,,,1,U,22224,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,0,CHEMBL622528,,,A,,,,Autocuration,,BAO_0000019
13071,,,,1,U,22224,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,0,CHEMBL622529,,,A,,,,Autocuration,,BAO_0000019
13072,,,,1,U,22224,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,0,CHEMBL622992,,,A,,,,Autocuration,,BAO_0000019
13073,,,,1,U,22224,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,0,CHEMBL622993,,,A,,,,Autocuration,,BAO_0000019
13074,,,,1,U,22224,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,0,CHEMBL622994,,,A,,,,Autocuration,,BAO_0000019
13075,,,,1,N,50597,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",1,CHEMBL622995,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13076,,,,1,N,50597,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",1,CHEMBL622996,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13077,,,,1,N,50597,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",1,CHEMBL622997,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13078,,,,1,N,50597,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",1,CHEMBL622998,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13079,,,,1,U,22224,,Cp max following ip administration at 1 mg/kg,0,CHEMBL622999,,,A,,,,Autocuration,,BAO_0000218
13080,,Plasma,,1,U,22224,1969.0,Maximum concentration in plasma was reported at 0.5 hour,0,CHEMBL623000,,,A,,In vivo,,Autocuration,,BAO_0000218
13081,,Plasma,,1,U,22224,1969.0,Maximum concentration in plasma was reported at 2 hour,0,CHEMBL623001,,,A,,In vivo,,Autocuration,,BAO_0000218
13082,,,,1,N,50594,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,1,CHEMBL623002,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13083,,,,1,U,22229,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),0,CHEMBL623003,,,P,,,,Autocuration,,BAO_0000100
13084,,,,1,U,22224,,Steady state concentration was evaluated,0,CHEMBL623004,,,A,,,,Autocuration,,BAO_0000019
13085,,,,1,U,22224,,Partition coefficient (logP),0,CHEMBL623005,,,A,,,,Autocuration,,BAO_0000019
13086,,,,1,U,22224,,Partition coefficient (logD7.4),0,CHEMBL623006,,,A,,,,Autocuration,,BAO_0000019
13087,,Liver,,1,N,50597,2107.0,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,1,CHEMBL623007,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13088,,Bone,,1,N,50597,10000001.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,1,CHEMBL623008,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13089,,Cerebellum,,1,N,50597,2037.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,1,CHEMBL876654,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13090,,,,1,N,50597,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,1,CHEMBL623009,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13091,,,,1,N,50597,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,1,CHEMBL623010,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13092,,Heart,,1,N,50597,948.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,1,CHEMBL623011,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13093,,Intestine,,1,N,50597,160.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,1,CHEMBL623012,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13094,,,,1,U,22224,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,0,CHEMBL623013,,,A,,,,Autocuration,,BAO_0000019
13095,,,,1,U,22224,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,0,CHEMBL623014,,,A,,,,Autocuration,,BAO_0000019
13096,,Urine,,1,U,22224,1088.0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,0,CHEMBL623015,,,A,,,,Autocuration,,BAO_0000019
13097,,Urine,,1,U,22224,1088.0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,0,CHEMBL623016,,,A,,,,Autocuration,,BAO_0000019
13098,,Urine,,1,U,22224,1088.0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,0,CHEMBL624858,,,A,,,,Autocuration,,BAO_0000019
13099,,,,1,N,50597,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,1,CHEMBL624859,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13100,,,,1,N,50597,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,CHEMBL624860,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13101,,,,1,N,50597,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,CHEMBL624861,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13102,,,,1,N,50597,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,1,CHEMBL624862,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13103,,,,1,N,50597,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,1,CHEMBL624863,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13104,,,,1,N,50597,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,CHEMBL876655,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13105,,,,1,N,50588,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,1,CHEMBL624864,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13106,,,,1,N,50588,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,1,CHEMBL624865,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13107,,,,1,N,50588,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,CHEMBL624866,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13108,,,,1,N,50588,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,1,CHEMBL624867,Canis lupus familiaris,,F,9615.0,,,Expert,,BAO_0000218
13109,,,,1,N,50588,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,1,CHEMBL624868,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13110,,,,1,N,50588,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,1,CHEMBL628450,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13111,,,,1,N,50588,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,1,CHEMBL628451,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13112,,,,1,N,50588,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,1,CHEMBL628452,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13113,,,,1,N,50588,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,CHEMBL628453,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13114,,,,1,N,50588,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,1,CHEMBL628454,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13115,,,,1,N,50588,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,1,CHEMBL628455,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13116,,,,1,N,50588,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,1,CHEMBL628456,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13117,,,,1,N,50588,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,CHEMBL628457,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13118,,,,1,N,50588,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,1,CHEMBL877505,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13119,,,,1,N,50588,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,1,CHEMBL628458,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13120,,,,1,N,50588,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,1,CHEMBL628459,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13121,,,,1,N,50588,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,1,CHEMBL628460,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13122,,,,1,N,50588,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,1,CHEMBL628461,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13123,,,,1,U,22224,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",0,CHEMBL628462,,,B,,,,Autocuration,,BAO_0000218
13124,,,,1,N,50588,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,CHEMBL628463,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13125,,,,1,N,50597,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",1,CHEMBL625666,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000218
13126,,,,1,U,22224,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,0,CHEMBL625667,,,B,,,,Autocuration,,BAO_0000218
13127,,,,1,N,50597,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,CHEMBL625668,Rattus norvegicus,,A,10116.0,,,Expert,,BAO_0000218
13128,,,,1,N,50597,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,CHEMBL625669,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13129,,,,1,U,22224,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,0,CHEMBL625670,,,A,,,,Autocuration,,BAO_0000019
13130,,,,1,N,50597,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,1,CHEMBL625671,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13131,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,1,CHEMBL625672,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
13132,,,,1,N,50602,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,1,CHEMBL625673,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
13133,,,,1,N,50602,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,1,CHEMBL625674,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
13134,,,,1,N,50602,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,1,CHEMBL625675,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
13135,,,,1,N,50602,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,1,CHEMBL627637,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
13136,,,,1,N,50602,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,1,CHEMBL627638,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
13137,,,,1,N,50602,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,1,CHEMBL627639,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
13138,,,,1,N,50602,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,1,CHEMBL627640,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
13139,,,,1,N,50602,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,1,CHEMBL627641,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
13140,,,,1,N,50602,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,1,CHEMBL627642,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
13141,,,,1,N,50602,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,1,CHEMBL877506,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
13142,,,,1,N,50594,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,1,CHEMBL627275,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13143,,,,1,N,50506,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",1,CHEMBL627643,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
13144,,,,1,N,50506,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",1,CHEMBL631246,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
13145,,,,1,N,50506,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",1,CHEMBL631247,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
13146,,,,1,N,50506,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,1,CHEMBL629532,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
13147,,,,1,N,50506,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,1,CHEMBL629533,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
13148,,,,1,N,50506,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,1,CHEMBL629534,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
13149,,,,1,N,50506,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,1,CHEMBL629535,Mustela putorius furo,,A,9669.0,,,Intermediate,,BAO_0000218
13150,,,,1,U,22224,,Pharmacokinetic parameter :drug bound to plasma was reported,0,CHEMBL625932,,,A,,,,Autocuration,,BAO_0000019
13151,,,,1,U,22224,,compound was evaluated for drug bound in plasma,0,CHEMBL625933,,,A,,,,Autocuration,,BAO_0000019
13152,,,,1,N,50597,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,1,CHEMBL625934,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13153,,,,1,U,22224,,Bioavailability,0,CHEMBL625935,Eutheria,,A,9347.0,,,Autocuration,,BAO_0000218
13154,,,,1,N,50597,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,1,CHEMBL625936,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13155,,,,1,N,50597,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,1,CHEMBL625937,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13156,,,,1,N,50588,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,1,CHEMBL625938,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13157,,Bile,,1,N,50597,1970.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,1,CHEMBL625939,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13158,,Bile,,1,N,50597,1970.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,1,CHEMBL625940,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13159,,Bile,,1,N,50597,1970.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,1,CHEMBL874464,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13160,,Bile,,1,N,50597,1970.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,1,CHEMBL625941,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13161,,Bile,,1,N,50597,1970.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,1,CHEMBL625942,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13162,,Bile,,1,N,50597,1970.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,1,CHEMBL625943,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13163,,Serum,,1,N,50587,1977.0,In vitro protein binding in human serum at 5 ug/ml,1,CHEMBL625944,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
13164,,,,1,U,22224,,Serum protein binding ability was measured,0,CHEMBL625945,,,A,,,,Autocuration,,BAO_0000019
13165,,,,1,U,22224,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),0,CHEMBL625946,,,A,,,,Autocuration,,BAO_0000019
13166,,,,1,U,22224,,Oral bioavailability in dog,0,CHEMBL625947,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
13167,,,,1,N,50597,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,1,CHEMBL625948,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13168,,,,1,U,22224,,Absolute oral bioavailability at an iv dose of 14 mg/kg,0,CHEMBL625949,,,A,,In vivo,,Autocuration,,BAO_0000218
13169,,,,1,U,22224,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,0,CHEMBL625950,,,A,,In vivo,,Autocuration,,BAO_0000218
13170,,,,1,U,22224,,Oral bioavailability (dose 15 mg/kg i.v.),0,CHEMBL625951,Eutheria,,A,9347.0,In vivo,,Autocuration,,BAO_0000218
13171,,,,1,U,22224,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,0,CHEMBL625952,,,A,,In vivo,,Autocuration,,BAO_0000218
13172,,,,1,U,22224,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,0,CHEMBL625953,,,A,,In vivo,,Autocuration,,BAO_0000218
13173,,,,1,U,22224,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,0,CHEMBL625954,,,A,,In vivo,,Autocuration,,BAO_0000218
13174,,,,1,U,22224,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,0,CHEMBL882959,,,A,,In vivo,,Autocuration,,BAO_0000218
13175,,,,1,N,50588,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,1,CHEMBL625955,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13176,,,,1,U,22224,,Bioavailability in ferret,0,CHEMBL625956,Mustela putorius furo,,A,9669.0,In vivo,,Autocuration,,BAO_0000218
13177,,,,1,N,100710,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,1,CHEMBL625957,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
13178,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,CHEMBL625958,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13179,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,CHEMBL625959,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13180,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,CHEMBL626642,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13181,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,CHEMBL631330,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13182,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,CHEMBL631331,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13183,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,CHEMBL631332,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13184,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,CHEMBL631333,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13185,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,CHEMBL632018,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13186,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,CHEMBL632019,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13187,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,CHEMBL632020,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13188,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,CHEMBL632021,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13189,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,CHEMBL632022,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13190,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,CHEMBL632023,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13191,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,CHEMBL632024,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13192,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,CHEMBL874472,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13193,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,CHEMBL632025,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13194,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,CHEMBL632026,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13195,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,CHEMBL632027,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13196,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,CHEMBL632028,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13197,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,CHEMBL626430,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13198,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,CHEMBL626431,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13199,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,CHEMBL626432,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13200,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,CHEMBL626433,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13201,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,CHEMBL626434,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13202,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,CHEMBL627280,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13203,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,CHEMBL627281,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13204,,,,1,N,50597,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,CHEMBL627282,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13205,,,,1,U,22224,,Total body clearance was measured at given dose,0,CHEMBL627283,,,A,,,,Autocuration,,BAO_0000019
13206,,,,1,U,22224,,Total body clearance was measured at given dose.,0,CHEMBL627284,,,A,,,,Autocuration,,BAO_0000218
13207,,,,1,N,50597,,Metabolic clearance from the body in rat,1,CHEMBL627285,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13208,,,,1,U,22224,,Renal clearance from the body,0,CHEMBL627286,,,A,,In vivo,,Autocuration,,BAO_0000218
13209,,,,1,N,50597,,Renal clearance from the body in rat,1,CHEMBL875477,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13210,,,,1,N,50597,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,1,CHEMBL627287,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13211,,,,1,N,50588,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,1,CHEMBL627288,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13212,,,,1,N,50597,,Total clearance from the body in rat,1,CHEMBL627289,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13213,,Plasma,,1,N,50597,1969.0,Clearance into cortex from rat plasma or PBS,1,CHEMBL627290,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13214,,,,1,U,22224,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,0,CHEMBL627291,,,A,,In vivo,,Autocuration,,BAO_0000218
13215,,,,1,U,22224,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,0,CHEMBL627292,,,A,,In vivo,,Autocuration,,BAO_0000218
13216,,,,1,U,22224,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,0,CHEMBL627293,,,A,,In vivo,,Autocuration,,BAO_0000218
13217,,,,1,U,22224,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,0,CHEMBL627294,,,A,,In vivo,,Autocuration,,BAO_0000218
13218,,,,1,U,22224,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,0,CHEMBL875478,,,A,,In vivo,,Autocuration,,BAO_0000218
13219,,,,1,U,22224,,Clearance was determined,0,CHEMBL627295,,,A,,In vivo,,Autocuration,,BAO_0000218
13220,,,,1,N,50594,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,1,CHEMBL627296,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13221,,,,1,N,50592,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,1,CHEMBL626119,Oryctolagus cuniculus,,A,9986.0,In vivo,,Intermediate,,BAO_0000218
13222,,,,1,N,50597,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,1,CHEMBL626120,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13223,,,,1,N,50597,,Clearance in rat after iv dose (100 ug/kg),1,CHEMBL626121,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13224,,,,1,U,22224,,Clearance in guinea pig,0,CHEMBL626122,Cavia porcellus,,A,10141.0,In vivo,,Autocuration,,BAO_0000218
13225,,,,1,N,50597,,Compound was evaluated for clearance in rat,1,CHEMBL626123,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13226,,,,1,N,50588,,Compound was evaluated for the clearance in dog,1,CHEMBL623456,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13227,,,,1,N,50597,,Compound was evaluated for the clearance in rat,1,CHEMBL623457,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13228,,,,1,N,50597,,Compound was tested in vivo for clearance after iv administration in the rat,1,CHEMBL623458,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13229,,,,1,U,22224,,IV clearance determined at an iv dose of 14 mg/kg,0,CHEMBL623459,,,A,,In vivo,,Autocuration,,BAO_0000218
13230,,,,1,U,22224,,IV clearance determined at an iv dose of 15.2 mg/kg,0,CHEMBL875484,,,A,,In vivo,,Autocuration,,BAO_0000218
13231,,,,1,U,22224,,IV clearance determined at an iv dose of 15 mg/kg,0,CHEMBL623460,,,A,,In vivo,,Autocuration,,BAO_0000218
13232,,,,1,U,22224,,IV clearance determined at an peroral dose of 30 mg/kg.,0,CHEMBL623461,,,A,,In vivo,,Autocuration,,BAO_0000218
13233,,,,1,U,22224,,IV clearance determined at an peroral dose of 30.2 mg/kg.,0,CHEMBL623462,,,A,,In vivo,,Autocuration,,BAO_0000218
13234,,,,1,U,22224,,IV clearance determined at an peroral dose of 30.3 mg/kg.,0,CHEMBL627386,,,A,,In vivo,,Autocuration,,BAO_0000218
13235,,Kidney,,1,N,50597,2113.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,1,CHEMBL627387,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13236,,Liver,,1,N,50597,2107.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,1,CHEMBL627388,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13237,,Lung,,1,N,50597,2048.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,1,CHEMBL627389,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13238,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,1,CHEMBL627390,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13239,,Plasma,,1,N,50597,1969.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,1,CHEMBL627391,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13240,,,,1,N,50597,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,1,CHEMBL627392,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13241,,Spleen,,1,N,50597,2106.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,1,CHEMBL627393,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13242,,Trachea,,1,N,50597,3126.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,1,CHEMBL627394,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13243,,Bone,,1,N,50597,10000001.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,1,CHEMBL627395,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13244,,Cerebellum,,1,N,50597,2037.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,1,CHEMBL875485,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13245,,,,1,N,50597,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,1,CHEMBL627396,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13246,,,,1,N,50597,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,1,CHEMBL627397,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13247,,Heart,,1,N,50597,948.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,1,CHEMBL627398,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13248,,Bone,,1,N,50597,10000001.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,1,CHEMBL627399,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13249,,Kidney,,1,N,50597,2113.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,1,CHEMBL627400,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13250,,Liver,,1,N,50597,2107.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,1,CHEMBL627401,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13251,,Lung,,1,N,50597,2048.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,1,CHEMBL627402,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13252,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,1,CHEMBL627403,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13253,,Plasma,,1,N,50597,1969.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,1,CHEMBL627404,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13254,,,,1,N,50597,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,1,CHEMBL623101,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13255,,Spleen,,1,N,50597,2106.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,1,CHEMBL877480,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13256,,Trachea,,1,N,50597,3126.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,1,CHEMBL623102,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13257,,Bone,,1,N,50597,10000001.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,1,CHEMBL623103,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13258,,Cerebellum,,1,N,50597,2037.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,1,CHEMBL623104,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13259,,,,1,N,50597,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,1,CHEMBL623105,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13260,,,,1,N,50597,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,1,CHEMBL623106,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13261,,Heart,,1,N,50597,948.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,1,CHEMBL623107,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13262,,Intestine,,1,N,50597,160.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,1,CHEMBL623108,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13263,,Kidney,,1,N,50597,2113.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,1,CHEMBL623109,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13264,,Liver,,1,N,50597,2107.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,1,CHEMBL623110,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13265,,Lung,,1,N,50597,2048.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,1,CHEMBL623111,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13266,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,1,CHEMBL625060,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13267,,Plasma,,1,N,50597,1969.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,1,CHEMBL625061,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13268,,,,1,N,50597,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,1,CHEMBL625062,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13269,,Spleen,,1,N,50597,2106.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,1,CHEMBL625063,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13270,,Trachea,,1,N,50597,3126.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,1,CHEMBL625064,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13271,,Bone,,1,N,50597,10000001.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,1,CHEMBL625065,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13272,,Cerebellum,,1,N,50597,2037.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,1,CHEMBL625066,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13273,,,,1,N,50597,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,1,CHEMBL625067,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13274,,,,1,N,50597,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,1,CHEMBL625068,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13275,,Heart,,1,N,50597,948.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,1,CHEMBL622159,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13276,,Intestine,,1,N,50597,160.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,1,CHEMBL622160,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13277,,Kidney,,1,N,50597,2113.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,1,CHEMBL622161,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13278,,Lung,,1,N,50597,2048.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,1,CHEMBL622162,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13279,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,1,CHEMBL622163,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13280,,Plasma,,1,N,50597,1969.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,1,CHEMBL622313,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13281,,,,1,N,50597,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,1,CHEMBL622314,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13282,,Spleen,,1,N,50597,2106.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,1,CHEMBL622315,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13283,,Trachea,,1,N,50597,3126.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,1,CHEMBL622316,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13284,,,,1,N,50212,,Normal diffusion coefficient in water for Escherichia coli,1,CHEMBL877486,Escherichia coli,,A,562.0,,,Intermediate,,BAO_0000218
13285,,,,1,U,22224,,Average max percent decrease in RVR (renal vascular resistance) was determined,0,CHEMBL622317,,,A,,,,Autocuration,,BAO_0000019
13286,,,,1,U,22224,,Average max percent decrease in RVR (renal vascular resistance) was determined.,0,CHEMBL622318,,,A,,,,Autocuration,,BAO_0000019
13287,,,,1,U,22224,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,0,CHEMBL622319,,,A,,,,Autocuration,,BAO_0000019
13288,,,,1,U,22224,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,0,CHEMBL622320,,,A,,,,Autocuration,,BAO_0000019
13289,,,,1,U,22224,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,0,CHEMBL622321,,,A,,,,Autocuration,,BAO_0000019
13290,,,,1,U,22224,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,0,CHEMBL622322,,,A,,,,Autocuration,,BAO_0000019
13291,,,,1,U,22224,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,0,CHEMBL622323,,,A,,,,Autocuration,,BAO_0000019
13292,,,,1,N,50597,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,1,CHEMBL622324,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13293,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1,CHEMBL622325,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13294,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,CHEMBL622326,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13295,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",1,CHEMBL877487,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13296,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,CHEMBL622327,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13297,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",1,CHEMBL622328,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13298,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1,CHEMBL622329,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13299,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,CHEMBL622330,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13300,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1,CHEMBL622331,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13301,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,CHEMBL622332,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13302,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",1,CHEMBL622333,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13303,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",0,CHEMBL627658,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13304,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",0,CHEMBL630428,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13305,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",0,CHEMBL630429,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13306,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",0,CHEMBL630430,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13307,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",0,CHEMBL630431,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13308,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,CHEMBL630432,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13309,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1,CHEMBL630433,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13310,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1,CHEMBL630434,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13311,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1,CHEMBL629372,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13312,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",1,CHEMBL629553,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13313,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1,CHEMBL629554,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13314,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1,CHEMBL874447,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13315,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1,CHEMBL629555,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13316,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1,CHEMBL629556,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13317,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",1,CHEMBL629557,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13318,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1,CHEMBL629558,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13319,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1,CHEMBL629559,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13320,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1,CHEMBL629560,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13321,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1,CHEMBL629561,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13322,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,CHEMBL629562,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13323,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1,CHEMBL629563,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13324,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,CHEMBL629564,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13325,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1,CHEMBL629565,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13326,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,CHEMBL629566,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13327,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,CHEMBL629567,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13328,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1,CHEMBL629568,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13329,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",1,CHEMBL629569,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13330,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1,CHEMBL629570,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13331,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",0,CHEMBL629571,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13332,,,,1,U,22224,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,0,CHEMBL629572,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13333,,,,1,U,22224,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,0,CHEMBL629573,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13334,,,,1,U,22224,,Bioavailability (dose 20 mg/kg),0,CHEMBL629574,Eutheria,,A,9347.0,In vivo,,Autocuration,,BAO_0000218
13335,,,,1,U,22224,,Bioavailability in dog,0,CHEMBL629575,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
13336,,,,1,U,22224,,Bioavailability in rat (Sprague-Dawley) (male),0,CHEMBL874448,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13337,,,,1,U,22224,,Bioavailability in monkey (dose 10 mg/kg i.d.),0,CHEMBL629576,Primates,,A,9443.0,In vivo,,Autocuration,,BAO_0000218
13338,,,,1,U,22224,,Bioavailability in rat,0,CHEMBL629577,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13339,,,,1,U,22224,,Bioavailability in rat,0,CHEMBL629578,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13340,,,,1,U,22224,,Bioavailability in dog (dose 3.0 mg/kg p.o.),0,CHEMBL629579,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
13341,,,,1,U,22224,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,0,CHEMBL882958,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
13342,,,,1,N,50505,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,1,CHEMBL629580,Pan troglodytes,,A,9598.0,In vivo,,Intermediate,,BAO_0000218
13343,,,,1,U,22224,,Bioavailability,0,CHEMBL629581,Eutheria,,A,9347.0,In vivo,,Autocuration,,BAO_0000218
13344,,,,1,U,22224,,Bioavailability in squirrel monkey,0,CHEMBL629582,Saimiri,,A,9520.0,In vivo,,Autocuration,,BAO_0000218
13345,,,,1,N,50588,,Bioavailability was evaluated in dog,1,CHEMBL628522,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13346,,,,1,N,100712,,Bioavailability was evaluated in hamster,1,CHEMBL625432,Cricetinae,,A,10026.0,In vivo,,Intermediate,,BAO_0000218
13347,,,,1,U,22224,,Bioavailability in rat,0,CHEMBL625433,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13348,,Plasma,,1,N,50597,1969.0,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,CHEMBL625434,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13349,,Plasma,,1,N,50597,1969.0,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,1,CHEMBL625435,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13350,,,,1,U,22224,,Bioavailability in rat (dose 10 mg/kg p.o.),0,CHEMBL625436,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13351,,,,1,N,100710,,Bioavailability was measured in cynomolgus monkeys.,1,CHEMBL874588,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
13352,,,,1,N,50594,,Bioavailability was measured in nude mice.,1,CHEMBL625437,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13353,,,,1,U,22224,,Bioavailability in ferret (dose 10 mg/kg i.d.),0,CHEMBL625438,Mustela putorius furo,,A,9669.0,In vivo,,Autocuration,,BAO_0000218
13354,,,,1,U,22224,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),0,CHEMBL625439,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
13355,,,,1,U,22224,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",0,CHEMBL625440,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
13356,,,,1,U,22224,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),0,CHEMBL625441,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
13357,,,,1,U,22224,,Bioavailability in rat (dose 10 mg/kg i.d.),0,CHEMBL625442,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13358,,,,1,N,50597,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,CHEMBL625443,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13359,,,,1,U,22224,,Bioavailability was determined; extremely poor,0,CHEMBL625444,,,A,,In vivo,,Autocuration,,BAO_0000218
13360,,,,1,N,50594,,% bioavailability in mice after oral administration of prodrug,1,CHEMBL625445,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13361,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,1,CHEMBL625446,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13362,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,1,CHEMBL882960,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13363,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,1,CHEMBL625447,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13364,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,1,CHEMBL625448,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13365,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,1,CHEMBL625449,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13366,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),1,CHEMBL874589,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13367,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,1,CHEMBL625450,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13368,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,1,CHEMBL625451,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13369,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,1,CHEMBL626584,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13370,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,1,CHEMBL626585,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13371,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,1,CHEMBL626586,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13372,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,1,CHEMBL626587,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13373,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,1,CHEMBL626588,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13374,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,1,CHEMBL626589,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13375,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,1,CHEMBL626590,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13376,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,1,CHEMBL626591,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13377,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,1,CHEMBL627181,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13378,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,1,CHEMBL628083,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13379,,,,1,U,22224,,IV clearance determined at an peroral dose of 15 mg/kg.,0,CHEMBL628084,,,A,,In vivo,,Autocuration,,BAO_0000218
13380,,,,1,N,50064,,Mouse oral clearance was measured against Hymenolepiasis nana.,1,CHEMBL628085,Hymenolepis nana,,F,102285.0,In vivo,,Expert,,BAO_0000218
13381,,,,1,N,50545,,Mouse oral clearance was measured against Nematospiroides dubius,1,CHEMBL628086,Heligmosomoides polygyrus,,F,6339.0,In vivo,,Expert,,BAO_0000218
13382,,,,1,U,22224,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,0,CHEMBL628087,,,F,,In vivo,,Autocuration,,BAO_0000218
13383,,,,1,N,50594,,Mouse oral clearance was measured against N. nana; NT is Not Tested,1,CHEMBL628088,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13384,,,,1,U,22224,,Mouse oral clearance was measured against N. nana; NT is Not Tested,0,CHEMBL628089,,,B,,In vivo,,Autocuration,,BAO_0000218
13385,,,,1,U,22224,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,0,CHEMBL628090,,,A,,In vivo,,Autocuration,,BAO_0000218
13386,,,,1,U,22224,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,0,CHEMBL628091,,,A,,In vivo,,Autocuration,,BAO_0000218
13387,,,,1,U,22224,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,0,CHEMBL628092,,,A,,In vivo,,Autocuration,,BAO_0000218
13388,,,,1,U,22224,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,0,CHEMBL628093,,,A,,In vivo,,Autocuration,,BAO_0000218
13389,,,,1,U,22224,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,0,CHEMBL875607,,,A,,In vivo,,Autocuration,,BAO_0000218
13390,,,,1,U,22224,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,0,CHEMBL625710,,,A,,In vivo,,Autocuration,,BAO_0000218
13391,,,,1,U,22224,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,0,CHEMBL625711,,,A,,In vivo,,Autocuration,,BAO_0000218
13392,,,,1,U,22224,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,0,CHEMBL625712,,,A,,In vivo,,Autocuration,,BAO_0000218
13393,,,,1,U,22224,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,0,CHEMBL625713,,,A,,In vivo,,Autocuration,,BAO_0000218
13394,,,,1,N,50588,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,1,CHEMBL625714,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13395,,,,1,N,50797,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,1,CHEMBL625715,Macaca mulatta,,A,9544.0,In vivo,,Intermediate,,BAO_0000218
13396,,,,1,N,50597,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,1,CHEMBL625716,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13397,,,,1,N,50597,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,1,CHEMBL625717,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13398,,,,1,N,50597,,Plasma clearance was determined for the compound in rats,1,CHEMBL625718,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13399,,,,1,N,50597,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,1,CHEMBL625719,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13400,,,,1,N,50597,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,1,CHEMBL625720,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13401,,,,1,N,50597,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,1,CHEMBL625721,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13402,,,,1,N,50597,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,1,CHEMBL625722,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13403,,,,1,N,50597,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,1,CHEMBL625723,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13404,,,,1,N,50545,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,1,CHEMBL625724,Heligmosomoides polygyrus,,A,6339.0,In vivo,,Intermediate,,BAO_0000218
13405,,,,1,N,50545,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,1,CHEMBL625725,Heligmosomoides polygyrus,,A,6339.0,In vivo,,Intermediate,,BAO_0000218
13406,,,,1,N,50545,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,1,CHEMBL625726,Heligmosomoides polygyrus,,A,6339.0,In vivo,,Intermediate,,BAO_0000218
13407,,,,1,N,50545,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,1,CHEMBL875608,Heligmosomoides polygyrus,,A,6339.0,In vivo,,Intermediate,,BAO_0000218
13408,,,,1,N,50545,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,1,CHEMBL625727,Heligmosomoides polygyrus,,A,6339.0,In vivo,,Intermediate,,BAO_0000218
13409,,Urine,,1,U,22224,1088.0,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,0,CHEMBL625728,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13410,,,,1,U,22224,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,0,CHEMBL625729,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13411,,,,1,U,22224,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,0,CHEMBL625730,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13412,,Urine,,1,U,22224,1088.0,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,0,CHEMBL625731,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13413,,Urine,,1,U,22224,1088.0,Urinary clearance was determined in rat at 25 mg/kg os dosage,0,CHEMBL626417,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
13414,,Urine,,1,N,50587,1088.0,Urinary clearance was determined at 100 mg/kg oral dosage in human,1,CHEMBL626418,Homo sapiens,,A,9606.0,In vivo,,Intermediate,,BAO_0000218
13415,,Urine,,1,N,50588,1088.0,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,1,CHEMBL626419,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13416,,Plasma,,1,N,50588,1969.0,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1,CHEMBL626592,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13417,,Plasma,,1,N,50597,1969.0,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1,CHEMBL626593,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13418,,,,1,N,50597,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,CHEMBL626594,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13419,,,,1,N,50588,,Clearance rate in dogs,1,CHEMBL625035,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13420,,,,1,U,22224,,Compound was measured for intrinsic clearance,0,CHEMBL625036,,,A,,In vitro,,Autocuration,,BAO_0000019
13421,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625037,,,P,,,,Autocuration,,BAO_0000100
13422,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625038,,,P,,,,Autocuration,,BAO_0000100
13423,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625039,,,P,,,,Autocuration,,BAO_0000100
13424,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625040,,,P,,,,Autocuration,,BAO_0000100
13425,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625041,,,P,,,,Autocuration,,BAO_0000100
13426,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625042,,,P,,,,Autocuration,,BAO_0000100
13427,,,,1,U,22224,,Partition coefficient of the compound,0,CHEMBL874411,,,A,,,,Autocuration,,BAO_0000019
13428,,,,1,U,22224,,Permeability,0,CHEMBL625043,,,A,,,,Autocuration,,BAO_0000019
13429,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625044,,,P,,,,Autocuration,,BAO_0000100
13430,,,,1,U,22224,,Partition coefficient (logD),0,CHEMBL625045,,,A,,,,Autocuration,,BAO_0000019
13431,,,,1,U,22229,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),0,CHEMBL625046,,,P,,,,Autocuration,,BAO_0000100
13432,,,,1,U,22229,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),0,CHEMBL625047,,,P,,,,Autocuration,,BAO_0000100
13433,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625048,,,P,,,,Autocuration,,BAO_0000100
13434,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625049,,,P,,,,Autocuration,,BAO_0000100
13435,,,,1,U,22229,,Calculated logarithm of partition coefficient (P) was determined,0,CHEMBL625050,,,P,,,,Autocuration,,BAO_0000100
13436,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625051,,,P,,,,Autocuration,,BAO_0000100
13437,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL874412,,,P,,,,Autocuration,,BAO_0000100
13438,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625052,,,P,,,,Autocuration,,BAO_0000100
13439,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL625053,,,P,,,,Autocuration,,BAO_0000100
13440,,,,1,U,22224,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,0,CHEMBL623250,,,A,,,,Autocuration,,BAO_0000019
13441,,,,1,U,22224,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,0,CHEMBL623251,,,A,,,,Autocuration,,BAO_0000019
13442,,,,1,U,22224,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,0,CHEMBL623252,,,A,,,,Autocuration,,BAO_0000019
13443,,,,1,U,22224,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,0,CHEMBL623253,,,A,,,,Autocuration,,BAO_0000019
13444,,,,1,U,22224,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,0,CHEMBL623254,,,A,,,,Autocuration,,BAO_0000019
13445,,,,1,U,22224,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,0,CHEMBL623255,,,A,,,,Autocuration,,BAO_0000019
13446,,,,1,U,22224,,Percent degradation of compound at a pH of 1 over a 18 hr period,0,CHEMBL626831,,,A,,,,Autocuration,,BAO_0000019
13447,,,,1,U,22224,,Percent degradation of compound at pH of 1 over an 18 hr period,0,CHEMBL877494,,,A,,,,Autocuration,,BAO_0000019
13448,,,,1,U,22224,,Delta Logarithm of Partition Coefficient value was determined.,0,CHEMBL626832,,,A,,,,Autocuration,,BAO_0000019
13449,,,,1,U,22224,,Delta logPoct-cyc,0,CHEMBL626833,,,A,,,,Autocuration,,BAO_0000019
13450,,,,1,U,22224,,Lipophilicity estimated on reversed phase TLC,0,CHEMBL626834,,,P,,,,Autocuration,,BAO_0000100
13451,,,,1,U,22224,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,0,CHEMBL626835,,,A,,,,Autocuration,,BAO_0000019
13452,,,,1,U,22224,,Delta logPoct-cyc,0,CHEMBL626836,,,A,,,,Autocuration,,BAO_0000019
13453,,,,1,U,22229,,Change in logarithm of partition coefficient of the compound,0,CHEMBL626837,,,P,,,,Autocuration,,BAO_0000100
13454,,,,1,U,22224,,Delta logD (pH 6.5),0,CHEMBL626838,,,A,,,,Autocuration,,BAO_0000019
13455,,,,1,U,22224,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",0,CHEMBL626839,,,P,,,,Autocuration,,BAO_0000100
13456,,,,1,U,22224,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,0,CHEMBL626840,,,A,,,,Autocuration,,BAO_0000019
13457,,,,1,U,22224,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),0,CHEMBL626841,,,A,,,,Autocuration,,BAO_0000019
13458,,,,1,U,22224,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,0,CHEMBL626842,,,A,,,,Autocuration,,BAO_0000219
13459,,,,1,U,22224,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,0,CHEMBL626843,,,A,,,,Autocuration,,BAO_0000219
13460,,,,1,N,50597,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,1,CHEMBL626844,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13461,,,,1,N,50597,,Amount of deuterium retained was reported after normal workup in rats,1,CHEMBL877495,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13462,,,,1,N,50597,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,1,CHEMBL626845,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13463,,,,1,N,50597,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,1,CHEMBL626846,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13464,,,,1,N,50597,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,1,CHEMBL626847,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13465,,,,1,N,50597,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,1,CHEMBL628677,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13466,,,,1,N,50597,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,1,CHEMBL628678,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13467,,,,1,U,22224,,Compound was subjected to electrochemical oxidation,0,CHEMBL628679,,,A,,,,Autocuration,,BAO_0000019
13468,,,,1,U,22224,,Compound was subjected to photochemical oxidation,0,CHEMBL628680,,,A,,,,Autocuration,,BAO_0000019
13469,,,,1,U,22224,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,0,CHEMBL628681,,,A,,,,Autocuration,,BAO_0000019
13470,,,,1,U,22224,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,0,CHEMBL628682,,,A,,,,Autocuration,,BAO_0000019
13471,,,,1,U,22224,,Oxidation of compound by methemoglobin in presence of hydroperoxide,0,CHEMBL628683,,,A,,,,Autocuration,,BAO_0000019
13472,,,,1,N,50597,,Percent diffusion through fuzzy rat skin after 48 h of incubation,1,CHEMBL628684,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13473,,,,1,U,22229,,Dissociation constant (pKa),0,CHEMBL877501,,,P,,,,Autocuration,,BAO_0000100
13474,,,,1,U,22224,,Dissociation constant value of the compound; ND means not determined.,0,CHEMBL628685,,,P,,,,Autocuration,,BAO_0000100
13475,,Blood,,1,N,50597,178.0,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,1,CHEMBL628686,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13476,,Blood,,1,N,50597,178.0,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,CHEMBL628687,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13477,,,,1,N,50597,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,1,CHEMBL628688,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13478,,,,1,N,50597,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,CHEMBL628689,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13479,,Liver,,1,N,50597,2107.0,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,1,CHEMBL628690,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13480,,Liver,,1,N,50597,2107.0,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,1,CHEMBL629363,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13481,,Spleen,,1,N,50597,2106.0,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,1,CHEMBL629364,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13482,,Spleen,,1,N,50597,2106.0,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,CHEMBL629365,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13483,,,,1,N,50597,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,1,CHEMBL629366,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13484,,Urine,,1,N,50597,1088.0,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,1,CHEMBL629367,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13485,,Feces,,1,N,50597,1988.0,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,CHEMBL629368,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13486,,Urine,,1,N,50597,1088.0,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,1,CHEMBL877502,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13487,,Cerebellum,,1,N,50594,2037.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,1,CHEMBL629369,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13488,,Brain,,1,N,50594,955.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,1,CHEMBL629370,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13489,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",0,CHEMBL629371,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13490,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",0,CHEMBL626276,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13491,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",0,CHEMBL626277,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13492,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",0,CHEMBL631250,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13493,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,CHEMBL631251,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13494,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1,CHEMBL631252,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13495,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",1,CHEMBL631253,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13496,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1,CHEMBL631254,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13497,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1,CHEMBL631255,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13498,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1,CHEMBL631256,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13499,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1,CHEMBL631257,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13500,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",1,CHEMBL628009,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13501,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1,CHEMBL628010,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13502,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1,CHEMBL628011,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13503,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",1,CHEMBL628012,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13504,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1,CHEMBL628013,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13505,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1,CHEMBL628014,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13506,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",1,CHEMBL628015,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13507,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,CHEMBL628016,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13508,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",1,CHEMBL874461,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13509,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,CHEMBL628017,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13510,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1,CHEMBL628018,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13511,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,CHEMBL628019,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13512,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,CHEMBL628020,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13513,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1,CHEMBL628021,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13514,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1,CHEMBL628022,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13515,,Urine,,1,N,50588,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1,CHEMBL628023,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13516,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",0,CHEMBL628024,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13517,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",0,CHEMBL628025,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13518,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",0,CHEMBL628026,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13519,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",0,CHEMBL628027,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13520,,Urine,,1,U,22224,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",0,CHEMBL628028,Simiiformes,,A,314293.0,,,Autocuration,,BAO_0000218
13521,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,CHEMBL628029,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13522,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",1,CHEMBL628030,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13523,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1,CHEMBL628031,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13524,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",1,CHEMBL628032,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13525,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1,CHEMBL628033,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13526,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",1,CHEMBL628034,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13527,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1,CHEMBL628035,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13528,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",1,CHEMBL628036,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13529,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1,CHEMBL874462,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13530,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,1,CHEMBL628037,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13531,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,1,CHEMBL628123,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13532,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,1,CHEMBL628124,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13533,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,1,CHEMBL628125,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13534,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,1,CHEMBL628126,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13535,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),1,CHEMBL628127,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13536,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,1,CHEMBL628128,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13537,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,1,CHEMBL628129,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13538,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,1,CHEMBL628130,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13539,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,1,CHEMBL628131,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13540,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,1,CHEMBL628132,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13541,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,1,CHEMBL628133,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13542,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,1,CHEMBL628134,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13543,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,1,CHEMBL628135,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13544,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,1,CHEMBL628136,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13545,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,1,CHEMBL628137,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13546,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,1,CHEMBL628138,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13547,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,1,CHEMBL628139,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13548,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,1,CHEMBL628140,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13549,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,1,CHEMBL628141,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13550,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,1,CHEMBL628142,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13551,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,1,CHEMBL628143,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13552,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,1,CHEMBL628144,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13553,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,1,CHEMBL628145,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13554,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,1,CHEMBL628146,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13555,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,1,CHEMBL625355,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13556,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,1,CHEMBL625356,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13557,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,1,CHEMBL625357,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13558,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,1,CHEMBL625527,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13559,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),1,CHEMBL875473,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13560,,,,1,N,50588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,1,CHEMBL625528,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13561,,,,1,N,50597,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,1,CHEMBL626304,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13562,,Artery,,1,N,50588,1637.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,1,CHEMBL624138,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13563,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624139,,,P,,,,Autocuration,,BAO_0000100
13564,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624140,,,P,,,,Autocuration,,BAO_0000100
13565,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624141,,,P,,,,Autocuration,,BAO_0000100
13566,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624142,,,P,,,,Autocuration,,BAO_0000100
13567,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624143,,,P,,,,Autocuration,,BAO_0000100
13568,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624144,,,P,,,,Autocuration,,BAO_0000100
13569,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624145,,,P,,,,Autocuration,,BAO_0000100
13570,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624146,,,P,,,,Autocuration,,BAO_0000100
13571,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624147,,,P,,,,Autocuration,,BAO_0000100
13572,,,,1,U,22229,,Calculated partition coefficient (clogP) (MacLogP),0,CHEMBL883123,,,P,,,,Autocuration,,BAO_0000100
13573,,,,1,U,22224,,Partition coefficient (logP),0,CHEMBL624148,,,A,,,,Autocuration,,BAO_0000019
13574,,,,1,U,22224,,Kinetic parameter was determined,0,CHEMBL874416,,,A,,,,Autocuration,,BAO_0000019
13575,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624149,,,P,,,,Autocuration,,BAO_0000100
13576,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL624150,,,P,,,,Autocuration,,BAO_0000100
13577,,,,1,U,22224,,Lipophilicity was determined,0,CHEMBL624151,,,P,,,,Autocuration,,BAO_0000100
13578,,,,1,U,22224,,Lipophilicity was determined,0,CHEMBL624152,,,P,,,,Autocuration,,BAO_0000100
13579,,,,1,U,22224,,Lipophilicity was determined,0,CHEMBL622139,,,P,,,,Autocuration,,BAO_0000100
13580,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL622140,,,P,,,,Autocuration,,BAO_0000100
13581,,,,1,U,22224,,Lipophilicity was determined,0,CHEMBL622141,,,P,,,,Autocuration,,BAO_0000100
13582,,,,1,U,22224,,Lipophilicity in octanol-water,0,CHEMBL622142,,,P,,,,Autocuration,,BAO_0000100
13583,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL622143,,,P,,,,Autocuration,,BAO_0000100
13584,,,,1,U,22229,,Octanol-water partition coefficient was determined,0,CHEMBL622144,,,P,,,,Autocuration,,BAO_0000100
13585,,,,1,U,22224,,Partition coefficient (logP),0,CHEMBL877473,,,A,,,,Autocuration,,BAO_0000019
13586,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL622145,,,P,,,,Autocuration,,BAO_0000100
13587,,,,1,U,22224,,Partition coefficient was determined; ND means not determined,0,CHEMBL622146,,,A,,,,Autocuration,,BAO_0000019
13588,,,,1,U,22229,,Calculated partition coefficient (clogP),0,CHEMBL622147,,,P,,,,Autocuration,,BAO_0000100
13589,,,,1,U,22224,,Partition coefficient of the compound,0,CHEMBL622148,,,A,,,,Autocuration,,BAO_0000019
13590,,,,1,U,22224,,Permeability was determined,0,CHEMBL883124,,,A,,,,Autocuration,,BAO_0000019
13591,,,,1,U,22229,,The compound was evaluated for the partition coefficient,0,CHEMBL622149,,,P,,,,Autocuration,,BAO_0000100
13592,,,,1,U,22224,,Partition coefficient (logP),0,CHEMBL622150,,,A,,,,Autocuration,,BAO_0000019
13593,,,,1,U,22224,,The lipophilicity was reported,0,CHEMBL622151,,,P,,,,Autocuration,,BAO_0000100
13594,,,,1,U,22229,,logarithm of the octanol-water partition coefficient for the compound,0,CHEMBL622152,,,P,,,,Autocuration,,BAO_0000100
13595,,,,1,U,22224,,Clogp value was determined,0,CHEMBL622153,,,A,,,,Autocuration,,BAO_0000019
13596,,,,1,U,22224,,Clp at a dose of 1.5 mg/kg,0,CHEMBL877474,,,A,,In vivo,,Autocuration,,BAO_0000218
13597,,,,1,U,22224,,Clp at a dose of 2.0 mg/kg,0,CHEMBL622154,,,A,,In vivo,,Autocuration,,BAO_0000218
13598,,Plasma,,1,U,22224,1969.0,"Clp, plasma clearance at a dose of 10 mg/kg",0,CHEMBL622155,,,A,,In vivo,,Autocuration,,BAO_0000218
13599,,Plasma,,1,U,22224,1969.0,"Clp, plasma clearance at a dose of 50 mg/kg",0,CHEMBL622156,,,A,,In vivo,,Autocuration,,BAO_0000218
13600,,Plasma,,1,N,50597,1969.0,Compound was tested for plasma clearance in rat,1,CHEMBL622157,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13601,,Plasma,,1,N,50597,1969.0,Compound was tested for plasma clearance in rat; Not determined,1,CHEMBL622158,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13602,,,,1,N,50597,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,1,CHEMBL622807,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13603,,,,1,N,50797,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,1,CHEMBL622808,Macaca mulatta,,A,9544.0,In vivo,,Intermediate,,BAO_0000218
13604,,,,1,U,22224,,Plasma clearance by iv administration at a dose 0.003 ug/mL,0,CHEMBL622809,,,A,,In vivo,,Autocuration,,BAO_0000218
13605,,,,1,U,22224,,Plasma clearance determined,0,CHEMBL622810,,,A,,In vivo,,Autocuration,,BAO_0000218
13606,,,,1,N,100712,,Plasma clearance after iv administration at 3 mg/kg in hamster,1,CHEMBL876653,Cricetinae,,A,10026.0,In vivo,,Intermediate,,BAO_0000218
13607,,,,1,N,100712,,Plasma clearance after iv administration at 4 mg/kg in hamster,1,CHEMBL622811,Cricetinae,,A,10026.0,In vivo,,Intermediate,,BAO_0000218
13608,,,,1,N,50597,,Rate of clearance in rat was determined,1,CHEMBL622986,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13609,,Plasma,,1,N,50597,1969.0,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,1,CHEMBL622987,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13610,,Plasma,,1,N,50597,1969.0,Total plasma clearance after iv dose of 5.10 mg/kg in rats,1,CHEMBL622988,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13611,,Plasma,,1,N,50597,1969.0,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,1,CHEMBL622989,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13612,,Plasma,,1,N,50597,1969.0,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,1,CHEMBL622990,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13613,,Plasma,,1,U,22224,1969.0,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,0,CHEMBL622991,Simiiformes,,A,314293.0,In vivo,,Autocuration,,BAO_0000218
13614,,Plasma,,1,N,50597,1969.0,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,1,CHEMBL622227,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13615,,Plasma,,1,N,50588,1969.0,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,1,CHEMBL622228,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13616,,,,1,N,50597,,Clpl value in rat,1,CHEMBL622229,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13617,,,,1,N,50512,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,1,CHEMBL622230,Cavia porcellus,,A,10141.0,In vivo,,Intermediate,,BAO_0000218
13618,,,,1,N,50597,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,1,CHEMBL622231,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13619,,,,1,N,100710,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,1,CHEMBL622232,Macaca fascicularis,,A,9541.0,In vivo,,Intermediate,,BAO_0000218
13620,,,,1,U,22224,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,0,CHEMBL622233,,,A,,In vivo,,Autocuration,,BAO_0000218
13621,,,,1,U,22224,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,0,CHEMBL622234,,,A,,In vivo,,Autocuration,,BAO_0000218
13622,,,,1,U,22224,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,0,CHEMBL622235,,,A,,In vivo,,Autocuration,,BAO_0000218
13623,,,,1,U,22224,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,0,CHEMBL622236,,,A,,In vivo,,Autocuration,,BAO_0000218
13624,,,,1,U,22224,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,0,CHEMBL622237,,,A,,In vivo,,Autocuration,,BAO_0000218
13625,,,,1,U,22224,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,0,CHEMBL877482,,,A,,In vivo,,Autocuration,,BAO_0000218
13626,,,,1,U,22224,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,0,CHEMBL622238,,,A,,In vivo,,Autocuration,,BAO_0000218
13627,,,,1,U,22224,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,0,CHEMBL622239,,,A,,In vivo,,Autocuration,,BAO_0000218
13628,,Blood,,1,U,22224,178.0,Cmax was calculated as maximum concentration reached in the blood,0,CHEMBL622240,,,A,,In vivo,,Autocuration,,BAO_0000218
13629,,Blood,,1,U,22224,178.0,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,0,CHEMBL622241,,,A,,In vivo,,Autocuration,,BAO_0000218
13630,,,,1,N,50597,,Cmax was determine after peroral administration at 10 mpk in Rat,1,CHEMBL631013,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13631,,,,1,N,50797,,Cmax was determine after peroral administration at 10 mpk in Rhesus,1,CHEMBL631014,Macaca mulatta,,A,9544.0,In vivo,,Intermediate,,BAO_0000218
13632,,,,1,N,50588,,Cmax was determine after peroral administration at 10 mpk in dog,1,CHEMBL631015,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
13633,,,,1,N,50597,,Cmax was determine after peroral administration at 160 mpk in Rat,1,CHEMBL631016,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13634,,,,1,N,50597,,Cmax was determine after peroral administration at 20 mpk in Rat,1,CHEMBL631017,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13635,,,,1,N,50597,,Cmax was determine after peroral administration at 50 mpk in Rat,1,CHEMBL631018,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13636,,,,1,U,22224,,Cmax was determined,0,CHEMBL631019,,,A,,In vivo,,Autocuration,,BAO_0000218
13637,,Brain,,1,N,50594,955.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,1,CHEMBL875761,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13638,,Brain,,1,N,50594,955.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,1,CHEMBL631020,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13639,,Brain,,1,N,50594,955.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,1,CHEMBL631669,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13640,,Brain,,1,N,50594,955.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,1,CHEMBL631670,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13641,,Striatum,,1,N,50594,2435.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,1,CHEMBL631671,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13642,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,1,CHEMBL631672,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13643,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,1,CHEMBL631673,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13644,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,1,CHEMBL631856,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13645,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,1,CHEMBL631857,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13646,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,1,CHEMBL631858,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13647,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,1,CHEMBL631859,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13648,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,1,CHEMBL631860,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13649,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,1,CHEMBL631861,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13650,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,1,CHEMBL631862,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13651,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,1,CHEMBL631863,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13652,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,1,CHEMBL631864,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13653,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,1,CHEMBL631865,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13654,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,1,CHEMBL631866,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13655,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,1,CHEMBL629360,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13656,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,1,CHEMBL629361,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13657,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,1,CHEMBL629362,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13658,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,1,CHEMBL630740,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13659,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,1,CHEMBL630741,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13660,,Blood,,1,N,50597,178.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,1,CHEMBL630742,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13661,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,1,CHEMBL630743,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13662,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,1,CHEMBL630744,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13663,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,1,CHEMBL630745,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13664,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,1,CHEMBL630746,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13665,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,1,CHEMBL630747,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13666,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,1,CHEMBL630748,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13667,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,1,CHEMBL632056,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13668,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,1,CHEMBL632057,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13669,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,1,CHEMBL632058,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13670,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,1,CHEMBL632059,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13671,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,1,CHEMBL632060,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13672,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,1,CHEMBL632061,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13673,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,1,CHEMBL629207,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13674,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,1,CHEMBL629208,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13675,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,1,CHEMBL629209,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13676,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,1,CHEMBL629210,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13677,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,1,CHEMBL629211,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13678,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,1,CHEMBL629212,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13679,,,,1,N,50597,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,1,CHEMBL629213,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13680,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1,CHEMBL629214,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13681,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",1,CHEMBL629215,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13682,,Urine,,1,N,50597,1088.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",1,CHEMBL635154,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13683,,,,1,N,50597,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,CHEMBL629216,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13684,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,1,CHEMBL629217,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13685,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,CHEMBL629218,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13686,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,CHEMBL629219,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13687,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,CHEMBL629220,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13688,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL629221,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13689,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,CHEMBL631127,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13690,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,1,CHEMBL631128,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13691,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,CHEMBL631129,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13692,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,CHEMBL631130,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13693,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,CHEMBL631131,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13694,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL631132,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13695,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,CHEMBL631133,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13696,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,1,CHEMBL631134,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13697,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,CHEMBL875120,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13698,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,CHEMBL631135,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13699,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),1,CHEMBL631136,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13700,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL631137,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13701,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,CHEMBL631138,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13702,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,1,CHEMBL631139,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13703,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,CHEMBL631140,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13704,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,CHEMBL631141,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13705,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,CHEMBL631142,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13706,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,CHEMBL631143,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13707,,,,1,N,50597,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,CHEMBL631144,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13708,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,1,CHEMBL631145,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13709,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,CHEMBL631146,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13710,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,1,CHEMBL631147,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13711,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,CHEMBL631148,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13712,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,CHEMBL631149,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13713,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,CHEMBL631150,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13714,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,CHEMBL631151,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13715,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,CHEMBL631152,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13716,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,CHEMBL631443,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13717,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,CHEMBL631444,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13718,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,CHEMBL631445,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13719,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,CHEMBL631446,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13720,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),1,CHEMBL631447,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13721,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,CHEMBL631448,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13722,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,1,CHEMBL631449,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13723,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,CHEMBL631450,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13724,,,,1,N,50588,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,CHEMBL629724,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13725,,Zone of skin,,1,N,50594,14.0,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL629725,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13726,,Zone of skin,,1,N,50594,14.0,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL629726,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13727,,Spleen,,1,N,50594,2106.0,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL629727,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13728,,Spleen,,1,N,50594,2106.0,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL630404,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13729,,Spleen,,1,N,50594,2106.0,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL630405,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13730,,Spleen,,1,N,50594,2106.0,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL630406,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13731,,Stomach,,1,N,50594,945.0,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL630407,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13732,,Stomach,,1,N,50594,945.0,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL630573,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13733,,Stomach,,1,N,50594,945.0,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL630574,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13734,,Stomach,,1,N,50594,945.0,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL630575,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13735,,,,1,N,50594,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL630576,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13736,,,,1,N,50594,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL630577,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13737,,,,1,N,50594,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL630578,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13738,,,,1,N,50594,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,CHEMBL630579,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
13739,,Kidney,,1,N,50594,2113.0,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),1,CHEMBL630580,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13740,,Kidney,,1,N,50594,2113.0,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,1,CHEMBL630581,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13741,,Kidney,,1,N,50594,2113.0,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),1,CHEMBL630582,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13742,,,,1,N,50594,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,1,CHEMBL630583,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13743,,,,1,N,50594,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),1,CHEMBL630584,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13744,,,,1,N,50594,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,1,CHEMBL630585,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13745,,,,1,N,50594,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),1,CHEMBL630586,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13746,,,,1,N,50594,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,1,CHEMBL630587,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13747,,,,1,N,50594,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),1,CHEMBL630588,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13748,,,,1,N,50594,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,1,CHEMBL630589,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13749,,,,1,N,50594,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),1,CHEMBL630590,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13750,,Feces,,1,U,22224,1988.0,Removal of 238-Plutonium(IV) in feces at 24 h,0,CHEMBL630591,,,A,,,,Autocuration,,BAO_0000019
13751,,Feces,,1,U,22224,1988.0,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),0,CHEMBL630592,,,A,,,,Autocuration,,BAO_0000019
13752,,,,1,U,22224,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,0,CHEMBL630593,,,A,,,,Autocuration,,BAO_0000019
13753,,,,1,U,22224,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),0,CHEMBL630594,,,A,,,,Autocuration,,BAO_0000019
13754,,Urine,,1,U,22224,1088.0,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),0,CHEMBL630595,,,A,,,,Autocuration,,BAO_0000019
13755,,Urine,,1,U,22224,1088.0,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),0,CHEMBL630596,,,A,,,,Autocuration,,BAO_0000019
13756,,Urine,,1,U,22224,1088.0,Removal of 238-Plutonium(IV) in urine after 0-24 h,0,CHEMBL630597,,,A,,,,Autocuration,,BAO_0000019
13757,,Urine,,1,U,22224,1088.0,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),0,CHEMBL630598,,,A,,,,Autocuration,,BAO_0000019
13758,,Urine,,1,U,22224,1088.0,Removal of 238-Plutonium(IV) in urine after 0-4 h,0,CHEMBL630599,,,A,,,,Autocuration,,BAO_0000019
13759,,Urine,,1,U,22224,1088.0,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),0,CHEMBL630600,,,A,,,,Autocuration,,BAO_0000019
13760,,Urine,,1,U,22224,1088.0,Removal of 238-Plutonium(IV) in urine after 4-24 h,0,CHEMBL630601,,,A,,,,Autocuration,,BAO_0000019
13761,,Urine,,1,U,22224,1088.0,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),0,CHEMBL630602,,,A,,,,Autocuration,,BAO_0000019
13762,,Urine,,1,U,22224,1088.0,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),0,CHEMBL630603,,,A,,,,Autocuration,,BAO_0000019
13763,,Urine,,1,U,22224,1088.0,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),0,CHEMBL630604,,,A,,,,Autocuration,,BAO_0000019
13764,,Blood,,1,N,50597,178.0,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL624869,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13765,,Blood,,1,N,50597,178.0,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL624870,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13766,,Blood,,1,N,50597,178.0,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL623189,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13767,,Blood,,1,N,50597,178.0,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL623190,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13768,,Blood,,1,N,50597,178.0,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL623191,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13769,,,,1,N,50597,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL623192,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13770,,,,1,N,50597,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL623193,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13771,,,,1,N,50597,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL623194,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13772,,,,1,N,50597,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL623195,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13773,,,,1,N,50597,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL623196,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13774,,,,1,N,50597,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,1,CHEMBL623197,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13775,,,,1,N,50597,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,CHEMBL623198,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13776,,,,1,N,50597,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,1,CHEMBL623199,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13777,,Muscle tissue,,1,N,50597,2385.0,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,1,CHEMBL623200,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13778,,Muscle tissue,,1,N,50597,2385.0,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,1,CHEMBL623201,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13779,,Muscle tissue,,1,N,50597,2385.0,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,1,CHEMBL623202,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13780,,Muscle tissue,,1,N,50597,2385.0,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,1,CHEMBL623203,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13781,,Muscle tissue,,1,N,50597,2385.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,1,CHEMBL623204,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13782,,Muscle tissue,,1,N,50597,2385.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,1,CHEMBL623205,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13783,,Muscle tissue,,1,N,50597,2385.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,1,CHEMBL623206,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13784,,Muscle tissue,,1,N,50597,2385.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,1,CHEMBL623207,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13785,,Muscle tissue,,1,N,50597,2385.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,1,CHEMBL623208,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13786,,Muscle tissue,,1,N,50597,2385.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,CHEMBL623209,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13787,,Muscle tissue,,1,N,50597,2385.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,1,CHEMBL623210,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13788,,,,1,N,50597,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,CHEMBL623211,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13789,,Uterus,,1,N,50597,995.0,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,1,CHEMBL623212,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13790,,,,1,U,22224,,Tested in vitro for intrinsic activity relative to quinpirole,0,CHEMBL623213,,,A,,,,Autocuration,,BAO_0000019
13791,,,,1,U,22224,,"Relative ion enhancement, determined in pulsed ultrafiltration",0,CHEMBL623214,,,A,,,,Autocuration,,BAO_0000019
13792,,,,1,U,22224,,% ionization at the pH 7.4 at 37 degree Centigrade,0,CHEMBL623215,,,A,,,,Autocuration,,BAO_0000019
13793,,,,1,U,22224,,Percentage ionization was measured,0,CHEMBL623216,,,A,,,,Autocuration,,BAO_0000019
13794,,,,1,N,50591,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,1,CHEMBL623217,Bos taurus,,A,9913.0,,,Intermediate,,BAO_0000218
13795,,,,1,U,22224,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,0,CHEMBL623218,,,A,,,,Autocuration,,BAO_0000019
13796,,,,1,U,22224,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,0,CHEMBL623913,,,A,,,,Autocuration,,BAO_0000019
13797,,,,1,U,22224,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,0,CHEMBL623914,,,A,,,,Autocuration,,BAO_0000019
13798,,,,1,U,22229,,Compound was evaluated for the partition coefficient in octanol/water,0,CHEMBL623915,,,P,,,,Autocuration,,BAO_0000100
13799,,,,1,U,22229,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),0,CHEMBL624080,,,P,,,,Autocuration,,BAO_0000100
13800,,,,1,U,22224,,Equilibrium constant measured by the pulse radiolysis at pH 7,0,CHEMBL624081,,,A,,,,Autocuration,,BAO_0000019
13801,,,,1,N,50587,,In vitro hydrolytic rate constant determined in human blood,1,CHEMBL624082,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
13802,,,,1,N,50587,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,1,CHEMBL625054,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
13803,,,,1,U,22224,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,0,CHEMBL877485,,,A,,,,Autocuration,,BAO_0000019
13804,,,,1,N,50594,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,1,CHEMBL625055,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13805,,,,1,N,50594,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,1,CHEMBL625056,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13806,,,,1,N,50587,,In vitro oxidation of compound in presence of human plasma,1,CHEMBL625057,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
13807,,,,1,U,22224,,In vitro oxidation of compound in presence of hydrogen peroxide,0,CHEMBL625058,,,A,,,,Autocuration,,BAO_0000019
13808,,,,1,N,50594,,In vitro oxidation of compound in presence of mouse brain homogenate,1,CHEMBL625059,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13809,,,,1,N,50594,,In vitro oxidation of compound in presence of mouse liver homogenate,1,CHEMBL629536,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13810,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,CHEMBL629537,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13811,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,CHEMBL629538,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13812,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,CHEMBL629539,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13813,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,CHEMBL874445,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13814,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,CHEMBL629540,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13815,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,CHEMBL629541,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13816,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,CHEMBL629542,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13817,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,CHEMBL630243,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13818,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,CHEMBL630244,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13819,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,CHEMBL630245,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13820,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,CHEMBL630246,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13821,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,CHEMBL630247,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13822,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,CHEMBL630248,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13823,,Blood,,1,N,50597,178.0,Biodistribution in rat blood at 240 minutes after dose administration.,1,CHEMBL630249,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13824,,Blood,,1,N,50597,178.0,Biodistribution in rat blood at 30 minutes after dose administration.,1,CHEMBL630250,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13825,,Blood,,1,N,50597,178.0,Biodistribution in rat blood at 360 minutes after dose administration.,1,CHEMBL630251,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13826,,Blood,,1,N,50597,178.0,Biodistribution in rat blood at 3 hr after dose administration.,1,CHEMBL630252,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13827,,Blood,,1,N,50597,178.0,Biodistribution in rat blood at 60 minutes after dose administration.,1,CHEMBL630408,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13828,,Cerebellum,,1,N,50597,2037.0,Biodistribution in rat cerebellum at 120 minutes after dose administration.,1,CHEMBL630409,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13829,,Cerebellum,,1,N,50597,2037.0,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,1,CHEMBL874446,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13830,,Cerebellum,,1,N,50597,2037.0,Biodistribution in rat cerebellum at 15 minutes after dose administration.,1,CHEMBL630410,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13831,,Cerebellum,,1,N,50597,2037.0,Biodistribution in rat cerebellum at 240 minutes after dose administration.,1,CHEMBL630411,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13832,,Cerebellum,,1,N,50597,2037.0,Biodistribution in rat cerebellum at 30 minutes after dose administration.,1,CHEMBL630412,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13833,,Cerebellum,,1,N,50597,2037.0,Biodistribution in rat cerebellum at 360 minutes after dose administration.,1,CHEMBL630413,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13834,,Cerebellum,,1,N,50597,2037.0,Biodistribution in rat cerebellum at 3 hr after dose administration.,1,CHEMBL630414,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13835,,Cerebellum,,1,N,50597,2037.0,Biodistribution in rat cerebellum at 60 minutes after dose administration.,1,CHEMBL630415,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13836,,,,1,N,50597,,Biodistribution in rat cortex at 120 minutes after dose administration.,1,CHEMBL630416,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13837,,,,1,N,50597,,Biodistribution in rat cortex at 1440 minutes after dose administration.,1,CHEMBL630417,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13838,,,,1,N,50597,,Biodistribution in rat cortex at 15 minutes after dose administration.,1,CHEMBL630418,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13839,,,,1,N,50597,,Biodistribution in rat cortex at 240 minutes after dose administration.,1,CHEMBL630419,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13840,,,,1,N,50597,,Biodistribution in rat cortex at 30 minutes after dose administration.,1,CHEMBL630420,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13841,,,,1,N,50597,,Biodistribution in rat cortex at 360 minutes after dose administration.,1,CHEMBL630421,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13842,,,,1,N,50597,,Biodistribution in rat cortex at 3 hr after dose administration.,1,CHEMBL630422,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13843,,,,1,N,50597,,Biodistribution in rat cortex at 60 minutes after dose administration.,1,CHEMBL630423,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13844,,Heart,,1,N,50597,948.0,Biodistribution in rat heart at 120 minutes after dose administration.,1,CHEMBL630424,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13845,,Heart,,1,N,50597,948.0,Biodistribution in rat heart at 15 minutes after dose administration.,1,CHEMBL630425,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13846,,Heart,,1,N,50597,948.0,Biodistribution in rat heart at 240 minutes after dose administration.,1,CHEMBL629462,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13847,,Heart,,1,N,50597,948.0,Biodistribution in rat heart at 30 minutes after dose administration.,1,CHEMBL630426,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13848,,Heart,,1,N,50597,948.0,Biodistribution in rat heart at 360 minutes after dose administration.,1,CHEMBL630427,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13849,,Heart,,1,N,50597,948.0,Biodistribution in rat heart at 3 hr after dose administration.,1,CHEMBL625877,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13850,,Heart,,1,N,50597,948.0,Biodistribution in rat heart at 60 minutes after dose administration.,1,CHEMBL625878,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13851,,Hippocampus,,1,N,50597,10000000.0,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,1,CHEMBL625879,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13852,,Hippocampus,,1,N,50597,10000000.0,Biodistribution in rat hippocampus at 240 minutes after dose administration.,1,CHEMBL625880,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13853,,Hippocampus,,1,N,50597,10000000.0,Biodistribution in rat hippocampus at 30 minutes after dose administration.,1,CHEMBL625881,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13854,,Hippocampus,,1,N,50597,10000000.0,Biodistribution in rat hippocampus at 360 minutes after dose administration.,1,CHEMBL625882,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13855,,Hippocampus,,1,N,50597,10000000.0,Biodistribution in rat hippocampus at 15 minutes after dose administration.,1,CHEMBL625883,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13856,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney at 120 minutes after dose administration.,1,CHEMBL625884,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13857,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney at 1440 minutes after dose administration.,1,CHEMBL625885,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13858,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney at 15 minutes after dose administration.,1,CHEMBL628649,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13859,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney at 240 minutes after dose administration.,1,CHEMBL628650,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13860,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney at 30 minutes after dose administration.,1,CHEMBL628651,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13861,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney at 360 minutes after dose administration.,1,CHEMBL628652,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13862,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney at 60 minutes after dose administration.,1,CHEMBL628653,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13863,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver at 120 minutes after dose administration.,1,CHEMBL628654,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13864,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver at 1440 minutes after dose administration.,1,CHEMBL628655,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13865,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver at 15 minutes after dose administration.,1,CHEMBL625238,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13866,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver at 240 minutes after dose administration.,1,CHEMBL625239,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13867,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver at 30 minutes after dose administration.,1,CHEMBL625240,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13868,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver at 360 minutes after dose administration.,1,CHEMBL625241,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13869,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver at 60 minutes after dose administration.,1,CHEMBL625242,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13870,,Lung,,1,N,50597,2048.0,Biodistribution in rat lung at 120 minutes after dose administration.,1,CHEMBL874587,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13871,,Lung,,1,N,50597,2048.0,Biodistribution in rat lung at 1440 minutes after dose administration.,1,CHEMBL625405,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13872,,Lung,,1,N,50597,2048.0,Biodistribution in rat lung at 15 minutes after dose administration.,1,CHEMBL625406,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13873,,Lung,,1,N,50597,2048.0,Biodistribution in rat lung at 240 minutes after dose administration.,1,CHEMBL625407,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13874,,Lung,,1,N,50597,2048.0,Biodistribution in rat lung at 30 minutes after dose administration.,1,CHEMBL625408,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13875,,Lung,,1,N,50597,2048.0,Biodistribution in rat lung at 360 minutes after dose administration.,1,CHEMBL625409,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13876,,Thoracic aorta,,1,N,50597,1515.0,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,1,CHEMBL625410,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13877,,Thoracic aorta,,1,N,50597,1515.0,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,1,CHEMBL625411,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13878,,Thoracic aorta,,1,N,50597,1515.0,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,1,CHEMBL625412,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13879,,Thoracic aorta,,1,N,50597,1515.0,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,1,CHEMBL625413,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13880,,Thoracic aorta,,1,N,50597,1515.0,Percent of maximal contractile response to compound in rat thoracic aorta strips v,1,CHEMBL625414,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13881,,Thoracic aorta,,1,N,50597,1515.0,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,1,CHEMBL625415,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13882,,Thoracic aorta,,1,N,50597,1515.0,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,1,CHEMBL625416,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13883,,Urine,,1,N,50597,1088.0,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,1,CHEMBL625417,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13884,,Feces,,1,N,50597,1988.0,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,1,CHEMBL625418,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13885,,Urine,,1,N,50597,1088.0,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,1,CHEMBL625419,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13886,,,,1,N,50597,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,1,CHEMBL625420,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13887,,,,1,N,50597,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,1,CHEMBL626996,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13888,,Feces,,1,N,50597,1988.0,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",1,CHEMBL626997,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13889,,Urine,,1,N,50597,1088.0,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",1,CHEMBL626998,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13890,,,,1,N,50597,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",1,CHEMBL626999,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13891,,,,1,N,50594,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,1,CHEMBL627000,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13892,,,,1,N,50594,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,1,CHEMBL627001,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13893,,,,1,N,50594,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,1,CHEMBL627002,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13894,,,,1,N,50594,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,1,CHEMBL627003,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13895,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,1,CHEMBL627004,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13896,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,1,CHEMBL627005,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13897,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,1,CHEMBL874594,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13898,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,1,CHEMBL627006,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13899,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,1,CHEMBL627007,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13900,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,1,CHEMBL627884,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13901,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,1,CHEMBL627885,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13902,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,1,CHEMBL627886,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13903,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,1,CHEMBL627887,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13904,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,1,CHEMBL627888,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13905,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,1,CHEMBL628057,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13906,,Urine,,1,N,50594,1088.0,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,1,CHEMBL627405,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
13907,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,CHEMBL627406,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13908,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,CHEMBL627407,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13909,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,CHEMBL627408,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13910,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,CHEMBL627409,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13911,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,CHEMBL875486,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13912,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,CHEMBL627410,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13913,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,CHEMBL627411,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13914,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,CHEMBL627412,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13915,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,CHEMBL627413,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13916,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,CHEMBL627414,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13917,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,CHEMBL627415,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13918,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,1,CHEMBL627416,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13919,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,CHEMBL627417,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13920,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,CHEMBL627418,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13921,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1,CHEMBL627419,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13922,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1,CHEMBL627320,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13923,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1,CHEMBL627321,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
13924,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL627322,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13925,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL627323,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13926,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL627491,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13927,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL627492,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13928,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL627493,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13929,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL627494,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13930,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL627495,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13931,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL627496,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13932,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL627497,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13933,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL627498,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13934,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL627499,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13935,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL627500,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13936,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL627501,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13937,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL625616,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13938,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL625617,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13939,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL625618,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13940,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL625619,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13941,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL625620,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13942,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL625621,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13943,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL625622,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13944,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL625788,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13945,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL625789,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13946,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL625790,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13947,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL625791,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13948,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL622334,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13949,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL622335,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13950,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL622336,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13951,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL622337,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13952,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL622338,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13953,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL622339,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13954,,,,1,N,50597,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL624153,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13955,,,,1,N,50597,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL628430,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13956,,,,1,N,50597,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL628431,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13957,,,,1,N,50597,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL628432,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13958,,,,1,N,50597,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL628433,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13959,,Spleen,,1,N,50597,2106.0,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,CHEMBL628434,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13960,,Spleen,,1,N,50597,2106.0,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,CHEMBL626789,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13961,,Spleen,,1,N,50597,2106.0,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",1,CHEMBL626790,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13962,,Spleen,,1,N,50597,2106.0,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,CHEMBL626791,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13963,,Spleen,,1,N,50597,2106.0,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,CHEMBL626792,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13964,,Spleen,,1,N,50597,2106.0,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,CHEMBL626793,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
13965,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,CHEMBL627436,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13966,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,CHEMBL627437,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13967,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,CHEMBL627438,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13968,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,CHEMBL627439,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13969,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,CHEMBL627440,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13970,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,CHEMBL627602,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13971,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,CHEMBL627603,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13972,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,CHEMBL627604,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13973,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,CHEMBL627605,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13974,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,CHEMBL627606,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13975,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,CHEMBL627607,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13976,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,CHEMBL627608,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13977,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,CHEMBL627609,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13978,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,CHEMBL627610,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13979,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,CHEMBL627611,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13980,,,,1,N,50597,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,CHEMBL627612,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
13981,,,,1,U,22229,,Octanol:water partition coefficient is evaluated,0,CHEMBL627613,,,P,,,,Autocuration,,BAO_0000100
13982,,,,1,U,22224,,Partition coefficient in 1-octanol/water system,0,CHEMBL627614,,,P,,,,Autocuration,,BAO_0000100
13983,,,,1,U,22224,,Partition coefficient in 1-octanol/water system measured using radio active compounds,0,CHEMBL627615,,,P,,,,Autocuration,,BAO_0000100
13984,,,,1,U,22224,,Partition coefficient in octanol/water system was determined,0,CHEMBL627616,,,P,,,,Autocuration,,BAO_0000100
13985,,,,1,U,22224,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,0,CHEMBL627617,,,P,,,,Autocuration,,BAO_0000100
13986,,,,1,U,22224,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,0,CHEMBL627618,,,A,,,,Autocuration,,BAO_0000019
13987,,,,1,U,22224,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",0,CHEMBL627619,,,A,,,,Autocuration,,BAO_0000019
13988,,,,1,U,22224,,Pseudo-first-order rate constant of the compound,0,CHEMBL627620,,,A,,,,Autocuration,,BAO_0000019
13989,,,,1,U,22224,,Pseudo-first-order rate constant with 1-min time point,0,CHEMBL627621,,,A,,,,Autocuration,,BAO_0000019
13990,,,,1,U,22224,,Pseudo-first-order rate constant without 1-min time point,0,CHEMBL627622,,,A,,,,Autocuration,,BAO_0000019
13991,,,,1,U,22224,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,0,CHEMBL627623,,,A,,,,Autocuration,,BAO_0000019
13992,,,,1,U,22224,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,0,CHEMBL627624,,,A,,,,Autocuration,,BAO_0000019
13993,,,,1,U,22224,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,0,CHEMBL627625,,,A,,,,Autocuration,,BAO_0000019
13994,,,,1,U,22224,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,0,CHEMBL628523,,,A,,,,Autocuration,,BAO_0000019
13995,,,,1,U,22224,,The alkaline hydrolysis second order rate constant(K OH) of the compound,0,CHEMBL628524,,,A,,,,Autocuration,,BAO_0000019
13996,,,,1,U,22224,,The efflux rate constant of the compound,0,CHEMBL628525,,,A,,,,Autocuration,,BAO_0000019
13997,,,,1,U,22224,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,0,CHEMBL625732,,,A,,,,Autocuration,,BAO_0000019
13998,,,,1,U,22224,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,0,CHEMBL625733,,,A,,,,Autocuration,,BAO_0000019
13999,,,,1,U,22224,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,0,CHEMBL625734,,,F,,,,Autocuration,,BAO_0000019
14000,,,,1,U,22224,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,0,CHEMBL625913,,,A,,,,Autocuration,,BAO_0000019
14001,,,,1,U,22224,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,0,CHEMBL625914,,,A,,,,Autocuration,,BAO_0000019
14002,,,,1,U,22224,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,0,CHEMBL625915,,,A,,,,Autocuration,,BAO_0000019
14003,,,,1,U,22224,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,0,CHEMBL625916,,,A,,,,Autocuration,,BAO_0000019
14004,,,,1,U,22224,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),0,CHEMBL625917,,,A,,,,Autocuration,,BAO_0000019
14005,,,,1,U,22224,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL625918,,,A,,,,Autocuration,,BAO_0000019
14006,,,,1,U,22224,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL625919,,,A,,,,Autocuration,,BAO_0000019
14007,,,,1,U,22224,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL625920,,,A,,,,Autocuration,,BAO_0000019
14008,,,,1,U,22224,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL874453,,,A,,,,Autocuration,,BAO_0000019
14009,,,,1,U,22224,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",0,CHEMBL625921,,,A,,,,Autocuration,,BAO_0000019
14010,,,,1,U,22224,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,0,CHEMBL625922,,,A,,,,Autocuration,,BAO_0000019
14011,,,,1,U,22224,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL625923,,,A,,,,Autocuration,,BAO_0000019
14012,,,,1,U,22224,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL625924,,,A,,,,Autocuration,,BAO_0000019
14013,,,,1,U,22224,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL625925,,,A,,,,Autocuration,,BAO_0000019
14014,,,,1,U,22224,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL625926,,,A,,,,Autocuration,,BAO_0000019
14015,,Lung,,1,N,50597,2048.0,Biodistribution in rat lung at 60 minutes after dose administration.,1,CHEMBL627704,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14016,,,,1,N,50597,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,1,CHEMBL627705,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14017,,,,1,N,50597,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,1,CHEMBL627706,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14018,,,,1,N,50597,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,1,CHEMBL627707,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14019,,,,1,N,50597,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,1,CHEMBL627708,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14020,,,,1,N,50597,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,1,CHEMBL628361,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14021,,,,1,N,50597,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,1,CHEMBL628362,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14022,,Striatum,,1,N,50597,2435.0,Biodistribution in rat striatum at 120 minutes after dose administration.,1,CHEMBL628363,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14023,,Striatum,,1,N,50597,2435.0,Biodistribution in rat striatum at 1440 minutes after dose administration.,1,CHEMBL628364,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14024,,Striatum,,1,N,50597,2435.0,Biodistribution in rat striatum at 15 minutes after dose administration.,1,CHEMBL628365,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14025,,Striatum,,1,N,50597,2435.0,Biodistribution in rat striatum at 240 minutes after dose administration.,1,CHEMBL874454,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14026,,Striatum,,1,N,50597,2435.0,Biodistribution in rat striatum at 30 minutes after dose administration.,1,CHEMBL628531,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14027,,Striatum,,1,N,50597,2435.0,Biodistribution in rat striatum at 360 minutes after dose administration.,1,CHEMBL628532,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14028,,Striatum,,1,N,50597,2435.0,Biodistribution in rat striatum at 3 hr after dose administration.,1,CHEMBL628533,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14029,,Striatum,,1,N,50597,2435.0,Biodistribution in rat striatum at 60 minutes after dose administration.,1,CHEMBL628534,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14030,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in rat thyroid at 120 minutes after dose administration.,1,CHEMBL628535,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14031,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in rat thyroid at 1440 minutes after dose administration.,1,CHEMBL628536,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14032,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in rat thyroid at 15 minutes after dose administration.,1,CHEMBL628537,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14033,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in rat thyroid at 240 minutes after dose administration.,1,CHEMBL628538,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14034,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in rat thyroid at 30 minutes after dose administration.,1,CHEMBL628539,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14035,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in rat thyroid at 360 minutes after dose administration.,1,CHEMBL630297,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14036,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in rat thyroid at 60 minutes after dose administration.,1,CHEMBL630298,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14037,,Brain,,1,N,50597,955.0,Biodistribution in rest of brain of rat 120 minutes after dose administration.,1,CHEMBL630299,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14038,,Brain,,1,N,50597,955.0,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,1,CHEMBL628094,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14039,,Brain,,1,N,50597,955.0,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,1,CHEMBL628095,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14040,,Brain,,1,N,50597,955.0,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,1,CHEMBL874648,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14041,,Brain,,1,N,50597,955.0,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,1,CHEMBL628096,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14042,,Brain,,1,N,50597,955.0,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,1,CHEMBL628097,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14043,,Brain,,1,N,50597,955.0,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,1,CHEMBL628098,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14044,,,,1,U,22224,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",0,CHEMBL628099,,,A,,,,Autocuration,,BAO_0000019
14045,,,,1,U,22224,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",0,CHEMBL628100,,,A,,,,Autocuration,,BAO_0000019
14046,,,,1,U,22224,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),0,CHEMBL628101,,,A,,,,Autocuration,,BAO_0000019
14047,,,,1,U,22224,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",0,CHEMBL628102,,,A,,,,Autocuration,,BAO_0000019
14048,,,,1,U,22224,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",0,CHEMBL628103,,,A,,,,Autocuration,,BAO_0000019
14049,,,,1,U,22224,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",0,CHEMBL628104,,,A,,,,Autocuration,,BAO_0000019
14050,,,,1,U,22224,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",0,CHEMBL628105,,,A,,,,Autocuration,,BAO_0000019
14051,,,,1,U,22224,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",0,CHEMBL628106,,,A,,,,Autocuration,,BAO_0000019
14052,,Urine,,1,N,50597,1088.0,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1,CHEMBL628107,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14053,,Urine,,1,U,22224,1088.0,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,0,CHEMBL628108,,,F,,,,Autocuration,,BAO_0000218
14054,,Urine,,1,N,50597,1088.0,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1,CHEMBL628109,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14055,,Urine,,1,U,22224,1088.0,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,0,CHEMBL625299,,,F,,,,Autocuration,,BAO_0000218
14056,,Urine,,1,N,50597,1088.0,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,1,CHEMBL625300,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14057,,Urine,,1,N,50597,1088.0,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,1,CHEMBL625301,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14058,,Urine,,1,N,50597,1088.0,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,1,CHEMBL625302,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14059,,Urine,,1,N,50597,1088.0,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,1,CHEMBL874649,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14060,,,,1,N,50597,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,1,CHEMBL625303,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14061,,,,1,N,50597,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,1,CHEMBL625463,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14062,,Liver,,1,N,50587,2107.0,In vitro metabolism in human liver microsomes,1,CHEMBL625464,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
14063,,,,1,N,50587,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,1,CHEMBL625465,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
14064,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1,CHEMBL625466,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14065,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,CHEMBL625467,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14066,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1,CHEMBL625468,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14067,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,1,CHEMBL625469,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14068,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,CHEMBL625470,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14069,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,CHEMBL632418,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14070,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,CHEMBL627250,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14071,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,1,CHEMBL627251,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14072,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,1,CHEMBL627252,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14073,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,CHEMBL627253,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14074,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,1,CHEMBL627254,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14075,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,CHEMBL875471,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14076,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,1,CHEMBL627255,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14077,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,CHEMBL627256,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14078,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,1,CHEMBL627257,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14079,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,CHEMBL627258,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14080,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,1,CHEMBL627259,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14081,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,CHEMBL627260,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14082,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,1,CHEMBL623256,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14083,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,CHEMBL874413,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14084,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,1,CHEMBL623257,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14085,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,CHEMBL623258,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14086,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,1,CHEMBL623259,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14087,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,1,CHEMBL623260,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14088,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,CHEMBL623261,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14089,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,1,CHEMBL623262,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14090,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,1,CHEMBL623263,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14091,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,CHEMBL623264,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14092,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,1,CHEMBL623265,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14093,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,CHEMBL623266,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14094,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,1,CHEMBL623267,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14095,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,1,CHEMBL623268,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14096,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,CHEMBL623269,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14097,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,CHEMBL623270,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14098,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,1,CHEMBL623271,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14099,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,1,CHEMBL623272,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14100,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,CHEMBL623273,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14101,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,1,CHEMBL623274,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14102,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,CHEMBL874414,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14103,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,1,CHEMBL623275,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14104,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,CHEMBL629150,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14105,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,CHEMBL623276,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14106,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,CHEMBL623277,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14107,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,1,CHEMBL623112,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14108,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,1,CHEMBL623113,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14109,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,CHEMBL623800,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14110,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,CHEMBL623801,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14111,,Spleen,,1,N,50597,2106.0,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,CHEMBL623802,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14112,,Uterus,,1,N,50597,995.0,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL623803,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14113,,Uterus,,1,N,50597,995.0,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL623970,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14114,,Uterus,,1,N,50597,995.0,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL623971,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14115,,Blood,,1,N,50597,178.0,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),1,CHEMBL623972,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14116,,Blood,,1,N,50597,178.0,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),1,CHEMBL623973,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14117,,Blood,,1,N,50597,178.0,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),1,CHEMBL623974,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14118,,Blood,,1,N,50597,178.0,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),1,CHEMBL623975,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14119,,Brain,,1,N,50597,955.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),1,CHEMBL623976,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14120,,Brain,,1,N,50597,955.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),1,CHEMBL623977,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14121,,Brain,,1,N,50597,955.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),1,CHEMBL623978,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14122,,Brain,,1,N,50597,955.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),1,CHEMBL623979,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14123,,,,1,N,50597,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),1,CHEMBL623980,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14124,,,,1,N,50597,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),1,CHEMBL623981,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14125,,,,1,N,50597,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),1,CHEMBL626278,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14126,,,,1,N,50597,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),1,CHEMBL626279,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14127,,,,1,N,50594,,Biodistribution in mice bladder plus excreted urine was determined,1,CHEMBL626280,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14128,,,,1,N,50594,,"Percentage biodistribution in mouse blood, 10 minutes post injection",1,CHEMBL626281,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14129,,,,1,N,50594,,"Percentage biodistribution in mouse blood, 30 minutes post injection",1,CHEMBL626282,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14130,,,,1,N,50594,,"Percentage biodistribution in mouse blood, 5 minutes post injection",1,CHEMBL626283,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14131,,,,1,N,50594,,"Percentage biodistribution in mouse blood, 60 minutes post injection",1,CHEMBL626284,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14132,,Brain,,1,N,50594,955.0,"Percentage biodistribution in mouse brain, 10 minutes post injection",1,CHEMBL626285,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14133,,Brain,,1,N,50594,955.0,"Percentage biodistribution in mouse brain, 30 minutes post injection",1,CHEMBL626286,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14134,,Brain,,1,N,50594,955.0,"Percentage biodistribution in mouse brain, 5 minutes post injection",1,CHEMBL626287,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14135,,Brain,,1,N,50594,955.0,"Percentage biodistribution in mouse brain, 60 minutes post injection",1,CHEMBL626288,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14136,,,,1,N,50594,,"Percentage biodistribution in mouse heart, 10 minutes post injection",1,CHEMBL626289,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14137,,,,1,N,50594,,"Percentage biodistribution in mouse heart, 30 minutes post injection",1,CHEMBL626290,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14138,,,,1,N,50594,,"Percentage biodistribution in mouse heart, 5 minutes post injection",1,CHEMBL626291,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14139,,,,1,N,50594,,"Percentage biodistribution in mouse heart, 60 minutes post injection",1,CHEMBL839888,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14140,,Intestine,,1,N,50594,160.0,"Percentage biodistribution in mouse intestine, 10 minutes post injection",1,CHEMBL626292,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14141,,Intestine,,1,N,50594,160.0,"Percentage biodistribution in mouse intestine, 30 minutes post injection",1,CHEMBL626293,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14142,,Intestine,,1,N,50594,160.0,"Percentage biodistribution in mouse intestine, 5 minutes post injection",1,CHEMBL626294,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14143,,Intestine,,1,N,50594,160.0,"Percentage biodistribution in mouse intestine, 60 minutes post injection",1,CHEMBL626295,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14144,,Liver,,1,N,50594,2107.0,"Percentage biodistribution in mouse liver, 10 minutes post injection",1,CHEMBL627659,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14145,,Liver,,1,N,50594,2107.0,"Percentage biodistribution in mouse liver, 30 minutes of post injection",1,CHEMBL627660,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14146,,Liver,,1,N,50594,2107.0,"Percentage biodistribution in mouse liver, 5 minutes post injection",1,CHEMBL627661,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14147,,Liver,,1,N,50594,2107.0,Biodistribution in mice liver at 60 minutes of post injection,1,CHEMBL627662,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14148,,Lung,,1,N,50594,2048.0,Biodistribution in mice lungs at 10 min of post injection,1,CHEMBL627663,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14149,,,,1,N,50594,,"Percentage biodistribution in mouse lung, 30 minutes post injection",1,CHEMBL627664,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14150,,,,1,N,50594,,"Percentage biodistribution in mousee lung, 5 minutes post injection",1,CHEMBL627665,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14151,,Lung,,1,N,50594,2048.0,Biodistribution in mice lungs at 60 min of post injection,1,CHEMBL627666,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14152,,Spleen,,1,N,50594,2106.0,Percentage biodistribution in mouse spleen,1,CHEMBL627667,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14153,,Stomach,,1,N,50594,945.0,Percentage biodistribution in mouse stomach,1,CHEMBL627668,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14154,,Urine,,1,N,50594,1088.0,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,1,CHEMBL627669,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14155,,Urinary bladder,,1,U,22224,1255.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,0,CHEMBL627670,,,A,,In vivo,,Autocuration,,BAO_0000218
14156,,Blood,,1,U,22224,178.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,0,CHEMBL627671,,,A,,In vivo,,Autocuration,,BAO_0000218
14157,,Bone element,,1,U,22224,1474.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,0,CHEMBL627672,,,A,,In vivo,,Autocuration,,BAO_0000218
14158,,,,1,U,22224,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,0,CHEMBL627673,,,A,,In vivo,,Autocuration,,BAO_0000218
14159,,Kidney,,1,U,22224,2113.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,0,CHEMBL627674,,,A,,In vivo,,Autocuration,,BAO_0000218
14160,,Liver,,1,U,22224,2107.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,0,CHEMBL627675,,,A,,In vivo,,Autocuration,,BAO_0000218
14161,,Lung,,1,U,22224,2048.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,0,CHEMBL627676,,,A,,In vivo,,Autocuration,,BAO_0000218
14162,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,0,CHEMBL627677,,,A,,In vivo,,Autocuration,,BAO_0000218
14163,,,,1,U,22224,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",0,CHEMBL627678,,,A,,,,Autocuration,,BAO_0000019
14164,,Serum,,1,N,50597,1977.0,Affinity for protein binding expressed as association constant in fresh rat serum,1,CHEMBL627679,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14165,,,,1,U,22224,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,0,CHEMBL627680,,,A,,,,Autocuration,,BAO_0000019
14166,,,,1,U,22224,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,0,CHEMBL627681,,,A,,,,Autocuration,,BAO_0000019
14167,,,,1,U,22224,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,0,CHEMBL627682,,,A,,,,Autocuration,,BAO_0000019
14168,,,,1,U,22224,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,0,CHEMBL627683,,,A,,,,Autocuration,,BAO_0000019
14169,,,,1,U,22224,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,0,CHEMBL627684,,,A,,,,Autocuration,,BAO_0000019
14170,,,,1,U,22224,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",0,CHEMBL874441,,,A,,,,Autocuration,,BAO_0000019
14171,,,,1,U,22224,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,0,CHEMBL627685,,,A,,,,Autocuration,,BAO_0000019
14172,,,,1,U,22224,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",0,CHEMBL627686,,,A,,,,Autocuration,,BAO_0000019
14173,,,,1,U,22224,,Apparent rate constant Koff for inactivation of dTMP synthase.,0,CHEMBL627687,,,A,,,,Autocuration,,BAO_0000019
14174,,,,1,U,22224,,The irreversible inhibitor activity by second order rate equation.,0,CHEMBL627688,,,A,,,,Autocuration,,BAO_0000019
14175,,,,1,N,50597,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,1,CHEMBL628038,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14176,,,,1,N,50597,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,1,CHEMBL628039,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14177,,,,1,N,50597,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,1,CHEMBL628040,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14178,,,,1,U,22224,,Dissociation rate calculated from the first-order equation using t1/2 value,0,CHEMBL628041,,,A,,,,Autocuration,,BAO_0000019
14179,,,,1,U,22224,,The compound was tested for Binding constant against DNA,0,CHEMBL630226,,,A,,,,Autocuration,,BAO_0000019
14180,,,,1,U,22224,,First order rate constant for cyclization of the compound,0,CHEMBL628042,,,A,,,,Autocuration,,BAO_0000019
14181,,,,1,U,22224,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,0,CHEMBL625232,,,A,,,,Autocuration,,BAO_0000019
14182,,,,1,U,22224,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,0,CHEMBL625233,,,A,,,,Autocuration,,BAO_0000019
14183,,,,1,U,22224,,Hydrolysis rate constant was determined,0,CHEMBL625979,,,A,,,,Autocuration,,BAO_0000019
14184,,,,1,U,22224,,Observed first order rate constant,0,CHEMBL625980,,,A,,,,Autocuration,,BAO_0000019
14185,,,,1,U,22224,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,0,CHEMBL625981,,,A,,,,Autocuration,,BAO_0000019
14186,,,,1,U,22224,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,0,CHEMBL625982,,,A,,,,Autocuration,,BAO_0000019
14187,,,,1,U,22224,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,0,CHEMBL625983,,,A,,,,Autocuration,,BAO_0000019
14188,,,,1,U,22224,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL625984,,,A,,,,Autocuration,,BAO_0000019
14189,,,,1,U,22224,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL625985,,,A,,,,Autocuration,,BAO_0000019
14190,,,,1,U,22224,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL625986,,,A,,,,Autocuration,,BAO_0000019
14191,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL625987,,,A,,,,Autocuration,,BAO_0000019
14192,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL625988,,,A,,,,Autocuration,,BAO_0000019
14193,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL625989,,,A,,,,Autocuration,,BAO_0000019
14194,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL625990,,,A,,,,Autocuration,,BAO_0000019
14195,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL625991,,,A,,,,Autocuration,,BAO_0000019
14196,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL625992,,,A,,,,Autocuration,,BAO_0000019
14197,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL625993,,,A,,,,Autocuration,,BAO_0000019
14198,,,,1,U,22224,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL631973,,,A,,,,Autocuration,,BAO_0000019
14199,,,,1,U,22224,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL632143,,,A,,,,Autocuration,,BAO_0000019
14200,,,,1,U,22224,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL632144,,,A,,,,Autocuration,,BAO_0000019
14201,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL632145,,,A,,,,Autocuration,,BAO_0000019
14202,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL632146,,,A,,,,Autocuration,,BAO_0000019
14203,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL632147,,,A,,,,Autocuration,,BAO_0000019
14204,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL632148,,,A,,,,Autocuration,,BAO_0000019
14205,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL632149,,,A,,,,Autocuration,,BAO_0000019
14206,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL632150,,,A,,,,Autocuration,,BAO_0000019
14207,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL632151,,,A,,,,Autocuration,,BAO_0000019
14208,,,,1,N,50587,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,1,CHEMBL632152,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
14209,,,,1,N,50587,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,1,CHEMBL632153,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
14210,,,,1,N,50587,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,1,CHEMBL632154,Homo sapiens,,A,9606.0,,,Intermediate,,BAO_0000218
14211,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,1,CHEMBL632155,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
14212,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,1,CHEMBL632156,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
14213,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,1,CHEMBL632157,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
14214,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,1,CHEMBL632158,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
14215,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,1,CHEMBL632159,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
14216,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,1,CHEMBL626305,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
14217,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,1,CHEMBL626306,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
14218,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,1,CHEMBL626307,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
14219,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,1,CHEMBL626308,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
14220,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,1,CHEMBL626479,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
14221,,,,1,N,50602,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,1,CHEMBL626480,Human herpesvirus 1,,A,10298.0,,,Intermediate,,BAO_0000218
14222,,,,1,U,22229,,Calculated partition coefficient (clogP) (MlogP),0,CHEMBL626481,,,P,,,,Autocuration,,BAO_0000100
14223,,,,1,U,22224,,Equipotent potent ratio relative to carbachol (nicotinic activity),0,CHEMBL626482,,,A,,,,Autocuration,,BAO_0000019
14224,,,,1,N,50588,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",1,CHEMBL626483,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14225,,,,1,N,50588,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",1,CHEMBL626484,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14226,,,,1,U,22229,,Solubility at pH 7.4 in micro g/mL;NA denotes available,0,CHEMBL626485,,,P,,,,Autocuration,,BAO_0000100
14227,,,,1,U,22229,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,0,CHEMBL626486,,,P,,,,Autocuration,,BAO_0000100
14228,,,,1,U,22229,,Solubility at pH 7.4 in ug/mL;NA denotes not available,0,CHEMBL626487,,,P,,,,Autocuration,,BAO_0000100
14229,,Plasma,,1,N,50588,1969.0,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,CHEMBL626488,Canis lupus familiaris,,A,9615.0,In vivo,,Intermediate,,BAO_0000218
14230,,Serum,,1,N,50597,1977.0,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,1,CHEMBL626489,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14231,,,,1,U,22224,,Area under the MAP curve measured over 5 min; ND means Not determined,0,CHEMBL626490,,,A,,,,Autocuration,,BAO_0000019
14232,,,,1,U,22224,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,0,CHEMBL626491,,,P,,,,Autocuration,,BAO_0000100
14233,,,,1,U,22229,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,0,CHEMBL626492,,,P,,,,Autocuration,,BAO_0000100
14234,,,,1,U,22224,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,0,CHEMBL626493,,,A,,,,Autocuration,,BAO_0000019
14235,,,,1,N,50597,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,1,CHEMBL626494,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14236,,,,1,U,22224,,Half life after oral tested,0,CHEMBL626495,,,A,,In vivo,,Autocuration,,BAO_0000218
14237,,Plasma,,1,N,50597,1969.0,Half life was determined in plasma of rat; NT indicates not tested,1,CHEMBL626496,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14238,,,,1,N,50597,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,1,CHEMBL626497,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14239,,,,1,U,22224,,Oral bioavailability after oral tested,0,CHEMBL626498,,,A,,In vivo,,Autocuration,,BAO_0000218
14240,,,,1,N,50597,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),1,CHEMBL626499,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14241,,,,1,N,50597,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),1,CHEMBL626500,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14242,,Plasma,,1,N,50597,1969.0,half life was determined in plasma of rat; NT indicates not tested,1,CHEMBL626501,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14243,,Plasma,,1,N,50597,1969.0,half life was determined in plasma of rat; NT means not tested,1,CHEMBL626502,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14244,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,1,CHEMBL626503,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14245,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,1,CHEMBL626504,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14246,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,1,CHEMBL626505,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14247,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,1,CHEMBL626506,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14248,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,1,CHEMBL626507,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14249,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,1,CHEMBL626508,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14250,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,1,CHEMBL626509,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14251,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,1,CHEMBL875480,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14252,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,1,CHEMBL626510,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14253,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,1,CHEMBL626511,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14254,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,1,CHEMBL626512,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14255,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,1,CHEMBL628208,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14256,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,1,CHEMBL628209,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14257,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,1,CHEMBL628210,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14258,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,1,CHEMBL628211,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14259,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,1,CHEMBL628212,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14260,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,1,CHEMBL628213,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14261,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,CHEMBL628214,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14262,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,CHEMBL628215,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14263,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,CHEMBL628216,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14264,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,CHEMBL626595,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14265,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,CHEMBL626596,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14266,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,CHEMBL626597,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14267,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,CHEMBL626598,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14268,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,CHEMBL622242,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14269,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,CHEMBL622243,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14270,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,CHEMBL622244,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14271,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,CHEMBL622245,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14272,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,CHEMBL622246,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14273,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,CHEMBL622247,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14274,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,CHEMBL622248,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14275,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,CHEMBL877483,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14276,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,CHEMBL622249,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14277,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,CHEMBL622250,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14278,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,CHEMBL622251,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14279,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,CHEMBL622252,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14280,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,CHEMBL622253,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14281,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,CHEMBL622254,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14282,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,CHEMBL622255,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14283,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,CHEMBL622256,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14284,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,CHEMBL622257,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14285,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,CHEMBL622258,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14286,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,CHEMBL622259,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14287,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,CHEMBL622927,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14288,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,CHEMBL622928,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14289,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,CHEMBL622929,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14290,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1,CHEMBL623182,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14291,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,CHEMBL623183,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14292,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,1,CHEMBL623184,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14293,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,CHEMBL623185,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14294,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,CHEMBL877484,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14295,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,CHEMBL627274,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14296,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,1,CHEMBL623186,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14297,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,1,CHEMBL623187,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14298,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,CHEMBL623188,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14299,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,1,CHEMBL628055,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14300,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,CHEMBL628056,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14301,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,1,CHEMBL628200,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14302,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,CHEMBL628201,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14303,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,1,CHEMBL628202,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14304,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,CHEMBL628203,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14305,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,1,CHEMBL628204,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14306,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,CHEMBL628205,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14307,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,1,CHEMBL628206,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14308,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),0,CHEMBL628207,,,A,,In vivo,,Autocuration,,BAO_0000218
14309,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,0,CHEMBL627220,,,A,,In vivo,,Autocuration,,BAO_0000218
14310,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,0,CHEMBL627221,,,A,,In vivo,,Autocuration,,BAO_0000218
14311,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),0,CHEMBL627222,,,A,,In vivo,,Autocuration,,BAO_0000218
14312,,,,1,U,22224,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,0,CHEMBL627223,,,A,,In vivo,,Autocuration,,BAO_0000218
14313,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,0,CHEMBL632062,,,A,,In vivo,,Autocuration,,BAO_0000218
14314,,Spleen,,1,U,22224,2106.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,0,CHEMBL632063,,,A,,In vivo,,Autocuration,,BAO_0000218
14315,,Urinary bladder,,1,U,22224,1255.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,0,CHEMBL632064,,,A,,In vivo,,Autocuration,,BAO_0000218
14316,,Blood,,1,U,22224,178.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,0,CHEMBL632065,,,A,,In vivo,,Autocuration,,BAO_0000218
14317,,Bone element,,1,U,22224,1474.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,0,CHEMBL632066,,,A,,In vivo,,Autocuration,,BAO_0000218
14318,,,,1,U,22224,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,0,CHEMBL632067,,,A,,In vivo,,Autocuration,,BAO_0000218
14319,,Kidney,,1,U,22224,2113.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,0,CHEMBL629188,,,A,,In vivo,,Autocuration,,BAO_0000218
14320,,Liver,,1,U,22224,2107.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,0,CHEMBL629189,,,A,,In vivo,,Autocuration,,BAO_0000218
14321,,Lung,,1,U,22224,2048.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,0,CHEMBL629190,,,A,,In vivo,,Autocuration,,BAO_0000218
14322,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,0,CHEMBL629191,,,A,,In vivo,,Autocuration,,BAO_0000218
14323,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),0,CHEMBL629192,,,A,,In vivo,,Autocuration,,BAO_0000218
14324,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,0,CHEMBL629193,,,A,,In vivo,,Autocuration,,BAO_0000218
14325,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),0,CHEMBL629194,,,A,,In vivo,,Autocuration,,BAO_0000218
14326,,,,1,U,22224,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,0,CHEMBL629195,,,A,,In vivo,,Autocuration,,BAO_0000218
14327,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,0,CHEMBL629373,,,A,,In vivo,,Autocuration,,BAO_0000218
14328,,Spleen,,1,U,22224,2106.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,0,CHEMBL629374,,,A,,In vivo,,Autocuration,,BAO_0000218
14329,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,0,CHEMBL629375,,,A,,In vivo,,Autocuration,,BAO_0000218
14330,,Urinary bladder,,1,U,22224,1255.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,0,CHEMBL629376,,,A,,In vivo,,Autocuration,,BAO_0000218
14331,,Blood,,1,U,22224,178.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,0,CHEMBL629377,,,A,,In vivo,,Autocuration,,BAO_0000218
14332,,Bone element,,1,U,22224,1474.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,0,CHEMBL629378,,,A,,In vivo,,Autocuration,,BAO_0000218
14333,,,,1,U,22224,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,0,CHEMBL629379,,,A,,In vivo,,Autocuration,,BAO_0000218
14334,,Kidney,,1,U,22224,2113.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,0,CHEMBL629151,,,A,,In vivo,,Autocuration,,BAO_0000218
14335,,Liver,,1,U,22224,2107.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,0,CHEMBL629152,,,A,,In vivo,,Autocuration,,BAO_0000218
14336,,Lung,,1,U,22224,2048.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,0,CHEMBL629153,,,A,,In vivo,,Autocuration,,BAO_0000218
14337,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,0,CHEMBL629154,,,A,,In vivo,,Autocuration,,BAO_0000218
14338,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),0,CHEMBL629155,,,A,,In vivo,,Autocuration,,BAO_0000218
14339,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,0,CHEMBL629156,,,A,,In vivo,,Autocuration,,BAO_0000218
14340,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,0,CHEMBL629157,,,A,,In vivo,,Autocuration,,BAO_0000218
14341,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),0,CHEMBL629158,,,A,,In vivo,,Autocuration,,BAO_0000218
14342,,,,1,U,22224,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,0,CHEMBL629159,,,A,,In vivo,,Autocuration,,BAO_0000218
14343,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,0,CHEMBL629160,,,A,,In vivo,,Autocuration,,BAO_0000218
14344,,Spleen,,1,U,22224,2106.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,0,CHEMBL629161,,,A,,In vivo,,Autocuration,,BAO_0000218
14345,,Urinary bladder,,1,U,22224,1255.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,0,CHEMBL629162,,,A,,In vivo,,Autocuration,,BAO_0000218
14346,,Blood,,1,U,22224,178.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,0,CHEMBL629163,,,A,,In vivo,,Autocuration,,BAO_0000218
14347,,Bone element,,1,U,22224,1474.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,0,CHEMBL629164,,,A,,In vivo,,Autocuration,,BAO_0000218
14348,,,,1,U,22224,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,0,CHEMBL629165,,,A,,In vivo,,Autocuration,,BAO_0000218
14349,,Liver,,1,U,22224,2107.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,0,CHEMBL629166,,,A,,In vivo,,Autocuration,,BAO_0000218
14350,,Lung,,1,U,22224,2048.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,0,CHEMBL629167,,,A,,In vivo,,Autocuration,,BAO_0000218
14351,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,0,CHEMBL629168,,,A,,In vivo,,Autocuration,,BAO_0000218
14352,,,,1,U,22224,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,0,CHEMBL629169,,,A,,,,Autocuration,,BAO_0000019
14353,,,,1,U,22224,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,0,CHEMBL629170,,,A,,,,Autocuration,,BAO_0000019
14354,,,,1,U,22224,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,0,CHEMBL631153,,,A,,,,Autocuration,,BAO_0000019
14355,,,,1,U,22224,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,0,CHEMBL875121,,,A,,,,Autocuration,,BAO_0000019
14356,,,,1,U,22224,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,0,CHEMBL631154,,,A,,,,Autocuration,,BAO_0000019
14357,,,,1,U,22224,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,0,CHEMBL631155,,,A,,,,Autocuration,,BAO_0000019
14358,,,,1,U,22224,,Hydrolysis rate constant was determined,0,CHEMBL631156,,,A,,,,Autocuration,,BAO_0000019
14359,,,,1,U,22224,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",0,CHEMBL631157,,,A,,,,Autocuration,,BAO_0000019
14360,,,,1,U,22224,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",0,CHEMBL631158,,,A,,,,Autocuration,,BAO_0000019
14361,,,,1,U,22224,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",0,CHEMBL631159,,,A,,,,Autocuration,,BAO_0000019
14362,,,,1,U,22224,,Observed second order rate constant,0,CHEMBL631160,,,A,,,,Autocuration,,BAO_0000019
14363,,,,1,U,22224,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,0,CHEMBL631161,,,A,,,,Autocuration,,BAO_0000019
14364,,,,1,U,22224,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,0,CHEMBL631162,,,A,,,,Autocuration,,BAO_0000019
14365,,,,1,U,22224,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,0,CHEMBL630313,,,A,,,,Autocuration,,BAO_0000019
14366,,,,1,U,22224,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",0,CHEMBL630314,,,A,,,,Autocuration,,BAO_0000019
14367,,,,1,U,22224,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",0,CHEMBL630315,,,A,,,,Autocuration,,BAO_0000019
14368,,,,1,U,22224,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL630316,,,A,,,,Autocuration,,BAO_0000019
14369,,,,1,U,22224,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL630986,,,A,,,,Autocuration,,BAO_0000019
14370,,,,1,U,22224,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL630987,,,A,,,,Autocuration,,BAO_0000019
14371,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL630988,,,A,,,,Autocuration,,BAO_0000019
14372,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL630989,,,A,,,,Autocuration,,BAO_0000019
14373,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL630990,,,A,,,,Autocuration,,BAO_0000019
14374,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL630991,,,A,,,,Autocuration,,BAO_0000019
14375,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL630992,,,A,,,,Autocuration,,BAO_0000019
14376,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL630993,,,A,,,,Autocuration,,BAO_0000019
14377,,,,1,U,22224,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,CHEMBL630994,,,A,,,,Autocuration,,BAO_0000019
14378,,,,1,N,50597,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,1,CHEMBL630995,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14379,,,,1,U,22224,,Association constant for compound at 31 degree C was determined,0,CHEMBL629252,,,A,,,,Autocuration,,BAO_0000019
14380,,,,1,U,22224,,Calculated antagonist equilibrium dissociation constant of the compound,0,CHEMBL629253,,,A,,,,Autocuration,,BAO_0000019
14381,,,,1,U,22224,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,0,CHEMBL629944,,,A,,,,Autocuration,,BAO_0000019
14382,,Trachea,,1,N,50512,3126.0,Dissociation constants vs LTE4 on guinea pig trachea,1,CHEMBL629945,Cavia porcellus,,A,10141.0,,,Intermediate,,BAO_0000218
14383,,,,1,U,22224,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",0,CHEMBL629946,,,A,,,,Autocuration,,BAO_0000019
14384,,,,1,U,22224,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",0,CHEMBL629947,,,A,,,,Autocuration,,BAO_0000019
14385,,,,1,U,22224,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",0,CHEMBL629948,,,A,,,,Autocuration,,BAO_0000019
14386,,,,1,U,22224,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",0,CHEMBL856024,,,A,,,,Autocuration,,BAO_0000019
14387,,,,1,U,22224,,Affinity constant KD value was derived from TMP,0,CHEMBL629949,,,A,,,,Autocuration,,BAO_0000019
14388,,,,1,U,22224,,Apparent dissociation (binding) rate constant was evaluated,0,CHEMBL629950,,,A,,,,Autocuration,,BAO_0000019
14389,,,,1,U,22224,,Dissociation constant (KD) of the compound,0,CHEMBL630127,,,P,,,,Autocuration,,BAO_0000100
14390,,,,1,U,22224,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,0,CHEMBL630128,,,P,,,,Autocuration,,BAO_0000100
14391,,,,1,U,22224,,Dissociation constant from ESR titration experiments,0,CHEMBL630129,,,P,,,,Autocuration,,BAO_0000100
14392,,,,1,U,22224,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),0,CHEMBL630130,,,,,,,Autocuration,,BAO_0000019
14393,,,,1,U,22224,,Dissociation constant was evaluated.,0,CHEMBL875234,,,P,,,,Autocuration,,BAO_0000100
14394,,,,1,U,22224,,Dissociation constant was reported,0,CHEMBL630131,,,P,,,,Autocuration,,BAO_0000100
14395,,,,1,N,50597,,Dissociation constant was determined in rat pituitary cells.,1,CHEMBL630132,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14396,,,,1,U,22224,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,0,CHEMBL630133,,,A,,,,Autocuration,,BAO_0000019
14397,,,,1,U,22224,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,0,CHEMBL630134,,,A,,,,Autocuration,,BAO_0000019
14398,,,,1,U,22224,,Equilibrium dissociation constant of the compound,0,CHEMBL630135,,,A,,,,Autocuration,,BAO_0000019
14399,,,,1,U,22224,,Equilibrium dissociation constant was determined,0,CHEMBL630136,,,A,,,,Autocuration,,BAO_0000019
14400,,,,1,U,22224,,Kinetic constant KD was evaluated,0,CHEMBL630137,,,A,,,,Autocuration,,BAO_0000019
14401,,,,1,U,22224,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,0,CHEMBL630138,,,A,,,,Autocuration,,BAO_0000019
14402,,,,1,U,22224,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,0,CHEMBL630139,,,A,,,,Autocuration,,BAO_0000019
14403,,,,1,U,22224,,Rate constant for hydrolysis in aqueous acetone.,0,CHEMBL630140,,,A,,,,Autocuration,,BAO_0000019
14404,,,,1,U,22224,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,0,CHEMBL875235,,,A,,,,Autocuration,,BAO_0000019
14405,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,1,CHEMBL876439,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14406,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,1,CHEMBL630605,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14407,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,1,CHEMBL630606,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14408,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,1,CHEMBL630607,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14409,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,1,CHEMBL630608,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14410,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,1,CHEMBL630609,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14411,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,1,CHEMBL630610,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14412,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,1,CHEMBL630611,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14413,,,,1,N,50597,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,1,CHEMBL629552,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14414,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,CHEMBL629733,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14415,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,CHEMBL629734,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14416,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,CHEMBL629735,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14417,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,CHEMBL629736,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14418,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,CHEMBL629737,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14419,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,CHEMBL629738,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14420,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,CHEMBL629739,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14421,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,CHEMBL629740,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14422,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,CHEMBL629741,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14423,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,CHEMBL629742,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14424,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,CHEMBL629743,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14425,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,CHEMBL629744,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14426,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,CHEMBL629745,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14427,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,CHEMBL629746,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14428,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,CHEMBL629747,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14429,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,CHEMBL629748,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14430,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,CHEMBL629749,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14431,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,CHEMBL629750,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14432,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,CHEMBL629751,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14433,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,CHEMBL629752,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14434,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,CHEMBL629753,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14435,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,CHEMBL629754,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14436,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,CHEMBL629755,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14437,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,CHEMBL629756,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14438,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,CHEMBL629757,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14439,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,CHEMBL629758,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14440,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,CHEMBL629759,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14441,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,CHEMBL629760,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14442,,,,1,N,50597,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,CHEMBL876443,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14443,,,,1,N,50588,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,1,CHEMBL629761,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14444,,,,1,N,50588,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,1,CHEMBL629762,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14445,,,,1,N,50594,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,CHEMBL629763,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14446,,,,1,N,50594,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,CHEMBL629764,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14447,,,,1,N,50594,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,CHEMBL629765,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14448,,,,1,N,50594,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,1,CHEMBL629766,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14449,,,,1,N,50594,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,CHEMBL629767,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14450,,,,1,N,50588,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,1,CHEMBL629768,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14451,,,,1,N,50594,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,1,CHEMBL629769,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14452,,,,1,N,50588,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,1,CHEMBL629770,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14453,,,,1,N,50588,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,1,CHEMBL629771,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14454,,,,1,N,50594,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,CHEMBL629772,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14455,,,,1,N,50594,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,CHEMBL629773,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14456,,,,1,N,50594,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,CHEMBL625455,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14457,,,,1,N,50594,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,1,CHEMBL625456,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14458,,,,1,N,50594,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,1,CHEMBL625457,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14459,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,CHEMBL625458,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14460,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,1,CHEMBL625459,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14461,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,CHEMBL875483,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14462,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,1,CHEMBL634779,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14463,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,1,CHEMBL625460,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14464,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,CHEMBL626117,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14465,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,1,CHEMBL626118,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14466,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,1,CHEMBL628342,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14467,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,CHEMBL628343,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14468,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,1,CHEMBL628344,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14469,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,CHEMBL628345,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14470,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,1,CHEMBL628346,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14471,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,1,CHEMBL628347,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14472,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,CHEMBL628348,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14473,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,CHEMBL628349,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14474,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,1,CHEMBL875611,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14475,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,1,CHEMBL628350,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14476,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,CHEMBL628351,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14477,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,1,CHEMBL628352,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14478,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,CHEMBL628353,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14479,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,1,CHEMBL628354,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14480,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,CHEMBL626667,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14481,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,CHEMBL626668,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14482,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,CHEMBL626669,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14483,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,1,CHEMBL626670,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14484,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,1,CHEMBL626671,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14485,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,CHEMBL626672,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14486,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,1,CHEMBL626673,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14487,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,CHEMBL626674,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14488,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,CHEMBL626675,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14489,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,1,CHEMBL626676,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14490,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,1,CHEMBL626677,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14491,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,CHEMBL626678,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14492,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,CHEMBL626679,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14493,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,CHEMBL875612,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14494,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,CHEMBL626680,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14495,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,CHEMBL626681,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14496,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,CHEMBL626682,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14497,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,CHEMBL626683,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14498,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,CHEMBL626684,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14499,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,CHEMBL626685,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14500,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,CHEMBL626686,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14501,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,CHEMBL626687,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14502,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,CHEMBL624978,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14503,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,CHEMBL624979,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14504,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,CHEMBL624980,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14505,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,CHEMBL624981,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14506,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,CHEMBL624982,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14507,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),0,CHEMBL627564,,,A,,In vivo,,Autocuration,,BAO_0000218
14508,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),0,CHEMBL627565,,,A,,In vivo,,Autocuration,,BAO_0000218
14509,,,,1,U,22224,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,0,CHEMBL627566,,,A,,In vivo,,Autocuration,,BAO_0000218
14510,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,0,CHEMBL627567,,,A,,In vivo,,Autocuration,,BAO_0000218
14511,,Spleen,,1,U,22224,2106.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,0,CHEMBL627568,,,A,,In vivo,,Autocuration,,BAO_0000218
14512,,Kidney,,1,U,22224,2113.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,0,CHEMBL627569,,,A,,In vivo,,Autocuration,,BAO_0000218
14513,,Urinary bladder,,1,U,22224,1255.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,0,CHEMBL627570,,,A,,In vivo,,Autocuration,,BAO_0000218
14514,,Blood,,1,U,22224,178.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,0,CHEMBL627571,,,A,,In vivo,,Autocuration,,BAO_0000218
14515,,Bone element,,1,U,22224,1474.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,0,CHEMBL627572,,,A,,In vivo,,Autocuration,,BAO_0000218
14516,,,,1,U,22224,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,0,CHEMBL627573,,,A,,In vivo,,Autocuration,,BAO_0000218
14517,,Kidney,,1,U,22224,2113.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,0,CHEMBL627574,,,A,,In vivo,,Autocuration,,BAO_0000218
14518,,Liver,,1,U,22224,2107.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,0,CHEMBL627575,,,A,,In vivo,,Autocuration,,BAO_0000218
14519,,Lung,,1,U,22224,2048.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,0,CHEMBL627576,,,A,,In vivo,,Autocuration,,BAO_0000218
14520,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,0,CHEMBL627577,,,A,,In vivo,,Autocuration,,BAO_0000218
14521,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),0,CHEMBL627578,,,A,,In vivo,,Autocuration,,BAO_0000218
14522,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,0,CHEMBL627579,,,A,,In vivo,,Autocuration,,BAO_0000218
14523,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,0,CHEMBL627580,,,A,,In vivo,,Autocuration,,BAO_0000218
14524,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),0,CHEMBL627581,,,A,,In vivo,,Autocuration,,BAO_0000218
14525,,,,1,U,22224,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,0,CHEMBL627582,,,A,,In vivo,,Autocuration,,BAO_0000218
14526,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,0,CHEMBL627583,,,A,,In vivo,,Autocuration,,BAO_0000218
14527,,Spleen,,1,U,22224,2106.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,0,CHEMBL627584,,,A,,In vivo,,Autocuration,,BAO_0000218
14528,,Prostate gland,,1,U,22224,2367.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,0,CHEMBL627585,,,A,,In vivo,,Autocuration,,BAO_0000218
14529,,Muscle tissue,,1,U,22224,2385.0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,0,CHEMBL627586,,,A,,In vivo,,Autocuration,,BAO_0000218
14530,,,,1,N,50597,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,1,CHEMBL627587,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14531,,,,1,N,50597,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,CHEMBL627588,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14532,,,,1,N,50597,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,1,CHEMBL628250,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14533,,,,1,N,50597,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,CHEMBL628251,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14534,,Hippocampus,,1,N,50597,10000000.0,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,1,CHEMBL628252,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14535,,Hippocampus,,1,N,50597,10000000.0,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,CHEMBL628253,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14536,,Hypothalamus,,1,N,50597,1898.0,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,1,CHEMBL628254,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14537,,Hypothalamus,,1,N,50597,1898.0,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1,CHEMBL877493,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14538,,,,1,N,50597,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,CHEMBL628255,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14539,,,,1,N,50597,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,CHEMBL628256,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14540,,Hippocampus,,1,N,50597,10000000.0,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,CHEMBL628257,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14541,,Hypothalamus,,1,N,50597,1898.0,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1,CHEMBL628258,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14542,,,,1,N,50597,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,CHEMBL628259,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14543,,,,1,N,50597,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,CHEMBL628429,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14544,,Hippocampus,,1,N,50597,10000000.0,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,CHEMBL626862,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14545,,Hypothalamus,,1,N,50597,1898.0,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,1,CHEMBL626863,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14546,,Cerebellum,,1,N,50597,2037.0,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,1,CHEMBL625886,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14547,,Cerebellum,,1,N,50597,2037.0,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,1,CHEMBL625887,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14548,,,,1,N,50597,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,1,CHEMBL625888,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14549,,,,1,N,50597,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,1,CHEMBL625889,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14550,,Hippocampus,,1,N,50597,10000000.0,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,1,CHEMBL625890,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14551,,Hippocampus,,1,N,50597,10000000.0,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,1,CHEMBL625891,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14552,,Hypothalamus,,1,N,50597,1898.0,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,1,CHEMBL625892,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14553,,Hypothalamus,,1,N,50597,1898.0,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,1,CHEMBL625893,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14554,,Cerebellum,,1,N,50597,2037.0,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,1,CHEMBL625894,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14555,,,,1,N,50597,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,1,CHEMBL625895,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14556,,,,1,U,22224,,Reaction rate parameter value for phosphate with transfer with respect to ATP,0,CHEMBL625896,,,A,,,,Autocuration,,BAO_0000019
14557,,,,1,U,22224,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",0,CHEMBL625897,,,A,,,,Autocuration,,BAO_0000019
14558,,,,1,U,22224,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",0,CHEMBL625898,,,A,,,,Autocuration,,BAO_0000019
14559,,,,1,U,22224,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",0,CHEMBL625899,,,A,,,,Autocuration,,BAO_0000019
14560,,,,1,U,22224,,Reaction rate parameter value for phosphate with transfer with respect to ATP,0,CHEMBL626124,,,A,,,,Autocuration,,BAO_0000019
14561,,,,1,N,50212,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,1,CHEMBL628500,Escherichia coli,,A,562.0,,,Intermediate,,BAO_0000218
14562,,,,1,N,50597,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",1,CHEMBL857856,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14563,,,,1,N,50597,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",1,CHEMBL628501,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14564,,,,1,U,22224,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",0,CHEMBL628502,,,A,,,,Autocuration,,BAO_0000019
14565,,,,1,U,22224,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,0,CHEMBL628503,,,A,,,,Autocuration,,BAO_0000019
14566,,,,1,U,22224,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,0,CHEMBL628504,,,A,,,,Autocuration,,BAO_0000019
14567,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",0,CHEMBL628505,,,A,,,,Autocuration,,BAO_0000019
14568,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",0,CHEMBL874452,,,A,,,,Autocuration,,BAO_0000019
14569,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",0,CHEMBL628506,,,A,,,,Autocuration,,BAO_0000019
14570,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",0,CHEMBL628507,,,A,,,,Autocuration,,BAO_0000019
14571,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",0,CHEMBL628508,,,A,,,,Autocuration,,BAO_0000019
14572,,,,1,U,22224,,Michaelis constant (KM) was evaluated,0,CHEMBL628509,,,A,,,,Autocuration,,BAO_0000019
14573,,,,1,U,22224,,Reaction rate parameter value for phosphate with transfer with respect to ATP,0,CHEMBL628510,,,A,,,,Autocuration,,BAO_0000019
14574,,,,1,U,22224,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,0,CHEMBL628511,,,B,,,,Autocuration,,BAO_0000019
14575,,,,1,U,22224,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,0,CHEMBL628512,,,B,,,,Autocuration,,BAO_0000019
14576,,,,1,U,22224,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,0,CHEMBL628513,,,B,,,,Autocuration,,BAO_0000019
14577,,,,1,U,22224,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,0,CHEMBL628514,,,B,,,,Autocuration,,BAO_0000019
14578,,,,1,U,22224,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,0,CHEMBL628515,,,A,,,,Autocuration,,BAO_0000019
14579,,,,1,U,22224,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,0,CHEMBL628516,,,A,,,,Autocuration,,BAO_0000019
14580,,,,1,U,22224,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),0,CHEMBL628517,,,A,,,,Autocuration,,BAO_0000019
14581,,,,1,U,22224,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),0,CHEMBL628518,,,A,,,,Autocuration,,BAO_0000019
14582,,,,1,U,22224,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,0,CHEMBL628519,,,A,,,,Autocuration,,BAO_0000019
14583,,,,1,U,22224,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,0,CHEMBL628520,,,A,,,,Autocuration,,BAO_0000019
14584,,,,1,U,22224,,Binding constant was determined,0,CHEMBL628521,,,A,,,,Autocuration,,BAO_0000019
14585,,,,1,U,22224,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,0,CHEMBL630443,,,A,,,,Autocuration,,BAO_0000019
14586,,,,1,U,22224,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,0,CHEMBL630444,,,A,,,,Autocuration,,BAO_0000019
14587,,,,1,U,22224,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,0,CHEMBL857732,,,A,,,,Autocuration,,BAO_0000019
14588,,,,1,U,22224,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,0,CHEMBL630445,,,P,,,,Autocuration,,BAO_0000100
14589,,,,1,U,22224,,Catalytic rate constant of the compound,0,CHEMBL630446,,,A,,,,Autocuration,,BAO_0000019
14590,,,,1,U,22224,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,0,CHEMBL630447,,,B,,,,Autocuration,,BAO_0000019
14591,,,,1,U,22224,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),0,CHEMBL630448,,,A,,,,Autocuration,,BAO_0000019
14592,,,,1,U,22224,,Catalytic rate constant against phospholipase A2 was determined,0,CHEMBL630449,,,A,,,,Autocuration,,BAO_0000019
14593,,,,1,U,22224,,"Compound was evaluated for catalytic constant, Kcat",0,CHEMBL630450,,,A,,,,Autocuration,,BAO_0000019
14594,,,,1,U,22224,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,0,CHEMBL630451,,,A,,,,Autocuration,,BAO_0000019
14595,,,,1,U,22224,,Kcat calculated from 0.693/T1/2,0,CHEMBL630452,,,A,,,,Autocuration,,BAO_0000019
14596,,,,1,U,22224,,Kcat was determined,0,CHEMBL630453,,,A,,,,Autocuration,,BAO_0000019
14597,,,,1,U,22224,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,0,CHEMBL630454,,,A,,,,Autocuration,,BAO_0000019
14598,,,,1,U,22224,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,0,CHEMBL630455,,,A,,,,Autocuration,,BAO_0000019
14599,,,,1,U,22224,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,0,CHEMBL631487,,,A,,,,Autocuration,,BAO_0000019
14600,,,,1,U,22224,,Kcat value was determined,0,CHEMBL631488,,,A,,,,Autocuration,,BAO_0000019
14601,,,,1,U,22224,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,0,CHEMBL876440,,,A,,,,Autocuration,,BAO_0000019
14602,,,,1,U,22224,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,0,CHEMBL631489,,,A,,,,Autocuration,,BAO_0000019
14603,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",0,CHEMBL857742,,,A,,,,Autocuration,,BAO_0000019
14604,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",0,CHEMBL631490,,,A,,,,Autocuration,,BAO_0000019
14605,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",0,CHEMBL631491,,,A,,,,Autocuration,,BAO_0000019
14606,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",0,CHEMBL631492,,,A,,,,Autocuration,,BAO_0000019
14607,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",0,CHEMBL631493,,,A,,,,Autocuration,,BAO_0000019
14608,,,,1,U,22224,,Kinetic parameter for rate of conversion to PABA was determined,0,CHEMBL631494,,,A,,,,Autocuration,,BAO_0000019
14609,,,,1,U,22224,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,0,CHEMBL631495,,,A,,,,Autocuration,,BAO_0000019
14610,,Feces,,1,N,50597,1988.0,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1,CHEMBL631496,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14611,,Urine,,1,N,50597,1088.0,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1,CHEMBL631497,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14612,,Urine,,1,N,50597,1088.0,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1,CHEMBL631498,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14613,,Urine,,1,N,50597,1088.0,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1,CHEMBL629776,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14614,,Urine,,1,N,50597,1088.0,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1,CHEMBL629777,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14615,,Urine,,1,N,50597,1088.0,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1,CHEMBL629778,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14616,,,,1,N,50597,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,1,CHEMBL630456,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14617,,,,1,N,50597,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,1,CHEMBL630457,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14618,,,,1,N,50597,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,1,CHEMBL630458,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14619,,,,1,N,50597,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,1,CHEMBL630459,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14620,,,,1,N,50597,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,1,CHEMBL630460,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14621,,,,1,N,50597,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,1,CHEMBL876550,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14622,,,,1,N,50597,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,1,CHEMBL630461,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14623,,,,1,N,50597,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,1,CHEMBL630462,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14624,,,,1,N,50597,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,1,CHEMBL630463,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14625,,,,1,N,50597,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,1,CHEMBL630464,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14626,,,,1,N,50597,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,1,CHEMBL630465,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14627,,,,1,N,50597,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,1,CHEMBL630466,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14628,,,,1,N,50597,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,1,CHEMBL630467,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14629,,,,1,N,50597,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,1,CHEMBL630633,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14630,,,,1,N,50597,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,1,CHEMBL630634,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14631,,,,1,N,50597,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,1,CHEMBL630635,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14632,,,,1,N,50597,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,1,CHEMBL630636,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14633,,,,1,N,50597,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,1,CHEMBL630637,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14634,,Feces,,1,N,50592,1988.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1,CHEMBL630638,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14635,,Feces,,1,N,50592,1988.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1,CHEMBL630639,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14636,,Feces,,1,N,50592,1988.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1,CHEMBL630640,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14637,,Feces,,1,N,50592,1988.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1,CHEMBL876551,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14638,,Urine,,1,N,50592,1088.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",1,CHEMBL630641,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14639,,Urine,,1,N,50592,1088.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1,CHEMBL630642,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14640,,Urine,,1,N,50592,1088.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1,CHEMBL630643,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14641,,Urine,,1,N,50592,1088.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1,CHEMBL630644,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14642,,Urine,,1,N,50592,1088.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1,CHEMBL630645,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14643,,Feces,,1,N,50592,1988.0,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1,CHEMBL625599,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14644,,Feces,,1,N,50592,1988.0,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1,CHEMBL625600,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14645,,Feces,,1,N,50592,1988.0,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1,CHEMBL625601,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14646,,Feces,,1,N,50592,1988.0,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1,CHEMBL625602,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14647,,Urine,,1,N,50592,1088.0,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",1,CHEMBL627470,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14648,,Urine,,1,N,50592,1088.0,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1,CHEMBL627471,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14649,,Urine,,1,N,50592,1088.0,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1,CHEMBL627472,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14650,,Urine,,1,N,50592,1088.0,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1,CHEMBL627473,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14651,,Urine,,1,N,50592,1088.0,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1,CHEMBL627474,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14652,,Blood,,1,N,50597,178.0,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL627475,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14653,,Blood,,1,N,50597,178.0,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL627476,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14654,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,CHEMBL627477,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14655,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,CHEMBL627478,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14656,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,CHEMBL627479,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14657,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,CHEMBL627480,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14658,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,CHEMBL627481,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14659,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,CHEMBL627482,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14660,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,CHEMBL627483,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14661,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,CHEMBL875636,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14662,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,CHEMBL625764,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14663,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,CHEMBL625765,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14664,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,1,CHEMBL625766,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14665,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,CHEMBL625767,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14666,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,CHEMBL625768,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14667,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1,CHEMBL625769,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14668,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1,CHEMBL625770,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14669,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1,CHEMBL625771,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14670,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,1,CHEMBL625772,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14671,,Urine,,1,N,50588,1088.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,CHEMBL625773,Canis lupus familiaris,,A,9615.0,,,Intermediate,,BAO_0000218
14672,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1,CHEMBL625774,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14673,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,1,CHEMBL625775,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14674,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,CHEMBL625776,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14675,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,CHEMBL625777,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14676,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,CHEMBL625778,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14677,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,1,CHEMBL625779,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14678,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,1,CHEMBL625780,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14679,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,CHEMBL625781,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14680,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,1,CHEMBL875637,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14681,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,CHEMBL626473,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14682,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,1,CHEMBL626474,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14683,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,CHEMBL626475,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14684,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,1,CHEMBL626476,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14685,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,CHEMBL634397,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14686,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,1,CHEMBL626477,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14687,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,CHEMBL631069,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14688,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,1,CHEMBL631070,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14689,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,CHEMBL631071,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14690,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,1,CHEMBL631072,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14691,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,CHEMBL631073,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14692,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,1,CHEMBL631074,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14693,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,1,CHEMBL631075,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14694,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,CHEMBL631725,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14695,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,1,CHEMBL631726,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14696,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,1,CHEMBL631727,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14697,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,CHEMBL631728,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14698,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,CHEMBL631729,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14699,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,1,CHEMBL631730,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14700,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,1,CHEMBL631731,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14701,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,CHEMBL631910,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14702,,Hippocampus,,1,N,50597,10000000.0,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,1,CHEMBL631911,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14703,,Hypothalamus,,1,N,50597,1898.0,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,1,CHEMBL631912,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14704,,Hypothalamus,,1,N,50597,1898.0,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,1,CHEMBL631913,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14705,,Blood,,1,N,50597,178.0,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631914,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14706,,Blood,,1,N,50597,178.0,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631915,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14707,,Blood,,1,N,50597,178.0,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL875778,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14708,,Blood,,1,N,50597,178.0,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631916,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14709,,Blood,,1,N,50597,178.0,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631917,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14710,,Blood,,1,N,50597,178.0,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631918,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14711,,Blood,,1,N,50597,178.0,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631919,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14712,,Blood,,1,N,50597,178.0,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL631920,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14713,,Blood,,1,N,50597,178.0,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631921,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14714,,Blood,,1,N,50597,178.0,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631922,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14715,,Blood,,1,N,50597,178.0,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL631923,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14716,,,,1,N,50597,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631924,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14717,,,,1,N,50597,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630234,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14718,,,,1,N,50597,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL630235,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14719,,,,1,N,50597,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630236,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14720,,,,1,N,50597,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630237,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14721,,,,1,N,50597,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630238,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14722,,,,1,N,50597,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630239,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14723,,,,1,N,50597,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL630303,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14724,,,,1,N,50597,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630304,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14725,,,,1,N,50597,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630305,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14726,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630306,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14727,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630307,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14728,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL630308,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14729,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630309,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14730,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL629309,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14731,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL629993,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14732,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL629994,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14733,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL629995,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14734,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631993,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14735,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631994,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14736,,Kidney,,1,N,50597,2113.0,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631995,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14737,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL631996,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14738,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631997,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14739,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631998,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14740,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631999,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14741,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL632000,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14742,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL632001,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14743,,Liver,,1,N,50597,2107.0,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL874424,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14744,,Liver,,1,N,50597,2107.0,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL632002,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14745,,Liver,,1,N,50597,2107.0,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL632003,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14746,,,,1,U,22224,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,0,CHEMBL632004,,,A,,,,Autocuration,,BAO_0000019
14747,,,,1,U,22224,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,0,CHEMBL632005,,,A,,,,Autocuration,,BAO_0000019
14748,,,,1,U,22224,,Compound was tested for amidase rate in the presence of N62C screen enzyme,0,CHEMBL632006,,,A,,,,Autocuration,,BAO_0000019
14749,,,,1,U,22224,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,0,CHEMBL632007,,,A,,,,Autocuration,,BAO_0000019
14750,,,,1,U,22224,,Compound was tested for amidase rate in the presence of S166C screen enzyme,0,CHEMBL632008,,,A,,,,Autocuration,,BAO_0000019
14751,,,,1,U,22224,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,0,CHEMBL632009,,,A,,,,Autocuration,,BAO_0000019
14752,,,,1,U,22224,,Compound was tested for esterase rate in the presence of N62C screen enzyme,0,CHEMBL632010,,,A,,,,Autocuration,,BAO_0000019
14753,,,,1,U,22224,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,0,CHEMBL857750,,,A,,,,Autocuration,,BAO_0000019
14754,,,,1,U,22224,,Compound was tested for esterase rate in the presence of S166C screen enzyme,0,CHEMBL632011,,,A,,,,Autocuration,,BAO_0000019
14755,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",0,CHEMBL632012,,,A,,,,Autocuration,,BAO_0000019
14756,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",0,CHEMBL632013,,,A,,,,Autocuration,,BAO_0000019
14757,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",0,CHEMBL632014,,,A,,,,Autocuration,,BAO_0000019
14758,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",0,CHEMBL629622,,,A,,,,Autocuration,,BAO_0000019
14759,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",0,CHEMBL629623,,,A,,,,Autocuration,,BAO_0000019
14760,,,,1,U,22224,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",0,CHEMBL629624,,,A,,,,Autocuration,,BAO_0000019
14761,,,,1,U,22224,,Ratio of Kcat to that of Km was determined,0,CHEMBL629625,,,A,,,,Autocuration,,BAO_0000019
14762,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",0,CHEMBL629626,,,A,,,,Autocuration,,BAO_0000019
14763,,,,1,U,22224,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",0,CHEMBL629627,,,A,,,,Autocuration,,BAO_0000019
14764,,,,1,U,22224,,"Compound was evaluated for constant, Kd",0,CHEMBL629628,,,A,,,,Autocuration,,BAO_0000019
14765,,,,1,U,22224,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,0,CHEMBL629629,,,A,,,,Autocuration,,BAO_0000019
14766,,,,1,U,22224,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,0,CHEMBL629630,,,A,,,,Autocuration,,BAO_0000019
14767,,,,1,U,22224,,Dissociation Constant of compound determined,0,CHEMBL856030,,,A,,,,Autocuration,,BAO_0000019
14768,,,,1,U,22224,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,0,CHEMBL629631,,,B,,,,Autocuration,,BAO_0000019
14769,,,,1,U,22224,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,0,CHEMBL629632,,,B,,,,Autocuration,,BAO_0000019
14770,,,,1,U,22224,,Dissociation constant of compound with Fructose was determined,0,CHEMBL629633,,,P,,,,Autocuration,,BAO_0000100
14771,,,,1,U,22224,,Dissociation constant of compound with Fructose was determined; Not determined,0,CHEMBL629634,,,P,,,,Autocuration,,BAO_0000100
14772,,,,1,U,22224,,Dissociation constant of compound with Lactulose was determined,0,CHEMBL629635,,,P,,,,Autocuration,,BAO_0000100
14773,,,,1,U,22224,,Dissociation constant of compound with Lactulose was determined; Not determined,0,CHEMBL629636,,,P,,,,Autocuration,,BAO_0000100
14774,,,,1,U,22224,,Dissociation constant of the Compound,0,CHEMBL629637,,,P,,,,Autocuration,,BAO_0000100
14775,,,,1,U,22224,,Dissociation constant by non-linear regression analysis,0,CHEMBL629638,,,P,,,,Autocuration,,BAO_0000100
14776,,,,1,U,22224,,Dissociation constant was determined,0,CHEMBL629639,,,P,,,,Autocuration,,BAO_0000100
14777,,,,1,U,22224,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,0,CHEMBL629640,,,P,,,,Autocuration,,BAO_0000100
14778,,,,1,U,22224,,Dissociation constant was determined,0,CHEMBL629641,,,P,,,,Autocuration,,BAO_0000100
14779,,,,1,U,22224,,Dissociation constant was determined,0,CHEMBL631344,,,P,,,,Autocuration,,BAO_0000100
14780,,Muscle tissue,,1,N,50597,2385.0,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,1,CHEMBL631345,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14781,,,,1,U,22224,,The dissociation constant determined by fluorescence displacement assay,0,CHEMBL631346,,,A,,,,Autocuration,,BAO_0000019
14782,,,,1,U,22224,,kd value surface plasmon resonance (SPR) method,0,CHEMBL631524,,,A,,,,Autocuration,,BAO_0000019
14783,,Muscle tissue,,1,N,50597,2385.0,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,1,CHEMBL631525,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14784,,,,1,U,22224,,First dissociation constant of the binding of compound to V30M TTR,0,CHEMBL631526,,,F,,,,Autocuration,,BAO_0000019
14785,,,,1,U,22224,,Second dissociation constant of the binding of compound to V30M TTR,0,CHEMBL631527,,,F,,,,Autocuration,,BAO_0000019
14786,,,,1,U,22224,,"Compound was evaluated for equilibrium constant, Ke",0,CHEMBL631528,,,A,,,,Autocuration,,BAO_0000019
14787,,Hypothalamus,,1,U,22224,1898.0,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,0,CHEMBL631529,,,A,,,,Autocuration,,BAO_0000019
14788,,Hypothalamus,,1,U,22224,1898.0,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,0,CHEMBL631530,,,A,,,,Autocuration,,BAO_0000019
14789,,,,1,U,22224,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,0,CHEMBL631531,,,A,,,,Autocuration,,BAO_0000019
14790,,,,1,U,22224,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,0,CHEMBL631532,,,A,,,,Autocuration,,BAO_0000019
14791,,,,1,U,22224,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,0,CHEMBL631533,,,A,,,,Autocuration,,BAO_0000019
14792,,,,1,N,50594,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,CHEMBL876552,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14793,,,,1,N,50594,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,1,CHEMBL631534,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14794,,,,1,N,50594,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,CHEMBL631535,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14795,,,,1,N,50594,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,CHEMBL631536,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14796,,,,1,N,50594,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,1,CHEMBL631537,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14797,,,,1,N,50594,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,1,CHEMBL631538,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14798,,,,1,N,50594,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,1,CHEMBL631539,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14799,,,,1,N,50594,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,CHEMBL631540,Mus musculus,,A,10090.0,,,Intermediate,,BAO_0000218
14800,,,,1,N,50597,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,CHEMBL625637,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14801,,,,1,N,50597,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,CHEMBL625638,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14802,,,,1,N,50597,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",1,CHEMBL625639,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14803,,Brain,,1,N,50597,955.0,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625640,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14804,,Brain,,1,N,50597,955.0,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625641,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14805,,Heart,,1,N,50597,948.0,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625642,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14806,,Heart,,1,N,50597,948.0,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625643,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14807,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625644,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14808,,Kidney,,1,N,50597,2113.0,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625645,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14809,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625646,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14810,,Liver,,1,N,50597,2107.0,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625647,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14811,,Lung,,1,N,50597,2048.0,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625648,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14812,,Lung,,1,N,50597,2048.0,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,1,CHEMBL625649,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14813,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625650,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14814,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625651,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14815,,Zone of skin,,1,N,50597,14.0,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625652,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14816,,Zone of skin,,1,N,50597,14.0,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625653,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14817,,Spleen,,1,N,50597,2106.0,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625654,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14818,,Spleen,,1,N,50597,2106.0,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,CHEMBL625655,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14819,,Blood,,1,N,50597,178.0,Biodistribution of Compound in rat blood after 15 minutes of administration,1,CHEMBL625656,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14820,,Blood,,1,N,50597,178.0,Biodistribution of Compound in rat blood after 2 minutes of administration,1,CHEMBL625657,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14821,,Brain,,1,N,50597,955.0,Biodistribution of Compound in rat brain after 15 minutes of administration,1,CHEMBL625658,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14822,,Brain,,1,N,50597,955.0,Biodistribution of Compound in rat brain after 2 minutes of administration,1,CHEMBL625659,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14823,,Heart,,1,N,50597,948.0,Biodistribution of Compound in rat heart after 15 minutes of administration,1,CHEMBL625660,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14824,,Heart,,1,N,50597,948.0,Biodistribution of Compound in rat heart after 2 minutes of administration,1,CHEMBL625661,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14825,,Liver,,1,N,50597,2107.0,Biodistribution of Compound in rat liver after 15 minutes of administration,1,CHEMBL625662,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14826,,Liver,,1,N,50597,2107.0,Biodistribution of Compound in rat liver after 2 minutes of administration,1,CHEMBL625663,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14827,,Lung,,1,N,50597,2048.0,Biodistribution of Compound in rat lung after 15 minutes of administration,1,CHEMBL875621,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14828,,Lung,,1,N,50597,2048.0,Biodistribution of Compound in rat lung after 2 minutes of administration,1,CHEMBL628382,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14829,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of Compound in rat muscle after 15 minutes of administration,1,CHEMBL628383,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14830,,Muscle tissue,,1,N,50597,2385.0,Biodistribution of Compound in rat muscle after 2 minutes of administration,1,CHEMBL628384,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14831,,,,1,N,50597,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,1,CHEMBL628385,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14832,,,,1,N,50597,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,1,CHEMBL875753,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14833,,,,1,N,50597,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,1,CHEMBL628386,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14834,,,,1,N,50597,,Organ distribution in rat blood 2 minutes after intravenous injection,1,CHEMBL628387,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14835,,,,1,N,50597,,Organ distribution in rat blood 2 hr after intravenous injection,1,CHEMBL628388,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14836,,,,1,N,50597,,Organ distribution in rat blood 30 minutes after intravenous injection,1,CHEMBL628389,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14837,,,,1,N,50597,,Organ distribution in rat blood 30 min after intravenous injection,1,CHEMBL632756,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14838,,,,1,N,50597,,Organ distribution in rat brain 2 minutes after intravenous injection,1,CHEMBL628390,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14839,,,,1,N,50597,,Organ distribution in rat brain 2 hr after intravenous injection,1,CHEMBL631811,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14840,,,,1,N,50597,,Organ distribution in rat brain 30 minutes after intravenous injection,1,CHEMBL631812,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14841,,,,1,N,50597,,Organ distribution in rat heart 2 minutes after intravenous injection,1,CHEMBL631813,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14842,,,,1,N,50597,,Organ distribution in rat heart 2 hr after intravenous injection,1,CHEMBL631814,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14843,,,,1,N,50597,,Organ distribution in rat heart 30 minutes after intravenous injection,1,CHEMBL631815,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14844,,,,1,N,50597,,Organ distribution in rat kidney 2 minutes after intravenous injection,1,CHEMBL631816,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14845,,,,1,N,50597,,Organ distribution in rat kidney 2 hr after intravenous injection,1,CHEMBL875758,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14846,,,,1,N,50597,,Organ distribution in rat kidney 30 minutes after intravenous injection,1,CHEMBL631817,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14847,,Liver,,1,N,50597,2107.0,Organ distribution in rat liver 2 minutes after intravenous injection,1,CHEMBL631818,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14848,,Liver,,1,N,50597,2107.0,Organ distribution in rat liver 2 hr after intravenous injection,1,CHEMBL631819,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14849,,Liver,,1,N,50597,2107.0,Organ distribution in rat liver 30 minutes after intravenous injection,1,CHEMBL631820,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14850,,,,1,N,50597,,Organ distribution in rat lung 2 minutes after intravenous injection,1,CHEMBL631821,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14851,,,,1,N,50597,,Organ distribution in rat lung 2 hr after intravenous injection,1,CHEMBL631822,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14852,,,,1,N,50597,,Organ distribution in rat lung 30 minutes after intravenous injection,1,CHEMBL631823,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14853,,Muscle tissue,,1,N,50597,2385.0,Organ distribution in rat muscle 2 minutes after intravenous injection,1,CHEMBL631824,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14854,,Muscle tissue,,1,N,50597,2385.0,Organ distribution in rat muscle 2 hr after intravenous injection,1,CHEMBL631825,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14855,,Muscle tissue,,1,N,50597,2385.0,Organ distribution in rat muscle 30 minutes after intravenous injection,1,CHEMBL631826,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14856,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),1,CHEMBL631827,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14857,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),1,CHEMBL631828,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14858,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),1,CHEMBL631829,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14859,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,CHEMBL875759,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14860,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,1,CHEMBL631830,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14861,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,1,CHEMBL631831,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14862,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,CHEMBL631832,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14863,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,1,CHEMBL631833,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14864,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,CHEMBL631834,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14865,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,1,CHEMBL631835,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14866,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,CHEMBL631836,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14867,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,CHEMBL631837,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14868,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,CHEMBL631838,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14869,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,1,CHEMBL631839,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14870,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,1,CHEMBL631840,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14871,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,CHEMBL631841,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14872,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,CHEMBL631842,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14873,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,CHEMBL631843,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14874,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,CHEMBL631844,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14875,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,CHEMBL631845,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14876,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,CHEMBL631846,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14877,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,CHEMBL875760,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14878,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,CHEMBL632199,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14879,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,CHEMBL631847,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14880,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,CHEMBL631848,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14881,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,CHEMBL628707,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14882,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,CHEMBL628708,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14883,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,CHEMBL628709,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14884,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,CHEMBL628710,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14885,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,CHEMBL628711,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14886,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,CHEMBL628712,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14887,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,CHEMBL628713,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14888,,Urine,,1,N,50597,1088.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,CHEMBL628714,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14889,,,,1,N,50597,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",1,CHEMBL628715,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14890,,,,1,U,22224,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,0,CHEMBL629179,,,A,,,,Autocuration,,BAO_0000019
14891,,,,1,U,22224,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,0,CHEMBL629180,,,A,,,,Autocuration,,BAO_0000019
14892,,,,1,U,22224,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,0,CHEMBL875108,,,A,,,,Autocuration,,BAO_0000019
14893,,Adrenal cortex,,1,U,22224,1235.0,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,0,CHEMBL629181,,,A,,,,Autocuration,,BAO_0000019
14894,,Adrenal cortex,,1,U,22224,1235.0,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,0,CHEMBL629182,,,A,,,,Autocuration,,BAO_0000019
14895,,,,1,U,22224,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,0,CHEMBL629183,,,A,,,,Autocuration,,BAO_0000019
14896,,,,1,U,22224,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,0,CHEMBL629184,,,A,,,,Autocuration,,BAO_0000019
14897,,Adrenal cortex,,1,U,22224,1235.0,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,0,CHEMBL629185,,,A,,,,Autocuration,,BAO_0000019
14898,,Adrenal cortex,,1,U,22224,1235.0,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,0,CHEMBL629186,,,A,,,,Autocuration,,BAO_0000019
14899,,,,1,U,22224,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,0,CHEMBL629187,,,A,,,,Autocuration,,BAO_0000019
14900,,,,1,U,22224,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,0,CHEMBL629887,,,A,,,,Autocuration,,BAO_0000019
14901,,,,1,U,22224,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,0,CHEMBL629888,,,A,,,,Autocuration,,BAO_0000019
14902,,,,1,U,22224,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,0,CHEMBL629889,,,A,,,,Autocuration,,BAO_0000019
14903,,Adrenal cortex,,1,U,22224,1235.0,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,0,CHEMBL629890,,,A,,,,Autocuration,,BAO_0000019
14904,,,,1,U,22224,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,0,CHEMBL629891,,,A,,,,Autocuration,,BAO_0000019
14905,,,,1,U,22224,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,0,CHEMBL629892,,,A,,,,Autocuration,,BAO_0000019
14906,,Adrenal cortex,,1,U,22224,1235.0,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,0,CHEMBL629893,,,A,,,,Autocuration,,BAO_0000019
14907,,,,1,U,22224,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,0,CHEMBL629894,,,A,,,,Autocuration,,BAO_0000019
14908,,,,1,U,22224,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,0,CHEMBL629895,,,A,,,,Autocuration,,BAO_0000019
14909,,,,1,U,22224,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",0,CHEMBL875109,Canis lupus familiaris,,A,9615.0,In vivo,,Autocuration,,BAO_0000218
14910,,,,1,U,22224,,Absolute bioavailability in male cynomolgus monkeys,0,CHEMBL629896,Macaca fascicularis,,A,9541.0,In vivo,,Autocuration,,BAO_0000218
14911,,,,1,U,22224,,Absolute bioavailability in maleSprague-Dawley rats,0,CHEMBL629897,Rattus norvegicus,,A,10116.0,In vivo,,Autocuration,,BAO_0000218
14912,,Liver,,1,N,50597,2107.0,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL629898,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14913,,Liver,,1,N,50597,2107.0,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630057,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14914,,Liver,,1,N,50597,2107.0,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630058,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14915,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630059,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14916,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630060,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14917,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL630061,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14918,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630062,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14919,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630063,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14920,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630064,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14921,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630065,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14922,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL630066,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14923,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630067,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14924,,Lung,,1,N,50597,2048.0,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630068,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14925,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631113,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14926,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631114,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14927,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL631115,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14928,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL631116,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14929,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630528,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14930,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630529,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14931,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630530,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14932,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL630531,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14933,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630532,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14934,,Muscle tissue,,1,N,50597,2385.0,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630533,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14935,,Blood,,1,N,50594,178.0,Biodistribution in normal mice blood after 120 hr,1,CHEMBL630534,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14936,,Blood,,1,N,50594,178.0,Biodistribution in normal mice blood after 24 hr,1,CHEMBL630535,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14937,,Blood,,1,N,50594,178.0,Biodistribution in normal mice blood after 4 hr,1,CHEMBL630536,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14938,,Bone,,1,N,50594,10000001.0,Biodistribution in normal mice bone after 120 hr,1,CHEMBL630537,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14939,,Bone,,1,N,50594,10000001.0,Biodistribution in normal mice bone after 24 hr,1,CHEMBL630538,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14940,,Bone,,1,N,50594,10000001.0,Biodistribution in normal mice bone after 4 hr,1,CHEMBL630539,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14941,,Heart,,1,N,50594,948.0,Biodistribution in normal mice heart after 120 hr,1,CHEMBL630540,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14942,,Heart,,1,N,50594,948.0,Biodistribution in normal mice heart after 24 hr,1,CHEMBL630541,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14943,,Heart,,1,N,50594,948.0,Biodistribution in normal mice heart after 4 hr,1,CHEMBL630542,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14944,,Kidney,,1,N,50594,2113.0,Biodistribution in normal mice kidney after 120 hr,1,CHEMBL630543,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14945,,Kidney,,1,N,50594,2113.0,Biodistribution in normal mice kidney after 24 hr,1,CHEMBL630544,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14946,,Kidney,,1,N,50594,2113.0,Biodistribution in normal mice kidney after 4 hr,1,CHEMBL630545,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14947,,Liver,,1,N,50594,2107.0,Biodistribution in normal mice liver after 120 hr,1,CHEMBL630546,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14948,,Liver,,1,N,50594,2107.0,Biodistribution in normal mice liver after 24 hr,1,CHEMBL630547,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14949,,Liver,,1,N,50594,2107.0,Biodistribution in normal mice liver after 4 hr,1,CHEMBL630548,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14950,,Spleen,,1,N,50594,2106.0,Biodistribution in normal mice spleen after 120 hr,1,CHEMBL630549,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14951,,Spleen,,1,N,50594,2106.0,Biodistribution in normal mice spleen after 24 hr,1,CHEMBL630550,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14952,,Spleen,,1,N,50594,2106.0,Biodistribution in normal mice spleen after 4 hr,1,CHEMBL876426,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
14953,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630551,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14954,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630552,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14955,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL630553,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14956,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630554,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14957,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630555,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14958,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630556,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14959,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630557,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14960,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,CHEMBL630558,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14961,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630559,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14962,,Spleen,,1,N,50597,2106.0,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL630560,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14963,,Thyroid gland,,1,N,50597,2046.0,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,CHEMBL876427,Rattus norvegicus,,A,10116.0,In vivo,,Intermediate,,BAO_0000218
14964,,,,1,N,50597,,The Kel values in female wistar rats.,1,CHEMBL630561,Rattus norvegicus,,A,10116.0,,,Intermediate,,BAO_0000218
14965,,,,1,U,22224,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,0,CHEMBL630562,,,A,,,,Autocuration,,BAO_0000019
14966,,,,1,U,22224,,Hydrolysis rate constant of the compound,0,CHEMBL630563,,,A,,,,Autocuration,,BAO_0000019
14967,,,,1,U,22229,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,0,CHEMBL629673,,,P,,,,Autocuration,,BAO_0000100
14968,,,,1,U,22224,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",0,CHEMBL629674,,,A,,,,Autocuration,,BAO_0000019
14969,,,,1,U,22224,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",0,CHEMBL629675,,,A,,,,Autocuration,,BAO_0000019
14970,,,,1,U,22224,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",0,CHEMBL629676,,,A,,,,Autocuration,,BAO_0000019
14971,,,,1,U,22224,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",0,CHEMBL629677,,,A,,,,Autocuration,,BAO_0000019
14972,,,,1,U,22224,,Apparent inactivation rate constant was evaluated,0,CHEMBL629678,,,A,,,,Autocuration,,BAO_0000019
14973,,,,1,U,22224,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,0,CHEMBL629679,,,A,,,,Autocuration,,BAO_0000019
14974,,,,1,U,22224,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,0,CHEMBL629680,,,A,,,,Autocuration,,BAO_0000019
14975,,,,1,U,22224,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,0,CHEMBL629681,,,A,,,,Autocuration,,BAO_0000019
14976,,,,1,U,22224,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,0,CHEMBL629682,,,A,,,,Autocuration,,BAO_0000019
14977,,,,1,U,22224,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,0,CHEMBL629683,,,A,,,,Autocuration,,BAO_0000019
14978,,,,1,U,22224,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,0,CHEMBL629684,,,F,,,,Autocuration,,BAO_0000019
14979,,,,1,U,22224,,Dissociation constant was determined,0,CHEMBL629685,,,P,,,,Autocuration,,BAO_0000100
14980,,,,1,U,22224,,Dissociation constant was determined,0,CHEMBL629686,,,P,,,,Autocuration,,BAO_0000100
14981,,,,1,U,22224,,Dissociation constant at pH 7.4,0,CHEMBL872932,,,P,,,,Autocuration,,BAO_0000100
14982,,,,1,U,22224,,Dissociation constant in presence of 1 mM dithiothreitol,0,CHEMBL629687,,,P,,,,Autocuration,,BAO_0000100
14983,,,,1,U,22224,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,0,CHEMBL872931,,,A,,,,Autocuration,,BAO_0000019
14984,,,,1,U,22224,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,0,CHEMBL628151,,,A,,,,Autocuration,,BAO_0000019
14985,,,,1,U,22224,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,0,CHEMBL628152,,,A,,,,Autocuration,,BAO_0000019
14986,,,,1,U,22224,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,0,CHEMBL628153,,,A,,,,Autocuration,,BAO_0000019
14987,,,,1,U,22224,,Kinetic constant for aromatization of androstenedione,0,CHEMBL628154,,,A,,,,Autocuration,,BAO_0000019
14988,,,,1,U,22224,,Kinetic constant for aromatization of testosterone,0,CHEMBL628155,,,A,,,,Autocuration,,BAO_0000019
14989,,,,1,U,22224,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,0,CHEMBL628156,,,A,,,,Autocuration,,BAO_0000019
14990,,,,1,U,22224,,Local inhibition constant was determined,0,CHEMBL628157,,,A,,,,Autocuration,,BAO_0000019
14991,,,,1,N,50347,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,1,CHEMBL857533,Saccharomyces cerevisiae,,A,4932.0,,,Intermediate,,BAO_0000218
14992,,,,1,U,22224,,Dissociation constant value of the compound,0,CHEMBL628158,,,P,,,,Autocuration,,BAO_0000100
14993,,Cornea,,1,U,22224,964.0,In vitro permeability through cornea without epithelium,0,CHEMBL628159,,,A,,,,Autocuration,,BAO_0000019
14994,,Cornea,,1,U,22224,964.0,In vitro permeability through intact cornea,0,CHEMBL875616,,,A,,,,Autocuration,,BAO_0000019
14995,,Cornea,,1,N,50592,964.0,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,1,CHEMBL628160,Oryctolagus cuniculus,,A,9986.0,,,Intermediate,,BAO_0000218
14996,,,,1,U,22224,,Rate of enzyme inactivation for the compound was determined,0,CHEMBL628161,,,A,,,,Autocuration,,BAO_0000019
14997,,Cornea,,1,U,22224,964.0,In vitro permeability through cornea without epithelium,0,CHEMBL628162,,,A,,,,Autocuration,,BAO_0000019
14998,,Cornea,,1,U,22224,964.0,In vitro permeability through intact cornea,0,CHEMBL628163,,,A,,,,Autocuration,,BAO_0000019
14999,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628164,,,A,,,,Autocuration,,BAO_0000019
15000,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628165,,,A,,,,Autocuration,,BAO_0000019
15001,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628166,,,A,,,,Autocuration,,BAO_0000019
15002,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628167,,,A,,,,Autocuration,,BAO_0000019
15003,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628168,,,A,,,,Autocuration,,BAO_0000019
15004,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628169,,,A,,,,Autocuration,,BAO_0000019
15005,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628170,,,A,,,,Autocuration,,BAO_0000019
15006,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628171,,,A,,,,Autocuration,,BAO_0000019
15007,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL627434,,,A,,,,Autocuration,,BAO_0000019
15008,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL627435,,,A,,,,Autocuration,,BAO_0000019
15009,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628110,,,A,,,,Autocuration,,BAO_0000019
15010,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628111,,,A,,,,Autocuration,,BAO_0000019
15011,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628112,,,A,,,,Autocuration,,BAO_0000019
15012,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628260,,,A,,,,Autocuration,,BAO_0000019
15013,,,,1,U,22224,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,CHEMBL628261,,,A,,,,Autocuration,,BAO_0000019
15014,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),1,CHEMBL628262,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
15015,,,,1,N,50587,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,1,CHEMBL628263,Homo sapiens,,A,9606.0,In vivo,,Intermediate,,BAO_0000218
15016,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),1,CHEMBL628264,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
15017,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),1,CHEMBL628265,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
15018,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),1,CHEMBL628266,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
15019,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),1,CHEMBL628267,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
15020,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,1,CHEMBL628268,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
15021,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),1,CHEMBL628269,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
15022,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),1,CHEMBL628270,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
15023,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),1,CHEMBL628271,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
15024,,,,1,N,50594,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),1,CHEMBL628272,Mus musculus,,A,10090.0,In vivo,,Intermediate,,BAO_0000218
1,,,,1,H,12052,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,8,CHEMBL615117,,,B,,,,Autocuration,,BAO_0000019
2,,,,1,U,22226,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,0,CHEMBL615118,,,F,,,,Autocuration,,BAO_0000219
3,,,,1,U,22226,,,0,CHEMBL615119,,,B,,,,Autocuration,,BAO_0000019
4,,,,1,H,104729,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,4,CHEMBL615120,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000249
5,,,,1,N,80001,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,CHEMBL615121,Homo sapiens,,F,9606.0,,143B,Intermediate,163.0,BAO_0000219
6,,,,1,N,80001,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,CHEMBL615122,Homo sapiens,,F,9606.0,,143B,Intermediate,163.0,BAO_0000219
7,,,,1,N,80001,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,1,CHEMBL615123,Mus musculus,,F,10090.0,,143B,Intermediate,163.0,BAO_0000219
8,,,,1,N,80001,,In vitro cell cytotoxicity was determined against 143B cell line,1,CHEMBL615124,Homo sapiens,,F,9606.0,,143B,Expert,163.0,BAO_0000219
9,,,,1,N,80001,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,1,CHEMBL615125,Homo sapiens,,F,9606.0,,143B,Intermediate,163.0,BAO_0000219
10,,,,1,N,80001,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,CHEMBL615126,Homo sapiens,,F,9606.0,,143B,Intermediate,163.0,BAO_0000219
11,,,,1,N,80001,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,CHEMBL615127,Homo sapiens,,F,9606.0,,143B,Intermediate,163.0,BAO_0000219
12,,,,1,N,80001,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,1,CHEMBL615128,Homo sapiens,,F,9606.0,,143B,Expert,163.0,BAO_0000219
13,,,,1,N,50185,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,CHEMBL857900,Staphylococcus aureus,,F,1280.0,,,Intermediate,,BAO_0000218
14,,,,1,N,50185,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,CHEMBL615129,Staphylococcus aureus,,F,1280.0,,,Intermediate,,BAO_0000218
15,,,,1,N,50185,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,CHEMBL615130,Staphylococcus aureus,,F,1280.0,,,Intermediate,,BAO_0000218
16,,,,1,N,50185,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,CHEMBL615131,Staphylococcus aureus,,F,1280.0,,,Intermediate,,BAO_0000218
17,,,,1,D,100122,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,9,CHEMBL884521,Rattus norvegicus,,A,10116.0,,,Expert,,BAO_0000357
18,,,,1,H,12054,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),8,CHEMBL615132,,,B,,,,Autocuration,,BAO_0000357
19,,,,1,H,12054,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,8,CHEMBL615133,,,B,,,,Autocuration,,BAO_0000019
20,,,,1,H,12054,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),8,CHEMBL615134,,,B,,,,Autocuration,,BAO_0000357
21,,,,1,H,12054,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),8,CHEMBL615135,,,B,,,,Autocuration,,BAO_0000357
22,,,,1,H,12054,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),8,CHEMBL615136,,,B,,,,Autocuration,,BAO_0000357
23,,,,1,H,12054,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,8,CHEMBL615137,,,B,,,,Autocuration,,BAO_0000357
24,,,,1,H,12054,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,8,CHEMBL615138,,,B,,,,Autocuration,,BAO_0000357
25,,,,1,U,22226,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",0,CHEMBL836324,,,B,,,,Autocuration,,BAO_0000219
26,,,,1,H,12054,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,8,CHEMBL615139,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000357
27,,,,1,H,12054,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),8,CHEMBL615140,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000357
28,,,,1,H,12426,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,8,CHEMBL615141,,,B,,,,Autocuration,,BAO_0000219
29,,,,1,H,12054,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,8,CHEMBL615142,soya bean,,B,3847.0,,,Autocuration,,BAO_0000357
30,,,,1,H,12054,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,8,CHEMBL615143,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
31,,,,1,H,12054,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,8,CHEMBL615144,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
32,,,,1,H,12054,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,8,CHEMBL872867,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
33,,,,1,H,12054,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,8,CHEMBL615145,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
34,,,,1,H,12054,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,8,CHEMBL615146,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
35,,,,1,H,12054,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,8,CHEMBL615147,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
36,,,,1,U,22226,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,0,CHEMBL615148,Rattus norvegicus,,A,10116.0,,,Autocuration,,BAO_0000019
37,,,,1,U,22226,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,0,CHEMBL615149,Escherichia coli,,B,562.0,,,Autocuration,,BAO_0000019
38,,,,1,U,22226,,Dissociation constant with dimeric 16S rRNA RNA construct B,0,CHEMBL615150,,,B,,,,Autocuration,,BAO_0000019
39,,,,1,M,22222,,Dissociation constant towards 16S rRNA construct A,3,CHEMBL615151,,,B,,,,Intermediate,,BAO_0000225
40,,,,1,M,22222,,Dissociation constant towards 16S rRNA construct B,3,CHEMBL615152,,,B,,,,Intermediate,,BAO_0000225
41,,,,1,M,100263,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,3,CHEMBL615153,Escherichia coli,,B,562.0,,,Expert,,BAO_0000225
42,,,,1,M,100263,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,3,CHEMBL615154,Escherichia coli,,B,562.0,,,Expert,,BAO_0000225
43,,,,1,H,13053,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),8,CHEMBL615155,,,B,,,,Autocuration,,BAO_0000019
44,,,,1,H,13053,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),8,CHEMBL615156,,,B,,,,Autocuration,,BAO_0000019
45,,,,1,H,20001,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,8,CHEMBL615157,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000019
46,,,,1,H,20001,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,8,CHEMBL615158,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000019
47,,,,1,D,12971,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",9,CHEMBL615159,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
48,,,,1,D,12971,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",9,CHEMBL615172,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
49,,,,1,D,12971,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",9,CHEMBL615173,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
50,,,,1,D,12971,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",9,CHEMBL615174,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
51,,,,1,H,13053,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),8,CHEMBL884518,,,B,,,,Autocuration,,BAO_0000019
52,,,,1,H,11512,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),8,CHEMBL615175,,,B,,,,Autocuration,,BAO_0000357
53,,,,1,H,11512,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,8,CHEMBL615176,,,B,,,,Autocuration,,BAO_0000357
54,,,,1,H,11512,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,8,CHEMBL615177,,,B,,,,Autocuration,,BAO_0000357
55,,,,1,D,104740,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,5,CHEMBL615178,Rattus norvegicus,Membranes,B,10116.0,,,Autocuration,,BAO_0000249
56,,,,1,N,80002,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,1,CHEMBL615179,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
57,,,,1,D,104835,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,7,CHEMBL615180,Rattus norvegicus,,F,10116.0,,Oocytes,Autocuration,,BAO_0000219
58,,,,1,D,104821,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,7,CHEMBL615181,Rattus norvegicus,,F,10116.0,,Oocytes,Autocuration,,BAO_0000219
59,,,,1,D,104848,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,7,CHEMBL615182,Rattus norvegicus,,F,10116.0,,Oocytes,Autocuration,,BAO_0000219
60,,,,1,N,80002,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,1,CHEMBL615183,Homo sapiens,,F,9606.0,,1A9,Expert,506.0,BAO_0000219
61,,,,1,N,80002,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,1,CHEMBL615184,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
62,,,,1,N,80002,,Cytotoxic activity against human ovarian cancer (1A9) cell line,1,CHEMBL615185,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
63,,,,1,N,80002,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,1,CHEMBL615186,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
64,,,,1,N,80002,,Effective dose of compound against replication of 1A9 cell line was evaluated,1,CHEMBL615187,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
65,,,,1,N,80002,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,1,CHEMBL885343,Homo sapiens,,F,9606.0,,1A9,Expert,506.0,BAO_0000219
66,,,,1,N,80002,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),1,CHEMBL615188,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
67,,,,1,N,80002,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,1,CHEMBL615189,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
68,,,,1,N,80002,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,1,CHEMBL615190,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
69,,,,1,N,80002,,Inhibitory activity against Taxol resistant 1A9 cell lines,1,CHEMBL615191,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
70,,,,1,N,80002,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,1,CHEMBL615192,Homo sapiens,,F,9606.0,,1A9,Expert,506.0,BAO_0000219
71,,,,1,N,80002,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,1,CHEMBL827083,Homo sapiens,,F,9606.0,,1A9,Expert,506.0,BAO_0000219
72,,,,1,N,80002,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,1,CHEMBL615193,Homo sapiens,,F,9606.0,,1A9,Expert,506.0,BAO_0000219
73,,,,1,N,80002,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,1,CHEMBL615194,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
74,,,,1,N,80002,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,1,CHEMBL615195,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
75,,,,1,N,80002,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,1,CHEMBL615196,Homo sapiens,,F,9606.0,,1A9,Intermediate,506.0,BAO_0000219
76,,,,1,N,81072,,Inhibitory concentration against Jurkat cells,1,CHEMBL615197,Homo sapiens,,F,9606.0,,Jurkat,Intermediate,503.0,BAO_0000219
77,,,,1,U,22226,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,0,CHEMBL615198,,,F,,,,Intermediate,,BAO_0000019
78,,,,1,D,100121,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,9,CHEMBL615199,Rattus norvegicus,,A,10116.0,,,Expert,,BAO_0000357
79,,,,1,H,11231,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",8,CHEMBL615200,,,B,,,,Expert,,BAO_0000357
80,,,,1,H,11231,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",8,CHEMBL615201,,,B,,,,Expert,,BAO_0000357
81,,,,1,H,11231,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",8,CHEMBL615202,,,B,,,,Expert,,BAO_0000357
82,,,,1,H,11231,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",8,CHEMBL615203,Candida albicans,Microsomes,B,5476.0,,,Autocuration,,BAO_0000251
83,,,,1,H,11231,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",8,CHEMBL615204,Candida albicans,Microsomes,B,5476.0,,,Autocuration,,BAO_0000251
84,,,,1,H,11231,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",8,CHEMBL615205,Saccharomyces cerevisiae,Microsomes,B,4932.0,,,Autocuration,,BAO_0000251
85,,,,1,H,11231,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",8,CHEMBL615206,Saccharomyces cerevisiae,Microsomes,B,4932.0,,,Autocuration,,BAO_0000251
86,,Liver,,1,H,12083,2107.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",8,CHEMBL615207,Sus scrofa,Microsomes,B,9823.0,,,Autocuration,,BAO_0000251
87,,,,1,H,11231,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",8,CHEMBL827084,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
88,,,,1,H,11231,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",8,CHEMBL615208,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
89,,,,1,H,11231,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",8,CHEMBL615209,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
90,,Liver,,1,D,12083,2107.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",9,CHEMBL615210,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
91,,Liver,,1,D,12083,2107.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",9,CHEMBL615211,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
92,,Liver,,1,D,12083,2107.0,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",9,CHEMBL615212,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
93,,,,1,H,11377,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),8,CHEMBL615213,,,B,,,,Expert,,BAO_0000357
94,,,,1,H,11377,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,8,CHEMBL615273,,,B,,,,Expert,,BAO_0000357
95,,,,1,N,81020,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,CHEMBL615274,Homo sapiens,,F,9606.0,,HepG2,Expert,726.0,BAO_0000219
96,,,,1,N,81020,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,1,CHEMBL615275,Homo sapiens,,F,9606.0,,HepG2,Intermediate,726.0,BAO_0000219
97,,,,1,N,81020,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,1,CHEMBL615276,Homo sapiens,,F,9606.0,,HepG2,Intermediate,726.0,BAO_0000219
98,,,,1,N,81020,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,1,CHEMBL615277,Homo sapiens,,F,9606.0,,HepG2,Intermediate,726.0,BAO_0000219
99,,,,1,N,81020,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,1,CHEMBL615326,Homo sapiens,,F,9606.0,,HepG2,Intermediate,726.0,BAO_0000219
100,,,,1,N,50606,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,CHEMBL883130,Hepatitis B virus,,F,10407.0,,,Expert,,BAO_0000218
101,,,,1,N,81020,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,1,CHEMBL884519,Homo sapiens,,F,9606.0,,HepG2,Intermediate,726.0,BAO_0000219
102,,,,1,N,81020,,Concentration required to inhibit 50% of 2.2.15 cell line,1,CHEMBL615327,Homo sapiens,,F,9606.0,,HepG2,Intermediate,726.0,BAO_0000219
103,,,,1,N,81020,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,1,CHEMBL615328,Homo sapiens,,A,9606.0,,HepG2,Intermediate,726.0,BAO_0000219
104,,,,1,N,50587,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,1,CHEMBL615329,Homo sapiens,,F,9606.0,,2.2.15,Intermediate,,BAO_0000218
105,,,,1,N,50587,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,1,CHEMBL615330,Homo sapiens,,F,9606.0,,2.2.15,Intermediate,,BAO_0000218
106,,,,1,N,50606,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",1,CHEMBL615331,Hepatitis B virus,,F,10407.0,,2.2.15,Expert,,BAO_0000218
107,,,,1,N,50587,,In vitro anti-HBV activity in 2.2.15 cells,1,CHEMBL615332,Homo sapiens,,F,9606.0,,2.2.15,Intermediate,,BAO_0000218
108,,,,1,N,50587,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,1,CHEMBL615333,Homo sapiens,,F,9606.0,,2.2.15,Intermediate,,BAO_0000218
109,,,,1,N,50587,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,1,CHEMBL615334,Homo sapiens,,F,9606.0,,2.2.15,Intermediate,,BAO_0000218
110,,,,1,N,50587,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,1,CHEMBL615335,Homo sapiens,,F,9606.0,,2.2.15,Intermediate,,BAO_0000218
111,,,,1,N,50587,,Cytotoxicity in 2.2.15 cells,1,CHEMBL615336,Homo sapiens,,F,9606.0,,2.2.15,Intermediate,,BAO_0000218
112,,,,1,N,50587,,Cytotoxicity in 2.2.15 cells; Not determined,1,CHEMBL615337,Homo sapiens,,F,9606.0,,2.2.15,Intermediate,,BAO_0000218
113,,,,1,N,50587,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,1,CHEMBL615338,Homo sapiens,,F,9606.0,,2.2.15,Intermediate,,BAO_0000218
114,,,,1,N,50587,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,1,CHEMBL615339,Homo sapiens,,F,9606.0,,2.2.15,Intermediate,,BAO_0000218
115,,,,1,N,50587,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,1,CHEMBL615340,Homo sapiens,,F,9606.0,,2.2.15,Intermediate,,BAO_0000218
116,,,,1,N,81020,,Antiviral activity against HBV was determined in 2.215 cell line,1,CHEMBL615341,Homo sapiens,,F,9606.0,,HepG2,Intermediate,726.0,BAO_0000219
117,,,,1,U,22226,,Inhibition of 20-HETE synthesis in human renal microsomes,0,CHEMBL615342,Homo sapiens,Microsomes,B,9606.0,,,Autocuration,,BAO_0000251
118,,,,1,U,22226,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,0,CHEMBL615343,,,B,,,,Autocuration,,BAO_0000019
119,,,,1,N,80612,,Inhibitory concentration against 2008 (ovarian) cells,1,CHEMBL615344,Homo sapiens,,F,9606.0,,2008,Intermediate,388.0,BAO_0000219
120,,,,1,N,80612,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,1,CHEMBL615345,Homo sapiens,,F,9606.0,,2008,Intermediate,388.0,BAO_0000219
121,,,,1,N,80612,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),1,CHEMBL615346,Homo sapiens,,F,9606.0,,2008,Intermediate,388.0,BAO_0000219
122,,,,1,N,80612,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,1,CHEMBL615347,Homo sapiens,,F,9606.0,,2008,Intermediate,388.0,BAO_0000219
123,,,,1,N,80612,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,1,CHEMBL615348,Homo sapiens,,F,9606.0,,2008,Intermediate,388.0,BAO_0000219
124,,,,1,N,80613,,In vitro inhibition of 2008/R ovarian cancer cell line,1,CHEMBL827085,Homo sapiens,,F,9606.0,,2008/R,Intermediate,561.0,BAO_0000219
125,,,,1,N,80613,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,1,CHEMBL615349,Homo sapiens,,F,9606.0,,2008/R,Intermediate,561.0,BAO_0000219
126,,,,1,N,80614,,In vitro inhibition of 2008/S ovarian cancer cell line,1,CHEMBL615350,Homo sapiens,,F,9606.0,,2008/S,Intermediate,389.0,BAO_0000219
127,,,,1,N,80614,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,1,CHEMBL615351,Homo sapiens,,F,9606.0,,2008/S,Intermediate,389.0,BAO_0000219
128,,,,1,S,100256,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,2,CHEMBL615352,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000220
129,,,,1,S,100256,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,2,CHEMBL615353,Homo sapiens,,B,9606.0,,,Intermediate,,BAO_0000220
130,,,,1,S,100256,,Inhibition of chymotrypsin-like activity of 20S proteasome,2,CHEMBL615354,,,B,,,,Expert,,BAO_0000220
131,,,,1,S,100256,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,2,CHEMBL615355,,,B,,,,Expert,,BAO_0000220
132,,,,1,S,100256,,Inhibitory activity against 20S proteosome,2,CHEMBL615356,,,B,,,,Intermediate,,BAO_0000220
133,,,,1,U,22226,,Compound was tested for inhibitory activity against tryptase,0,CHEMBL615357,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000019
134,,,,1,N,81020,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,1,CHEMBL615358,Homo sapiens,,F,9606.0,,HepG2,Intermediate,726.0,BAO_0000219
135,,,,1,N,81020,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,1,CHEMBL827086,Homo sapiens,,F,9606.0,,HepG2,Intermediate,726.0,BAO_0000219
136,,,,1,U,22226,,Compound was tested for the inhibition of Alpha-glucosidase,0,CHEMBL615359,,,B,,,,Autocuration,,BAO_0000019
137,,,,1,H,235,,Inhibitory concentration against human neutrophil elastase (HNE),8,CHEMBL615360,,,B,,,,Autocuration,,BAO_0000357
138,,Heart,,1,U,22226,948.0,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,0,CHEMBL615361,Rattus norvegicus,,F,10116.0,,,Autocuration,,BAO_0000218
139,,,,1,H,19640,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,8,CHEMBL615362,,,F,,,,Autocuration,,BAO_0000019
140,,,,1,H,19640,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,8,CHEMBL615363,,,F,,,,Expert,,BAO_0000019
141,,,,1,H,19640,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,8,CHEMBL615364,,,B,,,,Autocuration,,BAO_0000357
142,,,,1,H,19640,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,8,CHEMBL615365,,,F,,,,Expert,,BAO_0000019
143,,,,1,N,80360,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,1,CHEMBL615366,Mus musculus,,F,10090.0,,P338,Intermediate,524.0,BAO_0000219
144,,,,1,N,80360,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,1,CHEMBL615367,Mus musculus,,F,10090.0,,P338,Intermediate,524.0,BAO_0000219
145,,,,1,N,80384,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,1,CHEMBL615368,Homo sapiens,,F,9606.0,,PBL,Intermediate,554.0,BAO_0000219
146,,,,1,U,22226,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,0,CHEMBL615369,Ovis aries,,F,9940.0,,,Autocuration,,BAO_0000019
147,,,,1,U,22226,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,0,CHEMBL615370,Ovis aries,,F,9940.0,,,Autocuration,,BAO_0000019
148,,,,1,H,191,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),8,CHEMBL615673,,,B,,,,Autocuration,,BAO_0000357
149,,,,1,U,22226,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,0,CHEMBL615674,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
150,,,,1,U,22226,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,0,CHEMBL615675,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
151,,,,1,U,22226,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,0,CHEMBL615676,Homo sapiens,,F,9606.0,,CCRF-CEM,Autocuration,635.0,BAO_0000219
152,,,,1,U,22226,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,0,CHEMBL615677,Homo sapiens,,F,9606.0,,CCRF-CEM,Autocuration,635.0,BAO_0000219
153,,,,1,U,22226,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,0,CHEMBL615678,Homo sapiens,,F,9606.0,,CCRF-CEM,Autocuration,635.0,BAO_0000219
154,,,,1,U,22226,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,0,CHEMBL615679,Homo sapiens,,F,9606.0,,CCRF-CEM,Autocuration,635.0,BAO_0000219
155,,,,1,U,22226,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,0,CHEMBL615680,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
156,,,,1,U,22226,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,0,CHEMBL615681,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
157,,,,1,H,104290,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,6,CHEMBL857972,,,B,,,,Autocuration,,BAO_0000249
158,,,,1,N,50264,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,1,CHEMBL857899,Streptococcus pyogenes,,F,1314.0,,,Intermediate,,BAO_0000218
159,,,,1,N,50527,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),1,CHEMBL615371,Human herpesvirus 3,,F,10335.0,,,Intermediate,,BAO_0000218
160,,,,1,N,50527,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,1,CHEMBL615372,vericilla zoster virus,,F,10335.0,,HEL,Expert,468.0,BAO_0000218
161,,,,1,N,50527,,Antiviral activity against 07/1 strain of VZV; ND: No data,1,CHEMBL615373,vericilla zoster virus,,F,10335.0,,,Intermediate,,BAO_0000218
162,,,,1,N,50527,,Antiviral activity against 07/1 strain of VZV; ND=No data,1,CHEMBL615374,vericilla zoster virus,,F,10335.0,,,Intermediate,,BAO_0000218
163,,,,1,N,50145,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",1,CHEMBL615375,escherichia cloac,,F,561.0,,,Intermediate,,BAO_0000218
164,,,,1,U,22226,,Ratio of Ki at A2 to Ki at A1 receptors,0,CHEMBL615376,,,B,,,,Autocuration,,BAO_0000019
165,,,,1,H,11143,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",8,CHEMBL615377,Candida albicans,,B,5476.0,,,Expert,,BAO_0000249
166,,,,1,H,18077,,"Inhibition of 1,3-beta-glucan synthase",8,CHEMBL615378,Candida glabrata CBS 138,,B,284593.0,,,Expert,,BAO_0000357
167,,,,1,N,80609,,Inhibition of growth of 1-87 human tumor cell line,1,CHEMBL615379,Homo sapiens,,F,9606.0,,1-87 tumor cell line,Intermediate,832.0,BAO_0000219
168,,,,1,D,12166,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,9,CHEMBL615380,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000219
169,,,,1,D,100171,,Inhibitory activity against soybean 1-lipoxygenase (SLO),9,CHEMBL615381,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
170,,,,1,D,100171,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,9,CHEMBL615382,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
171,,,,1,D,100171,,% inhibition against soybean 1-lipoxygenase (SLO),9,CHEMBL615383,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
172,,,,1,D,100171,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,9,CHEMBL615384,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
173,,,,1,D,100171,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,9,CHEMBL615385,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
174,,,,1,D,100171,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,9,CHEMBL615386,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
175,,,,1,D,100171,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,9,CHEMBL615387,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
176,,,,1,D,100171,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,9,CHEMBL615388,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
177,,,,1,D,100171,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,9,CHEMBL615214,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
178,,,,1,D,100171,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,9,CHEMBL827087,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
179,,,,1,D,100171,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,9,CHEMBL615215,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
180,,,,1,D,100171,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,9,CHEMBL615216,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
181,,,,1,D,100171,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,9,CHEMBL615217,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
182,,,,1,D,100171,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,9,CHEMBL615218,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
183,,,,1,D,100171,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,9,CHEMBL615219,Glycine max,,B,3847.0,,,Autocuration,,BAO_0000357
184,,,,1,U,22226,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,0,CHEMBL615220,Mus musculus,,B,10090.0,,,Autocuration,,BAO_0000019
185,,,,1,N,80049,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),1,CHEMBL615221,Mus musculus,,F,10090.0,,C3H 10T1/2,Intermediate,294.0,BAO_0000219
186,,,,1,U,22226,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,0,CHEMBL615222,,,F,,,,Intermediate,,BAO_0000019
187,,,,1,H,11489,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),8,CHEMBL615223,,,B,,,,Autocuration,,BAO_0000357
188,,,,1,H,11862,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),8,CHEMBL615224,,,B,,,,Autocuration,,BAO_0000357
189,,,,1,H,11862,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,8,CHEMBL615225,,,B,,,,Autocuration,,BAO_0000357
190,,,,1,H,11489,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,8,CHEMBL615226,,,B,,,,Autocuration,,BAO_0000357
191,,,,1,H,11862,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,8,CHEMBL615227,,,B,,,,Autocuration,,BAO_0000357
192,,,,1,D,12347,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,9,CHEMBL615228,Bos taurus,,F,9913.0,,,Expert,,BAO_0000019
193,,,,1,D,100120,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,9,CHEMBL615229,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
194,,Adrenal gland,,1,D,100120,2369.0,Inhibition of 11 beta-hydroxylase from rat adrenal gland,9,CHEMBL615230,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
195,,,,1,D,100120,,Inhibition of rat adrenal 11-beta-hydroxylase,9,CHEMBL615231,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
196,,,,1,D,100120,,Inhibition of rat adrenal 11-beta-hydroxylase,9,CHEMBL884520,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
197,,,,1,D,100120,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,9,CHEMBL615232,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
198,,,,1,H,10328,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,8,CHEMBL615233,,,B,,,,Autocuration,,BAO_0000019
199,,,,1,H,11490,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,8,CHEMBL827088,,,B,,,,Autocuration,,BAO_0000357
200,,,,1,H,11490,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,8,CHEMBL615234,,,B,,,,Autocuration,,BAO_0000357
201,,,,1,H,11134,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,8,CHEMBL615235,,,F,,,,Autocuration,,BAO_0000019
202,,,,1,H,12052,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,8,CHEMBL615236,,,B,,,,Autocuration,,BAO_0000019
203,,,,1,H,11134,,Compound was tested in vitro for inhibition of 12-LO human platelet,8,CHEMBL615237,,,B,,,,Autocuration,,BAO_0000019
204,,,,1,H,11134,,Inhibitory concentration against human platelet 12-lipoxygenase,8,CHEMBL615238,,,F,,,,Autocuration,,BAO_0000019
205,,,,1,H,11134,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,8,CHEMBL615239,,,B,,,,Autocuration,,BAO_0000019
206,,,,1,D,11134,,Inhibitory concentration against human platelet 12-lipoxygenase,9,CHEMBL615240,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
207,,,,1,H,11835,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,8,CHEMBL615241,,,B,,,,Expert,,BAO_0000019
208,,,,1,H,11601,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,8,CHEMBL615242,,,B,,,,Expert,,BAO_0000357
209,,,,1,H,11134,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),8,CHEMBL615243,,,B,,,,Autocuration,,BAO_0000019
210,,,,1,H,11134,,Inhibitory activity against human platelet 12-lipoxygenase,8,CHEMBL615244,,,B,,,,Autocuration,,BAO_0000019
211,,,,1,H,11134,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,8,CHEMBL615245,,,B,,,,Autocuration,,BAO_0000019
212,,,,1,H,11134,,% inhibition against human platelet 12-lipoxygenase (12-HLO),8,CHEMBL615246,,,B,,,,Autocuration,,BAO_0000019
213,,,,1,H,11134,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,8,CHEMBL615247,,,B,,,,Autocuration,,BAO_0000019
214,,,,1,H,11134,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,8,CHEMBL615248,,,B,,,,Autocuration,,BAO_0000019
215,,,,1,H,11601,,Inhibitory activity towards porcine 12-lipoxygenase,8,CHEMBL615249,,,B,,,,Autocuration,,BAO_0000357
216,,,,1,H,11601,,Tested for inhibition against porcine 12-LO,8,CHEMBL615250,,,B,,,,Autocuration,,BAO_0000357
217,,,,1,H,12052,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,8,CHEMBL615251,,,B,,,,Autocuration,,BAO_0000019
218,,,,1,H,12052,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,8,CHEMBL615252,,,B,,,,Autocuration,,BAO_0000019
219,,,,1,H,12052,,In vitro inhibition of rat platelet 12-lipoxygenase,8,CHEMBL828340,,,B,,,,Expert,,BAO_0000019
220,,,,1,H,12052,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,8,CHEMBL615253,,,B,,,,Autocuration,,BAO_0000019
221,,,,1,H,12052,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,8,CHEMBL615254,,,B,,,,Autocuration,,BAO_0000019
222,,,,1,H,12052,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,8,CHEMBL615255,,,B,,,,Autocuration,,BAO_0000019
223,,,,1,H,12052,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,8,CHEMBL615256,,,B,,,,Autocuration,,BAO_0000019
224,,,,1,H,12052,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,8,CHEMBL615257,,,B,,,,Autocuration,,BAO_0000019
225,,,,1,H,12052,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,8,CHEMBL615258,,,B,,,,Autocuration,,BAO_0000019
226,,,,1,N,80007,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,1,CHEMBL615259,Homo sapiens,,F,9606.0,,41M,Intermediate,621.0,BAO_0000219
227,,,,1,N,80007,,In vitro antitumor activity against 41M cell line.,1,CHEMBL615260,Homo sapiens,,F,9606.0,,41M,Expert,621.0,BAO_0000219
228,,,,1,N,80007,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,1,CHEMBL615261,Homo sapiens,,F,9606.0,,41M,Intermediate,621.0,BAO_0000219
229,,,,1,N,80007,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,1,CHEMBL615262,Homo sapiens,,F,9606.0,,41M,Intermediate,621.0,BAO_0000219
230,,,,1,N,80007,,In vitro antitumor activity against 41McisR cell line.,1,CHEMBL615263,Homo sapiens,,F,9606.0,,41M,Expert,621.0,BAO_0000219
231,,,,1,N,80007,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,1,CHEMBL838393,Homo sapiens,,F,9606.0,,41M,Expert,621.0,BAO_0000219
232,,,,1,N,80007,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,1,CHEMBL615264,Homo sapiens,,F,9606.0,,41M,Intermediate,621.0,BAO_0000219
233,,,,1,D,84,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),9,CHEMBL615265,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
234,,,,1,D,68,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),9,CHEMBL615266,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
235,,,,1,H,68,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),8,CHEMBL615267,,,B,,,,Expert,,BAO_0000357
236,,,,1,H,10201,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,8,CHEMBL615268,,,B,,,,Expert,,BAO_0000357
237,,,,1,H,10201,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,8,CHEMBL615269,,,B,,,,Expert,,BAO_0000357
238,,,,1,H,10201,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,8,CHEMBL615270,,,B,,,,Expert,,BAO_0000357
239,,,,1,H,12220,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",8,CHEMBL615271,,,B,,,,Autocuration,,BAO_0000357
240,,,,1,H,11303,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",8,CHEMBL615272,Escherichia coli,,B,562.0,,,Autocuration,,BAO_0000357
241,,,,1,H,11303,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",8,CHEMBL615103,Escherichia coli,,B,562.0,,,Autocuration,,BAO_0000357
242,,,,1,H,11303,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",8,CHEMBL615104,Escherichia coli,,B,562.0,,,Autocuration,,BAO_0000357
243,,,,1,H,12220,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",8,CHEMBL615105,,,B,,,,Autocuration,,BAO_0000357
244,,,,1,H,12220,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",8,CHEMBL872866,,,B,,,,Autocuration,,BAO_0000357
245,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",8,CHEMBL615106,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
246,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",8,CHEMBL615107,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
247,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",8,CHEMBL615108,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
248,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",8,CHEMBL615109,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
249,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",8,CHEMBL615110,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
250,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",8,CHEMBL840105,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
251,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",8,CHEMBL615111,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
252,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",8,CHEMBL615112,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
253,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",8,CHEMBL615113,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
254,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",8,CHEMBL615114,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
255,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",8,CHEMBL615115,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
256,,,,1,H,11303,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",8,CHEMBL615116,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
257,,,,1,H,11303,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",8,CHEMBL615698,,,B,,,,Autocuration,,BAO_0000357
258,,,,1,U,22226,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",0,CHEMBL615699,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
259,,,,1,U,22226,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",0,CHEMBL615700,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
260,,,,1,H,100249,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,8,CHEMBL615701,Saccharomyces cerevisiae,,B,4932.0,,,Expert,,BAO_0000357
261,,,,1,U,22226,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,0,CHEMBL615702,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
262,,,,1,U,22226,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,0,CHEMBL615703,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
263,,,,1,U,22226,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",0,CHEMBL615704,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
264,,,,1,H,104698,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",6,CHEMBL615705,,,F,,,,Autocuration,,BAO_0000019
265,,,,1,H,104698,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",6,CHEMBL615706,,,F,,,,Autocuration,,BAO_0000019
266,,Ileum,,1,D,20033,2116.0,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,9,CHEMBL615707,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
267,,,,1,H,10623,,Stimulatory activity of intragastric pressure was tested in the rat,8,CHEMBL615708,,,F,,,,Expert,,BAO_0000019
268,,,,1,H,121,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,8,CHEMBL615709,,,B,,,,Autocuration,,BAO_0000357
269,,,,1,U,22226,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),0,CHEMBL615710,Rattus norvegicus,,F,10116.0,,,Autocuration,,BAO_0000218
270,,,,1,H,12688,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,8,CHEMBL615711,,,F,,,,Autocuration,,BAO_0000019
271,,,,1,D,121,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,9,CHEMBL615712,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
272,,,,1,D,121,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,9,CHEMBL836325,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
273,,,,1,H,12198,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,8,CHEMBL615713,,,F,,,,Autocuration,,BAO_0000019
274,,,,1,H,12198,,Inhibition constant of high-affinity 5-HT uptake,8,CHEMBL615714,,,B,,,,Autocuration,,BAO_0000357
275,,,,1,H,12198,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,8,CHEMBL615715,,,F,,,,Autocuration,,BAO_0000019
276,,,,1,H,12198,,Maximum rate was determined for high affinity transport of 5-HT,8,CHEMBL615716,,,F,,,,Autocuration,,BAO_0000019
277,,,,1,H,104714,,Compound was tested for agonistic activity against 5-HT uptake,4,CHEMBL615717,,,F,,,,Autocuration,,BAO_0000019
278,,,,1,H,10577,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,8,CHEMBL881818,,,B,,,,Expert,,BAO_0000019
279,,,,1,H,105,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,8,CHEMBL884540,Bos taurus,,B,9913.0,,,Expert,,BAO_0000357
280,,,,1,D,104744,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,5,CHEMBL615718,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
281,,,,1,H,104744,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,4,CHEMBL615719,,,B,,,,Autocuration,,BAO_0000224
282,,,,1,H,104744,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,4,CHEMBL615720,,Membranes,B,,,,Autocuration,,BAO_0000249
283,,,,1,H,104744,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,4,CHEMBL615721,,Membranes,B,,,,Autocuration,,BAO_0000249
284,,,,1,H,104744,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,4,CHEMBL615722,,,B,,,,Autocuration,,BAO_0000019
285,,,,1,H,51,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,8,CHEMBL615723,,,F,,,,Autocuration,,BAO_0000019
286,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,CHEMBL615724,,,B,,,,Autocuration,,BAO_0000221
287,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,8,CHEMBL615725,,,B,,,,Autocuration,,BAO_0000221
288,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,CHEMBL615726,,,B,,,,Autocuration,,BAO_0000221
289,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),8,CHEMBL615727,,,F,,In vivo,,Autocuration,,BAO_0000218
290,,,,1,D,105570,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,9,CHEMBL615728,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000019
291,,,,1,H,279,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,8,CHEMBL857971,,,B,,,CHO,Autocuration,449.0,BAO_0000219
292,,,,1,H,107,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,8,CHEMBL615729,,,B,,,,Autocuration,,BAO_0000357
293,,,,1,D,12687,,Efficacy against 5-hydroxytryptamine 2A receptor,9,CHEMBL615730,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
294,,,,1,H,12687,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,8,CHEMBL615731,,,F,,,,Expert,,BAO_0000019
295,,,,1,H,12687,,Relative potency towards 5-HT2A receptor of rat tail artery,8,CHEMBL615732,,,F,,,,Expert,,BAO_0000019
296,,,,1,H,12687,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,8,CHEMBL615733,,,F,,,,Expert,,BAO_0000019
297,,,,1,H,12687,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,8,CHEMBL615734,,,F,,,,Expert,,BAO_0000019
298,,,,1,H,12687,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,8,CHEMBL615735,,,F,,,,Autocuration,,BAO_0000019
299,,,,1,H,12687,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,8,CHEMBL615736,,,F,,,,Expert,,BAO_0000019
300,,Ileum,,1,D,20033,2116.0,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,9,CHEMBL615737,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
301,,Ileum,,1,D,20033,2116.0,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),9,CHEMBL615738,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
302,,Ileum,,1,D,20033,2116.0,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,9,CHEMBL615739,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
303,,,,1,H,10623,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,8,CHEMBL615278,,,B,,,,Autocuration,,BAO_0000357
304,,,,1,D,10623,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,9,CHEMBL615279,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
305,,,,1,H,168,,Binding affinity against 5-hydroxytryptamine 4 receptor,8,CHEMBL615280,,,B,,,,Expert,,BAO_0000357
306,,,,1,U,22226,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,0,CHEMBL615281,Gallus gallus,,B,9031.0,,,Autocuration,,BAO_0000019
307,,,,1,U,22226,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,0,CHEMBL615282,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
308,,,,1,U,22226,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,0,CHEMBL615283,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
309,,,,1,N,80156,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,1,CHEMBL615284,Homo sapiens,,B,9606.0,,HL-60,Autocuration,649.0,BAO_0000219
310,,,,1,U,22226,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,0,CHEMBL615285,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000019
311,,,,1,U,22226,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,0,CHEMBL615286,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000019
312,,,,1,D,104703,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,7,CHEMBL615287,Homo sapiens,,B,9606.0,,Oocytes,Autocuration,,BAO_0000219
313,,,,1,S,100256,,Chymotryptic inhibitory activity against 26S proteasome,2,CHEMBL615288,,,F,,,,Intermediate,,BAO_0000220
314,,,,1,S,100256,,Inhibitory activity against 26S proteasome degradation of IkB,2,CHEMBL615289,,,B,,,,Intermediate,,BAO_0000220
315,,,,1,N,81034,,In vitro inhibition of 2780/DOX ovarian cancer cell line,1,CHEMBL615290,Homo sapiens,,F,9606.0,,A2780,Intermediate,478.0,BAO_0000219
316,,,,1,N,81034,,In vitro inhibition of 2780/S ovarian cancer cell line,1,CHEMBL884522,Homo sapiens,,F,9606.0,,A2780,Intermediate,478.0,BAO_0000219
317,,,,1,U,22226,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,0,CHEMBL615291,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
318,,,,1,M,22222,,Association constant for binding to AATT 28-mer AATT hairpin,3,CHEMBL615292,,,B,,,,Intermediate,,BAO_0000225
319,,,,1,M,22222,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,3,CHEMBL615293,,,B,,,,Intermediate,,BAO_0000225
320,,,,1,M,22222,,Reaction Rate Parameter for 28-mer AATT hairpin,3,CHEMBL615294,,,B,,,,Intermediate,,BAO_0000225
321,,,,1,M,22222,,Reaction Rate Parameter for 28-mer AATT hairpin,3,CHEMBL615295,,,B,,,,Intermediate,,BAO_0000225
322,,,,1,U,22226,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),0,CHEMBL825021,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
323,,,,1,U,22226,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),0,CHEMBL615296,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
324,,,,1,U,22226,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,0,CHEMBL615297,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
325,,,,1,U,22226,,Cytotoxicity against cell line 2SC/20 determined by MTT test,0,CHEMBL615298,Cricetulus griseus,,F,10029.0,,,Autocuration,,BAO_0000019
326,,,,1,U,22226,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,0,CHEMBL615299,Cricetulus griseus,,F,10029.0,,,Autocuration,,BAO_0000019
327,,,,1,U,22226,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,0,CHEMBL615300,Cricetulus griseus,,F,10029.0,,,Autocuration,,BAO_0000019
328,,,,1,H,241,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,8,CHEMBL615301,,,B,,,,Autocuration,,BAO_0000357
329,,,,1,D,241,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,9,CHEMBL615302,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
330,,,,1,U,22226,,Selectivity ratio of ID50 in liver and heart,0,CHEMBL615303,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
331,,,,1,H,12132,,"Selectivity, ratio of relative ID50 in liver and heart",8,CHEMBL615304,,,B,,,,Autocuration,,BAO_0000019
332,,,,1,H,12132,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,8,CHEMBL615305,,,B,,,,Autocuration,,BAO_0000019
333,,,,1,H,12132,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",8,CHEMBL615306,,,B,,,,Autocuration,,BAO_0000218
334,,,,1,H,12132,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",8,CHEMBL615307,,,B,,,,Autocuration,,BAO_0000218
335,,,,1,H,12132,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",8,CHEMBL615308,,,B,,In vivo,,Autocuration,,BAO_0000218
336,,,,1,H,12132,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",8,CHEMBL615309,,,F,,In vivo,,Autocuration,,BAO_0000218
337,,,,1,U,22226,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",0,CHEMBL615310,,,B,,,,Autocuration,,BAO_0000019
338,,,,1,H,12132,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,8,CHEMBL615311,,,B,,,,Autocuration,,BAO_0000019
339,,,,1,U,22226,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",0,CHEMBL615312,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000019
340,,,,1,H,12132,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,8,CHEMBL615313,,,B,,,,Autocuration,,BAO_0000019
341,,,,1,H,12132,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,8,CHEMBL615314,,,F,,,,Autocuration,,BAO_0000019
342,,,,1,H,12132,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",8,CHEMBL615315,,,B,,,,Autocuration,,BAO_0000019
343,,,,1,U,22226,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",0,CHEMBL615316,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000218
344,,,,1,H,12132,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,8,CHEMBL615317,,,B,,In vivo,,Autocuration,,BAO_0000218
345,,,,1,H,12132,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",8,CHEMBL615318,,,B,,,,Autocuration,,BAO_0000218
346,,,,1,U,22226,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",0,CHEMBL615319,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000218
347,,,,1,H,12132,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",8,CHEMBL615320,,,B,,,,Autocuration,,BAO_0000019
348,,,,1,H,12132,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",8,CHEMBL615321,,,F,,,,Autocuration,,BAO_0000019
349,,,,1,U,22226,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",0,CHEMBL615322,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
350,,,,1,H,19690,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,8,CHEMBL615323,Escherichia coli,,B,562.0,,,Autocuration,,BAO_0000357
351,,,,1,H,19690,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,8,CHEMBL615407,Escherichia coli,,B,562.0,,,Autocuration,,BAO_0000357
352,,,,1,H,19690,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,8,CHEMBL857267,Escherichia coli,,B,562.0,,,Autocuration,,BAO_0000357
353,,,,1,H,19690,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,8,CHEMBL615408,Escherichia coli,,B,562.0,,,Autocuration,,BAO_0000357
354,,,,1,H,19690,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,8,CHEMBL615409,,,B,,,,Autocuration,,BAO_0000357
355,,,,1,H,19690,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,8,CHEMBL615410,,,B,,,,Autocuration,,BAO_0000357
356,,,,1,H,19690,,Inhibition constant against 3-dehydroquinate synthase,8,CHEMBL615411,,,B,,,,Autocuration,,BAO_0000357
357,,,,1,H,19690,,Association rate constant against 3-dehydroquinate synthase,8,CHEMBL615412,,,B,,,,Autocuration,,BAO_0000357
358,,,,1,H,19690,,Rate constant against 3-dehydroquinate synthase,8,CHEMBL615413,,,B,,,,Autocuration,,BAO_0000357
359,,,,1,U,22226,,Inhibitory activity against fuc-TVII,0,CHEMBL615414,,,B,,,,Autocuration,,BAO_0000019
360,,Liver,,1,D,12236,2107.0,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9,CHEMBL615415,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
361,,Liver,,1,D,12236,2107.0,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9,CHEMBL615416,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
362,,Liver,,1,D,12236,2107.0,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9,CHEMBL615417,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
363,,Liver,,1,D,12236,2107.0,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9,CHEMBL615418,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
364,,Liver,,1,D,12236,2107.0,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9,CHEMBL615419,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
365,,Liver,,1,D,12236,2107.0,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,9,CHEMBL615420,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
366,,Liver,,1,D,12236,2107.0,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,9,CHEMBL615421,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
367,,Liver,,1,D,12236,2107.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,9,CHEMBL615422,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
368,,Liver,,1,D,12236,2107.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,9,CHEMBL615423,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
369,,Liver,,1,D,12236,2107.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,9,CHEMBL872868,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
370,,Liver,,1,D,12236,2107.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,9,CHEMBL615424,Rattus norvegicus,Microsomes,B,10116.0,,,Autocuration,,BAO_0000251
371,,,,1,H,104832,,Inhibitory activity against 3-phosphoglycerate kinase.,4,CHEMBL825022,,,B,,,,Autocuration,,BAO_0000224
372,,,,1,H,104832,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,4,CHEMBL615425,,,B,,,,Autocuration,,BAO_0000224
373,,,,1,H,104832,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",4,CHEMBL615426,,,B,,,,Autocuration,,BAO_0000224
374,,,,1,D,10612,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,9,CHEMBL615427,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
375,,,,1,N,80616,,Cytotoxicity on 3677 melanoma cells,1,CHEMBL615428,Homo sapiens,,F,9606.0,,3677 melanoma cell line,Intermediate,844.0,BAO_0000219
376,,,,1,N,80616,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,1,CHEMBL615429,Homo sapiens,,F,9606.0,,3677 melanoma cell line,Intermediate,844.0,BAO_0000219
377,,,,1,N,80617,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,1,CHEMBL615430,Mus musculus,,F,10090.0,,MC-38,Intermediate,700.0,BAO_0000219
378,,,,1,U,22226,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,0,CHEMBL615431,Homo sapiens,,F,9606.0,,,Intermediate,,BAO_0000019
379,,,,1,U,22226,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,0,CHEMBL615432,,,F,,,B16,Autocuration,798.0,BAO_0000218
380,,,,1,U,22226,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,0,CHEMBL615433,,,F,,,B16,Autocuration,798.0,BAO_0000218
381,,,,1,D,12464,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,9,CHEMBL615434,Human rhinovirus 14,,F,12131.0,,,Expert,,BAO_0000019
382,,,,1,N,50085,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,1,CHEMBL615435,Human rhinovirus sp.,,F,169066.0,,,Intermediate,,BAO_0000218
383,,,,1,N,50679,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,1,CHEMBL615436,human rhinovirus type 14,,F,169066.0,,,Intermediate,,BAO_0000218
384,,,,1,N,50679,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,1,CHEMBL615437,human rhinovirus type 14,,F,169066.0,,,Intermediate,,BAO_0000218
385,,,,1,D,12464,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,9,CHEMBL615438,Human rhinovirus 14,,F,12131.0,,,Expert,,BAO_0000019
386,,,,1,D,12464,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,9,CHEMBL615439,Human rhinovirus 14,,F,12131.0,,,Expert,,BAO_0000019
387,,,,1,D,12464,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,9,CHEMBL615440,Human rhinovirus 14,,F,12131.0,,,Expert,,BAO_0000019
388,,,,1,D,12464,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,9,CHEMBL615441,Human rhinovirus 14,,F,12131.0,,,Expert,,BAO_0000019
389,,,,1,N,50665,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,1,CHEMBL615641,Enterovirus,,F,12059.0,,,Intermediate,,BAO_0000218
390,,,,1,N,50665,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,1,CHEMBL872065,Enterovirus,,F,12059.0,,,Intermediate,,BAO_0000218
391,,,,1,N,50665,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,1,CHEMBL825023,Enterovirus,,F,12059.0,,,Intermediate,,BAO_0000218
392,,,,1,N,50665,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,1,CHEMBL615642,Enterovirus,,F,12059.0,,,Intermediate,,BAO_0000218
393,,,,1,H,12464,,Inhibition of human rhinovirus 3C protease,8,CHEMBL615643,Human rhinovirus B,,B,147712.0,,,Expert,,BAO_0000357
394,,,,1,U,22226,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,0,CHEMBL615644,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000019
395,,,,1,N,80619,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),1,CHEMBL615645,Mus musculus,,F,10090.0,,3EM 37,Intermediate,833.0,BAO_0000218
396,,,,1,N,80619,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),1,CHEMBL615646,Mus musculus,,F,10090.0,,3EM 37,Intermediate,833.0,BAO_0000218
397,,,,1,N,80619,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),1,CHEMBL615647,Mus musculus,,F,10090.0,,3EM 37,Intermediate,833.0,BAO_0000218
398,,,,1,N,80619,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),1,CHEMBL615648,Mus musculus,,F,10090.0,,3EM 37,Intermediate,833.0,BAO_0000218
399,,,,1,N,80619,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,1,CHEMBL615649,Mus musculus,,F,10090.0,,3EM 37,Intermediate,833.0,BAO_0000218
400,,,,1,N,80619,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,1,CHEMBL615650,Mus musculus,,F,10090.0,,3EM 37,Intermediate,833.0,BAO_0000218
401,,,,1,N,80620,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,CHEMBL615651,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000218
402,,,,1,N,80620,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,CHEMBL615652,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000218
403,,,,1,N,80620,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,1,CHEMBL615653,Mus musculus,,F,10090.0,,3LL cell line,Expert,847.0,BAO_0000218
404,,,,1,N,80620,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,1,CHEMBL615654,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
405,,,,1,N,80620,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,1,CHEMBL615655,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
406,,,,1,N,80620,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,1,CHEMBL825024,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
407,,,,1,N,80620,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,1,CHEMBL615656,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
408,,,,1,N,80620,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,1,CHEMBL615657,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
409,,,,1,N,80620,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,1,CHEMBL615658,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
410,,,,1,N,80620,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,1,CHEMBL615659,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
411,,,,1,N,80620,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,1,CHEMBL615660,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
412,,,,1,N,80620,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,CHEMBL615661,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
413,,,,1,N,80620,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,1,CHEMBL615662,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
414,,,,1,N,80620,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,1,CHEMBL615663,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
415,,,,1,N,80620,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,1,CHEMBL615664,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
416,,,,1,N,80620,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,1,CHEMBL615665,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
417,,,,1,N,80620,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,CHEMBL615666,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
418,,,,1,N,80620,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,1,CHEMBL615667,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
419,,,,1,N,80620,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,1,CHEMBL615668,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
420,,,,1,N,80620,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,1,CHEMBL615669,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
421,,,,1,N,80620,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,1,CHEMBL615670,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
422,,,,1,N,80620,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,1,CHEMBL836739,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
423,,,,1,N,80620,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,1,CHEMBL615671,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
424,,,,1,N,80620,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,1,CHEMBL615672,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
425,,,,1,N,80620,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,1,CHEMBL615791,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
426,,,,1,N,80620,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,1,CHEMBL615792,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
427,,,,1,N,80620,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,1,CHEMBL615793,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
428,,,,1,N,80620,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,1,CHEMBL615794,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
429,,,,1,N,80620,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,1,CHEMBL615795,Mus musculus,,F,10090.0,,3LL cell line,Intermediate,847.0,BAO_0000219
430,,,,1,N,80621,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,1,CHEMBL615590,Homo sapiens,,F,9606.0,,3LLD122,Intermediate,971.0,BAO_0000219
431,,,,1,U,22226,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,0,CHEMBL615591,,,F,,,,Autocuration,,BAO_0000218
432,,,,1,U,22226,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,0,CHEMBL615592,,,F,,,,Autocuration,,BAO_0000218
433,,,,1,U,22226,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,0,CHEMBL615593,,,F,,,,Autocuration,,BAO_0000218
434,,,,1,U,22226,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,0,CHEMBL615594,,,F,,,,Autocuration,,BAO_0000218
435,,,,1,N,80951,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,CHEMBL615595,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
436,,,,1,N,80951,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,CHEMBL615596,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
437,,,,1,H,11169,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,8,CHEMBL615597,,,F,,,NIH3T3,Expert,723.0,BAO_0000219
438,,,,1,N,80951,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,1,CHEMBL615598,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
439,,,,1,N,80951,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,1,CHEMBL615599,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
440,,,,1,N,80951,,Effective dose against murine 3T3 fibroblasts cells,1,CHEMBL615600,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
441,,,,1,N,80951,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,1,CHEMBL615601,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
442,,,,1,N,80951,,Cytotoxic effect on 3T3 cells,1,CHEMBL615602,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
443,,,,1,N,80951,,Cytotoxic effect on 3T3 cells,1,CHEMBL615603,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
444,,,,1,N,80951,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,1,CHEMBL615604,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
445,,,,1,N,80951,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,CHEMBL615605,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
446,,,,1,N,80951,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,1,CHEMBL615606,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
447,,,,1,N,80951,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,1,CHEMBL884526,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
448,,,,1,N,80951,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,1,CHEMBL615607,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
449,,,,1,N,80951,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,1,CHEMBL615608,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
450,,,,1,N,80951,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,1,CHEMBL615609,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
451,,,,1,N,80951,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,1,CHEMBL615682,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
452,,,,1,N,80951,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,1,CHEMBL615683,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
453,,,,1,N,80951,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,1,CHEMBL615684,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000218
454,,,,1,D,104860,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,7,CHEMBL615685,Mus musculus,,F,10090.0,,,Autocuration,,BAO_0000219
455,,,,1,N,80951,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,1,CHEMBL615686,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
456,,,,1,N,80951,,Inhibitory activity against 3T3 cell line,1,CHEMBL615687,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
457,,,,1,N,80951,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,1,CHEMBL884523,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
458,,,,1,H,11169,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,8,CHEMBL615688,,,F,,,,Expert,,BAO_0000019
459,,,,1,N,80951,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,1,CHEMBL615689,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
460,,,,1,N,80951,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,1,CHEMBL615690,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
461,,,,1,H,11169,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,8,CHEMBL615691,,,F,,,,Expert,,BAO_0000019
462,,,,1,H,11169,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,8,CHEMBL615692,,,F,,,,Expert,,BAO_0000019
463,,,,1,N,80951,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,CHEMBL615693,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
464,,,,1,N,80951,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,1,CHEMBL615324,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
465,,,,1,D,9,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,9,CHEMBL615325,Homo sapiens,,F,9606.0,,NIH3T3,Expert,723.0,BAO_0000219
466,,,,1,D,9,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),9,CHEMBL615490,Homo sapiens,,F,9606.0,,NIH3T3,Expert,723.0,BAO_0000219
467,,,,1,D,188,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,9,CHEMBL615491,Homo sapiens,,F,9606.0,,NIH3T3,Expert,723.0,BAO_0000219
468,,,,1,D,188,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),9,CHEMBL615492,Homo sapiens,,F,9606.0,,NIH3T3,Expert,723.0,BAO_0000219
469,,,,1,N,80951,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,1,CHEMBL615493,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
470,,,,1,N,80951,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,1,CHEMBL615494,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
471,,,,1,N,80951,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,1,CHEMBL615495,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
472,,,,1,N,80951,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,1,CHEMBL615496,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
473,,,,1,N,80951,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,1,CHEMBL615497,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
474,,,,1,N,80951,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,1,CHEMBL615498,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
475,,,,1,N,80951,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,1,CHEMBL615499,Mus musculus,,A,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
476,,,,1,N,80951,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,1,CHEMBL835522,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
477,,,,1,N,80951,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,1,CHEMBL615500,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
478,,,,1,N,80951,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,CHEMBL615501,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
479,,,,1,N,80951,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,CHEMBL615502,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
480,,,,1,N,80951,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,CHEMBL615503,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
481,,,,1,N,80951,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,CHEMBL615504,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
482,,,,1,N,80951,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,CHEMBL615505,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
483,,,,1,N,80951,,Inhibition of swiss 3T3 mouse fibroblast proliferation,1,CHEMBL615506,Mus musculus,,F,10090.0,,NIH3T3,Expert,723.0,BAO_0000219
484,,,,1,N,80951,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,1,CHEMBL615507,Mus musculus,,F,10090.0,,NIH3T3,Intermediate,723.0,BAO_0000219
485,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,CHEMBL615508,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
486,,,,1,N,80006,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,1,CHEMBL615509,Mus musculus,,F,10090.0,,3T3-L1,Intermediate,620.0,BAO_0000219
487,,,,1,N,80006,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,1,CHEMBL615510,Mus musculus,,F,10090.0,,3T3-L1,Intermediate,620.0,BAO_0000219
488,,,,1,N,80006,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,1,CHEMBL615511,Mus musculus,,F,10090.0,,3T3-L1,Intermediate,620.0,BAO_0000219
489,,,,1,N,80006,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,1,CHEMBL615512,Mus musculus,,F,10090.0,,3T3-L1,Intermediate,620.0,BAO_0000219
490,,,,1,N,80006,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",1,CHEMBL615513,Mus musculus,,F,10090.0,,3T3-L1,Intermediate,620.0,BAO_0000218
491,,,,1,N,80006,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",1,CHEMBL615514,Mus musculus,,F,10090.0,,3T3-L1,Intermediate,620.0,BAO_0000218
492,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,1,CHEMBL615515,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000219
493,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,CHEMBL615516,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000219
494,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,CHEMBL615517,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000219
495,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,CHEMBL615518,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000219
496,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,CHEMBL615519,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000219
497,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,1,CHEMBL615520,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
498,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,1,CHEMBL615521,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
499,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,CHEMBL615522,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
500,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,CHEMBL615523,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
501,,,,1,N,80006,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,CHEMBL615524,,,F,,,3T3-L1,Expert,620.0,BAO_0000218
502,,,,1,N,80006,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,CHEMBL615525,,,F,,,3T3-L1,Expert,620.0,BAO_0000218
503,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,CHEMBL615526,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
504,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,CHEMBL615527,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
505,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,1,CHEMBL615528,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
506,,,,1,N,80006,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,CHEMBL615529,,,F,,,3T3-L1,Expert,620.0,BAO_0000218
507,,,,1,N,80006,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,CHEMBL615530,,,F,,,3T3-L1,Expert,620.0,BAO_0000218
508,,,,1,N,80006,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,CHEMBL615531,,,F,,,3T3-L1,Expert,620.0,BAO_0000218
509,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,CHEMBL615532,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000219
510,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,CHEMBL615533,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000219
511,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,CHEMBL615534,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000219
512,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,CHEMBL615535,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
513,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,CHEMBL615536,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
514,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,CHEMBL615537,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
515,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,CHEMBL615538,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
516,,,,1,N,80006,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,CHEMBL836166,,,F,,,3T3-L1,Intermediate,620.0,BAO_0000218
517,,,,1,H,11214,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,8,CHEMBL615539,,,F,,,3T3-L1,Expert,620.0,BAO_0000219
518,,,,1,N,80006,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,1,CHEMBL615540,Mus musculus,,F,10090.0,,3T3-L1,Intermediate,620.0,BAO_0000219
519,,,,1,H,11214,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,8,CHEMBL615541,,,F,,,3T3-L1,Expert,620.0,BAO_0000219
520,,,,1,N,80006,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,1,CHEMBL615542,Mus musculus,,F,10090.0,,3T3-L1,Expert,620.0,BAO_0000219
521,,,,1,N,80006,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,1,CHEMBL615543,Mus musculus,,F,10090.0,,3T3-L1,Intermediate,620.0,BAO_0000219
522,,,,1,N,80006,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,1,CHEMBL615544,Mus musculus,,F,10090.0,,3T3-L1,Expert,620.0,BAO_0000219
523,,,,1,N,80006,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,CHEMBL615545,Mus musculus,,F,10090.0,,3T3-L1,Expert,620.0,BAO_0000219
524,,,,1,N,80006,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,CHEMBL615546,Mus musculus,,F,10090.0,,3T3-L1,Expert,620.0,BAO_0000219
525,,,,1,N,80006,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,1,CHEMBL615547,Mus musculus,,F,10090.0,,3T3-L1,Expert,620.0,BAO_0000219
526,,,,1,N,80006,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,1,CHEMBL615548,Mus musculus,,F,10090.0,,3T3-L1,Expert,620.0,BAO_0000219
527,,,,1,N,80006,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,1,CHEMBL615549,Mus musculus,,F,10090.0,,3T3-L1,Expert,620.0,BAO_0000219
528,,,,1,N,80006,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,1,CHEMBL615550,Mus musculus,,F,10090.0,,3T3-L1,Expert,620.0,BAO_0000219
529,,,,1,N,80622,,Inhibitory activity against rat fibroblast (3Y1) cell line,1,CHEMBL615551,Rattus norvegicus,,F,10116.0,,3Y1 cell line,Intermediate,1118.0,BAO_0000219
530,,,,1,N,80622,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,1,CHEMBL615552,Rattus norvegicus,,F,10116.0,,3Y1 cell line,Expert,1118.0,BAO_0000219
531,,,,1,N,80622,,Cytotoxicity in 3Y1 cells.,1,CHEMBL615553,Rattus norvegicus,,F,10116.0,,3Y1 cell line,Expert,1118.0,BAO_0000219
532,,,,1,N,80622,,Cytostatic effect in 3Y1 cells.,1,CHEMBL615554,Rattus norvegicus,,F,10116.0,,3Y1 cell line,Expert,1118.0,BAO_0000219
533,,,,1,N,80622,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",1,CHEMBL615555,Rattus norvegicus,,F,10116.0,,3Y1 cell line,Intermediate,1118.0,BAO_0000219
534,,,,1,N,80622,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,1,CHEMBL615556,Rattus norvegicus,,F,10116.0,,3Y1 cell line,Expert,1118.0,BAO_0000219
535,,,,1,U,22226,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,0,CHEMBL615557,,,B,,,,Autocuration,,BAO_0000019
536,,,,1,U,22226,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,0,CHEMBL615558,,,B,,,,Autocuration,,BAO_0000019
537,,,,1,U,22226,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,0,CHEMBL872066,,,B,,,,Autocuration,,BAO_0000019
538,,,,1,D,11607,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,9,CHEMBL615559,Sus scrofa,,B,9823.0,,,Expert,,BAO_0000019
539,,,,1,H,11607,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,8,CHEMBL615560,,,B,,,,Autocuration,,BAO_0000019
540,,,,1,H,11607,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,8,CHEMBL615561,,,B,,,,Autocuration,,BAO_0000019
541,,,,1,H,11607,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,8,CHEMBL857062,,,B,,,,Expert,,BAO_0000019
542,,,,1,H,11607,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),8,CHEMBL615562,,,B,,,,Expert,,BAO_0000019
543,,,,1,H,11607,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,8,CHEMBL615563,,,B,,,,Autocuration,,BAO_0000019
544,,,,1,H,11607,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),8,CHEMBL615564,,,B,,,,Autocuration,,BAO_0000357
545,,,,1,H,11607,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,8,CHEMBL615565,,,B,,,,Autocuration,,BAO_0000019
546,,,,1,H,11607,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,8,CHEMBL615566,,,B,,,,Autocuration,,BAO_0000019
547,,,,1,D,11607,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,9,CHEMBL615567,Sus scrofa,,B,9823.0,,,Expert,,BAO_0000019
548,,,,1,H,11607,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,8,CHEMBL615568,,,B,,,,Autocuration,,BAO_0000019
549,,,,1,H,11607,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),8,CHEMBL615569,,,B,,,,Autocuration,,BAO_0000357
550,,,,1,H,11607,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,8,CHEMBL615570,,,B,,,,Autocuration,,BAO_0000019
551,,,,1,H,11607,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),8,CHEMBL615571,,,B,,,,Autocuration,,BAO_0000019
552,,,,1,H,104733,,Binding affinity against melatonin (MT1) receptor (pC1),4,CHEMBL615572,,,B,,,,Autocuration,,BAO_0000224
553,,,,1,U,22226,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,0,CHEMBL615573,,,B,,,,Autocuration,,BAO_0000019
554,,,,1,U,22226,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,0,CHEMBL615574,,,B,,,,Autocuration,,BAO_0000019
555,,,,1,U,22226,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,0,CHEMBL615575,,,B,,,,Autocuration,,BAO_0000019
556,,,,1,H,10619,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,8,CHEMBL615576,,,B,,,,Autocuration,,BAO_0000357
557,,,,1,H,10619,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,8,CHEMBL615577,,,B,,,,Autocuration,,BAO_0000357
558,,Hippocampus,,1,H,51,10000000.0,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,8,CHEMBL615578,,,B,,,,Autocuration,,BAO_0000221
559,,,,1,H,51,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,8,CHEMBL615579,,,B,,,,Expert,,BAO_0000357
560,,,,1,H,51,,Binding affinity for 5-hydroxytryptamine 1A receptor,8,CHEMBL615580,,,B,,,,Expert,,BAO_0000357
561,,,,1,H,51,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,8,CHEMBL615581,,,B,,,,Expert,,BAO_0000019
562,,Hippocampus,,1,H,51,10000000.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,8,CHEMBL615582,,,B,,,,Autocuration,,BAO_0000221
563,,Hippocampus,,1,H,51,10000000.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,8,CHEMBL615583,,,B,,,,Autocuration,,BAO_0000221
564,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,8,CHEMBL615584,,,B,,,,Autocuration,,BAO_0000221
565,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,CHEMBL833691,,,B,,,,Autocuration,,BAO_0000221
566,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,8,CHEMBL615585,,,B,,,,Autocuration,,BAO_0000221
567,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,8,CHEMBL615586,,,B,,,,Autocuration,,BAO_0000221
568,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,CHEMBL884524,,,B,,,,Autocuration,,BAO_0000221
569,,Hippocampus,,1,H,51,10000000.0,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,8,CHEMBL615587,,,B,,,,Autocuration,,BAO_0000221
570,,Hippocampus,,1,H,51,10000000.0,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",8,CHEMBL615588,,,B,,,,Autocuration,,BAO_0000221
571,,,,1,D,10576,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,9,CHEMBL615589,Rattus norvegicus,Membranes,B,10116.0,,,Expert,,BAO_0000249
572,,Hippocampus,,1,H,51,10000000.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,8,CHEMBL615442,Bos taurus,,B,9913.0,,,Expert,,BAO_0000221
573,,Hippocampus,,1,H,51,10000000.0,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,8,CHEMBL615443,,,B,,,,Autocuration,,BAO_0000221
574,,Hippocampus,,1,H,51,10000000.0,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,8,CHEMBL615444,,,B,,,,Autocuration,,BAO_0000221
575,,Hippocampus,,1,H,51,10000000.0,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,8,CHEMBL615445,,,B,,,,Expert,,BAO_0000221
576,,Hippocampus,,1,H,51,10000000.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,8,CHEMBL615446,,,B,,,,Autocuration,,BAO_0000221
577,,,,1,H,51,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,8,CHEMBL615447,,,B,,,CHO,Autocuration,449.0,BAO_0000219
578,,Hippocampus,,1,H,51,10000000.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,8,CHEMBL615448,,,B,,,,Expert,,BAO_0000221
579,,Hippocampus,,1,H,51,10000000.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,8,CHEMBL615449,,,B,,,,Expert,,BAO_0000221
580,,,,1,H,51,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,8,CHEMBL615450,,,B,,,CHO,Autocuration,449.0,BAO_0000219
581,,Hippocampus,,1,H,51,10000000.0,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",8,CHEMBL615451,,,B,,,,Expert,,BAO_0000221
582,,,,1,H,51,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,8,CHEMBL615452,,,B,,,,Autocuration,,BAO_0000357
583,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,8,CHEMBL615453,,,B,,,,Autocuration,,BAO_0000221
584,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,CHEMBL615454,,,B,,,,Autocuration,,BAO_0000221
585,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,8,CHEMBL615455,,,B,,,,Autocuration,,BAO_0000221
586,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,CHEMBL615456,,,B,,,,Autocuration,,BAO_0000221
587,,Hippocampus,,1,H,51,10000000.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,8,CHEMBL615457,,,B,,,,Autocuration,,BAO_0000221
588,,Hippocampus,,1,H,51,10000000.0,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,8,CHEMBL615458,,,B,,,,Expert,,BAO_0000218
589,,Hippocampus,,1,H,51,10000000.0,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,CHEMBL615459,,,B,,,,Expert,,BAO_0000221
590,,,,1,D,51,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",9,CHEMBL615460,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
591,,,,1,H,51,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,8,CHEMBL615461,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
592,,,,1,H,51,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,8,CHEMBL615462,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
593,,Hippocampus,,1,H,51,10000000.0,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,8,CHEMBL615463,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000221
594,,Ileum,,1,H,51,2116.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,8,CHEMBL615464,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
595,,Ileum,,1,H,51,2116.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,8,CHEMBL615465,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
596,,Ileum,,1,H,51,2116.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,8,CHEMBL615466,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
597,,Ileum,,1,H,51,2116.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,8,CHEMBL615467,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
598,,Ileum,,1,H,51,2116.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,8,CHEMBL615468,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
599,,Ileum,,1,H,51,2116.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,8,CHEMBL615469,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
600,,,,1,H,51,,Binding affinity against 5-hydroxytryptamine 1A receptor,8,CHEMBL615470,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000357
601,,,,1,H,51,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,8,CHEMBL615471,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000357
602,,,,1,H,51,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,8,CHEMBL615472,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000357
603,,Hippocampus,,1,H,106,10000000.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,8,CHEMBL883242,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
604,,Hippocampus,,1,H,106,10000000.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,8,CHEMBL615473,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000221
605,,,,1,H,11863,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),8,CHEMBL615474,Cricetulus griseus,,B,10029.0,,CHO,Autocuration,449.0,BAO_0000218
606,,,,1,H,51,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,8,CHEMBL615475,,,B,,,,Autocuration,,BAO_0000357
607,,,,1,H,51,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,8,CHEMBL615476,,,F,,,HeLa,Autocuration,308.0,BAO_0000219
608,,,,1,H,51,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,8,CHEMBL615477,,,F,,,HeLa,Autocuration,308.0,BAO_0000219
609,,,,1,H,51,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,8,CHEMBL615478,,,F,,,,Autocuration,,BAO_0000019
610,,,,1,H,51,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,8,CHEMBL615160,,,F,,,CHO,Autocuration,449.0,BAO_0000219
611,,,,1,H,51,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,8,CHEMBL615161,,,F,,,CHO,Expert,449.0,BAO_0000219
612,,,,1,H,51,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,8,CHEMBL615162,,,F,,,CHO,Autocuration,449.0,BAO_0000219
613,,,,1,H,51,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,8,CHEMBL615163,,,F,,,CHO,Autocuration,449.0,BAO_0000219
614,,,,1,H,51,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,8,CHEMBL615164,,,B,,,CHO,Expert,449.0,BAO_0000219
615,,,,1,H,51,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,8,CHEMBL615165,,,B,,,CHO,Expert,449.0,BAO_0000219
616,,,,1,H,51,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,8,CHEMBL615166,,,B,,,CHO,Autocuration,449.0,BAO_0000219
617,,,,1,H,51,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,8,CHEMBL615167,,,F,,,,Autocuration,,BAO_0000219
618,,,,1,D,51,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,9,CHEMBL615168,Homo sapiens,,B,9606.0,,HeLa,Expert,308.0,BAO_0000219
619,,,,1,D,51,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,9,CHEMBL615169,Homo sapiens,,B,9606.0,,HeLa,Expert,308.0,BAO_0000219
620,,,,1,D,51,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,9,CHEMBL615170,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
621,,,,1,D,51,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,9,CHEMBL615171,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
622,,,,1,H,51,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,8,CHEMBL615694,,,F,,,,Autocuration,,BAO_0000019
623,,,,1,H,51,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,8,CHEMBL615695,,,F,,,,Autocuration,,BAO_0000019
624,,,,1,H,51,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",8,CHEMBL615696,,,F,,,,Autocuration,,BAO_0000019
625,,,,1,H,51,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,8,CHEMBL615697,,,F,,,CHO,Autocuration,449.0,BAO_0000219
626,,,,1,D,51,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),9,CHEMBL859410,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
627,,,,1,H,51,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),8,CHEMBL615841,,,F,,,CHO,Autocuration,449.0,BAO_0000219
628,,,,1,D,51,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),9,CHEMBL615842,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
629,,,,1,H,51,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,8,CHEMBL835003,,,F,,,CHO,Autocuration,449.0,BAO_0000219
630,,,,1,H,51,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),8,CHEMBL615843,,,F,,,CHO,Autocuration,449.0,BAO_0000219
631,,,,1,D,51,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),9,CHEMBL615979,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
632,,,,1,H,51,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),8,CHEMBL615980,,,F,,,CHO,Autocuration,449.0,BAO_0000219
633,,,,1,D,51,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),9,CHEMBL615981,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
634,,,,1,D,51,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,9,CHEMBL615982,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
635,,,,1,D,51,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9,CHEMBL615983,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
636,,,,1,D,51,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",9,CHEMBL615984,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
637,,,,1,D,51,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",9,CHEMBL615985,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
638,,,,1,H,51,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,8,CHEMBL615986,,,F,,,CHO,Autocuration,449.0,BAO_0000219
639,,,,1,H,51,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,8,CHEMBL615987,,,F,,,CHO,Autocuration,449.0,BAO_0000219
640,,,,1,H,51,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,8,CHEMBL615988,,,F,,,CHO,Autocuration,449.0,BAO_0000219
641,,,,1,H,51,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,8,CHEMBL615989,,,F,,,CHO,Expert,449.0,BAO_0000219
642,,,,1,H,51,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,8,CHEMBL615990,,,F,,,CHO,Autocuration,449.0,BAO_0000219
643,,,,1,H,51,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,8,CHEMBL615991,,,F,,,CHO,Autocuration,449.0,BAO_0000219
644,,,,1,H,51,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,8,CHEMBL615992,,,F,,,CHO,Autocuration,449.0,BAO_0000219
645,,,,1,H,51,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,8,CHEMBL615993,,,F,,,CHO,Autocuration,449.0,BAO_0000219
646,,,,1,H,51,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,8,CHEMBL615994,,,F,,,CHO,Expert,449.0,BAO_0000219
647,,,,1,H,51,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,8,CHEMBL615995,,,F,,,CHO,Autocuration,449.0,BAO_0000219
648,,,,1,H,51,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,8,CHEMBL615996,,,F,,,CHO,Autocuration,449.0,BAO_0000219
649,,,,1,H,51,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,8,CHEMBL615997,,,F,,,CHO,Autocuration,449.0,BAO_0000219
650,,,,1,H,51,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",8,CHEMBL615998,,,F,,,,Autocuration,,BAO_0000019
651,,,,1,H,51,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",8,CHEMBL615999,,,F,,,,Autocuration,,BAO_0000019
652,,,,1,H,51,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,8,CHEMBL616000,,,F,,,,Autocuration,,BAO_0000019
653,,,,1,H,51,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,8,CHEMBL616001,,,F,,,HEK293,Autocuration,722.0,BAO_0000219
654,,,,1,D,51,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",9,CHEMBL616002,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
655,,,,1,H,51,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",8,CHEMBL616003,,,F,,,,Expert,,BAO_0000019
656,,,,1,D,51,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,9,CHEMBL616004,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
657,,,,1,D,51,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,9,CHEMBL616005,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
658,,,,1,H,51,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",8,CHEMBL616006,,,F,,,,Autocuration,,BAO_0000019
659,,,,1,H,51,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",8,CHEMBL616007,,,F,,,,Expert,,BAO_0000019
660,,,,1,H,51,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",8,CHEMBL616008,,,F,,,,Autocuration,,BAO_0000019
661,,,,1,H,51,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",8,CHEMBL616009,,,F,,,,Autocuration,,BAO_0000019
662,,,,1,H,51,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",8,CHEMBL616010,,,F,,,,Expert,,BAO_0000019
663,,,,1,D,51,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",9,CHEMBL616011,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
664,,,,1,D,51,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",9,CHEMBL615740,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
665,,,,1,H,51,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",8,CHEMBL615741,,,F,,,,Autocuration,,BAO_0000019
666,,,,1,H,51,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",8,CHEMBL615742,,,F,,,,Expert,,BAO_0000019
667,,,,1,H,51,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",8,CHEMBL615743,,,F,,,,Autocuration,,BAO_0000019
668,,,,1,H,51,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,8,CHEMBL615744,,,F,,,CHO,Autocuration,449.0,BAO_0000219
669,,,,1,H,51,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,8,CHEMBL615745,,,F,,,CHO,Expert,449.0,BAO_0000219
670,,,,1,H,51,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,8,CHEMBL615746,,,B,,,,Autocuration,,BAO_0000357
671,,,,1,H,51,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,8,CHEMBL615747,,,B,,,,Autocuration,,BAO_0000357
672,,,,1,H,51,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",8,CHEMBL615748,,,F,,,,Autocuration,,BAO_0000019
673,,,,1,H,51,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",8,CHEMBL615749,,,F,,,,Autocuration,,BAO_0000019
674,,,,1,H,51,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,8,CHEMBL615750,,,F,,,,Autocuration,,BAO_0000019
675,,,,1,D,51,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,9,CHEMBL616259,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
676,,,,1,H,51,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",8,CHEMBL616260,,,F,,,,Autocuration,,BAO_0000019
677,,,,1,D,51,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,9,CHEMBL616261,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
678,,,,1,D,51,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9,CHEMBL616262,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
679,,,,1,D,51,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",9,CHEMBL616263,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
680,,,,1,D,51,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,9,CHEMBL616264,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
681,,,,1,D,51,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,9,CHEMBL616265,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
682,,,,1,D,51,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9,CHEMBL616266,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
683,,,,1,D,51,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",9,CHEMBL616267,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
684,,,,1,D,51,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,9,CHEMBL616268,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
685,,,,1,D,51,,Inhibition of human 5-hydroxytryptamine 1A receptor,9,CHEMBL616269,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
686,,,,1,H,51,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,8,CHEMBL884528,,,B,,,CHO,Autocuration,449.0,BAO_0000219
687,,,,1,D,105,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,9,CHEMBL616270,,,B,,,HEK293,Expert,722.0,BAO_0000219
688,,,,1,H,51,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,8,CHEMBL616271,,,B,,,CHO,Autocuration,449.0,BAO_0000219
689,,,,1,H,51,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,8,CHEMBL616272,,,F,,,CHO,Autocuration,449.0,BAO_0000219
690,,,,1,H,51,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,8,CHEMBL616273,,,B,,,,Expert,,BAO_0000357
691,,,,1,D,51,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,9,CHEMBL616274,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
692,,,,1,H,51,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,8,CHEMBL616275,,,B,,,CHO,Autocuration,449.0,BAO_0000219
693,,,,1,H,51,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,8,CHEMBL616276,,,B,,,CHO,Autocuration,449.0,BAO_0000219
694,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,0,CHEMBL616277,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
695,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,0,CHEMBL616278,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
696,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,0,CHEMBL616279,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
697,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,0,CHEMBL616280,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
698,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,0,CHEMBL616281,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
699,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,0,CHEMBL616282,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
700,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,0,CHEMBL616283,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
701,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,0,CHEMBL616284,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
702,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,0,CHEMBL616285,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
703,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,0,CHEMBL616286,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
704,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,0,CHEMBL616287,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
705,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,0,CHEMBL616288,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
706,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,0,CHEMBL616289,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
707,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,0,CHEMBL615610,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
708,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,0,CHEMBL615611,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
709,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,0,CHEMBL615612,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
710,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,0,CHEMBL615613,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
711,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,0,CHEMBL615614,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
712,,,,1,U,22226,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,0,CHEMBL615615,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
713,,,,1,H,105093,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,4,CHEMBL615616,,,B,,,,Autocuration,,BAO_0000019
714,,Hypothalamus,,1,H,11923,1898.0,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,8,CHEMBL615617,,,B,,,,Autocuration,,BAO_0000249
715,,,,1,H,10577,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,8,CHEMBL615618,,,B,,,,Autocuration,,BAO_0000019
716,,,,1,H,10577,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,8,CHEMBL615619,,,B,,,,Autocuration,,BAO_0000019
717,,,,1,H,10577,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,8,CHEMBL615620,,,B,,,,Expert,,BAO_0000019
718,,,,1,H,55,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",8,CHEMBL615621,,,B,,,,Autocuration,,BAO_0000357
719,,,,1,H,55,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",8,CHEMBL615622,,,B,,,,Autocuration,,BAO_0000357
720,,,,1,H,12166,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),8,CHEMBL615623,,,F,,,,Autocuration,,BAO_0000019
721,,,,1,H,12166,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,8,CHEMBL615624,,,F,,,,Autocuration,,BAO_0000019
722,,,,1,H,12166,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,8,CHEMBL615625,,,F,,,,Autocuration,,BAO_0000019
723,,,,1,H,12166,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,8,CHEMBL767045,,,F,,,,Autocuration,,BAO_0000019
724,,,,1,H,55,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,8,CHEMBL615626,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
725,,,,1,H,55,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,8,CHEMBL615627,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
726,,,,1,H,55,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,8,CHEMBL615628,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000019
727,,,,1,H,55,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,8,CHEMBL615629,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000357
728,,,,1,D,55,,Inhibitory concentration against 5-lipoxygenase from human whole blood,9,CHEMBL615630,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
729,,,,1,H,55,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],8,CHEMBL615631,,,B,,,,Autocuration,,BAO_0000219
730,,,,1,H,17087,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,8,CHEMBL615632,,,F,,,,Autocuration,,BAO_0000218
731,,,,1,H,17087,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,8,CHEMBL615633,,,B,,,,Autocuration,,BAO_0000357
732,,,,1,H,17087,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,8,CHEMBL615634,,,F,,,,Autocuration,,BAO_0000218
733,,,,1,H,55,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,8,CHEMBL615635,Sus scrofa,,B,9823.0,,,Expert,,BAO_0000019
734,,,,1,H,12166,,In vitro inhibition of rat 5-Lipoxygenase,8,CHEMBL615636,,,B,,,,Expert,,BAO_0000357
735,,,,1,D,12166,,Inhibitory activity against 5-Lipoxygenase,9,CHEMBL615637,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
736,,,,1,H,12166,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,8,CHEMBL615638,,,B,,,RBL-1,Expert,702.0,BAO_0000219
737,,,,1,H,12166,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),8,CHEMBL615639,,,B,,,RBL-1,Autocuration,702.0,BAO_0000219
738,,,,1,H,12166,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,8,CHEMBL615640,,,B,,,RBL-1,Autocuration,702.0,BAO_0000219
739,,,,1,H,12166,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,8,CHEMBL615796,,,B,,,,Autocuration,,BAO_0000019
740,,,,1,H,12166,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],8,CHEMBL615845,,,B,,,,Autocuration,,BAO_0000219
741,,,,1,H,12166,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,8,CHEMBL615846,,,B,,,,Autocuration,,BAO_0000357
742,,,,1,H,12166,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,8,CHEMBL615847,,,B,,,RBL-1,Autocuration,702.0,BAO_0000219
743,,,,1,H,12166,,The compound was tested for inhibition of isolated 5-Lipoxygenase,8,CHEMBL615848,,,B,,,,Autocuration,,BAO_0000357
744,,,,1,U,22226,,Ratio of IC50 against 5-LO and COX,0,CHEMBL615849,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
745,,,,1,H,12166,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,8,CHEMBL615850,,,B,,,,Autocuration,,BAO_0000357
746,,,,1,H,12166,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,8,CHEMBL615851,,,B,,,,Autocuration,,BAO_0000357
747,,,,1,H,12166,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,8,CHEMBL615852,,,B,,,,Autocuration,,BAO_0000219
748,,,,1,H,12166,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,8,CHEMBL615853,,,F,,,,Autocuration,,BAO_0000019
749,,Prostate gland,,1,H,120,2367.0,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,8,CHEMBL884527,,,B,,,,Autocuration,,BAO_0000357
750,,,,1,U,22226,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,0,CHEMBL872871,Columba livia,,B,8932.0,,,Autocuration,,BAO_0000019
751,,,,1,U,22226,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,0,CHEMBL615854,Columba livia,,B,8932.0,,,Autocuration,,BAO_0000019
752,,,,1,U,22226,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,0,CHEMBL767046,Columba livia,,B,8932.0,,,Autocuration,,BAO_0000019
753,,,,1,H,10732,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,8,CHEMBL615855,,,B,,,,Autocuration,,BAO_0000357
754,,,,1,D,12198,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,9,CHEMBL615856,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
755,,,,1,D,12198,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),9,CHEMBL615857,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
756,,,,1,D,12198,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),9,CHEMBL615858,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
757,,Hippocampus,,1,H,10576,10000000.0,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,8,CHEMBL615859,,,B,,,,Expert,,BAO_0000221
758,,,,1,H,51,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,8,CHEMBL615860,,,B,,,,Autocuration,,BAO_0000357
759,,,,1,U,22226,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,0,CHEMBL615861,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
760,,,,1,U,22226,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,0,CHEMBL615862,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
761,,,,1,U,22226,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,0,CHEMBL615863,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
762,,,,1,U,22226,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,0,CHEMBL615864,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
763,,Hippocampus,,1,H,104744,10000000.0,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,4,CHEMBL615865,,,B,,,,Autocuration,,BAO_0000221
764,,Hippocampus,,1,H,104744,10000000.0,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,4,CHEMBL615866,,,B,,,,Autocuration,,BAO_0000221
765,,Hippocampus,,1,H,104744,10000000.0,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,4,CHEMBL615867,,,B,,,,Autocuration,,BAO_0000221
766,,,,1,H,104744,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,4,CHEMBL615868,,Membranes,B,,,,Autocuration,,BAO_0000249
767,,,,1,D,104744,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,5,CHEMBL615869,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000249
768,,,,1,D,104744,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,5,CHEMBL615870,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
769,,,,1,D,104744,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,5,CHEMBL615871,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
770,,,,1,H,104744,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,4,CHEMBL615872,,,B,,,,Autocuration,,BAO_0000224
771,,Hippocampus,,1,H,104744,10000000.0,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,4,CHEMBL833492,,,B,,,,Autocuration,,BAO_0000221
772,,Hippocampus,,1,H,104744,10000000.0,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,4,CHEMBL615873,,,B,,,,Autocuration,,BAO_0000221
773,,,,1,H,104744,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,4,CHEMBL615479,,,B,,,,Autocuration,,BAO_0000224
774,,,,1,H,104744,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,4,CHEMBL615480,,,B,,,,Autocuration,,BAO_0000019
775,,,,1,D,104744,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,5,CHEMBL615481,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000249
776,,,,1,H,104744,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,4,CHEMBL872869,,,B,,,,Autocuration,,BAO_0000019
777,,,,1,H,104744,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,4,CHEMBL615482,,,B,,,,Autocuration,,BAO_0000019
778,,Brain,,1,H,104744,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,4,CHEMBL615483,,,B,,,,Autocuration,,BAO_0000221
779,,Brain,,1,H,104744,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,4,CHEMBL615484,,,B,,,,Autocuration,,BAO_0000221
780,,,,1,H,104744,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,4,CHEMBL615485,,,B,,,,Autocuration,,BAO_0000019
781,,,,1,D,104744,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,5,CHEMBL615486,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
782,,,,1,H,104744,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,4,CHEMBL615487,,,B,,,,Autocuration,,BAO_0000224
783,,,,1,H,104744,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,4,CHEMBL615488,,,B,,,,Autocuration,,BAO_0000224
784,,,,1,H,104744,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,4,CHEMBL615489,,,B,,,,Autocuration,,BAO_0000224
785,,,,1,H,104744,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,4,CHEMBL615389,,,B,,,,Autocuration,,BAO_0000224
786,,,,1,H,104744,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,4,CHEMBL615390,,,B,,,,Autocuration,,BAO_0000019
787,,,,1,H,104744,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,4,CHEMBL615391,,,B,,,,Autocuration,,BAO_0000019
788,,,,1,H,104744,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,4,CHEMBL615392,,,B,,,,Autocuration,,BAO_0000224
789,,,,1,U,22226,,Affinity for 5-hydroxytryptamine 1 receptor,0,CHEMBL615393,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
790,,Brain,,1,H,104744,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,4,CHEMBL615394,,,B,,,,Autocuration,,BAO_0000221
791,,Brain,,1,H,104744,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,4,CHEMBL615395,,,B,,,,Autocuration,,BAO_0000221
792,,,,1,H,104744,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,4,CHEMBL615396,,,B,,,,Autocuration,,BAO_0000224
793,,Brain,,1,H,104744,955.0,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,4,CHEMBL615397,,,B,,,,Autocuration,,BAO_0000221
794,,,,1,H,104744,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,4,CHEMBL615398,,,B,,,,Autocuration,,BAO_0000019
795,,,,1,U,22226,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,0,CHEMBL615399,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
796,,,,1,H,104744,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,4,CHEMBL615400,,,B,,,,Autocuration,,BAO_0000019
797,,,,1,D,104744,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,5,CHEMBL615401,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
798,,,,1,U,22226,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,0,CHEMBL615402,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
799,,,,1,H,104744,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,4,CHEMBL615403,,,B,,,,Autocuration,,BAO_0000019
800,,Brain,,1,H,104744,955.0,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,4,CHEMBL615404,,,B,,,,Autocuration,,BAO_0000221
801,,,,1,H,104744,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,4,CHEMBL615781,,,B,,,,Autocuration,,BAO_0000019
802,,Brain,,1,H,104744,955.0,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,4,CHEMBL615782,,,B,,,,Autocuration,,BAO_0000220
803,,Brain,,1,H,104744,955.0,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,4,CHEMBL615783,,,B,,,,Autocuration,,BAO_0000221
804,,,,1,U,22226,,Compound was tested for binding affinity against 5-HT1 receptor,0,CHEMBL873481,,,B,,,,Autocuration,,BAO_0000019
805,,,,1,U,22226,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,0,CHEMBL615784,,,B,,,,Autocuration,,BAO_0000019
806,,,,1,H,10576,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,8,CHEMBL615785,,,B,,,,Expert,,BAO_0000357
807,,,,1,H,10576,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",8,CHEMBL615786,,,F,,,,Autocuration,,BAO_0000249
808,,,,1,H,10576,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,8,CHEMBL615787,,,F,,In vivo,,Autocuration,,BAO_0000218
809,,,,1,H,10576,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,8,CHEMBL615788,,,F,,In vivo,,Autocuration,,BAO_0000218
810,,,,1,H,10576,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,8,CHEMBL767044,,,F,,,,Autocuration,,BAO_0000019
811,,,,1,H,10576,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,8,CHEMBL615789,,,F,,In vivo,,Autocuration,,BAO_0000218
812,,,,1,H,10576,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,8,CHEMBL615790,,,F,,In vivo,,Autocuration,,BAO_0000218
813,,,,1,H,10576,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,8,CHEMBL615813,,,F,,,,Autocuration,,BAO_0000019
814,,,,1,H,10576,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,8,CHEMBL615814,,,F,,,,Autocuration,,BAO_0000219
815,,,,1,H,51,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,8,CHEMBL615815,,,F,,,,Expert,,BAO_0000219
816,,,,1,H,10576,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,8,CHEMBL615816,,,F,,,,Autocuration,,BAO_0000219
817,,,,1,H,10576,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,8,CHEMBL615817,,,B,,,,Expert,,BAO_0000249
818,,Hippocampus,,1,H,10576,10000000.0,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,8,CHEMBL615818,,,B,,,,Autocuration,,BAO_0000221
819,,Hippocampus,,1,H,10576,10000000.0,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,8,CHEMBL615819,,,B,,,,Autocuration,,BAO_0000221
820,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,8,CHEMBL615820,,Membranes,B,,,,Expert,,BAO_0000249
821,,Hippocampus,,1,D,10576,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,9,CHEMBL615821,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
822,,Hippocampus,,1,D,10576,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,9,CHEMBL615822,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
823,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,8,CHEMBL615823,,,B,,,,Expert,,BAO_0000221
824,,Hippocampus,,1,D,10576,10000000.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,9,CHEMBL615824,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
825,,Hippocampus,,1,D,10576,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,9,CHEMBL615825,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
826,,,,1,H,10576,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,8,CHEMBL615826,,,B,,,,Expert,,BAO_0000357
827,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,8,CHEMBL615827,,,B,,,,Expert,,BAO_0000249
828,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,8,CHEMBL615828,,,B,,,,Expert,,BAO_0000249
829,,Hippocampus,,1,H,10576,10000000.0,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,8,CHEMBL615829,,,B,,,,Expert,,BAO_0000221
830,,Hippocampus,,1,H,10576,10000000.0,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,8,CHEMBL615830,,,B,,,,Autocuration,,BAO_0000221
831,,Hippocampus,,1,H,10576,10000000.0,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,8,CHEMBL615831,,,B,,,,Expert,,BAO_0000221
832,,,,1,H,10576,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,8,CHEMBL615832,,,B,,,,Autocuration,,BAO_0000357
833,,,,1,H,10576,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,8,CHEMBL615833,,,B,,,,Autocuration,,BAO_0000019
834,,Hippocampus,,1,H,10576,10000000.0,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,8,CHEMBL615834,,,B,,,,Autocuration,,BAO_0000221
835,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,8,CHEMBL615835,,,B,,,,Intermediate,,BAO_0000249
836,,Hippocampus,,1,H,10576,10000000.0,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,8,CHEMBL615836,,,B,,,,Autocuration,,BAO_0000249
837,,,,1,D,10576,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,9,CHEMBL615837,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
838,,,,1,D,10576,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,9,CHEMBL615838,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
839,,,,1,H,10576,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",8,CHEMBL615839,,,B,,,,Expert,,BAO_0000249
840,,,,1,H,10576,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,8,CHEMBL884525,,,B,,,,Autocuration,,BAO_0000019
841,,,,1,H,10576,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,8,CHEMBL615840,,,B,,,,Autocuration,,BAO_0000249
842,,Hippocampus,,1,H,10576,10000000.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,8,CHEMBL615405,,,B,,,,Expert,,BAO_0000221
843,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,8,CHEMBL615406,,,B,,,,Expert,,BAO_0000019
844,,Hippocampus,,1,H,10576,10000000.0,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,8,CHEMBL615900,,,B,,,,Expert,,BAO_0000221
845,,Hippocampus,,1,H,10576,10000000.0,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,8,CHEMBL615901,,,B,,,,Expert,,BAO_0000221
846,,,,1,H,10576,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,8,CHEMBL615902,,,B,,,,Expert,,BAO_0000357
847,,Hippocampus,,1,H,10576,10000000.0,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,8,CHEMBL615903,,,B,,,,Autocuration,,BAO_0000221
848,,,,1,H,10576,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,8,CHEMBL615904,,,B,,,,Autocuration,,BAO_0000357
849,,,,1,H,10576,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,8,CHEMBL615905,,,B,,,,Expert,,BAO_0000357
850,,,,1,H,10576,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,8,CHEMBL615906,,,B,,,,Autocuration,,BAO_0000019
851,,,,1,H,10576,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,8,CHEMBL615907,,,F,,,,Autocuration,,BAO_0000019
852,,,,1,H,10576,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,8,CHEMBL615908,,,B,,,,Expert,,BAO_0000019
853,,Hippocampus,,1,H,10576,10000000.0,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,8,CHEMBL615909,,,B,,,,Autocuration,,BAO_0000221
854,,,,1,H,10576,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",8,CHEMBL615910,,,B,,,,Autocuration,,BAO_0000019
855,,,,1,H,10576,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",8,CHEMBL615911,,,B,,,,Autocuration,,BAO_0000019
856,,,,1,H,10576,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",8,CHEMBL615912,,,B,,,,Autocuration,,BAO_0000019
857,,,,1,H,10576,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,8,CHEMBL615913,,,B,,,,Expert,,BAO_0000019
858,,,,1,H,10576,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,8,CHEMBL615914,,,B,,,,Expert,,BAO_0000357
859,,Hippocampus,,1,H,10576,10000000.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,8,CHEMBL615915,,,B,,,,Autocuration,,BAO_0000221
860,,,,1,H,10576,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,8,CHEMBL615916,,,B,,,,Autocuration,,BAO_0000357
861,,,,1,H,10576,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,8,CHEMBL615917,,,B,,,,Expert,,BAO_0000357
862,,,,1,H,10576,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,8,CHEMBL615918,,,B,,,,Expert,,BAO_0000357
863,,Hippocampus,,1,H,10576,10000000.0,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,8,CHEMBL615919,,,B,,,,Expert,,BAO_0000249
864,,Hippocampus,,1,D,10576,10000000.0,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,9,CHEMBL615920,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
865,,,,1,H,10576,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,8,CHEMBL615921,,,B,,,,Autocuration,,BAO_0000357
866,,,,1,H,10576,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),8,CHEMBL615922,,,B,,,,Expert,,BAO_0000357
867,,,,1,D,10576,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",9,CHEMBL881290,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000249
868,,Hippocampus,,1,H,10576,10000000.0,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",8,CHEMBL615923,,,B,,,,Autocuration,,BAO_0000221
869,,Hippocampus,,1,H,10576,10000000.0,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,8,CHEMBL615924,,,F,,,,Autocuration,,BAO_0000221
870,,Hippocampus,,1,H,10576,10000000.0,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,8,CHEMBL615925,,,F,,,,Autocuration,,BAO_0000221
871,,,,1,D,10576,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,9,CHEMBL615926,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
872,,,,1,D,10576,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,9,CHEMBL615927,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
873,,Hippocampus,,1,H,10576,10000000.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,8,CHEMBL615928,,,B,,,,Autocuration,,BAO_0000221
874,,,,1,D,10576,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,9,CHEMBL615929,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
875,,Hippocampus,,1,H,10576,10000000.0,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,8,CHEMBL615930,,,B,,,,Autocuration,,BAO_0000221
876,,,,1,H,51,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,8,CHEMBL615931,,,B,,,CHO,Autocuration,449.0,BAO_0000219
877,,,,1,H,51,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,8,CHEMBL615932,,,F,,,CHO,Autocuration,449.0,BAO_0000219
878,,,,1,H,51,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,8,CHEMBL615933,,,F,,,CHO,Autocuration,449.0,BAO_0000219
879,,,,1,H,51,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,8,CHEMBL615934,,,B,,,,Autocuration,,BAO_0000357
880,,,,1,H,51,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,8,CHEMBL615935,,,B,,,,Autocuration,,BAO_0000357
881,,,,1,H,51,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",8,CHEMBL615936,,,F,,,,Autocuration,,BAO_0000019
882,,,,1,H,51,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,8,CHEMBL615937,,,B,,,CHO,Autocuration,449.0,BAO_0000219
883,,,,1,H,51,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,8,CHEMBL615938,,,B,,,,Autocuration,,BAO_0000357
884,,,,1,H,51,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),8,CHEMBL615797,,,B,,,,Autocuration,,BAO_0000357
885,,,,1,H,51,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL615798,,,B,,,,Autocuration,,BAO_0000357
886,,,,1,H,51,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,8,CHEMBL872870,,,B,,,,Autocuration,,BAO_0000357
887,,,,1,H,51,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,8,CHEMBL615799,,,B,,,,Autocuration,,BAO_0000357
888,,,,1,H,51,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,8,CHEMBL615800,,,B,,,,Autocuration,,BAO_0000357
889,,,,1,H,51,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,8,CHEMBL615801,,,F,,,HEK293,Autocuration,722.0,BAO_0000219
890,,,,1,H,51,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,8,CHEMBL615802,,,B,,,,Autocuration,,BAO_0000019
891,,,,1,H,51,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,8,CHEMBL615803,,,B,,,,Autocuration,,BAO_0000357
892,,,,1,H,51,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",8,CHEMBL835002,,,F,,,,Expert,,BAO_0000019
893,,,,1,H,51,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",8,CHEMBL615804,,,F,,,,Autocuration,,BAO_0000019
894,,,,1,H,51,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,8,CHEMBL615805,,,B,,,HeLa,Expert,308.0,BAO_0000219
895,,,,1,H,51,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,8,CHEMBL615806,,,B,,,CHO,Autocuration,449.0,BAO_0000219
896,,,,1,D,51,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,9,CHEMBL615807,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
897,,,,1,H,51,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,8,CHEMBL615808,,,B,,,,Autocuration,,BAO_0000357
898,,,,1,D,51,,Binding affinity against 5-hydroxytryptamine 1A receptor,9,CHEMBL615809,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
899,,,,1,H,51,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,8,CHEMBL615810,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
900,,,,1,H,51,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL615811,,,B,,,,Autocuration,,BAO_0000357
901,,,,1,H,51,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,8,CHEMBL615812,,,B,,,CHO,Autocuration,449.0,BAO_0000219
902,,,,1,H,51,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,8,CHEMBL615751,,,B,,,CHO,Autocuration,449.0,BAO_0000219
903,,,,1,H,51,,Binding affinity against human 5-hydroxytryptamine 1A receptor,8,CHEMBL615752,,,B,,,,Autocuration,,BAO_0000357
904,,,,1,H,51,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,8,CHEMBL615753,,,B,,,CHO,Expert,449.0,BAO_0000219
905,,,,1,H,51,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,8,CHEMBL615754,,,B,,,CHO,Autocuration,449.0,BAO_0000219
906,,,,1,H,51,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,8,CHEMBL615755,,,B,,,,Autocuration,,BAO_0000357
907,,,,1,D,51,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,9,CHEMBL615756,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
908,,,,1,H,51,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,8,CHEMBL615757,,,B,,,,Autocuration,,BAO_0000019
909,,,,1,H,51,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,8,CHEMBL615758,,,B,,,,Autocuration,,BAO_0000357
910,,,,1,H,51,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,8,CHEMBL615759,,,B,,,,Expert,,BAO_0000357
911,,,,1,H,51,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,8,CHEMBL615760,,,B,,,,Autocuration,,BAO_0000357
912,,,,1,H,51,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,8,CHEMBL615761,,,B,,,HeLa,Expert,308.0,BAO_0000219
913,,,,1,H,51,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,8,CHEMBL872104,,,B,,,,Autocuration,,BAO_0000357
914,,,,1,H,51,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,8,CHEMBL615762,,,B,,,,Autocuration,,BAO_0000357
915,,,,1,H,51,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,8,CHEMBL615763,,,B,,,,Autocuration,,BAO_0000357
916,,,,1,H,51,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,8,CHEMBL615764,,,B,,,,Autocuration,,BAO_0000357
917,,,,1,H,51,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),8,CHEMBL615765,,,B,,,Cell line,Autocuration,1167.0,BAO_0000219
918,,,,1,H,51,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),8,CHEMBL615766,,,B,,,,Autocuration,,BAO_0000019
919,,,,1,H,51,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL615767,,,B,,,,Autocuration,,BAO_0000357
920,,,,1,H,51,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL615768,,,B,,,,Expert,,BAO_0000357
921,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL615769,,,B,,,,Autocuration,,BAO_0000357
922,,,,1,H,51,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,8,CHEMBL615770,,,B,,,,Expert,,BAO_0000357
923,,,,1,H,51,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL615771,,,B,,,,Autocuration,,BAO_0000357
924,,,,1,H,51,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,8,CHEMBL615772,,,B,,,,Expert,,BAO_0000357
925,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,CHEMBL615773,,,B,,,,Autocuration,,BAO_0000357
926,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,8,CHEMBL615774,,,B,,,,Expert,,BAO_0000357
927,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL615775,,,B,,,,Autocuration,,BAO_0000357
928,,,,1,H,51,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,8,CHEMBL615776,,,B,,,,Autocuration,,BAO_0000357
929,,,,1,H,51,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL615777,,,B,,,,Expert,,BAO_0000357
930,,,,1,H,51,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,8,CHEMBL615778,,,B,,,,Autocuration,,BAO_0000219
931,,,,1,D,51,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,9,CHEMBL615779,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
932,,,,1,H,51,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,8,CHEMBL615780,,,B,,,,Autocuration,,BAO_0000357
933,,,,1,H,51,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,8,CHEMBL616298,,,B,,,,Autocuration,,BAO_0000357
934,,,,1,H,51,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,8,CHEMBL616299,,,B,,,,Autocuration,,BAO_0000357
935,,,,1,H,51,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,8,CHEMBL616300,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
936,,,,1,H,51,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,8,CHEMBL616301,,,F,,,CHO-K1,Expert,485.0,BAO_0000219
937,,,,1,H,51,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,8,CHEMBL616302,,,B,,,,Autocuration,,BAO_0000019
938,,,,1,H,51,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),8,CHEMBL616117,,,B,,,,Autocuration,,BAO_0000019
939,,,,1,H,51,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),8,CHEMBL616118,,,B,,,,Autocuration,,BAO_0000019
940,,,,1,H,51,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,8,CHEMBL616119,,,B,,,,Autocuration,,BAO_0000019
941,,,,1,D,51,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,9,CHEMBL616120,Homo sapiens,,B,9606.0,,HeLa,Expert,308.0,BAO_0000219
942,,,,1,H,51,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,8,CHEMBL616121,,,B,,,,Autocuration,,BAO_0000357
943,,,,1,H,51,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,8,CHEMBL616122,,,B,,,,Autocuration,,BAO_0000357
944,,,,1,H,51,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,8,CHEMBL616123,,,B,,,,Autocuration,,BAO_0000357
945,,,,1,D,51,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,9,CHEMBL616124,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
946,,,,1,H,51,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,8,CHEMBL616125,,,B,,,,Expert,,BAO_0000357
947,,,,1,H,51,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,8,CHEMBL616126,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
948,,,,1,H,51,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,8,CHEMBL616127,,,B,,,CHO,Autocuration,449.0,BAO_0000219
949,,,,1,H,51,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,8,CHEMBL616128,,,B,,,,Expert,,BAO_0000019
950,,,,1,H,51,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,8,CHEMBL616129,,,B,,,,Autocuration,,BAO_0000357
951,,,,1,H,51,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,8,CHEMBL616130,,,B,,,,Expert,,BAO_0000357
952,,,,1,H,51,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,8,CHEMBL616131,,,B,,,,Autocuration,,BAO_0000357
953,,,,1,H,51,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,8,CHEMBL616132,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
954,,,,1,D,51,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,9,CHEMBL616133,Homo sapiens,,B,9606.0,,HeLa,Expert,308.0,BAO_0000219
955,,,,1,H,51,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL616134,,,B,,,,Autocuration,,BAO_0000357
956,,,,1,H,51,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,8,CHEMBL616135,,,B,,,,Autocuration,,BAO_0000357
957,,,,1,D,51,,Affinity for 5-hydroxytryptamine 1A receptor subtype,9,CHEMBL616136,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
958,,,,1,H,51,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,8,CHEMBL616137,,,B,,,,Autocuration,,BAO_0000019
959,,,,1,H,51,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,8,CHEMBL872105,,,B,,,,Autocuration,,BAO_0000019
960,,,,1,H,51,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,8,CHEMBL616138,,,B,,,,Autocuration,,BAO_0000357
961,,,,1,D,51,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,9,CHEMBL616139,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
962,,,,1,H,51,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",8,CHEMBL616140,,,F,,,,Autocuration,,BAO_0000019
963,,,,1,H,51,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,8,CHEMBL616141,,,B,,,,Expert,,BAO_0000019
964,,,,1,H,51,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL616142,,,B,,,,Autocuration,,BAO_0000357
965,,,,1,H,51,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,8,CHEMBL616143,,,B,,,,Autocuration,,BAO_0000357
966,,,,1,H,51,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,8,CHEMBL616144,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
967,,,,1,H,51,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,8,CHEMBL616145,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
968,,,,1,H,51,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,8,CHEMBL616012,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
969,,,,1,H,51,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,8,CHEMBL616013,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
970,,,,1,H,51,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",8,CHEMBL616014,,,F,,,,Autocuration,,BAO_0000019
971,,,,1,H,51,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",8,CHEMBL616015,,,F,,,,Autocuration,,BAO_0000019
972,,,,1,H,51,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",8,CHEMBL616016,,,F,,,,Autocuration,,BAO_0000019
973,,,,1,H,51,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,8,CHEMBL616017,,,F,,In vivo,,Autocuration,,BAO_0000218
974,,,,1,H,51,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,8,CHEMBL616018,,,B,,,,Autocuration,,BAO_0000019
975,,,,1,H,51,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,8,CHEMBL616019,,,F,,,,Autocuration,,BAO_0000019
976,,,,1,H,51,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,8,CHEMBL616020,,,F,,,,Autocuration,,BAO_0000019
977,,,,1,H,51,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,8,CHEMBL858018,,,B,,,,Autocuration,,BAO_0000357
978,,,,1,H,51,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,8,CHEMBL616021,,,F,,,HEK293,Autocuration,722.0,BAO_0000219
979,,,,1,H,51,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",8,CHEMBL616022,,,F,,,,Expert,,BAO_0000019
980,,,,1,H,51,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",8,CHEMBL616023,,,F,,,,Autocuration,,BAO_0000019
981,,,,1,H,51,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",8,CHEMBL616024,,,F,,,,Autocuration,,BAO_0000019
982,,,,1,H,51,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",8,CHEMBL616025,,,F,,,,Autocuration,,BAO_0000019
983,,,,1,H,51,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,8,CHEMBL616026,,,F,,,CHO,Autocuration,449.0,BAO_0000219
984,,,,1,H,51,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",8,CHEMBL616027,,,F,,,,Autocuration,,BAO_0000019
985,,,,1,D,51,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",9,CHEMBL616028,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
986,,,,1,D,51,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,9,CHEMBL616029,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
987,,,,1,H,51,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,8,CHEMBL616030,,,B,,,CHO,Expert,449.0,BAO_0000219
988,,,,1,H,51,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,8,CHEMBL616031,,,B,,,,Expert,,BAO_0000019
989,,,,1,D,51,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,9,CHEMBL616032,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
990,,,,1,D,51,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,9,CHEMBL616033,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
991,,,,1,H,51,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,8,CHEMBL616034,,,F,,,,Autocuration,,BAO_0000019
992,,,,1,H,51,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,8,CHEMBL616035,,,F,,,,Autocuration,,BAO_0000019
993,,,,1,H,51,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,8,CHEMBL616036,,,F,,,,Autocuration,,BAO_0000019
994,,,,1,H,51,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,8,CHEMBL616037,,,F,,,,Autocuration,,BAO_0000019
995,,,,1,H,51,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,8,CHEMBL616038,,,F,,,,Autocuration,,BAO_0000019
996,,,,1,H,51,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,8,CHEMBL616039,,,F,,,,Autocuration,,BAO_0000019
997,,,,1,H,51,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,8,CHEMBL616040,,,F,,,,Autocuration,,BAO_0000019
998,,,,1,D,51,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9,CHEMBL616041,Homo sapiens,,F,9606.0,,HeLa,Expert,308.0,BAO_0000219
999,,,,1,D,51,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9,CHEMBL616042,Homo sapiens,,F,9606.0,,HeLa,Expert,308.0,BAO_0000219
1000,,,,1,D,51,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9,CHEMBL616043,Homo sapiens,,F,9606.0,,HeLa,Expert,308.0,BAO_0000219
1001,,,,1,H,51,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",8,CHEMBL616044,,,F,,,,Autocuration,,BAO_0000019
1002,,,,1,H,51,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",8,CHEMBL616045,,,F,,,,Autocuration,,BAO_0000019
1003,,,,1,H,51,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,8,CHEMBL616046,,,F,,,HEK293,Autocuration,722.0,BAO_0000219
1004,,,,1,H,51,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),8,CHEMBL616047,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1005,,,,1,H,51,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,8,CHEMBL616048,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1006,,,,1,D,51,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),9,CHEMBL616049,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
1007,,,,1,H,51,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),8,CHEMBL616050,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1008,,,,1,H,51,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,8,CHEMBL616051,,,F,,,,Expert,,BAO_0000219
1009,,,,1,H,51,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,8,CHEMBL616212,,,F,,,,Autocuration,,BAO_0000219
1010,,,,1,H,51,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",8,CHEMBL616213,,,F,,,,Autocuration,,BAO_0000019
1011,,,,1,H,51,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,8,CHEMBL616214,,,B,,In vitro,,Expert,,BAO_0000219
1012,,,,1,H,51,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,8,CHEMBL616215,,,B,,In vitro,,Expert,,BAO_0000219
1013,,,,1,H,51,,Binding activity radioligand.,8,CHEMBL616216,,,B,,,,Autocuration,,BAO_0000357
1014,,,,1,H,51,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,8,CHEMBL616217,,,B,,,,Autocuration,,BAO_0000019
1015,,,,1,H,51,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,8,CHEMBL616218,,,B,,,,Autocuration,,BAO_0000357
1016,,,,1,H,51,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,8,CHEMBL616219,,,B,,,,Autocuration,,BAO_0000357
1017,,,,1,H,51,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,8,CHEMBL616220,,,B,,,,Autocuration,,BAO_0000357
1018,,,,1,D,51,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,9,CHEMBL833493,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1019,,,,1,H,51,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,8,CHEMBL616221,,,B,,,,Autocuration,,BAO_0000357
1020,,,,1,D,51,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,9,CHEMBL616222,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
1021,,,,1,H,51,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,8,CHEMBL616223,,,F,,,,Autocuration,,BAO_0000019
1022,,,,1,H,51,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,8,CHEMBL616224,,,F,,,,Autocuration,,BAO_0000019
1023,,,,1,H,51,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,8,CHEMBL616225,,,B,,,,Expert,,BAO_0000019
1024,,,,1,D,51,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,9,CHEMBL616226,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
1025,,,,1,H,51,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,8,CHEMBL616227,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1026,,,,1,H,51,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,8,CHEMBL616228,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1027,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,8,CHEMBL616229,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1028,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,8,CHEMBL616230,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1029,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,8,CHEMBL616231,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1030,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,8,CHEMBL616232,,,B,,,,Autocuration,,BAO_0000357
1031,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,8,CHEMBL616233,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1032,,,,1,H,51,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,8,CHEMBL857973,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1033,,,,1,H,51,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,8,CHEMBL616234,,,B,,,,Autocuration,,BAO_0000219
1034,,,,1,H,51,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,8,CHEMBL616235,,,B,,,,Autocuration,,BAO_0000357
1035,,,,1,H,51,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,8,CHEMBL616236,,,B,,,HeLa,Expert,308.0,BAO_0000219
1036,,,,1,H,51,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,8,CHEMBL616237,,,B,,,,Expert,,BAO_0000019
1037,,,,1,H,51,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,8,CHEMBL616238,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1038,,,,1,H,51,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,8,CHEMBL616239,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1039,,,,1,H,51,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,8,CHEMBL616240,,,B,,,,Autocuration,,BAO_0000219
1040,,,,1,D,51,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,9,CHEMBL616241,Homo sapiens,,B,9606.0,,HeLa,Expert,308.0,BAO_0000219
1041,,,,1,H,51,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,8,CHEMBL616242,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1042,,,,1,H,51,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",8,CHEMBL616243,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1043,,,,1,D,51,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,9,CHEMBL616244,,,B,,,,Expert,,BAO_0000357
1044,,,,1,D,51,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,9,CHEMBL616245,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000357
1045,,,,1,H,106,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,8,CHEMBL616246,,,B,,,,Autocuration,,BAO_0000357
1046,,,,1,H,105,,Binding affinity against 5-HT1D receptor,8,CHEMBL616247,,,B,,,,Autocuration,,BAO_0000357
1047,,,,1,H,105,,Binding affinity against 5-hydroxytryptamine 1A receptor,8,CHEMBL616248,,,B,,,,Autocuration,,BAO_0000357
1048,,,,1,H,107,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,8,CHEMBL616249,,,B,,,,Autocuration,,BAO_0000357
1049,,,,1,H,10576,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,8,CHEMBL616250,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000357
1050,,,,1,H,51,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,8,CHEMBL616251,,,B,,,,Autocuration,,BAO_0000357
1051,,,,1,H,11863,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,8,CHEMBL616252,,,F,,In vivo,,Autocuration,,BAO_0000218
1052,,,,1,H,11863,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,8,CHEMBL616253,,,F,,In vivo,,Autocuration,,BAO_0000218
1053,,,,1,H,11863,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,8,CHEMBL616254,,,F,,In vivo,,Autocuration,,BAO_0000218
1054,,,,1,D,11863,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,9,CHEMBL616255,Mus musculus,,F,10090.0,,,Expert,,BAO_0000218
1055,,,,1,D,11863,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,9,CHEMBL832872,Mus musculus,,F,10090.0,,,Expert,,BAO_0000218
1056,,,,1,D,11863,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,9,CHEMBL616256,Mus musculus,,F,10090.0,,,Expert,,BAO_0000218
1057,,,,1,D,11863,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,9,CHEMBL616257,Mus musculus,,F,10090.0,,,Expert,,BAO_0000218
1058,,,,1,D,11863,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,9,CHEMBL616258,Mus musculus,,F,10090.0,,,Expert,,BAO_0000218
1059,,,,1,D,11863,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,9,CHEMBL616384,Mus musculus,,F,10090.0,,,Expert,,BAO_0000218
1060,,Hippocampus,,1,H,11863,10000000.0,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,8,CHEMBL616385,,,B,,,,Autocuration,,BAO_0000221
1061,,,,1,H,11863,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,8,CHEMBL616386,,,B,,,,Expert,,BAO_0000357
1062,,Hippocampus,,1,D,11863,10000000.0,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,9,CHEMBL616387,Mus musculus,,B,10090.0,,,Expert,,BAO_0000221
1063,,Hippocampus,,1,H,11863,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,8,CHEMBL616388,,,B,,,,Autocuration,,BAO_0000221
1064,,Hippocampus,,1,D,11863,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,9,CHEMBL616389,Mus musculus,,B,10090.0,,,Expert,,BAO_0000221
1065,,Hippocampus,,1,H,11863,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,8,CHEMBL616390,,,B,,,,Autocuration,,BAO_0000221
1066,,,,1,H,11863,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,8,CHEMBL616391,,,B,,,,Autocuration,,BAO_0000357
1067,,Hippocampus,,1,D,11863,10000000.0,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,9,CHEMBL616392,Mus musculus,,B,10090.0,,,Expert,,BAO_0000221
1068,,,,1,H,51,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,8,CHEMBL616393,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1069,,,,1,H,51,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,8,CHEMBL616394,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1070,,,,1,H,51,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,8,CHEMBL616395,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
1071,,,,1,H,51,,Compound was evaluated for the binding affinity at 5- HT1A receptor,8,CHEMBL616396,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1072,,,,1,H,51,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,8,CHEMBL872907,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
1073,,,,1,H,51,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,8,CHEMBL616397,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
1074,,,,1,H,51,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,8,CHEMBL616398,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
1075,,,,1,H,51,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,8,CHEMBL616399,Sus scrofa,,B,9823.0,,,Expert,,BAO_0000357
1076,,,,1,H,51,,Binding activity radioligand.,8,CHEMBL857065,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1077,,,,1,H,51,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,8,CHEMBL616400,Sus scrofa,,B,9823.0,,,Expert,,BAO_0000019
1078,,,,1,H,51,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,8,CHEMBL616401,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
1079,,,,1,H,10624,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,8,CHEMBL616402,,,B,,,,Expert,,BAO_0000019
1080,,,,1,H,51,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,8,CHEMBL616403,Sus scrofa,,B,9823.0,,,Expert,,BAO_0000019
1081,,Hippocampus,,1,H,51,10000000.0,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,8,CHEMBL616404,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000221
1082,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,8,CHEMBL616405,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000249
1083,,,,1,H,51,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,8,CHEMBL616406,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
1084,,,,1,H,51,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,8,CHEMBL616407,Sus scrofa,,F,9823.0,,,Expert,,BAO_0000019
1085,,,,1,H,51,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,8,CHEMBL616408,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
1086,,,,1,D,10576,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,9,CHEMBL616409,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000249
1087,,Hippocampus,,1,D,10576,10000000.0,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",9,CHEMBL616410,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1088,,,,1,H,10576,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,8,CHEMBL616411,,,B,,,,Autocuration,,BAO_0000357
1089,,,,1,D,10576,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",9,CHEMBL616412,Rattus norvegicus,Membranes,F,10116.0,,,Expert,,BAO_0000249
1090,,Hippocampus,,1,D,10576,10000000.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",9,CHEMBL616413,Rattus norvegicus,Membranes,F,10116.0,,,Expert,,BAO_0000249
1091,,Hippocampus,,1,H,10576,10000000.0,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,8,CHEMBL616414,,,B,,,,Autocuration,,BAO_0000221
1092,,Hippocampus,,1,D,10576,10000000.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,9,CHEMBL616415,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1093,,,,1,H,10576,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,8,CHEMBL616416,,,B,,,,Autocuration,,BAO_0000019
1094,,,,1,H,10576,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,8,CHEMBL616417,,,B,,,,Expert,,BAO_0000357
1095,,,,1,H,10576,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,8,CHEMBL616418,,,B,,,,Autocuration,,BAO_0000357
1096,,,,1,H,10576,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,8,CHEMBL616419,,,B,,In vitro,,Autocuration,,BAO_0000219
1097,,,,1,H,10576,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,8,CHEMBL616420,,,B,,,,Autocuration,,BAO_0000357
1098,,,,1,H,10576,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,8,CHEMBL616421,,Membranes,B,,,,Autocuration,,BAO_0000249
1099,,,,1,H,10576,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,8,CHEMBL616422,,Membranes,B,,,,Autocuration,,BAO_0000249
1100,,,,1,H,10576,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,8,CHEMBL616423,,Membranes,B,,,,Expert,,BAO_0000249
1101,,,,1,D,10576,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,9,CHEMBL616424,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1102,,,,1,H,10576,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,8,CHEMBL616425,,,B,,,,Expert,,BAO_0000357
1103,,,,1,H,10576,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,8,CHEMBL616426,,,B,,,,Expert,,BAO_0000357
1104,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,8,CHEMBL616427,,,B,,,,Autocuration,,BAO_0000221
1105,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,8,CHEMBL616428,,,B,,,,Autocuration,,BAO_0000221
1106,,Hippocampus,,1,H,10576,10000000.0,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,8,CHEMBL616290,,,B,,,,Autocuration,,BAO_0000221
1107,,,,1,D,10576,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,9,CHEMBL616052,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1108,,,,1,H,10576,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,8,CHEMBL616053,,,B,,,,Autocuration,,BAO_0000357
1109,,,,1,H,10576,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,8,CHEMBL616054,,,B,,,,Autocuration,,BAO_0000249
1110,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,CHEMBL616055,,,B,,,,Autocuration,,BAO_0000357
1111,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,8,CHEMBL616056,,,B,,,,Autocuration,,BAO_0000357
1112,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,8,CHEMBL616057,,,B,,,,Expert,,BAO_0000019
1113,,Brain,,1,D,10576,955.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,9,CHEMBL616058,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1114,,Brain,,1,H,10576,955.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,8,CHEMBL616059,,,B,,,,Autocuration,,BAO_0000221
1115,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,8,CHEMBL616060,,,B,,,,Autocuration,,BAO_0000249
1116,,Hippocampus,,1,D,10576,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,9,CHEMBL616061,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1117,,Hippocampus,,1,H,10576,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,8,CHEMBL616062,,,B,,,,Expert,,BAO_0000221
1118,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,8,CHEMBL616063,,,B,,,,Autocuration,,BAO_0000249
1119,,Striatum,,1,H,10576,2435.0,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",8,CHEMBL616064,,,B,,,,Autocuration,,BAO_0000249
1120,,,,1,D,10576,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,9,CHEMBL616065,Rattus norvegicus,Membranes,B,10116.0,,,Expert,,BAO_0000249
1121,,,,1,D,10576,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,9,CHEMBL616066,Rattus norvegicus,Membranes,B,10116.0,,,Expert,,BAO_0000249
1122,,Hippocampus,,1,H,10576,10000000.0,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL616067,,,B,,,,Autocuration,,BAO_0000221
1123,,Hippocampus,,1,H,10576,10000000.0,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,8,CHEMBL616068,,,B,,,,Autocuration,,BAO_0000221
1124,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,8,CHEMBL616069,,,B,,,,Intermediate,,BAO_0000221
1125,,,,1,H,10576,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,8,CHEMBL616070,,,B,,,,Expert,,BAO_0000249
1126,,Hippocampus,,1,H,10576,10000000.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,8,CHEMBL616071,,,B,,,,Autocuration,,BAO_0000221
1127,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,8,CHEMBL616072,,,B,,,,Expert,,BAO_0000221
1128,,Hippocampus,,1,H,10576,10000000.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,8,CHEMBL616073,,,B,,,,Autocuration,,BAO_0000221
1129,,Hippocampus,,1,H,10576,10000000.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,8,CHEMBL616074,,,B,,,,Autocuration,,BAO_0000221
1130,,,,1,H,10576,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,8,CHEMBL616075,,,B,,,,Expert,,BAO_0000019
1131,,,,1,H,10576,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,8,CHEMBL616076,,,B,,,,Autocuration,,BAO_0000357
1132,,,,1,D,10576,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,9,CHEMBL616077,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1133,,,,1,D,10576,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,9,CHEMBL616078,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1134,,,,1,D,10576,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,9,CHEMBL616079,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1135,,,,1,D,10576,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,9,CHEMBL616080,Rattus norvegicus,,B,10116.0,,CHO-K1,Expert,485.0,BAO_0000219
1136,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,CHEMBL616081,,,B,,,,Autocuration,,BAO_0000357
1137,,Hippocampus,,1,D,10576,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,9,CHEMBL616082,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1138,,Hippocampus,,1,H,10576,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,8,CHEMBL616083,,,B,,,,Autocuration,,BAO_0000221
1139,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,8,CHEMBL616084,,,B,,,,Autocuration,,BAO_0000019
1140,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,8,CHEMBL616085,,,B,,,,Expert,,BAO_0000019
1141,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,8,CHEMBL616086,,,B,,,,Autocuration,,BAO_0000019
1142,,Hippocampus,,1,H,10576,10000000.0,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",8,CHEMBL616087,,,B,,,,Autocuration,,BAO_0000221
1143,,,,1,H,10576,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,8,CHEMBL616088,,,B,,,,Expert,,BAO_0000357
1144,,,,1,H,10576,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,8,CHEMBL616089,,,B,,,,Autocuration,,BAO_0000019
1145,,,,1,D,10576,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,9,CHEMBL616090,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1146,,,,1,H,10576,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,8,CHEMBL616091,,,B,,,,Autocuration,,BAO_0000357
1147,,Striatum,,1,H,10576,2435.0,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",8,CHEMBL616092,,Membranes,B,,,,Autocuration,,BAO_0000249
1148,,,,1,H,10576,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),8,CHEMBL616093,,,B,,,,Autocuration,,BAO_0000357
1149,,,,1,H,10576,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),8,CHEMBL616094,,,B,,In vivo,,Autocuration,,BAO_0000218
1150,,Brain,,1,H,10576,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,8,CHEMBL616095,,,B,,,,Autocuration,,BAO_0000221
1151,,,,1,D,10576,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,9,CHEMBL616096,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1152,,,,1,H,10576,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,8,CHEMBL616097,,,B,,,,Expert,,BAO_0000249
1153,,,,1,D,10576,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,9,CHEMBL616098,Rattus norvegicus,Membranes,B,10116.0,,,Expert,,BAO_0000249
1154,,Hippocampus,,1,H,10576,10000000.0,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,8,CHEMBL616099,,,B,,,,Autocuration,,BAO_0000221
1155,,Hippocampus,,1,H,10576,10000000.0,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,8,CHEMBL616100,,,B,,,,Autocuration,,BAO_0000221
1156,,,,1,H,10576,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,8,CHEMBL616101,,,B,,,,Expert,,BAO_0000357
1157,,,,1,H,10576,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,8,CHEMBL616102,,,B,,,,Expert,,BAO_0000249
1158,,,,1,H,10576,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,8,CHEMBL616103,,,B,,,,Autocuration,,BAO_0000357
1159,,,,1,H,10576,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,8,CHEMBL616104,,,B,,,,Expert,,BAO_0000019
1160,,,,1,H,10576,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",8,CHEMBL616105,,,B,,,,Expert,,BAO_0000019
1161,,,,1,D,10576,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,9,CHEMBL616106,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1162,,,,1,H,10576,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,8,CHEMBL616107,,,B,,,,Autocuration,,BAO_0000019
1163,,,,1,H,10576,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,8,CHEMBL616108,,,B,,,,Expert,,BAO_0000357
1164,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,8,CHEMBL616109,,,B,,,,Expert,,BAO_0000221
1165,,,,1,H,10576,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,8,CHEMBL616110,,,B,,,,Autocuration,,BAO_0000357
1166,,,,1,H,10576,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,8,CHEMBL616111,,,B,,,CHO,Expert,449.0,BAO_0000219
1167,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,8,CHEMBL616112,,,B,,,,Expert,,BAO_0000019
1168,,Hippocampus,,1,H,10576,10000000.0,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,8,CHEMBL616113,,,B,,,,Autocuration,,BAO_0000221
1169,,,,1,H,10576,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,8,CHEMBL616114,,,B,,,,Autocuration,,BAO_0000019
1170,,,,1,H,10576,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,8,CHEMBL616115,,,B,,,,Autocuration,,BAO_0000019
1171,,,,1,H,10576,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,8,CHEMBL616116,,,B,,,,Autocuration,,BAO_0000357
1172,,Brain,,1,H,10576,955.0,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,8,CHEMBL615844,,,B,,,,Expert,,BAO_0000221
1173,,Hippocampus,,1,H,10576,10000000.0,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,8,CHEMBL615939,,,B,,,,Expert,,BAO_0000221
1174,,,,1,H,10576,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,8,CHEMBL615940,,,B,,,,Expert,,BAO_0000019
1175,,Hippocampus,,1,H,10576,10000000.0,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,8,CHEMBL615941,,,B,,,,Expert,,BAO_0000221
1176,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,8,CHEMBL615942,,,B,,,,Autocuration,,BAO_0000221
1177,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,8,CHEMBL615943,,,B,,,,Autocuration,,BAO_0000221
1178,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,8,CHEMBL615944,,,B,,,,Autocuration,,BAO_0000221
1179,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,8,CHEMBL615945,,,B,,,,Autocuration,,BAO_0000221
1180,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,8,CHEMBL615946,,,B,,,,Autocuration,,BAO_0000221
1181,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,8,CHEMBL615947,,,B,,,,Autocuration,,BAO_0000221
1182,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,8,CHEMBL615948,,,B,,,,Autocuration,,BAO_0000221
1183,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,8,CHEMBL615949,,,B,,,,Autocuration,,BAO_0000221
1184,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,8,CHEMBL615950,,,B,,,,Autocuration,,BAO_0000221
1185,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,8,CHEMBL615951,,,B,,,,Autocuration,,BAO_0000221
1186,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,8,CHEMBL615952,,,B,,,,Autocuration,,BAO_0000221
1187,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,8,CHEMBL615953,,,B,,,,Autocuration,,BAO_0000221
1188,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,8,CHEMBL615954,,,B,,,,Autocuration,,BAO_0000221
1189,,Hippocampus,,1,D,10576,10000000.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,9,CHEMBL615955,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1190,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,8,CHEMBL615956,,,B,,,,Autocuration,,BAO_0000221
1191,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,8,CHEMBL615957,,,B,,,,Autocuration,,BAO_0000221
1192,,,,1,H,10576,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,8,CHEMBL615958,,,B,,,,Expert,,BAO_0000019
1193,,,,1,H,10576,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,8,CHEMBL615959,,,B,,,,Expert,,BAO_0000019
1194,,,,1,H,10576,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),8,CHEMBL615960,,,B,,,,Autocuration,,BAO_0000019
1195,,,,1,H,10576,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),8,CHEMBL615961,,,B,,,,Autocuration,,BAO_0000019
1196,,Brain,,1,H,10576,955.0,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,8,CHEMBL615962,,,B,,,,Expert,,BAO_0000221
1197,,,,1,H,10576,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,8,CHEMBL615963,,,B,,,,Expert,,BAO_0000019
1198,,,,1,H,10576,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,8,CHEMBL615964,,,B,,,,Autocuration,,BAO_0000019
1199,,,,1,H,10576,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,8,CHEMBL615965,,,B,,,,Autocuration,,BAO_0000019
1200,,,,1,H,10576,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,8,CHEMBL615966,,,B,,,CHO,Expert,449.0,BAO_0000219
1201,,,,1,H,10576,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,8,CHEMBL615967,,,B,,,,Expert,,BAO_0000249
1202,,,,1,H,10576,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,8,CHEMBL615968,,,B,,,,Expert,,BAO_0000019
1203,,,,1,H,10576,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),8,CHEMBL615969,,,B,,,CHO,Autocuration,449.0,BAO_0000218
1204,,,,1,H,10576,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),8,CHEMBL615970,,,B,,,,Autocuration,,BAO_0000218
1205,,,,1,D,10576,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,9,CHEMBL615971,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1206,,,,1,H,10576,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,8,CHEMBL615972,,Membranes,B,,,,Expert,,BAO_0000249
1207,,,,1,H,10576,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,8,CHEMBL615973,,,B,,,,Autocuration,,BAO_0000249
1208,,,,1,H,10576,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,8,CHEMBL615974,,,B,,,,Autocuration,,BAO_0000249
1209,,,,1,D,51,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,9,CHEMBL615975,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
1210,,,,1,H,10576,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,8,CHEMBL615976,,,B,,,,Expert,,BAO_0000249
1211,,Hippocampus,,1,D,10576,10000000.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,9,CHEMBL872106,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1212,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,8,CHEMBL615977,,,B,,,,Autocuration,,BAO_0000357
1213,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,8,CHEMBL615978,,,B,,,,Autocuration,,BAO_0000357
1214,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,8,CHEMBL616166,,,B,,,,Autocuration,,BAO_0000357
1215,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,8,CHEMBL616167,,,B,,,,Autocuration,,BAO_0000357
1216,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,8,CHEMBL616168,,,B,,,,Autocuration,,BAO_0000357
1217,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,8,CHEMBL616169,,,B,,,,Autocuration,,BAO_0000357
1218,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,8,CHEMBL616170,,,B,,,,Autocuration,,BAO_0000357
1219,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,8,CHEMBL616171,,,B,,,,Autocuration,,BAO_0000357
1220,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,8,CHEMBL616172,,,B,,,,Autocuration,,BAO_0000357
1221,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,8,CHEMBL616173,,,B,,,,Autocuration,,BAO_0000357
1222,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,8,CHEMBL616174,,,B,,,,Autocuration,,BAO_0000357
1223,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,8,CHEMBL616175,,,B,,,,Autocuration,,BAO_0000357
1224,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,8,CHEMBL616176,,,B,,,,Autocuration,,BAO_0000357
1225,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,8,CHEMBL616177,,,B,,,,Autocuration,,BAO_0000357
1226,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,8,CHEMBL616178,,,B,,,,Autocuration,,BAO_0000357
1227,,,,1,H,10576,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,8,CHEMBL616179,,,B,,,,Autocuration,,BAO_0000019
1228,,,,1,H,10576,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,8,CHEMBL616180,,,B,,,,Autocuration,,BAO_0000357
1229,,,,1,H,10576,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,8,CHEMBL616181,,,B,,,,Autocuration,,BAO_0000357
1230,,,,1,H,10576,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,8,CHEMBL616182,,,B,,,,Autocuration,,BAO_0000019
1231,,Hippocampus,,1,H,10576,10000000.0,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,8,CHEMBL616183,,,B,,,,Autocuration,,BAO_0000221
1232,,,,1,H,10576,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,8,CHEMBL615874,,,B,,,,Expert,,BAO_0000019
1233,,,,1,D,10576,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,9,CHEMBL615875,Rattus norvegicus,,B,10116.0,,CHO-K1,Expert,485.0,BAO_0000219
1234,,,,1,H,10576,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,8,CHEMBL615876,,,B,,,,Autocuration,,BAO_0000019
1235,,,,1,H,10576,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,8,CHEMBL615877,,,B,,,,Autocuration,,BAO_0000019
1236,,,,1,H,10576,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),8,CHEMBL615878,,,B,,,,Autocuration,,BAO_0000357
1237,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,8,CHEMBL615879,,,B,,,,Expert,,BAO_0000357
1238,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,8,CHEMBL615880,,,B,,,,Expert,,BAO_0000357
1239,,,,1,H,10576,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",8,CHEMBL615881,,,B,,,,Autocuration,,BAO_0000019
1240,,,,1,D,10576,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",9,CHEMBL615882,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1241,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,8,CHEMBL615883,,,F,,In vivo,,Autocuration,,BAO_0000218
1242,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),8,CHEMBL615884,,,F,,In vivo,,Autocuration,,BAO_0000218
1243,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),8,CHEMBL615885,,,F,,In vivo,,Autocuration,,BAO_0000218
1244,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),8,CHEMBL615886,,,F,,In vivo,,Autocuration,,BAO_0000218
1245,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),8,CHEMBL615887,,,F,,In vivo,,Autocuration,,BAO_0000218
1246,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),8,CHEMBL615888,,,F,,In vivo,,Autocuration,,BAO_0000218
1247,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),8,CHEMBL615889,,,F,,In vivo,,Autocuration,,BAO_0000218
1248,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),8,CHEMBL615890,,,F,,In vivo,,Autocuration,,BAO_0000218
1249,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),8,CHEMBL615891,,,F,,In vivo,,Autocuration,,BAO_0000218
1250,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),8,CHEMBL615892,,,F,,In vivo,,Autocuration,,BAO_0000218
1251,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),8,CHEMBL615893,,,F,,In vivo,,Autocuration,,BAO_0000218
1252,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),8,CHEMBL615894,,,F,,In vivo,,Autocuration,,BAO_0000218
1253,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),8,CHEMBL615895,,,F,,In vivo,,Autocuration,,BAO_0000218
1254,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),8,CHEMBL615896,,,F,,In vivo,,Autocuration,,BAO_0000218
1255,,,,1,H,10576,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,8,CHEMBL615897,,,F,,In vivo,,Autocuration,,BAO_0000218
1256,,,,1,D,10576,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",9,CHEMBL615898,Rattus norvegicus,Membranes,F,10116.0,,,Expert,,BAO_0000249
1257,,,,1,H,10576,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,8,CHEMBL615899,,,B,,,,Autocuration,,BAO_0000019
1258,,,,1,H,10576,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,8,CHEMBL616291,,,B,,,,Autocuration,,BAO_0000019
1259,,,,1,H,10576,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,8,CHEMBL616292,,,B,,,,Autocuration,,BAO_0000357
1260,,,,1,H,10576,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",8,CHEMBL616293,,,F,,,,Autocuration,,BAO_0000249
1261,,Hippocampus,,1,H,10576,10000000.0,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,8,CHEMBL616294,,,B,,,,Expert,,BAO_0000221
1262,,Hippocampus,,1,H,10576,10000000.0,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,8,CHEMBL616295,,,B,,,,Autocuration,,BAO_0000249
1263,,Brain,,1,H,10576,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,8,CHEMBL616296,,,B,,,,Autocuration,,BAO_0000221
1264,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,8,CHEMBL616297,,,F,,,,Autocuration,,BAO_0000019
1265,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,8,CHEMBL616605,,,F,,,,Autocuration,,BAO_0000019
1266,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,8,CHEMBL616606,,,F,,,,Autocuration,,BAO_0000019
1267,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,8,CHEMBL616607,,,F,,,,Autocuration,,BAO_0000019
1268,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,8,CHEMBL616608,,,F,,,,Expert,,BAO_0000019
1269,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,8,CHEMBL616609,,,F,,,,Autocuration,,BAO_0000019
1270,,,,1,D,10576,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,9,CHEMBL616610,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
1271,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,8,CHEMBL616611,,,F,,,,Autocuration,,BAO_0000019
1272,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,8,CHEMBL616612,,,F,,,,Expert,,BAO_0000019
1273,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,8,CHEMBL616613,,,F,,,,Autocuration,,BAO_0000019
1274,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,8,CHEMBL616614,,,F,,,,Expert,,BAO_0000019
1275,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,8,CHEMBL616615,,,F,,,,Autocuration,,BAO_0000019
1276,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,8,CHEMBL616616,,,F,,,,Expert,,BAO_0000019
1277,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,8,CHEMBL616617,,,F,,,,Autocuration,,BAO_0000019
1278,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,8,CHEMBL616618,,,F,,,,Autocuration,,BAO_0000019
1279,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,8,CHEMBL616619,,,F,,,,Autocuration,,BAO_0000019
1280,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,8,CHEMBL616620,,,F,,,,Expert,,BAO_0000019
1281,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,8,CHEMBL616621,,,F,,,,Expert,,BAO_0000019
1282,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,8,CHEMBL616622,,,F,,,,Autocuration,,BAO_0000019
1283,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,8,CHEMBL616146,,,F,,,,Expert,,BAO_0000019
1284,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,8,CHEMBL832873,,,F,,,,Autocuration,,BAO_0000019
1285,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,8,CHEMBL616147,,,F,,,,Autocuration,,BAO_0000019
1286,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,8,CHEMBL872872,,,F,,,,Autocuration,,BAO_0000019
1287,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,8,CHEMBL616148,,,F,,,,Autocuration,,BAO_0000019
1288,,Hippocampus,,1,H,10576,10000000.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,8,CHEMBL616149,,,B,,,,Autocuration,,BAO_0000221
1289,,Hippocampus,,1,H,10576,10000000.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,8,CHEMBL616150,,,B,,,,Expert,,BAO_0000221
1290,,,,1,D,10576,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,9,CHEMBL616151,Rattus norvegicus,Membranes,B,10116.0,,,Expert,,BAO_0000249
1291,,Hippocampus,,1,H,10576,10000000.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,8,CHEMBL872873,,,B,,,,Expert,,BAO_0000221
1292,,Hippocampus,,1,H,10576,10000000.0,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,8,CHEMBL616670,,,B,,,,Autocuration,,BAO_0000221
1293,,Hippocampus,,1,H,10576,10000000.0,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,8,CHEMBL616671,,,B,,,,Autocuration,,BAO_0000221
1294,,,,1,D,10576,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",9,CHEMBL884861,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000249
1295,,,,1,H,10576,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,8,CHEMBL616672,,,B,,,,Autocuration,,BAO_0000357
1296,,,,1,H,10576,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,8,CHEMBL616673,,,B,,,,Autocuration,,BAO_0000019
1297,,,,1,H,10576,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,8,CHEMBL616674,,,F,,,,Expert,,BAO_0000019
1298,,,,1,H,10576,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,8,CHEMBL616675,,,B,,,,Autocuration,,BAO_0000357
1299,,Hippocampus,,1,H,10576,10000000.0,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,8,CHEMBL616676,,,B,,,,Autocuration,,BAO_0000221
1300,,Hippocampus,,1,H,10576,10000000.0,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,8,CHEMBL616677,,,B,,,,Autocuration,,BAO_0000221
1301,,Hippocampus,,1,H,10576,10000000.0,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,8,CHEMBL616678,,,B,,,,Autocuration,,BAO_0000221
1302,,,,1,D,10576,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,9,CHEMBL616679,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1303,,Hippocampus,,1,H,10576,10000000.0,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,8,CHEMBL616680,,,B,,,,Expert,,BAO_0000221
1304,,Hippocampus,,1,H,10576,10000000.0,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,8,CHEMBL616681,,,B,,,,Autocuration,,BAO_0000221
1305,,Hippocampus,,1,H,10576,10000000.0,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,8,CHEMBL616682,,,B,,,,Autocuration,,BAO_0000221
1306,,Hippocampus,,1,H,10576,10000000.0,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,8,CHEMBL616683,,,B,,,,Autocuration,,BAO_0000221
1307,,Hippocampus,,1,H,10576,10000000.0,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,8,CHEMBL616684,,,B,,,,Autocuration,,BAO_0000221
1308,,Hippocampus,,1,H,10576,10000000.0,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,8,CHEMBL616685,,,B,,,,Autocuration,,BAO_0000221
1309,,Brain,,1,H,10576,955.0,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,8,CHEMBL616686,,,B,,,,Autocuration,,BAO_0000221
1310,,,,1,H,10576,,Affinity for 5-hydroxytryptamine 1A receptor site,8,CHEMBL616687,,,B,,,,Autocuration,,BAO_0000357
1311,,,,1,H,10576,,Affinity for 5-hydroxytryptamine 1A receptor site,8,CHEMBL616688,,,B,,,,Autocuration,,BAO_0000357
1312,,Hippocampus,,1,H,10576,10000000.0,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,8,CHEMBL616689,,,B,,,,Autocuration,,BAO_0000221
1313,,,,1,H,10576,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,8,CHEMBL616690,,,B,,,,Autocuration,,BAO_0000357
1314,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,8,CHEMBL616691,,,B,,,,Expert,,BAO_0000357
1315,,Hippocampus,,1,D,10576,10000000.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,9,CHEMBL616692,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1316,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,8,CHEMBL616693,,,B,,,,Expert,,BAO_0000249
1317,,,,1,D,10576,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",9,CHEMBL616694,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1318,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,8,CHEMBL616695,,,B,,,,Autocuration,,BAO_0000221
1319,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,8,CHEMBL616696,,,B,,,,Autocuration,,BAO_0000357
1320,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,8,CHEMBL616697,,,B,,,,Autocuration,,BAO_0000357
1321,,,,1,H,10576,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,8,CHEMBL616698,,,B,,,,Autocuration,,BAO_0000357
1322,,,,1,D,10576,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,9,CHEMBL616949,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1323,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,8,CHEMBL616950,,,B,,,,Autocuration,,BAO_0000221
1324,,,,1,H,10576,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,8,CHEMBL832875,,,B,,,,Autocuration,,BAO_0000357
1325,,Brain,,1,H,10576,955.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,8,CHEMBL616951,,,B,,,,Expert,,BAO_0000221
1326,,Brain,,1,H,10576,955.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,8,CHEMBL616952,,,B,,,,Expert,,BAO_0000221
1327,,,,1,H,10576,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,8,CHEMBL616953,,,B,,,,Expert,,BAO_0000357
1328,,,,1,H,10576,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,8,CHEMBL616954,,,B,,,,Autocuration,,BAO_0000357
1329,,,,1,H,106,,GTPgammaS radioligand binding assay,8,CHEMBL616955,,,B,,,,Autocuration,,BAO_0000357
1330,,,,1,H,106,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,8,CHEMBL616956,,,B,,,,Autocuration,,BAO_0000357
1331,,,,1,H,106,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,8,CHEMBL616957,,,F,,,,Autocuration,,BAO_0000019
1332,,,,1,H,106,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,8,CHEMBL616958,,,F,,,,Autocuration,,BAO_0000019
1333,,,,1,H,106,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,8,CHEMBL616959,,,B,,,,Autocuration,,BAO_0000357
1334,,,,1,H,106,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,8,CHEMBL616960,,,B,,,,Autocuration,,BAO_0000357
1335,,,,1,H,106,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,8,CHEMBL616961,,,F,,,,Autocuration,,BAO_0000019
1336,,,,1,H,106,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,8,CHEMBL616962,,,B,,,HeLa,Expert,308.0,BAO_0000219
1337,,,,1,H,106,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,8,CHEMBL616963,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
1338,,,,1,D,106,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,9,CHEMBL616524,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1339,,,,1,H,106,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,8,CHEMBL616525,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1340,,,,1,H,106,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,8,CHEMBL872908,,,B,,,,Autocuration,,BAO_0000019
1341,,,,1,H,106,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,8,CHEMBL616526,,,B,,,,Autocuration,,BAO_0000019
1342,,,,1,D,106,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,9,CHEMBL616527,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1343,,,,1,H,106,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,8,CHEMBL616528,,,B,,,,Expert,,BAO_0000219
1344,,,,1,H,106,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,8,CHEMBL616529,,,B,,,,Autocuration,,BAO_0000357
1345,,,,1,H,106,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,8,CHEMBL616530,,,B,,,,Autocuration,,BAO_0000357
1346,,,,1,H,106,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,8,CHEMBL616531,,,B,,,,Expert,,BAO_0000357
1347,,,,1,H,106,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,8,CHEMBL616532,,,B,,,,Autocuration,,BAO_0000357
1348,,,,1,H,106,,Binding affinity towards 5-hydroxytryptamine 1B receptor,8,CHEMBL616533,,,B,,,,Autocuration,,BAO_0000357
1349,,,,1,H,106,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,8,CHEMBL616534,,,B,,,,Expert,,BAO_0000357
1350,,,,1,H,106,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,8,CHEMBL616535,,,B,,,,Expert,,BAO_0000357
1351,,,,1,H,106,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,8,CHEMBL616536,,,B,,,,Autocuration,,BAO_0000357
1352,,,,1,H,106,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,8,CHEMBL616537,,,B,,,,Autocuration,,BAO_0000357
1353,,,,1,H,106,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,8,CHEMBL616538,,,F,,,CHO-K1,Expert,485.0,BAO_0000219
1354,,,,1,H,106,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,8,CHEMBL616539,,,F,,,,Expert,,BAO_0000019
1355,,,,1,H,106,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,8,CHEMBL616540,,,B,,,,Expert,,BAO_0000019
1356,,,,1,H,106,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,8,CHEMBL616429,,,B,,,,Autocuration,,BAO_0000357
1357,,,,1,H,106,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,8,CHEMBL616430,,,B,,,,Expert,,BAO_0000357
1358,,,,1,D,106,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,9,CHEMBL616431,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000219
1359,,,,1,D,106,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,9,CHEMBL616432,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1360,,,,1,D,106,,Affinity for 5-hydroxytryptamine 1B receptor subtype,9,CHEMBL616433,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1361,,,,1,D,106,,Binding affinity for human 5-hydroxytryptamine 1B receptor,9,CHEMBL616434,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1362,,,,1,H,106,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,8,CHEMBL616435,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1363,,,,1,H,106,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,8,CHEMBL616436,,,B,,,,Expert,,BAO_0000019
1364,,,,1,H,106,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,8,CHEMBL616437,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
1365,,,,1,H,106,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,8,CHEMBL616438,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
1366,,,,1,H,106,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,8,CHEMBL616439,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
1367,,,,1,D,106,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,9,CHEMBL616440,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1368,,,,1,H,106,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,8,CHEMBL616441,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
1369,,,,1,H,106,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,8,CHEMBL616442,,,B,,,,Expert,,BAO_0000357
1370,,,,1,H,106,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,8,CHEMBL616443,,,B,,,,Autocuration,,BAO_0000357
1371,,,,1,H,106,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,8,CHEMBL616444,,,B,,,CHO-K1,Expert,485.0,BAO_0000219
1372,,,,1,D,106,,Binding activity against human 5-hydroxytryptamine 1B receptor,9,CHEMBL616445,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1373,,,,1,D,106,,Binding activity against human 5-hydroxytryptamine 1B receptor,9,CHEMBL616446,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1374,,,,1,D,106,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,9,CHEMBL616447,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
1375,,,,1,H,106,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,8,CHEMBL616448,,,B,,,,Autocuration,,BAO_0000357
1376,,,,1,H,106,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,8,CHEMBL616449,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1377,,,,1,H,106,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,8,CHEMBL616450,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1378,,,,1,H,106,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,8,CHEMBL857974,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1379,,,,1,H,106,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,8,CHEMBL616451,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1380,,,,1,H,106,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,8,CHEMBL616452,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1381,,,,1,H,106,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,8,CHEMBL616453,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1382,,,,1,H,106,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,8,CHEMBL616454,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1383,,,,1,D,106,,Binding affinity for human 5-hydroxytryptamine 1B receptor,9,CHEMBL616455,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1384,,,,1,H,106,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,8,CHEMBL616456,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1385,,,,1,H,106,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,8,CHEMBL616457,,,B,,,,Autocuration,,BAO_0000357
1386,,,,1,H,106,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,8,CHEMBL616458,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1387,,,,1,H,106,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",8,CHEMBL616459,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1388,,,,1,H,106,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,8,CHEMBL616460,,,F,,,,Expert,,BAO_0000019
1389,,,,1,H,106,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,8,CHEMBL616461,,,F,,,,Expert,,BAO_0000019
1390,,,,1,H,106,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",8,CHEMBL616462,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1391,,,,1,H,106,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",8,CHEMBL616463,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1392,,,,1,H,105,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",8,CHEMBL616464,,,F,,,,Autocuration,,BAO_0000019
1393,,,,1,H,105,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,8,CHEMBL616465,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1394,,,,1,H,17105,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,8,CHEMBL832874,,,B,,,,Autocuration,,BAO_0000357
1395,,,,1,H,106,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,8,CHEMBL616184,Oryctolagus cuniculus,,F,9986.0,,,Autocuration,,BAO_0000019
1396,,,,1,H,106,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,8,CHEMBL616185,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
1397,,,,1,H,106,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",8,CHEMBL616186,Oryctolagus cuniculus,,B,9986.0,,,Intermediate,,BAO_0000019
1398,,,,1,H,106,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,8,CHEMBL616187,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
1399,,,,1,H,10577,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,8,CHEMBL616188,,,B,,,,Expert,,BAO_0000357
1400,,,,1,D,10577,,Binding affinity for 5-hydroxytryptamine 1B receptor,9,CHEMBL873475,,,B,,,,Intermediate,,BAO_0000357
1401,,Striatum,,1,D,10577,2435.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,9,CHEMBL616189,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1402,,,,1,H,10577,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,8,CHEMBL616190,,,B,,,,Expert,,BAO_0000357
1403,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,8,CHEMBL616191,,,B,,,,Autocuration,,BAO_0000357
1404,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,8,CHEMBL616192,,,B,,,,Autocuration,,BAO_0000357
1405,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,8,CHEMBL616193,,,B,,,,Autocuration,,BAO_0000357
1406,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,8,CHEMBL616194,,,B,,,,Autocuration,,BAO_0000357
1407,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,8,CHEMBL616195,,,B,,,,Autocuration,,BAO_0000357
1408,,,,1,H,10576,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,8,CHEMBL616196,,,B,,,,Autocuration,,BAO_0000357
1409,,Hippocampus,,1,H,10576,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,8,CHEMBL616197,,,B,,,,Autocuration,,BAO_0000249
1410,,,,1,H,10576,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,8,CHEMBL616198,,,B,,,,Intermediate,,BAO_0000019
1411,,Hippocampus,,1,H,10576,10000000.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,8,CHEMBL616199,,,B,,,,Autocuration,,BAO_0000221
1412,,Hippocampus,,1,H,10576,10000000.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,8,CHEMBL616200,,,B,,,,Expert,,BAO_0000221
1413,,Hippocampus,,1,H,10576,10000000.0,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,8,CHEMBL616201,,,B,,,,Expert,,BAO_0000221
1414,,Hippocampus,,1,H,10576,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,8,CHEMBL616202,,,B,,,,Expert,,BAO_0000221
1415,,Hippocampus,,1,H,10576,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,8,CHEMBL616203,,,B,,,,Expert,,BAO_0000221
1416,,Hippocampus,,1,H,10576,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,8,CHEMBL616204,,,B,,,,Expert,,BAO_0000221
1417,,Hippocampus,,1,H,10576,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,8,CHEMBL616205,,,B,,,,Expert,,BAO_0000221
1418,,Hippocampus,,1,H,10576,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,8,CHEMBL616206,,,B,,,,Expert,,BAO_0000221
1419,,,,1,H,10576,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,8,CHEMBL616207,,,B,,,,Expert,,BAO_0000249
1420,,,,1,H,10576,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,8,CHEMBL616208,,,B,,,,Autocuration,,BAO_0000249
1421,,,,1,H,10576,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,8,CHEMBL616209,,,B,,,,Autocuration,,BAO_0000249
1422,,,,1,H,10576,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,8,CHEMBL616210,,,B,,,,Expert,,BAO_0000357
1423,,Hippocampus,,1,H,10576,10000000.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,8,CHEMBL616211,,,B,,,,Expert,,BAO_0000221
1424,,Hippocampus,,1,H,10576,10000000.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,8,CHEMBL616504,,,B,,,,Autocuration,,BAO_0000221
1425,,Hippocampus,,1,D,10576,10000000.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,9,CHEMBL616505,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1426,,,,1,H,10576,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,8,CHEMBL616506,,,F,,,,Autocuration,,BAO_0000019
1427,,Hippocampus,,1,H,10576,10000000.0,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,8,CHEMBL872107,,,B,,,,Autocuration,,BAO_0000221
1428,,Hippocampus,,1,D,10576,10000000.0,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,9,CHEMBL616507,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1429,,,,1,H,10576,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,8,CHEMBL616303,,,B,,,,Autocuration,,BAO_0000249
1430,,Hippocampus,,1,H,10576,10000000.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,8,CHEMBL616304,,,B,,,,Autocuration,,BAO_0000221
1431,,Hippocampus,,1,H,10576,10000000.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,8,CHEMBL616305,,,B,,,,Expert,,BAO_0000221
1432,,Hippocampus,,1,H,10576,10000000.0,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,8,CHEMBL616306,,,F,,,,Intermediate,,BAO_0000221
1433,,,,1,H,10576,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,8,CHEMBL616307,,,B,,,,Autocuration,,BAO_0000357
1434,,Hippocampus,,1,D,10576,10000000.0,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,9,CHEMBL881829,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1435,,,,1,H,10576,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,8,CHEMBL616308,,,B,,,,Expert,,BAO_0000357
1436,,,,1,H,10576,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,8,CHEMBL616309,,,B,,,,Autocuration,,BAO_0000019
1437,,,,1,H,10576,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,8,CHEMBL616310,,,B,,,,Expert,,BAO_0000019
1438,,,,1,H,10576,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,8,CHEMBL616311,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1439,,,,1,H,10576,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,8,CHEMBL616312,,,B,,,,Expert,,BAO_0000357
1440,,,,1,H,10576,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,8,CHEMBL616313,,,B,,,,Autocuration,,BAO_0000357
1441,,Hippocampus,,1,D,10576,10000000.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,9,CHEMBL616314,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1442,,Hippocampus,,1,H,10576,10000000.0,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,8,CHEMBL616315,,,B,,,,Autocuration,,BAO_0000221
1443,,Hippocampus,,1,H,10576,10000000.0,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,8,CHEMBL616567,,,B,,,,Autocuration,,BAO_0000221
1444,,Hippocampus,,1,H,10576,10000000.0,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,8,CHEMBL616568,,,B,,,,Autocuration,,BAO_0000221
1445,,,,1,H,10576,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,8,CHEMBL616569,,,B,,,,Intermediate,,BAO_0000019
1446,,,,1,H,10576,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,8,CHEMBL616570,,,B,,,,Expert,,BAO_0000357
1447,,,,1,H,10576,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,8,CHEMBL616571,,,B,,,,Autocuration,,BAO_0000357
1448,,Hippocampus,,1,H,10576,10000000.0,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,8,CHEMBL616572,,,B,,,,Autocuration,,BAO_0000221
1449,,,,1,H,10576,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,8,CHEMBL616573,,,B,,,,Expert,,BAO_0000249
1450,,,,1,D,10576,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,9,CHEMBL616574,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1451,,Hippocampus,,1,H,10576,10000000.0,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,8,CHEMBL616575,,,B,,,,Expert,,BAO_0000221
1452,,Hippocampus,,1,H,10576,10000000.0,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,8,CHEMBL872108,,,B,,,,Autocuration,,BAO_0000221
1453,,,,1,H,10576,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,8,CHEMBL616576,,,B,,,,Autocuration,,BAO_0000357
1454,,,,1,H,10576,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,8,CHEMBL616577,,,B,,,,Autocuration,,BAO_0000249
1455,,,,1,H,10576,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,8,CHEMBL616578,,,B,,,,Autocuration,,BAO_0000249
1456,,,,1,H,10576,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,8,CHEMBL616579,,,B,,,,Expert,,BAO_0000357
1457,,,,1,D,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,9,CHEMBL616580,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1458,,,,1,H,10576,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,8,CHEMBL616581,,,B,,,,Autocuration,,BAO_0000019
1459,,Hippocampus,,1,H,10576,10000000.0,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,8,CHEMBL616582,,,B,,,,Autocuration,,BAO_0000221
1460,,Hippocampus,,1,H,10576,10000000.0,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,8,CHEMBL616583,,,B,,,,Expert,,BAO_0000221
1461,,Hippocampus,,1,D,10576,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,9,CHEMBL616584,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1462,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,CHEMBL616585,,,B,,,,Expert,,BAO_0000357
1463,,Hippocampus,,1,D,10576,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,9,CHEMBL616586,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1464,,Hippocampus,,1,H,10576,10000000.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,8,CHEMBL616587,,,B,,,,Autocuration,,BAO_0000221
1465,,Hippocampus,,1,H,10576,10000000.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,8,CHEMBL616588,,,B,,,,Autocuration,,BAO_0000221
1466,,Hippocampus,,1,H,10576,10000000.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,8,CHEMBL616589,,,B,,,,Autocuration,,BAO_0000221
1467,,Hippocampus,,1,H,10576,10000000.0,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,8,CHEMBL616590,,,B,,,,Expert,,BAO_0000221
1468,,,,1,H,10576,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",8,CHEMBL616591,,,B,,,CHO,Expert,449.0,BAO_0000219
1469,,,,1,H,10576,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,8,CHEMBL616592,,,B,,,,Expert,,BAO_0000357
1470,,,,1,H,10576,,The inhibition activity of 5-HT1A at 1 uM,8,CHEMBL616593,,,B,,,,Autocuration,,BAO_0000357
1471,,,,1,H,10576,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",8,CHEMBL616594,,,B,,,CHO-K1,Expert,485.0,BAO_0000219
1472,,,,1,H,10576,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,8,CHEMBL616595,,,B,,,,Expert,,BAO_0000249
1473,,,,1,H,10576,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,8,CHEMBL616596,,,B,,,,Autocuration,,BAO_0000357
1474,,Hippocampus,,1,H,10576,10000000.0,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,8,CHEMBL616597,,,B,,,,Autocuration,,BAO_0000221
1475,,Hippocampus,,1,H,10576,10000000.0,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,8,CHEMBL616598,,,B,,,,Expert,,BAO_0000221
1476,,,,1,D,10576,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,9,CHEMBL616599,Rattus norvegicus,Membranes,F,10116.0,,,Expert,,BAO_0000249
1477,,Hippocampus,,1,D,10576,10000000.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",9,CHEMBL616600,Rattus norvegicus,Membranes,F,10116.0,,,Expert,,BAO_0000249
1478,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,8,CHEMBL616601,,,B,,,,Autocuration,,BAO_0000019
1479,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,8,CHEMBL616602,,,B,,,,Autocuration,,BAO_0000019
1480,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,8,CHEMBL616603,,,B,,,,Autocuration,,BAO_0000019
1481,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,8,CHEMBL616604,,,B,,,,Autocuration,,BAO_0000019
1482,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,8,CHEMBL616316,,,B,,,,Autocuration,,BAO_0000249
1483,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,8,CHEMBL616317,,,B,,,,Autocuration,,BAO_0000249
1484,,,,1,D,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,9,CHEMBL616318,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1485,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,8,CHEMBL616319,,,B,,,,Autocuration,,BAO_0000221
1486,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,8,CHEMBL616320,,,B,,,,Autocuration,,BAO_0000221
1487,,Hippocampus,,1,D,10576,10000000.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,9,CHEMBL616321,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1488,,,,1,H,10576,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,8,CHEMBL616322,,,F,,,,Autocuration,,BAO_0000019
1489,,,,1,H,10576,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,8,CHEMBL616323,,,F,,,,Autocuration,,BAO_0000019
1490,,,,1,H,10576,,Ratio of binding affinity to 5-HT 1A and D2 receptor,8,CHEMBL616324,,,B,,,,Autocuration,,BAO_0000357
1491,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,8,CHEMBL616325,,,B,,,,Autocuration,,BAO_0000221
1492,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,8,CHEMBL616326,,,B,,,,Autocuration,,BAO_0000221
1493,,Hippocampus,,1,H,10576,10000000.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,8,CHEMBL616327,,,B,,,,Autocuration,,BAO_0000221
1494,,,,1,H,10576,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,8,CHEMBL616328,,,B,,,,Autocuration,,BAO_0000357
1495,,,,1,H,10576,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),8,CHEMBL858110,,,B,,,,Autocuration,,BAO_0000249
1496,,,,1,H,10576,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),8,CHEMBL616329,,,F,,,,Autocuration,,BAO_0000249
1497,,,,1,H,10576,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),8,CHEMBL616330,,,B,,,,Autocuration,,BAO_0000249
1498,,,,1,H,10576,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),8,CHEMBL616331,,,F,,,,Autocuration,,BAO_0000249
1499,,,,1,H,10576,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,8,CHEMBL616332,,,F,,,,Autocuration,,BAO_0000249
1500,,Brain,,1,H,10576,955.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,8,CHEMBL857063,,,B,,,,Autocuration,,BAO_0000249
1501,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,8,CHEMBL616333,,,B,,,,Autocuration,,BAO_0000019
1502,,,,1,H,10576,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,8,CHEMBL616334,,,F,,,,Expert,,BAO_0000019
1503,,Hippocampus,,1,H,10576,10000000.0,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,8,CHEMBL616335,,,B,,,,Autocuration,,BAO_0000221
1504,,,,1,H,10576,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,8,CHEMBL616336,,,B,,,,Autocuration,,BAO_0000019
1505,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,8,CHEMBL616337,,,B,,,,Expert,,BAO_0000249
1506,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,8,CHEMBL616338,,,B,,,,Autocuration,,BAO_0000019
1507,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,8,CHEMBL616339,,,B,,,,Autocuration,,BAO_0000221
1508,,Hippocampus,,1,H,10576,10000000.0,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,8,CHEMBL616340,,,B,,,,Autocuration,,BAO_0000221
1509,,,,1,H,10576,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,8,CHEMBL616341,,,B,,,,Autocuration,,BAO_0000357
1510,,,,1,D,10576,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,9,CHEMBL616342,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1511,,,,1,D,10576,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,9,CHEMBL616343,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1512,,,,1,H,10576,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,8,CHEMBL616344,,,B,,,,Expert,,BAO_0000019
1513,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,8,CHEMBL616345,,,B,,,,Expert,,BAO_0000357
1514,,,,1,H,10576,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,8,CHEMBL616346,,,B,,,,Expert,,BAO_0000019
1515,,Hippocampus,,1,H,10576,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,8,CHEMBL616347,,,B,,,,Autocuration,,BAO_0000221
1516,,,,1,H,10576,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,8,CHEMBL616348,,,B,,,,Expert,,BAO_0000019
1517,,,,1,H,10576,,Binding affinity at 5-hydroxytryptamine 1A receptor,8,CHEMBL616349,,,B,,,,Expert,,BAO_0000357
1518,,,,1,D,10576,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,9,CHEMBL616152,Rattus norvegicus,Membranes,B,10116.0,,,Expert,,BAO_0000249
1519,,,,1,H,10576,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,8,CHEMBL616153,,,B,,,,Autocuration,,BAO_0000249
1520,,,,1,H,10576,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",8,CHEMBL616154,,,B,,,,Expert,,BAO_0000019
1521,,,,1,H,10576,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,8,CHEMBL616155,,,B,,,,Autocuration,,BAO_0000019
1522,,Hippocampus,,1,D,10576,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,9,CHEMBL616156,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1523,,Hippocampus,,1,D,10576,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,9,CHEMBL616157,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
1524,,Hippocampus,,1,H,10576,10000000.0,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,8,CHEMBL616158,,,B,,,,Autocuration,,BAO_0000221
1525,,,,1,H,10576,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,8,CHEMBL616159,,,B,,,,Autocuration,,BAO_0000357
1526,,,,1,H,10576,,pKi value against rat 5-hydroxytryptamine 1A receptor.,8,CHEMBL616160,,,B,,,,Expert,,BAO_0000357
1527,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,8,CHEMBL616161,,,B,,,,Autocuration,,BAO_0000019
1528,,,,1,H,10576,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,8,CHEMBL616162,,,F,,,,Autocuration,,BAO_0000019
1529,,,,1,D,12687,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,9,CHEMBL616163,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1530,,,,1,H,10626,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,8,CHEMBL616164,,Membranes,B,,,,Expert,,BAO_0000249
1531,,Brain,,1,H,10576,955.0,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,8,CHEMBL616165,,,B,,,,Autocuration,,BAO_0000221
1532,,,,1,H,51,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,8,CHEMBL616355,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
1533,,,,1,H,10576,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,8,CHEMBL616356,,,F,,,,Autocuration,,BAO_0000019
1534,,Brain,,1,H,10576,955.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,8,CHEMBL616357,,,B,,,,Autocuration,,BAO_0000221
1535,,,,1,H,10576,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",8,CHEMBL616358,,,B,,,,Autocuration,,BAO_0000019
1536,,,,1,H,51,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,8,CHEMBL616359,,,B,,,,Autocuration,,BAO_0000357
1537,,,,1,H,51,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,8,CHEMBL616360,,,B,,,,Expert,,BAO_0000357
1538,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,CHEMBL616361,,,B,,,,Expert,,BAO_0000357
1539,,,,1,H,51,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,8,CHEMBL616362,,,B,,,,Autocuration,,BAO_0000357
1540,,,,1,H,51,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,8,CHEMBL616363,,Brain membranes,B,,,,Autocuration,,BAO_0000249
1541,,,,1,H,51,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,8,CHEMBL616364,,,B,,,,Autocuration,,BAO_0000357
1542,,,,1,H,51,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,8,CHEMBL616365,,,B,,,,Autocuration,,BAO_0000357
1543,,,,1,H,51,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,8,CHEMBL616366,,,B,,,,Expert,,BAO_0000357
1544,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,CHEMBL872906,,,B,,,,Expert,,BAO_0000357
1545,,,,1,H,51,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,8,CHEMBL616367,,,B,,,,Autocuration,,BAO_0000357
1546,,,,1,H,51,,Binding affinity against 5-hydroxytryptamine 1A receptor,8,CHEMBL616368,,,B,,,,Autocuration,,BAO_0000357
1547,,,,1,H,51,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,8,CHEMBL616369,,,B,,,,Autocuration,,BAO_0000357
1548,,,,1,D,51,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,9,CHEMBL616370,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1549,,,,1,D,51,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,9,CHEMBL616371,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1550,,,,1,H,51,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,8,CHEMBL616372,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1551,,,,1,H,51,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,8,CHEMBL616373,,,B,,,,Expert,,BAO_0000219
1552,,,,1,H,51,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,CHEMBL616374,,,B,,In vivo,,Autocuration,,BAO_0000218
1553,,Hippocampus,,1,H,51,10000000.0,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,CHEMBL616375,,,B,,,,Autocuration,,BAO_0000221
1554,,,,1,H,51,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,8,CHEMBL616376,,,B,,,,Autocuration,,BAO_0000357
1555,,,,1,H,51,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,8,CHEMBL857064,,,B,,,,Expert,,BAO_0000357
1556,,,,1,H,51,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,8,CHEMBL616377,,,B,,,,Autocuration,,BAO_0000357
1557,,,,1,H,51,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,8,CHEMBL616378,,,B,,,,Autocuration,,BAO_0000357
1558,,,,1,H,51,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,8,CHEMBL616379,,,B,,,,Autocuration,,BAO_0000357
1559,,,,1,H,11863,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,8,CHEMBL616380,,,B,,,,Autocuration,,BAO_0000357
1560,,,,1,H,11863,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,8,CHEMBL616381,,,B,,,,Autocuration,,BAO_0000357
1561,,,,1,H,11863,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,8,CHEMBL616382,,,B,,,,Autocuration,,BAO_0000357
1562,,,,1,H,11863,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,8,CHEMBL616383,,,B,,,,Autocuration,,BAO_0000357
1563,,,,1,D,11863,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,9,CHEMBL616350,Mus musculus,,B,10090.0,,CHO,Expert,449.0,BAO_0000219
1564,,,,1,H,11863,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,8,CHEMBL616351,,,B,,,,Autocuration,,BAO_0000357
1565,,,,1,H,11863,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,8,CHEMBL616352,,,B,,,,Autocuration,,BAO_0000357
1566,,,,1,H,11863,,Binding affinity against 5-hydroxytryptamine 1A receptor,8,CHEMBL616353,,,B,,,,Autocuration,,BAO_0000357
1567,,,,1,H,11863,,Binding affinity against serotonergic 5-HT1a receptor,8,CHEMBL616354,,,B,,,,Autocuration,,BAO_0000357
1568,,,,1,H,11863,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,8,CHEMBL616508,,,B,,,,Autocuration,,BAO_0000357
1569,,,,1,D,11863,,Binding affinity for 5-hydroxytryptamine 1A receptor,9,CHEMBL616559,Mus musculus,,B,10090.0,,,Expert,,BAO_0000357
1570,,,,1,H,11863,,Binding affinity at 5-hydroxytryptamine 1A receptor,8,CHEMBL616560,,,B,,,,Autocuration,,BAO_0000357
1571,,,,1,H,11863,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",8,CHEMBL616561,,,B,,,,Autocuration,,BAO_0000357
1572,,,,1,H,11863,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,8,CHEMBL616562,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1573,,,,1,H,11863,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,8,CHEMBL616563,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1574,,,,1,H,11863,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,8,CHEMBL616564,,,B,,,,Autocuration,,BAO_0000357
1575,,,,1,H,11863,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,8,CHEMBL616565,,,B,,,,Autocuration,,BAO_0000357
1576,,,,1,H,11863,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,8,CHEMBL616566,,,B,,,,Autocuration,,BAO_0000218
1577,,,,1,H,11863,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,8,CHEMBL616989,,,B,,,,Autocuration,,BAO_0000357
1578,,,,1,H,11863,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,8,CHEMBL857975,,,B,,,,Autocuration,,BAO_0000357
1579,,,,1,D,11863,,Binding affinity against 5-hydroxytryptamine 1A receptor,9,CHEMBL616990,Mus musculus,,B,10090.0,,,Expert,,BAO_0000357
1580,,,,1,H,11863,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,8,CHEMBL616991,,,B,,,,Autocuration,,BAO_0000357
1581,,,,1,H,11863,,Tested against 5-hydroxytryptamine 1A receptor,8,CHEMBL616992,,,B,,,,Autocuration,,BAO_0000357
1582,,,,1,H,11863,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,8,CHEMBL616993,,,B,,,,Autocuration,,BAO_0000357
1583,,,,1,H,106,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,8,CHEMBL616994,Oryctolagus cuniculus,,B,9986.0,,,Expert,,BAO_0000019
1584,,,,1,H,106,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,8,CHEMBL616995,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
1585,,,,1,D,105571,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,9,CHEMBL616996,Gorilla gorilla,,B,9593.0,,HEK293,Intermediate,722.0,BAO_0000219
1586,,,,1,H,106,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,8,CHEMBL616997,Cavia porcellus,,F,10141.0,In vivo,,Autocuration,,BAO_0000218
1587,,,,1,H,106,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,8,CHEMBL616998,Cavia porcellus,,F,10141.0,In vivo,,Autocuration,,BAO_0000218
1588,,,,1,H,106,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,8,CHEMBL616999,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
1589,,,,1,H,106,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,8,CHEMBL617000,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
1590,,,,1,H,106,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,8,CHEMBL617001,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
1591,,,,1,H,106,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,8,CHEMBL858111,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
1592,,,,1,H,106,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,8,CHEMBL617002,,,F,,,,Autocuration,,BAO_0000019
1593,,,,1,H,106,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),8,CHEMBL617003,,,F,,,,Autocuration,,BAO_0000019
1594,,,,1,H,106,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),8,CHEMBL617004,,,F,,,,Autocuration,,BAO_0000019
1595,,,,1,D,106,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,9,CHEMBL617005,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
1596,,,,1,D,106,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,9,CHEMBL616623,Homo sapiens,,F,9606.0,,CHO-K1,Expert,485.0,BAO_0000219
1597,,,,1,H,106,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,8,CHEMBL616624,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1598,,,,1,H,106,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,8,CHEMBL883243,,,B,,,,Autocuration,,BAO_0000357
1599,,,,1,H,106,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,8,CHEMBL616625,,,F,,,,Autocuration,,BAO_0000019
1600,,,,1,H,106,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",8,CHEMBL616626,,,F,,,CHO,Expert,449.0,BAO_0000219
1601,,,,1,H,106,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,8,CHEMBL616627,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1602,,,,1,H,106,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,8,CHEMBL616628,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1603,,,,1,H,106,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,8,CHEMBL616629,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1604,,,,1,H,106,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,8,CHEMBL616630,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1605,,,,1,H,106,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",8,CHEMBL616631,,,F,,,,Expert,,BAO_0000019
1606,,,,1,H,106,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",8,CHEMBL616632,,,F,,,,Autocuration,,BAO_0000019
1607,,,,1,D,106,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,9,CHEMBL616633,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1608,,,,1,H,106,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,8,CHEMBL616634,,,B,,,CHO,Expert,449.0,BAO_0000219
1609,,,,1,H,106,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,8,CHEMBL616635,,,B,,,,Autocuration,,BAO_0000357
1610,,,,1,D,106,,Binding affinity against 5-hydroxytryptamine 1B receptor,9,CHEMBL885358,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1611,,,,1,D,106,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,9,CHEMBL616636,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
1612,,,,1,H,106,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,8,CHEMBL616637,,,B,,,CHO,Expert,449.0,BAO_0000219
1613,,,,1,H,106,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,8,CHEMBL616638,,,B,,,,Autocuration,,BAO_0000357
1614,,,,1,H,106,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,8,CHEMBL616639,,,B,,,CHO,Expert,449.0,BAO_0000219
1615,,,,1,H,106,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,8,CHEMBL616640,,,B,,,CHO,Expert,449.0,BAO_0000219
1616,,,,1,H,106,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,8,CHEMBL616641,,,B,,,CHO,Expert,449.0,BAO_0000219
1617,,,,1,H,106,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,8,CHEMBL616642,,,B,,,CHO,Expert,449.0,BAO_0000219
1618,,,,1,H,106,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,8,CHEMBL616643,,,B,,,CHO,Expert,449.0,BAO_0000219
1619,,,,1,H,106,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),8,CHEMBL616644,,,B,,,,Autocuration,,BAO_0000357
1620,,,,1,H,106,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,8,CHEMBL616645,,,B,,,,Autocuration,,BAO_0000357
1621,,,,1,H,105,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),8,CHEMBL616646,Oryctolagus cuniculus,,F,9986.0,,,Autocuration,,BAO_0000019
1622,,,,1,H,105,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),8,CHEMBL616647,Oryctolagus cuniculus,,F,9986.0,,,Expert,,BAO_0000019
1623,,,,1,H,105,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),8,CHEMBL616509,,,B,,,,Autocuration,,BAO_0000357
1624,,,,1,H,105,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),8,CHEMBL616510,,,B,,,,Autocuration,,BAO_0000357
1625,,,,1,H,105,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,8,CHEMBL616511,,,B,,,,Autocuration,,BAO_0000357
1626,,,,1,H,105,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,8,CHEMBL616512,Bos taurus,,B,9913.0,,,Expert,,BAO_0000357
1627,,,,1,H,105,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,8,CHEMBL616513,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1628,,Striatum,,1,H,105,2435.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,8,CHEMBL616514,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000019
1629,,,,1,H,105,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,8,CHEMBL616515,Bos taurus,,B,9913.0,,,Expert,,BAO_0000357
1630,,,,1,H,105,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,8,CHEMBL616516,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000019
1631,,,,1,H,105,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,8,CHEMBL616517,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1632,,,,1,H,105,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,8,CHEMBL616518,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1633,,,,1,H,105,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,8,CHEMBL616519,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1634,,,,1,H,105,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,8,CHEMBL616520,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1635,,,,1,H,105,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,8,CHEMBL616521,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1636,,,,1,H,105,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,8,CHEMBL616522,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1637,,,,1,H,105,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,8,CHEMBL884531,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1638,,,,1,H,105,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,8,CHEMBL616523,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1639,,Striatum,,1,H,105,2435.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,8,CHEMBL616731,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000019
1640,,,,1,H,105,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,8,CHEMBL616732,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000019
1641,,,,1,H,105,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,8,CHEMBL616733,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1642,,,,1,H,105,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,8,CHEMBL616734,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1643,,,,1,H,105,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,8,CHEMBL616735,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000249
1644,,,,1,H,105,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,8,CHEMBL616736,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000249
1645,,,,1,H,105,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,8,CHEMBL616737,Bos taurus,,F,9913.0,,,Expert,,BAO_0000019
1646,,,,1,H,105,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,8,CHEMBL616738,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000019
1647,,,,1,H,105,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,8,CHEMBL616739,Bos taurus,,F,9913.0,,,Expert,,BAO_0000019
1648,,,,1,H,105,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,8,CHEMBL616740,Bos taurus,,F,9913.0,,,Expert,,BAO_0000019
1649,,,,1,H,105,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,8,CHEMBL616741,Bos taurus,,F,9913.0,,,Expert,,BAO_0000019
1650,,,,1,H,105,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,8,CHEMBL616742,Gorilla gorilla,,B,9593.0,,HEK293,Autocuration,722.0,BAO_0000219
1651,,,,1,D,105570,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,9,CHEMBL616743,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000019
1652,,,,1,D,105570,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,9,CHEMBL616744,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000019
1653,,,,1,D,105570,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,9,CHEMBL616745,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000019
1654,,,,1,D,105570,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,9,CHEMBL616746,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000019
1655,,,,1,D,105570,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,9,CHEMBL616747,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000019
1656,,,,1,D,105570,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,9,CHEMBL616748,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000019
1657,,,,1,D,105570,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,9,CHEMBL616648,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000019
1658,,,,1,D,105570,,Binding affinity against 5-hydroxytryptamine 1D receptor,9,CHEMBL616649,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
1659,,,,1,D,105570,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,9,CHEMBL616650,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
1660,,,,1,D,105570,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,9,CHEMBL616651,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000218
1661,,,,1,D,105570,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,9,CHEMBL616652,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000218
1662,,,,1,D,105570,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,9,CHEMBL616653,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000218
1663,,,,1,D,105570,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,9,CHEMBL616654,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000218
1664,,,,1,D,105570,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,9,CHEMBL616655,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000019
1665,,,,1,D,105570,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,9,CHEMBL616656,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
1666,,,,1,H,105,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,8,CHEMBL616657,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000019
1667,,Striatum,,1,D,105570,2435.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,9,CHEMBL616658,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
1668,,,,1,D,105570,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,9,CHEMBL616659,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
1669,,,,1,H,51,,Binding affinity against 5-hydroxytryptamine 1D receptor,8,CHEMBL616660,,,B,,,,Autocuration,,BAO_0000357
1670,,,,1,H,106,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,8,CHEMBL616661,,,B,,,,Autocuration,,BAO_0000357
1671,,,,1,H,105,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,8,CHEMBL616662,,,F,,,,Expert,,BAO_0000019
1672,,,,1,H,105,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,8,CHEMBL616663,,,F,,,,Autocuration,,BAO_0000019
1673,,,,1,H,105,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,8,CHEMBL616664,,,F,,,,Autocuration,,BAO_0000019
1674,,,,1,D,105,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",9,CHEMBL881820,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
1675,,,,1,H,105,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",8,CHEMBL616665,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1676,,,,1,H,105,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,8,CHEMBL616666,,,B,,,CHO,Expert,449.0,BAO_0000219
1677,,,,1,H,105,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,8,CHEMBL616667,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1678,,,,1,H,105,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",8,CHEMBL616668,,,F,,,CHO,Expert,449.0,BAO_0000219
1679,,,,1,D,105,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",9,CHEMBL616669,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
1680,,,,1,H,105,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",8,CHEMBL617040,,,F,,,CHO,Expert,449.0,BAO_0000219
1681,,,,1,H,105,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",8,CHEMBL617041,,,F,,,CHO,Autocuration,449.0,BAO_0000219
1682,,,,1,H,105,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",8,CHEMBL617042,,,F,,,CHO,Expert,449.0,BAO_0000219
1683,,,,1,H,105,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",8,CHEMBL617043,,,F,,,CHO,Expert,449.0,BAO_0000219
1684,,,,1,H,105,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,8,CHEMBL617044,,,F,,,,Autocuration,,BAO_0000019
1685,,,,1,H,105,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,8,CHEMBL617045,,,F,,,CHO,Expert,449.0,BAO_0000219
1686,,,,1,D,105,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",9,CHEMBL617046,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
1687,,,,1,D,105,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",9,CHEMBL617047,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
1688,,,,1,H,105,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",8,CHEMBL617048,,,F,,,,Expert,,BAO_0000019
1689,,,,1,H,105,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",8,CHEMBL616897,,,F,,,,Autocuration,,BAO_0000019
1690,,,,1,D,105,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",9,CHEMBL616898,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
1691,,,,1,D,105,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,9,CHEMBL858201,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
1692,,,,1,H,105,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,8,CHEMBL616899,,,F,,,,Autocuration,,BAO_0000019
1693,,,,1,H,105,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),8,CHEMBL616900,,,B,,In vitro,,Autocuration,,BAO_0000219
1694,,,,1,H,105,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,8,CHEMBL616901,,,B,,,CHO,Expert,449.0,BAO_0000219
1695,,,,1,H,105,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,8,CHEMBL616902,,,B,,,,Autocuration,,BAO_0000357
1696,,,,1,D,105,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9,CHEMBL616903,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
1697,,,,1,H,105,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,8,CHEMBL616904,,,B,,,CHO,Expert,449.0,BAO_0000219
1698,,,,1,H,105,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,8,CHEMBL616905,,,B,,,,Autocuration,,BAO_0000357
1699,,,,1,H,105,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,8,CHEMBL616906,,,B,,,CHO,Expert,449.0,BAO_0000219
1700,,,,1,H,105,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,8,CHEMBL616907,,,B,,,CHO,Expert,449.0,BAO_0000219
1701,,,,1,H,105,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,8,CHEMBL616908,,,B,,,CHO,Expert,449.0,BAO_0000219
1702,,,,1,D,105,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9,CHEMBL616909,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
1703,,,,1,D,105,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9,CHEMBL616910,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
1704,,,,1,H,105,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,8,CHEMBL616911,,,B,,,CHO,Expert,449.0,BAO_0000219
1705,,,,1,H,105,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,8,CHEMBL616912,,,B,,,CHO,Expert,449.0,BAO_0000219
1706,,,,1,H,105,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),8,CHEMBL616913,,,B,,,,Autocuration,,BAO_0000357
1707,,,,1,D,105,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,9,CHEMBL616914,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
1708,,,,1,H,105,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,8,CHEMBL616915,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1709,,,,1,H,105,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,8,CHEMBL616916,,,B,,,,Autocuration,,BAO_0000019
1710,,,,1,D,105,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,9,CHEMBL616917,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1711,,,,1,H,105,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",8,CHEMBL616918,,,B,,,,Autocuration,,BAO_0000357
1712,,,,1,H,105,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,8,CHEMBL616919,,,B,,,,Expert,,BAO_0000219
1713,,,,1,H,105,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,8,CHEMBL616920,,,B,,,,Autocuration,,BAO_0000357
1714,,,,1,H,105,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,8,CHEMBL872914,,,B,,,,Autocuration,,BAO_0000357
1715,,,,1,H,105,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,8,CHEMBL616921,,,B,,,,Autocuration,,BAO_0000357
1716,,,,1,H,105,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,8,CHEMBL616922,,,B,,,,Expert,,BAO_0000357
1717,,,,1,H,105,,Binding affinity towards 5-hydroxytryptamine 1D receptor,8,CHEMBL616923,,,B,,,,Autocuration,,BAO_0000357
1718,,,,1,H,105,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,8,CHEMBL616924,,,B,,,,Expert,,BAO_0000357
1719,,,,1,H,105,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,8,CHEMBL875909,,,B,,,,Expert,,BAO_0000357
1720,,,,1,H,105,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,8,CHEMBL616925,,,B,,,,Autocuration,,BAO_0000357
1721,,,,1,H,105,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,8,CHEMBL616926,,,B,,,,Autocuration,,BAO_0000357
1722,,,,1,H,105,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,8,CHEMBL616927,,,B,,,,Autocuration,,BAO_0000357
1723,,,,1,H,105,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,8,CHEMBL616928,,,F,,,CHO-K1,Expert,485.0,BAO_0000219
1724,,,,1,D,105,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),9,CHEMBL616929,Homo sapiens,,B,9606.0,In vitro,,Expert,,BAO_0000219
1725,,,,1,D,105,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,9,CHEMBL616930,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1726,,,,1,H,105,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,8,CHEMBL616931,,,B,,,,Expert,,BAO_0000019
1727,,,,1,H,105,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,8,CHEMBL616932,,,B,,,,Autocuration,,BAO_0000357
1728,,,,1,H,105,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,8,CHEMBL616933,,,B,,,,Expert,,BAO_0000357
1729,,,,1,D,105,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,9,CHEMBL616934,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000219
1730,,,,1,D,105,,Binding affinity for human 5-hydroxytryptamine 1D receptor,9,CHEMBL616935,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1731,,,,1,H,105,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,8,CHEMBL616936,,,B,,,,Autocuration,,BAO_0000357
1732,,,,1,D,105,,Affinity for 5-hydroxytryptamine 1D receptor subtype,9,CHEMBL616937,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1733,,,,1,D,105,,Binding affinity for human 5-hydroxytryptamine 1D receptor,9,CHEMBL616938,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1734,,,,1,H,105,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,8,CHEMBL616939,,,B,,,,Autocuration,,BAO_0000019
1735,,,,1,H,105,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,8,CHEMBL616940,,,B,,,,Expert,,BAO_0000019
1736,,,,1,D,105,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,9,CHEMBL616941,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1737,,,,1,H,105,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,8,CHEMBL616942,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
1738,,,,1,H,105,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,8,CHEMBL616943,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
1739,,,,1,H,104802,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,4,CHEMBL616944,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1740,,,,1,H,105,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",8,CHEMBL616945,,,F,,,,Autocuration,,BAO_0000019
1741,,,,1,H,105,,Binding activity radioligand.,8,CHEMBL616946,,,B,,,,Autocuration,,BAO_0000357
1742,,,,1,H,105,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,8,CHEMBL616947,,,B,,,,Autocuration,,BAO_0000019
1743,,,,1,H,105,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,8,CHEMBL616948,,,B,,,CHO-K1,Expert,485.0,BAO_0000219
1744,,,,1,H,105,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,8,CHEMBL616851,,,B,,,,Autocuration,,BAO_0000357
1745,,,,1,H,105,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,8,CHEMBL616852,,,B,,,,Autocuration,,BAO_0000357
1746,,,,1,H,105,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,8,CHEMBL616853,,,B,,,,Autocuration,,BAO_0000357
1747,,,,1,D,105,,Binding activity against human 5-hydroxytryptamine 1D receptor,9,CHEMBL616854,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1748,,,,1,D,105,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,9,CHEMBL616855,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
1749,,,,1,H,105,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,8,CHEMBL616856,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1750,,,,1,H,105,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,8,CHEMBL616857,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1751,,,,1,H,105,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,8,CHEMBL616858,,,B,,,,Autocuration,,BAO_0000357
1752,,,,1,H,105,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,8,CHEMBL616859,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1753,,,,1,H,105,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,8,CHEMBL616860,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1754,,,,1,H,105,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,8,CHEMBL616861,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1755,,,,1,H,105,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,8,CHEMBL616541,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1756,,,,1,H,105,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,8,CHEMBL616542,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1757,,,,1,H,105,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,8,CHEMBL616543,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1758,,,,1,D,105,,Binding affinity for human 5-hydroxytryptamine 1D receptor,9,CHEMBL616544,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1759,,,,1,H,105,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,8,CHEMBL616545,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1760,,,,1,H,105,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,8,CHEMBL616546,,,B,,,,Autocuration,,BAO_0000357
1761,,,,1,H,105,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,8,CHEMBL616547,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1762,,,,1,H,105,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",8,CHEMBL616548,,,B,,,CHO,Autocuration,449.0,BAO_0000219
1763,,,,1,H,105,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,8,CHEMBL616549,,,F,,,,Expert,,BAO_0000019
1764,,,,1,H,105,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,8,CHEMBL616550,,,F,,,,Expert,,BAO_0000019
1765,,,,1,H,108,,Binding affinity against 5-HT2C receptor,8,CHEMBL857066,,,B,,,,Autocuration,,BAO_0000357
1766,,,,1,H,108,,Binding affinity against 5-hydroxytryptamine 1D receptor,8,CHEMBL616551,,,B,,,,Autocuration,,BAO_0000357
1767,,,,1,H,10577,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,8,CHEMBL616552,,,B,,,,Autocuration,,BAO_0000357
1768,,,,1,H,10577,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,8,CHEMBL832876,,,F,,,,Autocuration,,BAO_0000019
1769,,,,1,H,10577,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",8,CHEMBL616553,,,B,,,,Expert,,BAO_0000019
1770,,,,1,H,10577,,Binding affinity towards 5-HT1B was determined,8,CHEMBL616554,,,B,,,,Autocuration,,BAO_0000357
1771,,,,1,H,10577,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,8,CHEMBL616555,,,B,,,,Expert,,BAO_0000019
1772,,,,1,H,10577,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",8,CHEMBL616556,,,B,,,,Expert,,BAO_0000019
1773,,,,1,H,10577,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",8,CHEMBL616557,,,B,,,,Autocuration,,BAO_0000019
1774,,,,1,H,10577,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,8,CHEMBL616558,,,B,,,,Expert,,BAO_0000019
1775,,,,1,D,10577,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,9,CHEMBL616749,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1776,,,,1,H,10577,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,8,CHEMBL616750,,,B,,,,Autocuration,,BAO_0000357
1777,,,,1,H,10577,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",8,CHEMBL616751,,,B,,,,Autocuration,,BAO_0000357
1778,,,,1,H,10577,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,8,CHEMBL616752,,,B,,,,Autocuration,,BAO_0000249
1779,,Striatum,,1,H,10577,2435.0,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,8,CHEMBL616753,,,B,,,,Autocuration,,BAO_0000019
1780,,,,1,D,10577,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,9,CHEMBL616754,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1781,,,,1,H,10577,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,8,CHEMBL616755,,,B,,,,Autocuration,,BAO_0000019
1782,,Striatum,,1,H,10577,2435.0,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,8,CHEMBL616756,,,B,,,,Autocuration,,BAO_0000019
1783,,Striatum,,1,H,10577,2435.0,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,8,CHEMBL616757,,,B,,,,Autocuration,,BAO_0000019
1784,,Striatum,,1,H,10577,2435.0,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,8,CHEMBL616758,,,B,,,,Autocuration,,BAO_0000357
1785,,,,1,H,10577,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,8,CHEMBL616759,,,B,,,,Autocuration,,BAO_0000249
1786,,,,1,H,10577,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,8,CHEMBL616760,,,B,,,,Autocuration,,BAO_0000357
1787,,Striatum,,1,H,10577,2435.0,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,8,CHEMBL616761,,,B,,,,Autocuration,,BAO_0000019
1788,,Striatum,,1,H,10577,2435.0,Binding affinity against 5-HT1B serotonin receptor in rat striatum,8,CHEMBL616762,,,B,,,,Autocuration,,BAO_0000019
1789,,,,1,H,10577,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,8,CHEMBL616763,,,B,,,,Autocuration,,BAO_0000019
1790,,,,1,H,10577,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,8,CHEMBL872909,,,B,,,,Expert,,BAO_0000357
1791,,,,1,H,10577,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,8,CHEMBL616764,,,B,,,,Autocuration,,BAO_0000357
1792,,,,1,D,10577,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,9,CHEMBL616765,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1793,,Striatum,,1,H,10577,2435.0,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,8,CHEMBL616766,,,B,,,,Autocuration,,BAO_0000357
1794,,Striatum,,1,H,10577,2435.0,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,8,CHEMBL616767,,,B,,,,Autocuration,,BAO_0000357
1795,,,,1,H,10577,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,8,CHEMBL616768,,,B,,,,Autocuration,,BAO_0000357
1796,,,,1,H,10577,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,8,CHEMBL616769,,,B,,,,Autocuration,,BAO_0000357
1797,,,,1,H,10577,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,8,CHEMBL616770,,,B,,,,Autocuration,,BAO_0000019
1798,,,,1,H,10577,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,8,CHEMBL616771,,,B,,,,Autocuration,,BAO_0000019
1799,,Striatum,,1,H,10577,2435.0,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,8,CHEMBL616772,,,B,,,,Autocuration,,BAO_0000019
1800,,,,1,H,10577,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,8,CHEMBL616773,,,B,,,,Expert,,BAO_0000019
1801,,,,1,H,10577,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,8,CHEMBL616774,,,B,,,,Autocuration,,BAO_0000019
1802,,,,1,H,10577,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,8,CHEMBL616775,,,B,,,,Autocuration,,BAO_0000357
1803,,,,1,H,10577,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,8,CHEMBL616776,,,B,,,,Autocuration,,BAO_0000249
1804,,,,1,H,10577,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,8,CHEMBL616777,,,B,,,,Autocuration,,BAO_0000357
1805,,,,1,H,10577,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,8,CHEMBL616778,,,B,,,,Autocuration,,BAO_0000357
1806,,,,1,D,10577,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,9,CHEMBL616779,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000249
1807,,,,1,D,10577,,Binding affinity towards 5-hydroxytryptamine 1B receptor,9,CHEMBL616780,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1808,,,,1,H,10577,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,8,CHEMBL616781,,,B,,,,Autocuration,,BAO_0000019
1809,,,,1,H,10577,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,8,CHEMBL616782,,,B,,,,Autocuration,,BAO_0000357
1810,,,,1,H,10577,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,8,CHEMBL616783,,,B,,,,Autocuration,,BAO_0000357
1811,,Striatum,,1,H,10577,2435.0,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,8,CHEMBL616784,,,B,,,,Expert,,BAO_0000019
1812,,,,1,H,10577,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,8,CHEMBL616785,,,B,,,,Autocuration,,BAO_0000357
1813,,Brain,,1,H,10577,955.0,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,8,CHEMBL857067,,,B,,,,Autocuration,,BAO_0000249
1814,,,,1,H,10577,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,8,CHEMBL616786,,,B,,,,Autocuration,,BAO_0000019
1815,,Brain,,1,H,10577,955.0,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,8,CHEMBL616787,,,B,,,,Autocuration,,BAO_0000249
1816,,,,1,H,10577,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,8,CHEMBL616788,,,B,,,,Autocuration,,BAO_0000357
1817,,,,1,H,10577,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,8,CHEMBL616789,,,B,,,,Autocuration,,BAO_0000357
1818,,,,1,D,10577,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,9,CHEMBL616790,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1819,,,,1,H,10577,,Binding affinity at 5-hydroxytryptamine 1B receptor,8,CHEMBL616791,,,B,,,,Expert,,BAO_0000357
1820,,,,1,H,10577,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,8,CHEMBL616792,,,B,,,,Autocuration,,BAO_0000019
1821,,,,1,D,10577,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,9,CHEMBL616793,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000249
1822,,,,1,H,10577,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,8,CHEMBL616794,,,B,,,,Autocuration,,BAO_0000357
1823,,,,1,H,10577,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,8,CHEMBL616795,,,B,,,,Autocuration,,BAO_0000357
1824,,,,1,H,104686,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,4,CHEMBL616796,,,B,,,,Autocuration,,BAO_0000019
1825,,,,1,H,106,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,8,CHEMBL616797,,,B,,,,Autocuration,,BAO_0000357
1826,,,,1,H,106,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,8,CHEMBL616798,,Brain membranes,B,,,,Autocuration,,BAO_0000249
1827,,,,1,H,106,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,8,CHEMBL616799,,,B,,,,Autocuration,,BAO_0000357
1828,,,,1,H,106,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,8,CHEMBL616800,,,B,,,,Autocuration,,BAO_0000357
1829,,,,1,H,106,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,8,CHEMBL616801,,,B,,,,Autocuration,,BAO_0000357
1830,,,,1,H,106,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,8,CHEMBL616802,,,B,,,,Autocuration,,BAO_0000357
1831,,,,1,H,106,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,8,CHEMBL616803,,,B,,,,Autocuration,,BAO_0000357
1832,,,,1,H,106,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,8,CHEMBL857068,,,B,,,,Expert,,BAO_0000357
1833,,,,1,H,106,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,8,CHEMBL616804,,,B,,,,Autocuration,,BAO_0000357
1834,,,,1,H,106,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,8,CHEMBL616805,,,B,,,,Autocuration,,BAO_0000357
1835,,,,1,H,106,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,8,CHEMBL616806,,,B,,,,Autocuration,,BAO_0000357
1836,,,,1,H,106,,Binding affinity against 5-hydroxytryptamine 1B receptor,8,CHEMBL616807,,,B,,,,Autocuration,,BAO_0000357
1837,,,,1,H,106,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,8,CHEMBL616808,,,B,,,,Autocuration,,BAO_0000357
1838,,,,1,H,106,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,8,CHEMBL616809,,,B,,,,Autocuration,,BAO_0000357
1839,,,,1,H,106,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,8,CHEMBL616810,,,B,,,,Autocuration,,BAO_0000357
1840,,,,1,H,104802,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,4,CHEMBL616811,,,B,,,,Autocuration,,BAO_0000224
1841,,,,1,H,108,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,8,CHEMBL616812,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
1842,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,8,CHEMBL616813,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1843,,,,1,H,108,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,8,CHEMBL616814,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1844,,,,1,H,108,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,8,CHEMBL616815,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1845,,,,1,H,108,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,8,CHEMBL616816,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1846,,,,1,H,108,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,8,CHEMBL616817,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1847,,,,1,H,108,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,8,CHEMBL616818,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1848,,,,1,H,108,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,8,CHEMBL616819,Sus scrofa,,B,9823.0,,,Expert,,BAO_0000357
1849,,,,1,H,108,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,8,CHEMBL616820,Sus scrofa,,B,9823.0,,,Expert,,BAO_0000357
1850,,,,1,H,108,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,8,CHEMBL616821,Sus scrofa,,B,9823.0,,,Expert,,BAO_0000019
1851,,,,1,H,108,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,8,CHEMBL616822,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1852,,,,1,H,108,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,8,CHEMBL616823,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
1853,,,,1,D,12689,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,9,CHEMBL616824,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000357
1854,,,,1,D,12689,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,9,CHEMBL616825,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000357
1855,,,,1,D,12689,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,9,CHEMBL616826,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000357
1856,,,,1,D,12689,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,9,CHEMBL616827,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1857,,,,1,D,12689,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,9,CHEMBL616828,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000357
1858,,,,1,D,12689,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,9,CHEMBL616829,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000357
1859,,,,1,D,12689,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,9,CHEMBL616830,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
1860,,,,1,D,12689,,Binding affinity against 5-hydroxytryptamine 1C receptor,9,CHEMBL616831,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
1861,,,,1,D,12689,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",9,CHEMBL616832,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
1862,,,,1,D,12689,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",9,CHEMBL616833,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
1863,,,,1,D,12689,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",9,CHEMBL616834,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
1864,,,,1,D,12689,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",9,CHEMBL829595,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
1865,,,,1,D,12689,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,9,CHEMBL616835,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000357
1866,,,,1,D,12689,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,9,CHEMBL872910,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000249
1867,,,,1,H,12689,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,8,CHEMBL616836,,,B,,,,Expert,,BAO_0000357
1868,,,,1,D,12689,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,9,CHEMBL616837,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000357
1869,,,,1,D,12689,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,9,CHEMBL616466,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
1870,,,,1,D,12689,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,9,CHEMBL616467,Rattus norvegicus,,B,10116.0,,HEK293,Autocuration,722.0,BAO_0000219
1871,,,,1,H,108,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,8,CHEMBL616468,,,B,,,,Autocuration,,BAO_0000357
1872,,,,1,H,108,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,8,CHEMBL616469,,,B,,,,Autocuration,,BAO_0000357
1873,,,,1,H,108,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,8,CHEMBL616470,,,B,,,,Autocuration,,BAO_0000357
1874,,,,1,H,12689,,Binding affinity against 5-hydroxytryptamine 1C receptor,8,CHEMBL616471,,,B,,,,Autocuration,,BAO_0000357
1875,,,,1,H,12689,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,8,CHEMBL616472,,,B,,,,Autocuration,,BAO_0000357
1876,,,,1,H,12689,,Binding affinity against 5-hydroxytryptamine 1C receptor,8,CHEMBL616473,,,B,,,,Autocuration,,BAO_0000357
1877,,,,1,H,12689,,Binding affinity against serotonergic 5-HT1c receptor,8,CHEMBL616474,,,B,,,,Autocuration,,BAO_0000357
1878,,,,1,H,12689,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,8,CHEMBL616475,,,B,,,,Autocuration,,BAO_0000357
1879,,,,1,H,12689,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,8,CHEMBL616476,,,B,,,,Autocuration,,BAO_0000357
1880,,,,1,H,105,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),8,CHEMBL616477,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
1881,,,,1,H,104686,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,4,CHEMBL616478,,,B,,,,Autocuration,,BAO_0000224
1882,,,,1,H,104686,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,4,CHEMBL616479,,,B,,,,Autocuration,,BAO_0000224
1883,,,,1,H,104686,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,4,CHEMBL616480,,,B,,,,Autocuration,,BAO_0000019
1884,,,,1,D,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,5,CHEMBL616481,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
1885,,,,1,D,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,5,CHEMBL616482,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000249
1886,,Brain,,1,D,104686,955.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,5,CHEMBL884713,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000221
1887,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,4,CHEMBL616483,,,B,,,,Autocuration,,BAO_0000224
1888,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,4,CHEMBL616484,,,B,,,,Autocuration,,BAO_0000224
1889,,,,1,H,104686,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,4,CHEMBL616485,,,B,,,,Autocuration,,BAO_0000019
1890,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,4,CHEMBL616486,,,B,,,,Autocuration,,BAO_0000224
1891,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,4,CHEMBL616487,,,B,,,,Autocuration,,BAO_0000224
1892,,,,1,H,104686,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,4,CHEMBL616488,,,B,,,,Autocuration,,BAO_0000224
1893,,,,1,H,104686,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,4,CHEMBL616489,,,B,,,,Autocuration,,BAO_0000019
1894,,,,1,H,104686,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,4,CHEMBL616490,,,B,,,,Autocuration,,BAO_0000019
1895,,,,1,H,104686,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,4,CHEMBL616491,,,B,,,,Autocuration,,BAO_0000019
1896,,,,1,H,104686,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,4,CHEMBL616492,,,B,,,,Autocuration,,BAO_0000019
1897,,,,1,H,104686,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,4,CHEMBL616493,,,B,,,,Autocuration,,BAO_0000019
1898,,,,1,H,104686,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,4,CHEMBL616494,,,B,,,,Autocuration,,BAO_0000019
1899,,,,1,H,104686,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,4,CHEMBL616495,,,B,,,,Autocuration,,BAO_0000019
1900,,,,1,H,104686,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,4,CHEMBL616496,,,B,,,,Autocuration,,BAO_0000019
1901,,,,1,H,104686,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,4,CHEMBL616497,,,B,,,,Autocuration,,BAO_0000019
1902,,,,1,H,104686,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,4,CHEMBL616498,,,B,,,,Autocuration,,BAO_0000019
1903,,,,1,H,104686,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,4,CHEMBL616499,,,B,,,,Autocuration,,BAO_0000019
1904,,,,1,H,104686,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,4,CHEMBL616500,,,B,,,,Autocuration,,BAO_0000019
1905,,Brain,,1,D,104686,955.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,5,CHEMBL616501,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000221
1906,,Brain,,1,H,104686,955.0,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,4,CHEMBL616502,,,B,,,,Autocuration,,BAO_0000221
1907,,,,1,H,104686,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,4,CHEMBL884529,,Membranes,B,,,,Autocuration,,BAO_0000249
1908,,,,1,H,104686,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,4,CHEMBL616503,,Membranes,B,,,,Autocuration,,BAO_0000249
1909,,,,1,H,104686,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,4,CHEMBL616964,,,B,,,,Autocuration,,BAO_0000224
1910,,,,1,H,104686,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,4,CHEMBL616965,,Membranes,B,,,,Autocuration,,BAO_0000249
1911,,,,1,H,104686,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,4,CHEMBL616966,,,B,,,,Autocuration,,BAO_0000224
1912,,,,1,H,104686,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,4,CHEMBL616967,,,B,,,,Autocuration,,BAO_0000224
1913,,,,1,D,104686,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,5,CHEMBL616968,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
1914,,,,1,H,104686,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,4,CHEMBL616969,,,B,,,,Autocuration,,BAO_0000224
1915,,,,1,H,104686,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,4,CHEMBL884530,,,B,,,,Autocuration,,BAO_0000019
1916,,,,1,H,104686,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,4,CHEMBL616970,,,B,,,,Autocuration,,BAO_0000224
1917,,,,1,H,104686,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,4,CHEMBL616971,,,B,,,,Autocuration,,BAO_0000224
1918,,,,1,H,104686,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",4,CHEMBL616972,,,B,,,,Autocuration,,BAO_0000224
1919,,,,1,H,104686,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,4,CHEMBL616973,,,B,,,,Autocuration,,BAO_0000224
1920,,,,1,H,104686,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,4,CHEMBL616974,,,B,,,,Autocuration,,BAO_0000224
1921,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,4,CHEMBL616975,,,B,,,,Autocuration,,BAO_0000019
1922,,,,1,H,104686,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,4,CHEMBL616976,,,B,,,,Autocuration,,BAO_0000019
1923,,,,1,H,104686,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,4,CHEMBL616977,,,B,,,,Autocuration,,BAO_0000224
1924,,,,1,H,104686,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,4,CHEMBL616978,,,B,,,,Autocuration,,BAO_0000224
1925,,,,1,H,104686,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,4,CHEMBL616979,,,B,,,,Autocuration,,BAO_0000224
1926,,,,1,H,104686,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,4,CHEMBL616980,,,B,,,,Autocuration,,BAO_0000224
1927,,,,1,H,104686,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,4,CHEMBL616981,,Membranes,B,,,,Autocuration,,BAO_0000249
1928,,,,1,H,104686,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,4,CHEMBL616982,,Membranes,B,,,,Autocuration,,BAO_0000249
1929,,,,1,H,104686,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,4,CHEMBL616983,,,B,,,,Autocuration,,BAO_0000224
1930,,,,1,H,104686,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,4,CHEMBL616984,,,B,,,,Autocuration,,BAO_0000019
1931,,,,1,D,104686,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,5,CHEMBL616985,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
1932,,,,1,H,104686,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,4,CHEMBL616986,,,B,,,,Autocuration,,BAO_0000224
1933,,,,1,H,104686,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,4,CHEMBL616987,,,B,,,,Autocuration,,BAO_0000224
1934,,,,1,H,104686,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,4,CHEMBL616988,,,B,,,,Autocuration,,BAO_0000019
1935,,,,1,H,104686,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,4,CHEMBL617243,,,B,,,,Autocuration,,BAO_0000019
1936,,,,1,H,104686,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,4,CHEMBL617244,,,B,,,,Autocuration,,BAO_0000019
1937,,,,1,D,104686,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,5,CHEMBL617245,Rattus norvegicus,,B,10116.0,,CHO-K1,Autocuration,485.0,BAO_0000219
1938,,,,1,H,104686,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,4,CHEMBL617246,,Membranes,B,,,,Autocuration,,BAO_0000249
1939,,,,1,H,104686,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),4,CHEMBL617546,,,B,,,,Autocuration,,BAO_0000224
1940,,,,1,H,104686,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),4,CHEMBL617547,,Brain membranes,B,,,,Autocuration,,BAO_0000249
1941,,,,1,H,104686,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,4,CHEMBL617548,,,B,,In vitro,,Autocuration,,BAO_0000219
1942,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor,4,CHEMBL617549,,,B,,,,Autocuration,,BAO_0000224
1943,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,4,CHEMBL617550,,,B,,,,Autocuration,,BAO_0000224
1944,,,,1,H,104686,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,4,CHEMBL617551,,,B,,,,Autocuration,,BAO_0000224
1945,,,,1,H,104686,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,4,CHEMBL617552,,Membranes,B,,,,Autocuration,,BAO_0000249
1946,,,,1,H,104686,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,4,CHEMBL617553,,Membranes,B,,,,Autocuration,,BAO_0000249
1947,,Thoracic aorta,,1,H,104686,1515.0,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,4,CHEMBL617554,,,F,,,,Autocuration,,BAO_0000019
1948,,,,1,H,104686,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,4,CHEMBL617555,,,B,,,,Autocuration,,BAO_0000019
1949,,,,1,H,104686,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,4,CHEMBL617556,,,B,,,,Autocuration,,BAO_0000224
1950,,,,1,H,10624,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,8,CHEMBL617557,,,B,,,,Autocuration,,BAO_0000357
1951,,,,1,H,10624,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,8,CHEMBL617558,,,B,,,,Autocuration,,BAO_0000357
1952,,,,1,H,17106,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,8,CHEMBL617559,,,B,,,,Expert,,BAO_0000357
1953,,,,1,D,17106,,Binding affinity for 5-hydroxytryptamine 1D receptor,9,CHEMBL617560,,,B,,,,Expert,,BAO_0000357
1954,,,,1,H,17106,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,8,CHEMBL617561,,,B,,,,Autocuration,,BAO_0000249
1955,,,,1,H,17106,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,8,CHEMBL617562,,,B,,,,Autocuration,,BAO_0000249
1956,,Striatum,,1,H,17106,2435.0,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,8,CHEMBL617563,,,B,,,,Autocuration,,BAO_0000357
1957,,,,1,H,17106,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,8,CHEMBL617564,,,F,,,,Autocuration,,BAO_0000019
1958,,,,1,H,17106,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,8,CHEMBL617565,,,B,,,,Expert,,BAO_0000019
1959,,,,1,H,17106,,Binding activity radioligand.,8,CHEMBL856076,,,B,,,,Autocuration,,BAO_0000357
1960,,,,1,H,17106,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,8,CHEMBL617566,,,B,,,,Autocuration,,BAO_0000019
1961,,,,1,H,17106,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,8,CHEMBL875911,,,B,,,,Expert,,BAO_0000019
1962,,,,1,H,17106,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,8,CHEMBL617567,,,B,,,,Autocuration,,BAO_0000019
1963,,,,1,H,17106,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,8,CHEMBL617568,,,B,,,,Autocuration,,BAO_0000249
1964,,,,1,H,17106,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,8,CHEMBL617569,,,B,,,,Expert,,BAO_0000019
1965,,,,1,H,17106,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,8,CHEMBL617570,,,B,,,,Expert,,BAO_0000249
1966,,,,1,H,17106,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,8,CHEMBL617571,,,B,,,,Autocuration,,BAO_0000357
1967,,,,1,H,105,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,8,CHEMBL617572,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
1968,,,,1,H,105,,The compound was tested for intrinsic activity against 5-HT1D receptor,8,CHEMBL617573,Oryctolagus cuniculus,,B,9986.0,,,Expert,,BAO_0000357
1969,,,,1,H,105,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,8,CHEMBL617574,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
1970,,,,1,H,105,,The compound was tested for binding affinity against 5-HT1D receptor,8,CHEMBL617575,Oryctolagus cuniculus,,B,9986.0,,,Expert,,BAO_0000357
1971,,,,1,H,10578,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,8,CHEMBL617576,,,B,,,,Autocuration,,BAO_0000357
1972,,,,1,H,10578,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,8,CHEMBL617577,,,F,,,,Autocuration,,BAO_0000019
1973,,,,1,H,10578,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,8,CHEMBL617578,,,F,,,,Autocuration,,BAO_0000019
1974,,,,1,H,10578,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,8,CHEMBL617579,,,B,,,,Autocuration,,BAO_0000357
1975,,,,1,H,10578,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,8,CHEMBL617580,,,B,,,,Expert,,BAO_0000019
1976,,,,1,H,10578,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,8,CHEMBL617581,,,B,,,,Autocuration,,BAO_0000249
1977,,,,1,H,10578,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,8,CHEMBL617582,,,B,,,,Autocuration,,BAO_0000357
1978,,,,1,H,10578,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,8,CHEMBL617583,,,B,,,,Expert,,BAO_0000019
1979,,,,1,H,105,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,8,CHEMBL617584,,,B,,,,Autocuration,,BAO_0000357
1980,,,,1,H,105,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,8,CHEMBL617585,,,B,,,,Autocuration,,BAO_0000357
1981,,,,1,H,105,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,8,CHEMBL875912,,,B,,,,Autocuration,,BAO_0000357
1982,,,,1,H,105,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,8,CHEMBL617586,,,B,,,,Autocuration,,BAO_0000357
1983,,,,1,H,105,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,8,CHEMBL617587,,,B,,,,Autocuration,,BAO_0000357
1984,,,,1,H,105,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,8,CHEMBL617588,,,B,,,,Autocuration,,BAO_0000357
1985,,,,1,H,105,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,8,CHEMBL857980,,,B,,,,Autocuration,,BAO_0000357
1986,,,,1,H,105,,Tested against 5-hydroxytryptamine 1D receptor,8,CHEMBL617589,,,B,,,,Autocuration,,BAO_0000357
1987,,,,1,H,105,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,8,CHEMBL617590,,,B,,,,Autocuration,,BAO_0000357
1988,,,,1,H,105,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,8,CHEMBL617591,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1989,,,,1,D,105,,Binding affinity against 5-Hydroxytryptamine 1D receptor,9,CHEMBL617592,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
1990,,,,1,H,105,,,8,CHEMBL617593,,,B,,,,Autocuration,,BAO_0000357
1991,,,,1,H,106,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,8,CHEMBL617594,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
1992,,,,1,H,105,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,8,CHEMBL617595,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
1993,,,,1,H,105,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,8,CHEMBL617596,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1994,,,,1,H,105,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,8,CHEMBL617597,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
1995,,,,1,H,105,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,8,CHEMBL617598,,,B,,,,Autocuration,,BAO_0000019
1996,,,,1,H,105,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,8,CHEMBL872916,,,B,,,,Autocuration,,BAO_0000357
1997,,,,1,H,105,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,8,CHEMBL617599,,,B,,,,Expert,,BAO_0000357
1998,,,,1,H,105,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,8,CHEMBL617091,,,B,,,,Autocuration,,BAO_0000357
1999,,,,1,H,105,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",8,CHEMBL617092,,,B,,,CHO-K1,Expert,485.0,BAO_0000219
2000,,,,1,H,105,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,8,CHEMBL617093,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
2001,,,,1,H,105,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,8,CHEMBL617094,,,F,,,,Autocuration,,BAO_0000019
2002,,,,1,H,105,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,8,CHEMBL617095,,,F,,,,Autocuration,,BAO_0000019
2003,,,,1,H,105,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,8,CHEMBL617096,,,F,,,,Autocuration,,BAO_0000019
2004,,,,1,H,105,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,8,CHEMBL617097,,,F,,,,Autocuration,,BAO_0000019
2005,,,,1,H,105,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,8,CHEMBL617098,,,F,,,,Autocuration,,BAO_0000019
2006,,,,1,H,105,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,8,CHEMBL617301,,,B,,,,Autocuration,,BAO_0000357
2007,,,,1,H,105,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,8,CHEMBL617302,,,B,,,,Autocuration,,BAO_0000357
2008,,,,1,H,105,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,8,CHEMBL617303,,,B,,,,Autocuration,,BAO_0000357
2009,,,,1,H,105,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,8,CHEMBL617304,,,B,,,,Expert,,BAO_0000357
2010,,,,1,H,105,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",8,CHEMBL617305,,,B,,,CHO,Expert,449.0,BAO_0000219
2011,,,,1,D,105,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,9,CHEMBL617306,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000219
2012,,,,1,H,17106,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,8,CHEMBL617307,,,B,,,,Autocuration,,BAO_0000357
2013,,,,1,H,105,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,8,CHEMBL617308,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
2014,,,,1,H,105,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,8,CHEMBL617309,,,B,,,,Autocuration,,BAO_0000357
2015,,,,1,H,105,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,8,CHEMBL617310,,,B,,,,Autocuration,,BAO_0000357
2016,,,,1,H,105,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,8,CHEMBL617311,,,B,,,,Autocuration,,BAO_0000357
2017,,,,1,H,105,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,8,CHEMBL617312,,,B,,,,Autocuration,,BAO_0000357
2018,,,,1,H,105,,Affinity against 5-hydroxytryptamine 1D receptor alpha,8,CHEMBL617313,,,B,,,,Autocuration,,BAO_0000357
2019,,,,1,H,105,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,8,CHEMBL617314,,,B,,,,Expert,,BAO_0000357
2020,,,,1,H,106,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,8,CHEMBL617315,,,F,,,,Autocuration,,BAO_0000019
2021,,,,1,H,106,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,8,CHEMBL617316,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2022,,,,1,H,106,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,8,CHEMBL617317,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2023,,,,1,H,106,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",8,CHEMBL617318,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2024,,,,1,H,106,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,8,CHEMBL617319,,,B,,,,Autocuration,,BAO_0000019
2025,,,,1,D,106,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,9,CHEMBL617320,,,B,,,,Expert,,BAO_0000357
2026,,,,1,D,106,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,9,CHEMBL617321,,,B,,,,Expert,,BAO_0000357
2027,,,,1,D,106,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,9,CHEMBL617322,,,B,,,,Expert,,BAO_0000357
2028,,,,1,H,106,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,8,CHEMBL616862,,,B,,,,Autocuration,,BAO_0000357
2029,,,,1,H,106,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,8,CHEMBL616863,,,B,,,,Autocuration,,BAO_0000357
2030,,,,1,H,106,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,8,CHEMBL616864,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2031,,,,1,H,106,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,8,CHEMBL616865,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
2032,,,,1,H,106,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,8,CHEMBL616866,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
2033,,,,1,H,106,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,8,CHEMBL616867,,,F,,,,Autocuration,,BAO_0000019
2034,,,,1,H,106,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",8,CHEMBL616868,,,B,,,CHO-K1,Expert,485.0,BAO_0000219
2035,,,,1,H,105,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,8,CHEMBL616869,,,B,,,,Expert,,BAO_0000357
2036,,,,1,H,106,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",8,CHEMBL616870,,,B,,,CHO,Expert,449.0,BAO_0000219
2037,,,,1,H,105,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,8,CHEMBL616871,,,F,,,CHO-K1,Autocuration,485.0,BAO_0000219
2038,,,,1,H,105,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,8,CHEMBL616872,,,F,,,CHO-K1,Autocuration,485.0,BAO_0000219
2039,,,,1,H,105,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,8,CHEMBL616873,,,F,,,CHO-K1,Autocuration,485.0,BAO_0000219
2040,,,,1,H,105,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,8,CHEMBL616838,,,F,,,CHO-K1,Autocuration,485.0,BAO_0000219
2041,,,,1,H,105,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,8,CHEMBL616839,,,B,,,,Autocuration,,BAO_0000357
2042,,,,1,H,106,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,8,CHEMBL616840,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
2043,,,,1,H,105,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,8,CHEMBL616841,,,B,,,,Autocuration,,BAO_0000357
2044,,,,1,H,105,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,8,CHEMBL616842,,,B,,,,Autocuration,,BAO_0000357
2045,,,,1,H,105,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,8,CHEMBL857976,,,B,,,,Expert,,BAO_0000357
2046,,,,1,H,10618,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,8,CHEMBL616843,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2047,,,,1,D,10618,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,9,CHEMBL616844,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2048,,,,1,H,10618,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,8,CHEMBL616845,,,B,,,,Autocuration,,BAO_0000357
2049,,,,1,D,10618,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,9,CHEMBL616846,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2050,,,,1,H,10618,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,8,CHEMBL616847,,,B,,,,Autocuration,,BAO_0000357
2051,,,,1,H,10618,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,8,CHEMBL616848,,,B,,,,Autocuration,,BAO_0000019
2052,,,,1,H,10618,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,8,CHEMBL616849,,,B,,,,Autocuration,,BAO_0000357
2053,,,,1,H,10618,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,8,CHEMBL872911,,,B,,,,Autocuration,,BAO_0000357
2054,,,,1,H,10618,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,8,CHEMBL616850,,,B,,,,Autocuration,,BAO_0000019
2055,,,,1,D,10618,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,9,CHEMBL616699,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
2056,,,,1,H,10618,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,8,CHEMBL616700,,,B,,,,Autocuration,,BAO_0000357
2057,,,,1,H,10618,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,8,CHEMBL616701,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2058,,,,1,H,10618,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,8,CHEMBL616702,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2059,,,,1,H,10618,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,8,CHEMBL616703,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2060,,,,1,H,10618,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,8,CHEMBL616704,,,B,,,,Autocuration,,BAO_0000357
2061,,,,1,H,10618,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,8,CHEMBL616705,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2062,,,,1,H,10618,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,8,CHEMBL616706,,,B,,,,Autocuration,,BAO_0000357
2063,,,,1,H,10618,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,8,CHEMBL616707,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2064,,,,1,H,10618,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,8,CHEMBL616708,,,B,,,,Autocuration,,BAO_0000357
2065,,,,1,H,10618,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,8,CHEMBL616709,,,B,,,,Autocuration,,BAO_0000357
2066,,,,1,H,10618,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,8,CHEMBL616710,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2067,,,,1,H,10618,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,8,CHEMBL616711,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2068,,,,1,H,10618,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",8,CHEMBL616712,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2069,,,,1,H,10618,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,8,CHEMBL616713,,,B,,,,Autocuration,,BAO_0000357
2070,,,,1,H,10618,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,8,CHEMBL616714,,,B,,,,Autocuration,,BAO_0000357
2071,,,,1,H,10618,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,8,CHEMBL616715,,,B,,,,Autocuration,,BAO_0000357
2072,,,,1,H,10618,,Binding affinity towards 5-hydroxytryptamine 1E receptor,8,CHEMBL616716,,,B,,,,Autocuration,,BAO_0000357
2073,,,,1,H,279,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",8,CHEMBL616717,,,F,,,,Autocuration,,BAO_0000019
2074,,,,1,H,279,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",8,CHEMBL616718,,,F,,,,Expert,,BAO_0000019
2075,,,,1,H,279,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,8,CHEMBL875905,,,F,,,,Autocuration,,BAO_0000019
2076,,,,1,H,279,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,8,CHEMBL616719,,,F,,,,Autocuration,,BAO_0000019
2077,,,,1,H,279,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",8,CHEMBL616720,,,F,,,,Expert,,BAO_0000019
2078,,,,1,H,279,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,8,CHEMBL616721,,,B,,,,Autocuration,,BAO_0000357
2079,,,,1,H,279,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,8,CHEMBL616722,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2080,,,,1,H,279,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),8,CHEMBL616723,,,B,,,,Autocuration,,BAO_0000357
2081,,,,1,H,279,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,8,CHEMBL616724,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2082,,,,1,H,279,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,8,CHEMBL616725,,,B,,,,Autocuration,,BAO_0000357
2083,,,,1,H,279,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,8,CHEMBL616726,,,B,,,,Autocuration,,BAO_0000357
2084,,,,1,H,279,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,8,CHEMBL616727,,,B,,,,Autocuration,,BAO_0000357
2085,,,,1,H,279,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,8,CHEMBL616728,,,B,,,,Autocuration,,BAO_0000357
2086,,,,1,H,279,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,8,CHEMBL616729,,,B,,,,Autocuration,,BAO_0000357
2087,,,,1,H,279,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,8,CHEMBL616730,,,B,,,,Expert,,BAO_0000019
2088,,,,1,H,279,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,8,CHEMBL617125,,,B,,,,Autocuration,,BAO_0000357
2089,,,,1,H,279,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,8,CHEMBL857977,,,B,,,,Autocuration,,BAO_0000357
2090,,,,1,H,279,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,8,CHEMBL617126,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2091,,,,1,H,279,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,8,CHEMBL617127,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2092,,,,1,H,279,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,8,CHEMBL617128,,,B,,,,Autocuration,,BAO_0000357
2093,,,,1,H,279,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,8,CHEMBL617129,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2094,,,,1,H,279,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,8,CHEMBL617130,,,B,,,,Autocuration,,BAO_0000357
2095,,,,1,H,279,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,8,CHEMBL617131,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2096,,,,1,H,279,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",8,CHEMBL617132,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2097,,,,1,H,279,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",8,CHEMBL617133,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2098,,,,1,H,279,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,8,CHEMBL617134,,,B,,,,Autocuration,,BAO_0000357
2099,,,,1,H,279,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,8,CHEMBL617135,,,B,,,,Autocuration,,BAO_0000357
2100,,,,1,H,279,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,8,CHEMBL617136,,,B,,,,Autocuration,,BAO_0000357
2101,,,,1,H,104686,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",4,CHEMBL617137,,,B,,,,Autocuration,,BAO_0000019
2102,,,,1,H,104686,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",4,CHEMBL617138,,,B,,,,Autocuration,,BAO_0000019
2103,,,,1,H,104686,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",4,CHEMBL617139,,,B,,,,Autocuration,,BAO_0000019
2104,,,,1,H,12687,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,8,CHEMBL617140,,,B,,,,Autocuration,,BAO_0000019
2105,,,,1,H,104686,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",4,CHEMBL617141,,,F,,In vivo,,Autocuration,,BAO_0000218
2106,,,,1,H,104686,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,4,CHEMBL858112,,,F,,,,Autocuration,,BAO_0000019
2107,,,,1,H,17005,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,8,CHEMBL617142,,,B,,,,Intermediate,,BAO_0000019
2108,,,,1,U,22226,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",0,CHEMBL617143,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000019
2109,,,,1,U,22226,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,0,CHEMBL617144,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000019
2110,,,,1,U,22226,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,0,CHEMBL617145,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000019
2111,,,,1,U,22226,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,0,CHEMBL617146,,,B,,,,Autocuration,,BAO_0000019
2112,,,,1,H,104784,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,4,CHEMBL617147,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000019
2113,,,,1,H,104784,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,4,CHEMBL617148,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000019
2114,,,,1,H,104784,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,4,CHEMBL617149,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000019
2115,,,,1,H,104784,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,4,CHEMBL617150,,,B,,,,Autocuration,,BAO_0000224
2116,,,,1,H,104784,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,4,CHEMBL617151,,,B,,,,Autocuration,,BAO_0000224
2117,,,,1,H,104784,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,4,CHEMBL617201,,,B,,,,Autocuration,,BAO_0000224
2118,,,,1,H,10209,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,8,CHEMBL617202,,,B,,,,Autocuration,,BAO_0000357
2119,,,,1,H,104826,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,4,CHEMBL617203,,,B,,In vivo,,Autocuration,,BAO_0000218
2120,,,,1,H,104826,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,4,CHEMBL617204,,,B,,,,Autocuration,,BAO_0000019
2121,,,,1,H,104826,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,4,CHEMBL617205,,,B,,,,Autocuration,,BAO_0000224
2122,,,,1,D,104826,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,5,CHEMBL617206,Mus musculus,,B,10090.0,,,Autocuration,,BAO_0000019
2123,,,,1,H,104826,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,4,CHEMBL617207,,,B,,In vivo,,Autocuration,,BAO_0000218
2124,,,,1,D,104826,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,5,CHEMBL617208,Mus musculus,,B,10090.0,,,Autocuration,,BAO_0000019
2125,,,,1,H,104826,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,4,CHEMBL617209,,,B,,,,Autocuration,,BAO_0000224
2126,,,,1,H,104826,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,4,CHEMBL617210,,,B,,,,Autocuration,,BAO_0000224
2127,,,,1,H,104826,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,4,CHEMBL617211,,,B,,,,Autocuration,,BAO_0000224
2128,,,,1,D,104826,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,5,CHEMBL617212,Mus musculus,,B,10090.0,,,Autocuration,,BAO_0000019
2129,,,,1,H,104784,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,4,CHEMBL617213,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000224
2130,,,,1,H,104784,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,4,CHEMBL617214,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000224
2131,,,,1,U,22226,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,0,CHEMBL617215,,,B,,,,Autocuration,,BAO_0000221
2132,,,,1,U,22226,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,0,CHEMBL617216,,,B,,,,Autocuration,,BAO_0000221
2133,,,,1,H,17005,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,8,CHEMBL617217,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
2134,,,,1,H,104686,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,4,CHEMBL617218,,,B,,,,Autocuration,,BAO_0000019
2135,,,,1,H,104686,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,4,CHEMBL872913,,,B,,,,Autocuration,,BAO_0000019
2136,,,,1,H,104826,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,4,CHEMBL617219,,,B,,,,Autocuration,,BAO_0000019
2137,,,,1,H,104686,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,4,CHEMBL873482,,,B,,,,Autocuration,,BAO_0000224
2138,,,,1,D,104686,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,5,CHEMBL617220,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2139,,,,1,H,104686,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,4,CHEMBL617221,,,B,,,,Autocuration,,BAO_0000019
2140,,,,1,H,104686,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,4,CHEMBL617222,,,B,,,,Autocuration,,BAO_0000019
2141,,,,1,H,104686,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,4,CHEMBL875906,,,F,,,,Autocuration,,BAO_0000019
2142,,,,1,H,104686,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,4,CHEMBL617223,,,B,,,,Autocuration,,BAO_0000019
2143,,,,1,H,104686,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,4,CHEMBL617224,,,B,,,,Autocuration,,BAO_0000224
2144,,,,1,D,104686,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,5,CHEMBL617225,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
2145,,,,1,H,104686,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,4,CHEMBL617226,,,B,,,,Autocuration,,BAO_0000224
2146,,,,1,H,104686,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,4,CHEMBL617227,,,B,,,,Autocuration,,BAO_0000224
2147,,,,1,H,104686,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,4,CHEMBL617228,,,B,,,,Autocuration,,BAO_0000224
2148,,,,1,H,104686,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,4,CHEMBL617229,,,B,,,,Autocuration,,BAO_0000224
2149,,,,1,H,104686,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,4,CHEMBL617230,,,B,,,,Autocuration,,BAO_0000224
2150,,,,1,H,104686,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",4,CHEMBL617231,,,B,,,,Autocuration,,BAO_0000224
2151,,,,1,H,104686,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,4,CHEMBL617232,,,B,,,,Autocuration,,BAO_0000224
2152,,,,1,H,104686,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,4,CHEMBL617233,,,B,,,,Autocuration,,BAO_0000224
2153,,,,1,H,104686,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,4,CHEMBL617234,,,B,,,,Autocuration,,BAO_0000224
2154,,,,1,H,104686,,Compound was tested for the inhibition of quipazine induced head twitches in rats,4,CHEMBL617235,,,F,,,,Autocuration,,BAO_0000019
2155,,,,1,H,104686,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,4,CHEMBL617236,,,F,,,,Autocuration,,BAO_0000019
2156,,Hippocampus,,1,H,104686,10000000.0,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,4,CHEMBL617237,,,B,,,,Autocuration,,BAO_0000221
2157,,Hippocampus,,1,H,104686,10000000.0,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,4,CHEMBL617238,,,B,,,,Autocuration,,BAO_0000221
2158,,Brain,,1,D,104686,955.0,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,5,CHEMBL617239,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000221
2159,,,,1,H,104686,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,4,CHEMBL617240,,,B,,,,Autocuration,,BAO_0000019
2160,,,,1,H,104686,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,4,CHEMBL617241,,Membranes,B,,,,Autocuration,,BAO_0000249
2161,,,,1,H,104686,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,4,CHEMBL875907,,Membranes,B,,,,Autocuration,,BAO_0000249
2162,,,,1,H,104686,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,4,CHEMBL617242,,,B,,,,Autocuration,,BAO_0000019
2163,,,,1,H,104686,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,4,CHEMBL617152,,,F,,,,Autocuration,,BAO_0000019
2164,,Brain,,1,D,104686,955.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,5,CHEMBL617153,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000221
2165,,,,1,D,104686,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,5,CHEMBL617154,Rattus norvegicus,Membranes,B,10116.0,,,Autocuration,,BAO_0000249
2166,,Brain,,1,H,104686,955.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,4,CHEMBL617155,,,B,,,,Autocuration,,BAO_0000221
2167,,,,1,H,104686,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,4,CHEMBL617156,,,F,,,,Autocuration,,BAO_0000019
2168,,,,1,H,104686,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,4,CHEMBL617157,,,F,,,,Autocuration,,BAO_0000019
2169,,,,1,H,104686,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,4,CHEMBL617158,,,F,,,,Autocuration,,BAO_0000019
2170,,,,1,H,104686,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,4,CHEMBL617159,,,F,,,,Autocuration,,BAO_0000019
2171,,,,1,H,104686,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,4,CHEMBL617160,,,F,,,,Autocuration,,BAO_0000019
2172,,,,1,H,104686,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,4,CHEMBL858113,,,F,,,,Autocuration,,BAO_0000019
2173,,Brain,,1,H,104686,955.0,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,4,CHEMBL617247,,,B,,,,Autocuration,,BAO_0000220
2174,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,4,CHEMBL617248,,,B,,,,Autocuration,,BAO_0000019
2175,,Brain,,1,H,104686,955.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,4,CHEMBL617249,,,B,,,,Autocuration,,BAO_0000249
2176,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,4,CHEMBL617250,,,B,,,,Autocuration,,BAO_0000019
2177,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,4,CHEMBL617251,,,B,,,,Autocuration,,BAO_0000019
2178,,,,1,D,104686,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,5,CHEMBL617252,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2179,,,,1,H,104686,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,4,CHEMBL617006,,,B,,,,Autocuration,,BAO_0000019
2180,,,,1,H,104686,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,4,CHEMBL617007,,,B,,,,Autocuration,,BAO_0000019
2181,,,,1,H,104686,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",4,CHEMBL617008,,,F,,,,Autocuration,,BAO_0000019
2182,,,,1,H,104686,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,4,CHEMBL617009,,,B,,,,Autocuration,,BAO_0000019
2183,,,,1,D,104686,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,5,CHEMBL617010,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
2184,,,,1,D,104686,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,5,CHEMBL857978,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2185,,,,1,D,104686,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,5,CHEMBL617011,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2186,,,,1,D,104686,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,5,CHEMBL617012,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2187,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,4,CHEMBL617013,,,B,,,,Autocuration,,BAO_0000224
2188,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,4,CHEMBL617014,,,B,,,,Autocuration,,BAO_0000249
2189,,,,1,H,104686,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,4,CHEMBL617015,,,B,,,,Autocuration,,BAO_0000019
2190,,,,1,H,104686,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,4,CHEMBL617016,,,B,,,,Autocuration,,BAO_0000019
2191,,,,1,H,104686,,pKi value for 5-hydroxytryptamine 2 receptor binding site,4,CHEMBL617017,,,B,,,,Autocuration,,BAO_0000224
2192,,Brain,,1,H,104686,955.0,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,4,CHEMBL617018,,,B,,,,Autocuration,,BAO_0000221
2193,,,,1,H,104686,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,4,CHEMBL617019,,,F,,,,Autocuration,,BAO_0000019
2194,,,,1,H,105075,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,4,CHEMBL617020,,,B,,,,Autocuration,,BAO_0000019
2195,,,,1,H,105075,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,4,CHEMBL617021,,,B,,,,Autocuration,,BAO_0000019
2196,,,,1,H,105075,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,4,CHEMBL617022,,,B,,,,Autocuration,,BAO_0000019
2197,,,,1,H,105075,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,4,CHEMBL617023,,,B,,,,Autocuration,,BAO_0000019
2198,,,,1,H,105075,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,4,CHEMBL617024,,,B,,,,Autocuration,,BAO_0000019
2199,,,,1,H,105075,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,4,CHEMBL617025,,,B,,,,Autocuration,,BAO_0000019
2200,,,,1,H,105075,,Hill coefficient of compound was determined,4,CHEMBL617026,,,B,,,,Autocuration,,BAO_0000224
2201,,,,1,U,22226,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,0,CHEMBL617027,,,B,,,,Autocuration,,BAO_0000019
2202,,,,1,D,104686,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,5,CHEMBL617028,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2203,,,,1,H,12687,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,8,CHEMBL617029,,,B,,,,Expert,,BAO_0000019
2204,,,,1,H,12687,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,8,CHEMBL875908,,,B,,,,Expert,,BAO_0000019
2205,,,,1,H,12687,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),8,CHEMBL617030,,,B,,,,Autocuration,,BAO_0000357
2206,,,,1,H,12687,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),8,CHEMBL617031,,,B,,,,Autocuration,,BAO_0000019
2207,,,,1,H,12687,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,8,CHEMBL617032,,,B,,,,Autocuration,,BAO_0000019
2208,,,,1,D,104686,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,5,CHEMBL617033,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
2209,,,,1,H,104686,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",4,CHEMBL617034,,,B,,,,Autocuration,,BAO_0000224
2210,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,4,CHEMBL617035,,,B,,,,Autocuration,,BAO_0000224
2211,,,,1,H,104686,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",4,CHEMBL617036,,,B,,,,Autocuration,,BAO_0000019
2212,,,,1,H,104784,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,4,CHEMBL617037,,,B,,,,Autocuration,,BAO_0000224
2213,,,,1,U,22226,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,0,CHEMBL617038,,,B,,,,Autocuration,,BAO_0000219
2214,,,,1,H,104784,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",4,CHEMBL617039,,,B,,,,Autocuration,,BAO_0000219
2215,,,,1,H,104784,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,4,CHEMBL617161,,,B,,,,Autocuration,,BAO_0000224
2216,,,,1,H,104784,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,4,CHEMBL617162,,,B,,,,Autocuration,,BAO_0000224
2217,,,,1,H,104784,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,4,CHEMBL617163,,,B,,,,Autocuration,,BAO_0000224
2218,,,,1,H,104784,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,4,CHEMBL617164,,,B,,,,Autocuration,,BAO_0000224
2219,,,,1,H,104784,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,4,CHEMBL617165,,Brain membranes,B,,,,Autocuration,,BAO_0000249
2220,,,,1,H,104784,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,4,CHEMBL617166,,,B,,,,Autocuration,,BAO_0000224
2221,,,,1,H,104784,,Binding affinity towards 5-HT2 receptor,4,CHEMBL617167,,,B,,,,Autocuration,,BAO_0000224
2222,,,,1,H,104784,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,4,CHEMBL872912,,,B,,,,Autocuration,,BAO_0000224
2223,,,,1,H,104784,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,4,CHEMBL617168,,,B,,,,Autocuration,,BAO_0000224
2224,,,,1,H,104686,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,4,CHEMBL617169,,,B,,,,Autocuration,,BAO_0000224
2225,,,,1,H,104784,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,4,CHEMBL617170,,,B,,,,Autocuration,,BAO_0000224
2226,,,,1,H,104784,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,4,CHEMBL617171,,,B,,,,Autocuration,,BAO_0000224
2227,,,,1,H,104784,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,4,CHEMBL617172,,,B,,,,Autocuration,,BAO_0000224
2228,,,,1,H,104784,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,4,CHEMBL617173,,,B,,,,Autocuration,,BAO_0000224
2229,,,,1,U,22226,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,0,CHEMBL617174,,,B,,,,Autocuration,,BAO_0000019
2230,,,,1,H,104784,,5-hydroxytryptamine 2 receptor binding affinity,4,CHEMBL617175,,,B,,,,Autocuration,,BAO_0000224
2231,,,,1,H,17005,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,8,CHEMBL617176,,,B,,,,Autocuration,,BAO_0000357
2232,,,,1,H,17005,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,8,CHEMBL617177,,,B,,,,Autocuration,,BAO_0000357
2233,,,,1,H,104784,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,4,CHEMBL617178,,,B,,,,Autocuration,,BAO_0000224
2234,,,,1,H,104784,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,4,CHEMBL617179,,,B,,,,Autocuration,,BAO_0000224
2235,,,,1,H,104784,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,4,CHEMBL617180,,,B,,,,Autocuration,,BAO_0000224
2236,,,,1,H,17005,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,8,CHEMBL617181,,,B,,,,Autocuration,,BAO_0000357
2237,,,,1,H,17005,,Binding affinity against 5-hydroxytryptamine 2 receptor,8,CHEMBL617182,,,B,,,,Autocuration,,BAO_0000357
2238,,,,1,H,17005,,Binding affinity against 5-hydroxytryptamine 2 receptor,8,CHEMBL617183,,,B,,,,Autocuration,,BAO_0000357
2239,,,,1,H,17005,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,8,CHEMBL617184,,,B,,,,Autocuration,,BAO_0000357
2240,,,,1,H,17005,,Binding affinity against serotonergic 5-HT2 receptor,8,CHEMBL617185,,,B,,,,Autocuration,,BAO_0000357
2241,,,,1,H,17005,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,8,CHEMBL617186,,,B,,,,Autocuration,,BAO_0000357
2242,,,,1,H,17005,,Compound was evaluated for the binding affinity at 5- HT2 receptor,8,CHEMBL617187,,,B,,,,Autocuration,,BAO_0000357
2243,,,,1,H,17005,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,8,CHEMBL617188,,,B,,,,Autocuration,,BAO_0000357
2244,,,,1,H,17005,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,8,CHEMBL617189,,,B,,,,Autocuration,,BAO_0000218
2245,,,,1,D,104784,,Inhibitory activity against cloned human 5-HT2 receptor,5,CHEMBL617190,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000224
2246,,,,1,D,104784,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",5,CHEMBL617191,Homo sapiens,,B,9606.0,,CHO,Autocuration,449.0,BAO_0000219
2247,,,,1,D,104784,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",5,CHEMBL617192,Homo sapiens,,B,9606.0,,CHO,Autocuration,449.0,BAO_0000219
2248,,,,1,D,104784,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",5,CHEMBL617193,Homo sapiens,,B,9606.0,,CHO,Autocuration,449.0,BAO_0000219
2249,,,,1,D,104784,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",5,CHEMBL617194,Homo sapiens,,B,9606.0,,CHO,Autocuration,449.0,BAO_0000219
2250,,,,1,H,104784,,Binding affinity towards 5-hydroxytryptamine 2 receptor,4,CHEMBL617195,,,B,,,,Autocuration,,BAO_0000224
2251,,,,1,H,104784,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,4,CHEMBL881830,,,B,,,,Autocuration,,BAO_0000224
2252,,,,1,H,17005,,Binding affinity towards 5-hydroxytryptamine 2 receptor,8,CHEMBL617196,,,B,,,,Autocuration,,BAO_0000357
2253,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,4,CHEMBL617197,,,B,,,,Autocuration,,BAO_0000224
2254,,,,1,H,17005,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,8,CHEMBL617198,,,B,,,,Expert,,BAO_0000357
2255,,,,1,H,17005,,Binding affinity towards 5-hydroxytryptamine 2A receptor,8,CHEMBL873476,,,B,,,,Expert,,BAO_0000357
2256,,,,1,H,17005,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,8,CHEMBL617199,,,B,,,,Expert,,BAO_0000019
2257,,,,1,H,107,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,8,CHEMBL617200,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000357
2258,,,,1,H,51,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,8,CHEMBL617484,,,B,,,,Autocuration,,BAO_0000357
2259,,,,1,H,107,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,8,CHEMBL617485,,,B,,,,Autocuration,,BAO_0000357
2260,,,,1,H,51,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,8,CHEMBL617486,,,B,,,,Autocuration,,BAO_0000357
2261,,,,1,H,107,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,8,CHEMBL858022,,,B,,,,Autocuration,,BAO_0000357
2262,,,,1,H,107,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,8,CHEMBL617049,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2263,,,,1,D,107,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,9,CHEMBL617050,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
2264,,,,1,H,107,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,8,CHEMBL617051,,,F,,,,Autocuration,,BAO_0000219
2265,,,,1,H,107,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,8,CHEMBL617052,,,F,,,,Autocuration,,BAO_0000219
2266,,,,1,H,107,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,8,CHEMBL617053,,,F,,,,Autocuration,,BAO_0000219
2267,,,,1,H,107,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",8,CHEMBL617054,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2268,,,,1,H,107,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",8,CHEMBL617055,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2269,,,,1,H,107,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,8,CHEMBL882924,,,B,,,,Autocuration,,BAO_0000357
2270,,,,1,D,107,,Inhibition of human 5-hydroxytryptamine 2A receptor,9,CHEMBL617056,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2271,,,,1,H,107,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,8,CHEMBL617057,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2272,,,,1,H,107,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,8,CHEMBL617058,,,B,,,,Expert,,BAO_0000219
2273,,,,1,H,107,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),8,CHEMBL617059,,,B,,,,Autocuration,,BAO_0000357
2274,,,,1,H,107,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,8,CHEMBL617060,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2275,,,,1,H,107,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,8,CHEMBL617061,,,B,,,CHO,Expert,449.0,BAO_0000219
2276,,,,1,H,107,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,8,CHEMBL617062,,,B,,,L929,Expert,307.0,BAO_0000219
2277,,,,1,H,107,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,8,CHEMBL617063,,,B,,,CHO,Expert,449.0,BAO_0000219
2278,,,,1,H,107,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,8,CHEMBL617064,,,F,,,,Autocuration,,BAO_0000019
2279,,,,1,H,107,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,8,CHEMBL617065,,,F,,,,Autocuration,,BAO_0000019
2280,,,,1,H,107,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,8,CHEMBL617066,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2281,,,,1,H,107,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,8,CHEMBL617067,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2282,,,,1,H,107,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,8,CHEMBL617068,,,F,,,,Autocuration,,BAO_0000019
2283,,,,1,H,107,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,8,CHEMBL617069,,,F,,,,Autocuration,,BAO_0000019
2284,,,,1,H,107,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,CHEMBL617070,,,F,,,,Autocuration,,BAO_0000019
2285,,,,1,H,107,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,8,CHEMBL617071,,,B,,,,Autocuration,,BAO_0000357
2286,,,,1,H,107,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,CHEMBL872915,,,B,,,,Autocuration,,BAO_0000357
2287,,,,1,H,107,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,8,CHEMBL617072,,,B,,,,Autocuration,,BAO_0000357
2288,,,,1,H,107,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,8,CHEMBL617073,,,B,,,,Autocuration,,BAO_0000357
2289,,,,1,H,107,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,8,CHEMBL617074,,,B,,,,Autocuration,,BAO_0000357
2290,,,,1,H,107,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,8,CHEMBL617075,,,B,,,CHO,Expert,449.0,BAO_0000219
2291,,,,1,H,107,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,8,CHEMBL617076,,,B,,,,Autocuration,,BAO_0000357
2292,,,,1,D,107,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,9,CHEMBL617077,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000019
2293,,,,1,H,107,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,8,CHEMBL617078,,,B,,,,Expert,,BAO_0000357
2294,,,,1,D,107,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,9,CHEMBL617079,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2295,,,,1,H,107,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,8,CHEMBL617080,,,B,,,,Autocuration,,BAO_0000357
2296,,,,1,H,107,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,8,CHEMBL617081,,,B,,,CHO,Expert,449.0,BAO_0000219
2297,,,,1,H,107,,Binding affinity towards human 5-HT2A receptor in BEK cells,8,CHEMBL617082,,,B,,,,Expert,,BAO_0000219
2298,,,,1,H,107,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,8,CHEMBL617083,,,B,,,,Autocuration,,BAO_0000357
2299,,,,1,H,107,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,8,CHEMBL617084,,,B,,,,Autocuration,,BAO_0000357
2300,,,,1,D,107,,Binding affinity for human 5-hydroxytryptamine 2A receptor,9,CHEMBL617085,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2301,,,,1,H,107,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,8,CHEMBL617086,,,B,,,,Autocuration,,BAO_0000357
2302,,,,1,H,107,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,8,CHEMBL617087,,,B,,,,Autocuration,,BAO_0000219
2303,,,,1,H,107,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,8,CHEMBL617088,,,B,,,,Autocuration,,BAO_0000357
2304,,,,1,H,107,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,8,CHEMBL617089,,,B,,,,Autocuration,,BAO_0000357
2305,,,,1,H,107,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",8,CHEMBL617090,,,B,,,,Expert,,BAO_0000019
2306,,,,1,H,107,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,8,CHEMBL617513,,,B,,,,Autocuration,,BAO_0000357
2307,,,,1,H,107,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,8,CHEMBL617514,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2308,,,,1,H,107,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,8,CHEMBL617515,,,B,,,,Autocuration,,BAO_0000019
2309,,,,1,H,107,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,8,CHEMBL617516,,,B,,,,Autocuration,,BAO_0000357
2310,,,,1,D,107,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,9,CHEMBL617517,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2311,,,,1,D,107,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,9,CHEMBL617518,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
2312,,,,1,H,107,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,8,CHEMBL617519,,,B,,,,Autocuration,,BAO_0000357
2313,,,,1,D,107,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,9,CHEMBL617520,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2314,,,,1,H,107,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,8,CHEMBL617521,,,B,,,,Autocuration,,BAO_0000357
2315,,,,1,D,107,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,9,CHEMBL617522,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2316,,,,1,H,107,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,8,CHEMBL617523,,,B,,,,Autocuration,,BAO_0000357
2317,,,,1,H,107,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,8,CHEMBL617524,,,B,,,,Autocuration,,BAO_0000357
2318,,,,1,H,104686,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,4,CHEMBL617525,,,B,,,,Autocuration,,BAO_0000019
2319,,,,1,D,104686,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,5,CHEMBL617526,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2320,,,,1,H,104686,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,4,CHEMBL617527,,,B,,,,Autocuration,,BAO_0000224
2321,,,,1,H,104686,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,4,CHEMBL617528,,,B,,,,Autocuration,,BAO_0000019
2322,,,,1,H,104686,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,4,CHEMBL617529,,,B,,,,Autocuration,,BAO_0000019
2323,,,,1,H,104686,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,4,CHEMBL617530,,,B,,,,Autocuration,,BAO_0000224
2324,,,,1,H,104686,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,4,CHEMBL617531,,,B,,,,Autocuration,,BAO_0000019
2325,,,,1,H,104686,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,4,CHEMBL617532,,,B,,,,Autocuration,,BAO_0000019
2326,,,,1,H,104686,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,4,CHEMBL617533,,,B,,,,Autocuration,,BAO_0000019
2327,,,,1,H,104686,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,4,CHEMBL617534,,,B,,,,Autocuration,,BAO_0000019
2328,,,,1,H,104686,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,4,CHEMBL617535,,,B,,,,Autocuration,,BAO_0000224
2329,,,,1,H,104686,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,4,CHEMBL617536,,,B,,,,Autocuration,,BAO_0000224
2330,,,,1,H,104686,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,4,CHEMBL617537,,,B,,,,Autocuration,,BAO_0000224
2331,,,,1,H,104686,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,4,CHEMBL617538,,,B,,,,Autocuration,,BAO_0000224
2332,,,,1,H,104686,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,4,CHEMBL617539,,,B,,In vitro,,Autocuration,,BAO_0000219
2333,,,,1,D,104686,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,5,CHEMBL617540,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
2334,,,,1,D,104686,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,5,CHEMBL617541,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
2335,,,,1,H,104686,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,4,CHEMBL617542,,,B,,,,Autocuration,,BAO_0000224
2336,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,4,CHEMBL617543,,,B,,,,Autocuration,,BAO_0000224
2337,,,,1,D,104686,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,5,CHEMBL617544,Rattus norvegicus,,B,10116.0,,CHO-K1,Autocuration,485.0,BAO_0000219
2338,,,,1,D,104686,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,5,CHEMBL617545,Rattus norvegicus,,B,10116.0,,CHO-K1,Autocuration,485.0,BAO_0000219
2339,,,,1,D,104686,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,5,CHEMBL617413,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2340,,,,1,H,104686,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,4,CHEMBL617414,,,B,,,,Autocuration,,BAO_0000019
2341,,,,1,D,104686,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,5,CHEMBL617415,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2342,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor,4,CHEMBL617416,,,B,,,,Autocuration,,BAO_0000224
2343,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,4,CHEMBL617417,,,B,,,,Autocuration,,BAO_0000224
2344,,,,1,H,104686,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",4,CHEMBL617418,,,B,,,,Autocuration,,BAO_0000019
2345,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,4,CHEMBL617419,,,B,,,,Autocuration,,BAO_0000019
2346,,,,1,H,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,4,CHEMBL617420,,,B,,,,Autocuration,,BAO_0000224
2347,,,,1,D,104686,,Affinity for 5-hydroxytryptamine 2 receptor,5,CHEMBL617421,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
2348,,,,1,H,104686,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,4,CHEMBL617422,,,B,,,,Autocuration,,BAO_0000224
2349,,,,1,H,104686,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,4,CHEMBL617423,,,B,,,,Autocuration,,BAO_0000019
2350,,,,1,H,104686,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,4,CHEMBL617424,,,B,,,,Autocuration,,BAO_0000019
2351,,,,1,H,104686,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,4,CHEMBL617425,,,B,,,,Autocuration,,BAO_0000019
2352,,,,1,H,104686,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),4,CHEMBL617426,,,B,,,,Autocuration,,BAO_0000224
2353,,,,1,H,104686,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),4,CHEMBL617427,,,B,,In vivo,,Autocuration,,BAO_0000218
2354,,Brain,,1,H,104686,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,4,CHEMBL617428,,,B,,,,Autocuration,,BAO_0000221
2355,,,,1,H,104686,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,4,CHEMBL617429,,,B,,,,Autocuration,,BAO_0000224
2356,,,,1,H,104686,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,4,CHEMBL617430,,,B,,,,Autocuration,,BAO_0000019
2357,,,,1,H,104686,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,4,CHEMBL617431,,,B,,,,Autocuration,,BAO_0000019
2358,,Frontal cortex,,1,H,104686,1870.0,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,4,CHEMBL617432,,,B,,,,Autocuration,,BAO_0000019
2359,,,,1,H,104686,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,4,CHEMBL617433,,,B,,,,Autocuration,,BAO_0000224
2360,,,,1,H,104686,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,4,CHEMBL617434,,,B,,,,Autocuration,,BAO_0000224
2361,,,,1,D,104686,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,5,CHEMBL617435,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
2362,,,,1,H,104686,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,4,CHEMBL617436,,,B,,,,Autocuration,,BAO_0000019
2363,,Striatum,,1,D,104686,2435.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,5,CHEMBL617437,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2364,,,,1,H,104686,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",4,CHEMBL617438,,,B,,,,Autocuration,,BAO_0000019
2365,,,,1,H,104686,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",4,CHEMBL617439,,,B,,,,Autocuration,,BAO_0000019
2366,,,,1,H,104686,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,4,CHEMBL617440,,,B,,,,Autocuration,,BAO_0000224
2367,,,,1,H,104686,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,4,CHEMBL617441,,,B,,,,Autocuration,,BAO_0000224
2368,,,,1,D,104686,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,5,CHEMBL872918,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2369,,,,1,D,104686,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,5,CHEMBL617442,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2370,,,,1,H,104686,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,4,CHEMBL617443,,,B,,,,Autocuration,,BAO_0000019
2371,,,,1,H,104686,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,4,CHEMBL617444,,,B,,,,Autocuration,,BAO_0000019
2372,,,,1,H,104686,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,4,CHEMBL617445,,,B,,,,Autocuration,,BAO_0000019
2373,,,,1,H,104686,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,4,CHEMBL617446,,,B,,,,Autocuration,,BAO_0000019
2374,,,,1,H,104686,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,4,CHEMBL617447,,,B,,,,Autocuration,,BAO_0000249
2375,,,,1,H,104686,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,4,CHEMBL617448,,,B,,,,Autocuration,,BAO_0000019
2376,,,,1,H,104686,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,4,CHEMBL617449,,,B,,,,Autocuration,,BAO_0000019
2377,,,,1,H,104686,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,4,CHEMBL617450,,,B,,,,Autocuration,,BAO_0000019
2378,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,4,CHEMBL617451,,,B,,,,Autocuration,,BAO_0000019
2379,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,4,CHEMBL617452,,,B,,,,Autocuration,,BAO_0000019
2380,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,4,CHEMBL617453,,,B,,,,Autocuration,,BAO_0000019
2381,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,4,CHEMBL617660,,,B,,,,Autocuration,,BAO_0000019
2382,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,4,CHEMBL617661,,,B,,,,Autocuration,,BAO_0000019
2383,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,4,CHEMBL617662,,,B,,,,Autocuration,,BAO_0000019
2384,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,4,CHEMBL872919,,,B,,,,Autocuration,,BAO_0000019
2385,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,4,CHEMBL617663,,,B,,,,Autocuration,,BAO_0000019
2386,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,4,CHEMBL617664,,,B,,,,Autocuration,,BAO_0000019
2387,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,4,CHEMBL617665,,,B,,,,Autocuration,,BAO_0000019
2388,,,,1,H,104686,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,4,CHEMBL617666,,,B,,,,Autocuration,,BAO_0000019
2389,,,,1,H,104686,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,4,CHEMBL617667,,,B,,,,Autocuration,,BAO_0000019
2390,,,,1,H,104686,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,4,CHEMBL617668,,,B,,,,Autocuration,,BAO_0000249
2391,,,,1,H,104686,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,4,CHEMBL617669,,,B,,,,Autocuration,,BAO_0000249
2392,,,,1,H,104686,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,4,CHEMBL617670,,,B,,,,Autocuration,,BAO_0000224
2393,,,,1,D,104686,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,5,CHEMBL617671,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
2394,,,,1,H,104686,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,4,CHEMBL617672,,,B,,,,Autocuration,,BAO_0000224
2395,,,,1,H,104686,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,4,CHEMBL617673,,,B,,,,Autocuration,,BAO_0000019
2396,,,,1,H,104686,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,4,CHEMBL617674,,,B,,,,Autocuration,,BAO_0000224
2397,,,,1,H,104686,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,4,CHEMBL617675,,,B,,,,Autocuration,,BAO_0000019
2398,,,,1,H,104686,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,4,CHEMBL617676,,,B,,,,Autocuration,,BAO_0000019
2399,,,,1,H,104686,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,4,CHEMBL617677,,,B,,,,Autocuration,,BAO_0000019
2400,,,,1,D,104686,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,5,CHEMBL617678,,,B,,,,Autocuration,,BAO_0000019
2401,,,,1,H,104686,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,4,CHEMBL617679,,,B,,,,Autocuration,,BAO_0000224
2402,,,,1,H,104686,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,4,CHEMBL617680,,,B,,,,Autocuration,,BAO_0000224
2403,,,,1,H,104686,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,4,CHEMBL617681,,,B,,,,Autocuration,,BAO_0000019
2404,,Brain,,1,H,104686,955.0,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,4,CHEMBL617682,,,B,,,,Autocuration,,BAO_0000221
2405,,,,1,H,104686,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,4,CHEMBL617683,,,B,,,,Autocuration,,BAO_0000224
2406,,,,1,H,104686,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,4,CHEMBL617684,,,B,,,,Autocuration,,BAO_0000224
2407,,,,1,D,104686,,Binding affinity towards 5-hydroxytryptamine 2 receptor,5,CHEMBL617685,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
2408,,,,1,H,104686,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,4,CHEMBL617686,,,B,,,,Autocuration,,BAO_0000019
2409,,,,1,H,104686,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,4,CHEMBL617687,,,B,,,,Autocuration,,BAO_0000224
2410,,,,1,H,104686,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,4,CHEMBL617688,,,B,,,,Autocuration,,BAO_0000224
2411,,,,1,H,104686,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,4,CHEMBL617689,,,F,,,,Autocuration,,BAO_0000019
2412,,,,1,H,104686,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,4,CHEMBL617690,,,F,,,,Autocuration,,BAO_0000019
2413,,,,1,H,104686,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",4,CHEMBL617691,,,F,,In vivo,,Autocuration,,BAO_0000218
2414,,,,1,H,104686,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",4,CHEMBL617692,,,F,,In vivo,,Autocuration,,BAO_0000218
2415,,,,1,H,104686,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",4,CHEMBL617693,,,F,,In vivo,,Autocuration,,BAO_0000218
2416,,,,1,H,104686,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",4,CHEMBL617694,,,F,,In vivo,,Autocuration,,BAO_0000218
2417,,Brain,,1,H,12687,955.0,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,8,CHEMBL857985,,,B,,,,Expert,,BAO_0000221
2418,,,,1,D,12687,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,9,CHEMBL617695,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2419,,,,1,H,12687,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,8,CHEMBL617696,,,B,,,,Autocuration,,BAO_0000019
2420,,,,1,H,12687,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,8,CHEMBL617697,,,B,,,,Autocuration,,BAO_0000357
2421,,,,1,D,12687,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,9,CHEMBL617257,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2422,,,,1,D,12687,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,9,CHEMBL617258,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2423,,,,1,H,12687,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,8,CHEMBL617259,,,B,,,,Expert,,BAO_0000019
2424,,,,1,H,12687,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,8,CHEMBL617260,,,B,,,,Autocuration,,BAO_0000357
2425,,,,1,D,12687,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,9,CHEMBL617261,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2426,,,,1,H,12687,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,8,CHEMBL617262,,,B,,,,Autocuration,,BAO_0000019
2427,,,,1,H,12687,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,8,CHEMBL617263,,,B,,,,Expert,,BAO_0000019
2428,,,,1,H,12687,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,8,CHEMBL617264,,,B,,,,Autocuration,,BAO_0000019
2429,,,,1,D,12687,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,9,CHEMBL617265,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2430,,,,1,H,12687,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,8,CHEMBL617266,,Membranes,B,,,,Autocuration,,BAO_0000249
2431,,,,1,H,12687,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,8,CHEMBL617267,,,B,,,,Autocuration,,BAO_0000019
2432,,,,1,H,12687,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,8,CHEMBL617268,,,B,,,,Expert,,BAO_0000019
2433,,,,1,H,12687,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,8,CHEMBL617269,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2434,,,,1,H,12687,,Kinetic inhibition constant evaluated by measuring serotonergic activity,8,CHEMBL617323,,,B,,,,Expert,,BAO_0000357
2435,,,,1,H,12687,,Serotonergic activity of the compound.,8,CHEMBL617324,,,B,,,,Autocuration,,BAO_0000357
2436,,,,1,H,12687,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,8,CHEMBL617325,,,B,,,,Autocuration,,BAO_0000249
2437,,,,1,D,12687,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,9,CHEMBL617326,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2438,,,,1,H,12687,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,8,CHEMBL617327,,,B,,,,Expert,,BAO_0000249
2439,,,,1,D,12687,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,9,CHEMBL617328,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
2440,,,,1,D,12687,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,9,CHEMBL617329,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
2441,,,,1,D,12687,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,9,CHEMBL617330,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
2442,,,,1,H,12687,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,CHEMBL617331,,,B,,,,Autocuration,,BAO_0000357
2443,,,,1,H,12687,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,8,CHEMBL617332,,,B,,,,Autocuration,,BAO_0000357
2444,,,,1,H,107,,Binding affinity towards 5-hydroxytryptamine 2A receptor,8,CHEMBL617333,,,B,,,,Expert,,BAO_0000357
2445,,,,1,H,107,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,8,CHEMBL617334,,,B,,,,Autocuration,,BAO_0000357
2446,,,,1,H,107,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,8,CHEMBL617335,,,B,,,,Autocuration,,BAO_0000357
2447,,,,1,H,107,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,8,CHEMBL617336,,,B,,,,Autocuration,,BAO_0000357
2448,,,,1,H,107,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,8,CHEMBL617337,,,B,,,,Autocuration,,BAO_0000357
2449,,,,1,D,107,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,9,CHEMBL617338,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2450,,,,1,H,107,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,8,CHEMBL617339,,,B,,,,Autocuration,,BAO_0000357
2451,,,,1,H,107,,Binding affinity towards 5-hydroxytryptamine 2A receptor,8,CHEMBL617340,,,B,,,,Expert,,BAO_0000357
2452,,,,1,H,107,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,8,CHEMBL617341,,,B,,,,Autocuration,,BAO_0000357
2453,,,,1,H,107,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,8,CHEMBL617342,,,B,,,,Expert,,BAO_0000357
2454,,,,1,H,107,,Affinity for 5-hydroxytryptamine 2A receptor,8,CHEMBL617343,,,B,,,,Expert,,BAO_0000357
2455,,,,1,H,107,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,8,CHEMBL617344,,,B,,,NIH3T3,Expert,723.0,BAO_0000219
2456,,,,1,H,107,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,8,CHEMBL617345,,,B,,,,Expert,,BAO_0000357
2457,,,,1,H,107,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,8,CHEMBL617346,,,B,,,,Expert,,BAO_0000357
2458,,,,1,H,107,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,8,CHEMBL617347,,,B,,,,Autocuration,,BAO_0000357
2459,,,,1,H,107,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,8,CHEMBL617348,,,B,,,,Autocuration,,BAO_0000357
2460,,,,1,H,107,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,8,CHEMBL617349,,,B,,,,Autocuration,,BAO_0000357
2461,,,,1,H,107,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,8,CHEMBL617350,,,F,,,,Autocuration,,BAO_0000019
2462,,,,1,H,107,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,8,CHEMBL872339,,,B,,,,Expert,,BAO_0000357
2463,,,,1,H,107,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,8,CHEMBL617351,,,B,,,,Autocuration,,BAO_0000357
2464,,,,1,H,107,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,8,CHEMBL617352,,,B,,,,Expert,,BAO_0000357
2465,,,,1,H,107,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,8,CHEMBL617353,,,B,,,,Autocuration,,BAO_0000357
2466,,,,1,H,107,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,8,CHEMBL617354,,,B,,,,Autocuration,,BAO_0000357
2467,,,,1,H,107,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,8,CHEMBL617355,,,B,,,,Autocuration,,BAO_0000357
2468,,,,1,H,107,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,8,CHEMBL617356,Mus musculus,,B,10090.0,,CHO,Expert,449.0,BAO_0000219
2469,,,,1,H,107,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,8,CHEMBL617357,,,B,,,,Autocuration,,BAO_0000357
2470,,,,1,H,107,,Binding affinity at 5-hydroxytryptamine 2A receptor,8,CHEMBL617358,,,B,,,,Autocuration,,BAO_0000357
2471,,,,1,H,107,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,8,CHEMBL617359,,,B,,,,Expert,,BAO_0000357
2472,,,,1,H,107,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,8,CHEMBL617360,,,B,,,,Autocuration,,BAO_0000357
2473,,,,1,H,107,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,8,CHEMBL875913,,,B,,,,Autocuration,,BAO_0000357
2474,,,,1,H,107,,Affinity against 5-hydroxytryptamine 2A receptor,8,CHEMBL617361,,,B,,,,Autocuration,,BAO_0000357
2475,,,,1,D,107,,Binding affinity against 5-Hydroxytryptamine 2A receptor,9,CHEMBL617362,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2476,,,,1,H,107,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,8,CHEMBL617363,,,B,,,,Autocuration,,BAO_0000357
2477,,,,1,H,107,,Tested against 5-hydroxytryptamine 2A receptor,8,CHEMBL617364,,,B,,,,Autocuration,,BAO_0000357
2478,,,,1,H,105075,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,4,CHEMBL617365,,,B,,,,Autocuration,,BAO_0000224
2479,,,,1,H,105075,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,4,CHEMBL617366,,,B,,,,Autocuration,,BAO_0000224
2480,,,,1,H,105075,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,4,CHEMBL617367,,,B,,,,Autocuration,,BAO_0000224
2481,,,,1,H,105075,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,4,CHEMBL617368,,,B,,,,Autocuration,,BAO_0000224
2482,,,,1,H,107,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),8,CHEMBL617369,,,B,,,,Autocuration,,BAO_0000357
2483,,,,1,D,227,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,9,CHEMBL617370,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2484,,,,1,D,227,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,9,CHEMBL617371,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
2485,,,,1,H,227,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),8,CHEMBL617372,,,B,,,,Autocuration,,BAO_0000357
2486,,,,1,D,227,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,9,CHEMBL617373,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2487,,,,1,H,227,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,8,CHEMBL617374,,,F,,,,Autocuration,,BAO_0000019
2488,,,,1,H,227,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,8,CHEMBL617375,,,F,,,,Autocuration,,BAO_0000019
2489,,,,1,H,227,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,8,CHEMBL617376,,,F,,,,Autocuration,,BAO_0000019
2490,,,,1,H,227,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,8,CHEMBL617377,,,F,,,,Autocuration,,BAO_0000019
2491,,,,1,H,227,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,8,CHEMBL617378,,,F,,,,Autocuration,,BAO_0000019
2492,,,,1,H,227,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,8,CHEMBL617379,,,F,,,,Autocuration,,BAO_0000019
2493,,,,1,H,227,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,8,CHEMBL617380,,,B,,,,Autocuration,,BAO_0000357
2494,,,,1,H,227,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,8,CHEMBL617381,,,B,,,,Autocuration,,BAO_0000357
2495,,,,1,H,227,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,8,CHEMBL617382,,,B,,,,Autocuration,,BAO_0000357
2496,,,,1,H,107,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,8,CHEMBL617383,,,B,,,,Autocuration,,BAO_0000357
2497,,,,1,H,107,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,8,CHEMBL617384,,,B,,,,Expert,,BAO_0000357
2498,,,,1,H,107,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,8,CHEMBL617385,,,B,,,,Expert,,BAO_0000357
2499,,,,1,H,107,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,8,CHEMBL617386,,,B,,,,Autocuration,,BAO_0000019
2500,,,,1,H,107,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,8,CHEMBL617387,,,B,,,,Autocuration,,BAO_0000019
2501,,,,1,H,107,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,8,CHEMBL617388,,,B,,,NIH3T3,Autocuration,723.0,BAO_0000219
2502,,,,1,H,107,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,8,CHEMBL617389,,,F,,,CHO,Autocuration,449.0,BAO_0000219
2503,,,,1,D,107,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9,CHEMBL617390,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
2504,,,,1,H,104817,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,4,CHEMBL617391,,,B,,,,Autocuration,,BAO_0000224
2505,,,,1,H,107,,Binding activity radioligand.,8,CHEMBL617392,,,B,,,,Autocuration,,BAO_0000357
2506,,,,1,H,107,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,8,CHEMBL617393,,,B,,,,Autocuration,,BAO_0000019
2507,,,,1,H,107,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,8,CHEMBL617394,,,B,,,L929,Autocuration,307.0,BAO_0000219
2508,,,,1,H,107,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,8,CHEMBL617395,,,B,,,L929,Expert,307.0,BAO_0000219
2509,,,,1,H,107,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,8,CHEMBL617396,,,B,,,L929,Expert,307.0,BAO_0000219
2510,,,,1,H,107,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,8,CHEMBL617397,,,B,,,L929,Autocuration,307.0,BAO_0000219
2511,,,,1,H,107,,Binding affinity against 5-HT2A receptor,8,CHEMBL617398,,,B,,,,Autocuration,,BAO_0000357
2512,,,,1,H,107,,Binding affinity against 5-hydroxytryptamine 2A receptor,8,CHEMBL617399,,,B,,,,Autocuration,,BAO_0000357
2513,,,,1,H,107,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,8,CHEMBL617400,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2514,,,,1,H,107,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,8,CHEMBL617401,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2515,,,,1,D,107,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,9,CHEMBL617402,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2516,,,,1,D,107,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9,CHEMBL617403,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2517,,,,1,H,107,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,8,CHEMBL617404,,,B,,,,Expert,,BAO_0000357
2518,,,,1,D,107,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9,CHEMBL857981,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2519,,,,1,D,107,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9,CHEMBL617405,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2520,,,,1,D,107,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,9,CHEMBL617253,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2521,,,,1,H,107,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,8,CHEMBL617254,,,B,,,,Expert,,BAO_0000357
2522,,,,1,H,107,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,8,CHEMBL617255,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2523,,,,1,H,107,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,8,CHEMBL617256,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2524,,,,1,H,107,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,8,CHEMBL616874,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2525,,,,1,D,107,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,9,CHEMBL616875,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2526,,,,1,H,107,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,8,CHEMBL616876,,,B,,,HEK293,Expert,722.0,BAO_0000219
2527,,,,1,H,107,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",8,CHEMBL616877,,,B,,,HEK293,Expert,722.0,BAO_0000219
2528,,,,1,D,107,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,9,CHEMBL616878,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2529,,,,1,H,107,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,8,CHEMBL616879,,,B,,,HEK293,Expert,722.0,BAO_0000219
2530,,,,1,H,107,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,8,CHEMBL616880,,,B,,,HEK293,Expert,722.0,BAO_0000219
2531,,,,1,D,107,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9,CHEMBL616881,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2532,,,,1,H,107,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,8,CHEMBL616882,,,B,,,NIH3T3,Autocuration,723.0,BAO_0000219
2533,,,,1,H,107,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,8,CHEMBL616883,,,B,,,NIH3T3,Autocuration,723.0,BAO_0000219
2534,,,,1,H,107,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,8,CHEMBL616884,,,B,,,NIH3T3,Autocuration,723.0,BAO_0000219
2535,,,,1,H,107,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,8,CHEMBL616885,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2536,,,,1,H,107,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,8,CHEMBL616886,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
2537,,,,1,H,107,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,8,CHEMBL616887,,,B,,,CHO-K1,Expert,485.0,BAO_0000219
2538,,,,1,D,107,,Binding affinity for human 5-hydroxytryptamine 2A receptor,9,CHEMBL616888,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2539,,,,1,H,107,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,8,CHEMBL616889,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2540,,,,1,H,107,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,8,CHEMBL616890,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2541,,,,1,D,107,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,9,CHEMBL616891,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
2542,,,,1,H,107,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,8,CHEMBL616892,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2543,,,,1,H,107,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",8,CHEMBL616893,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2544,,,,1,H,10620,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,8,CHEMBL616894,,,F,,,NIH3T3,Autocuration,723.0,BAO_0000219
2545,,,,1,H,107,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,8,CHEMBL616895,,,B,,,NIH3T3,Expert,723.0,BAO_0000219
2546,,,,1,H,10620,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,8,CHEMBL616896,,,F,,,,Autocuration,,BAO_0000019
2547,,,,1,H,10621,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,8,CHEMBL617099,,,B,,,,Autocuration,,BAO_0000357
2548,,,,1,H,10621,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,8,CHEMBL617100,,,B,,,,Autocuration,,BAO_0000357
2549,,,,1,H,107,,Binding affinity against rabbit aorta 5-HT2A receptor,8,CHEMBL884532,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000357
2550,,,,1,H,107,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,8,CHEMBL617101,Oryctolagus cuniculus,,B,9986.0,,,Expert,,BAO_0000357
2551,,,,1,H,107,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,8,CHEMBL617102,Oryctolagus cuniculus,,B,9986.0,,,Expert,,BAO_0000357
2552,,,,1,H,107,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,8,CHEMBL617103,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
2553,,,,1,H,107,,The compound was tested for binding affinity against 5-HT2A receptor,8,CHEMBL617104,Oryctolagus cuniculus,,B,9986.0,,,Expert,,BAO_0000357
2554,,,,1,H,10576,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,8,CHEMBL857979,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
2555,,,,1,H,12687,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,8,CHEMBL857502,,,B,,,,Autocuration,,BAO_0000019
2556,,,,1,H,12687,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,8,CHEMBL617105,,,B,,,,Autocuration,,BAO_0000019
2557,,Stomach,,1,H,12687,945.0,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,8,CHEMBL858021,,,B,,,,Autocuration,,BAO_0000019
2558,,Stomach,,1,D,12687,945.0,Binding affinity for 5-HT 2A in rat stomach fundus,9,CHEMBL875910,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2559,,,,1,H,12687,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,8,CHEMBL617106,,,B,,,,Autocuration,,BAO_0000019
2560,,,,1,H,12687,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,8,CHEMBL617107,,,B,,,NIH3T3,Expert,723.0,BAO_0000219
2561,,,,1,H,12687,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,8,CHEMBL617108,,,F,,,,Autocuration,,BAO_0000019
2562,,,,1,H,12687,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,8,CHEMBL617109,,,F,,,,Autocuration,,BAO_0000019
2563,,,,1,H,12687,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,8,CHEMBL617110,,,B,,,,Autocuration,,BAO_0000357
2564,,,,1,H,12687,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,8,CHEMBL617111,,,B,,,,Autocuration,,BAO_0000357
2565,,,,1,D,12687,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,9,CHEMBL617112,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
2566,,,,1,H,12687,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,8,CHEMBL617113,,,B,,,,Autocuration,,BAO_0000357
2567,,,,1,H,12687,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,8,CHEMBL617114,,,B,,,,Autocuration,,BAO_0000357
2568,,,,1,H,12687,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,8,CHEMBL617115,,,B,,,,Autocuration,,BAO_0000357
2569,,,,1,H,12687,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,8,CHEMBL617116,,,F,,,,Autocuration,,BAO_0000219
2570,,,,1,H,12687,,Efficacy at 5-hydroxytryptamine 2A receptor,8,CHEMBL617117,,,F,,,,Autocuration,,BAO_0000019
2571,,,,1,H,12687,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),8,CHEMBL617118,,,B,,,,Autocuration,,BAO_0000357
2572,,,,1,D,12687,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),9,CHEMBL617119,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2573,,,,1,D,12687,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),9,CHEMBL617120,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2574,,,,1,D,12687,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,9,CHEMBL617121,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000219
2575,,,,1,H,12687,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,8,CHEMBL617122,,,F,,,,Autocuration,,BAO_0000219
2576,,,,1,H,12687,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,8,CHEMBL617123,,,B,,,,Autocuration,,BAO_0000019
2577,,,,1,H,12687,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,8,CHEMBL617124,,,B,,,,Expert,,BAO_0000019
2578,,,,1,H,12687,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,8,CHEMBL617600,,,B,,,,Expert,,BAO_0000249
2579,,,,1,H,12687,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,8,CHEMBL617601,,,B,,,,Expert,,BAO_0000357
2580,,,,1,H,12687,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,8,CHEMBL882923,,,B,,,,Expert,,BAO_0000019
2581,,,,1,H,12687,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,8,CHEMBL617602,,,B,,,,Autocuration,,BAO_0000357
2582,,,,1,H,12687,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,8,CHEMBL617603,,,B,,,,Autocuration,,BAO_0000019
2583,,,,1,H,12687,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,8,CHEMBL617604,,,B,,,,Autocuration,,BAO_0000357
2584,,,,1,H,12687,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,8,CHEMBL617605,,,B,,,,Expert,,BAO_0000019
2585,,,,1,H,12687,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,8,CHEMBL617606,,,B,,,,Expert,,BAO_0000019
2586,,,,1,D,12687,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,9,CHEMBL617607,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2587,,,,1,H,12687,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,CHEMBL617455,,,B,,,,Autocuration,,BAO_0000249
2588,,,,1,D,12687,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,9,CHEMBL617456,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2589,,,,1,H,12687,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),8,CHEMBL617457,,,B,,,,Expert,,BAO_0000357
2590,,,,1,D,12687,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,9,CHEMBL617458,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2591,,,,1,D,12687,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,9,CHEMBL617459,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2592,,,,1,H,12687,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,8,CHEMBL617460,,,B,,,,Expert,,BAO_0000357
2593,,,,1,H,12687,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",8,CHEMBL617461,,,B,,,,Expert,,BAO_0000357
2594,,,,1,D,12687,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,9,CHEMBL617462,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2595,,,,1,H,12687,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,8,CHEMBL617463,,,B,,,,Autocuration,,BAO_0000357
2596,,,,1,H,12687,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",8,CHEMBL617464,,,B,,,,Autocuration,,BAO_0000019
2597,,,,1,H,12687,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",8,CHEMBL617465,,,B,,,,Autocuration,,BAO_0000019
2598,,,,1,H,12687,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,8,CHEMBL617466,,,B,,,,Expert,,BAO_0000019
2599,,,,1,H,12687,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,8,CHEMBL617467,,,B,,,,Autocuration,,BAO_0000019
2600,,,,1,H,12687,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,8,CHEMBL617468,,,B,,,,Expert,,BAO_0000019
2601,,,,1,H,12687,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,8,CHEMBL617469,,,B,,,,Autocuration,,BAO_0000019
2602,,,,1,H,12687,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,8,CHEMBL617470,,,B,,,,Autocuration,,BAO_0000019
2603,,,,1,H,12687,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,8,CHEMBL617471,,,B,,,,Autocuration,,BAO_0000019
2604,,,,1,H,12687,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,8,CHEMBL617472,,,B,,,NIH3T3,Expert,723.0,BAO_0000219
2605,,,,1,H,12687,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,8,CHEMBL617473,,,B,,,,Expert,,BAO_0000357
2606,,,,1,D,12687,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,9,CHEMBL617474,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2607,,,,1,D,12687,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,9,CHEMBL617475,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2608,,Brain,,1,H,12687,955.0,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,8,CHEMBL617476,,,B,,,,Autocuration,,BAO_0000221
2609,,,,1,H,12687,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,8,CHEMBL617477,,,B,,,,Expert,,BAO_0000357
2610,,,,1,H,12687,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,8,CHEMBL617478,,,B,,,NIH3T3,Expert,723.0,BAO_0000219
2611,,,,1,H,12687,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",8,CHEMBL617479,,,F,,,,Autocuration,,BAO_0000221
2612,,,,1,H,12687,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,8,CHEMBL617480,,,B,,,,Autocuration,,BAO_0000357
2613,,,,1,H,12687,,Binding affinity against 5-hydroxytryptamine 2A receptor,8,CHEMBL617481,,,B,,,,Expert,,BAO_0000357
2614,,,,1,H,12687,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,8,CHEMBL617482,,,B,,,,Expert,,BAO_0000019
2615,,,,1,H,12687,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,8,CHEMBL617483,,,B,,,,Autocuration,,BAO_0000019
2616,,,,1,H,12687,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,8,CHEMBL621528,,,B,,,,Autocuration,,BAO_0000357
2617,,,,1,D,12687,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,9,CHEMBL621529,Rattus norvegicus,,B,10116.0,,NIH3T3,Expert,723.0,BAO_0000219
2618,,,,1,H,12687,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,8,CHEMBL621530,,,B,,,,Expert,,BAO_0000357
2619,,,,1,H,12687,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,CHEMBL621531,,,B,,,,Expert,,BAO_0000357
2620,,,,1,D,12687,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,9,CHEMBL621532,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2621,,,,1,H,12687,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,8,CHEMBL621533,,,B,,,,Expert,,BAO_0000357
2622,,,,1,H,12687,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,8,CHEMBL621534,,,B,,,CHO,Expert,449.0,BAO_0000219
2623,,,,1,H,12687,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,8,CHEMBL621535,,,B,,,,Autocuration,,BAO_0000019
2624,,,,1,H,12687,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,8,CHEMBL621536,,,B,,,,Autocuration,,BAO_0000357
2625,,,,1,H,12687,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,8,CHEMBL621537,,,B,,,,Autocuration,,BAO_0000357
2626,,,,1,D,12687,,Binding affinity for 5-hydroxytryptamine 2A receptor,9,CHEMBL621538,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2627,,,,1,H,12687,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,8,CHEMBL621539,,,B,,,,Autocuration,,BAO_0000019
2628,,,,1,H,12687,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,8,CHEMBL621540,,,B,,,,Autocuration,,BAO_0000019
2629,,,,1,H,12687,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,8,CHEMBL621541,,,B,,,,Autocuration,,BAO_0000019
2630,,,,1,H,12687,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,8,CHEMBL621542,,,B,,,,Autocuration,,BAO_0000019
2631,,,,1,H,12687,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,8,CHEMBL621543,,,B,,,,Expert,,BAO_0000357
2632,,,,1,H,12687,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,8,CHEMBL621544,,,B,,,,Expert,,BAO_0000357
2633,,,,1,D,12687,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,9,CHEMBL621545,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2634,,,,1,H,12687,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,CHEMBL621546,,,B,,,,Autocuration,,BAO_0000357
2635,,,,1,H,12687,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,8,CHEMBL621547,,,B,,,,Autocuration,,BAO_0000357
2636,,,,1,H,12687,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,8,CHEMBL618692,,,B,,,NIH3T3,Expert,723.0,BAO_0000219
2637,,,,1,H,12687,,Binding affinity towards 5-hydroxytryptamine 2A receptor,8,CHEMBL618693,,,B,,,,Autocuration,,BAO_0000357
2638,,,,1,H,12687,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,8,CHEMBL872922,,,B,,,,Autocuration,,BAO_0000357
2639,,,,1,H,12687,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,8,CHEMBL618694,,,B,,,,Autocuration,,BAO_0000357
2640,,,,1,D,12687,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,9,CHEMBL618695,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2641,,,,1,H,12687,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,8,CHEMBL618696,,,B,,,,Autocuration,,BAO_0000357
2642,,,,1,H,12687,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,8,CHEMBL618697,,,B,,,,Expert,,BAO_0000357
2643,,,,1,H,12687,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,8,CHEMBL618892,,,B,,,,Autocuration,,BAO_0000357
2644,,,,1,H,12687,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,8,CHEMBL618893,,,B,,,,Autocuration,,BAO_0000357
2645,,,,1,H,12687,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,8,CHEMBL618894,,,B,,,,Autocuration,,BAO_0000357
2646,,,,1,H,12687,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,8,CHEMBL618895,,,B,,,NIH3T3,Expert,723.0,BAO_0000219
2647,,,,1,D,12687,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,9,CHEMBL618896,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2648,,Caudate-putamen,,1,H,12687,5383.0,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,8,CHEMBL618897,,,B,,,,Autocuration,,BAO_0000019
2649,,,,1,H,12687,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,8,CHEMBL618898,,,B,,,,Autocuration,,BAO_0000357
2650,,,,1,H,12687,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,8,CHEMBL618899,,,B,,,,Autocuration,,BAO_0000357
2651,,,,1,H,12687,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,8,CHEMBL618900,,,B,,,,Autocuration,,BAO_0000357
2652,,,,1,H,12687,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,8,CHEMBL618901,,,B,,,,Autocuration,,BAO_0000019
2653,,,,1,H,12687,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,8,CHEMBL618902,,,B,,,,Autocuration,,BAO_0000357
2654,,Hippocampus,,1,D,12687,10000000.0,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,9,CHEMBL618903,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000221
2655,,,,1,H,12687,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,8,CHEMBL618904,,,B,,,,Autocuration,,BAO_0000357
2656,,,,1,H,12687,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,8,CHEMBL618905,,,B,,,,Autocuration,,BAO_0000357
2657,,,,1,H,12687,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,8,CHEMBL618906,,,B,,,,Autocuration,,BAO_0000357
2658,,,,1,H,12687,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,8,CHEMBL618907,,,B,,,NIH3T3,Expert,723.0,BAO_0000219
2659,,,,1,H,12687,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,8,CHEMBL618908,,,B,,,,Autocuration,,BAO_0000019
2660,,,,1,H,12687,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,8,CHEMBL617909,,,B,,,,Autocuration,,BAO_0000357
2661,,,,1,H,12687,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,8,CHEMBL617910,,,B,,,,Expert,,BAO_0000019
2662,,Brain,,1,H,12687,955.0,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,8,CHEMBL617911,,,B,,,,Autocuration,,BAO_0000221
2663,,,,1,H,12687,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,CHEMBL872923,,,B,,,,Autocuration,,BAO_0000249
2664,,,,1,H,12687,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,CHEMBL617912,,,B,,,,Autocuration,,BAO_0000249
2665,,,,1,D,12687,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,9,CHEMBL617913,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2666,,,,1,H,12687,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,CHEMBL617914,,,B,,,,Expert,,BAO_0000249
2667,,,,1,H,12687,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,CHEMBL617915,,,B,,,,Autocuration,,BAO_0000249
2668,,,,1,H,12687,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,CHEMBL617916,,,B,,,,Autocuration,,BAO_0000249
2669,,,,1,D,12687,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,9,CHEMBL617917,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2670,,,,1,H,12687,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,8,CHEMBL617918,,,B,,,,Expert,,BAO_0000019
2671,,,,1,H,12687,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,8,CHEMBL617919,,,B,,,,Autocuration,,BAO_0000019
2672,,,,1,D,12687,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,9,CHEMBL617920,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2673,,,,1,D,12687,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,9,CHEMBL617921,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2674,,,,1,D,105102,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",5,CHEMBL617922,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000224
2675,,,,1,H,12687,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,8,CHEMBL617923,,,B,,,,Autocuration,,BAO_0000357
2676,,,,1,H,12687,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,CHEMBL617924,,,B,,,,Autocuration,,BAO_0000357
2677,,,,1,H,12687,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,8,CHEMBL617925,,,B,,,,Autocuration,,BAO_0000357
2678,,,,1,D,12687,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,9,CHEMBL617926,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2679,,,,1,H,12687,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,8,CHEMBL617927,,,B,,,,Autocuration,,BAO_0000357
2680,,,,1,H,12687,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,8,CHEMBL617928,,,B,,,,Autocuration,,BAO_0000357
2681,,,,1,D,12687,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,9,CHEMBL617929,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2682,,,,1,H,12687,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,8,CHEMBL617930,,,B,,,,Expert,,BAO_0000019
2683,,,,1,H,12687,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,8,CHEMBL617931,,,B,,,,Autocuration,,BAO_0000019
2684,,,,1,H,12687,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,8,CHEMBL617932,,,B,,,,Autocuration,,BAO_0000019
2685,,,,1,H,12687,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,8,CHEMBL617933,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2686,,,,1,H,12687,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,8,CHEMBL617934,,,B,,,,Autocuration,,BAO_0000019
2687,,,,1,H,12687,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,8,CHEMBL617935,,,B,,,,Autocuration,,BAO_0000019
2688,,,,1,H,12687,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,8,CHEMBL617936,,,B,,,,Autocuration,,BAO_0000357
2689,,,,1,H,12687,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,8,CHEMBL617937,,,B,,,,Autocuration,,BAO_0000019
2690,,,,1,H,12687,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,8,CHEMBL617938,,,B,,,,Autocuration,,BAO_0000019
2691,,,,1,H,12687,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,8,CHEMBL617939,,,B,,,,Autocuration,,BAO_0000218
2692,,,,1,H,12687,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,8,CHEMBL617940,,,B,,,,Autocuration,,BAO_0000218
2693,,,,1,H,12687,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,8,CHEMBL617941,,,B,,,,Autocuration,,BAO_0000218
2694,,,,1,H,12687,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,8,CHEMBL617942,,,B,,,,Expert,,BAO_0000357
2695,,,,1,H,12687,,Ratio of pKi of 5-HT2A to that of D2 receptor,8,CHEMBL617943,,,B,,,,Expert,,BAO_0000357
2696,,,,1,H,105093,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,4,CHEMBL617944,,,B,,,,Expert,,BAO_0000224
2697,,,,1,H,105093,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,4,CHEMBL617945,,,B,,,,Expert,,BAO_0000224
2698,,,,1,H,105075,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,4,CHEMBL617946,,,B,,,,Expert,,BAO_0000224
2699,,,,1,H,12687,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,8,CHEMBL617947,,,B,,,,Autocuration,,BAO_0000357
2700,,,,1,H,12687,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,8,CHEMBL617948,,,B,,,,Expert,,BAO_0000357
2701,,,,1,H,12687,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,8,CHEMBL858116,,,F,,,,Autocuration,,BAO_0000019
2702,,,,1,H,12687,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,8,CHEMBL617949,,,F,,,,Autocuration,,BAO_0000019
2703,,,,1,H,12687,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,8,CHEMBL617950,,,F,,,,Autocuration,,BAO_0000019
2704,,Thoracic aorta,,1,H,12687,1515.0,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,8,CHEMBL617951,,,F,,,,Expert,,BAO_0000019
2705,,Thoracic aorta,,1,H,12687,1515.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,8,CHEMBL617952,,,F,,,,Expert,,BAO_0000019
2706,,Thoracic aorta,,1,H,12687,1515.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,8,CHEMBL617953,,,F,,,,Autocuration,,BAO_0000019
2707,,,,1,H,12687,,Binding activity radioligand.,8,CHEMBL617954,,,B,,,,Autocuration,,BAO_0000357
2708,,,,1,H,12687,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,8,CHEMBL617955,,,B,,,,Expert,,BAO_0000019
2709,,,,1,H,12687,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,8,CHEMBL857071,,,B,,,,Autocuration,,BAO_0000019
2710,,,,1,H,12687,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,8,CHEMBL617270,,,B,,,,Expert,,BAO_0000019
2711,,,,1,H,12687,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,8,CHEMBL617271,,,B,,,N1E-115,Autocuration,339.0,BAO_0000219
2712,,,,1,H,12687,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,8,CHEMBL617272,,,B,,,N1E-115,Autocuration,339.0,BAO_0000219
2713,,,,1,H,12687,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,8,CHEMBL617273,,,B,,,,Autocuration,,BAO_0000019
2714,,,,1,D,12687,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,9,CHEMBL617274,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
2715,,,,1,H,108,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,8,CHEMBL617275,,,B,,,,Autocuration,,BAO_0000357
2716,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 2C receptor,8,CHEMBL617276,,,B,,,,Autocuration,,BAO_0000357
2717,,,,1,H,108,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,8,CHEMBL617277,,,B,,,,Autocuration,,BAO_0000357
2718,,,,1,H,108,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,8,CHEMBL617278,,,B,,,,Expert,,BAO_0000019
2719,,,,1,H,108,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,8,CHEMBL617279,,,B,,,,Expert,,BAO_0000019
2720,,,,1,H,108,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,8,CHEMBL617280,,,B,,,,Expert,,BAO_0000019
2721,,,,1,H,108,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,8,CHEMBL617281,,,B,,,,Autocuration,,BAO_0000357
2722,,,,1,H,108,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,8,CHEMBL617282,,,B,,,,Autocuration,,BAO_0000357
2723,,,,1,H,108,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,8,CHEMBL617283,,,B,,,,Expert,,BAO_0000019
2724,,,,1,H,108,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,8,CHEMBL617284,,,B,,,,Expert,,BAO_0000019
2725,,,,1,H,108,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,8,CHEMBL617285,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2726,,,,1,H,108,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,8,CHEMBL617286,,,B,,,,Autocuration,,BAO_0000019
2727,,,,1,D,108,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,9,CHEMBL617287,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2728,,,,1,H,108,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,8,CHEMBL617288,,,B,,,,Expert,,BAO_0000357
2729,,,,1,H,108,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,8,CHEMBL617289,,,B,,,,Autocuration,,BAO_0000357
2730,,,,1,H,108,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,8,CHEMBL872917,,,B,,,,Autocuration,,BAO_0000357
2731,,,,1,H,108,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,8,CHEMBL617290,,,B,,,,Autocuration,,BAO_0000357
2732,,,,1,H,108,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,8,CHEMBL617291,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2733,,,,1,H,108,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,8,CHEMBL617292,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2734,,,,1,H,108,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,8,CHEMBL617293,,,B,,,NIH3T3,Autocuration,723.0,BAO_0000219
2735,,,,1,D,108,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9,CHEMBL617294,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
2736,,,,1,H,108,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,8,CHEMBL617295,,,B,,,,Expert,,BAO_0000019
2737,,,,1,H,108,,Binding activity radioligand.,8,CHEMBL617296,,,B,,,,Autocuration,,BAO_0000357
2738,,,,1,H,108,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,8,CHEMBL617297,,,B,,,,Autocuration,,BAO_0000019
2739,,,,1,H,108,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,8,CHEMBL617298,,,B,,,CHO,Expert,449.0,BAO_0000219
2740,,,,1,H,108,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,8,CHEMBL617299,,,B,,,CHO,Expert,449.0,BAO_0000219
2741,,,,1,H,108,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,8,CHEMBL617300,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2742,,,,1,H,108,,Binding affinity against 5-HT2C receptor,8,CHEMBL617454,,,B,,,,Autocuration,,BAO_0000357
2743,,,,1,H,108,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,8,CHEMBL617505,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2744,,,,1,D,108,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,9,CHEMBL617506,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2745,,,,1,D,108,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,9,CHEMBL617507,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2746,,,,1,H,108,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,8,CHEMBL617508,,,B,,,,Expert,,BAO_0000357
2747,,,,1,D,108,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,9,CHEMBL857982,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2748,,,,1,D,108,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,9,CHEMBL617509,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2749,,,,1,D,108,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,9,CHEMBL617510,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2750,,,,1,H,108,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,8,CHEMBL617511,,,B,,,,Autocuration,,BAO_0000357
2751,,,,1,H,108,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,8,CHEMBL617512,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2752,,,,1,H,108,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,8,CHEMBL617749,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2753,,,,1,H,108,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,8,CHEMBL617750,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2754,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,8,CHEMBL617751,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2755,,,,1,H,108,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,8,CHEMBL617752,,,B,,,HEK293,Expert,722.0,BAO_0000219
2756,,,,1,H,108,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",8,CHEMBL617753,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2757,,,,1,H,108,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",8,CHEMBL617754,,,B,,,HEK293,Expert,722.0,BAO_0000219
2758,,,,1,D,108,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,9,CHEMBL617755,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2759,,,,1,H,108,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",8,CHEMBL617756,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2760,,,,1,H,108,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,8,CHEMBL617757,,,B,,,HEK293,Expert,722.0,BAO_0000219
2761,,,,1,H,108,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,8,CHEMBL617758,,,B,,,HEK293,Expert,722.0,BAO_0000219
2762,,,,1,H,108,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,8,CHEMBL617759,,,B,,,NIH3T3,Autocuration,723.0,BAO_0000219
2763,,,,1,H,108,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,8,CHEMBL617760,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2764,,,,1,H,108,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,8,CHEMBL617761,,,B,,,CHO-K1,Expert,485.0,BAO_0000219
2765,,,,1,D,108,,Binding affinity against 5-hydroxytryptamine 2C receptor,9,CHEMBL617762,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2766,,,,1,H,108,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,8,CHEMBL617763,,,B,,,,Autocuration,,BAO_0000357
2767,,,,1,H,108,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,8,CHEMBL857983,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2768,,,,1,H,108,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,8,CHEMBL617764,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2769,,,,1,H,108,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,8,CHEMBL617765,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
2770,,,,1,H,108,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,8,CHEMBL617766,,,F,,,,Autocuration,,BAO_0000019
2771,,Hippocampus,,1,H,108,10000000.0,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,8,CHEMBL617767,,,F,,,,Autocuration,,BAO_0000221
2772,,,,1,H,108,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,8,CHEMBL617768,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2773,,,,1,H,108,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",8,CHEMBL617769,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2774,,,,1,H,11864,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,8,CHEMBL858023,,,B,,,,Autocuration,,BAO_0000357
2775,,Stomach,,1,H,11864,945.0,Binding affinity analysed on 5-HT 2C in rat stomach fundus,8,CHEMBL617770,,,B,,,,Autocuration,,BAO_0000019
2776,,Stomach,,1,H,11864,945.0,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,8,CHEMBL617771,,,B,,,,Autocuration,,BAO_0000019
2777,,,,1,H,11864,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,8,CHEMBL617772,,,F,,,A9,Autocuration,625.0,BAO_0000219
2778,,,,1,H,11864,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,8,CHEMBL617773,,,B,,,NIH3T3,Autocuration,723.0,BAO_0000219
2779,,,,1,H,11864,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,8,CHEMBL617850,,,B,,,NIH3T3,Autocuration,723.0,BAO_0000219
2780,,,,1,H,11864,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,8,CHEMBL617851,,,B,,,NIH3T3,Autocuration,723.0,BAO_0000219
2781,,,,1,H,11864,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,8,CHEMBL617852,,,F,,,,Autocuration,,BAO_0000019
2782,,Stomach,,1,H,12689,945.0,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,8,CHEMBL858024,Mus musculus,,B,10090.0,,,Autocuration,,BAO_0000019
2783,,Stomach,,1,D,12689,945.0,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,9,CHEMBL617853,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2784,,,,1,H,108,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,8,CHEMBL617854,,,B,,,,Expert,,BAO_0000357
2785,,,,1,H,108,,Binding affinity for 5-hydroxytryptamine 2C receptor,8,CHEMBL873477,Sus scrofa,,B,9823.0,,,Expert,,BAO_0000357
2786,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 2C receptor,8,CHEMBL617855,,,B,,,,Expert,,BAO_0000357
2787,,,,1,H,108,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,8,CHEMBL617856,,,B,,,,Expert,,BAO_0000019
2788,,,,1,H,108,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,8,CHEMBL617857,,,B,,,,Autocuration,,BAO_0000019
2789,,,,1,H,108,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,8,CHEMBL617858,,,B,,,,Autocuration,,BAO_0000249
2790,,,,1,H,108,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,8,CHEMBL617859,,,B,,,,Autocuration,,BAO_0000357
2791,,,,1,H,108,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,8,CHEMBL617860,,,B,,,,Autocuration,,BAO_0000357
2792,,,,1,H,108,,Binding activity radioligand.,8,CHEMBL617861,,,B,,,,Autocuration,,BAO_0000357
2793,,,,1,H,108,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,8,CHEMBL617862,,,B,,,,Expert,,BAO_0000019
2794,,,,1,H,108,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,8,CHEMBL617863,,,B,,,,Autocuration,,BAO_0000019
2795,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,8,CHEMBL617864,,,B,,,,Autocuration,,BAO_0000249
2796,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,8,CHEMBL617649,,,B,,,,Autocuration,,BAO_0000249
2797,,,,1,H,108,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,8,CHEMBL617650,Sus scrofa,,F,9823.0,,,Expert,,BAO_0000019
2798,,,,1,H,108,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,8,CHEMBL617651,Sus scrofa,,F,9823.0,,,Expert,,BAO_0000019
2799,,,,1,H,108,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,8,CHEMBL617652,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
2800,,,,1,H,108,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,8,CHEMBL857072,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000019
2801,,,,1,H,108,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,8,CHEMBL617653,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
2802,,,,1,H,12687,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,8,CHEMBL617654,,,B,,,,Autocuration,,BAO_0000019
2803,,,,1,H,12689,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,8,CHEMBL617655,,,F,,,,Autocuration,,BAO_0000019
2804,,,,1,H,12689,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,8,CHEMBL617656,,,B,,,,Expert,,BAO_0000357
2805,,,,1,H,12689,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,8,CHEMBL617657,,,B,,,,Autocuration,,BAO_0000357
2806,,,,1,H,12689,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,8,CHEMBL617658,,,B,,,,Autocuration,,BAO_0000357
2807,,,,1,D,12689,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,9,CHEMBL617659,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2808,,,,1,D,12689,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,9,CHEMBL617838,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2809,,,,1,D,12689,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,9,CHEMBL617839,Rattus norvegicus,Brain membranes,B,10116.0,,,Expert,,BAO_0000249
2810,,,,1,H,12689,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,8,CHEMBL617840,,,B,,,,Autocuration,,BAO_0000357
2811,,,,1,H,12689,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,8,CHEMBL617841,,,B,,,,Autocuration,,BAO_0000019
2812,,,,1,H,12689,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,8,CHEMBL875915,,,B,,,,Autocuration,,BAO_0000019
2813,,,,1,H,12689,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,8,CHEMBL617842,,,B,,In vitro,,Expert,,BAO_0000219
2814,,,,1,H,12689,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,8,CHEMBL617843,,,B,,,NIH3T3,Expert,723.0,BAO_0000219
2815,,,,1,H,12689,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,8,CHEMBL617844,,,B,,,,Expert,,BAO_0000357
2816,,,,1,H,12689,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,8,CHEMBL617845,,,B,,,,Expert,,BAO_0000357
2817,,,,1,H,12689,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,8,CHEMBL617846,,,B,,,NIH3T3,Expert,723.0,BAO_0000219
2818,,,,1,H,12689,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,8,CHEMBL617847,,,B,,,,Autocuration,,BAO_0000357
2819,,,,1,H,12689,,Binding affinity against 5-hydroxytryptamine 2C receptor,8,CHEMBL617848,,,B,,,,Expert,,BAO_0000357
2820,,,,1,H,12689,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,8,CHEMBL617849,,,B,,,,Autocuration,,BAO_0000357
2821,,,,1,H,12689,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,8,CHEMBL621507,,,B,,,,Expert,,BAO_0000357
2822,,,,1,H,12689,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,8,CHEMBL621508,,,B,,,,Expert,,BAO_0000357
2823,,,,1,H,12689,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,8,CHEMBL621509,,,B,,,,Autocuration,,BAO_0000019
2824,,,,1,H,12689,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,8,CHEMBL621510,,,B,,,,Autocuration,,BAO_0000019
2825,,,,1,H,12689,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,8,CHEMBL621511,,,B,,,,Autocuration,,BAO_0000019
2826,,,,1,H,12689,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,8,CHEMBL621512,,,B,,,A9,Expert,625.0,BAO_0000219
2827,,,,1,H,12689,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,8,CHEMBL621513,,,B,,,,Autocuration,,BAO_0000357
2828,,,,1,H,12689,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,8,CHEMBL621514,,,B,,,,Expert,,BAO_0000357
2829,,,,1,H,12689,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,8,CHEMBL621515,,,B,,In vitro,,Expert,,BAO_0000219
2830,,,,1,H,12689,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,8,CHEMBL621516,,,B,,,,Autocuration,,BAO_0000219
2831,,Caudate-putamen,,1,H,12689,5383.0,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,8,CHEMBL621517,,,B,,,,Autocuration,,BAO_0000019
2832,,,,1,H,12689,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,8,CHEMBL621518,,,B,,,,Autocuration,,BAO_0000357
2833,,,,1,H,12689,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,8,CHEMBL621519,,,B,,,,Autocuration,,BAO_0000019
2834,,,,1,H,12689,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,8,CHEMBL621520,,,B,,,,Autocuration,,BAO_0000357
2835,,,,1,H,12689,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,8,CHEMBL621521,,,B,,,,Autocuration,,BAO_0000357
2836,,,,1,H,12689,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,8,CHEMBL621522,,,B,,,,Autocuration,,BAO_0000357
2837,,,,1,H,12689,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,8,CHEMBL621523,,,B,,,,Expert,,BAO_0000219
2838,,,,1,H,12689,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,8,CHEMBL621524,,,B,,,,Autocuration,,BAO_0000357
2839,,,,1,D,12689,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,9,CHEMBL621525,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2840,,,,1,H,12689,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,8,CHEMBL872921,,,B,,,,Autocuration,,BAO_0000357
2841,,,,1,H,12689,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,8,CHEMBL621526,,,B,,,,Autocuration,,BAO_0000357
2842,,,,1,H,12689,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,8,CHEMBL621527,,,B,,,,Expert,,BAO_0000219
2843,,,,1,D,12689,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,9,CHEMBL617865,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2844,,,,1,H,12689,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,8,CHEMBL617866,,,B,,,,Autocuration,,BAO_0000357
2845,,,,1,H,12689,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,8,CHEMBL617867,,,B,,,,Autocuration,,BAO_0000019
2846,,,,1,H,12689,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,8,CHEMBL617487,,,B,,,,Autocuration,,BAO_0000357
2847,,,,1,H,12689,,Binding affinity for 5-hydroxytryptamine 2C receptor,8,CHEMBL617488,,,B,,,,Expert,,BAO_0000357
2848,,,,1,H,12689,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,8,CHEMBL617489,,,B,,,,Autocuration,,BAO_0000357
2849,,,,1,H,12689,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,8,CHEMBL617490,,,B,,,,Autocuration,,BAO_0000019
2850,,,,1,H,12689,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,8,CHEMBL617491,,,B,,,,Autocuration,,BAO_0000019
2851,,,,1,H,12689,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,8,CHEMBL617492,,,B,,,,Autocuration,,BAO_0000019
2852,,,,1,H,12689,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,8,CHEMBL617493,,,B,,,,Autocuration,,BAO_0000019
2853,,,,1,H,12689,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,8,CHEMBL617494,,,B,,,,Autocuration,,BAO_0000357
2854,,,,1,D,12689,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,9,CHEMBL617495,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
2855,,,,1,H,12689,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,8,CHEMBL617496,,,B,,,,Autocuration,,BAO_0000357
2856,,,,1,H,12689,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,8,CHEMBL617497,,,B,,,CHO-K1,Autocuration,485.0,BAO_0000219
2857,,,,1,H,12689,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,8,CHEMBL617498,,,B,,,,Autocuration,,BAO_0000357
2858,,,,1,H,12689,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,8,CHEMBL617499,,,B,,,,Autocuration,,BAO_0000357
2859,,,,1,H,12689,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,8,CHEMBL617500,,,F,,,,Autocuration,,BAO_0000019
2860,,,,1,H,108,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,8,CHEMBL617501,,,B,,,,Autocuration,,BAO_0000357
2861,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 2C receptor,8,CHEMBL617502,,,B,,,,Expert,,BAO_0000357
2862,,,,1,H,227,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,8,CHEMBL617503,,,B,,,,Autocuration,,BAO_0000357
2863,,,,1,H,227,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,8,CHEMBL617504,,,B,,,,Autocuration,,BAO_0000357
2864,,,,1,H,227,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,8,CHEMBL617406,,,B,,,,Autocuration,,BAO_0000357
2865,,,,1,D,227,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,9,CHEMBL617407,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000019
2866,,,,1,H,227,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,8,CHEMBL617408,,,B,,,,Autocuration,,BAO_0000357
2867,,,,1,H,227,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,8,CHEMBL617409,,,B,,,,Autocuration,,BAO_0000357
2868,,,,1,H,227,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,8,CHEMBL617410,,,B,,,,Autocuration,,BAO_0000357
2869,,,,1,H,227,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,8,CHEMBL617411,,,B,,,,Autocuration,,BAO_0000357
2870,,,,1,H,227,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,8,CHEMBL617412,,,B,,,,Autocuration,,BAO_0000019
2871,,,,1,D,227,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,9,CHEMBL617774,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2872,,,,1,D,227,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,9,CHEMBL617775,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2873,,,,1,D,227,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,9,CHEMBL617776,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2874,,,,1,D,227,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9,CHEMBL617777,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
2875,,,,1,D,227,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9,CHEMBL617778,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
2876,,,,1,H,227,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",8,CHEMBL617779,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2877,,,,1,H,227,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,8,CHEMBL617780,,,B,,,HEK293,Expert,722.0,BAO_0000219
2878,,,,1,H,227,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",8,CHEMBL617781,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2879,,,,1,D,227,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,9,CHEMBL617782,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2880,,,,1,D,227,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,9,CHEMBL617783,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2881,,,,1,H,227,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,8,CHEMBL617784,,,B,,,,Autocuration,,BAO_0000357
2882,,,,1,H,227,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,8,CHEMBL617785,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2883,,,,1,H,227,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,8,CHEMBL857984,,,B,,,HEK293,Expert,722.0,BAO_0000219
2884,,,,1,H,227,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,8,CHEMBL617786,,,B,,,HEK293,Expert,722.0,BAO_0000219
2885,,,,1,H,227,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,8,CHEMBL617787,,,B,,,HEK293,Expert,722.0,BAO_0000219
2886,,,,1,D,227,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,9,CHEMBL617788,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2887,,,,1,D,227,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,9,CHEMBL617789,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
2888,,,,1,H,227,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,8,CHEMBL617790,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2889,,,,1,H,227,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,8,CHEMBL617791,,,B,,,CHO-K1,Expert,485.0,BAO_0000219
2890,,,,1,H,227,,Binding affinity against 5-hydroxytryptamine 2B receptor,8,CHEMBL617608,,,B,,,,Expert,,BAO_0000357
2891,,,,1,H,227,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,8,CHEMBL617609,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2892,,,,1,H,227,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,8,CHEMBL617610,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2893,,,,1,H,227,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,8,CHEMBL617611,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2894,,,,1,H,227,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",8,CHEMBL617612,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2895,,,,1,H,227,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",8,CHEMBL617613,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
2896,,,,1,H,227,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,8,CHEMBL617614,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
2897,,Stomach,,1,H,12688,945.0,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,8,CHEMBL617615,,,B,,,,Expert,,BAO_0000019
2898,,Stomach,,1,H,12688,945.0,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,8,CHEMBL858114,,,B,,,,Expert,,BAO_0000357
2899,,Stomach,,1,H,12688,945.0,Affinity against serotonergic receptor in the isolated rat stomach fundus,8,CHEMBL617616,,,B,,,,Autocuration,,BAO_0000357
2900,,Stomach,,1,D,12688,945.0,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,9,CHEMBL617617,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
2901,,,,1,D,12688,,Antagonistic against 5-hydroxytryptamine 2B receptor,9,CHEMBL875914,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
2902,,Stomach,,1,H,12688,945.0,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,8,CHEMBL617618,,,F,,,,Autocuration,,BAO_0000019
2903,,Stomach,,1,D,12688,945.0,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,9,CHEMBL617619,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2904,,,,1,H,12688,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,8,CHEMBL617620,,,F,,,,Autocuration,,BAO_0000019
2905,,,,1,H,12688,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,8,CHEMBL617621,,,F,,,,Autocuration,,BAO_0000019
2906,,,,1,H,12688,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,8,CHEMBL617622,,,F,,,,Autocuration,,BAO_0000019
2907,,Stomach,,1,D,12688,945.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,9,CHEMBL617623,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2908,,Stomach,,1,D,12688,945.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,9,CHEMBL617624,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2909,,Stomach,,1,D,12688,945.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,9,CHEMBL617625,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2910,,Stomach,,1,D,12688,945.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,9,CHEMBL617626,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
2911,,Stomach,,1,H,12688,945.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,8,CHEMBL617627,,,F,,,,Autocuration,,BAO_0000019
2912,,Stomach,,1,H,12688,945.0,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,8,CHEMBL617628,,,F,,,,Expert,,BAO_0000019
2913,,Stomach,,1,H,12688,945.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,8,CHEMBL617629,,,F,,,,Autocuration,,BAO_0000019
2914,,Stomach,,1,H,12688,945.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,8,CHEMBL858115,,,F,,,,Autocuration,,BAO_0000019
2915,,Stomach,,1,D,12688,945.0,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,9,CHEMBL617630,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
2916,,Thoracic aorta,,1,H,12688,1515.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,8,CHEMBL617631,,,F,,,,Autocuration,,BAO_0000019
2917,,,,1,H,12688,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,8,CHEMBL617632,,,B,,,,Autocuration,,BAO_0000357
2918,,,,1,H,12688,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,8,CHEMBL617633,,,B,,,,Expert,,BAO_0000357
2919,,,,1,H,12688,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,8,CHEMBL617634,,,B,,,,Autocuration,,BAO_0000357
2920,,,,1,H,12688,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,8,CHEMBL617635,,,B,,,,Autocuration,,BAO_0000357
2922,,Stomach,,1,D,12688,945.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,9,CHEMBL617637,Rattus norvegicus,,F,10116.0,,,Autocuration,,BAO_0000019
2923,,,,1,H,227,,Binding affinity against 5-hydroxytryptamine 1A receptor,8,CHEMBL617638,,,B,,,,Autocuration,,BAO_0000357
2924,,,,1,H,227,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,8,CHEMBL617639,,,B,,,,Autocuration,,BAO_0000357
2925,,,,1,H,227,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,8,CHEMBL617640,,,B,,,,Autocuration,,BAO_0000357
2926,,,,1,H,227,,Evaluated for the binding affinity to 5-HT 2B receptor,8,CHEMBL617641,,,B,,,,Autocuration,,BAO_0000357
2927,,,,1,H,227,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,8,CHEMBL617642,,,B,,,,Autocuration,,BAO_0000357
2928,,,,1,H,227,,Binding affinities against 5-hydroxytryptamine 2B receptor,8,CHEMBL617643,,,B,,,,Autocuration,,BAO_0000357
2929,,,,1,H,227,,Binding affinities towards 5-hydroxytryptamine 2B receptor,8,CHEMBL617644,,,B,,,,Autocuration,,BAO_0000357
2930,,,,1,H,227,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,8,CHEMBL617645,,,B,,,,Autocuration,,BAO_0000357
2931,,,,1,H,108,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,8,CHEMBL617646,,,B,,,,Expert,,BAO_0000357
2932,,,,1,H,108,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,8,CHEMBL617647,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
2933,,,,1,H,108,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,8,CHEMBL617648,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
2934,,,,1,H,108,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,8,CHEMBL617875,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
2935,,,,1,H,108,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,8,CHEMBL617876,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
2936,,,,1,H,108,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,8,CHEMBL617877,Bos taurus,,B,9913.0,,,Expert,,BAO_0000357
2937,,,,1,H,108,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,8,CHEMBL617878,Bos taurus,,B,9913.0,,,Expert,,BAO_0000357
2938,,,,1,H,108,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,8,CHEMBL617879,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
2939,,,,1,H,108,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,8,CHEMBL617880,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000019
2940,,Striatum,,1,D,20033,2435.0,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,9,CHEMBL617881,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
2941,,,,1,H,51,,Binding affinity against 5-HT1A receptor,8,CHEMBL857073,,,B,,,,Autocuration,,BAO_0000357
2942,,,,1,H,108,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,8,CHEMBL617882,,,F,,,CHO,Expert,449.0,BAO_0000219
2943,,,,1,D,108,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,9,CHEMBL617883,Homo sapiens,,F,9606.0,,CHO,Expert,449.0,BAO_0000219
2944,,,,1,H,108,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,8,CHEMBL617884,,,F,,,,Autocuration,,BAO_0000219
2945,,,,1,H,108,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,8,CHEMBL617885,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2946,,,,1,H,108,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",8,CHEMBL617886,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2947,,,,1,D,108,,Inhibition of human 5-hydroxytryptamine 2C receptor,9,CHEMBL617887,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2948,,,,1,H,108,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),8,CHEMBL617888,,,B,,,,Autocuration,,BAO_0000357
2949,,,,1,H,108,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,8,CHEMBL617889,,,B,,,,Autocuration,,BAO_0000019
2950,,,,1,H,108,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,8,CHEMBL617890,,,B,,,,Autocuration,,BAO_0000357
2951,,,,1,H,108,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,8,CHEMBL617891,,,B,,,,Autocuration,,BAO_0000357
2952,,,,1,H,108,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,8,CHEMBL617892,,,B,,,,Autocuration,,BAO_0000357
2953,,,,1,H,108,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,8,CHEMBL617893,,,B,,,CHO,Expert,449.0,BAO_0000219
2954,,,,1,H,108,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,8,CHEMBL617894,,,B,,,CHO,Expert,449.0,BAO_0000219
2955,,,,1,H,108,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,8,CHEMBL617895,,,B,,,CHO,Expert,449.0,BAO_0000219
2956,,,,1,H,108,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,8,CHEMBL617896,,,B,,,CHO,Autocuration,449.0,BAO_0000219
2957,,,,1,D,108,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,9,CHEMBL617897,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2958,,,,1,H,108,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,8,CHEMBL617898,,,F,,,,Autocuration,,BAO_0000019
2959,,,,1,H,108,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,8,CHEMBL617899,,,F,,,,Autocuration,,BAO_0000019
2960,,,,1,H,108,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,8,CHEMBL617900,Rattus norvegicus,,B,10116.0,,CHO,Expert,449.0,BAO_0000219
2961,,,,1,H,108,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,8,CHEMBL617901,,,F,,,,Autocuration,,BAO_0000019
2962,,,,1,H,108,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,8,CHEMBL617902,,,F,,,,Autocuration,,BAO_0000019
2963,,,,1,H,108,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,8,CHEMBL617903,,,F,,,,Autocuration,,BAO_0000019
2964,,,,1,H,108,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,8,CHEMBL617904,,,B,,,,Autocuration,,BAO_0000357
2965,,,,1,H,108,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,8,CHEMBL617905,,,B,,,,Autocuration,,BAO_0000357
2966,,,,1,H,108,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,8,CHEMBL617906,,,B,,,,Autocuration,,BAO_0000357
2967,,,,1,H,108,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,8,CHEMBL617907,,,B,,,,Autocuration,,BAO_0000357
2968,,,,1,H,108,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,8,CHEMBL617908,,,B,,,,Autocuration,,BAO_0000357
2969,,,,1,H,108,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,8,CHEMBL620617,,,B,,,CHO,Expert,449.0,BAO_0000219
2970,,,,1,D,108,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,9,CHEMBL620618,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000019
2971,,,,1,H,108,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,8,CHEMBL620619,,,B,,,,Expert,,BAO_0000357
2972,,,,1,D,108,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,9,CHEMBL620620,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
2973,,,,1,H,108,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,8,CHEMBL620621,,,B,,,,Autocuration,,BAO_0000357
2974,,,,1,D,104698,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,7,CHEMBL872920,Rattus norvegicus,Membranes,B,10116.0,,,Autocuration,,BAO_0000249
2975,,,,1,H,104698,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,6,CHEMBL620622,,,B,,,,Autocuration,,BAO_0000223
2976,,,,1,D,104698,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,7,CHEMBL620623,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2977,,,,1,H,104698,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,6,CHEMBL620624,,,B,,,,Autocuration,,BAO_0000019
2978,,,,1,H,104698,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,6,CHEMBL620625,,,B,,,,Autocuration,,BAO_0000019
2979,,,,1,H,104698,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,6,CHEMBL620626,,,B,,,,Autocuration,,BAO_0000219
2980,,,,1,H,104698,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,6,CHEMBL621307,,,B,,,,Autocuration,,BAO_0000019
2981,,,,1,H,104698,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,6,CHEMBL621308,,,B,,,,Autocuration,,BAO_0000019
2982,,,,1,H,104698,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,6,CHEMBL621309,,,B,,,,Autocuration,,BAO_0000223
2983,,,,1,H,104698,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,6,CHEMBL621310,,,B,,,,Autocuration,,BAO_0000223
2984,,,,1,H,104698,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,6,CHEMBL621311,,,B,,,,Autocuration,,BAO_0000223
2985,,,,1,H,104698,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",6,CHEMBL621502,,,B,,,,Autocuration,,BAO_0000249
2986,,,,1,H,104698,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",6,CHEMBL621503,,,B,,,,Autocuration,,BAO_0000249
2987,,,,1,H,104698,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,6,CHEMBL621504,,Membranes,B,,,,Autocuration,,BAO_0000249
2988,,,,1,H,104698,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,6,CHEMBL621505,,,B,,,,Autocuration,,BAO_0000223
2989,,,,1,H,104698,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,6,CHEMBL621506,,,B,,,,Autocuration,,BAO_0000019
2990,,,,1,H,104698,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,6,CHEMBL619781,,,B,,,,Autocuration,,BAO_0000223
2991,,,,1,H,104698,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,6,CHEMBL619782,,,B,,,,Autocuration,,BAO_0000223
2992,,,,1,H,104698,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,6,CHEMBL619783,,,B,,,,Autocuration,,BAO_0000019
2993,,,,1,D,104698,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,7,CHEMBL619784,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
2994,,,,1,H,104698,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,6,CHEMBL619785,,,B,,,,Autocuration,,BAO_0000249
2995,,,,1,H,104698,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,6,CHEMBL619786,,,B,,,,Autocuration,,BAO_0000223
2996,,,,1,H,104698,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,6,CHEMBL619787,,,B,,,,Autocuration,,BAO_0000019
2997,,,,1,H,104698,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,6,CHEMBL872925,,,B,,,,Autocuration,,BAO_0000019
2998,,,,1,H,104698,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,6,CHEMBL619788,,,B,,,,Autocuration,,BAO_0000019
2999,,,,1,H,104698,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,6,CHEMBL619789,,,B,,,,Autocuration,,BAO_0000249
3000,,,,1,H,104698,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,6,CHEMBL619790,,,B,,,,Autocuration,,BAO_0000249
3001,,,,1,H,104698,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,6,CHEMBL619791,,,B,,,,Autocuration,,BAO_0000019
3002,,,,1,H,104698,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,6,CHEMBL619792,,,B,,,,Autocuration,,BAO_0000019
3003,,,,1,H,104698,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,6,CHEMBL619793,,Membranes,B,,,,Autocuration,,BAO_0000249
3004,,,,1,D,104698,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,7,CHEMBL619794,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000223
3005,,Brain,,1,H,104698,955.0,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,6,CHEMBL619795,,,B,,,,Autocuration,,BAO_0000221
3006,,,,1,H,104698,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,6,CHEMBL619796,,,B,,,,Autocuration,,BAO_0000019
3007,,,,1,H,104698,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,6,CHEMBL620448,,,B,,,,Autocuration,,BAO_0000223
3008,,,,1,H,104698,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,6,CHEMBL620449,,,B,,,,Autocuration,,BAO_0000223
3009,,,,1,H,104698,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,6,CHEMBL620450,,,B,,,,Autocuration,,BAO_0000223
3010,,,,1,H,104698,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,6,CHEMBL620451,,,B,,,,Autocuration,,BAO_0000223
3011,,,,1,H,104698,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,6,CHEMBL620631,,,B,,,,Autocuration,,BAO_0000223
3012,,,,1,H,104698,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,6,CHEMBL620632,,,B,,,,Autocuration,,BAO_0000019
3013,,,,1,H,104698,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,6,CHEMBL620633,,,B,,,,Autocuration,,BAO_0000019
3014,,,,1,H,104698,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,6,CHEMBL620634,,,B,,,,Autocuration,,BAO_0000223
3015,,,,1,H,104698,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,6,CHEMBL620635,,,B,,,,Autocuration,,BAO_0000019
3016,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,6,CHEMBL620636,,,F,,In vivo,,Autocuration,,BAO_0000218
3017,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,6,CHEMBL620637,,,F,,In vivo,,Autocuration,,BAO_0000218
3018,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,6,CHEMBL620638,,,F,,In vivo,,Autocuration,,BAO_0000218
3019,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,6,CHEMBL620639,,,F,,In vivo,,Autocuration,,BAO_0000218
3020,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,6,CHEMBL620640,,,F,,In vivo,,Autocuration,,BAO_0000218
3021,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,6,CHEMBL620641,,,F,,In vivo,,Autocuration,,BAO_0000218
3022,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,6,CHEMBL620642,,,F,,In vivo,,Autocuration,,BAO_0000218
3023,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,6,CHEMBL620643,,,F,,In vivo,,Autocuration,,BAO_0000218
3024,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,6,CHEMBL620644,,,F,,In vivo,,Autocuration,,BAO_0000218
3025,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,6,CHEMBL620645,,,F,,In vivo,,Autocuration,,BAO_0000218
3026,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,6,CHEMBL620646,,,F,,In vivo,,Autocuration,,BAO_0000218
3027,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,6,CHEMBL620647,,,F,,In vivo,,Autocuration,,BAO_0000218
3028,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,6,CHEMBL620648,,,F,,In vivo,,Autocuration,,BAO_0000218
3029,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,6,CHEMBL620649,,,F,,In vivo,,Autocuration,,BAO_0000218
3030,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,6,CHEMBL620650,,,F,,In vivo,,Autocuration,,BAO_0000218
3031,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,6,CHEMBL620651,,,F,,In vivo,,Autocuration,,BAO_0000218
3032,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,6,CHEMBL872875,,,F,,In vivo,,Autocuration,,BAO_0000218
3033,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,6,CHEMBL620652,,,F,,In vivo,,Autocuration,,BAO_0000218
3034,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,6,CHEMBL620653,,,F,,,,Autocuration,,BAO_0000019
3035,,,,1,H,104698,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,6,CHEMBL857076,,,B,,,,Autocuration,,BAO_0000019
3036,,,,1,D,104698,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,7,CHEMBL620654,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3037,,,,1,H,104698,,Binding activity radioligand.,6,CHEMBL620655,,,B,,,,Autocuration,,BAO_0000223
3038,,,,1,H,104698,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,6,CHEMBL620656,,Brain membranes,B,,,,Autocuration,,BAO_0000249
3039,,,,1,H,104698,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,6,CHEMBL620657,,Brain membranes,B,,,,Autocuration,,BAO_0000249
3040,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,8,CHEMBL620658,,,B,,,,Autocuration,,BAO_0000357
3041,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,8,CHEMBL620659,,,B,,,,Autocuration,,BAO_0000357
3042,,,,1,H,108,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,8,CHEMBL620660,,,B,,,,Autocuration,,BAO_0000357
3043,,,,1,H,108,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,8,CHEMBL620661,,,B,,,,Autocuration,,BAO_0000357
3044,,,,1,H,108,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,8,CHEMBL620662,,,B,,,,Autocuration,,BAO_0000357
3045,,,,1,H,108,,Affinity for 5-hydroxytryptamine 2C receptor,8,CHEMBL620663,,,B,,,,Expert,,BAO_0000357
3046,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,8,CHEMBL620664,,,B,,,,Autocuration,,BAO_0000357
3047,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,8,CHEMBL620665,,,B,,,,Expert,,BAO_0000357
3048,,,,1,H,108,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,8,CHEMBL620666,,,B,,,,Autocuration,,BAO_0000357
3049,,,,1,H,108,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,8,CHEMBL620667,,,B,,,,Autocuration,,BAO_0000357
3050,,,,1,H,108,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,8,CHEMBL620668,,,B,,,,Expert,,BAO_0000357
3051,,,,1,H,108,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,8,CHEMBL620669,,,B,,,,Autocuration,,BAO_0000357
3052,,,,1,H,108,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,8,CHEMBL620670,,,B,,,,Expert,,BAO_0000357
3053,,,,1,H,108,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,8,CHEMBL620671,,,B,,,,Autocuration,,BAO_0000357
3054,,,,1,H,108,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,8,CHEMBL620672,,,B,,,,Autocuration,,BAO_0000357
3055,,,,1,H,108,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,8,CHEMBL620673,,,B,,,,Autocuration,,BAO_0000357
3056,,,,1,H,108,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,8,CHEMBL620674,,,B,,,,Autocuration,,BAO_0000357
3057,,,,1,H,108,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,8,CHEMBL620675,,,B,,,,Autocuration,,BAO_0000357
3058,,,,1,H,108,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,8,CHEMBL620676,,,B,,,,Autocuration,,BAO_0000357
3059,,,,1,H,108,,Affinity against 5-hydroxytryptamine 2C receptor,8,CHEMBL621382,,,B,,,,Autocuration,,BAO_0000357
3060,,,,1,D,108,,Binding affinity against 5-hydroxytryptamine 2C receptor,9,CHEMBL621383,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3061,,,,1,H,108,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,8,CHEMBL621384,,,B,,,,Autocuration,,BAO_0000357
3062,,,,1,H,144,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,8,CHEMBL621385,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
3063,,,,1,H,144,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,8,CHEMBL617989,Bos taurus,,B,9913.0,,,Autocuration,,BAO_0000357
3064,,,,1,H,104714,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,4,CHEMBL617990,Cavia porcellus,,F,10141.0,,,Expert,,BAO_0000019
3065,,Ileum,,1,H,104714,2116.0,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,4,CHEMBL875085,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3066,,,,1,H,104714,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,4,CHEMBL617991,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3067,,,,1,H,104714,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,4,CHEMBL617992,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3068,,Ileum,,1,H,104714,2116.0,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,4,CHEMBL617993,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3069,,Ileum,,1,H,104714,2116.0,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,4,CHEMBL617994,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3070,,,,1,H,104714,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,4,CHEMBL617995,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3071,,,,1,H,104714,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,4,CHEMBL617996,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3072,,,,1,H,104714,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,4,CHEMBL617997,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3073,,,,1,H,104714,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,4,CHEMBL617998,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3074,,,,1,H,104714,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,4,CHEMBL617999,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3075,,,,1,H,104714,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,4,CHEMBL618000,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3076,,Ileum,,1,H,104714,2116.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",4,CHEMBL617815,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000221
3077,,Ileum,,1,H,104714,2116.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",4,CHEMBL617816,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000221
3078,,Ileum,,1,H,104714,2116.0,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,4,CHEMBL617817,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000221
3079,,Ileum,,1,H,104714,2116.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,4,CHEMBL617818,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3080,,Ileum,,1,H,104714,2116.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,4,CHEMBL617819,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3081,,,,1,H,104714,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,4,CHEMBL617820,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000223
3082,,Ileum,,1,H,104714,2116.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,4,CHEMBL617821,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3083,,Ileum,,1,H,104714,2116.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),4,CHEMBL617822,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000221
3084,,Ileum,,1,H,104714,2116.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),4,CHEMBL617823,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000221
3085,,Ileum,,1,H,104714,2116.0,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,4,CHEMBL617824,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000221
3086,,Ileum,,1,H,104714,2116.0,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,4,CHEMBL617825,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000221
3087,,Ileum,,1,H,104714,2116.0,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,4,CHEMBL617826,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000221
3088,,Ileum,,1,H,104714,2116.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,4,CHEMBL617827,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3089,,Ileum,,1,H,104714,2116.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),4,CHEMBL617828,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000221
3090,,Ileum,,1,H,104714,2116.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,4,CHEMBL617829,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3091,,Ileum,,1,H,104714,2116.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,4,CHEMBL617830,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3092,,Ileum,,1,H,104714,2116.0,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,4,CHEMBL617831,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3093,,Ileum,,1,H,104714,2116.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,4,CHEMBL617832,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3094,,,,1,U,22226,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,0,CHEMBL617833,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000019
3095,,,,1,H,51,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,8,CHEMBL617834,,,B,,,,Autocuration,,BAO_0000357
3096,,,,1,D,104714,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,5,CHEMBL617835,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000223
3097,,,,1,H,104714,,Binding affinity towards 5-HT3 receptor,4,CHEMBL617836,,,B,,,,Autocuration,,BAO_0000223
3098,,,,1,H,104714,,Binding activity radioligand.,4,CHEMBL617837,,,B,,,,Autocuration,,BAO_0000223
3099,,,,1,H,104714,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,4,CHEMBL620392,,,B,,,,Autocuration,,BAO_0000019
3100,,,,1,H,104714,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,4,CHEMBL620393,,,B,,,,Autocuration,,BAO_0000223
3101,,,,1,H,104714,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,4,CHEMBL620394,,,B,,,,Autocuration,,BAO_0000223
3102,,,,1,H,104714,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,4,CHEMBL620395,,,B,,,,Autocuration,,BAO_0000223
3103,,,,1,U,22226,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,0,CHEMBL620396,,,B,,,,Autocuration,,BAO_0000019
3104,,,,1,H,105030,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,4,CHEMBL620582,,,B,,,NG108-15,Expert,433.0,BAO_0000219
3105,,,,1,H,105030,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",4,CHEMBL620583,,,B,,In vivo,,Autocuration,,BAO_0000218
3106,,,,1,H,105030,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),4,CHEMBL620584,,,B,,,,Autocuration,,BAO_0000019
3107,,,,1,H,105030,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,4,CHEMBL620585,,,B,,,,Autocuration,,BAO_0000224
3108,,,,1,H,105030,,Compound was evaluated for the binding affinity at 5- HT3 receptor,4,CHEMBL620586,,,B,,,,Autocuration,,BAO_0000224
3109,,,,1,H,105030,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),4,CHEMBL620587,,,B,,,,Autocuration,,BAO_0000019
3110,,,,1,H,105030,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,4,CHEMBL620588,,,B,,,,Autocuration,,BAO_0000019
3111,,,,1,H,105030,,5-hydroxytryptamine 3 receptor agonism in mouse,4,CHEMBL620589,,,F,,,,Autocuration,,BAO_0000218
3112,,,,1,H,105030,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,4,CHEMBL620590,,,B,,,,Autocuration,,BAO_0000219
3113,,,,1,H,105030,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,4,CHEMBL617956,,,B,,,,Autocuration,,BAO_0000019
3114,,,,1,H,105030,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,4,CHEMBL617957,,,B,,,,Autocuration,,BAO_0000019
3115,,,,1,H,105030,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,4,CHEMBL617958,,,B,,,,Autocuration,,BAO_0000224
3116,,,,1,H,105030,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,4,CHEMBL617959,,,B,,,,Autocuration,,BAO_0000219
3117,,,,1,H,105030,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,4,CHEMBL617960,,,B,,,,Autocuration,,BAO_0000219
3118,,,,1,H,105030,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,4,CHEMBL617961,,,B,,,,Autocuration,,BAO_0000224
3119,,,,1,H,105030,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,4,CHEMBL617962,,,B,,In vitro,,Autocuration,,BAO_0000219
3120,,,,1,H,105030,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,4,CHEMBL617963,,,B,,,N1E-115,Autocuration,339.0,BAO_0000219
3121,,,,1,H,11765,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,8,CHEMBL617964,,,B,,,,Autocuration,,BAO_0000019
3122,,,,1,H,11765,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,8,CHEMBL617965,,,B,,,,Autocuration,,BAO_0000219
3123,,,,1,D,10630,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,9,CHEMBL617966,Mus musculus,,B,10090.0,,,Autocuration,,BAO_0000357
3124,,,,1,H,17106,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,8,CHEMBL857074,,,B,,,,Autocuration,,BAO_0000019
3125,,,,1,H,144,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,8,CHEMBL617967,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
3126,,,,1,H,144,,Binding activity radioligand.,8,CHEMBL617968,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000357
3127,,,,1,H,104714,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,4,CHEMBL617969,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000223
3128,,,,1,H,104714,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,4,CHEMBL617970,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000223
3129,,,,1,H,104714,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,4,CHEMBL617971,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000223
3130,,,,1,H,104714,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,4,CHEMBL617972,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
3131,,,,1,H,104714,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),4,CHEMBL617973,Oryctolagus cuniculus,,F,9986.0,,,Autocuration,,BAO_0000019
3132,,,,1,H,104714,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),4,CHEMBL617974,Oryctolagus cuniculus,,F,9986.0,,,Autocuration,,BAO_0000019
3133,,Ileum,,1,H,104714,2116.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),4,CHEMBL617975,Oryctolagus cuniculus,,F,9986.0,,,Autocuration,,BAO_0000221
3134,,,,1,H,104714,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),4,CHEMBL617976,Oryctolagus cuniculus,,F,9986.0,,,Autocuration,,BAO_0000019
3135,,,,1,H,104714,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),4,CHEMBL617977,Oryctolagus cuniculus,,F,9986.0,,,Autocuration,,BAO_0000019
3136,,,,1,H,104714,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),4,CHEMBL617978,Oryctolagus cuniculus,,F,9986.0,,,Autocuration,,BAO_0000019
3137,,,,1,H,104714,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),4,CHEMBL617979,Oryctolagus cuniculus,,F,9986.0,,,Autocuration,,BAO_0000019
3138,,,,1,H,104714,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,4,CHEMBL617980,Oryctolagus cuniculus,,B,9986.0,,CHO,Autocuration,449.0,BAO_0000219
3139,,,,1,D,104698,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,7,CHEMBL617981,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3140,,,,1,H,12020,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),8,CHEMBL617982,,,B,,,,Autocuration,,BAO_0000019
3141,,,,1,H,12020,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),8,CHEMBL617983,,,B,,,,Autocuration,,BAO_0000357
3142,,,,1,D,104698,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,7,CHEMBL617984,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3143,,,,1,H,104698,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",6,CHEMBL617985,,,B,,,,Autocuration,,BAO_0000019
3144,,Heart,,1,H,104698,948.0,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",6,CHEMBL617986,,,F,,In vivo,,Autocuration,,BAO_0000218
3145,,Heart,,1,H,104698,948.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",6,CHEMBL617987,,,F,,,,Autocuration,,BAO_0000019
3146,,Heart,,1,H,104698,948.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",6,CHEMBL617988,,,F,,,,Autocuration,,BAO_0000019
3147,,Heart,,1,H,104698,948.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",6,CHEMBL617792,,,F,,,,Autocuration,,BAO_0000019
3148,,Heart,,1,H,104698,948.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",6,CHEMBL617793,,,F,,,,Autocuration,,BAO_0000019
3149,,,,1,H,104698,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",6,CHEMBL617794,,,F,,,,Autocuration,,BAO_0000019
3150,,,,1,H,104698,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",6,CHEMBL617795,,,F,,,,Autocuration,,BAO_0000019
3151,,,,1,H,104698,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",6,CHEMBL617796,,,F,,,,Autocuration,,BAO_0000019
3152,,,,1,H,104698,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",6,CHEMBL617797,,,F,,,,Autocuration,,BAO_0000019
3153,,,,1,D,104698,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),7,CHEMBL617798,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
3154,,,,1,H,104698,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),6,CHEMBL617799,,,F,,In vivo,,Autocuration,,BAO_0000218
3155,,,,1,D,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,7,CHEMBL617800,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
3156,,,,1,D,104698,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,7,CHEMBL617801,Rattus norvegicus,,F,10116.0,,,Autocuration,,BAO_0000019
3157,,,,1,D,104698,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,7,CHEMBL617802,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
3158,,,,1,D,104698,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),7,CHEMBL617803,Rattus norvegicus,,F,10116.0,,,Autocuration,,BAO_0000019
3159,,,,1,H,104698,,Binding affinity towards 5-HT3 receptor in rat was evaluated,6,CHEMBL617804,,,B,,,,Autocuration,,BAO_0000019
3160,,,,1,D,104698,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,7,CHEMBL617805,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3161,,,,1,H,104698,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,6,CHEMBL617806,,,B,,,,Autocuration,,BAO_0000223
3162,,,,1,H,104698,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,6,CHEMBL617807,,,B,,,,Autocuration,,BAO_0000019
3163,,,,1,H,104698,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,6,CHEMBL617808,,,B,,,,Autocuration,,BAO_0000019
3164,,,,1,H,104698,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,6,CHEMBL617809,,,B,,,,Autocuration,,BAO_0000249
3165,,,,1,H,104698,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,6,CHEMBL617810,,,B,,,,Autocuration,,BAO_0000019
3166,,Brain,,1,H,104698,955.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,6,CHEMBL617811,,,B,,,,Autocuration,,BAO_0000249
3167,,Brain,,1,H,104698,955.0,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,6,CHEMBL617812,,,B,,,,Autocuration,,BAO_0000221
3168,,,,1,H,104698,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,6,CHEMBL617813,,,B,,,,Autocuration,,BAO_0000249
3169,,,,1,H,104698,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,6,CHEMBL617814,,,B,,,,Autocuration,,BAO_0000249
3170,,,,1,H,104698,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,6,CHEMBL617698,,,B,,,,Autocuration,,BAO_0000019
3171,,,,1,D,104698,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,7,CHEMBL617699,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3172,,,,1,D,104698,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,7,CHEMBL617700,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3173,,,,1,D,104698,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,7,CHEMBL617701,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000223
3174,,,,1,H,104698,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,6,CHEMBL617702,,,B,,,,Autocuration,,BAO_0000019
3175,,,,1,H,104698,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",6,CHEMBL617703,,Membranes,B,,,,Autocuration,,BAO_0000249
3176,,,,1,D,104698,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,7,CHEMBL617704,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3177,,,,1,H,104698,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,6,CHEMBL617705,,,B,,,,Autocuration,,BAO_0000223
3178,,,,1,D,104698,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,7,CHEMBL617706,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000223
3179,,,,1,H,104698,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),6,CHEMBL617707,,,B,,,NG108-15,Autocuration,433.0,BAO_0000219
3180,,,,1,H,104698,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,6,CHEMBL617708,,,B,,,NG108-15,Autocuration,433.0,BAO_0000219
3181,,,,1,H,104698,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,6,CHEMBL617709,,,B,,,,Autocuration,,BAO_0000019
3182,,,,1,H,104698,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,6,CHEMBL617710,,,B,,,,Autocuration,,BAO_0000019
3183,,,,1,H,104698,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,6,CHEMBL882925,,,B,,,,Autocuration,,BAO_0000019
3184,,,,1,H,104698,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,6,CHEMBL617711,,,B,,,,Autocuration,,BAO_0000019
3185,,,,1,H,104698,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,6,CHEMBL617712,,,F,,,,Autocuration,,BAO_0000019
3186,,,,1,D,104698,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,7,CHEMBL617713,Rattus norvegicus,,F,10116.0,,,Autocuration,,BAO_0000019
3187,,,,1,H,104698,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",6,CHEMBL617714,,,F,,,,Autocuration,,BAO_0000019
3188,,,,1,H,104698,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,6,CHEMBL617715,,,F,,,,Autocuration,,BAO_0000218
3189,,,,1,H,104698,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,6,CHEMBL617716,,,F,,In vivo,,Autocuration,,BAO_0000218
3190,,,,1,H,104698,,Inhibition of 5-HT evoked reflex bradycardia in rat.,6,CHEMBL617717,,,F,,,,Autocuration,,BAO_0000218
3191,,,,1,H,104698,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617718,,,F,,In vivo,,Autocuration,,BAO_0000218
3192,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617719,,,F,,In vivo,,Autocuration,,BAO_0000218
3193,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),6,CHEMBL617720,,,F,,In vivo,,Autocuration,,BAO_0000218
3194,,,,1,D,104698,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,7,CHEMBL617721,Rattus norvegicus,,F,10116.0,In vivo,,Autocuration,,BAO_0000218
3195,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617722,,,F,,In vivo,,Autocuration,,BAO_0000218
3196,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,6,CHEMBL617723,,,F,,In vivo,,Autocuration,,BAO_0000218
3197,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617724,,,F,,In vivo,,Autocuration,,BAO_0000218
3198,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617725,,,F,,In vivo,,Autocuration,,BAO_0000218
3199,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617726,,,F,,In vivo,,Autocuration,,BAO_0000218
3200,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617727,,,F,,In vivo,,Autocuration,,BAO_0000218
3201,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617728,,,F,,In vivo,,Autocuration,,BAO_0000218
3202,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617729,,,F,,In vivo,,Autocuration,,BAO_0000218
3203,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,6,CHEMBL617730,,,F,,In vivo,,Autocuration,,BAO_0000218
3204,,,,1,H,104698,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617731,,,F,,In vivo,,Autocuration,,BAO_0000218
3205,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617732,,,F,,In vivo,,Autocuration,,BAO_0000218
3206,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617733,,,F,,In vivo,,Autocuration,,BAO_0000218
3207,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617734,,,F,,In vivo,,Autocuration,,BAO_0000218
3208,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,6,CHEMBL872874,,,F,,In vivo,,Autocuration,,BAO_0000218
3209,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,6,CHEMBL617735,,,F,,In vivo,,Autocuration,,BAO_0000218
3210,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,6,CHEMBL617736,,,F,,In vivo,,Autocuration,,BAO_0000218
3211,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,6,CHEMBL617737,,,F,,In vivo,,Autocuration,,BAO_0000218
3212,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,6,CHEMBL617738,,,F,,In vivo,,Autocuration,,BAO_0000218
3213,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617739,,,F,,In vivo,,Autocuration,,BAO_0000218
3214,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617740,,,F,,In vivo,,Autocuration,,BAO_0000218
3215,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617741,,,F,,In vivo,,Autocuration,,BAO_0000218
3216,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617742,,,F,,In vivo,,Autocuration,,BAO_0000218
3217,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617743,,,F,,In vivo,,Autocuration,,BAO_0000218
3218,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617744,,,F,,In vivo,,Autocuration,,BAO_0000218
3219,,,,1,H,104698,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,6,CHEMBL617745,,,F,,In vivo,,Autocuration,,BAO_0000218
3220,,,,1,H,104698,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",6,CHEMBL617746,,,F,,,,Autocuration,,BAO_0000218
3221,,,,1,H,104698,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",6,CHEMBL617747,,,F,,,,Autocuration,,BAO_0000218
3222,,,,1,H,104698,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,6,CHEMBL617748,,,F,,In vivo,,Autocuration,,BAO_0000218
3223,,,,1,H,104698,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,6,CHEMBL618909,,,F,,In vivo,,Autocuration,,BAO_0000218
3224,,,,1,H,104698,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,6,CHEMBL618910,,,F,,In vivo,,Autocuration,,BAO_0000218
3225,,,,1,H,104698,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,6,CHEMBL618911,,,F,,In vivo,,Autocuration,,BAO_0000218
3226,,,,1,H,104698,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,6,CHEMBL618912,,,F,,In vivo,,Autocuration,,BAO_0000218
3227,,,,1,H,104698,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),6,CHEMBL618913,,,F,,In vivo,,Autocuration,,BAO_0000218
3228,,,,1,H,104698,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,6,CHEMBL618914,,,F,,,,Autocuration,,BAO_0000019
3229,,,,1,H,104698,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,6,CHEMBL618915,,,F,,,,Autocuration,,BAO_0000019
3230,,,,1,D,104698,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,7,CHEMBL618916,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000223
3231,,,,1,H,104698,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,6,CHEMBL618917,,,F,,,,Autocuration,,BAO_0000019
3232,,Hippocampus,,1,D,104698,10000000.0,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,7,CHEMBL618918,,,B,,,,Intermediate,,BAO_0000221
3233,,,,1,D,104698,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,7,CHEMBL618919,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3234,,,,1,D,104698,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,7,CHEMBL618920,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3235,,,,1,H,104698,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,6,CHEMBL618921,,,B,,,,Autocuration,,BAO_0000223
3236,,,,1,H,104698,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,6,CHEMBL618922,,,B,,,,Autocuration,,BAO_0000019
3237,,,,1,H,104698,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,6,CHEMBL618923,,,B,,,,Autocuration,,BAO_0000019
3238,,,,1,H,104698,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,6,CHEMBL618924,,,B,,,,Autocuration,,BAO_0000019
3239,,,,1,H,104698,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,6,CHEMBL618925,,,B,,,,Autocuration,,BAO_0000019
3240,,,,1,H,104698,,Binding affinity towards 5-HT3 receptor in rat was evaluated,6,CHEMBL618926,,,B,,,,Autocuration,,BAO_0000019
3241,,Ileum,,1,D,20033,2116.0,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,9,CHEMBL618927,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3242,,Ileum,,1,D,20033,2116.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,9,CHEMBL618928,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3243,,Ileum,,1,D,20033,2116.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",9,CHEMBL618929,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3244,,Ileum,,1,D,20033,2116.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",9,CHEMBL618930,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3245,,Ileum,,1,D,20033,2116.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",9,CHEMBL618931,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3246,,Ileum,,1,D,20033,2116.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",9,CHEMBL619594,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3247,,Ileum,,1,D,20033,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",9,CHEMBL619595,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3248,,Ileum,,1,D,20033,2116.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,9,CHEMBL619596,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3249,,Ileum,,1,D,20033,2116.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,9,CHEMBL619755,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3250,,Ileum,,1,D,20033,2116.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,9,CHEMBL619756,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3251,,Ileum,,1,D,20033,2116.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,9,CHEMBL619757,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3252,,Ileum,,1,D,20033,2116.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,9,CHEMBL619758,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3253,,Ileum,,1,D,20033,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",9,CHEMBL619759,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3254,,Ileum,,1,D,20033,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",9,CHEMBL619760,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3255,,Ileum,,1,D,20033,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",9,CHEMBL619761,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3256,,Ileum,,1,D,20033,2116.0,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,9,CHEMBL619762,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3257,,Ileum,,1,D,20033,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",9,CHEMBL619763,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3258,,Ileum,,1,D,20033,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",9,CHEMBL617868,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3259,,,,1,D,20033,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,9,CHEMBL617869,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3260,,Striatum,,1,D,20033,2435.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,9,CHEMBL882926,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000249
3261,,Striatum,,1,D,20033,2435.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,9,CHEMBL617870,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000249
3262,,Striatum,,1,D,20033,2435.0,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,9,CHEMBL617871,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3263,,Striatum,,1,D,20033,2435.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,9,CHEMBL617872,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3264,,Striatum,,1,D,20033,2435.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,9,CHEMBL617873,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3265,,Striatum,,1,D,20033,2435.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,9,CHEMBL617874,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3266,,Ileum,,1,D,20033,2116.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,9,CHEMBL619067,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3267,,Ileum,,1,D,20033,2116.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,9,CHEMBL619068,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3268,,Ileum,,1,D,20033,2116.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,9,CHEMBL619069,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3269,,,,1,D,20033,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,9,CHEMBL619070,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3270,,,,1,D,20033,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,9,CHEMBL619071,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3271,,,,1,D,20033,,Agonistic activity against 5-hydroxytryptamine 4 receptor,9,CHEMBL619072,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000019
3272,,,,1,D,20033,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,9,CHEMBL619073,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000019
3273,,,,1,D,20033,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,9,CHEMBL619074,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000019
3274,,,,1,D,20033,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,9,CHEMBL619075,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3275,,Striatum,,1,D,20033,2435.0,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,9,CHEMBL619076,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3276,,Striatum,,1,D,20033,2435.0,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,9,CHEMBL619077,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3277,,Striatum,,1,D,20033,2435.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,9,CHEMBL619078,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000249
3278,,Striatum,,1,D,20033,2435.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,9,CHEMBL619079,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000249
3279,,Ileum,,1,D,20033,2116.0,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,9,CHEMBL619080,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000221
3280,,,,1,D,20033,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,9,CHEMBL619081,Cavia porcellus,,B,10141.0,,,Expert,,BAO_0000357
3281,,,,1,D,20033,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,9,CHEMBL619082,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3282,,,,1,D,20033,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,9,CHEMBL619083,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3283,,,,1,D,20033,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,9,CHEMBL619084,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3284,,Ileum,,1,D,20033,2116.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,9,CHEMBL859397,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3285,,Ileum,,1,D,20033,2116.0,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,9,CHEMBL619085,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3286,,Ileum,,1,D,20033,2116.0,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,9,CHEMBL619086,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3287,,Ileum,,1,D,20033,2116.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,9,CHEMBL619087,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3288,,Ileum,,1,D,20033,2116.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,9,CHEMBL619088,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3289,,,,1,D,20033,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,9,CHEMBL619089,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3290,,,,1,H,168,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,8,CHEMBL619090,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000357
3291,,,,1,D,20033,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,9,CHEMBL619091,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000019
3292,,,,1,D,20033,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,9,CHEMBL619092,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3293,,,,1,D,20033,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,9,CHEMBL619093,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000019
3294,,,,1,H,168,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,8,CHEMBL619094,Cavia porcellus,,B,10141.0,,HEK293,Autocuration,722.0,BAO_0000219
3295,,,,1,D,20033,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,9,CHEMBL619095,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000019
3296,,,,1,D,20033,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,9,CHEMBL857988,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3297,,,,1,D,20033,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,9,CHEMBL619096,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3298,,Striatum,,1,D,20033,2435.0,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,9,CHEMBL619097,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3299,,Hippocampus,,1,D,20033,10000000.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,9,CHEMBL619098,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000221
3300,,,,1,D,20033,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,9,CHEMBL619751,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3301,,,,1,D,20033,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,9,CHEMBL619752,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3302,,Ileum,,1,D,20033,2116.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,9,CHEMBL875096,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3303,,,,1,H,108,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,8,CHEMBL619004,,,B,,,,Autocuration,,BAO_0000357
3304,,,,1,H,168,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,8,CHEMBL619005,,,B,,,,Autocuration,,BAO_0000357
3305,,,,1,H,168,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,8,CHEMBL619006,,,B,,,,Autocuration,,BAO_0000019
3306,,,,1,H,168,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,8,CHEMBL619007,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
3307,,,,1,H,168,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,8,CHEMBL619008,,,B,,,,Autocuration,,BAO_0000357
3308,,,,1,H,168,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,8,CHEMBL619009,,,B,,,,Autocuration,,BAO_0000357
3309,,,,1,H,168,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",8,CHEMBL619010,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
3310,,,,1,H,10622,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,8,CHEMBL619011,,,B,,,,Autocuration,,BAO_0000357
3311,,,,1,H,10622,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,8,CHEMBL619012,,,B,,,,Autocuration,,BAO_0000357
3312,,,,1,H,10622,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,8,CHEMBL619013,,,B,,,,Autocuration,,BAO_0000219
3313,,,,1,H,10622,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,8,CHEMBL619014,,,B,,,,Autocuration,,BAO_0000357
3314,,Cardiac atrium,,1,H,11249,2081.0,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,8,CHEMBL857503,,,F,,,,Autocuration,,BAO_0000019
3315,,Cardiac atrium,,1,H,11249,2081.0,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,8,CHEMBL619015,,,F,,,,Autocuration,,BAO_0000019
3316,,,,1,H,11249,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,8,CHEMBL619016,,,B,,,,Autocuration,,BAO_0000357
3317,,Hippocampus,,1,H,11249,10000000.0,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,8,CHEMBL619017,,,B,,,,Autocuration,,BAO_0000221
3318,,Hippocampus,,1,H,168,10000000.0,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,8,CHEMBL619018,Sus scrofa,,B,9823.0,,,Autocuration,,BAO_0000221
3319,,,,1,H,168,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,8,CHEMBL619019,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
3320,,,,1,D,10623,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,9,CHEMBL619020,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
3321,,,,1,H,10623,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,8,CHEMBL619021,,,F,,,,Autocuration,,BAO_0000019
3322,,,,1,H,10623,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,8,CHEMBL619022,,,B,,,,Autocuration,,BAO_0000357
3323,,,,1,H,10623,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,8,CHEMBL619023,,,B,,,,Autocuration,,BAO_0000357
3324,,,,1,H,10623,,lntrinsic activity relative to 5-HT receptor,8,CHEMBL619024,,,F,,,,Autocuration,,BAO_0000019
3325,,,,1,H,10623,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,8,CHEMBL619025,,,F,,,,Autocuration,,BAO_0000019
3326,,,,1,H,10623,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,8,CHEMBL619026,,,F,,,,Expert,,BAO_0000019
3327,,,,1,H,10623,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,8,CHEMBL619027,,,F,,,,Autocuration,,BAO_0000019
3328,,,,1,H,10623,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,8,CHEMBL619028,,,F,,,,Autocuration,,BAO_0000019
3329,,,,1,H,10623,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,8,CHEMBL619029,,,F,,,,Autocuration,,BAO_0000019
3330,,,,1,H,10623,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,8,CHEMBL619030,,,F,,,,Autocuration,,BAO_0000019
3331,,,,1,H,10623,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,8,CHEMBL619031,,,B,,,,Expert,,BAO_0000357
3332,,,,1,H,10623,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,8,CHEMBL619032,,,F,,,,Autocuration,,BAO_0000019
3333,,,,1,D,10623,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,9,CHEMBL619033,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
3334,,,,1,H,10623,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,8,CHEMBL619034,,,B,,,,Autocuration,,BAO_0000357
3335,,,,1,H,10623,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,8,CHEMBL619035,,,B,,,,Autocuration,,BAO_0000357
3336,,,,1,H,10623,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,8,CHEMBL619036,,,B,,,,Autocuration,,BAO_0000357
3337,,,,1,D,10623,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,9,CHEMBL619037,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
3338,,Striatum,,1,H,10623,2435.0,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,8,CHEMBL619038,,,B,,,,Autocuration,,BAO_0000249
3339,,,,1,H,10623,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,8,CHEMBL619039,,,B,,,,Autocuration,,BAO_0000249
3340,,,,1,H,10623,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,8,CHEMBL619040,,,B,,,,Expert,,BAO_0000249
3341,,Striatum,,1,D,10623,2435.0,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,9,CHEMBL619041,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000019
3342,,Striatum,,1,H,10623,2435.0,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,8,CHEMBL619042,,,B,,,,Autocuration,,BAO_0000019
3343,,Striatum,,1,H,10623,2435.0,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,8,CHEMBL619043,,,B,,,,Expert,,BAO_0000249
3344,,Striatum,,1,H,10623,2435.0,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,8,CHEMBL619044,,,B,,,,Expert,,BAO_0000019
3345,,Striatum,,1,H,10623,2435.0,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,8,CHEMBL619045,,,B,,,,Expert,,BAO_0000249
3346,,Striatum,,1,H,10623,2435.0,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,8,CHEMBL619046,,,B,,,,Expert,,BAO_0000249
3347,,,,1,H,10623,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,8,CHEMBL619047,,,B,,,,Expert,,BAO_0000249
3348,,Brain,,1,H,10623,955.0,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,8,CHEMBL619048,,,F,,,,Autocuration,,BAO_0000221
3349,,,,1,H,10623,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,8,CHEMBL859398,,,F,,,,Autocuration,,BAO_0000019
3350,,,,1,H,10623,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,8,CHEMBL619049,,,F,,,,Autocuration,,BAO_0000019
3351,,,,1,H,10623,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,8,CHEMBL857886,,,F,,,,Autocuration,,BAO_0000019
3352,,,,1,H,10623,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,8,CHEMBL619050,,,F,,,,Autocuration,,BAO_0000019
3353,,,,1,H,10623,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,8,CHEMBL620591,,,F,,,,Autocuration,,BAO_0000019
3354,,,,1,D,10623,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,9,CHEMBL620592,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
3355,,Striatum,,1,H,10623,2435.0,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,8,CHEMBL620593,,,B,,,,Expert,,BAO_0000249
3356,,,,1,D,10623,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,9,CHEMBL620594,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
3357,,,,1,H,10623,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,8,CHEMBL875079,,,F,,,,Expert,,BAO_0000019
3358,,,,1,H,10623,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,8,CHEMBL620595,,,F,,,,Expert,,BAO_0000019
3359,,,,1,D,10623,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,9,CHEMBL620596,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
3360,,,,1,H,10623,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,8,CHEMBL620597,,,F,,,,Autocuration,,BAO_0000019
3361,,,,1,H,10623,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,8,CHEMBL620598,,,F,,,,Expert,,BAO_0000019
3362,,,,1,H,10623,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),8,CHEMBL620599,,,F,,,,Expert,,BAO_0000218
3363,,,,1,H,10623,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,8,CHEMBL620600,,,F,,,,Autocuration,,BAO_0000019
3364,,,,1,H,168,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,8,CHEMBL620601,Rattus norvegicus,,F,10116.0,,,Autocuration,,BAO_0000019
3365,,,,1,H,168,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,8,CHEMBL620602,,,F,,,,Autocuration,,BAO_0000019
3366,,,,1,H,168,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,8,CHEMBL620603,,,B,,,,Autocuration,,BAO_0000357
3367,,,,1,H,168,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,8,CHEMBL620604,,,B,,,,Autocuration,,BAO_0000357
3368,,,,1,H,168,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,8,CHEMBL620605,,,B,,,,Autocuration,,BAO_0000357
3369,,,,1,H,168,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,8,CHEMBL620606,,,B,,,,Autocuration,,BAO_0000357
3370,,,,1,H,168,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,8,CHEMBL620607,,,F,,,,Autocuration,,BAO_0000019
3371,,,,1,H,168,,In vitro binding affinity towards 5-HT4 receptor was determined,8,CHEMBL620608,,,B,,,,Autocuration,,BAO_0000357
3372,,,,1,H,168,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,8,CHEMBL620609,,,F,,,,Autocuration,,BAO_0000019
3373,,,,1,H,168,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,8,CHEMBL620610,,,F,,,,Autocuration,,BAO_0000019
3374,,,,1,H,168,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,8,CHEMBL620611,,,B,,,,Autocuration,,BAO_0000357
3375,,,,1,H,168,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,8,CHEMBL620612,,,B,,,,Autocuration,,BAO_0000357
3376,,,,1,H,168,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,8,CHEMBL620613,,,B,,,,Autocuration,,BAO_0000357
3377,,,,1,H,168,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,8,CHEMBL620614,,,B,,,,Autocuration,,BAO_0000357
3378,,,,1,H,168,,Binding affinity against 5-Hydroxytryptamine 4 receptor,8,CHEMBL620615,,,B,,,,Expert,,BAO_0000357
3379,,,,1,H,104698,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,6,CHEMBL857075,,Brain membranes,B,,,,Autocuration,,BAO_0000249
3380,,,,1,H,104698,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,6,CHEMBL620616,,Brain membranes,B,,,,Autocuration,,BAO_0000249
3381,,,,1,H,104698,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,6,CHEMBL619411,,Brain membranes,B,,,,Autocuration,,BAO_0000249
3382,,,,1,H,104698,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,6,CHEMBL619412,,,B,,,,Autocuration,,BAO_0000019
3383,,,,1,D,104698,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,7,CHEMBL619413,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3384,,Hippocampus,,1,H,104698,10000000.0,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,6,CHEMBL619414,,,B,,,,Autocuration,,BAO_0000221
3385,,,,1,H,104698,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,6,CHEMBL619415,,,B,,,,Autocuration,,BAO_0000019
3386,,,,1,H,104698,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,6,CHEMBL619416,,,B,,,,Autocuration,,BAO_0000019
3387,,,,1,H,104698,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,6,CHEMBL619417,,,F,,,,Autocuration,,BAO_0000019
3388,,,,1,D,104698,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,7,CHEMBL619418,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000223
3389,,,,1,D,104698,,Binding affinity against 5-Hydroxytryptamine 3 receptor,7,CHEMBL619419,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000223
3390,,,,1,H,104698,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,6,CHEMBL619420,,,B,,,,Autocuration,,BAO_0000019
3391,,,,1,H,104698,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,6,CHEMBL619421,,,B,,,,Autocuration,,BAO_0000249
3392,,,,1,D,104698,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,7,CHEMBL619422,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3393,,,,1,H,104698,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,6,CHEMBL619423,,,B,,,,Autocuration,,BAO_0000019
3394,,,,1,H,104698,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,6,CHEMBL875080,,,B,,,,Autocuration,,BAO_0000019
3395,,,,1,H,104698,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,6,CHEMBL619424,,,B,,,,Autocuration,,BAO_0000019
3396,,,,1,H,104698,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,6,CHEMBL619425,,,B,,,,Autocuration,,BAO_0000249
3397,,,,1,H,104698,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,6,CHEMBL619426,,,B,,,,Autocuration,,BAO_0000223
3398,,,,1,H,104698,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,6,CHEMBL619427,,,B,,,,Autocuration,,BAO_0000223
3399,,,,1,D,104698,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,7,CHEMBL619645,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000223
3400,,,,1,D,10576,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",9,CHEMBL619646,,,B,,,,Expert,,BAO_0000249
3401,,Brain,,1,H,12020,955.0,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,8,CHEMBL619647,,,F,,,,Autocuration,,BAO_0000221
3402,,,,1,H,12020,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,8,CHEMBL619648,,,F,,,,Autocuration,,BAO_0000019
3403,,,,1,H,12020,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,8,CHEMBL619165,,,F,,,,Autocuration,,BAO_0000019
3404,,,,1,H,12020,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,8,CHEMBL620719,,,F,,In vivo,,Autocuration,,BAO_0000218
3405,,,,1,H,12020,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,8,CHEMBL872924,,,B,,,,Autocuration,,BAO_0000019
3406,,,,1,H,12020,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,8,CHEMBL620720,,,B,,,,Autocuration,,BAO_0000357
3407,,,,1,H,12020,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,8,CHEMBL620721,,,B,,,,Autocuration,,BAO_0000019
3408,,,,1,H,12020,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,8,CHEMBL620722,,,B,,,,Autocuration,,BAO_0000019
3409,,,,1,H,104698,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",6,CHEMBL620723,,,B,,,,Autocuration,,BAO_0000019
3410,,,,1,H,12020,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,8,CHEMBL620724,,,B,,,,Autocuration,,BAO_0000019
3411,,,,1,H,104698,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,6,CHEMBL620725,,,B,,,,Autocuration,,BAO_0000249
3412,,,,1,D,12020,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,9,CHEMBL620726,Rattus norvegicus,,F,10116.0,,,Autocuration,,BAO_0000019
3413,,,,1,H,144,,Binding affinity towards 5-hydroxytryptamine 3 receptor,8,CHEMBL620727,,,B,,,,Expert,,BAO_0000357
3414,,,,1,H,104714,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,4,CHEMBL620728,,,B,,,,Autocuration,,BAO_0000223
3415,,,,1,U,22226,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,0,CHEMBL620729,,,B,,,,Autocuration,,BAO_0000019
3416,,,,1,H,104714,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,4,CHEMBL858288,,,F,,,,Autocuration,,BAO_0000019
3417,,,,1,H,104714,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,4,CHEMBL620730,,,B,,,,Autocuration,,BAO_0000223
3418,,,,1,H,104714,,Binding affinity towards 5-hydroxytryptamine 3 receptor,4,CHEMBL620731,,,B,,,,Autocuration,,BAO_0000223
3419,,,,1,H,104714,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,4,CHEMBL620732,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3420,,,,1,H,104714,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,4,CHEMBL618042,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3421,,,,1,H,104714,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,4,CHEMBL618043,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3422,,,,1,H,104714,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,4,CHEMBL618044,,,B,,,,Autocuration,,BAO_0000223
3423,,,,1,H,104714,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,4,CHEMBL618045,,,F,,,,Autocuration,,BAO_0000019
3424,,,,1,H,104714,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,4,CHEMBL618046,,,B,,,,Autocuration,,BAO_0000223
3425,,,,1,H,104714,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,4,CHEMBL618047,,,F,,,,Autocuration,,BAO_0000019
3426,,,,1,H,104714,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,4,CHEMBL875084,,,F,,,,Autocuration,,BAO_0000019
3427,,,,1,H,104714,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,4,CHEMBL618048,,,F,,,,Autocuration,,BAO_0000019
3428,,,,1,H,104714,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,4,CHEMBL618049,,,B,,,,Autocuration,,BAO_0000223
3429,,,,1,H,104714,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,4,CHEMBL619764,,,F,,,,Autocuration,,BAO_0000019
3430,,,,1,H,104714,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,4,CHEMBL619765,,,F,,,,Autocuration,,BAO_0000019
3431,,,,1,H,104714,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,4,CHEMBL619766,,,F,,,,Autocuration,,BAO_0000019
3432,,,,1,H,104714,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,4,CHEMBL619767,,,B,,,,Autocuration,,BAO_0000223
3433,,,,1,H,104714,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,4,CHEMBL619768,,,B,,,,Autocuration,,BAO_0000223
3434,,,,1,H,104714,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,4,CHEMBL619769,,,F,,,,Autocuration,,BAO_0000019
3435,,,,1,H,104714,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,4,CHEMBL619770,,,B,,,,Autocuration,,BAO_0000223
3436,,,,1,H,104714,,Binding affinity towards 5-hydroxytryptamine 3 receptor,4,CHEMBL619771,,,B,,,,Autocuration,,BAO_0000223
3437,,,,1,H,104714,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,4,CHEMBL619772,,,B,,,,Autocuration,,BAO_0000219
3438,,,,1,H,104714,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,4,CHEMBL619773,,,B,,,,Autocuration,,BAO_0000223
3439,,,,1,H,104714,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,4,CHEMBL619774,,,B,,,NG108-15,Autocuration,433.0,BAO_0000219
3440,,,,1,H,104714,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,4,CHEMBL875083,,,B,,,,Autocuration,,BAO_0000019
3441,,,,1,H,104714,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,4,CHEMBL620718,,,B,,,NG108-15,Autocuration,433.0,BAO_0000219
3442,,,,1,H,104714,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,4,CHEMBL618127,,,B,,,,Autocuration,,BAO_0000223
3443,,,,1,H,104714,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,4,CHEMBL618128,,,B,,,,Autocuration,,BAO_0000223
3444,,,,1,H,104714,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,4,CHEMBL618129,,,B,,In vitro,,Autocuration,,BAO_0000219
3445,,,,1,H,104714,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,4,CHEMBL618130,,,B,,,,Autocuration,,BAO_0000223
3446,,,,1,H,104714,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,4,CHEMBL618131,,,F,,,,Autocuration,,BAO_0000019
3447,,,,1,H,104714,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,4,CHEMBL618132,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3448,,,,1,H,104714,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,4,CHEMBL618133,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3449,,,,1,H,104714,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,4,CHEMBL618134,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3450,,,,1,H,104714,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,4,CHEMBL618135,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3451,,,,1,H,104714,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,4,CHEMBL618136,,,B,,,,Autocuration,,BAO_0000223
3452,,,,1,H,104714,,Binding affinity towards 5-hydroxytryptamine 3 receptor,4,CHEMBL618137,,,B,,,,Autocuration,,BAO_0000223
3453,,,,1,H,104714,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,4,CHEMBL618138,,,B,,,,Autocuration,,BAO_0000223
3454,,,,1,H,104714,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,4,CHEMBL618139,,,B,,,,Autocuration,,BAO_0000223
3455,,,,1,H,104714,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,4,CHEMBL618140,,,B,,,,Autocuration,,BAO_0000223
3456,,,,1,H,104714,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,4,CHEMBL618141,,,B,,,,Autocuration,,BAO_0000223
3457,,,,1,H,108,,Binding affinity for 5-hydroxytryptamine 2C receptor,8,CHEMBL873478,,,B,,,,Expert,,BAO_0000357
3458,,,,1,H,104698,,Binding affinity towards 5-hydroxytryptamine 3 receptor,6,CHEMBL618142,,,B,,,,Autocuration,,BAO_0000223
3459,,,,1,H,144,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,8,CHEMBL618143,,,B,,,,Autocuration,,BAO_0000357
3460,,,,1,H,144,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,8,CHEMBL618144,,,B,,,,Autocuration,,BAO_0000357
3461,,,,1,H,144,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,8,CHEMBL618145,,,B,,,,Autocuration,,BAO_0000357
3462,,,,1,H,104714,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,4,CHEMBL618146,,,B,,,,Autocuration,,BAO_0000223
3463,,,,1,H,104714,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,4,CHEMBL618147,,,B,,,,Autocuration,,BAO_0000223
3464,,,,1,H,104714,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,4,CHEMBL618148,,,B,,,,Autocuration,,BAO_0000223
3465,,,,1,H,144,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,8,CHEMBL618149,,,B,,,,Autocuration,,BAO_0000019
3466,,,,1,H,144,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,8,CHEMBL872927,,,B,,,,Autocuration,,BAO_0000357
3467,,,,1,H,144,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,8,CHEMBL618150,,,B,,,,Autocuration,,BAO_0000357
3468,,,,1,H,144,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,8,CHEMBL618151,,,B,,,,Autocuration,,BAO_0000357
3469,,,,1,H,144,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,8,CHEMBL875094,,,B,,,,Autocuration,,BAO_0000357
3470,,,,1,H,144,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,8,CHEMBL618152,,,B,,,,Autocuration,,BAO_0000019
3471,,,,1,H,144,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,8,CHEMBL618153,,,B,,,,Autocuration,,BAO_0000357
3472,,,,1,H,144,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,8,CHEMBL618888,,,B,,,,Autocuration,,BAO_0000357
3473,,,,1,H,144,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,8,CHEMBL618889,,,F,,,,Autocuration,,BAO_0000019
3474,,,,1,H,144,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,8,CHEMBL618890,,,B,,,,Autocuration,,BAO_0000357
3475,,,,1,H,144,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,8,CHEMBL618891,,,B,,,,Autocuration,,BAO_0000019
3476,,,,1,H,144,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,8,CHEMBL619054,,,B,,,,Autocuration,,BAO_0000019
3477,,,,1,H,104714,,Binding affinity against the 5-hydroxytryptamine 3 receptor,4,CHEMBL619055,,,B,,,,Autocuration,,BAO_0000223
3478,,,,1,H,144,,Binding affinity against human 5-hydroxytryptamine 3A receptor,8,CHEMBL619056,,,B,,,,Autocuration,,BAO_0000357
3479,,,,1,H,144,,Percent efficacy against 5-hydroxytryptamine 3A receptor,8,CHEMBL619057,,,F,,,,Autocuration,,BAO_0000019
3480,,,,1,H,144,,Binding affinity against human 5-hydroxytryptamine 3A receptor,8,CHEMBL619058,,,B,,,,Autocuration,,BAO_0000357
3481,,,,1,D,12020,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,9,CHEMBL619059,Rattus norvegicus,,F,10116.0,,Oocytes,Expert,,BAO_0000219
3482,,,,1,D,12020,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,9,CHEMBL619060,Rattus norvegicus,,F,10116.0,,Oocytes,Expert,,BAO_0000219
3483,,,,1,D,12020,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,9,CHEMBL875095,Rattus norvegicus,,F,10116.0,,Oocytes,Expert,,BAO_0000219
3484,,Ileum,,1,D,20033,2116.0,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,9,CHEMBL619061,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3485,,Ileum,,1,D,20033,2116.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,9,CHEMBL619062,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000221
3486,,,,1,D,20033,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,9,CHEMBL619063,Cavia porcellus,,F,10141.0,,,Intermediate,,BAO_0000019
3487,,Ileum,,1,D,20033,2116.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,9,CHEMBL619064,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000221
3488,,,,1,D,20033,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,9,CHEMBL619065,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000357
3489,,Ileum,,1,D,20033,2116.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,9,CHEMBL619066,Cavia porcellus,,B,10141.0,,,Intermediate,,BAO_0000221
3490,,Ileum,,1,H,10209,2116.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,8,CHEMBL619775,,,B,,,,Autocuration,,BAO_0000221
3491,,,,1,H,10209,,Affinity against 5-hydroxytryptamine 7 receptor,8,CHEMBL619776,,,B,,,,Autocuration,,BAO_0000357
3492,,,,1,H,104841,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,4,CHEMBL619777,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000224
3493,,,,1,H,104841,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,4,CHEMBL619778,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000224
3494,,Ileum,,1,H,104841,2116.0,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,4,CHEMBL619779,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000221
3495,,,,1,H,104841,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",4,CHEMBL619780,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000224
3496,,,,1,H,104841,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",4,CHEMBL619166,Cavia porcellus,,B,10141.0,,,Autocuration,,BAO_0000224
3497,,,,1,H,104841,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,4,CHEMBL619167,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3498,,,,1,H,104841,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,4,CHEMBL619168,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3499,,Cardiac atrium,,1,D,168,2081.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,9,CHEMBL619169,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000219
3500,,Cardiac atrium,,1,D,168,2081.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,9,CHEMBL619170,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000219
3501,,,,1,D,104841,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",5,CHEMBL619171,Homo sapiens,,F,9606.0,,,Autocuration,,BAO_0000019
3502,,Cardiac atrium,,1,D,168,2081.0,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",9,CHEMBL619172,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000219
3503,,,,1,U,22226,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,0,CHEMBL619173,Mus musculus,,B,10090.0,,,Autocuration,,BAO_0000019
3504,,,,1,U,22226,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,0,CHEMBL619174,Mus musculus,,B,10090.0,,,Autocuration,,BAO_0000019
3505,,,,1,H,104705,,5-hydroxytryptamine receptor binding affinity was determined in rats,4,CHEMBL619175,,,B,,,,Autocuration,,BAO_0000019
3506,,,,1,H,104705,,Binding affinity at rat 5-hydroxytryptamine receptor.,4,CHEMBL619176,,,B,,,,Autocuration,,BAO_0000224
3507,,,,1,H,104705,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,4,CHEMBL619177,,,B,,,,Autocuration,,BAO_0000019
3508,,,,1,H,104705,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,4,CHEMBL619178,,,B,,,,Autocuration,,BAO_0000224
3509,,,,1,H,104705,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,4,CHEMBL619179,,,B,,,,Autocuration,,BAO_0000224
3510,,Stomach,,1,H,104705,945.0,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,4,CHEMBL619180,,,F,,,,Autocuration,,BAO_0000019
3511,,Stomach,,1,H,104705,945.0,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,4,CHEMBL619181,,,F,,,,Autocuration,,BAO_0000019
3512,,,,1,H,104705,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,4,CHEMBL619182,,,F,,,,Autocuration,,BAO_0000019
3513,,,,1,H,104705,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,4,CHEMBL619183,,,B,,,,Autocuration,,BAO_0000224
3514,,,,1,H,104705,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",4,CHEMBL619184,,,B,,,,Autocuration,,BAO_0000224
3515,,Hippocampus,,1,H,10576,10000000.0,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,8,CHEMBL619185,,,B,,,,Autocuration,,BAO_0000221
3516,,,,1,H,12198,,Binding affinity for rat 5-hydroxytryptamine transporter.,8,CHEMBL619186,,,B,,,,Expert,,BAO_0000357
3517,,,,1,H,104705,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,4,CHEMBL619187,,,B,,,,Autocuration,,BAO_0000019
3518,,,,1,D,104705,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,5,CHEMBL619188,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3519,,,,1,D,104705,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,5,CHEMBL619189,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
3520,,Brain,,1,D,12198,955.0,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,9,CHEMBL619190,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000019
3521,,Cerebellum,,1,D,12198,2037.0,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,9,CHEMBL619191,Rattus norvegicus,,F,10116.0,,,Expert,,BAO_0000221
3522,,,,1,D,104705,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,5,CHEMBL619192,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3523,,,,1,D,104705,,Percent binding affinity against 5-hydroxytryptamine receptor,5,CHEMBL619193,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
3524,,,,1,U,22226,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,0,CHEMBL619194,,,B,,,,Autocuration,,BAO_0000019
3525,,,,1,D,104705,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,5,CHEMBL619195,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
3526,,,,1,D,104705,,Affinity against 5-hydroxytryptamine receptor was determined,5,CHEMBL619196,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000224
3527,,Stomach,,1,D,104705,945.0,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,5,CHEMBL619197,Rattus norvegicus,,B,10116.0,,,Autocuration,,BAO_0000019
3528,,,,1,D,121,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,9,CHEMBL619198,Homo sapiens,,B,9606.0,In vitro,,Expert,,BAO_0000219
3529,,,,1,D,121,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,9,CHEMBL875081,Homo sapiens,,B,9606.0,In vitro,,Expert,,BAO_0000219
3530,,,,1,H,18065,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,8,CHEMBL884712,,,B,,,,Autocuration,,BAO_0000357
3531,,,,1,H,121,,Inhibition of 5-hydroxytryptamine reuptake,8,CHEMBL884710,,,B,,,,Expert,,BAO_0000357
3532,,,,1,H,18065,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",8,CHEMBL619199,,,F,,,,Autocuration,,BAO_0000019
3533,,,,1,H,18065,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",8,CHEMBL619200,,,F,,,,Autocuration,,BAO_0000019
3534,,,,1,H,18065,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",8,CHEMBL619201,,,F,,,,Autocuration,,BAO_0000019
3535,,,,1,H,18065,,Tested for 5-hydroxytryptamine receptor uptake,8,CHEMBL619202,,,F,,,,Autocuration,,BAO_0000019
3536,,,,1,D,51,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,9,CHEMBL619203,Homo sapiens,,B,9606.0,,CHO,Expert,449.0,BAO_0000219
3537,,,,1,D,51,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,9,CHEMBL619204,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
3538,,,,1,H,10576,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,8,CHEMBL619205,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000249
3539,,,,1,H,10576,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,8,CHEMBL619206,,,B,,,,Autocuration,,BAO_0000357
3540,,,,1,H,10576,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,8,CHEMBL619207,,,B,,,,Expert,,BAO_0000249
3541,,Striatum,,1,H,10825,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,8,CHEMBL619208,,,F,,,,Autocuration,,BAO_0000019
3542,,Striatum,,1,H,10825,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,8,CHEMBL619209,,,F,,,,Autocuration,,BAO_0000019
3543,,Striatum,,1,H,10825,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,8,CHEMBL619210,,,F,,,,Autocuration,,BAO_0000019
3544,,Striatum,,1,H,10825,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,8,CHEMBL619211,,,F,,,,Autocuration,,BAO_0000019
3545,,Striatum,,1,H,10825,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,8,CHEMBL619212,,,F,,,,Autocuration,,BAO_0000019
3546,,Striatum,,1,H,10825,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,8,CHEMBL620681,,,F,,,,Autocuration,,BAO_0000019
3547,,Striatum,,1,H,10825,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,8,CHEMBL620682,,,F,,,,Autocuration,,BAO_0000019
3548,,Striatum,,1,H,10825,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,8,CHEMBL620683,,,F,,,,Autocuration,,BAO_0000019
3549,,Striatum,,1,H,10825,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,8,CHEMBL620684,,,F,,,,Autocuration,,BAO_0000019
3550,,Striatum,,1,H,10825,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,8,CHEMBL620685,,,F,,,,Autocuration,,BAO_0000019
3551,,Striatum,,1,H,10825,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,8,CHEMBL620686,,,F,,,,Autocuration,,BAO_0000019
3552,,Limbic system,,1,H,10825,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,8,CHEMBL620687,,,F,,,,Autocuration,,BAO_0000019
3553,,Limbic system,,1,H,10825,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,8,CHEMBL620688,,,F,,,,Autocuration,,BAO_0000019
3554,,Limbic system,,1,H,10825,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,8,CHEMBL620689,,,F,,,,Autocuration,,BAO_0000019
3555,,Limbic system,,1,H,10825,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,8,CHEMBL620690,,,F,,,,Autocuration,,BAO_0000019
3556,,Limbic system,,1,H,10825,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,8,CHEMBL620691,,,F,,,,Autocuration,,BAO_0000019
3557,,Limbic system,,1,H,10825,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,8,CHEMBL620692,,,F,,,,Autocuration,,BAO_0000019
3558,,Limbic system,,1,H,10825,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,8,CHEMBL620693,,,F,,,,Autocuration,,BAO_0000019
3559,,,,1,H,168,,Binding affinity against 5-hydroxytryptamine 4 receptor,8,CHEMBL620694,,,B,,,,Expert,,BAO_0000357
3560,,,,1,H,168,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,8,CHEMBL857986,,,F,,,,Autocuration,,BAO_0000019
3561,,,,1,H,168,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,8,CHEMBL620695,,,B,,,,Autocuration,,BAO_0000357
3562,,,,1,H,168,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,8,CHEMBL620696,,,B,,,,Expert,,BAO_0000357
3563,,,,1,H,168,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,8,CHEMBL620697,,,B,,,,Autocuration,,BAO_0000357
3564,,,,1,H,168,,Binding affinity towards 5-hydroxytryptamine 4 receptor,8,CHEMBL620698,,,B,,,,Autocuration,,BAO_0000357
3565,,,,1,H,168,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,8,CHEMBL620699,,,B,,,,Autocuration,,BAO_0000357
3566,,,,1,H,168,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,8,CHEMBL620700,,,B,,,,Autocuration,,BAO_0000357
3567,,,,1,H,168,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,8,CHEMBL620701,,,B,,,COS-7,Autocuration,643.0,BAO_0000219
3568,,,,1,H,168,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,8,CHEMBL875082,,,B,,,COS-7,Autocuration,643.0,BAO_0000219
3569,,,,1,H,168,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,8,CHEMBL620702,,,B,,,COS-7,Autocuration,643.0,BAO_0000219
3570,,,,1,H,168,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,8,CHEMBL620703,,,B,,,COS-7,Autocuration,643.0,BAO_0000219
3571,,,,1,H,168,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,8,CHEMBL620704,,,B,,,C6,Autocuration,673.0,BAO_0000219
3572,,,,1,H,168,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,8,CHEMBL620705,,,B,,,C6,Expert,673.0,BAO_0000219
3573,,,,1,H,168,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,8,CHEMBL620706,,,B,,,C6,Expert,673.0,BAO_0000219
3574,,,,1,H,168,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,8,CHEMBL620707,,,B,,,C6,Expert,673.0,BAO_0000219
3575,,,,1,H,10624,,Binding affinity towards 5-hydroxytryptamine 5 receptor,8,CHEMBL620708,,,B,,,,Expert,,BAO_0000357
3576,,,,1,H,105,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,8,CHEMBL620709,,,B,,,,Autocuration,,BAO_0000357
3577,,,,1,D,10624,,Binding affinity against 5-hydroxytryptamine 5A receptor,9,CHEMBL620710,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3578,,,,1,H,10624,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,8,CHEMBL620711,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3579,,,,1,D,10624,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,9,CHEMBL620712,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3580,,,,1,D,10624,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,9,CHEMBL620713,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3581,,,,1,D,10624,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,9,CHEMBL620714,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3582,,,,1,D,10624,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,9,CHEMBL620715,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3583,,,,1,H,10624,,Binding affinity towards 5-HT5A receptor,8,CHEMBL620716,,,B,,,,Autocuration,,BAO_0000357
3584,,,,1,H,10624,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,8,CHEMBL620717,,,B,,,,Expert,,BAO_0000357
3585,,,,1,H,10624,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,8,CHEMBL618072,,,B,,,,Autocuration,,BAO_0000357
3586,,,,1,H,10624,,Binding affinity towards cloned human 5-HT5A receptor was determined,8,CHEMBL857987,,,B,,,,Autocuration,,BAO_0000357
3587,,,,1,H,10624,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,8,CHEMBL618073,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3588,,,,1,H,10624,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,8,CHEMBL618074,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3589,,,,1,H,10624,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),8,CHEMBL618075,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3590,,,,1,D,10625,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,9,CHEMBL618076,Mus musculus,,B,10090.0,,,Expert,,BAO_0000357
3591,,,,1,D,10625,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,9,CHEMBL618077,Mus musculus,,B,10090.0,,,Expert,,BAO_0000357
3592,,,,1,D,10625,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,9,CHEMBL618078,Mus musculus,,B,10090.0,,,Expert,,BAO_0000357
3593,,,,1,D,10625,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,9,CHEMBL881821,Mus musculus,,B,10090.0,,,Expert,,BAO_0000357
3594,,,,1,D,10625,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,9,CHEMBL618079,Mus musculus,,B,10090.0,,,Expert,,BAO_0000357
3595,,,,1,H,10625,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,8,CHEMBL618080,,,B,,,,Expert,,BAO_0000357
3596,,,,1,H,10576,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,8,CHEMBL618081,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3597,,,,1,H,10626,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,8,CHEMBL618082,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3598,,,,1,H,10624,,Binding affinity towards 5-HT5a receptor,8,CHEMBL618083,,,B,,,,Expert,,BAO_0000357
3599,,,,1,D,10624,,Binding affinity towards 5-hydroxytryptamine 5A receptor,9,CHEMBL618084,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3600,,,,1,H,10624,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,8,CHEMBL618085,,,B,,,,Expert,,BAO_0000357
3601,,,,1,H,10624,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,8,CHEMBL618086,,,B,,,,Expert,,BAO_0000357
3602,,,,1,H,10624,,Binding affinities against 5-hydroxytryptamine 5A receptor,8,CHEMBL875092,,,B,,,,Autocuration,,BAO_0000357
3603,,,,1,H,10624,,Binding affinities towards 5-hydroxytryptamine 5A receptor,8,CHEMBL618087,,,B,,,,Autocuration,,BAO_0000357
3604,,,,1,H,10624,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,8,CHEMBL872926,,,B,,,,Autocuration,,BAO_0000357
3605,,,,1,H,104714,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,4,CHEMBL618088,Cavia porcellus,,F,10141.0,,,Autocuration,,BAO_0000019
3606,,,,1,H,104714,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,4,CHEMBL618089,,,B,,,,Autocuration,,BAO_0000223
3607,,,,1,D,10627,,Inhibition of human 5-hydroxytryptamine 6 receptor,9,CHEMBL618090,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3608,,,,1,D,10627,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,9,CHEMBL618091,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3609,,,,1,H,10627,,Inhibition against human 5-hydroxytryptamine 6 receptor,8,CHEMBL618092,,,B,,,,Autocuration,,BAO_0000357
3610,,,,1,D,10627,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,9,CHEMBL618093,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3611,,,,1,H,10627,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,8,CHEMBL618094,,,B,,,HeLa,Expert,308.0,BAO_0000219
3612,,,,1,D,10627,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,9,CHEMBL618095,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3613,,,,1,D,10627,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,9,CHEMBL875093,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3614,,,,1,D,10627,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,9,CHEMBL618096,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3615,,,,1,D,10627,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,9,CHEMBL618118,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3616,,,,1,D,10627,,Binding affinity against 5-hydroxytryptamine 6 receptor,9,CHEMBL618119,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3617,,,,1,H,10627,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,8,CHEMBL618120,,,B,,,,Expert,,BAO_0000357
3618,,,,1,H,10627,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,8,CHEMBL618121,,,B,,,,Autocuration,,BAO_0000357
3619,,,,1,H,10627,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",8,CHEMBL618122,,,B,,,HEK293,Expert,722.0,BAO_0000219
3620,,,,1,H,10627,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,8,CHEMBL618123,,,B,,,,Autocuration,,BAO_0000357
3621,,,,1,H,10627,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,8,CHEMBL618124,,,B,,,HEK293,Expert,722.0,BAO_0000219
3622,,,,1,H,10627,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,8,CHEMBL618125,,,B,,,,Autocuration,,BAO_0000357
3623,,,,1,D,10627,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,9,CHEMBL618126,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
3624,,,,1,H,10627,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,8,CHEMBL618236,,,B,,,,Expert,,BAO_0000019
3625,,,,1,H,10627,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,8,CHEMBL618237,,,B,,,,Expert,,BAO_0000019
3626,,,,1,H,10627,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,8,CHEMBL618238,,,B,,,COS-7,Expert,643.0,BAO_0000219
3627,,,,1,D,10627,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,9,CHEMBL618239,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3628,,,,1,H,10627,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,8,CHEMBL618240,,,B,,,,Autocuration,,BAO_0000019
3629,,,,1,H,10627,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,8,CHEMBL618241,,,B,,,,Autocuration,,BAO_0000357
3630,,,,1,H,10627,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,8,CHEMBL859399,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3631,,,,1,H,10627,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,8,CHEMBL618242,,,F,,,,Autocuration,,BAO_0000019
3632,,,,1,H,10627,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,8,CHEMBL857991,,,B,,,,Autocuration,,BAO_0000357
3633,,,,1,H,10627,,Binding affinity against human 5-hydroxytryptamine 6 receptor,8,CHEMBL619951,,,B,,,,Expert,,BAO_0000357
3634,,,,1,D,10627,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,9,CHEMBL619952,Homo sapiens,,B,9606.0,,HeLa,Expert,308.0,BAO_0000219
3635,,,,1,D,10627,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,9,CHEMBL619953,Homo sapiens,,B,9606.0,,HeLa,Expert,308.0,BAO_0000219
3636,,,,1,H,10627,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,8,CHEMBL619954,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
3637,,,,1,H,10627,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,8,CHEMBL619955,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
3638,,,,1,H,10627,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,8,CHEMBL619956,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
3639,,,,1,H,10627,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,8,CHEMBL619957,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3640,,,,1,H,10627,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,8,CHEMBL619958,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3641,,,,1,H,10627,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,8,CHEMBL620627,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3642,,,,1,H,10627,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,8,CHEMBL620628,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3643,,,,1,H,10627,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,8,CHEMBL620629,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
3644,,,,1,H,10627,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,8,CHEMBL620630,,,B,,,,Autocuration,,BAO_0000357
3645,,,,1,H,10627,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,8,CHEMBL620782,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
3646,,,,1,H,10627,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,8,CHEMBL620783,,,B,,,,Autocuration,,BAO_0000357
3647,,,,1,H,10627,,Binding affinity against human 5-hydroxytryptamine 6 receptor,8,CHEMBL620784,,,B,,,,Expert,,BAO_0000357
3648,,,,1,H,10627,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,8,CHEMBL620785,,,B,,,HeLa,Expert,308.0,BAO_0000219
3649,,,,1,H,10627,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),8,CHEMBL857992,,,B,,,,Autocuration,,BAO_0000357
3650,,,,1,H,10627,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,8,CHEMBL620786,,,B,,,,Autocuration,,BAO_0000219
3651,,,,1,H,10627,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,8,CHEMBL620787,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
3652,,,,1,H,10627,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",8,CHEMBL620788,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
3653,,,,1,H,10627,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",8,CHEMBL620789,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
3654,,,,1,H,10627,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",8,CHEMBL620790,,,B,,,HeLa,Autocuration,308.0,BAO_0000219
3655,,,,1,H,10628,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,8,CHEMBL620791,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3656,,,,1,H,10628,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,8,CHEMBL620792,,,B,,,,Autocuration,,BAO_0000019
3657,,,,1,H,10628,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,8,CHEMBL620793,,,B,,,,Autocuration,,BAO_0000357
3658,,,,1,H,10628,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,8,CHEMBL620794,,,B,,,,Autocuration,,BAO_0000357
3659,,,,1,D,10627,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,9,CHEMBL620795,Homo sapiens,,B,9606.0,,HeLa,Autocuration,308.0,BAO_0000219
3660,,,,1,H,10627,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,8,CHEMBL620796,,,B,,,,Expert,,BAO_0000357
3661,,,,1,H,10627,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,8,CHEMBL620797,,,B,,,,Autocuration,,BAO_0000357
3662,,,,1,D,10627,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,9,CHEMBL620798,Homo sapiens,,F,9606.0,,,Expert,,BAO_0000019
3663,,,,1,H,10627,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,8,CHEMBL620799,,,B,,,,Autocuration,,BAO_0000357
3664,,,,1,H,10627,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,8,CHEMBL620800,,,B,,,,Expert,,BAO_0000357
3665,,,,1,H,10627,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,8,CHEMBL620801,,,B,,,,Autocuration,,BAO_0000357
3666,,,,1,H,10627,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,8,CHEMBL875100,,,B,,,,Autocuration,,BAO_0000357
3667,,,,1,H,10627,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,8,CHEMBL620802,,,B,,,,Autocuration,,BAO_0000357
3668,,,,1,H,10627,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,8,CHEMBL620803,,,F,,,,Expert,,BAO_0000019
3669,,,,1,H,10627,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,8,CHEMBL620804,,,F,,,,Expert,,BAO_0000019
3670,,,,1,H,10627,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,8,CHEMBL620805,,,B,,,,Autocuration,,BAO_0000357
3671,,,,1,H,10627,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,8,CHEMBL620806,,,B,,,,Autocuration,,BAO_0000357
3672,,,,1,H,10627,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,8,CHEMBL620807,,,B,,,,Autocuration,,BAO_0000357
3673,,,,1,H,10627,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,8,CHEMBL620808,,,B,,,,Autocuration,,BAO_0000357
3674,,,,1,H,10627,,Binding affinities against 5-hydroxytryptamine 6 receptor,8,CHEMBL620809,,,B,,,,Autocuration,,BAO_0000357
3675,,,,1,H,10627,,Binding affinities towards 5-hydroxytryptamine 6 receptor,8,CHEMBL620810,,,B,,,,Autocuration,,BAO_0000357
3676,,,,1,D,10627,,Binding affinity towards 5-hydroxytryptamine 6 receptor,9,CHEMBL620811,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3677,,,,1,H,10627,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,8,CHEMBL620812,,,B,,,,Autocuration,,BAO_0000357
3678,,,,1,H,10627,,Affinity against 5-hydroxytryptamine 6 receptor,8,CHEMBL620813,,,B,,,,Autocuration,,BAO_0000357
3679,,,,1,H,10627,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],8,CHEMBL620814,,,B,,,,Autocuration,,BAO_0000357
3680,,,,1,D,10209,,Inhibition of human 5-hydroxytryptamine 7 receptor,9,CHEMBL620815,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3681,,,,1,H,10209,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,8,CHEMBL620816,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3682,,,,1,H,10209,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,8,CHEMBL620817,,,B,,,,Autocuration,,BAO_0000357
3683,,,,1,H,10209,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),8,CHEMBL620818,,,B,,,,Autocuration,,BAO_0000357
3684,,,,1,H,10209,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,8,CHEMBL620819,,,B,,,HEK293,Expert,722.0,BAO_0000219
3685,,,,1,D,10209,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,9,CHEMBL620820,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3686,,,,1,H,10209,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,8,CHEMBL620821,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3687,,,,1,D,10209,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,9,CHEMBL620822,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3688,,,,1,D,10209,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,9,CHEMBL620823,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3689,,,,1,D,10209,,Binding affinity against 5-hydroxytryptamine 7 receptor,9,CHEMBL620824,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3690,,,,1,H,10209,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,8,CHEMBL620825,,,B,,,CHO,Expert,449.0,BAO_0000219
3691,,,,1,H,10209,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,8,CHEMBL872930,,,B,,,,Autocuration,,BAO_0000357
3692,,,,1,H,10209,,Binding affinity towards 5-hydroxytryptamine 7 receptor,8,CHEMBL620826,,,B,,,,Autocuration,,BAO_0000357
3693,,,,1,H,10209,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,8,CHEMBL620827,,,B,,,,Autocuration,,BAO_0000357
3694,,,,1,H,10209,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,8,CHEMBL620828,,,B,,,,Autocuration,,BAO_0000357
3695,,,,1,H,10209,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,8,CHEMBL620829,,,B,,,,Autocuration,,BAO_0000357
3696,,,,1,H,10209,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,8,CHEMBL620830,,,B,,,HEK293,Expert,722.0,BAO_0000219
3697,,,,1,H,10209,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,8,CHEMBL620831,,,B,,,,Expert,,BAO_0000019
3698,,,,1,H,10209,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,8,CHEMBL620832,,,B,,,,Expert,,BAO_0000019
3699,,,,1,D,10209,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,9,CHEMBL621548,Homo sapiens,,B,9606.0,,,Expert,,BAO_0000357
3700,,,,1,H,10209,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,8,CHEMBL621549,,,B,,,,Autocuration,,BAO_0000019
3701,,,,1,H,10209,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,8,CHEMBL621550,,,B,,,,Autocuration,,BAO_0000357
3702,,,,1,H,10209,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,8,CHEMBL621551,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3703,,,,1,H,10209,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,8,CHEMBL621552,,,B,,,,Autocuration,,BAO_0000019
3704,,,,1,H,10209,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,8,CHEMBL857077,,,B,,,,Autocuration,,BAO_0000357
3705,,,,1,H,10209,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,8,CHEMBL618158,,,B,,,,Autocuration,,BAO_0000357
3706,,,,1,D,10209,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,9,CHEMBL618159,Homo sapiens,,B,9606.0,,COS-7,Expert,643.0,BAO_0000219
3707,,,,1,H,10209,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,8,CHEMBL875101,,,B,,,COS-7,Autocuration,643.0,BAO_0000219
3708,,,,1,D,10209,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,9,CHEMBL618160,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
3709,,,,1,H,10209,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,8,CHEMBL618161,,,B,,,,Expert,,BAO_0000357
3710,,,,1,H,10209,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,8,CHEMBL618162,,,B,,,HEK293,Expert,722.0,BAO_0000219
3711,,,,1,H,10209,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,8,CHEMBL618163,,,B,,,,Expert,,BAO_0000357
3712,,,,1,H,10209,,Binding affinity against 5-hydroxytryptamine 7 human receptors,8,CHEMBL618164,,,B,,,,Autocuration,,BAO_0000357
3713,,,,1,H,10209,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,8,CHEMBL618165,,,B,,,,Expert,,BAO_0000219
3714,,,,1,H,10209,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,8,CHEMBL618166,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3715,,,,1,H,10209,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,8,CHEMBL857989,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3716,,,,1,H,10209,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,8,CHEMBL619888,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3717,,,,1,H,10209,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,8,CHEMBL619889,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3718,,,,1,H,10209,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,8,CHEMBL619890,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3719,,,,1,H,10209,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,8,CHEMBL619891,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3720,,,,1,H,10209,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),8,CHEMBL619892,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3721,,,,1,D,10209,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,9,CHEMBL619893,,,B,,,HEK293,Expert,722.0,BAO_0000219
3722,,,,1,H,10209,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),8,CHEMBL619894,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3723,,,,1,D,10209,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,9,CHEMBL619895,,,B,,,HEK293,Intermediate,722.0,BAO_0000219
3724,,,,1,D,10209,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,9,CHEMBL619896,,,B,,,,Intermediate,,BAO_0000357
3725,,,,1,H,10209,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,8,CHEMBL619897,,,B,,,COS-7,Autocuration,643.0,BAO_0000219
3726,,,,1,H,10209,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,8,CHEMBL619898,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3727,,,,1,H,10209,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,8,CHEMBL619899,,,B,,,HEK293,Expert,722.0,BAO_0000219
3728,,,,1,H,10209,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),8,CHEMBL619900,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3729,,,,1,D,10209,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,9,CHEMBL619901,Homo sapiens,,B,9606.0,,HEK293,Expert,722.0,BAO_0000219
3730,,,,1,H,10209,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,8,CHEMBL620580,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3731,,,,1,H,10209,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,8,CHEMBL620581,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3732,,,,1,H,10209,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",8,CHEMBL620733,,,B,,,HEK293,Autocuration,722.0,BAO_0000219
3733,,,,1,D,10209,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,9,CHEMBL620734,Homo sapiens,,B,9606.0,,,Autocuration,,BAO_0000357
3734,,,,1,D,10022,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,9,CHEMBL620735,Mus musculus,,B,10090.0,,,Expert,,BAO_0000357
3735,,,,1,H,10209,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,8,CHEMBL620736,Oryctolagus cuniculus,,B,9986.0,,,Autocuration,,BAO_0000019
3736,,,,1,H,11923,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,8,CHEMBL620737,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3737,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,8,CHEMBL620738,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3738,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,8,CHEMBL620739,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3739,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,8,CHEMBL620740,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3740,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,8,CHEMBL620741,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3741,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,8,CHEMBL620742,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3742,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,8,CHEMBL620743,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3743,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,8,CHEMBL620744,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3744,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,8,CHEMBL620745,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3745,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,8,CHEMBL620746,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3746,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,8,CHEMBL620747,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3747,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,8,CHEMBL620748,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3748,,,,1,H,11923,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,8,CHEMBL620749,,,B,,,CHO,Autocuration,449.0,BAO_0000219
3749,,,,1,H,11923,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,8,CHEMBL620750,,,B,,,,Expert,,BAO_0000357
3750,,,,1,D,11923,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,9,CHEMBL620751,Rattus norvegicus,,B,10116.0,,,Expert,,BAO_0000357
3751,,,,1,H,11923,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,8,CHEMBL620752,,,B,,,,Expert,,BAO_0000357
